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1 PREFACE 
This guideline is one of three pieces of the National Institute for Health and Clinical 
Excellence‘s (NICE) guidance developed to advise on alcohol-use disorders. The present 
guideline addresses the management of alcohol dependence and harmful alcohol use in 
people aged 10 years and older including: assessment, pharmacological interventions, 
psychological and psychosocial interventions, and settings of assisted withdrawal and 
rehabilitation. The two other NICE guidelines address: (1) the prevention of alcohol-use 
disorders in people aged 10 years and older, which is public health guidance on the price 
of alcohol, advertising and availability of alcohol, how best to detect alcohol misuse both 
in and out of primary care and brief interventions to manage alcohol misuse in these 
settings (NICE, 2010a); and (2) the assessment and clinical management in people aged 10 
years and older of acute alcohol withdrawal, including delirium tremens (DTs), liver 
damage, acute and chronic pancreatitis and the management of Wernicke‘s 
encephalopathy (NICE, 2010b).  
 
This guideline will sometimes use the term alcohol misuse, which will encompass both 
people with alcohol dependence and harmful alcohol use. 
 
The guideline recommendations have been developed by a multidisciplinary team of 
healthcare professionals, as well as lay member, service user and carer representatives, 
and guideline methodologists, after careful consideration of the best available evidence. It 
is intended that the guideline will be useful to clinicians and service commissioners in 
providing and planning high-quality care for people who misuse alcohol while also 
emphasising the importance of the experience of care for them and their carers. 
 
Although the evidence base is rapidly expanding, there are a number of major gaps in the 
literature and future revisions of this guideline will incorporate new scientific evidence as 
it develops. The guideline makes a number of research recommendations specifically to 
address gaps in the evidence base. In the meantime, it is hoped that the guideline will 
assist clinicians, people who misuse alcohol and their carers by identifying the merits of 
particular treatment approaches where the evidence from research and clinical experience 
exists.  
1.1 NATIONAL GUIDELINES 
1.1.1 What are clinical practice guidelines? 
Clinical practice guidelines are ‗systematically developed statements that assist clinicians 
and patients in making decisions about appropriate treatment for specific conditions‘ 
(Mann, 1996). They are derived from the best available research evidence, using 
predetermined and systematic methods to identify and evaluate the evidence relating to 
the specific condition in question. Where evidence is lacking, the guidelines incorporate 
statements and recommendations based upon the consensus statements developed by the 
Guideline Development Group (GDG). 
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Clinical guidelines are intended to improve the process and outcomes of healthcare in a 
number of different ways. They can: 
 provide up-to-date evidence-based recommendations for the management of 
conditions and disorders by healthcare professionals 
 be used as the basis to set standards to assess the practice of healthcare 
professionals 
 form the basis for education and training of healthcare professionals 
 assist people with alcohol dependence and harmful alcohol use and their carers in 
making informed decisions about their treatment and care 
 improve communication between healthcare professionals, people with alcohol 
dependence and harmful alcohol use and their carers 
 help identify priority areas for further research. 
1.1.2 Uses and limitations of clinical guidelines 
Guidelines are not a substitute for professional knowledge and clinical judgement. They 
can be limited in their usefulness and applicability by a number of different factors: the 
availability of high-quality research evidence, the quality of the methodology used in the 
development of the guideline, the generalisability of research findings and the uniqueness 
of individuals who misuse alcohol. 
 
Although the quality of research in this field is variable, the methodology used here 
reflects current international understanding on the appropriate practice for guideline 
development (Appraisal of Guidelines for Research and Evaluation Instrument [AGREE], 
www.agreetrust.org; AGREE, 2003), ensuring the collection and selection of the best 
research evidence available and the systematic generation of treatment recommendations 
applicable to the majority of people who misuse alcohol. However, there will always be 
some people and situations for which clinical guideline recommendations are not readily 
applicable. This guideline does not, therefore, override the individual responsibility of 
healthcare professionals to make appropriate decisions in the circumstances of the 
individual, in consultation with the person with alcohol dependence and harmful alcohol 
use or their carer.  
 
In addition to the clinical evidence, cost-effectiveness information, where available, is 
taken into account in the generation of statements and recommendations of the clinical 
guidelines. While national guidelines are concerned with clinical and cost effectiveness, 
issues of affordability and implementation costs are to be determined by the National 
Health Service (NHS). 
 
In using guidelines, it is important to remember that the absence of empirical evidence for 
the effectiveness of a particular intervention is not the same as evidence for 
ineffectiveness. In addition, and of particular relevance in mental health, evidence-based 
treatments are often delivered within the context of an overall treatment programme 
including a range of activities, the purpose of which may be to help engage the person and 
provide an appropriate context for the delivery of specific interventions. It is important to 
maintain and enhance the service context in which these interventions are delivered; 
otherwise the specific benefits of effective interventions will be lost. Indeed, the 
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importance of organising care in order to support and encourage a good therapeutic 
relationship is at times as important as the specific treatments offered. 
1.1.3 Why develop national guidelines? 
NICE was established as a Special Health Authority for England and Wales in 1999, with a 
remit to provide a single source of authoritative and reliable guidance for patients, 
professionals and the public. NICE guidance aims to improve standards of care, diminish 
unacceptable variations in the provision and quality of care across the NHS, and ensure 
that the health service is patient centred. All guidance is developed in a transparent and 
collaborative manner, using the best available evidence and involving all relevant 
stakeholders. 
 
NICE generates guidance in a number of different ways, three of which are relevant here. 
First, national guidance is produced by the Technology Appraisal Committee to give 
robust advice about a particular treatment, intervention, procedure or other health 
technology. Second, NICE commissions public health intervention guidance focused on 
types of activity (interventions) that help to reduce people‘s risk of developing a disease or 
condition or help to promote or maintain a healthy lifestyle. Third, NICE commissions the 
production of national clinical practice guidelines focused upon the overall treatment and 
management of a specific condition. To enable this latter development, NICE has 
established four National Collaborating Centres in conjunction with a range of 
professional organisations involved in healthcare.  
1.1.4 The National Collaborating Centre for Mental Health 
This guideline has been commissioned by NICE and developed within the National 
Collaborating Centre for Mental Health (NCCMH). The NCCMH is a collaboration of the 
professional organisations involved in the field of mental health, national patient and 
carer organisations, and a number of academic institutions and NICE. The NCCMH is 
funded by NICE and is led by a partnership between the Royal College of Psychiatrists 
and the British Psychological Society‘s Centre for Outcomes Research and Effectiveness.  
1.1.5 From national guidelines to local implementation 
Once a national guideline has been published and disseminated, local healthcare groups 
will be expected to produce a plan and identify resources for implementation, along with 
appropriate timetables. Subsequently, a multidisciplinary group involving commissioners 
of healthcare, primary care and specialist mental health professionals, and harmful 
drinkers and their carers should undertake the translation of the implementation plan 
locally, taking into account both the recommendations set out in this guideline and the 
priorities set in the National Service Framework for Mental Health (Department of Health, 
1999) and related documentation. The nature and pace of the local plan will reflect local 
healthcare needs and the nature of existing services; full implementation may take 
considerable time, especially where substantial training needs are identified. 
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1.1.6 Auditing the implementation of guidelines 
This guideline identifies key areas of clinical practice and service delivery for local and 
national audit. Although the generation of audit standards is an important and necessary 
step in the implementation of this guidance, a more broadly based implementation 
strategy will be developed. Nevertheless, it should be noted that the Care Quality 
Commission will monitor the extent to which Primary Care Trusts, trusts responsible for 
mental health and social care, and Health Authorities have implemented these guidelines.  
1.2 THE NATIONAL ALCOHOL DEPENDENCE AND 
HARMFUL ALCOHOL USE GUIDELINE  
1.2.1 Who has developed this guideline? 
The GDG was convened by the NCCMH and supported by funding from NICE. The GDG 
included lay member, service user and carer representatives, and professionals from 
psychiatry, clinical psychology, general practice, nursing and psychiatric pharmacy. 
 
Staff from the NCCMH provided leadership and support throughout the process of 
guideline development, undertaking systematic searches, information retrieval, appraisal 
and systematic review of the evidence. Members of the GDG received training in the 
process of guideline development from NCCMH staff, and the service user and carer 
representatives received training and support from the NICE Patient and Public 
Involvement Programme. The NICE Guidelines Technical Advisor provided advice and 
assistance regarding aspects of the guideline development process. 
 
All GDG members made formal declarations of interest at the outset, which were updated 
at every GDG meeting. The GDG met a total of 12 times throughout the process of 
guideline development. It met as a whole, but key topics were led by a national expert in 
the relevant topic. The GDG was supported by the NCCMH technical team, with 
additional expert advice from special advisors where needed. The group oversaw the 
production and synthesis of research evidence before presentation. All statements and 
recommendations in this guideline have been generated and agreed by the whole GDG. 
1.2.2 For whom is this guideline intended? 
This guideline is relevant for adults with alcohol dependence and harmful alcohol use as 
the primary diagnosis, and covers the care provided by primary, community, secondary, 
tertiary and other healthcare professionals who have direct contact with, and make 
decisions concerning the care of, adults with alcohol dependence and harmful alcohol use.  
 
The guideline will also be relevant to the work, but will not specifically cover the practice, 
of those in: 
 occupational health services 
 social services 
 forensic services 
 the independent sector. 
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The experience of alcohol misuse can affect the whole family and often the community. 
The guideline recognises the role of both in the treatment and support of people with 
alcohol dependence and harmful alcohol use. 
1.2.3 Specific aims of this guideline 
The guideline makes recommendations for the treatment and management of alcohol 
dependence and harmful alcohol use. It aims to: 
 improve access and engagement with treatment and services for people who 
misuse alcohol 
 evaluate the role of specific psychological and psychosocial interventions in the 
treatment of alcohol dependence and harmful alcohol use 
 evaluate the role of specific pharmacological interventions in the treatment of 
alcohol dependence and harmful alcohol use 
 integrate the above to provide best-practice advice on the care of people with 
alcohol dependence and harmful alcohol use and their family and carers 
 promote the implementation of best clinical practice through the development of 
recommendations tailored to the requirements of the NHS in England and Wales. 
1.2.4  The structure of this guideline 
The guideline is divided into chapters, each covering a set of related topics. The first three 
chapters provide an introduction to guidelines, the topic and the methods used to update 
this guideline. Chapter 4 provides the evidence for the experience of care of people who 
misuse alcohol and their carers. Chapter 5 to Chapter 7 provide the evidence that 
underpins the recommendations about the treatment and management of alcohol misuse.  
 
Each evidence chapter begins with a general introduction to the topic that sets the 
recommendations in context. Depending on the nature of the evidence, narrative reviews 
or meta-analyses were conducted, and the structure of the chapters varies accordingly. 
Where appropriate, details about current practice, the evidence base and any research 
limitations are provided. Where meta-analyses were conducted, information is given 
about the review protocol and studies included in the review. Clinical evidence 
summaries are then used to summarise the data presented. Health economic evidence is 
then presented (where appropriate), followed by a section (from evidence to 
recommendations) that draws together the clinical and health economic evidence, and 
provides a rationale for the recommendations. On the CD-ROM, further details are 
provided about included/excluded studies, the evidence, and the previous guideline 
methodology (see Table 1 below for details). 
 
Table 1: Appendices on CD-ROM 
Clinical study characteristics tables Appendix 16 
Clinical evidence forest plots Appendix 17 
GRADE evidence profiles Appendix 18 
Evidence tables for economic studies Appendix 19 
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2 ALCOHOL DEPENDENCE AND 
HARMFUL ALCOHOL USE 
2.1 INTRODUCTION  
This guideline is concerned with the identification, assessment and management of 
alcohol dependence and harmful alcohol use1 in people aged 10 years and older. In 2008, 
alcoholic beverages were consumed by 87% of the population in England, which is 
equivalent to 36 million people (adults aged 16 years or over) (Fuller, 2009). Drinking 
alcohol is widely socially accepted and associated with relaxation and pleasure, and some 
people drink alcohol without experiencing harmful effects. However, a growing number 
of people experience physical, social and psychological harmful effects of alcohol. Some 
24%2 of the adult population in England, including 33% of men and 16% of women, 
consumes alcohol in a way that is potentially or actually harmful to their health or well-
being (McManus et al., 2009). Four per cent3 of adults in England are alcohol dependent 
(6% men; 2% women) which involves a significant degree of addiction to alcohol, making 
it difficult for them to reduce their drinking or abstain in spite of increasingly serious 
harm (Drummond et al., 2005). Alcohol dependence and harmful alcohol use are 
recognised as mental health disorders by the World Health Organization (WHO, 1992; see 
Section 2.2). Although not an official diagnostic term, we will use ‗alcohol misuse‘ as a 
collective term to encompass alcohol dependence and harmful alcohol use throughout this 
guideline. 
 
The physical harm related to alcohol is a consequence of its toxic and dependence-
producing properties. Ethanol (or ethyl alcohol) in alcoholic beverages is produced by the 
fermentation of sugar by yeast. It is a small molecule which is rapidly absorbed in the gut 
and is distributed to, and has effects in, every part of the body. Most organs in the body 
can be affected by the toxic effects of alcohol, resulting in more than 60 different diseases. 
The risks of developing these diseases are related to the amount of alcohol consumed over 
time, with different diseases having different levels of risk. For example, the risk of 
developing breast cancer increases in a linear way, in which even small amounts of 
alcohol increase risk. With alcoholic liver disease the risk is curvilinear, with harm 
increasing more steeply with increasing alcohol consumption. In the case of 
cardiovascular disease, a modest beneficial effect has been reported with moderate 
amounts of alcohol, although recent research suggests this effect may have been 
overestimated (Ofori-Adjei et al., 2007). During pregnancy alcohol can cause harm to the 
foetus, which can cause prematurity, stillbirth and the developmental disorder fetal 
alcohol syndrome. 
                                                 
1 Several terms including ‗alcoholism‘, ‗alcohol addiction‘, ‗alcohol abuse‘ and ‗problem drinking‘ have been 
used in the past to describe disorders related to alcohol consumption. However, ‗alcohol dependence‘ and 
‗harmful alcohol use‘ are used throughout this guideline to be consistent with WHO‘s International 
Classification of Mental Disorders, 10th Revision (WHO, 1992). 
2 Defined as scoring 8 or more on the Alcohol Use Disorders Identification Test (AUDIT). 
3 Defined as scoring 16 or more on the AUDIT. 
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Alcohol is rapidly absorbed in the gut and reaches the brain soon after drinking. This 
quickly leads to changes in coordination which increase the risk of accidents and injuries, 
particularly when driving a vehicle or operating machinery, and when combined with 
other sedative drugs (for example, benzodiazepines). Its adverse effects on mood and 
judgement can increase the risk of violence and violent crime. Heavy chronic alcohol 
consumption increases the risk of mental health disorders including depression, anxiety, 
psychosis, impairments of memory and learning, alcohol dependence and an increased 
risk of suicide. Both acute and chronic heavy drinking can contribute to a wide range of 
social problems including domestic violence and marital breakdown, child abuse and 
neglect, absenteeism and job loss (Drummond, 1990; Velleman & Orford, 1999; Head et al., 
2002).  
 
The physical harm related to alcohol has been increasing in the UK in the past three 
decades. Deaths from alcoholic liver disease have doubled since 1980 (Leon & 
McCambridge, 2006) compared with a decrease in many other European countries. 
Alcohol related hospital admissions increased by 85% between 2002–03 and 2008–09, 
accounting for 945,000 admissions with a primary or secondary diagnosis wholly or partly 
related to alcohol in 2006–07, 7% of all hospital admissions (North West Public Health 
Observatory, 2010). 
 
Alcohol is a psychoactive substance with properties known to cause dependence (or 
addiction). If compared within the framework of the 1971 Convention on Psychotropic 
Substances, alcohol would qualify as a dependence-producing substance warranting 
international control (United Nations, 1977; Ofori-Adjei et al., 2007). Alcohol shares some 
of its dependence producing mechanisms with other psychoactive addictive drugs. 
Although a smaller proportion of the population who consume alcohol become dependent 
than is the case with some illegal drugs such as cocaine, it is nevertheless a significant 
problem due to much the larger number of people who consume alcohol (Kandel et al., 
1997). 
 
Alcohol presents particularly serious consequences in young people due to a higher level 
of vulnerability to the adverse effects of alcohol (see Section 2.12 on special populations, 
below).  
 
Heavy drinking in adolescence can affect brain development and has a higher risk of 
organ damage in the developing body (Zeigler et al., 2005). Alcohol consumption before 
the age of 13 years, for example, is associated with a four-fold increased risk of alcohol 
dependence in adulthood (Dawson et al., 2008; Hingson & Zha, 2009). Other groups who 
are also at higher risk of alcohol-related harm include: the elderly, those with pre-existing 
illnesses or who are taking a range of medicines that interact with alcohol, and the socially 
disadvantaged (O‘Connell et al., 2003; Marmot et al., 2010). A given amount of alcohol will 
also be more harmful in women compared with men due to differences in body mass and 
composition, hence the government‘s recommended sensible-drinking guidelines are 
lower for women than men. Nevertheless, or perhaps as a consequence, women tend to 
seek help for alcohol misuse earlier in their drinking career than do men (Schuckit, 2009). 
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2.2 DEFINITIONS 
The definition of harmful alcohol use in this guideline is that of WHOs International 
Classification of Diseases, 10th Revision (The ICD–10 Classification of Mental and Behavioural 
Disorders) (ICD–10; WHO, 1992):  
 
a pattern of psychoactive substance use that is causing damage to health. The damage may be 
physical (e.g. hepatitis) or mental (e.g. depressive episodes secondary to heavy alcohol intake). 
Harmful use commonly, but not invariably, has adverse social consequences; social 
consequences in themselves, however, are not sufficient to justify a diagnosis of harmful use.  
 
The term was introduced in ICD–10 and replaced ‗non-dependent use‘ as a diagnostic 
term. The closest equivalent in other diagnostic systems (for example, the Diagnostic and 
Statistical Manual of Mental Disorders of the American Psychiatric Association [APA, 1994], 
currently in its fourth edition [DSM–IV]) is ‗alcohol abuse‘, which usually includes social 
consequences. 
 
The term ‗hazardous use‘ appeared in the draft version of ICD–10 to indicate a pattern of 
substance use that increases the risk of harmful consequences for the user. This is not a 
current diagnostic term within ICD–10. Nevertheless it continues to be used by WHO in 
its public health programme (WHO, 2010a; 2010b). 
 
In ICD–10 the ‗dependence syndrome‘ is defined as: 
 
a cluster of behavioural, cognitive, and physiological phenomena that develop after repeated 
substance use and that typically include a strong desire to take the drug, difficulties in 
controlling its use, persisting in its use despite harmful consequences, a higher priority given 
to drug use than to other activities and obligations, increased tolerance, and sometimes a 
physical withdrawal state. 
 
In more common language and in earlier disease classification systems this has been 
referred to as ‗alcoholism‘. However, the term ‗alcohol dependence‘ is preferred as it is 
more precise and more reliably defined and measured using the criteria of ICD–10 ( 
Text Box 1).  
 
Text Box 1: ICD–10 diagnostic guidelines for the dependence syndrome (WHO, 1992) 
A definite diagnosis of dependence should usually be made only if three or more of 
the following have been present together at some time during the previous year: 
 
(a) a strong desire or sense of compulsion to take the substance;  
(b) difficulties in controlling substance-taking behaviour in terms of its onset, 
termination, or levels of use;  
(c) a physiological withdrawal state when substance use has ceased or been reduced, 
as evidenced by: the characteristic withdrawal syndrome for the substance; or use of 
the same (or a closely related) substance with the intention of relieving or avoiding 
withdrawal symptoms; 
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(d) evidence of tolerance, such that increased doses of the psychoactive substances 
are required in order to achieve effects originally produced by lower doses (clear 
examples of this are found in alcohol- and opiate-dependent individuals who may 
take daily doses sufficient to incapacitate or kill non-tolerant users); 
(e) progressive neglect of alternative pleasures or interests because of psychoactive 
substance use, increased amount of time necessary to obtain or take the substance or 
to recover from its effects; 
(f) persisting with substance use despite clear evidence of overtly harmful 
consequences, such as harm to the liver through excessive drinking, depressive mood 
states consequent to periods of heavy substance use, or drug-related impairment of 
cognitive functioning; efforts should be made to determine that the user was actually, 
or could be expected to be, aware of the nature and extent of the harm. 
 
Narrowing of the personal repertoire of patterns of psychoactive substance use has 
also been described as a characteristic feature (for example, a tendency to drink 
alcoholic drinks in the same way on weekdays and weekends, regardless of social 
constraints that determine appropriate drinking behaviour). 
 
It is an essential characteristic of the dependence syndrome that either psychoactive 
substance taking or a desire to take a particular substance should be present; the 
subjective awareness of compulsion to use drugs is most commonly seen during 
attempts to stop or control substance use. 
 
 
 
Alcohol dependence is also a category of mental disorder in DSM–IV (APA, 1994), 
although the criteria are slightly different from those used by ICD–10. For example a 
strong desire or compulsion to use substances is not included in DSM–IV, whereas more 
criteria relate to harmful consequences of use. It should be noted that DSM is currently 
under revision, but the final version of DSM–V will not be published until 2013 (APA, 
2010). 
 
Although alcohol dependence is defined in ICD–10 and DSM–IV in categorical terms for 
diagnostic and statistical purposes as being either present or absent, in reality dependence 
exists on a continuum of severity. Therefore, it is helpful from a clinical perspective to 
subdivide dependence into categories of mild, moderate and severe. People with mild 
dependence (those scoring 15 or less on the Severity of Alcohol Dependence 
Questionnaire [SADQ]; ) usually do not need assisted alcohol withdrawal. People with 
moderate dependence (with a SADQ score of between 15 and 30) usually need assisted 
alcohol withdrawal, which can typically be managed in a community setting unless there 
are other risks. People who are severely alcohol dependent (with a SADQ score of 31 or 
more) will need assisted alcohol withdrawal, typically in an inpatient or residential 
setting. In this guideline these definitions of severity are used to guide selection of 
appropriate interventions. 
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2.3 EPIDEMIOLOGY OF ALCOHOL 
2.3.1 Prevalence 
Alcohol was consumed by 87% of the UK population in the past year (Fuller, 2009). 
Amongst those who are current abstainers, some have never consumed alcohol for 
religious, cultural or other reasons, and some have consumed alcohol in the past but not in 
the past year. This latter group includes people who have been harmful drinkers or 
alcohol dependent in the past and who have stopped because of experiencing the harmful 
effects of alcohol. 
 
Amongst those who currently consume alcohol there is a wide spectrum of alcohol 
consumption, from the majority who are moderate drinkers through to a smaller number 
of people who regularly consume a litre of spirits per day or more and who will typically 
be severely alcohol dependent. However, it is important to note that most of the alcohol 
consumed by the population is drunk by a minority of heavy drinkers. 
 
The Department of Health has introduced definitions that relate to different levels of 
drinking risk. One UK unit of alcohol is defined as 8 g (or 10 ml) of pure ethanol4. The 
Department of Health recommends that adult men should not regularly drink more than 
four units of alcohol per day and women no more than three units (Department of Health, 
1995). This definition implies the need for alcohol-free or lower alcohol consumption days. 
Below this level, alcohol consumption is regarded a ‗low risk‘ in terms of health or social 
harms. The government‘s advice on alcohol in pregnancy is to abstain (Department of 
Health, 2008a). The Royal College of Psychiatrists‘ advice is to drink less than 21 units of 
alcohol per week in men and 14 units in women, which is consistent with government 
advice if alcohol-free days are included in the weekly drinking pattern (Royal College of 
Psychiatrists, 1986). Those people who drink above these levels but have not yet 
experienced alcohol-related harm are regarded as hazardous drinkers: that is, their 
drinking is at a level which increases the risk of harm in the future. These 
recommendations are based on longitudinal research on the impact of different levels of 
alcohol consumption on mortality. Above 50 units of alcohol per day in men and 35 units 
in women is regarded as ‗definitely harmful‘ (Royal College of Psychiatrists, 1986). Those 
drinking more than eight units per day in men and six units in women are regarded by the 
government as ‗binge drinkers‘ (Prime Minister‘s Strategy Unit, 2004). Again, these 
definitions are based on longitudinal research on the effects of alcohol consumption on 
adverse consequences including accidents, injuries and other forms of harm. 
 
Most of the data on the English population‘s drinking patterns comes from the General 
Household Survey, the Health Survey for England and the Psychiatric Morbidity Survey 
(Robinson & Bulger, 2010; Craig et al., 2009; McManus et al., 2009). In terms of hazardous 
drinking, in 2008, 21% of adult men were drinking between 22 and 50 units per week, and 
15% of adult women were drinking between 15 and 35 units; a further 7% of men and 5% 
of women were harmful drinkers, drinking above 50 and 35 units per week, respectively. 
                                                 
4 The UK unit definition differs from definitions of standard drinks in some other countries. For example, a 
UK unit contains two thirds of the quantity of ethanol that a US ‗standard drink‘ has. 
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In addition, 21% of adult men and 14% of women met the government‘s criteria for binge 
drinking. There were regional variations in the prevalence of these drinking patterns. 
Hazardous drinking among men varied from 24% in the West Midlands to 32% in 
Yorkshire and Humber, and in women from 15% in the East of England to 25% in the 
North East. Harmful drinking in men varied from 5% in the East Midlands to 11% in 
Yorkshire and Humber, and in women from 2% in the East of England to 7% in Yorkshire 
and Humber. Binge drinking among men varied from 19% in the West Midlands to 29% in 
Yorkshire and Humber and among women from 11% in East of England to 21% in 
Yorkshire and Humber (Robinson & Bulger, 2010).  
 
There is a lack of reliable data on the prevalence of alcohol dependence because UK 
general-population surveys do not include questionnaires that provide an ICD–10 
diagnosis of alcohol dependence (for example, the WHO Composite International 
Diagnostic Interview). Instead the most reliable estimate of alcohol dependence comes 
from the Psychiatric Morbidity Survey, which used a WHO measure of alcohol use 
disorders: the Alcohol Use Disorders Identification Test (AUDIT; Babor et al., 2001). A 
score of 16 or more on this questionnaire is indicative of possible alcohol dependence 
(Drummond et al., 2005). The Alcohol Needs Assessment Research Project (ANARP) in 
England found the prevalence of alcohol dependence to be 4% in 16- to 64-year-old adults: 
6% of men and 2% of women (Drummond et al., 2005). This equates to a population of 1.1 
million people in England with alcohol dependence. There was considerable regional 
variation in the prevalence of alcohol dependence from 2% in East Midlands to 5% in the 
North West. The prevalence of hazardous and harmful drinking and dependence are 
highest in 16- to 24-year-olds and decrease steadily with age. Hazardous and harmful 
drinking is 1.6 times greater in the white population than in the black and minority ethnic 
population. However, alcohol dependence is approximately equally prevalent in these 
two populations (see Section 2.12 on special populations, below). 
 
While the government and Royal Colleges‘ definitions of harmful drinking and risk levels 
of alcohol consumption provide useful benchmarks to estimate prevalence of alcohol use 
disorders in the general population and monitor trends over time, they have a number of 
limitations. This is particularly apparent when examining an individual‘s risk of alcohol 
related harm at a given level of alcohol consumption. 
 
According to WHO, alcohol is implicated as a risk factor in over 60 health disorders 
including high blood pressure, stroke, coronary heart disease, liver cirrhosis and various 
cancers. The extent to which these disorders are attributable to alcohol varies. This is 
known as the Alcohol Attributable Fraction (AAF). The AAF for alcoholic liver disease 
and alcohol poisoning is 1 (or 100% alcohol attributable) (WHO, 2000). For other diseases 
such as cancer and heart disease the AAF is less than 1 (that is, partly attributable to 
alcohol) or 0 (that is, not attributable to alcohol). Further, the AAF varies with age and 
gender. Also, as noted earlier, the risk with increasing levels of alcohol consumption is 
different for different health disorders. Risk of a given level of alcohol consumption is also 
related to gender, body weight, nutritional status, concurrent use of a range of 
medications, mental health status, contextual factors and social deprivation, amongst 
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other factors. Therefore, it is impossible to define a level at which alcohol is universally 
without risk of harm. 
2.3.2 Mental health 
Alcohol is strongly associated with a wide range of mental health problems. Depression, 
anxiety, drug misuse, nicotine dependence, and self-harm are commonly associated with 
excessive alcohol consumption. Up to 41% of suicides are attributable to alcohol and 23% 
of people who engage in deliberate self-harm are alcohol dependent (Merrill et al., 1992; 
Demirbas et al., 2003). Amongst adults admitted to inpatient mental health services, 
hazardous and harmful alcohol use increased the risk of a suicidal presentation by a factor 
of three, and alcohol dependence increased the risk by a factor of eight (McCloud et al., 
2004). In the same study, 49% of patients admitted were hazardous and harmful drinkers, 
including 53% of men and 44% of women, and 22% of the total population were alcohol 
dependent (Barnaby et al., 2003). These prevalence rates are considerably higher than the 
general population, particularly in women. 
 
A UK study found that 26% of community mental health team patients were hazardous or 
harmful drinkers and 9% were alcohol dependent (Weaver et al., 2003). In the same study 
examining patients attending specialist alcohol treatment services, overall 85% had a 
psychiatric disorder in addition to alcohol dependence. Eighty-one per cent had an 
affective and/or anxiety disorder (severe depression, 34%; mild depression, 47%, anxiety, 
32%), 53% had a personality disorder and 19% had a psychotic disorder. 
2.3.3 Social problems 
Alcohol is implicated in relationship breakdown, domestic violence and poor parenting, 
including child neglect and abuse. It is estimated that over 1 million children are affected 
by parental alcohol misuse and up to 60% of child protection cases involve alcohol (Prime 
Minister‘s Strategy Unit, 2003). Alcohol also contributes to unsafe sex and unplanned 
pregnancy, financial problems and homelessness. Up to a half of homeless people are 
alcohol dependent (Gill et al., 1996).  
 
In terms of productivity, alcohol contributes to absenteeism, accidents in the workplace 
and decline in work performance. Up to 17 million working days are lost annually in the 
UK due to alcohol related absences and 58,000 working years are lost annually due to 
premature deaths related to alcohol (Leontaridi, 2003). Alcohol misuse can also lead to job 
loss and over 38,000 people of working age in England were claiming Incapacity Benefit 
with a diagnosis of ‗alcoholism‘ – nearly 2% of all claimants (Deacon et al., 2007).  
2.3.4 Criminality 
There were 986,000 violent incidents in England and Wales in 2009–10, where the victim 
believed the offender to be under the influence of alcohol, accounting for 50% of all violent 
crimes (Flatley et al., 2010). Nearly half of all offences of criminal damage are alcohol 
related, and alcohol is implicated in domestic violence, sexual assaults, burglary, theft, 
robbery and murder (Prime Minister‘s Strategy Unit, 2003). In 2008, it was estimated that 
13,020 reported road casualties (6% of all road casualties) occurred when someone was 
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driving whilst over the legal alcohol limit. The provisional number of people estimated to 
have been killed in drink-drive accidents was 430 in 2008 (17% of all road fatalities) 
(Department of Transport, 2009). 
 
Approximately two thirds of male prisoners and over one third of female prisoners are 
hazardous or harmful drinkers, and up to 70% of probation clients are hazardous or 
harmful drinkers (Singleton et al., 1998). 
2.3.5 Public health impact 
WHO has estimated the global burden of disease due to alcohol using AAFs, as described 
above, and found that alcohol accounts for 4% of all disease burden world wide (Rehm et 
al., 2004). Alcohol is the third leading cause of disability in the developed world after 
smoking and hypertension. Using the same methodology, nearly 15,000 deaths in England 
are caused by alcohol per annum, 3% of all deaths (Jones et al., 2008). Men had more than 
double the risk of alcohol attributable deaths compared with women, and deaths of 16- to 
24–year-olds are 20 times more likely to be the result of alcohol compared with deaths of 
those aged 75 years and over (23% of all deaths in 16- to 24-year-olds), mostly due to acute 
effects of alcohol: intentional self-harm and road traffic accidents. In those over 35 years 
old, alcohol-related deaths are more commonly due to chronic physical illness from 
alcohol, for example alcoholic liver disease, malignant cancers of the oesophagus and 
breast, and hypertension. 
 
The health consequences of alcohol, including deaths from alcoholic liver disease, have 
been increasing in the UK compared with a reduction in many other European countries 
(Leon & McCambridge, 2006). Further the age at which deaths from alcoholic liver disease 
occur has been falling in the UK, which is partly attributable to increasing alcohol 
consumption in young people (Office for National Statistics, 2003). 
 
Alcohol related hospital admissions increased by 85% between 2002–03 and 2008–09. For 
conditions directly attributable to alcohol, admissions increased by 81% between 2002–03 
and 2008–09. In 2008–09, there were 945,000 hospital admissions in England where alcohol 
was either a primary or secondary diagnosis (North West Public Health Observatory, 
2009). Alcohol related admissions increase steeply with age, peaking in the 60- to 64-year-
old age group (Deacon et al., 2007). 
 
Data on alcohol related attendances at accident and emergency departments are not 
routinely collected nationally in England. However, a 24-hour weekend survey of 36 
accident and emergency departments found that 40% of attendances were alcohol related 
and at peak times (midnight to 5 a.m. at weekends) this rises to 70% (Drummond et al., 
2005). Harmful and dependent drinkers are much more likely to be frequent accident and 
emergency department attenders, attending on average five times per annum. Between 20 
and 30% of medical admissions, and one third of primary care attendances, are alcohol 
related (Kouimtsidis et al., 2003; Royal College of Physicians, 2001; Coulton et al., 2006). 
Further, people who are alcohol dependent are twice as likely as moderate drinkers to 
visit their general practitioner (GP) (Fuller et al., 2009). 
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2.4 AETIOLOGY 
There is no single factor that accounts for the variation in individual risk of developing 
alcohol-use disorders. The evidence suggests that harmful alcohol use and alcohol 
dependence have a wide range of causal factors, some of which interact with each other to 
increase risk. 
2.4.1 Family history 
It is well established that alcohol dependence runs in families. In general, offspring of 
parents with alcohol dependence are four times more likely to develop alcohol 
dependence. Evidence from genetic studies, particularly those in twins, has clearly 
demonstrated a genetic component to the risk of alcohol dependence. A meta-analysis of 
9,897 twin pairs from Australian and US studies found the heritability of alcohol 
dependence in excess of 50% (Goldman et al., 2005). However, a meta-analysis of 50 
family, twin and adoption studies showed the heritability of alcohol misuse to be at most 
30 to 36% (Walters, 2002). Whatever the true heritability, these studies indicate that genetic 
factors may explain only part of the aetiology of alcohol dependence. The remaining 
variation is accounted for by environmental factors and their interaction with genetic 
factors. While no single gene for alcohol dependence has so far been identified, a range of 
genes that determine brain function have been implicated (Agrawal et al., 2008). 
2.4.2 Psychological factors 
There is good evidence that a range of psychological factors contribute to the risk of 
developing alcohol-use disorders. Various learning theories have provided evidence of an 
important role of learning in alcohol dependence. Conditioning theories provide an 
explanation for the development of alcohol dependence. Alcohol, being a psychoactive 
drug, has reinforcing properties, for example through its pleasurable effects and its ability 
to relieve negative mood states such as anxiety. Conditioning can also explain why people 
become particularly sensitive to stimuli or cues associated with alcohol consumption, for 
example the sight and smell of a favourite drink, such that these cues can trigger craving 
for and continued use of alcohol, including relapse after a period of abstinence 
(Drummond et al., 1990). 
 
Social learning theory also provides some explanations of increased risk of excessive 
drinking and the development of alcohol dependence. People can learn from families and 
peer groups through a process of modelling patterns of drinking and expectancies (beliefs) 
about the effects of alcohol. Teenagers with higher positive expectancies (for example, that 
drinking is pleasurable and desirable) are more likely to start drinking at an earlier age 
and to drink more heavily (Christiansen et al., 1989; Dunn & Goldman, 1998). 
2.4.3 Personality factors 
The idea that a particular ‗addictive personality‘ leads to the development of alcohol 
dependence is popular with some addiction counsellors, but does not have strong support 
from research. Often with patients in treatment for alcohol dependence, it is difficult to 
disentangle the effects of alcohol on the expression of personality and behaviour from 
those personality factors that preceded alcohol dependence. Nevertheless, people who are 
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alcohol dependent have a 21-fold higher risk of also having antisocial personality disorder 
(ASPD; Regier et al., 1990), and people with ASPD have a higher risk of severe alcohol 
dependence (Goldstein et al., 2007). Recent evidence points to the importance of 
disinhibition traits, such as novelty and sensation seeking, and poor impulse control, as 
factors related to increased risk of both alcohol and drug dependence, which may have a 
basis in abnormal brain function in the pre-frontal cortex (Kalivas & Volkow, 2005; Dick et 
al., 2007). 
2.4.4 Psychiatric comorbidity 
As noted earlier, people who are alcohol dependent have higher rates of comorbidity with 
other psychiatric disorders, particularly depression, anxiety, post-traumatic stress 
disorder (PTSD), psychosis and drug misuse, than people in the general population. 
Alcohol can, temporarily at least, reduce the symptoms of anxiety and depression, leading 
to the theory that alcohol use in this situation is a form of ‗self-medication‘. This theory, 
however, lacks clear experimental support, and the longer-term effects of alcohol worsen 
these disorders. 
2.4.5 Stress, adverse life events and abuse 
There is clear evidence that adverse life events can trigger excessive drinking and may 
predispose to the development of alcohol dependence. This is particularly apparent in 
alcohol dependence developing later in life following, for example, a bereavement or job 
loss. Stressful life situations or events can also trigger heavy drinking. People who are 
alcohol dependent also report much higher levels of childhood abuse and neglect, 
particularly sexual abuse. One UK study found 54% of female and 24% of male alcohol 
dependent patients identified themselves as victims of sexual abuse, mostly before the age 
of 16 years (Moncrieff et al., 1996). Further, they were more likely to have a family history 
of alcohol misuse, and began drinking and developed alcohol dependence earlier than 
those without such a history. 
2.4.6 Other environmental and cultural factors 
There is a wide range of other environmental factors which predispose to the 
development of alcohol-use disorders (Cook, 1994). These include the affordability and 
availability of alcohol, high consumption rates in the general population, occupational risk 
factors (such as working in the alcohol or hospitality industries), social pressure to drink, 
and religious- and culturally-related attitudes towards alcohol.  
2.5 COURSE OF HARMFUL ALCOHOL USE AND 
DEPENDENCE 
Harmful alcohol use and dependence are relatively uncommon before the age of 15 years, 
but increase steeply to reach a peak in the early 20s, this being the period when harmful 
drinking and alcohol dependence are most likely to begin. One US general population 
study found the prevalence of alcohol dependence to be 2% in 12- to 17-year-olds, rising to 
12% in 18- to 20–year-olds (Grant et al., 2004a). Thereafter, the prevalence of alcohol-use 
disorders declines steadily with age. The same US study found the prevalence of 
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dependence was 4% in 30- to 34-year-olds and 1.5% in 50- to 54-year-olds. A similar UK 
study found the prevalence of alcohol dependence to be 6% in 16- to 19-year-olds, 8.2% in 
20- to 24–year-olds, 3.6% in 30- to 34-year-olds and 2.3% in 50- to 54–year-olds 
(Drummond et al., 2005). Therefore, it is clear that there is substantial remission from 
alcohol-use disorders over time. Much of this remission takes place without contact with 
alcohol treatment services (Dawson et al., 2005a). 
 
However, it is also known that people who develop alcohol dependence at a younger age 
tend to have a more chronic course (Dawson et al., 2008). Further, while a large proportion 
of those who meet the criteria for alcohol dependence in their 20s will remit over the 
following two decades; those who remain alcohol dependent in their 40s will tend to have 
a more chronic course. This is the typical age group of people entering specialist alcohol 
treatment. Most studies examining the outcome of people attending alcohol treatment find 
that 70 to 80% will relapse in the year following treatment, with the highest rate of relapse 
taking place in the first 3 months after completing treatment (Hunt et al., 1971; Raistrick et 
al., 2006). Those who remain abstinent from alcohol for the first year after treatment have a 
relatively low risk of relapse thereafter (Schuckit, 2009). Factors associated with a worse 
outcome include having less social stability and support (for example, those without jobs, 
families or stable housing), lacking a social network of non-drinkers, a family history of 
alcohol dependence, psychiatric comorbidity, multiple previous treatment episodes and 
history of disengagement from treatment. 
 
In contrast with the relatively positive prognosis in younger people who are alcohol 
dependent in the general population, the longer term prognosis of alcohol dependence for 
people entering specialist treatment is comparatively poor. Over a 10-year period about 
one third have continuing alcohol problems, a third show some improvement and a third 
have a good outcome (either abstinence or moderate drinking) (Edwards et al., 1988). The 
mortality rate is high in this population, nearly four times the age-adjusted rate for people 
without alcohol dependence. Those who are more severely alcohol dependent are less 
likely to achieve lasting stable moderate drinking and have a higher mortality than those 
who are less dependent (Marshall et al., 1994). It is important to note that most of the 
excess mortality is largely accounted for by lung cancer and heart disease, which are 
strongly related to continued tobacco smoking. 
2.6 PHARMACOLOGY OF ALCOHOL 
Following ingestion, alcohol is rapidly absorbed by the gut and enters the bloodstream 
with a peak in blood alcohol concentration after 30 to 60 minutes. Alcohol is then 
distributed around every part of the body. It readily crosses the blood–brain barrier to 
enter the brain where it causes subjective or psychoactive and behavioural effects, and, 
following high levels of chronic alcohol intake, it can cause cognitive impairment and 
brain damage. 
 
Alcohol is excreted in urine, sweat and breath, but the main method of elimination from 
the body is by metabolism in the liver, where it is converted to acetaldehyde and acetate. 
These metabolites are then excreted from the body, primarily in urine. The rate at which 
alcohol is metabolised and the extent to which an individual is affected by a given dose of 
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alcohol is highly variable from one individual to another. These individual differences 
affect drinking behaviour and the potential for alcohol-related harm and alcohol 
dependence. Also, the effects of alcohol vary in the same individual over time depending 
on several factors including whether food has been consumed, rate of drinking, nutritional 
status, environmental context and concurrent use of other psychoactive drugs. Therefore, 
it is very difficult to predict the effects of a given amount of alcohol both between 
individuals and within individuals over time. For instance the impact on the liver varies 
clinically, so that some experience liver failure early on in their drinking career, whilst in 
others drinking heavily, liver function is relatively normal. 
 
Alcohol is a toxic substance and its toxicity is related to the quantity and duration of 
alcohol consumption. It can have toxic effects on every organ in the body. In the brain, in a 
single drinking episode increasing levels of alcohol lead initially to stimulation, 
experienced as pleasure, excitement and talkativeness. At increasing concentrations 
alcohol causes sedation leading to sensations of relaxation, then later to slurred speech, 
unsteadiness, loss of coordination, incontinence, coma and ultimately death through 
alcohol poisoning, due to the sedation of the vital brain functions on breathing and 
circulation. 
 
The dependence-producing properties of alcohol have been studied extensively in the last 
20 years. Alcohol affects a wide range of neurotransmitter systems in the brain, leading to 
the features of alcohol dependence. The main neurotransmitter systems affected by 
alcohol are GABA, glutamate, dopamine and opioid (Nutt, 1999). The action of alcohol on 
GABA is similar to the effects of other sedatives such as benzodiazepines and is 
responsible for alcohol‘s sedating and anxiolytic properties (Krystal et al., 2006). 
Glutamate is a major neurotransmitter responsible for brain stimulation, and alcohol 
affects glutamate through its inhibitory action on N-methyl D-aspartate (NMDA)-type 
glutamate receptors, producing amnesia (for example, blackouts) and sedation (Krystal et 
al., 1999).  
 
Chronic alcohol consumption leads to the development of tolerance through a process of 
neuroadaptation: receptors in the brain gradually adapt to the effects of alcohol, to 
compensate for stimulation or sedation. This is experienced by the individual as the same 
amount of alcohol having less effect over time. This can lead to an individual increasing 
alcohol consumption to achieve the desired psychoactive effects. The key 
neurotransmitters involved in tolerance are gamma-aminobutyric acid (GABA) and 
glutamate, with chronic alcohol intake associated with reduced GABA inhibitory function 
and increased NMDA-glutamatergic activity (Krystal et al., 2003; 2006). This GABA–
glutamate imbalance is acceptable in the presence of alcohol, which increases GABA and 
reduces NMDA-glutamate activity. However, when the alcohol-dependent individual 
stops drinking, the imbalance between these neurotransmitter systems now results in the 
brain becoming overactive after a few hours, leading to unpleasant withdrawal symptoms 
such as anxiety, sweating, craving, seizures and hallucinations. This can be life threatening 
in severe cases and requires urgent medical treatment. Repeated withdrawal is also 
thought to underlie the toxic effect of alcohol on neurons, leading to cognitive impairment 
and brain damage (Loeber et al., 2009). The effects of alcohol withdrawal can take up to 
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between 3 months and 1 year to fully recover from (referred to as the protracted 
withdrawal syndrome). Even then, the brain remains abnormally sensitive to alcohol and, 
when drinking is resumed, tolerance and withdrawal can return within a few days 
(known as reinstatement) (Edwards & Gross, 1976). This makes it extremely difficult for a 
person who has developed alcohol dependence to return to sustained moderate drinking. 
 
The brain‘s endogenous opioid system is also affected by alcohol (Oswald & Wand, 2004). 
Alcohol stimulates endogenous opioids, which are thought to be related to the 
pleasurable, reinforcing effects of alcohol. Opioids in turn stimulate the dopamine system 
in the brain, which is thought to be responsible for appetite for a range of appetitive 
behaviours including regulation of appetite for food, sex and psychoactive drugs. The 
dopamine system is also activated by stimulant drugs such as amphetamines and cocaine, 
and it is through this process that the individual seeks more drugs or alcohol (Robinson & 
Berridge, 2008; Everitt et al., 2008). There is evidence that drugs which block the opioid 
neurotransmitters, such as naltrexone, can reduce the reinforcing or pleasurable properties 
of alcohol and so reduce relapse in alcohol dependent patients (Anton, 2008). 
2.7 IDENTIFICATION AND DIAGNOSIS 
People with alcohol use disorders commonly present to health, social and criminal justice 
agencies, often with problems associated with their alcohol use, but they less often seek 
help for the alcohol problem itself. Further, alcohol use disorders are seldom identified by 
health and social care professionals. One recent study found that UK GPs routinely 
identify only a small proportion of people with alcohol use disorders who present to 
primary care (less than 2% of hazardous or harmful drinkers; less than 5% of alcohol-
dependent drinkers) (Cheeta et al., 2008). This has important implications for the 
prevention and treatment of alcohol use disorders. Failure to identify alcohol-use 
disorders means that many people do not get access to alcohol interventions until the 
problems are more chronic and difficult to treat. Further, failure to address an underlying 
alcohol problem may undermine the effectiveness of treatment for the presenting health 
problem (for example, depression or high blood pressure). 
 
Screening and brief intervention delivered by a non-specialist practitioner is a cost 
effective approach for hazardous and harmful drinkers (NICE, 2010a). However, for 
people who are alcohol dependent, brief interventions are less effective and referral to a 
specialist service is likely to be necessary (Moyer et al., 2001). It is important, therefore, 
that health and social care professionals are able to identify and appropriately refer 
harmful drinkers who do not respond to brief interventions, and those who are alcohol 
dependent, to appropriate specialist services. In acute hospitals, psychiatry liaison teams 
or specialist addiction liaison psychiatry staff can provide a useful in-reach service 
including the provision of staff training in alcohol identification and brief interventions, 
advice on management of alcohol withdrawal, and referral to specialist alcohol services in 
the community (Moriarty et al., 2010). Addiction psychiatrists also have an important role 
in liaison with general psychiatrists in the optimal management of people with alcohol 
and mental health comorbidity (Boland et al., 2008). 
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Around one third of people presenting to specialist alcohol services in England are self-
referred and approximately one third are referred by non-specialist health or social care 
professionals (Drummond et al., 2005). The majority of the remainder are referred by other 
specialist addiction services or criminal justice services. At the point of entry to treatment, 
it is essential that patients are appropriately diagnosed and assessed in order to decide on 
the most appropriate treatment and management, assess the level of risk, such as self-
harm and risk to others, and identify co-occurring problems that may need particular 
attention, for example psychiatric comorbidity, physical illness, problems with housing, 
vulnerability and pregnancy (National Treatment Agency for Substance Misuse, 2006). 
Therefore assessment should not be narrowly focused on alcohol consumption, but should 
include all areas of physical, psychological and social functioning. 
 
Because alcohol dependence is associated with a higher level of problems and a more 
chronic course, and requires a higher level of medical and psychiatric intervention, it is 
essential that practitioners in specialist alcohol services are able to appropriately diagnose 
and assess alcohol dependence. 
2.8 THE ROLE OF TREATMENT AND MANAGEMENT 
As noted above, many people will recover from alcohol use disorders without specialist 
treatment and many will reduce their alcohol intake following a change in circumstances, 
such as parenthood, marriage or taking on a responsible job. Hazardous and harmful 
drinkers may respond to a brief intervention provided in primary care without requiring 
access to specialist treatment (NICE, 2010a). For others, their alcohol problems are 
overcome with the help of a mutual aid organisation, such as Alcoholics Anonymous (AA; 
see Section 2.10). Nevertheless, many will require access to specialist treatment by virtue 
of having more severe or chronic alcohol problems, or a higher level of complications of 
their drinking (for example, social isolation, psychiatric comorbidity and severe alcohol 
withdrawal). 
 
The primary role of specialist treatment is to assist the individual to reduce or stop 
drinking alcohol in a safe manner (National Treatment Agency for Substance Misuse, 
2006). At the initial stages of engagement with specialist services, service users may be 
ambivalent about changing their drinking behaviour or dealing with their problems. At 
this stage, work on enhancing the service user‘s motivation towards making changes and 
engagement with treatment will be particularly important. 
 
For most people who are alcohol dependent the most appropriate goal in terms of alcohol 
consumption should be to aim for complete abstinence. With an increasing level of alcohol 
dependence, a return to moderate or ‗controlled‘ drinking becomes increasingly difficult 
(Edwards & Gross, 1976; Schuckit, 2009). Further, for people with significant psychiatric or 
physical comorbidity (for example, depressive disorder or alcoholic liver disease), 
abstinence is the appropriate goal. However, hazardous and harmful drinkers and those 
with a low level of alcohol dependence may be able to achieve a goal of moderate alcohol 
consumption (Raistrick et al., 2006). Where a client has a goal of moderation but the 
clinician believes there are considerable risks in doing so, the clinician should provide 
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strong advice that abstinence is most appropriate, but should not deny the client treatment 
if the advice is unheeded (Raistrick et al., 2006). 
 
For people who are alcohol dependent, the next stage of treatment may require medically 
assisted alcohol withdrawal, if necessary with medication to control the symptoms and 
complications of withdrawal. For people with severe alcohol dependence and/or 
significant physical or psychiatric comorbidity, this may require assisted alcohol 
withdrawal in an inpatient or residential setting, such as a specialist NHS inpatient 
addiction treatment unit (Specialist Clinical Addiction Network, 2006). For the majority, 
however, alcohol withdrawal can be managed in the community either as part of shared 
care with the patient‘s GP or in an outpatient or home-based assisted alcohol withdrawal 
programme, with appropriate professional and family support (Raistrick et al., 2006). 
Treatment of alcohol withdrawal is, however, only the beginning of rehabilitation and, for 
many, a necessary precursor to a longer term treatment process. Withdrawal management 
should therefore not be seen as a stand-alone treatment. 
 
People who are alcohol dependent and who have recently stopped drinking are 
vulnerable to relapse, and often have many unresolved co-occurring problems which 
predispose to relapse (for example, psychiatric comorbidity and social problems) (Marlatt 
& Gordon, 1985). In this phase, the primary role of treatment is the prevention of relapse. 
This should include interventions aimed primarily at the drinking behaviour, including 
psychosocial and pharmacological interventions, and interventions aimed at dealing with 
co-occurring problems. Interventions aimed at preventing relapse include individual 
therapy (for example, motivational enhancement therapy [MET], cognitive behavioural 
therapy [CBT]), group and family based therapies, community-based and residential 
rehabilitation programmes, medications to attenuate drinking or promote abstinence (for 
example, naltrexone, acamprosate or disulfiram) and interventions promoting social 
support and integration (for example, social behavioural network therapy or 12-step 
facilitation) (Raistrick et al., 2006). 
 
Although psychiatric comorbidity is common in people seeking help for alcohol use 
disorders, this will usually resolve within a few weeks of abstinence from alcohol without 
formal psychiatric intervention (Petrakis et al., 2002). However, a proportion of people 
with psychiatric comorbidity, usually those in whom the mental disorder preceded 
alcohol dependence, will require psychosocial or pharmacological interventions 
specifically for the comorbidity. Self-harm and suicide are relatively common in people 
who are alcohol dependent (Sher, 2006). Therefore, treatment staff need to be trained to 
identify, monitor and, if necessary, treat or refer to an appropriate mental health specialist 
those patients with comorbidity which persists beyond the withdrawal period, and/or are 
at risk of self-harm or suicide. Patients with complex psychological issues related to 
trauma, sexual abuse or bereavement will require specific interventions delivered by 
appropriately trained personnel (Raistrick et al., 2006). 
 
Often, people who are alcohol dependent (particularly in the immediate post-withdrawal 
period) find it difficult to cope with typical life challenges such as managing their finances 
or dealing with relationships. They will therefore require additional support directed at 
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these areas of social functioning. Specific social problems such as homelessness, isolation, 
marital breakdown, child care issues including parenting problems, child abuse and 
neglect will require referral to, and liaison with, appropriate social care services (National 
Treatment Agency for Substance Misuse, 2006). A proportion of service users entering 
specialist treatment are involved with the criminal justice system and some may be 
entering treatment as a condition of a court order. Therefore, appropriate liaison with 
criminal justice services is essential for this group. 
 
People who are alcohol dependent are often unable to take care of their health during 
drinking periods and are at high risk of developing a wide range of health problems 
because of their drinking (Rehm et al., 2003). Treatment staff therefore need to be able to 
identify and assess physical health consequences of alcohol use, and refer patients to 
appropriate medical services. 
 
In the later stages of treatment, the focus will be more on reintegration into society and 
restoration of normal function, including establishing a healthy lifestyle, finding stable 
housing, re-entering employment, re-establishing contact with their families, and forming 
appropriate and fulfilling relationships (National Treatment Agency for Substance 
Misuse, 2006). All of these factors are important in promoting longer term stable recovery. 
2.9 CURRENT CARE IN THE NATIONAL HEALTH SERVICE 
A recent alcohol needs-assessment in England identified nearly 700 agencies providing 
specialist alcohol treatment, with an estimated workforce of 4,250 and an annual spend of 
between £186 million and £217 million (Drummond et al., 2005; National Audit Office, 
2008). The majority of agencies (70%) were community based and the remainder were 
residential, including inpatient units in the NHS, and residential rehabilitation 
programmes mainly provided by the non-statutory or private sector. Overall, 
approximately half of all alcohol services are provided by the non-statutory sector but are 
typically funded by the NHS or local authorities. Approximately one third of specialist 
alcohol services exclusively provide treatment for people with alcohol problems, but the 
majority (58%) provide services for both drug and alcohol misuse. 
 
In terms of services provided by community specialist agencies, the majority (63%) 
provide structured psychological interventions either on an individual basis or as part of a 
structured community programme (Drummond et al., 2005). There is considerable 
variation in the availability and access to specialist alcohol services both in community 
settings and in inpatient settings where provision of specialist psychiatric liaison services 
with responsibility for alcohol misuse is also very variable. Only 30% provide some form 
of assisted alcohol withdrawal programme, and few (less than 20%) provide medications 
for relapse prevention. Of the residential programmes, 45% provide inpatient medically-
assisted alcohol withdrawal and 60% provide residential rehabilitation with some overlap 
between the two treatment modalities. The rehabilitation programmes are typically of 3 to 
6 months duration and the alcohol withdrawal programmes are typically of 2 to 3 weeks 
duration. 
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It is estimated that approximately 63,000 people entered specialist treatment for alcohol 
use disorders in 2003–04 (Drummond et al., 2005). The recently established NATMS 
reported 104,000 people entering 1,464 agencies in 2008–09, of whom 70,000 were new 
presentations (National Treatment Agency, 2009a). However, it is not possible to identify 
what proportion of services is being provided by primary care under the enhanced care 
provision as opposed to specialist alcohol agencies. 
 
However, the 2004 ANARP found that only one out of 18 people who were alcohol 
dependent in the general population accessed treatment per annum. Access varied 
considerably from one in 12 in the North West to one in 102 in the North East of England 
(Drummond et al., 2005).  
 
Although not directly comparable because of different methodology, a low level of access 
to treatment is regarded as one in ten (Rush, 1990). A recent Scottish national alcohol 
needs-assessment using the same methods as ANARP found treatment access to be higher 
than in England, with one in 12 accessing treatment per annum. This level of access may 
have improved in England since 2004 based on the NATMS data. However, the National 
Audit Office (2008) reported that the spending on specialist alcohol services by Primary 
Care Trusts was not based on a clear understanding of the level of need in different parts 
of England. There is therefore some way to go in making alcohol treatment accessible 
throughout England. 
2.10  SERVICE USER ORGANISATIONS 
There are several organisations available in England to provide mutual aid for service 
users and their families. The largest and longest established such organisation is 
Alcoholics Anonymous. Founded in the US in the 1930s, AA is based on a ‘12-step‘ 
programme, and the ‗12 traditions‘ of AA. The programme includes acceptance that one is 
powerless over alcohol, acceptance of the role of a higher power and the role of the 
support of other members. AA is self-financing and the seventh tradition is that AA 
groups should decline outside contributions. In 2009, AA membership worldwide was 
reported as nearly 2 million (Alcoholics Anonymous, 2009). While AA might not suit all 
people who misuse alcohol, its advantages include its wide availability and open access.  
 
Allied to AA are Al-anon and Alateen, jointly known as Al-anon Family Groups. Al-anon 
uses the same 12 steps as AA with some modifications and is focused on meeting the 
needs of friends and family members of alcoholics. Again, meetings are widely available 
and provide helpful support beyond what can be provided by specialist treatment 
services. 
 
Another organisation developing England is Self-Management and Recovery Training 
(SMART). Its development is being supported by Alcohol Concern, a leading UK alcohol 
charity, and the Department of Health. SMART is another mutual aid organisation but is 
based more on cognitive behavioural principles and provides an alternative or adjunct to 
AA (see www.smartrecovery.org).  
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2.11  IMPACT ON FAMILIES 
The adverse effects of alcohol dependence on family members are considerable. Marriages 
where one or both partners have an alcohol problem are twice as likely to end in divorce 
as those in which alcohol is not a problem. Nearly a million children live with one or more 
parents who misuse alcohol and 6% of adults report having grown up in such a family. 
Alcohol is implicated in a high proportion of cases of child neglect and abuse, and heavy 
drinking was identified as a factor in 50% of child protection cases (Orford et al., 2005)  
 
Partners of people with harmful alcohol use and dependence experience higher rates of 
domestic violence than where alcohol misuse is not a feature. Some 70% of men who 
assault their partners do so under the influence of alcohol (Murphy et al, 2005). Family 
members of people who are alcohol dependent have high rates of psychiatric morbidity, 
and growing up with someone who misuses alcohol increases the likelihood of teenagers 
taking up alcohol early and developing alcohol problems themselves (Latendresse et al., 
2010). 
 
All of this points to the importance of addressing the needs of family members of people 
who misuse alcohol. This includes the need for specialist treatment services to assess the 
impact of the individual‘s drinking on family members, and the need to ensure the safety 
of children living with people who misuse alcohol. 
2.12  SPECIAL POPULATIONS  
There are several special populations which require separate consideration by virtue of 
having particular needs that are often not well met by mainstream services, or require 
particular considerations in commissioning or delivering care, or who require 
modification of general treatment guidelines. This section provides an overview of the 
issues for each special population. Specific guidance applying to special populations will 
be referred to in the appropriate section in subsequent chapters. 
2.12.1  Children and young people 
While drinking and alcohol use disorders are relatively rare under the age of 10 years, the 
prevalence increases steeply from the teens to peak in the early 20s. The UK has the 
highest rate of underage drinking in Western Europe (Hibell et al., 2009). This is of 
particular concern as alcohol presents particularly serious consequences in young people 
due to a higher level of vulnerability to the adverse effects of alcohol. Heavy drinking in 
adolescence can affect brain development and has a higher risk of organ damage in the 
developing body (Brown et al., 2008).  
 
The number of adolescents consuming alcohol has decreased to 54% between 1988 and 
2007, but the amount consumed by those drinking doubled over the same period to 12.7 
units per week (Fuller, 2008). Regular alcohol consumption in adolescence is associated 
with increased accidents, risky behaviour (including unprotected sex, antisocial behaviour 
and violence) and decreased family, social and educational functioning. There is evidence 
of an association between hazardous alcohol consumption in adolescence and increased 
level of alcohol dependence in early and later adulthood (Hingson et al., 2006). For 
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example, alcohol consumption before the age of 13 years is associated with a four-fold 
increased risk of alcohol dependence in adulthood. Adolescents with early signs of alcohol 
misuse who are not seeking treatment are a critical group to target interventions towards. 
Adolescent alcohol-related attendances at accident and emergency departments saw a 
tenfold increase in the UK since 1990 and a recent audit estimates 65,000 alcohol-related 
adolescent attendances occur annually.  
 
Comorbid psychiatric disorders are considered to be ‗the rule, not the exception‘ for 
young people with alcohol use disorders (Perepletchikova et al., 2008). Data from the US 
National Comorbidity study demonstrated that the majority of lifetime disorders in their 
sample were comorbid disorders (Kessler et al., 1996). This common occurrence of alcohol 
use disorders and other substance use disorders along with other psychiatric disorders 
notes the importance of a comprehensive assessment and management of all disorders. 
Disruptive behaviour disorders are the most common comorbid psychiatric disorders 
among young people with substance-use disorder. Those with conduct disorder and 
substance-use disorder are more difficult to treat, have a higher treatment dropout rate 
and have a worse prognosis. This strong association between conduct disorder and 
substance-use disorder is considered to be reciprocal, with each exacerbating the 
expression of the other. Conduct disorder usually precedes or coincides with the onset of 
substance-use disorder, with conduct disorder severity found to predict substance-use 
severity. Significantly higher rates of ADHD have been reported in young people with 
substance-use disorders; data from untreated adults with ADHD indicate a higher risk of 
developing substance-use disorders and at an earlier age compared with treated controls 
as well as a more prolonged course of substance-use disorders. However, those young 
people with ADHD and co-occurring conduct disorder or bipolar disorders are at highest 
risk of development of substance-use disorders.  
 
High rates of depression and anxiety have been reported in adolescents with alcohol use 
disorders, with increased rates of suicidality. Among clinical populations for alcohol use 
disorders there was an increased rate of anxiety symptoms and disorder, PTSD and social 
phobias (Clark et al., 1997a; Clark et al., 1997b). For young people the presentation may be 
different because dependence is not common, with binge drinking being the pattern seen 
more often, frequently alongside polydrug use. Criminality and offending behaviour are 
often closely related to alcohol misuse in children and adolescents. Liaison with criminal 
justice services is necessary to ensure that appropriate co-ordination of care and effective 
communication and information-sharing protocols are in place. 
 
In addition to the problems presented by comorbid disorders, the concept of dependence 
and criteria for diagnosis (DSM–IV or ICD–10) has limitations when applied to 
adolescents because of the low prevalence of withdrawal symptoms and the low 
specificity of tolerance in this age group (Chung et al., 2001). The adolescent therefore may 
continue drinking despite problems, which manifest as difficulties with school attendance, 
co-morbid behavioural difficulties, peer affiliation and arguments at home. 
  
As has been noted previously, relationships with parents, carers and the children in their 
care are often damaged by alcohol misuse (Copello et al., 2005). The prevalence of alcohol 
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use disorders in the victims and perpetrators of domestic violence provides an important 
rationale for the exploration of these issues. Sexual abuse has been found to be prevalent 
in alcohol dependent drinkers seeking treatment and may be a particular concern with 
young people with alcohol misuse problems (Moncrieff et al., 1996). For young people, 
both their own alcohol misuse and that of their parents or carers may be a safeguarding 
concern. The Children Act 2004 places a statutory duty on services providing assessments 
to make arrangements to ensure that their functions are discharged with regard to the 
need to safeguard and promote the welfare of children. Services that are involved with 
those who misuse alcohol fit into a wider context of safeguarding young people from 
harm and need to work to ensure that the rights of children, young people and their 
parents are respected. Local protocols between alcohol treatment services and local 
safeguarding and family services determine the specific actions to be taken (HM 
Government, 2006; Department for Children, Schools and Families, Department of Health 
and National Treatment Agency for Substance Misuse [Department for Children, Schools 
and Families, National Treatment Agency & Department of Health, 2009]).  
2.12.2  Current service provision for children and young people  
In the UK, most treatment is community based and provided as part of a range of services 
and models. These can be services provided by child and adolescent mental health 
services (CAMHS) in Tier 2 and Tier 3 services, specific CAMHS addiction services and 
other commissioned specialist services that are formed by a range of practitioners 
(generally Tier 2 and Tier 3 collaborating from the youth offending teams, the looked after 
teams and voluntary sector). Much of the focus is on engagement, health promotion and 
retention in services. In addition, in the UK, services that offer treatment tend to prioritise 
drug misuse such as opiate or cannabis misuse and not alcohol. Given the comorbidity 
noted above, many adolescents having alcohol treatment are often seen in specialist 
services, such as Youth Offending Teams, or specialist services for young people with 
conduct disorders, such as the newly-developed multisystemic therapy teams 
(Department of Health, 2007), although identification and treatment of their dependence 
and/or harmful use may not be fully explored. In the US, adolescents with substance-use 
disorders receive treatment in a variety of settings including community, residential and 
criminal justice settings, and home-based treatment. However, there is little research 
evaluating the differences between these settings. As a consequence, there is little clear 
evidence to determine the most appropriate treatment environments. The American 
Academy of Child and Adolescent Psychiatry (2001) recommend that factors affecting the 
choice of setting should include: the need to provide a safe environment; motivation of the 
adolescent and his/her family to cooperate with treatment; the need for structure and 
limit-setting; the presence of additional medical or psychiatric conditions and the 
associated risks; the availability of specific types of treatment settings for adolescents; 
preferences for treatment in a particular setting; and past treatment failure in a less 
restrictive/intensive setting.  
2.12.3  Older people 
The prevalence of alcohol use disorders declines with increasing age, but the rate of 
detection by health professionals may be underestimated in older people because of a lack 
of clinical suspicion or misdiagnosis (O‘Connell et al., 2003). Nevertheless, the proportion 
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of older people drinking above the government‘s recommended levels has recently been 
increasing in the UK. The proportion of men aged 65 to 74 years who drank more than 
four units per day in the past week increased from 18 to 30% between 1998 and 2008 
(Fuller et al., 2009). In women of the same age, the increase in drinking more than three 
units per day was from 6 to 14%. Also, as noted earlier, alcohol related admissions to 
hospital increase steeply with age although the prevalence of heavy drinking is lower in 
this group. This may partly reflect the cumulative effects of lifetime alcohol consumption 
as well as the general increasing risk of hospital admission with advancing age. 
 
Further it is important to note that due to age-related changes in metabolism, intercurrent 
ill health, changing life circumstances and interactions with medications, sensible drinking 
guidelines for younger adults may not be applicable to older people (Reid & Anderson, 
1997). Equivalent levels of alcohol consumption will give rise to a higher blood alcohol 
concentration in older people compared with younger people (Reid & Anderson, 1997). 
The US National Institute of Alcohol Abuse and Alcoholism (NIAAA) has therefore 
recommended people over the age of 65 years should drink no more than one drink (1.5 
UK units) per day and no more than seven drinks (10.5 UK units) per week. There are no 
similar recommendations for older people in the UK. A related issue is that standard 
alcohol screening tools such as the AUDIT may require a lower threshold to be applied in 
older people (O‘Connell et al., 2003).  
 
Older people are at least as likely as younger people to benefit from alcohol treatment 
(Curtis et al., 1989). Clinicians therefore need to be vigilant to identify and treat older 
people who misuse alcohol. As older people are more likely to have comorbid physical 
and mental health problems and be socially isolated, a lower threshold for admission for 
assisted alcohol withdrawal may be required (Dar, 2006). Further, in view of changes in 
metabolism, potential drug interactions and physical comorbidity, dosages for 
medications to treat alcohol withdrawal and prevent relapse may need to be reduced in 
older people (Dar, 2006). These issues are dealt with in more detail in the relevant 
chapters, 
2.12.4  Homeless people 
There is a high prevalence of alcohol misuse (as well as mental and physical health, and 
social problems) amongst people who are homeless. The prevalence of alcohol use 
disorders in this population has been reported to be between 38 and 50% in the UK 
(Harrison & Luck, 1997; Gill et al., 1996). In the US, studies of this population typically 
report prevalence rates of 20 to 45%, depending on sampling methods and definitions 
(Institute of Medicine, 1988).  
 
Homeless people who misuse alcohol have particular difficulties in engaging mainstream 
alcohol services, often due to difficulties in attending planned appointments. 
 
Homelessness is associated with a poorer clinical outcome, although this may also be due 
to the higher levels of comorbidity and social isolation in this population rather than the 
homelessness per se. Hence services need to be tailored to maximise engagement with this 
population. 
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This has led to the development of specific alcohol services for homeless drinkers, 
including assertive outreach and ‗wet‘ hostels. In wet hostels, residents are able to 
continue drinking, but do so in an environment that aims to minimise the harm associated 
with drinking and address other issues including homelessness (Institute of Medicine, 
1988; Harrison & Luck, 1997). Such hostels tend to be located in urban centres where there 
is a higher concentration of homeless drinkers. Assertive outreach and ‗crisis‘ centres have 
been developed to attract homeless people who misuse alcohol into treatment (Freimanis, 
1993). Further a lower threshold for admission for assisted alcohol withdrawal and 
residential rehabilitation will often be required with this population. 
2.12.5  People from ethnic minority groups 
It is often asserted that people from ethnic minority groups are under-represented in 
specialist alcohol treatment services (Harrison & Luck, 1997). The reality is that the 
situation is likely to be more complex and depends on which specific ethnic group and the 
prevalence of alcohol misuse in that group (Drummond, 2009). Based on the Psychiatric 
Morbidity Survey, the ANARP study found that people from ethnic minority groups as a 
whole had a lower prevalence of hazardous and harmful drinking compared with the 
white population (ratio of 1:1.7) whereas alcohol dependence was approximately equal in 
prevalence (ratio of 1:1.1) (Drummond et al., 2005). However this study was unable to 
compare different ethnic minority groups. Nevertheless, because people from ethnic 
minority groups have approximately the same prevalence of alcohol dependence as the 
white population, if access to treatment is equal, one would expect the population in 
treatment to have approximately the same proportion of people for ethnic minorities. The 
ethnic minority population in England is 13% from the 2001 census. The NATMS found 
that in 2008–09 the proportion from ethnic minorities is 9%, suggesting some under-
representation (National Treatment Agency and Department of Health, 2010). However, it 
is not clear what proportion of NATMS attenders were hazardous/harmful or dependent 
drinkers, which may account for the difference in proportions. 
 
Marmot and colleagues (1984) found that cirrhosis mortality rates are higher than the 
national average for men from the Asian subcontinent and Ireland, but lower than average 
for men of African–Caribbean origin. Cirrhosis mortality was lower in Asian and African–
Caribbean women but higher in Irish women. However, because there were few total 
deaths in ethnic minority groups this may lead to large errors in estimating prevalence in 
this population. Studies in England have tended to find over-representation of Indian, 
Scottish and Irish born people and under-representation in those of African–Caribbean or 
Pakistani origin (Harrison & Luck, 1997). This may partly be due to differences in 
prevalence rates of alcohol misuse. But differences in culturally-related beliefs and help-
seeking as well as availability of interpreters or treatment personnel from appropriate 
ethnic minority groups may also account for some of these differences (Drummond, 2009). 
There are relatively few specific specialist alcohol services for people from ethnic minority 
groups, although some examples of good practice exist (Harrison & Luck, 1997). 
2.12.6  Women 
Thom and Green (1996) identified three main factors that may account for a historical 
under-representation of women in specialist alcohol services. Women tend to perceive 
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their problems differently from men, with a greater tendency not to identify themselves as 
‗alcoholic‘. They are more likely to experience stigma in relation to their drinking than 
men and have concerns about their children being taken into care. Also, women regard 
the services as less suited to their needs than men do. Few services tend to provide 
childcare facilities or women only services. Nevertheless, more women are now accessing 
treatment. The ANARP study found that, taking account of the lower prevalence of 
alcohol dependence in women compared with men (ratio of 1:3), they were nevertheless 
1.6 times more likely to access treatment (Drummond et al., 2005). Women are also more 
likely to seek help for alcohol misuse than men in the US (Schuckit, 2009). This may 
indicate that some of the barriers identified by Thom and Green may have been overcome. 
However, services need to be sensitive to the particular needs of women. There is also a 
need to develop services for pregnant women. This is the subject of a separate NICE 
guideline on complex pregnancies (NICE, 2010c). 
2.13  ECONOMIC IMPACT 
The alcohol misuse and the problems related to present a considerable cost to society. 
Estimates of the economic costs attempt to assess in monetary terms the damage that 
results from the misuse of alcohol. These costs include expenditures on alcohol-related 
problems and opportunities that are lost because of alcohol (NIAAA, 1991). 
 
Many challenges exist in estimating the costs required for cost-of-illness studies in health, 
there are two such challenges that are particularly relevant to the case of alcohol misuse. 
First, researchers attempt to identify costs that are caused by, and not merely associated 
with, alcohol misuse, yet it is often hard to establish causation (Cook, 1990; NIAAA, 1991). 
Second, many costs resulting from alcohol misuse cannot be measured directly. This is 
especially true of costs that involve placing a value on lost productivity. Researchers use 
mathematical and statistical methods to estimate such costs, yet recognise that this is 
imprecise. Moreover, costs of pain and suffering of both people who misuse alcohol and 
people affected by them cannot be estimated in a reliable way, and are therefore not 
considered in most cost studies. These challenges highlight the fact that although the 
economic cost of alcohol misuse can be estimated, it cannot be measured precisely. 
Nevertheless, estimates of the cost give us an idea of the dimensions of the problem and 
the breakdown of costs suggests to us which categories are most costly (NIAAA, 1991). 
 
The first category of costs is that of treating the medical consequences of alcohol misuse 
and treating alcohol misuse. The second category of health-related costs includes losses in 
productivity by workers who misuse alcohol. The third category of health-related costs is 
the loss to society because of premature deaths due to alcohol misuse. In addition to the 
health-related costs of alcohol misuse are costs involving the criminal justice system, social 
care, property losses from alcohol-related motor vehicle crashes and fires, and lost 
productivity of the victims of alcohol-related crime and individuals imprisoned as a 
consequence of alcohol-related crime (NIAAA, 1991). 
 
The UK Cabinet Office recently estimated that the cost of alcohol to society was £25.1 
billion per annum (Department of Health, 2007). A recent report by the Department of 
Health estimated an annual cost of £2.7 billion attributable to alcohol harm to the NHS in 
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England (Department of Health, 2008a). Hospital inpatient and day visits accounted for 
44% of these total costs, whilst accident & emergency visits and ambulance services 
accounted for 38%. However, Crime and disorder costs amount to £7.3 billion per annum, 
including costs for policing, drink driving, courts and the criminal justice system, and 
costs to services both in anticipation, and in dealing with the consequences, of alcohol 
related crime (Prime Minister‘s Strategy Unit, 2003). The estimated costs in the workplace 
amount to some £6.4 billion through lost productivity, absenteeism, alcohol-related 
sickness and premature deaths (Prime Minister‘s Strategy Unit, 2003). 
 
For the European Union, US and Canada social costs of alcohol were estimated to be 
around €270 billion (2003 prices) (Anderson and Baumberg, 2005), US$185 billion (1998 
prices) (WHO, 2004), and CA$14.6 billion (2002 prices) (Rehm et al., 2006a), respectively. 
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3 METHODS USED TO DEVELOP THIS 
GUIDELINE 
3.1 OVERVIEW 
The development of this guideline drew upon methods outlined by NICE (further 
information is available in The Guidelines Manual [NICE, 2009a]). A team of health 
professionals, lay representatives and technical experts known as the Guideline 
Development Group (GDG), with support from the NCCMH staff, undertook the 
development of a patient-centred, evidence-based guideline. There are six basic steps in 
the process of developing a guideline: 
 
 Define the scope, which sets the parameters of the guideline and provides a focus 
and steer for the development work. 
 Define review questions considered important for practitioners and service users 
 Develop criteria for evidence searching and search for evidence. 
 Design validated protocols for systematic review and apply to evidence recovered 
by search. 
 Synthesise and (meta-) analyse data retrieved, guided by the review questions, and 
produce GRADE evidence profiles and summaries. 
 Answer review questions with evidence-based recommendations for clinical 
practice. 
 
The clinical practice recommendations made by the GDG are therefore derived from the 
most up-to-date and robust evidence base for the clinical and cost effectiveness of the 
treatments and services used in the treatment and management of alcohol dependence 
and harmful alcohol use. In addition, to ensure a service user and carer focus, the concerns 
of service users and carers regarding health and social care have been highlighted and 
addressed by recommendations agreed by the whole GDG. 
3.2 THE SCOPE 
Guideline topics are selected by the Department of Health and the Welsh Assembly 
Government, which identify the main areas to be covered by the guideline in a specific 
remit (see The Guidelines Manual [NICE, 2009a] for further information). The NCCMH 
developed a scope for the guideline based on the remit. The purpose of the scope is to: 
 
 provide an overview of what the guideline will include and exclude 
 identify the key aspects of care that must be included 
 set the boundaries of the development work and provide a clear framework to 
enable work to stay within the priorities agreed by NICE and the National 
Collaborating Centre, and the remit from the Department of Health/Welsh 
Assembly Government 
 inform the development of the review questions and search strategy 
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 inform professionals and the public about expected content of the guideline  
 keep the guideline to a reasonable size to ensure that its development can be 
carried out within the allocated period. 
 
An initial draft of the scope was sent to registered stakeholders who had agreed to attend 
a scoping workshop. The workshop was used to: 
 
 obtain feedback on the selected key clinical issues 
 identify which patient or population subgroups should be specified (if any) 
 seek views on the composition of the GDG 
 encourage applications for GDG membership. 
 
The draft scope was subject to consultation with registered stakeholders over a 4-week 
period. During the consultation period, the scope was posted on the NICE website 
(www.nice.org.uk). Comments were invited from stakeholder organisations and the 
Guideline Review Panel (GRP). Further information about the GRP can also be found on 
the NICE website. The NCCMH and NICE reviewed the scope in light of comments 
received, and the revised scope was signed off by the GRP. 
3.3 THE GUIDELINE DEVELOPMENT GROUP 
The GDG consisted of: professionals in psychiatry, clinical psychology, nursing, social 
work, and general practice; academic experts in psychiatry and psychology; and service 
user, lay member and carer representatives. The guideline development process was 
supported by staff from the NCCMH, who undertook the clinical and health economics 
literature searches, reviewed and presented the evidence to the GDG, managed the 
process and contributed to drafting the guideline. 
3.3.1 Guideline Development Group meetings 
Twelve GDG meetings were held between March 2009 and September 2010. During each 
day-long GDG meeting, in a plenary session, review questions and clinical and economic 
evidence were reviewed and assessed, and recommendations formulated. At each 
meeting, all GDG members declared any potential conflicts of interest, and service user 
and carer concerns were routinely discussed as part of a standing agenda. 
3.3.2 Topic groups 
The GDG divided its workload along clinically relevant lines to simplify the guideline 
development process, and GDG members formed smaller topic groups to undertake 
guideline work in that area of clinical practice. Topic group membership was decided after 
a discussion between all GDG members, and each topic group was chaired by a GDG 
member with expert knowledge of the topic area (one of the healthcare professionals). 
Topic Group 1 covered questions relating to pharmacological intervention. Topic Group 2 
covered psychological and psychosocial interventions. Topic Group 3 covered assessment 
of alcohol misuse, Topic Group 4 covered service user and carer experiences of care, and 
Topic Group 5 covered delivery settings for treatment.  These groups were designed to 
efficiently manage the large volume of evidence appraisal prior to presenting it to the 
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GDG as a whole. Topic groups refined the review questions and the clinical definitions of 
treatment interventions, reviewed and prepared the evidence with the systematic 
reviewer before presenting it to the GDG as a whole, and helped the GDG to identify 
further expertise in the topic. Topic group leaders reported the status of the group‘s work 
as part of the standing agenda. They also introduced and led the GDG discussion of the 
evidence review for that topic and assisted the GDG Chair in drafting the section of the 
guideline relevant to the work of each topic group. All statements and recommendations 
in this guideline have been agreed by the whole GDG. 
3.3.3 Service users and carers 
Individuals with direct experience of services gave an integral service-user focus to the 
GDG and the guideline. The GDG included service user, carer and lay representatives 
who contributed as full GDG members to writing the review questions, helping to ensure 
that the evidence addressed their views and preferences, highlighting sensitive issues and 
terminology relevant to the guideline, and bringing service-user research to the attention 
of the GDG. In drafting the guideline, they contributed to writing Chapter 4 and identified 
recommendations from the service user and carer perspective. 
3.3.4 Special advisors 
Special advisors, who had specific expertise in one or more aspects of treatment and 
management relevant to the guideline, assisted the GDG, commenting on specific aspects 
of the developing guideline and making presentations to the GDG. Appendix 3 lists those 
who agreed to act as special advisors. 
3.3.5 National and international experts 
National and international experts in the area under review were identified through the 
literature search and through the experience of the GDG members. These experts were 
contacted to recommend unpublished or soon-to-be published studies to ensure that up-
to-date evidence was included in the development of the guideline. They informed the 
group about completed trials at the pre-publication stage, systematic reviews in the 
process of being published, studies relating to the cost effectiveness of treatment, and trial 
data if the GDG could be provided with full access to the complete trial report. Appendix 
6 lists researchers who were contacted. 
3.3.6 Integration of other guidelines on alcohol-use disorders 
In addition to this guideline, there are two other pieces of NICE guidance addressing 
alcohol-use disorders outlined in Chapter 1. During development, steering group 
meetings have been held in which representatives from the three development groups 
meet to discuss any issues, such as overlapping areas of review work and integration of 
the guidelines.  
3.4 CLINICAL QUESTIONS 
Review (clinical) questions were used to guide the identification and interrogation of the 
evidence base relevant to the topic of the guideline. The draft review questions were 
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discussed by the GDG at the first few meetings and amended as necessary. Where 
appropriate, the questions were refined once the evidence had been searched and, where 
necessary, subquestions were generated. Questions submitted by stakeholders were also 
discussed by the GDG and the rationale for not including any questions was recorded in 
the minutes. The final list of review questions can be found in Appendix 7. 
 
For questions about interventions, the PICO (Patient, Intervention, Comparison and 
Outcome) framework was used (see  
Table 2). 
 
Table 2: Features of a well-formulated question on effectiveness intervention – the 
PICO guide 
Patients/population  Which patients or population of patients are we interested in? How 
can they be best described? Are there subgroups that need to be 
considered? 
Intervention Which intervention, treatment or approach should be used? 
Comparison What is/are the main alternative/s to compare with the 
intervention? 
Outcome What is really important for the patient? Which outcomes should be 
considered: intermediate or short-term measures; mortality; 
morbidity and treatment complications; rates of relapse; late 
morbidity and readmission; return to work, physical and social 
functioning and other measures such as quality of life; general 
health status? 
 
Questions relating to assessment and diagnosis do not involve an intervention designed to 
treat a particular condition, therefore the PICO framework was not used. Rather, the 
questions were designed to identify key issues specifically relevant to diagnostic tests, for 
example, their accuracy, reliability and safety.  
 
In some situations, the prognosis of a particular condition is of fundamental importance, 
over and above its general significance in relation to specific interventions. Areas where 
this is particularly likely to occur relate to assessment of risk, for example in terms of 
behaviour modification or screening and early intervention. In addition, review questions 
related to issues of service delivery are occasionally specified in the remit from the 
Department of Health/Welsh Assembly Government. In these cases, appropriate review 
questions were developed to be clear and concise. 
 
To help facilitate the literature review, a note was made of the best study design type to 
answer each question. There are four main types of review question of relevance to NICE 
guidelines. These are listed in Table 3. For each type of question the best primary study 
design varies, where ‗best‘ is interpreted as ‗least likely to give misleading answers to the 
question‘.  
 
However, in all cases, a well-conducted systematic review (of the appropriate type of 
study) is likely to always yield a better answer than a single study. 
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Deciding on the best design type to answer a specific review question does not mean that 
studies of different design types addressing the same question were discarded. 
 
Table 3: Best study design to answer each type of question 
Type of question Best primary study design 
Effectiveness or other impact of an 
intervention  
Randomised controlled trial (RCT); other studies 
that may be considered in the absence of RCTs are 
the following: internally/externally controlled 
before and after trial, interrupted time-series 
Accuracy of information (for 
example, risk factor, test, prediction 
rule) 
Comparing the information against a valid gold 
standard in a randomised trial or inception cohort 
study 
Rates (of disease, patient experience, 
rare side effects) 
Prospective cohort, registry, cross-sectional study 
 
The GDG classified each review question into one of three groups: (1) questions 
concerning good practice; (2) questions likely to have little or no directly relevant 
evidence; and (3) questions likely to have a good evidence base. Questions concerning 
good practice were answered by the GDG using informal consensus. For questions that 
were unlikely to have a good evidence base, a brief descriptive review was initially 
undertaken and then the GDG used informal consensus to reach a decision (see Section 
3.5.7). For questions with a good evidence base, the review process followed the methods 
outlined in Section 3.5.1. 
3.5 CLINICAL EVIDENCE METHODS 
The aim of the clinical evidence review was to systematically identify and synthesise 
relevant evidence from the literature to answer the specific review questions developed by 
the GDG. Thus, clinical practice recommendations are evidence-based where possible and, 
if evidence is not available, informal consensus methods are used (see Section 3.5.7) and 
the need for future research is specified. 
3.5.1 The search process 
Scoping searches 
A broad preliminary search of the literature was undertaken in September 2008 to obtain 
an overview of the issues likely to be covered by the scope and to help define key areas. 
Searches were restricted to clinical guidelines, health technology assessment (HTA) 
reports, key systematic reviews and RCTs, and conducted in the following databases and 
websites:  
 
 British Medical Journal Clinical Evidence 
 Canadian Medical Association (CMA) Infobase (Canadian guidelines) 
 Clinical Policy and Practice Program of the New South Wales Department of 
Health (Australia) 
 Clinical Practice Guidelines (Australian Guidelines) 
 Cochrane Central Register of Controlled Trials (CENTRAL) 
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 Cochrane Database of Abstracts of Reviews of Effects (DARE)  
 Cochrane Database of Systematic Reviews (CDSR) 
 Excerpta Medica Database (EMBASE) 
 Guidelines International Network (G-I-N) 
 Health Evidence Bulletin Wales 
 Health Management Information Consortium (HMIC) 
 HTA database (technology assessments) 
 Medical Literature Analysis and Retrieval System Online (MEDLINE)/MEDLINE 
in Process  
 National Health and Medical Research Council (NHMRC)  
 National Library for Health (NLH) Guidelines Finder 
 New Zealand Guidelines Group  
 NHS Centre for Reviews and Dissemination (CRD) 
 OmniMedicalSearch 
 Scottish Intercollegiate Guidelines Network (SIGN)  
 Turning Research Into Practice (TRIP) 
 United States Agency for Healthcare Research and Quality (AHRQ) 
 Websites of NICE and the National Institute for Health Research (NIHR) HTA 
Programme for guidelines and HTAs in development.  
 
Existing NICE guidelines were updated where necessary. Other relevant guidelines were 
assessed for quality using the AGREE instrument (AGREE Collaboration, 2003). The 
evidence base underlying high-quality existing guidelines was utilised and updated as 
appropriate. Further information about this process can be found in The Guidelines Manual 
(NICE, 2009a). 
Systematic literature searches 
After the scope was finalised, a systematic search strategy was developed to locate all of 
the relevant evidence. The balance between sensitivity (the power to identify all studies on 
a particular topic) and specificity (the ability to exclude irrelevant studies from the results) 
was carefully considered, and a decision made to utilise a broad approach to searching, to 
maximise the retrieval of evidence to all parts of the guideline. Searches were restricted to: 
systematic reviews, meta-analyses, RCTs, observational studies, quasi-experimental 
studies and qualitative research. Searches were conducted in the following databases:  
 
 AMED  
 CINAHL  
 EMBASE 
 MEDLINE/MEDLINE In-Process 
 Psychological Information Database (PsycINFO)  
 Cochrane Database of Abstracts of Reviews of Effects (DARE)  
 Cochrane Database of Systematic Reviews (CDSR) 
 Cochrane Central Register of Controlled Trials (CENTRAL) 
 HTA database  
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For standard mainstream bibliographic databases (AMED, CINAHL, EMBASE, MEDLINE 
and PsycINFO), search terms for alcohol dependence and harmful alcohol use were 
combined with study design filters for systematic reviews, RCTs and qualitative research. 
For searches generated in databases with collections of study designs at their focus 
(DARE, CDSR, CENTRAL and HTA), search terms for alcohol dependence and harmful 
alcohol use were used without a filter. The sensitivity of this approach was aimed at 
minimising the risk of overlooking relevant publications, due to inaccurate or incomplete 
indexing of records, as well as potential weaknesses resulting from more focused search 
strategies (for example, for interventions).  
 
For focused searches, terms for case management and assertive community treatment 
(ACT) were combined with terms for alcohol dependence and harmful alcohol use, and 
filters for observational and quasi-experimental studies.  
Reference Manager 
Citations from each search were downloaded into Reference Manager (a software product 
for managing references and formatting bibliographies) and duplicates removed. Records 
were then screened against the inclusion criteria of the reviews before being quality 
appraised (see Section 3.5.2). To keep the process both replicable and transparent, the 
unfiltered search results were saved and retained for future potential re-analysis.  
Search filters 
The search filters for systematic reviews and RCTs are adaptations of filters designed by 
the Centre for Reviews and Dissemination (CRD) and the Health Information Research 
Unit of McMaster University, Ontario. The qualitative, observational and quasi-
experimental filters were developed in-house. Each filter comprises index terms relating to 
the study type(s) and associated textwords for the methodological description of the 
design(s).  
Date and language restrictions 
Date restrictions were not applied, except for searches of systematic reviews which were 
limited to research published from 1993 onwards. Systematic database searches were 
initially conducted in June 2008 up to the most recent searchable date. Search updates 
were generated on a 6-monthly basis, with the final re-runs carried out in March 2010 
ahead of the guideline consultation. After this point, studies were only included if they 
were judged by the GDG to be exceptional (for example, if the evidence was likely to 
change a recommendation).  
 
Post-guideline searching: following the draft guideline consultation, searches for 
observational and quasi-experimental studies were conducted for case management and 
ACT.  
 
Although no language restrictions were applied at the searching stage, foreign language 
papers were not requested or reviewed unless they were of particular importance to a 
review question.  
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Other search methods 
Other search methods involved: (1) scanning the reference lists of all eligible publications 
(systematic reviews, stakeholder evidence and included studies) for more published 
reports and citations of unpublished research; (2) sending lists of studies meeting the 
inclusion criteria to subject experts (identified through searches and the GDG) and asking 
them to check the lists for completeness, and to provide information of any published or 
unpublished research for consideration (see Appendix 3); (3) checking the tables of 
contents of key journals for studies that might have been missed by the database and 
reference list searches; (4) tracking key papers in the Science Citation Index (prospectively) 
over time for further useful references.  
 
Full details of the search strategies and filters used for the systematic review of clinical 
evidence are provided in Appendix 9.  
Study selection and quality assessment  
All primary-level studies included after the first scan of citations were acquired in full and 
re-evaluated for eligibility at the time when they were being entered into the study 
information database. More specific eligibility criteria were developed for each review 
question and are described in the relevant clinical evidence chapters. Eligible systematic 
reviews and primary-level studies were critically appraised for methodological quality 
(see Appendix 11 for methodology checklists). The eligibility of each study was confirmed 
by at least one member of the appropriate topic group. 
 
For some review questions, it was necessary to prioritise the evidence with respect to the 
UK context (that is, external validity). To make this process explicit, the topic groups took 
into account the following factors when assessing the evidence: 
 
 participant factors (for example, gender, age and ethnicity) 
 provider factors (for example, model fidelity, the conditions under which the 
intervention was performed and the availability of experienced staff to undertake 
the procedure) 
 cultural factors (for example, differences in standard care and differences in the 
welfare system). 
 
It was the responsibility of each topic group to decide which prioritisation factors were 
relevant to each review question in light of the UK context. Any issues and discussions 
within topic groups were brought back to the wider GDG for further consideration.  
Unpublished evidence 
The GDG used a number of criteria when deciding whether or not to accept unpublished 
data. First, the evidence must have been accompanied by a trial report containing 
sufficient detail to properly assess the quality of the data. Second, the evidence must have 
been submitted with the understanding that data from the study and a summary of the 
study‘s characteristics would be published in the full guideline. Therefore, the GDG did 
not accept evidence submitted as commercial in confidence. However, the GDG 
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recognised that unpublished evidence submitted by investigators might later be retracted 
by those investigators if the inclusion of such data would jeopardise publication of their 
research. 
3.5.2  Data extraction 
Study characteristics and outcome data were extracted from all eligible studies that met 
the minimum quality criteria using a Word-based form (see Appendix 11). 
 
In most circumstances, for a given outcome (continuous and dichotomous), where more 
than 50% of the number randomised to any group were lost to follow-up, the data were 
excluded from the analysis (except for the outcome ‗leaving the study early‘, in which 
case, the denominator was the number randomised). Where possible, dichotomous 
efficacy outcomes were calculated on an intention-to-treat basis (that is, a ‘once-
randomised-always-analyse‘ basis). Where there was good evidence that those 
participants who ceased to engage in the study were likely to have an unfavourable 
outcome, early withdrawals were included in both the numerator and denominator. 
Adverse effects were entered into Review Manager, as reported by the study authors, 
because it is usually not possible to determine whether early withdrawals had an 
unfavourable outcome. Where there was limited data for a particular review, the 50% rule 
was not applied. In these circumstances, the evidence was downgraded due to the risk of 
bias. 
 
Where some of the studies failed to report standard deviations (for a continuous outcome) 
and where an estimate of the variance could not be computed from other reported data or 
obtained from the study author, the following approach was taken.5 
 
When the number of studies with missing standard deviations was less than one third and 
when the total number of studies was at least ten, the pooled standard deviation was 
imputed (calculated from all the other studies in the same meta-analysis that used the 
same version of the outcome measure). In this case, the appropriateness of the imputation 
was made by comparing the standardised mean differences (SMDs) of those trials that had 
reported standard deviations against the hypothetical SMDs of the same trials based on 
the imputed standard deviations. If they converged, the meta-analytical results were 
considered to be reliable. 
 
When the conditions above could not be met, standard deviations were taken from 
another related systematic review (if available). In this case, the results were considered to 
be less reliable. 
 
The meta-analysis of survival data, such as time to any drinking episode, was based on log 
hazard ratios and standard errors. Since individual patient data were not available in 
included studies, hazard ratios and standard errors calculated from a Cox proportional 
                                                 
5 Based on the approach suggested by Furukawa and colleagues (2006). Handbook for Systematic Reviews of 
Interventions, 5.0.2, Higgins et al., 2009). Data were summarised using the generic inverse variance method, 
using Review Manager. 
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hazard model were extracted. Where necessary, standard errors were calculated from 
confidence intervals (CIs) or p-value according to standard formulae (see Cochrane  
 
Consultation with another reviewer or members of the GDG was used to overcome 
difficulties with coding. Data from studies included in existing systematic reviews were 
extracted independently by one reviewer and cross-checked with the existing data set. 
Where possible, two independent reviewers extracted data from new studies. Where 
double data extraction was not possible, data extracted by one reviewer was checked by 
the second reviewer. Disagreements were resolved through discussion. Where consensus 
could not be reached, a third reviewer or GDG members resolved the disagreement. 
Masked assessment (that is, blind to the journal from which the article comes, the authors, 
the institution and the magnitude of the effect) was not used since it is unclear that doing 
so reduces bias (Jadad et al., 1996; Berlin, 2001). 
3.5.3 Synthesising the evidence 
Meta-analysis 
Where possible, meta-analysis was used to synthesise the evidence using Review 
Manager. If necessary, reanalyses of the data or sub-analyses were used to answer review 
questions not addressed in the original studies or reviews.  
 
Dichotomous outcomes were analysed as relative risks (RR) with the associated 95% CI 
(for an example, see Figure 1). A relative risk (also called a risk ratio) is the ratio of the 
treatment event rate to the control event rate. An RR of 1 indicates no difference between 
treatment and control. In Figure 1, the overall RR of 0.73 indicates that the event rate (that 
is, non-remission rate) associated with intervention A is about three quarters of that with 
the control intervention or, in other words, the RR reduction is 27%.  
 
The CI shows a range of values within which we are 95% confident that the true effect will 
lie. If the effect size has a CI that does not cross the ‗line of no effect‘, then the effect is 
commonly interpreted as being statistically significant. 
 
Figure 1: Example of a forest plot displaying dichotomous data 
Review: NCCMH clinical guideline review (Example)
Comparison: 01 Intervention A compared to a control group                                                                 
Outcome: 01 Number of people who did not show remission                                                                
Study  Intervention A  Control  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Intervention A vs. control
 Griffiths1994             13/23              27/28         38.79      0.59 [0.41, 0.84]        
 Lee1986                   11/15              14/15         22.30      0.79 [0.56, 1.10]        
 Treasure1994              21/28              24/27         38.92      0.84 [0.66, 1.09]        
Subtotal (95% CI)       45/66              65/70        100.00      0.73 [0.61, 0.88]
Test for heterogeneity: Chi² = 2.83, df = 2 (P = 0.24), I² = 29.3%
Test for overall effect: Z = 3.37 (P = 0.0007)
 0.2  0.5  1  2  5
 Favours intervention  Favours control  
 
Continuous outcomes were analysed using the SMD because different measures were 
used in different studies to estimate the same underlying effect (for an example, see  
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Figure 2). If reported by study authors, intention-to-treat data, using a valid method for 
imputation of missing data, were preferred over data only from people who completed 
the study. 
 
 
Review: NCCMH clinical guideline review (Example)
Comparison: 01 Intervention A compared to a control group                                                                 
Outcome: 03 Mean frequency (endpoint)                                                                                  
Study  Intervention A  Control  SMD (fixed)  Weight  SMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
01 Intervention A vs. control
Freeman1988             32      1.30(3.40)          20      3.70(3.60)      25.91     -0.68 [-1.25, -0.10]      
Griffiths1994           20      1.25(1.45)          22      4.14(2.21)      17.83     -1.50 [-2.20, -0.81]      
Lee1986                 14      3.70(4.00)          14     10.10(17.50)     15.08     -0.49 [-1.24, 0.26]       
Treasure1994            28     44.23(27.04)         24     61.40(24.97)     27.28     -0.65 [-1.21, -0.09]      
Wolf1992                15      5.30(5.10)          11      7.10(4.60)      13.90     -0.36 [-1.14, 0.43]       
Subtotal (95% CI)    109                          91 100.00     -0.74 [-1.04, -0.45]
Test for heterogeneity: Chi² = 6.13, df = 4 (P = 0.19), I² = 34.8%
Test for overall effect: Z = 4.98 (P < 0.00001)
 -4  -2  0  2  4
 Favours intervention  Favours control  
 
Figure 2: Example of a forest plot displaying continuous data 
 
The number needed to treat for benefit (NNTB) or the number needed to treat for harm 
(NNTH) was reported for each outcome where the baseline risk (that is, the control group 
event rate) was similar across studies. In addition, numbers needed to treat (NNTs) 
calculated at follow-up were only reported where the length of follow-up was similar 
across studies. When the length of follow-up or baseline risk varies (especially with low 
risk), the NNT is a poor summary of the treatment effect (Deeks, 2002).  
Heterogeneity 
To check for consistency of effects among studies, both the I2 statistic and the chi-squared 
test of heterogeneity, as well as a visual inspection of the forest plots were used. The I2 
statistic describes the proportion of total variation in study estimates that is due to 
heterogeneity (Higgins & Thompson, 2002). The I2 statistic was interpreted in the follow 
way based on Higgins and Green (2009): 
 
 0 to 40%: might not be important 
 30 to 60%: may represent moderate heterogeneity 
 50 to 90%: may represent substantial heterogeneity 
 75 to 100%: considerable heterogeneity. 
 
Two factors were used to make a judgement about importance of the observed value of I2: 
First, the magnitude and direction of effects, and second, the strength of evidence for 
heterogeneity (for example, p-value from the chi-squared test, or a CI for I2). 
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Publication bias 
Where there was sufficient data, we intended to use funnel plots to explore the possibility 
of publication bias. Asymmetry of the plot would be taken to indicate possible publication 
bias and investigated further. However, due to a paucity of data, funnel plots could not be 
used. 
 
Where necessary, an estimate of the proportion of eligible data that were missing (because 
some studies did not include all relevant outcomes) was calculated for each analysis. 
3.5.4  Summary statistics used to evaluate assessment instruments 
The main outcomes that need to be extracted from diagnostic accuracy studies are 
sensitivity, specificity, positive predictive validity and negative predictive validity. These 
are discussed in detail below. Negative likelihood ratios, positive likelihood ratios, and 
area under the curve will also be briefly described. In addition, definitions of relevant 
validation and reliability assessment strategies will be provided below. 
 
The sensitivity of an instrument refers to the proportion of those with the condition who 
test positive. An instrument that detects a low percentage of cases will not be very helpful 
in determining the numbers of patients who should receive a known effective treatment, 
because many individuals who should receive the treatment will not do so. This would 
make for poor planning, and underestimate the prevalence of the disorder and the costs of 
treatments to the community. As the sensitivity of an instrument increases, the number of 
false negatives it detects will decrease. 
 
The specificity of an instrument refers to the proportion of those without the condition 
who test negative. This is important so that well individuals are not given treatments they 
do not need. As the specificity of an instrument increases, the number of false positives 
will decrease. 
 
To illustrate this: from a population in which the point prevalence rate of alcohol 
dependence is 10% (that is, 10% of the population has alcohol dependence at any one 
time), 1000 people are given a test which has 90% sensitivity and 85% specificity. It is 
known that 100 people in this population have alcohol dependence, but the test detects 
only 90 (true positives), leaving ten undetected (false negatives). It is also known that 900 
people do not have alcohol dependence, and the test correctly identifies 765 of these (true 
negatives), but classifies 135 incorrectly as having alcohol dependence (false positives). 
The positive predictive value of the test (the number correctly identified as having alcohol 
dependence as a proportion of positive tests) is 40% (90/90+135), and the negative 
predictive value (the number correctly identified as not having alcohol dependence as a 
proportion of negative tests) is 98% (765/765+10). Therefore, in this example, a positive 
test result is correct in only 40% of cases, whilst a negative result can be relied upon in 
98% of cases.  
 
The example above illustrates some of the main differences between positive predictive 
values and negative predictive values in comparison with sensitivity and specificity. For 
both positive predictive values and negative predictive values prevalence explicitly forms 
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part of their calculation (see Altman & Bland, 1994a). When the prevalence of a disorder is 
low in a population this is generally associated with a higher negative predictive value 
and a lower positive predictive value. Therefore although these statistics are concerned 
with issues probably more directly applicable to clinical practice (for example, the 
probability that a person with a positive test result actually has alcohol dependence) they 
are largely dependent on the characteristics of the populations sampled and cannot be 
universally applied (Altman & Bland, 1994a).  
 
In contrast, sensitivity and specificity do not theoretically depend on prevalence (Altman 
& Bland, 1994b). For example, sensitivity is concerned with the performance of an 
identification test conditional on a person having depression. Therefore the higher false 
positives often associated with samples of low prevalence will not affect such estimates. 
The advantage of this approach is that sensitivity and specificity can be applied across 
populations (Altman & Bland, 1994b). However, the main disadvantage is that clinicians 
tend to find such estimates more difficult to interpret. 
 
Criterion validity (or predictive validity)  evaluated when the purpose is to use an 
instrument to estimate some important form of behaviour that is external to the measuring 
instrument itself, the latter being referred to as the criterion (Nunnally, 1978). Criterion 
validity evaluates how well scores on a measure relate to real-world behaviours such as 
motivation for treatment and long-term treatment outcomes. The degree of 
correspondence between the test and the criterion is estimated by the size of their 
correlation. 
 
Construct validity  refers to the experimental demonstration that a test is measuring the 
construct it was intended to measure. Relationships among items, domains, and concepts 
conform to a priori hypotheses concerning logical relationships that should exist with other 
measures or characteristics of patients and patient groups (Brown, 1994). 
 
Content validity  is derived from the degree to which a test is a representative sample of 
the content of whatever objectives or specifications the test was originally designed to 
measure (Brown, 1994).  
 
Inter-rater reliability  refers to the degree to which observers, or raters, are consistent 
in their scoring on a measurement scale. Internal reliability gives an indication of how 
much homogeneity or consensus there is amongst the raters (Allen, 2003). 
 
Test–retest reliability  is determined by administering the measurement instrument 
two or more times to each subject. If the correlation between scores is high, the 
measurement instrument can be said to have good test–retest reliability. This is desirable 
when measuring constructs which are not expected to change over time, for example 
family history of alcoholism, age of onset of problem drinking and general expectancies of 
alcohol effects. In contrast, when measuring more transient constructs such as cravings 
and treatment motivation, the test–retest reliability would be expected to be lower (Allen, 
2003). 
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Internal consistency is a measure based on the correlation between different items 
within the scale itself. For instruments designed to measure a single phenomenon, these 
correlation coefficients should be high (Allen, 2003). 
 
3.5.5  Presenting the data to the Guideline Development Group 
Study characteristics tables and, where appropriate, forest plots generated with Review 
Manager were presented to the GDG. 
 
Where meta-analysis was not appropriate and/or possible, the reported results from each 
primary-level study were included in the study characteristics table (and, where 
appropriate, in a narrative review). 
Evidence profile tables 
A GRADE6 evidence profile was used to summarise both the quality of the evidence and 
the results of the evidence synthesis (see Table 4 for an example of an evidence profile). 
The GRADE approach is based on a sequential assessment of the quality of evidence, 
followed by judgement about the balance between desirable and undesirable effects, and 
subsequent decision about the strength of a recommendation. 
 
For each outcome, quality may be reduced depending on the following factors: 
 
 study design (randomised trial, observational study, or any other evidence) 
 limitations (based on the quality of individual studies) 
 inconsistency (see Section 3.5.3 for how consistency was assessed) 
 indirectness (that is, how closely the outcome measures, interventions and 
participants match those of interest) 
 imprecision (based on the CI around the effect size). 
 
For observational studies, the quality may be increased if there is a large effect, plausible 
confounding would have changed the effect, or there is evidence of a dose–response 
gradient (details would be provided under the other considerations column). Each 
evidence profile also included a summary of the findings: number of patients included in 
each group, an estimate of the magnitude of the effect and the overall quality of the 
evidence for each outcome. 
                                                 
6 For further information about GRADE, see www.gradeworkinggroup.org. 
 54 
 
Table 4: Example of GRADE evidence profile 
Quality assessment 
Summary of findings 
No. of patients Effect Quality 
No. of 
studies 
Design Limitations Inconsistency Indirectness Imprecision Other Intervention Control 
Relative 
(95% CI) 
Absolute  
Outcome 1 
6 Randomised 
trials 
No serious 
limitations 
No serious 
inconsistency 
No serious 
indirectness 
Very 
serious1,2 
None 
8/191 7/150 
RR 0.94  
(0.39 to 2.23) 
0 fewer per 100 
(from 3 fewer to 
6 more) 
 
LOW 
Outcome 2 
3 Randomised 
trials 
No serious 
limitations 
No serious 
inconsistency 
No serious 
indirectness 
No serious 
imprecision 
None 
120/600 220/450 
RR 0.39  
(0.23 to 0.65) 
30 fewer per 100 
(from 17 fewer to 
38 fewer) 
 
HIGH 
Outcome 3 
3 Randomised 
trials 
No serious 
limitations 
Serious 
inconsistency3 
No serious 
indirectness 
Very 
serious1,2 
None 
83 81 - 
MD -1.51  
(-3.81 to 0.8) 
 
VERY LOW 
Outcome 4 
3 Randomised 
trials 
No serious 
limitations 
No serious 
inconsistency 
No serious 
indirectness 
Serious1 None 
88 93 - 
SMD -0.26  
(-0.50 to -0.03) 
 
MODERATE 
Outcome 5 
4 Randomised 
trials 
No serious 
limitations 
No serious 
inconsistency 
No serious 
indirectness 
Very 
serious1,2 
None 
109 114 - 
SMD -0.13  
(-0.6 to 0.34) 
 
LOW 
1 Optimal information size not met. 
2 The CI includes (a) no effect and (b) appreciable benefit or appreciable harm. 
3 Considerable heterogeneity. 
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3.5.6  Forming the clinical summaries and recommendations 
Once the GRADE evidence profiles relating to a particular review question were 
completed, summary evidence tables were developed (these tables are presented in 
the evidence chapters). Finally, the systematic reviewer in conjunction with the topic 
group lead produced a clinical evidence summary. 
 
After the GRADE profiles and clinical summaries were presented to the GDG, the 
associated recommendations were drafted. In making recommendations, the GDG 
took into account the trade-off between the benefits and downsides of treatment as 
well as other important factors, such as economic considerations, social value 
judgements7, the requirements to prevent discrimination and to promote equality8, 
and the group‘s awareness of practical issues (Eccles et al., 1998; NICE, 2009a). 
3.5.7 Method used to answer a review question in the absence of 
appropriately designed, high-quality research 
In the absence of appropriately designed, high-quality research, or where the GDG 
were of the opinion (on the basis of previous searches or their knowledge of the 
literature) that there were unlikely to be such evidence, an informal consensus 
process was adopted. This process focused on those questions that the GDG 
considered a priority.  
Informal consensus 
The starting point for the process of informal consensus was that a member of the 
topic group identified, with help from the systematic reviewer, a narrative review 
that most directly addressed the review question. Where this was not possible, a 
brief review of the recent literature was initiated. 
 
This existing narrative review or new review was used as a basis for beginning an 
iterative process to identify lower levels of evidence relevant to the review question 
and to lead to written statements for the guideline. The process involved a number 
of steps:  
 
1. A description of what is known about the issues concerning the clinical 
question was written by one of the topic group members. 
2. Evidence from the existing review or new review was then presented in 
narrative form to the GDG and further comments were sought about the 
evidence and its perceived relevance to the review question. 
3. Based on the feedback from the GDG, additional information was sought and 
added to the information collected. This may include studies that did not 
directly address the review question but were thought to contain relevant 
data. 
                                                 
7 See NICE (2008b). 
8 See NICE‘s equality scheme: www.nice.org.uk/aboutnice/howwework/NICEEqualityScheme.jsp. 
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4. If, during the course of preparing the report, a significant body of primary-
level studies (of appropriate design to answer the question) were identified, a 
full systematic review was done. 
5. At this time, subject possibly to further reviews of the evidence, a series of 
statements that directly addressed the review question were developed. 
6. Following this, on occasions and as deemed appropriate by the development 
group, the report was then sent to appointed experts outside of the GDG for 
peer review and comment. The information from this process was then fed 
back to the GDG for further discussion of the statements. 
7. Recommendations were then developed and could also be sent for further 
external peer review [amend as appropriate]. 
8. After this final stage of comment, the statements and recommendations were 
again reviewed and agreed upon by the GDG. 
3.6  HEALTH ECONOMICS METHODS 
The aim of the health economics was to contribute to the guideline‘s development by 
providing evidence on the cost effectiveness of interventions for alcohol misuse 
covered in the guideline. This was achieved by: 
 
 systematic literature review of existing economic evidence 
 decision-analytic economic modelling. 
 
Systematic reviews of economic literature were conducted in all areas covered in the 
guideline. Economic modelling was undertaken in areas with likely major resource 
implications, where the current extent of uncertainty over cost effectiveness was 
significant and economic analysis was expected to reduce this uncertainty, in 
accordance with the Guidelines Manual (NICE, 2009a). Prioritisation of areas for 
economic modelling was a joint decision between the Health Economist and the 
GDG. The rationale for prioritising review questions for economic modelling was set 
out in an economic plan agreed between NICE, the GDG, the Health Economist and 
the other members of the technical team. The following economic questions were 
selected as key issues that were addressed by economic modelling: 
 
1) What is the preferred method of medically-assisted withdrawal, in terms of 
clinical and cost-effectiveness (taking into consideration the benefits/adverse 
effects) and for which people and in which setting (taking into account the 
nature of intervention in each setting)? 
- Community (taking into account levels of supervision: structured versus 
unstructured day programme) 
- Residential 
- Inpatient: mental health or acute hospital 
- Prisons. 
 
2) For people who are alcohol dependent or harmful drinkers, which 
pharmacological interventions aimed at attenuation of drinking/maintenance 
of abstinence are clinically and cost-effective? 
 57 
 
 
3) For people who are alcohol dependent or harmful drinkers, which 
psychological and psychosocial interventions aimed at attenuation of 
drinking/maintenance of abstinence are clinically and cost-effective? 
 
4) For people who are alcohol dependent or harmful drinkers, which 
combination of psychological/psychosocial and pharmacological 
interventions aimed at attenuation of drinking/maintenance of abstinence are 
clinically and cost-effective? 
 
In addition, literature on the health-related quality of life of people with alcohol-use 
disorders was systematically searched to identify studies reporting appropriate 
utility scores that could be utilised in a cost-utility analysis. 
 
The rest of this section describes the methods adopted in the systematic literature 
review of economic studies. Methods employed in economic modelling are 
described in the respective sections of the guideline. 
3.6.1  Literature search strategy for economic evidence 
Scoping searches 
A broad preliminary search of the literature was undertaken in September 2008 to 
obtain an overview of the issues likely to be covered by the scope, and help define 
key areas. Searches were restricted to economic studies and HTA reports, and 
conducted in the following databases:  
 
 EMBASE 
 MEDLINE / MEDLINE In-Process 
 Health Technology Assessment (HTA) database (technology assessments) 
 NHS Economic Evaluation Database (NHS EED). 
Systematic literature searches 
After the scope was finalised, a systematic search strategy was developed to locate 
all the relevant evidence. The balance between sensitivity (the power to identify all 
studies on a particular topic) and specificity (the ability to exclude irrelevant studies 
from the results) was carefully considered, and a decision made to utilise a broad 
approach to searching to maximise retrieval of evidence to all parts of the guideline. 
Searches were restricted to economic studies and HTA reports, and conducted in the 
following databases:  
 
 CINAHL  
 EconLit 
 EMBASE 
 MEDLINE/MEDLINE In-Process 
 PsycINFO  
 HTA database (technology assessments) 
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 NHS Economic Evaluation Database (NHS EED) 
 
Any relevant economic evidence arising from the clinical scoping searches was also 
made available to the health economist during the same period.  
 
For standard mainstream bibliographic databases (CINAHL, EMBASE, MEDLINE 
and PsycINFO), search terms on alcohol dependence and harmful alcohol use were 
combined with a search filter for health economic studies. For searches generated in 
topic-specific databases (HTA, NHS EED), search terms on alcohol dependence and 
harmful alcohol use were used without a filter. The sensitivity of this approach was 
aimed at minimising the risk of overlooking relevant publications, due to inaccurate 
or incomplete indexing of records on the databases, as well as potential weaknesses 
resulting from more focused search strategies (for example, for interventions).  
Reference Manager 
Citations from each search were downloaded into Reference Manager and duplicates 
removed. Records were then screened against the inclusion criteria of the reviews 
before being quality appraised. To keep the process both replicable and transparent, 
the unfiltered search results were saved and retained for future potential re-analysis.  
Search filters 
The search filter for health economics is an adaptation of a filter designed by the 
CRD. The filter comprises a combination of controlled vocabulary and free-text 
retrieval methods.  
Date and language restrictions 
All of the searches were restricted to research published from 1993 onwards. 
Systematic database searches were initially conducted in June 2008 up to the most 
recent searchable date. Search updates were generated on a 6-monthly basis, with 
the final re-runs carried out in March 2010 ahead of the guideline consultation. After 
this point, studies were included only if they were judged by the GDG to be 
exceptional (for example, if the evidence was likely to change a recommendation).  
 
Although no language restrictions were applied at the searching stage, foreign 
language papers were not requested or reviewed unless they were of particular 
importance to an area under review.  
Other search methods 
Other search methods involved scanning the reference lists of all eligible 
publications (systematic reviews, stakeholder evidence and included studies from 
the economic and clinical reviews) to identify further studies for consideration. 
 
Full details of the search strategies and filter used for the systematic review of health 
economic evidence are provided in Appendix 12.  
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3.6.2  Inclusion criteria for economic studies 
The following methods were applied to select studies identified by the economic 
searches for further consideration 
 
 No restriction was placed on language or publication status of the papers. 
 
  Studies published from 1998 onwards that reported data from financial year 
1997–98 onwards were included. This date restriction was imposed in order 
to obtain data relevant to current healthcare settings and costs. 
 
 Only studies from Organisation for Economic Co-operation and Development 
member-countries were included, because the aim of the review was to 
identify economic information transferable to the UK context. 
 
 Selection criteria based on types of clinical conditions and patients as well as 
interventions assessed were identical to the clinical literature review. 
 
 Studies were included provided that sufficient details regarding methods and 
results were available to enable the methodological quality of the study to be 
assessed, and provided that the study‘s data and results were extractable. 
Poster presentations of abstracts were excluded; however, they were 
included if they reported utility data required for a cost-utility analysis, 
when no other data were available.  
 
 Full economic evaluations that compared two or more relevant options and 
considered both costs and consequences (that is, cost–consequence analysis, 
cost effectiveness analysis, cost–utility analysis or cost–benefit analysis) as 
well as cost analyses that compared only costs between two or more 
interventions were included in the review. 
 
 Economic studies were included if they used clinical effectiveness data from 
an RCT, a prospective cohort study, or a systematic review and meta-
analysis of clinical studies. Studies that had a mirror-image or other 
retrospective design were excluded from the review. 
 
 Studies were included only if the examined interventions were clearly 
described. This involved the dosage and route of administration and the 
duration of treatment in the case of pharmacological therapies; and the types 
of health professionals involved as well as the frequency and duration of 
treatment in the case of psychological interventions. Evaluations in which 
medications were treated as a class were excluded from further 
consideration. 
 
 Studies that adopted a very narrow perspective, ignoring major categories of 
costs to the NHS, were excluded; for example, studies that estimated 
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exclusively drug acquisition costs or hospitalisation costs were considered 
non-informative to the guideline development process. 
3.6.3  Applicability and quality criteria for economic studies 
All economic papers eligible for inclusion were appraised for their applicability and 
quality using the methodology checklist for economic evaluations recommended by 
NICE (NICE, 2009a), which is shown in Appendix 13 of this guideline. The 
methodology checklist for economic evaluations was also applied to the economic 
models developed specifically for this guideline. All studies that fully or partially 
met the applicability and quality criteria described in the methodology checklist 
were considered during the guideline development process, along with the results of 
the economic modelling conducted specifically for this guideline.  
3.6.4  Presentation of economic evidence 
The economic evidence considered in the guideline is provided in the respective 
evidence chapters, following presentation of the relevant clinical evidence. The 
references to included studies and to those that were potentially relevant but did not 
meet the inclusion criteria can be found in Appendix 19, as well as the evidence 
tables with the characteristics and results of economic studies included in the review. 
Methods and results of economic modelling undertaken alongside the guideline 
development process are presented in the relevant evidence chapters. Characteristics 
and results of all economic studies considered during the guideline development 
process (including modelling studies conducted for this guideline) are summarised 
in economic evidence profiles accompanying respective GRADE clinical evidence 
profiles in Appendix 18. 
3.6.5  Results of the systematic search of economic literature 
Publications that were clearly not relevant to the topic (that is, economic issues and 
information on health-related quality of life in harmful drinkers and people with 
alcohol dependency) were excluded at the sifting stage first. The abstracts of all 
potentially relevant publications were then assessed against the inclusion criteria for 
economic evaluations by the health economist. Full texts of the studies potentially 
meeting the inclusion criteria (including those for which eligibility was not clear 
from the abstract) were obtained. Studies that did not meet the inclusion criteria, 
were duplicates, were secondary publications of one study, or had been updated in 
more recent publications were subsequently excluded. Economic evaluations eligible 
for inclusion were then appraised for their applicability and quality using the 
methodology checklist for economic evaluations. Finally, economic studies that fully 
or partially met the applicability and quality criteria were considered at formulation 
of the guideline recommendations. 
3.7  STAKEHOLDER CONTRIBUTIONS 
Professionals, service users, and companies have contributed to and commented on 
the guideline at key stages in its development. Stakeholders for this guideline 
include: 
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 service user and carer stakeholders: the national service-user and carer 
organisations that represent people whose care is described in this guideline  
 professional stakeholders: the national organisations that represent healthcare 
professionals who are providing services to service users 
 commercial stakeholders: the companies that manufacture medicines used in 
the treatment of alcohol dependence and harmful alcohol use 
 Primary Care Trusts 
 Department of Health and Welsh Assembly Government. 
 
NICE clinical guidelines are produced for the NHS in England and Wales, so a 
‗national‘ organisation is defined as one that represents England and/or Wales, or 
has a commercial interest in England and/or Wales. 
 
Stakeholders have been involved in the guideline‘s development at the following 
points:  
 
 commenting on the initial scope of the guideline and attending a briefing 
meeting held by NICE 
 contributing possible review questions and lists of evidence to the GDG 
during the initial scoping phase of the guideline 
 commenting on the draft of the guideline 
 highlighting factual errors in the pre-publication check. 
3.8  VALIDATION OF THE GUIDELINE 
Registered stakeholders had an opportunity to comment on the draft guideline, 
which was posted on the NICE website during the consultation period. Following 
the consultation, all comments from stakeholders and others were responded to, and 
the guideline updated as appropriate. The GRP also reviewed the guideline and 
checked that stakeholders' comments had been addressed.  
 
Following the consultation period, the GDG finalised the recommendations and the 
NCCMH produced the final documents. These were then submitted to NICE for the 
pre-publication check where stakeholders are given the opportunity to highlight 
factual errors. Any errors are corrected by the NCCMH, then the guideline is 
formally approved by NICE and issued as guidance to the NHS in England and 
Wales. 
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4 EXPERIENCE OF CARE  
4.1 INTRODUCTION 
This chapter provides an overview of the experience of people who misuse alcohol 
and their families/carers in the form of a review of the qualitative literature. As part 
of the process of drafting this chapter, the GDG and review team elicited personal 
accounts from people who misuse alcohol and their family/carers. The personal 
accounts that were received from service users were from people who had 
experienced long-standing (almost life-long) problems with alcohol and identified 
themselves as ‗alcoholic‘. For this reason, the GDG judged that it could not include 
them in this chapter because they did not illustrate the breadth of experience 
covered by this guideline, which ranges from occasional harmful drinking to mild, 
moderate and severe dependence. (The personal accounts that were received and the 
methods used to elicit them can be found in Appendix 14.)  
 
As the guideline also aims to address support needs for families/carers, a thematic 
analysis was conducted using transcripts from people with parents who misuse 
alcohol. These were accessed from the National Association for Children of 
Alcoholics (NACOA) website (www.nacoa.org.uk). NACOA provides information 
and support to people (whether still in childhood or in adulthood) of parents who 
misuse alcohol and the website includes personal experiences from such people in 
narrative form. However, there were some limitations to the thematic analysis. 
Because the review team relied only on transcripts submitted to NACOA, 
information on other issues that could be particularly pertinent for children with 
parents who misuse alcohol may not have been identified. Moreover, people who 
have visited the NACOA website to submit their accounts may over-represent a 
help-seeking population. Finally, while some accounts are based on experiences 
which occurred recently, others occurred a long time ago; therefore there may be 
differences in attitudes, information and services available. For these reasons this 
analysis was not included in Chapter 4, but it can be found in Appendix 14. 
4.2 REVIEW OF THE QUALITATIVE LITERATURE 
4.2.1 Introduction 
A systematic search for published reviews of relevant qualitative studies of people 
who misuse alcohol was undertaken. The aim of the review was to explore the 
experience of care for people who misuse alcohol and their families and carers in 
terms of the broad topics of receiving a diagnosis, accessing services and having 
treatment.  
4.2.2 Clinical questions 
 For people who misuse alcohol, what are their experiences of having problems with 
alcohol, of access to services and of treatment? 
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For families and carers of people who misuse alcohol, what are their experiences of 
caring for people with an alcohol problem and what support is available for families 
and carers? 
4.2.3 Evidence search 
Reviews were sought of qualitative studies that used relevant first-hand experiences 
of people who misuse alcohol and their families/carers. For more information about 
the databases searched, see Table 5. 
 
Table 5: Databases searched and inclusion/exclusion criteria for clinical 
evidence 
Electronic databases CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design Systematic reviews and narratives of qualitative studies, 
qualitative studies 
Population People who are alcohol dependent or harmful drinkers, families 
and carers, staff who work in alcohol services 
Outcomes None specified – any narrative description of service user/carer 
experience of alcohol misuse  
 
4.2.4 Studies considered 
Based on the advice of the GDG, this review was focused on qualitative research 
only because it was felt to be most appropriate to answer questions about the 
experience of care of those with alcohol dependence or alcohol misuse. As good 
quality qualitative research exists within the literature, quantitative and survey 
studies were excluded.  
 
The search found 33 qualitative studies which met the inclusion criteria (Aira et al., 
2003; Allen et al., 2005; Bacchus, 1999; Beich et al., 2002; Burman, 1997; Copeland, 
1997; Dyson, 2007; Gance-Cleveland, 2004; Hartney et al., 2003; Hyams et al., 1996; 
Jethwa, 20099; Kaner et al., 2006; Lock, 2004; Lock et al., 2002; Mohatt et al., 2007; 
Morjaria & Orford, 2002; Murray, 1998; Nelson-Zlupko et al., 1996; Nielsen, 2003; 
Orford et al., 1998; Orford et al., 2002; Orford et al.,2005; Orford et al.,2006; Orford et 
al.,2008; Orford et al., 2009; Rolfe et al., 2005; Rolfe et al., 2009; Smith, 2004; 
Vandermause, 2007; Vandermause & Wood, 2009; Vandevelde et al., 2003; Vargas & 
Luis, 2008; Yeh et al., 2009). 
 
Thirty-four studies considered for the review did not meet the inclusion criteria 
(Amiesen, 2005; Bargiel-Matusiewicz & Ziebaczewska, 2006; Brown et al., 1992; Chan 
et al., 1997; Coffinet & Laugier, 2008; Cunningham & Sobell, 2009; De Guzman et al., 
                                                 
9 It should be noted that the qualitative patient interviews from the Jethwa (2009) study were not 
published with the paper, but were received from a member of the GDG. The review team received 
written permission from the author to use the interviews to identify any themes relevant to this 
section.  
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2006; De Maeyer et al., 2008; Grant, 1997; Giovazolias & Davis, 2005; Grebot et al., 
2008, Happell et al., 2002; Hoerter et al., 2004; Kahan et al., 2004; Kaner et al., 1999; 
Karel et al., 2000; Koski-Jannes, 1998; Laudet, 2003; MacDonald et al., 2007; 
Mackenzie & Allen, 2003; Miller et al., 2006; Orford et al., 2009; Pettinati et al., 2003; 
Pithouse & Arnell, 1996; Rychtarik et al., 2000; Sellman & Joyce, 1996; Strobbe et al., 
2004; Swift et al., 1998; Thomas & Miller, 2007; Tonigan et al., 2000; Tucker et al., 2009; 
Vuchinich & Tucker, 1996; Wells et al., 2007; White et al., 2004; Wild et al., 1998). The 
most common reasons for exclusion were that alcohol was not the primary substance 
used; or there was not a high enough percentage of people who were alcohol 
dependent or reaching harmful levels of alcohol consumption; or the studies were 
quantitative or surveys. 
 
The characteristics of all of the studies reviewed in this section have been 
summarised in Appendix 16a. The included studies have been categorised under six 
main headings: experience of alcohol misuse, access and engagement, experience of 
assessment and treatment for alcohol misuse, experience of recovery, and carer 
experiences and staff experiences. 
4.2.5 Experience of alcohol misuse 
One of the main themes that emerged under the heading of ‗experience of alcohol 
misuse‘ was reasons for discontinuation of drinking. There were seven studies 
(Burman, 1997; Hartney et al., 2003; Jethwa, 2009; Mohatt et al., 2007; Nielsen, 2003; 
Rolfe et al., 2005; Yeh et al., 2009) that looked at people‘s motivation for stopping 
drinking in populations of people who drank heavily and were untreated. All 
studies mentioned that a significant motivation to discontinue drinking stemmed 
from external factors such as relationships, employment and education. 
Responsibility for others was a particular catalyst in maintaining motivation to stop 
drinking (for example, having a child, loss of a family member, or 
divorce/separation from a partner).  
Rolfe and colleagues (2005) found that participants specified three key reasons for 
decreasing alcohol consumption. The first was ‗needing to‘ decrease their alcohol 
consumption to minimise harm, once there was a realisation that alcohol was having 
a direct negative impact on their emotional and physical well-being. Both Rolfe and 
colleagues (2005) and Burman (1997) reported that the onset of physical problems 
was a significant motivation to stop drinking: ‘You need that scare to do it … you don’t 
pack it in until you’ve had that scare and reached rock bottom‘. The second reason was 
‗having to‘ decrease alcohol consumption due to work or relationship factors. The 
third was ‗being able to cut down‘, which referred to no longer feeling the need or 
desire to consume alcohol and was typically inspired by a positive or negative 
change in a specific area of their life (for example, medical treatment or change in 
employment).  
 
In the qualitative component of their study, Hartney and colleagues (2003) found 
that most participants did not have a sense of being unable to stop drinking alcohol, 
and issues such as relationships or driving a car would be prioritised over 
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continuing to drink. This furthers the idea that, for untreated heavy drinkers, 
triggers and cues for alcohol consumption are largely socially determined. Another 
interesting finding was the conscious process that many participants went through 
in order to find moderation strategies to apply to their alcohol consumption. This 
was largely based around an observation of their own drinking in relation to other 
people‘s drinking levels, and disconnecting themselves from a drinking ‗taboo‘ or 
what they considered to be ‗dependence‘, including concealing evidence of alcohol 
consumption or the effects of physical withdrawal.  
 
Nielsen (2003) found that participants in Denmark used different ways to narratively 
describe and contextualise their drinking behaviour. Several participants categorised 
their alcohol consumption as ‗cultural drinking‘, where alcohol was used in a social 
and cultural context. Cultural drinking is a way of normalising alcohol consumption 
within a social environment (such as drinking at a party). Moreover, participants in 
this study distinguished their own heavy alcohol consumption from what they 
perceived as ‗real alcoholics‘, who appeared to be more out of control: ‘Real alcoholics 
are drinking in the streets’. 
 
Other patterns of drinking included symptomatic drinking, where patients drink as 
a reaction to external influences (for example, workload or relationship difficulties) 
or internal influences (for example, mental health problems). Cultural drinkers were 
found to use therapy and treatment more for information and feedback, rather than 
for the helpfulness of their therapists. Cultural drinkers tended to rely on their own 
willpower to cut back on their drinking. Conversely, those who were symptomatic 
drinkers used alcohol more as a way to solve problems and were more reliant and 
engaged in their treatment sessions with their therapists. Lastly, the Nielsen (2003) 
study highlights the process of heavy drinking and the ‗turning point‘ that many 
harmful and dependent drinkers experience once the realisation is made that their 
alcohol consumption needs to change and treatment is needed. This turning point is 
in line with what Burman (1997) and Mohatt and colleagues (2007) found as well, in 
that participants typically experience an accumulation of negative alcohol related 
events, and this prompts the decision to give up drinking. A period of reflection 
regarding their alcohol misuse may follow, and a key event often precipitates the 
motivation to stop drinking, and leads to a turning point.  
 
Recently, Jethwa (2009) interviewed people who were alcohol dependent and found 
that six of the ten participants interviewed started drinking in response to a stressful 
life event (for example, depression, bereavement, or breakdown of a relationship). 
Other common reasons included familial history of drinking, being lured in by social 
networks, or just liking the taste of alcohol. Interestingly, once the decision was 
made to quit drinking, nearly all of the participants did not find it difficult once this 
‗turning point‘ was reached.  
 
Yeh and colleagues (2009) conducted a study to look into the process of abstinence 
for alcohol-dependent people in Taiwan and discuss their challenges in abstaining 
from alcohol. Based on previous theories and the interviews, Yeh and colleagues 
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(2009) identified a cycle of dependence, comprising the stages of indulgence, 
ambivalence and attempt (the IAA cycle). In the first stage of indulgence, alcohol-
dependent people feel a loss of control over their alcohol consumption, and to 
overcome unpleasant physical or mental states, they consume more alcohol, 
exacerbating their dependence: 
 
When I had physical problems and saw the doctor, they never got better. But I felt 
good when I had a drink. I started relying on alcohol and started wanting to drink all 
the time. Drinking would help me feel better. 
 
In the ambivalent stage, people want to seek help but the will to drink is stronger 
than to remain abstinent. In the attempt phase, people try to remain abstinent but, 
due to a lack of coping strategies in situations that trigger alcohol consumption, 
many relapse.  
 
Dyson (2007) found that recovery from alcohol dependence arose from a culmination 
or combination of consequences, coupled with the realisation that life was 
unbearable as it was: 
 
My real recovery began when I admitted that my life had become unmanageable and 
that I could not control the drink. I experienced a deep change in thinking – sobriety 
had to be the most important thing in my life. 
 
Several participants pointed out that their decision to pursue recovery and 
abstinence had to be made on their own and could not be made or influenced much 
by others: ‘It was something I had to do on my own and I had to do it for me, not for anyone 
else’. Evidently this personal decision has important implications for the carers 
around them. The key to begin recovery appears to be the individual‘s willingness 
and readiness to stop drinking (Dyson, 2007).  
 
An earlier study by Orford and colleagues (1998) looked at social support in coping 
with alcohol and drug problems at home, using a cross-cultural comparison between 
Mexican and English families. The main cross-cultural differences were that positive 
social support for Mexican relatives stemmed mostly from family, whereas English 
relatives mentioned self-help sources, professionals and friends in addition to 
family. The accounts from the participants mentioned family and friend support as 
more unsupportive or more negative for the English families. Conversely, the 
Mexican families often mentioned their family and neighbours as significant 
contributors of support. The researchers explored the participant‘s perceptions of the 
positive and negative drawbacks to their heavy drinking. The negative aspects 
included increased vulnerability to arguments and fights, and the unpleasant 
physical effects of drinking (such as waking up tired, stomach upsets and 
headaches). Many participants mentioned the adverse effects alcohol had had on 
their physical and mental health. Interestingly, several participants mentioned 
drinking in order to cope with difficult life events, but masked this association with 
coping and alcohol by terming it being ‗relaxed‘. Many submerged the notion of 
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coping by using the fact that alcohol helped them relax in distressing situations. 
Thus, the long-term psychological and short-term physical consequences were noted 
as the principle drawbacks of harmful alcohol consumption, whereas coping, 
feelings of being carefree and relaxed, seem to constitute the positive aspects of 
drinking.  
4.2.6 Access and engagement  
In the review of the qualitative literature, several themes emerged under the broad 
heading of ‗access and engagement‘ to services for alcohol misuse, including the 
factors that may act as barriers to accessing treatment services, such as external and 
internal stigma, ethnicity and gender. This review also identified ‗reasons for 
seeking help‘ as a theme emerging from the included studies. There were eight 
studies from which themes of access and engagement emerged (Vargas & Luis, 2008; 
Dyson, 2007; Lock, 2004; Vandevelde et al., 2003; Vandermause & Wood, 2009; 
Nelson-Zlupko et al., 1996; Copeland, 1997; Rolfe et al., 2009; Orford et al., 2006). 
Stigma 
Dyson (2007) found that all participants used strategies to hide their alcohol 
dependence, including covering up the extent of their alcohol consumption. This 
was primarily due to the fear of being judged or stigmatised: ‘I knew that I was ill but 
was too worried about how other people would react. I felt I would be judged’. All 
participants in the study had some contact with healthcare professionals in an 
attempt to control or reduce their drinking. GPs were described as being particularly 
helpful and supportive, and nurses and other healthcare workers as less 
understanding and more dismissive, especially those in accident and emergency 
departments; this contrasts with another study (Lock, 2004), where people who 
misuse alcohol found primary care nurses to be helpful. Social stigma can also occur 
from groups in the community. For example, Morjaria and Orford (2002) highlight in 
their study that South Asian men in the UK often perceive that members of their 
religious community could influence their desire to consume alcohol, and 
furthermore, once religious leaders in the community expressed disapproval of 
alcohol consumption, there was more encouragement towards being abstinent from 
alcohol.  
Ethnicity 
Vandevelde and colleagues‘ (2003) study of treatment for substance misuse looked at 
cultural responsiveness from professionals and clients‘ perspectives in Belgium. 
People from minority groups found it difficult to openly discuss their emotional 
problems due to cultural factors, such as cultural honour and respect. Participants 
stressed the absence of ethno-cultural peers in substance misuse treatment facilities, 
and how this made it hard to maintain the motivation to complete treatment. 
Although this study had a focus on substance misuse (that is, both drugs and 
alcohol), it is important to note its generalisability to alcohol services and treatment.  
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Gender  
Vandermause and Wood (2009) and Nelson-Zlupko and colleagues (1996) both 
looked at experiences and interactions of women with healthcare practitioners in the 
United States. Many women described waiting until their symptoms were severe 
before they would seek out healthcare services: 
 
…it’s hard for me to go in … and it’s not someplace that I want to be, especially when 
I know that I have to be there. I know that I’m ill, I don’t want to admit it… I have to 
get my temperature taken and my blood pressure and they gotta look at my eyes and 
my ears … find out what it is that I’ve got from somebody else sharing a bottle you 
know. 
 
Once the women sought help from a healthcare professional, several felt angry and 
frustrated after repeated clinic visits resulted in being turned away, treated poorly, 
or silenced by comments from healthcare professionals. Some women would go in 
needing to be treated for a physical health problem, and the practitioner would 
address the alcohol problem while ignoring the primary physical complaint.  
 
Conversely, other women were satisfied about how they were treated in interactions 
with their practitioners, which influenced perceptions of the healthcare services, 
seeking out treatment, and feeling comfortable about disclosing their alcohol use: 
 
I was confused and angry, and the doctor made me feel comfortable, even though I was 
very very ill … he let me know that I was an individual person but I had a problem 
that could be arrested. He was very compassionate very empathetic with me and told 
me the medical facts about what was happening to me, why I was the way I was and 
he told me a little bit about treatment, what it would do … so I was able to relax 
enough and stop and listen rather than become defensive… 
 
When women specifically sought treatment for their alcohol use, the authors 
suggested that there was a crucial need for healthcare practitioners to make the 
patient feel comfortable and acknowledge their alcohol problem in addition to 
addressing any other physical health problems.  
 
Nelson-Zlupko and colleagues (1996) found that individual counselling might be 
important in determining whether a woman is retained or drops out of treatment. 
Many women felt that what they wanted from treatment was someone to ‗be there 
for them‘ and lend support. A therapist‘s ability to treat their patients with dignity, 
respect and genuine concern was evaluated as more important than individual 
therapist characteristics (such as ethnicity or age). Some women mentioned that 
good counsellors were those who: 
 
…view you as a person and a woman, not just an addict. They see you have a lot of 
needs and they try to come up with some kind of a plan. 
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Both Nelson-Zlupko and colleagues (1996), and Copeland (1997), highlighted that 
childcare was a particular need for women as it was not widely available in 
treatment. When childcare was available, this was perceived to be among one of the 
most helpful services in improving attendance and use of treatment and 
drug/alcohol services. In addition, women felt strongly about the availability and 
structure of outpatient services offered and felt there should be more flexible 
outpatient programmes taking place in, for example in the evenings or at weekends.  
 
Copeland‘s (1997) Australian study was of women who self-managed change in 
their alcohol dependence and the barriers that they faced in accessing treatment. One 
of the central themes of the study was the social stigma that women felt as being 
drug or alcohol dependent. Seventy-eight per cent of participants felt that women 
were more ‗looked down upon‘ as a result of their drinking, and the additional 
burden of an alcohol or drug problem only increased the stigma. Some women 
reported that the feeling of being stigmatised impacted on their willingness to seek 
treatment:  
 
There is the whole societal thing that women shouldn’t show themselves to be so out 
of control … that stigma thing was part of the reason for not seeking treatment. 
 
In line with this, Rolfe and colleagues (2009) interviewed women in the UK about 
their own perceptions of their heavy alcohol consumption and its relation to a wider 
social perspective. Many women claimed that stigma was a major obstacle to 
accessing treatment services and that, while men did carry stigma as heavy drinkers, 
there was an additional stigma for women due to the way a ‗heavy drinking woman‘ 
was perceived within society. The interviews emphasised that women need to 
perform a ‗balancing act‘ to avoid being stigmatised as a ‗manly‘ woman or as 
someone with alcohol dependence. These discourses are important in understanding 
the perception of gender differences in heavy alcohol consumption and ways in 
which stigma can affect women, and their ability and willingness to seek treatment 
for their alcohol use.  
Reasons for seeking help  
A study conducted by Orford and colleagues (2006) investigated the reasons for 
entering alcohol treatment in the UK. The study was based on pre-treatment 
interviews from participants who were about to commence the UK Alcohol 
Treatment Trial (UKATT) and receive either MET or social behavioural network 
therapy (SBNT) for alcohol dependence or harmful alcohol use. Reasons for entering 
alcohol treatment included the realisation of worsening problems and accumulating 
multiple problems relating to alcohol use, which had a negative impact on both 
family members and the participants‘ health. Participants were also interviewed 
about reasons for seeking professional treatment as opposed to unaided or mutual 
self-help. Common reasons for seeking formal help included such help being 
suggested by primary care workers, a strong belief in the medical model and in 
counselling or psychological therapy, or feelings of helplessness.  
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Accessing help: reasons and preferences  
Lock (2004) conducted a focus group study with patients registered with general 
practices in England. Participants were classified as ‗sensible‘ or ‗heavy/binge 
drinkers‘. Participants responded positively to advice delivered in an appropriate 
context and by a healthcare professional with whom they had developed a rapport. 
Overall, the GP was deemed to be the preferred healthcare professional with whom 
to discuss alcohol issues and deliver brief alcohol interventions. Practice nurses were 
also preferred due to the perception that they were more understanding and more 
approachable than other healthcare workers. Most said they would rather go straight 
to their GP with any concern about alcohol, either because the GP had a sense of the 
patient‘s history, had known them for a long time or because they were traditionally 
who the person would go to see. It was assumed that the GP would have the 
training and experience to deal with the problem, and refer to a specialist if 
necessary. Alcohol workers were perceived by many as the person to go to with 
more severe alcohol misuse because they were experts, but this also carried the 
stigma of being perceived to have a severe alcohol problem. Seeing a counsellor was 
also perceived as negative in some ways, as there would be a stigma surrounding 
mental health problems and going to therapy.  
4.2.7 Experience of assessment and treatment for alcohol misuse 
In the review of the qualitative literature, several themes emerged under the broad 
heading of ‗experience of treatment for alcohol misuse‘, including experience of 
assessment (pre-treatment), assisted withdrawal, other treatments (such as 
psychological interventions) and treatment setting (inpatient). In this review of 
assessment and treatment, there were six studies included (Hyams et al., 1996; 
Orford et al., 2005; Orford et al., 2009; Allen et al., 2005; Smith, 2004; Bacchus, 1999; 
Dyson, 2007).  
Experience of assessment (pre-treatment) 
Hyams and colleagues (1996) interviewed service users about their experience and 
satisfaction with the assessment interview prior to engagement in alcohol treatment. 
The study had both a quantitative and qualitative aspect to it. The qualitative 
component assessed the best and worst aspects of the assessment interview. Thirty-
three of the 131 participants said that the therapeutic relationship with the 
interviewer was most beneficial (as assessed by ‗The interviewer‘s understanding of 
the real me‘, ‗Friendliness of the interviewer‘ and ‗A feeling of genuine care about 
my problems‘). Twenty participants appreciated the ability to talk generally and 
therapeutically to the interviewer about their problems. Eight participants reported 
that the assessment interview provided them with a sense of increased awareness 
about their alcohol use and its impact on their lives: ‘I found insight into why I drink…’ 
Others found that the assessment interview was crucial in taking the first step into 
treatment: ‘Glad that I did attend the interview,’ and ‘Given me some hope’. 
 
Although participants identified few drawbacks regarding the interview, they did 
cite general nervousness particularly about starting the interview. Some criticised 
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the interviewer for not giving enough feedback or not having enough time to talk. 
Several participants felt that it was distressing to have to reveal so much information 
about their drinking problems and to come to a state of painful awareness about 
their problem. This study is noteworthy because it highlights the importance of a 
thorough assessment prior to entering alcohol treatment that allows participants to 
speak freely to an accepting, empathetic interviewer and that, if a positive 
experience for the service user, will increase engagement and motivation to change 
in subsequent alcohol treatment programmes.  
 
In line with these findings, Orford and colleagues (2005) found that a comprehensive 
pre-treatment assessment was perceived by participants to have motivational and 
self-realising aspects to it. Many participants expressed that this assessment was 
influential in increasing motivation to undergo their alcohol treatment.  
Experience of assisted withdrawal 
Two studies, Allen and colleagues (2005) and Smith (2004) captured the patient 
experience of medically-assisted withdrawal programmes for alcohol misuse in both 
the UK and Australia. Both studies found that participants expressed fears about the 
future and a hesitation about coping with life events that had previously been 
associated with alcohol consumption: 
 
I feel safe in the environment but I don’t feel safe with my thoughts at the moment 
because I can’t use alcohol or any drug to cope with it… 
 
The most common themes emerged around fears regarding social environment, the 
physical effects of withdrawal and medication prescribed during detoxification. 
Participants discussed fears about returning to their homes after detoxification, and 
how to lead a life without alcohol: 
 
When you’ve done the first few days [of detoxification], you get your head back 
together and start to think, How am I going to be able to cope outside? You know 
you’ve got to leave here sometime, so how am I going to cope? 
 
Participants also expressed significant concerns about the effects of medication, 
although there were also a number of positive experiences of medication which were 
referred to but were not described in detail. Some participants feared that their 
medication would be addictive:  
 
I didn’t want another problem of having to get off something as well as the booze. I 
was worried that I could get addicted to the tablets as well and then start craving for 
those. 
 
Nearly all participants were apprehensive about the transmission of information 
about medication between the staff and themselves; they felt they had inadequate 
information about what medication they were taking, why they were taking it and 
the effects it may have on them: 
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I didn’t know what they were, what they were going to do to me … they didn’t tell me 
why I was taking them. 
 
It is clear from this study that providing adequate information about assisted 
withdrawal and medication procedures needs to be ensured in alcohol services.  
 
A significant proportion of participants also expressed fears about the physical 
effects of withdrawal, and any pain and/or distress that may be a side effect of the 
detoxification programme. Those who had had previous medically-assisted 
withdrawals prior to this study seemed to have the greatest fears. Lastly, 
participants discussed fears about their future and were concerned about their 
ability to cope once completing the detoxification programme. These fears mostly 
stemmed from difficult interpersonal situations and coping strategies: 
 
I’m worried about having too much time on my hands; the day goes so much quicker 
with a few drinks inside you.  
 
In both studies, participants expressed a lack of confidence and an inability to resist 
temptation; they also felt that they were not being accepted back into their original 
social networks where heavy drinking was perceived as the norm. Additionally, 
fears about the future were related to a feeling that the hospital setting was too far 
removed from real life: 
 
It’s nice and safe in here. You are secure in here. But it’s not real life is it? And it tells 
you nothing about how you are going to cope when you are back in the same old 
situations with the same old problems. 
 
Participants in the Smith (2004) study also articulated feelings of being out of control 
during their admission to treatment. These feelings of distress revolved around the 
difficulty to alter their alcohol consumption, and stick to a reduced consumption 
level or abstinence:  
 
You get well physically and you start thinking clearly … you start telling yourself 
you’re over it … you might maintain some kind of normal drinking activity for a 
short period of time. I just believe that I can’t keep doing it. I don’t want to. 
 
With each medically-assisted withdrawal, the goal of abstinence seemed more 
distant – the thought of this was anxiety-provoking for many participants as they felt 
they would be unable to maintain abstinence in the future. After medically-assisted 
withdrawal, they would have to return to a life where all their personal, professional 
and relationship difficulties still existed but were previously associated with alcohol.  
 
Conversely, there were positive feelings about treatment, as most felt they had taken 
steps to bring about positive changes in their lives by seeking treatment. The facility 
enabled participants to have respite from their lives as well as social and emotional 
support from other participants in the programme. The authors suggested that 
nurses could assist participants in reducing negative feelings (such as shame) by 
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closely observing behaviour and being more sensitive and empathetic to service 
users‘ feelings, thereby strengthening therapeutic communication between staff and 
patients.  
Experience of psychological treatment  
Orford and colleagues (2005, 2008) carried out a content analysis of service users‘ 
perspectives on change during a psychological intervention for their alcohol 
dependence in UKATT. Participants highlighted that psychological treatment had 
helped them to think differently, for example about fearing the future and focusing 
on the downside of drinking. Others talked of adopting a more positive outlook or 
more alcohol-focused thinking (for example, paying attention to the physical 
consequences such as liver disease or brain damage). Several participants mentioned 
that, ‘the questions, the talking, being honest, being open – that was positive [of treatment]’. 
Other factors to which change was attributed to were awareness of the consequences 
of drinking and feeling comfortable talking about their alcohol consumption.  
Experience of support from family and voluntary organisations  
Orford and colleagues (2005) also found that the influence of family and friends 
helped in promoting change in alcohol consumption. Treatment seemed to assist 
participants in finding non-drink related activities and friends, and seeking out more 
support from their social networks to deal with problematic situations involving 
alcohol. Supportive networks provided by AA and the 12-step programme 
facilitated recovery for participants in the Dyson (2007) study as well, because they 
were able to be with others who genuinely understood their experiences and 
fostered a sense of acceptance: ‘Here was a bunch of people who really understood where I 
was coming from’.  
Experience of treatment setting – inpatient  
Bacchus (1999) carried out a study about opinions of inpatient treatment for drug 
and alcohol dependence. Over one third of participants reported that they would 
have preferred to enter treatment sooner because there was an urgent need to 
maintain treatment motivation and receive acute medical care: 
 
When you make that decision to ask for help, you need it straight away. If you have to 
wait a long time to get in you just lose your motivation and you might just give up. 
 
Participants also felt frustrated about the lack of communication and liaison from the 
referring agency during the waiting period. The structured individual and group 
counselling treatment programme was seen as a generally effective way of 
improving self-confidence and self-esteem. Educational group discussions about 
substance use and risks were particularly positively regarded. Recreational groups 
(for example, art therapy, exercise and cookery) also proved to be beneficial in terms 
of engaging in other non-drink related activities. One of the most positive aspects of 
treatment noted by participants was the quality of the therapeutic relationships. Staff 
attitudes, support, and being non-judgemental and empathetic were all mentioned 
as crucial components of a positive experience in treatment. Sixty-two per cent of 
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patients had made prior arrangements with staff for aftercare treatment and 
expressed satisfaction with the arrangements. The only exception was that patients 
wished for more detailed information about the next phase of their treatment.  
4.2.8 Experience of recovery 
Four studies (Burman, 1997; Mohatt et al., 2007; Morjaria & Orford, 2002; Yeh et al., 
2009) looked at the experience and process of recovery for people who misuse 
alcohol. All studies with the exception of Yeh and colleagues (2009) looked at 
recovery from the standpoint of drinkers who were untreated. Nearly all the studies 
highlighted the importance of utilising active coping and moderation strategies in 
order to stop consuming alcohol, and a number of the studies touch on the 
importance of positive social support networks, faith and self-help groups.  
 
Morjaria and Orford (2002) examined the role of religion and spirituality in 
promoting recovery from drinking problems, specifically in AA programmes and in 
South Asian men. Both South Asian men and men in AA began recovery once there 
was a feeling of hitting ‗rock bottom‘ or of reaching a turning point where they felt 
their drinking must stop. Both groups drew on faith to help promote recovery, but 
the South Asian men already had a developed faith from which to draw upon, 
whereas the men in AA had to come to accept a set of beliefs or value system and 
develop religious faith to help promote abstinence.  
 
In terms of self-recovery strategies, participants in Burman (1997), Yeh and 
colleagues (2009) and Mohatt and colleagues (2007) often utilised recovery strategies 
that mirrored those in formal treatment, consisting of drawing on social support 
networks and avoiding alcohol and alcohol-related situations. Seeing another person 
giving up alcohol also helped to promote abstinence and motivation, again 
highlighting the necessity of positive support networks. Another stage of sobriety 
for participants in Mohatt‘s study (2007) involved a more gradual acceptance of their 
vulnerability towards consuming alcohol and continuing to strategise and resist the 
urge to drink. Additional coping strategies outlined by Burman (1997) were: setting 
a time limit for recovery; discussing their goals and plans with others to help keep 
them on track; and keeping reminders of negative experiences to help prevent 
further relapse.  
 
Similar to those in formal treatment programmes, once in the midst of self-recovery, 
participants reported a number of positive changes since abstaining (for example, 
increased energy and memory, self-awareness and empowerment), and more 
external benefits including regaining trust from their social networks and 
reintegrating into society. Negative consequences of abstinence included edginess 
and physical side effects, family problems, struggles with craving and a loss of a 
specific social circle or group previously related to alcohol.  
 
Taken together, the self-recovery studies highlight the process of abstinence for 
alcoholics, stressing that the path is not straightforward, and assistance from self-
help groups and social support networks are crucial to help ensure a better recovery.  
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4.2.9 Carer experiences  
Four studies (Gance-Cleveland, 2004; Murray, 1998; Orford et al., 1998; Orford et al., 
2002) were found that could be categorised under the heading ‗carer experiences‘.  
 
Orford and colleagues (1998) conducted cross-sectional interview and questionnaire 
studies with a series of family members in two sociocultural groups, in Mexico City 
and in west of England. They found that there were three approaches to interacting 
with their family members who misuse alcohol: (1) tolerating; (2) engaging; and (3) 
withdrawing. In the first approach, the carer would tolerate inaction and support the 
person in a passive way. Some carers mentioned taking the ‗engaging‘ position with 
their family members in an attempt to change unacceptable and excessive substance 
use. Some forms of engagement were more controlling and emotional in nature; 
others more assertive and supportive. Lastly, some carers mentioned emotionally 
and physically withdrawing from their family members with an alcohol problem 
(for example, asking their alcohol-using family member to leave the house). This was 
seen as a way to detach oneself from the alcohol problem of their family member. 
One form of coping that carers also mentioned was that one needs to enforce 
supportive and assertive coping:  
 
You need to be very strong, to be there and talk to [him/her] but still stick to your 
own values and beliefs in life.  
 
There was significant overlap between the coping strategies outlined by both 
families from England and from Mexico. Families in both countries used assertive 
and supportive ways of coping with their family member‘s alcohol problem, either 
through direct confrontation, financial or emotional sacrifice. Thus, even given a 
different sociocultural context, there are several common ways for carers to cope and 
interact with a family member with an alcohol problem.  
 
Orford and colleagues (2002) interviewed the close relatives of untreated heavy 
drinkers. Most relatives recognised the positive aspects of their family member 
consuming alcohol (for example, social benefits) and reported a few drawbacks to 
drinking. Many family members contrasted their family member‘s current problem 
with how their problem used to be. Other family members used controlling tactics 
(for example, checking bottles) as a way to monitor their family members, while 
others tried to be tolerant and accepting of their family member‘s drinking 
behaviour.  
 
There are two qualitative studies that have looked at the perspectives and 
experiences of people whose parents misuse alcohol. Murray (1998) conducted a 
qualitative analysis of five in-depth accounts of adolescents with parents who 
misuse alcohol and found four main themes: (1) ‗The nightmare‘, which includes 
betrayal (abuse/abandonment), over-responsibility, shame, fear, anger, lack of trust 
and the need to escape; (2) ‗The lost dream‘- which consists of loss of identity and 
childhood (lack of parenting, comparing oneself with others, unrealistic 
expectations); (3) ‗The dichotomies‘, which is the struggle between dichotomies, for 
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example, love and hate (towards parents), fear and hope (towards the future) and 
denial and reality; (4) ‗The awakening‘, which is gaining an understanding of the 
problem, realising alcohol is not an answer (possibly through their own 
experiences), realising they were not to blame and regaining a sense of self.  
 
Another qualitative study (Gance-Cleveland, 2004) investigated the benefit of a 
school-based support group for children with parents who misuse alcohol and found 
that the group helped them to identify commonalities with each other, feel that they 
were understood, support and challenge each other, and share coping strategies. The 
children who took part also felt that the group was a trusted and safe place in which 
they could reveal secrets and feel less isolated and lonely, that it enabled them to be 
more aware of the impact of addiction on family dynamics, and helped them 
increase resilience and do better at school (Gance-Cleveland, 2004). In conclusion, 
talking to others (especially with those who have had similar experiences) was found 
to be helpful in terms of coping, making friendships and understanding more about 
alcohol misuse.  
4.2.10  Staff experiences  
There were six studies (Aira et al., 2003; Beich et al., 2002; Kaner et al., 2006; Lock et 
al., 2002; Vandermause, 2007; Vandevelde et al., 2003, Vargas & Luis, 2008) looking at 
the experience of staff who work with people who misuse alcohol. There were 
several themes emerging from staff experiences, the first being hesitancy in 
delivering brief interventions to people who misuse alcohol. Staff implementing the 
WHO screening and brief intervention programme in Denmark found that it was 
difficult to establish a rapport with patients who screened positive for alcohol 
misuse and ensure adherence with the intervention (Beich et al., 2002). In England, 
primary care practitioners had little confidence in their ability to deliver brief 
interventions and override negative reactions from patients (Lock et al., 2002). 
Furthermore, because alcohol misuse can be a sensitive and emotional topic, a 
significant proportion of the staff in the studies expressed a lack of confidence about 
their ability to counsel patients effectively on lifestyle issues (Aira et al., 2003; Beich et 
al., 2002; Lock et al., 2002): 
 
The patient does not bring it up and obviously is hiding it … [Alcohol] is a more 
awkward issue; which of course must be brought up… 
 
Approaching emotional problems related to substance misuse through the medical 
dimension might facilitate the treatment of minority groups, because it was 
perceived that emotional problems were more often expressed somatically 
(Vandevelde et al., 2003). 
 
A positive experience with a service user involved an assessment using effective 
diagnostic tools where staff were able to employ an indirect, non-confrontational 
approach and service users were able to discuss their problems and tell their story at 
their own pace (Vandermause, 2007).  
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Both Beich and colleagues (2002) and Lock and colleagues (2002) highlighted that 
brief interventions and confronting service users regarding their alcohol 
consumption was important; there were, however, a number of significant barriers 
to delivering these interventions effectively (for example, the fear of eliciting 
negative reactions from their patients). Staff interviewed in the Vandermause (2007) 
qualitative study also found that staff had concerns about defining alcohol as 
problematic for their patients.  
 
Aira and colleagues (2003) found that staff were not ready to routinely inquire about 
alcohol consumption in their consultations, unless an alcohol problem was 
specifically indicated (for example, the service user was experiencing sleeplessness, 
high blood pressure or dyspepsia). Even when they were aware of alcohol misuse in 
advance, staff still had significant difficulty in finding the ideal opportunity to raise 
the issue with their patients. If they did not know in advance about a drinking 
problem, they did not raise the issue.  
 
Kaner and colleagues (2006) looked at GPs‘ own drinking behaviour in relation to 
recognising alcohol-related risks and problems in their patients. The interviews 
indicated that GPs‘ perceived their own drinking behaviour in two ways. Some GPs 
drew on their own drinking behaviour when talking to patients, as it could be seen 
as an opportunity to enable patients to gain insight into alcohol issues, facilitate 
discussion and incorporate empathy into the interaction. Other GPs separated their 
own drinking behaviour from that of ‗others‘, thereby only recognising at-risk 
behaviours in patients who were least like them.  
 
Vargas and Luis (2008) interviewed nurses from public district health units in Brazil, 
and discovered that despite alcoholism being perceived as a disease by most of the 
nurses, the patients who misuse alcohol who seek treatment are still stigmatised: 
 
We generally think the alcohol addict is a bum, an irresponsible person, we give them 
all of these attributes and it doesn’t occur to you that [he/she] is sick. 
 
Furthermore, the nurses interviewed seemed to express little hope and optimism for 
their patients because they believed that after being assisted and detoxified, they 
would relapse and continue drinking: 
 
he comes here looking for care, takes some glucose and some medications, and as soon 
as he is discharged he goes back to the... drink. 
 
This study highlights the extent of external stigma that those who misuse alcohol can 
face within the healthcare setting, and how it could prevent positive change due to 
an apprehension about continually accessing services or seeking help.  
 
All six studies made recommendations for improving staff experience when 
engaging with people who misuse alcohol, with an emphasis on training, 
communication skills and engaging patients about alcohol consumption, combined 
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with a flexible approach to enhance dialogue and interaction. However, although 
many healthcare professionals received training about delivering brief interventions, 
many lacked the confidence to do so and questioned their ability to motivate their 
patients to reduce their alcohol consumption. Staff also frequently cited a lack of 
guidance concerning alcohol consumption and health. Clear health messages, better 
preparation and training, and more support were cited as recommendations for 
future programmes. As many healthcare professionals found screening for excessive 
alcohol use created more problems than it solved, perhaps improving screening 
procedures could improve the experience of staff delivering these interventions.  
4.2.11  Summary of the literature 
The evidence from the qualitative literature provides some important insights into 
the experience of people who misuse alcohol, their carers and staff. Problematic 
alcohol consumption appears to stem from a range of environmental and social 
factors, including using alcohol to cope with stressful life events, having family 
members with alcohol or drug problems and/or social situations that encourage the 
consumption of alcohol. A cycle of dependence then begins wherein the person goes 
through stages of indulgence in, ambivalence towards and attempts to abstain from 
alcohol (Yeh et al., 2009), resulting in a loss of control over their alcohol 
consumption. This leads to the consumption of more alcohol to counteract 
unpleasant physical or mental states. As the alcohol consumption becomes harmful, 
there seems to be an accumulation of negative alcohol-related events. These can 
become the catalyst for change in the person‘s life, when the person realises that 
their alcohol problem requires further assistance and/or treatment. This readiness or 
willingness to change needs to be determined by the person who misuses alcohol, 
sometimes with support and insight from their social networks – readiness to change 
cannot be imposed externally. These differing patterns of alcohol consumption and 
reasons for deciding to engage in treatment or change one‘s behaviour mean that 
treatment services need to understand an individual‘s reasons for drinking and how 
this may influence treatment. 
 
With regard to access and engagement in treatment, once people who misuse alcohol 
had made the conscious decision to abstain from or reduce their drinking, they were 
more willing to access treatment, although external factors and the motivational 
skills of healthcare professional may also play a part. Barriers to treatment included 
internal and external stigma, an apprehension towards discussing alcohol-related 
issues with healthcare professionals, and a fear of treatment and the unpleasant 
effects of stopping drinking. As a group, women felt that they faced additional 
barriers to treatment in the form of more social stigma, and the need for childcare 
while seeking and undergoing treatment. In addition, women felt that they received 
less support from treatment providers, and would benefit from a more empathetic 
and therapeutic approach. The studies focusing on women and alcohol problems 
emphasise that a non-judgemental atmosphere in primary care is necessary in order 
to foster openness and willingness to change with regard to their alcohol problems. 
 
 79 
 
In one study looking at the impact of ethnicity and culture on access to treatment, 
participants from an ethnic minority report having mostly positive experiences with 
healthcare practitioners, but improvements could be made to the system in the form 
of more ethno-cultural peers and increased awareness of culture and how it shapes 
alcohol consumption and misuse.  
 
The literature strongly suggests that assessments that incorporate motivational cues 
are crucial in ensuring and promoting readiness to change early on in the treatment 
process. Having open and friendly interviewers conducting the assessments also 
seems to have an effect on increasing disclosure of information and the person‘s 
willingness to enter into subsequent alcohol treatment.  
 
Although there were some positive experiences of medication, the qualitative 
literature highlights consistent fears surrounding assisted withdrawal and the 
unpleasant effects one may experience while in treatment. Many participants across 
studies fear the future and not being able to adopt appropriate coping strategies that 
will assist in preventing relapse once they return to their familiar social milieu. More 
information from staff in alcohol services may be beneficial in alleviating patient‘s 
fears about treatment.  
 
Psychological treatment was seen to facilitate insight into one‘s drinking behaviour 
and understand the downsides of drinking. Talking with a therapist honestly and 
openly about alcohol helped in alleviating fears about the future and developing 
coping strategies. Within a residential treatment programme setting, a therapeutic 
ethos and a strong therapeutic relationship were regarded as the most positive 
aspects of alcohol treatment.  
 
Active coping and moderation strategies, self-help groups, rehabilitation 
programmes and aftercare programmes were found to be helpful in preventing 
relapse post-treatment, and social support networks may serve as an additional 
motivation to change and can help promote long-term recovery. It should be noted 
that these findings were from studies of untreated drinkers, so this should be 
interpreted with caution if generalising to a population formally in treatment. 
Emphasis on a therapeutic relationship between healthcare practitioners and 
patients and good communication seem integral to promoting recovery. Social 
support, empathic feedback, and adequate information provision also facilitate the 
recovery process.  
 
Family and friends can have an important role in supporting a person with an 
alcohol problem to promote and maintain change, but in order to do this they 
require information and support from healthcare professionals. But the strain on 
carers can be challenging and they may require a carer‘s assessment.  
 
From a staff perspective, the qualitative studies suggest that many staff in primary 
care have feelings of inadequacy when delivering interventions for alcohol misuse 
and lack the training they need to work confidently in this area. An improvement in 
 80 
 
staff training is required to facilitate access and engagement in treatment for people 
with alcohol problems. When interventions were successfully delivered, assessment 
and diagnostic tools were seen as crucial. In addition, thorough assessment and 
diagnostic tools may aid in the process of assessing and treating patients with 
alcohol use disorders.  
 
Even if they were aware of a problem, many healthcare professionals felt they had 
inadequate training, lack of resources, or were unable to carry out motivational 
techniques themselves. More training about harmful drinking populations and 
associated interventions, as well as more awareness about how to interact with these 
populations from a primary care perspective, should be considered.  
4.3 FROM EVIDENCE TO RECOMMENDATIONS 
In reviewing the qualitative literature, the GDG were able to make a number of 
recommendations addressing experience of care. However, it should be noted that 
some of the evidence reviewed in this chapter contributed to the formulation of 
recommendations in other chapters, in particular Chapter 5.  
 
Stigma was a prevalent theme in the literature review. It was experienced both 
externally (mostly from healthcare professionals) and internally; internal stigma 
could result in concealment of the person‘s alcohol problem from others due to fear 
or shame, therefore healthcare professionals should take this into account when 
working with people who misuse alcohol and ensure that the setting is conducive to 
full disclosure of the person‘s problems. The positive aspects and benefits of a 
therapeutic relationship both in a treatment setting and in assessment procedures 
were cited frequently. This highlights the need for healthcare professionals to 
interact with people who misuse alcohol in an encouraging and non-judgemental 
manner. A number of studies also focused on the importance of good information 
about alcohol misuse and about its treatment (particularly assisted withdrawal), and 
the GDG makes a detailed recommendation about provision of comprehensive and 
accessible information. 
 
The GDG also makes a number of recommendations regarding working with 
families and carers. Given the challenges of caring for someone with an alcohol 
problem, as described in the review of the literature, more information and support 
should be available to carers and there should be an emphasis on including them in 
the treatment process, if this is appropriate and the service user agrees. Furthermore, 
with the understanding of how important positive social support networks are in 
maintaining positive change, helping carers supporting their supportive role is 
crucial in order to promote change.  
 
Children of parents who have alcohol problems will have specific needs that should 
be recognised. They may struggle to form stable relationships and their education 
and own mental health may be affected. More opportunities to support those who 
have parents with alcohol problems, as well as finding ways for them to talk about 
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their emotions, would be beneficial and may help prevent the child or young person 
developing their own alcohol problems later in life.  
4.4 RECOMMENDATIONS 
Building a trusting relationship and providing information  
4.4.1.1 When working with people who misuse alcohol: 
 build a trusting relationship and work in a supportive, empathic and 
non-judgmental manner 
 take into account that stigma and discrimination are often associated 
with alcohol misuse and that minimising the problem may be part of 
the service user‘s presentation 
 make sure that discussions take place in settings in which 
confidentiality, privacy and dignity are respected. 
4.4.1.2 When working with people who misuse alcohol: 
 provide information appropriate to their level of understanding about 
the nature and treatment of alcohol misuse to support choice from a 
range of evidence-based treatments 
 avoid clinical language without explanation 
 make sure that comprehensive written information is available in an 
appropriate language or, for those who cannot use written text, in an 
accessible format  
 provide independent interpreters (that is, someone who is not known 
to the service user) if needed. 
Working with and supporting families and carers  
4.4.1.3 Encourage families and carers to be involved in the treatment and care of 
people who misuse alcohol to help support and maintain positive change. 
4.4.1.4 When families and carers are involved in supporting a person who misuses 
alcohol, discuss concerns about the impact of alcohol misuse on themselves 
and other family members, and: 
 provide written and verbal information on alcohol misuse and its 
management, including how families and carers can support the 
service user 
 offer a carer‘s assessment where necessary 
 negotiate with the service user and their family or carer about the 
family or carer‘s involvement in their care and the sharing of 
information; make sure the service user‘s, family‘s and carer‘s right to 
confidentiality is respected. 
 82 
 
4.4.1.5 All staff in contact with parents who misuse alcohol and who have care of or 
regular contact with their children, should: 
 take account of the impact of the parent‘s drinking on the parent-child 
relationship and the child‘s development, education, mental and 
physical health, own alcohol use, safety and social network 
 be aware of and comply with the requirements of the Children Act 
(2004). 
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5 ORGANISATION AND DELIVERY 
OF CARE  
SECTION 1 – INTRODUCTION TO THE 
ORGANISATION AND DELIVERY OF CARE 
5.1 INTRODUCTION 
This chapter provides an overview of the types of services available for people who 
misuse alcohol and how they are currently organised, and reviews the evidence to 
guide future development and improvements in service provision. The key concepts 
underpinning service organisation and delivery will be explained and their nature 
and role will be defined. These concepts will build on existing guidance in the field, 
notably Models of Care for Alcohol Misusers (MoCAM) developed by the National 
Treatment Agency and the Department of Health (Department of Health, 2006a) and 
the Review of the Effectiveness of Treatment for Alcohol Problems (Raistrick et al., 2006). 
Where relevant parallel guidance from NICE on alcohol services will be referred to, 
in particular the NICE guideline on prevention and early detection (NICE, 2010a) 
and the NICE guideline on management of alcohol-related physical complications 
(NICE, 2010b). Because this guideline was the last in the suite of NICE guidelines on 
alcohol misuse to be developed, this chapter aims to integrate and provide an 
overview of how the various guidelines are related in order to support the 
development of a comprehensive pathway for the care and treatment of alcohol 
misuse. 
 
In Chapter 2 it was highlighted that alcohol service commissioning and provision 
across England is variable and in some cases poorly integrated (National Audit 
Office, 2008). Hence the availability of alcohol services and the extent to which they 
meet the needs of people who misuse alcohol vary across England (Drummond et al., 
2005). The GDG also took the view that there is a lack of clarity in the field about 
which kinds of alcohol services are most beneficial for which people – for example, 
who should be treated in a community setting compared with a residential setting, 
what constitutes an adequate assessment of individual‘s presenting needs and how 
an individual‘s care can be most appropriately coordinated. These are all key 
questions that need to be addressed. This lack of clarity has resulted in diverse 
commissioning and provision of alcohol services. 
 
This chapter will also highlight that the provision of care for people who misuse 
alcohol is not solely the responsibility of the agencies and staff who specialise in 
alcohol treatment. Staff across a wide range of health, social care and criminal justice 
services, who are not exclusively working with people who misuse alcohol but 
regularly come into contact with them in the course of providing other services, also 
have a crucial role to play in helping people to access appropriate care. In some 
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cases, staff that are not alcohol treatment specialists (most notably those working in 
primary care) will have a role in delivering key elements of an integrated care 
pathway for this population. 
 
The chapter begins by describing the organising principles of care for people who 
misuse alcohol, followed by a description of the different types of services and how 
they are currently organised; where relevant, existing definitions and frameworks 
will be referred to. We will then review the principles and methods of care delivery, 
including assessment, care coordination, integrated care pathways and stepped care. 
We will review evidence on case management, stepped care, ACT, assessment, 
assisted alcohol withdrawal and care delivered in residential versus community 
settings. The chapter will conclude with a description of the main care pathways 
stemming from the findings of the evidence review. 
5.2 ORGANISING PRINCIPLES OF CARE 
The introductory chapter highlighted the diverse range and severity of alcohol 
misuse that exist in the general population, from hazardous and harmful drinking 
through to alcohol dependence of varying degrees of severity. Alcohol misuse is 
associated with a wide range of physical, psychological and social problems, some of 
which are a direct consequence of drinking and others are incidental, but often 
highly relevant, in planning and delivering individual care. For example, a harmful 
alcohol user who is homeless and suffering from mental health problems may have 
more significant care needs than a more severely dependent drinker who has stable 
accommodation and employment and no psychiatric comorbidity.  
 
It was also noted in Chapter 2 that in many cases alcohol misuse remits without any 
form of formal intervention or contact with the health or social care system, let alone 
specialist alcohol treatment. Studies of what has been referred to as ‗spontaneous 
remission‘ from alcohol misuse find that this is often attributed, by individuals, to 
both positive and negative life events, such as getting married, taking on childcare 
responsibilities, or experiencing a negative consequence of drinking such as being 
arrested, having an accident or experiencing alcoholic hepatitis. It therefore follows 
that not everyone in the general population who meets the criteria for a diagnosis of 
an alcohol-use disorder requires specialist treatment. Often a brief intervention from 
a GP, for example, may be sufficient to help an individual reduce their drinking to a 
less harmful level (see NICE guideline on prevention and early detection [NICE, 
2010a]). 
 
Nevertheless, the level of alcohol consumption, and the severity of alcohol 
dependence and alcohol-related problems, are positively correlated such that people 
with more severe alcohol dependence usually have more severe problems and 
greater care needs (Wu & Ringwalt, 2004). Also, a proportion of people will require 
professional intervention to achieve sufficient change in their drinking behaviour, or 
to shorten the course of their alcohol-use disorder. 
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A useful framework for this spectrum of need and the intensity of professional 
responses was provided by Raistrick and colleagues (2006), adapted from work 
originally developed the US Institute of Medicine (2003) (Figure 3). Whilst the 
authors noted that alcohol problems exist on a continuum of severity rather than in 
categories, and that an individual can move between categories over time, the 
framework provides a useful general principle that people with more severe 
problems generally require more intensive and specialised interventions. While 
matching people who misuse alcohol to different treatment intensities based on the 
severity of their problems has some empirical support (Mattson et al., 1994) this has 
not generally been borne out in studies designed specifically to test matching 
hypotheses (DRUMMOND2009). This issue will be explored in more detail 
throughout this guideline. 
 
 
Figure 3: A spectrum of responses to alcohol problems. Reproduced from a review 
of the effectiveness of treatment for alcohol problems (Raistrick et al., 2006). 
 
Figure 3 is a schematic representation of the population of England, with the 
spectrum of alcohol problems experienced by the population and their relative 
prevalence shown along the upper side of the figure. Responses to these problems 
are shown along the lower side. The dotted lines suggest that primary prevention, 
simple brief intervention, extended brief intervention and less-intensive treatment 
may have effects beyond their main target area. Although the figure is not drawn to 
scale, the prevalence in the population of each of the categories of alcohol problem is 
approximated by the area of the triangle occupied; most people have no alcohol 
problems, a very large number show risky consumption but no current problems, 
many have risky consumption and less serious alcohol problems, some have 
moderate dependence and problems and a few have severe dependence or 
complicated alcohol problems. 
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5.3 SERVICES FOR PEOPLE WHO MISUSE ALCOHOL 
5.3.1 Introduction 
The provision of alcohol services in England, from the Second World War until 
around the 1970s, was driven by a view of alcoholism as an all-or-nothing disease 
state, affecting a relatively small proportion of the population and requiring 
intensive, specialist treatment with the goal of complete abstinence from alcohol, 
often provided in inpatient specialist units closely affiliated with the AA fellowship 
(DRUMMOND2009). From the 1970s, there came greater recognition of a wider 
spectrum of alcohol misuse that could respond to less intensive interventions as well 
as the development of public health approaches to alcohol misuse. This, combined 
with evidence from randomised trials which questioned the value of inpatient 
treatment, led to a shift towards more community-based care and early brief 
interventions provided by GPs. Many of the large regional inpatient alcohol units in 
England subsequently closed and many of the NHS staff moved to work in newly 
created community alcohol teams, along with growth in community-based non-
statutory alcohol counselling services. The current service provision in England with 
its patchwork of brief alcohol interventions provided by GPs, NHS and non-
statutory specialist community alcohol services, some remaining NHS inpatient 
units providing mainly assisted alcohol withdrawal, and a declining number of 
residential alcohol rehabilitation agencies, mostly in the non-statutory or private 
sectors, are a legacy of this gradual and incomplete shift towards community-based 
care. 
5.3.2 Classification of interventions and services 
Services and interventions for alcohol misuse can be classified in several different 
ways. Models of Care in the Treatment of Adult Drug Misusers (National Treatment 
Agency for Substance Misuse, 2002; 2006b) and MoCAM (Department of Health, 
2006a) describe individual interventions as belonging to different tiers, within a 4-
tier framework. As noted in MoCAM this has been widely interpreted in the field as 
individual agencies rather than interventions belonging to tiers, which has had 
unintended consequences. Interventions are individual elements of care (for 
example, a brief intervention, assisted alcohol withdrawal or CBT) which, when 
combined, comprise a programme of care for the individual. These interventions 
can, and often are, delivered by a range of both generic (for example, GPs, 
physicians in acute hospitals, prison healthcare staff) and alcohol-specialist staff 
working in a wide range of agencies (for example, NHS, non-statutory, criminal 
justice, and social care). So the tier to which an intervention belongs is determined by 
its nature and intensity, rather than the agency delivering it. 
5.3.3 Alcohol interventions 
Within MoCAM, Tier 1 interventions include identification of alcohol misuse; 
provision of information on sensible drinking; simple brief interventions to reduce 
alcohol related harm; and referral of those with alcohol dependence or harm for 
more intensive interventions. These can be delivered by a wide range of staff in a 
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various settings, including accident and emergency departments, primary care, acute 
hospitals, mental health services, criminal justice services and social services. 
 
Tier 2 interventions include open-access facilities and outreach that provide: alcohol-
specific advice, information and support; extended brief interventions; and triage 
assessment and referral of those with more serious alcohol-related problems for ‗care 
planned‘ treatment. ‗Care planned‘ treatment refers to the process of planning and 
reviewing care within the context of structured alcohol treatment, and this is located 
within Tier 3. If staff have the appropriate competencies to deliver Tier 2 
interventions, these can be delivered by the same range of agencies as Tier 1 
interventions.  
 
Tier 3 interventions include the provision of community-based specialist alcohol 
misuse assessment, and alcohol treatment that is coordinated and planned (see 
below). These include comprehensive assessment, structured psychological 
interventions or pharmacological interventions which aim to prevent relapse, 
community-based assisted alcohol withdrawal, day programmes and specialist 
alcohol liaison provided to for example, acute hospitals by specialist staff. Tier 3 
interventions are usually provided by staff working in specialist alcohol treatment 
agencies both NHS and non-statutory (although the latter are often funded by the 
NHS to provide these interventions). Important exceptions to this are GPs who may 
provide more specialised interventions within a Direct Enhanced Services contract 
(NHS Employers, 2008). Interventions provided by GPs often involve assisted 
alcohol withdrawal in the community or prescribing medication for relapse 
prevention. As with interventions in other tiers, staff need to have the relevant 
competence to be able to provide them safely and effectively. 
 
Tier 4 interventions include the provision of residential, specialised alcohol treatments 
that are planned and coordinated, to ensure continuity of care and aftercare. These 
interventions include comprehensive assessment, inpatient assisted alcohol 
withdrawal and structured psychosocial interventions provided in a residential 
setting, including residential rehabilitation. ‗Wet‘ hostels also fit within this tier, 
although they operate more on a ‗harm reduction‘ than an abstinence-oriented 
model of care. Tier 4 interventions are usually provided by specialist alcohol 
inpatient or residential rehabilitation units. However, assisted alcohol withdrawal is 
often provided in other residential settings, including acute hospitals, mental health 
inpatient services, police custody and prisons, delivered by medical and other staff 
whose primary role is not specialist alcohol treatment. 
5.3.4 Agencies 
A diverse range of health, social care and criminal justice agencies provide alcohol 
interventions. These agencies can be classified into specialist alcohol treatment 
agencies, whose primary role it is to provide interventions for people who misuse 
alcohol, and generic agencies, which are not primarily focused on alcohol treatment 
(National Treatment Agency for Substance Misuse, 2006). In practice the majority of 
specialist alcohol agencies also provide treatment for people who misuse drugs, or 
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both drugs and alcohol. Specialist alcohol treatment agencies are provided by NHS 
trusts (usually mental health NHS trusts), non-statutory agencies and the private 
sector, with considerable overlap in the range of interventions provided across the 
different sectors. However, many of these agencies are funded by the NHS. Some 
agencies provide both community-based and residential interventions, whereas 
others primarily deliver interventions in one setting. For example, specialist NHS 
alcohol treatment services often have a community alcohol (or drug and alcohol) 
team linked to a specialist inpatient alcohol treatment unit in the same locality, with 
some staff working in both settings. Some non-statutory agencies exclusively 
provide residential rehabilitation with a regional or national catchment area, or 
community-based day programmes with a smaller local catchment area. There is 
considerable diversity in the nature of provision across agencies and different parts 
of the country, in part reflecting differences in commissioning patterns (Drummond 
et al., 2005) 
 
A national survey of alcohol treatment agencies in England, conducted in 2005 as 
part of the ANARP (Drummond et al., 2005), identified 696 agencies providing 
specialist alcohol interventions. Nearly 69% of alcohol agencies were community 
based and 31% were residential services. One third were primarily alcohol services 
and 58% were combined drug and alcohol services. Over half of all agencies were 
non-statutory, one-third statutory (NHS) and 8% private sector. Interventions 
provided by these agencies were classified according to MoCAM criteria. 
Community agencies most commonly provided advice, briefer treatments and 
structured psychological interventions. Residential agencies most commonly 
provided residential rehabilitation and inpatient treatment, including assisted 
withdrawal. Overall, 45% of community agencies and 46% of residential agencies 
provided assisted alcohol withdrawal. Residential agencies reported greater severity 
of alcohol misuse in their client group, with 91% of clients said to be alcohol 
dependent compared with 71% of community agency clients (Drummond et al., 
2005). The estimated annual spend on specialist alcohol treatment in England was 
£217 million and the estimated number of whole time equivalent staff working in 
this field was 4,250 (Drummond et al., 2005). 
 
The American Society of Addiction Medicine (ASAM) has developed criteria to 
define different types of services, some of which are partly relevant to the UK. Some 
aspects of their classification are helpful in understanding the terminology used later 
in this chapter in the evidence review and the GDG recommendations. 
 
ASAM defines four levels of care (ASAM, 2001) (see Text Box 2). Level I outpatient 
treatment involves regular scheduled sessions at a specialist treatment centre, 
whereas Level II refers to more intensive outpatient treatment/partial 
hospitalisation. Both fit within Tier 3 community-based interventions in the MoCAM 
framework, but they offer a different intensity of intervention. Level II is closest to 
what has been described in England as an intensive day programme, although the 
typical programme in England does not offer a 7 days per week service. The Level I 
care is the more typical provision in England.  
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ASAM Levels III and IV both fit within MoCAM Tier 4 interventions. Level III is 
residential (medically monitored) treatment which is closest to residential 
rehabilitation in England and provides medical cover, often by local GPs who are 
not necessarily specialists in alcohol treatment. Level IV is medically managed 
intensive inpatient treatment which is closest to NHS provided inpatient treatment 
and is usually led by specialist addiction psychiatrists in England.  
 
Text Box 2: Levels of care for addiction treatment (ASAM, 2001) 
Level I – Outpatient treatment 
Treatment provided in regularly scheduled sessions at a treatment centre, 
designed to help the individual achieve changes in their alcohol use and 
physical, psychological and social functioning 
 
Level II – Intensive outpatient treatment/partial hospitalisation 
An organised outpatient service that delivers treatment services during the day, 
before or after work or school, in the evenings or on weekends. Such treatment 
may include medical and psychiatric assessment and treatment, medication, 
psychological interventions, and educational, housing and employment 
support. 
 
Level III – Residential (medically-monitored) treatment 
Organised services staffed by designated addiction treatment and mental health 
personnel who provide a planned regimen of care in a 24-hour live-in setting. 
Such services adhere to defined sets of policies and procedures. They are 
housed in, or affiliated with, permanent facilities where patients can reside 
safely. They are staffed 24 hours a day. They all serve individuals who need 
safe and stable living environments in order to develop their recovery skills. 
Such living environments may be housed in the same facility where treatment 
services are provided or they may be in a separate facility affiliated with the 
treatment provider 
 
Level IV – Medically-managed intensive inpatient treatment 
Provide a planned regimen of 24-hour medically directed evaluation, care and 
treatment of mental and substance-related disorders in an acute care inpatient 
setting. They are staffed by designated addiction specialist doctors, including 
psychiatrists, as well as other mental-health and specialist addiction clinicians. 
Such services are delivered under a defined set of policies and procedures and 
have permanent facilities that include inpatient beds. They provide care to 
patients whose mental and substance-related problems are so severe that they 
require primary biomedical, psychiatric and nursing care. Treatment is 
provided 24 hours a day, and the full resources of a general acute care hospital 
or psychiatric hospital are available. The treatment is specific to mental and 
substance-related disorders – however, the skills of the interdisciplinary team 
and the availability of support services allow the conjoint treatment of any co-
occurring biomedical conditions that need to be addressed.  
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In England, generic agencies providing interventions for people who misuse alcohol 
are also diverse. Important among these are general NHS services and criminal 
justice agencies. Within the NHS, GPs frequently come into contact with people who 
misuse alcohol and have an important role to play in providing Tier 1 interventions, 
including early identification, advice, brief intervention and referral of patients to 
specialist alcohol agencies. Some primary care staff, including GPs, practice nurses 
and counsellors, also provide more complex alcohol interventions including assisted 
alcohol withdrawal, and psychological and pharmacological interventions. 
Sometimes this is provided in a collaborative shared care arrangement with a 
specialist alcohol treatment agency in liaison with specialist addiction psychiatrists 
and nurses. Some GPs also provide medical support to residential non-statutory 
agencies such as assisted alcohol withdrawal.  
 
In relation to the criminal justice system, forensic medical examiners are often called 
upon to provide assessment and management of detainees in police custody who are 
misuse alcohol. This often includes the management of acute conditions, such as 
severe alcohol intoxication or alcohol withdrawal. Prison health services also have a 
key role in the assessment and management of prisoners who misuse alcohol, 
including assessment and management of assisted alcohol withdrawal.  
 
In acute hospitals a wide range of healthcare professionals come into contact with 
people who misuse alcohol. In particular, staff in accident and emergency 
departments often encounter patients with alcohol related presentations, such as 
accidents and injuries sustained whilst intoxicated with alcohol, and can play an 
important role in early identification and intervention. Alcohol-misusing patients 
admitted to acute hospitals, either in an emergency or for elective treatment, present 
an opportunity for early identification and intervention. Some acute hospitals will 
have specialist alcohol liaison teams, often led by addiction psychiatrists or nurses, 
who support the acute care staff and provide staff training, assessment, intervention 
and referral to specialist alcohol agencies. Accident and emergency department staff 
also encounter patients presenting in acute unplanned alcohol withdrawal (NICE, 
2010b) and some of these patients will require assisted alcohol withdrawal.  
 
Alcohol misuse is common in clients attending mental health services, particularly 
among the severely mentally ill (Weaver et al., 2003), but seldom identified by mental 
health staff (Barnaby et al., 2003). This represents an important missed opportunity 
to provide early alcohol intervention or referral to specialist services. Also, mental 
health clients attending both inpatient and community mental health services will 
often require assisted alcohol withdrawal. Given the wide range of physical co-
morbidities associated with alcohol use, there are also potential benefits from 
improving generic staff competencies in a wider range of healthcare settings. Staff 
working in these generic settings need to be competent to identify, assess and 
manage the complications of alcohol misuse. Some mental health trusts have an 
addiction liaison service provided by specialist addiction psychiatrists and nurses in 
a model similar to that described above for acute hospitals. 
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5.3.5 Coordination and organisation of care 
From the foregoing it is apparent that the range of interventions, and the agencies 
that provide them, are highly complex and diverse, with considerable geographic 
variation. This diversity presents challenges both for the person who misuses alcohol 
and at a treatment system level. For the person entering treatment for the first time, 
the array of interventions, agencies and staff can be bewildering. Service users, 
therefore, need considerable help in orientation and understanding what is available 
to them and what services they might require. Also, the alcohol interventions an 
individual requires may be provided by several different agencies in the course of an 
episode of care, as well as needing care from a range of generic agencies for physical, 
psychological or social problems. As clients move between different agencies there is 
considerable potential for premature disengagement. There is therefore the care of 
an individual client needs to be planned and coordinated. 
5.3.6 Case coordination  
Several terms have been used to describe the coordination of care within specialist 
alcohol services, including case management, keyworking, care coordination, care 
planning and assertive outreach. In MoCAM (Department of Health, 2006a) there is 
an expectation that all cases would be case coordinated. These include harmful 
drinkers who respond to a brief intervention but do not usually require more 
intensive form of case coordination such as case management. More severely 
dependent drinkers with complex mental or physical comorbidities or social needs 
usually require considerable case management due to the complex nature of their 
problems and/or the wide range of agencies involved. Some studies reviewed in this 
chapter include more assertive approaches in supporting clients, including ACT.  
 
In this guideline we mainly use two terms: case coordination and case management. 
Case coordination describes the coordination of an individual‘s care whilst in a 
treatment episode. It is limited in its responsibilities and may involve little or no 
direct contact with the patient, but rather the focus is on assuring all agreed elements 
of the care package are linked together and communicated in a clear and effective 
manner. Case management, as defined in this guideline, is a more substantial 
endeavour and has several elements. The individual case manager is responsible for 
assessment of the individual client‘s needs, development of a care plan in 
collaboration with the client and relevant others (including relatives and carers, 
other staff in specialist and generic agencies involved in the client‘s care), 
coordination of the delivery of interventions and services, providing support to the 
client to assist in access to and engagement with services and interventions. The case 
manager will often use psychological interventions such as motivational 
interviewing to enhance the client‘s readiness to engage with treatment. The case 
manager is also responsible for monitoring the outcome of interventions and 
revising the care plan accordingly. Case management is a skilled task which requires 
appropriately competent clinical staff to deliver it effectively. Further, to discharge 
this function effectively, case managers need to limit the number of clients they can 
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support at any one time. Case management is a Tier 3/4 intervention within 
MoCAM and should begin with a comprehensive specialist clinical assessment. 
5.3.7 Integrated care pathways and stepped care 
An integrated care pathway ‗describes the nature and anticipated course of 
treatment for a particular client and a predetermined plan of treatment‘. Integrated 
care pathways have a function at both an individual and a treatment system level. At 
the individual level the care plan should describe the client‘s personalised care 
pathway, designed to meet the assessed needs, the planned interventions, and the 
agencies and staff intended to deliver them. The pathway needs to be integrated 
such that it shows a logical progression of steps, with interventions being provided 
at the appropriate stages. For example, an alcohol-dependent client may initially 
require inpatient assisted alcohol withdrawal followed by a structured psychosocial 
intervention in an alcohol day programme, followed by specialised psychotherapy 
for PTSD, followed by vocational services to support a return to work. Each of these 
elements of care may be delivered by different agencies in different locations, and 
the pathway needs to be integrated to deliver maximum benefit and minimise the 
client‘s premature disengagement. 
 
Stepped care is a method of organising and providing services in the most cost 
efficient way to meet individual needs (Sobell & Sobell, 2000). Two defining 
characteristics are common to all stepped-care systems (Davison, 2000). The first 
concerns the provision of the least restrictive and least costly intervention (including 
assessments) that will be effective for an individual‘s presenting problems, and the 
second is concerned with building in a self-correcting mechanism. Escalating levels 
of response to the complexity or severity of the disorder are often implicit in the 
organisation and delivery of many healthcare interventions, but a stepped-care 
system is an explicit attempt to formalise the delivery and monitoring of patient flow 
through the system. In establishing a stepped care approach, consideration should 
not only be given to the degree of restrictiveness associated with a treatment, and its 
costs and effectiveness, but also the likelihood of its uptake by a patient and the 
likely impact that an unsuccessful intervention will have on the probability of other 
interventions being taken up. 
 
Within this approach people who misuse alcohol are initially offered the least 
intensive intervention that is acceptable and most likely to be effective for them, 
followed by increasingly intensive interventions for those not responding to the less 
intensive interventions. A stepped care algorithm effectively describes an integrated 
care pathway which accommodates individual needs and responses to interventions 
(DRUMMOND2009). This approach has gained increasing currency in other mental 
health disorders, including depression (NICE, 2009b). Stepped care approach has 
also been supported by recent guidance from the National Treatment Agency and 
the Department of Health (National Treatment Agency for Substance Misuse, 2006; 
Raistrick et al., 2006). The evidence for stepped care for alcohol misuse is reviewed 
later in this chapter. 
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5.3.8 Relationship of this guidance to other NICE guidelines 
This guideline is focused on the identification, assessment and management of 
harmful alcohol use and alcohol dependence (alcohol misuse). The NICE guideline 
on prevention and early detection (NICE, 2010a) is concerned with a range of 
preventive strategies for alcohol-use disorders. This includes screening for alcohol 
misuse and brief intervention, which is not only a Tier 1 alcohol intervention but also 
potentially acts as a gateway to other more intensive interventions for alcohol 
misuse. The NICE guideline on management of alcohol-related physical 
complications (NICE, 2010b) is focused on the management of a wide range of 
physical consequences of alcohol misuse. These include the management of assisted 
alcohol withdrawal in acute hospital settings, which are Tier 4 interventions. 
However, the guideline is restricted to the management of unplanned assisted 
alcohol withdrawal – that is, in circumstances where a patient presents to hospital 
already in a state of alcohol withdrawal. This guideline is concerned with a much 
wider range of potential scenarios where people who misuse alcohol may require 
assisted alcohol withdrawal, including where assisted withdrawal is provided in a 
planned way as part of an integrated programme of alcohol specialist care, and 
where people are identified as being at risk of developing alcohol withdrawal in 
acute hospitals or prison settings and therefore require planned assisted alcohol 
withdrawal. 
SECTION 2 – EVALUATING THE 
ORGANISATION OF CARE FOR PEOPLE 
WHO MISUSE ALCOHOL 
5.4 CLINICAL QUESTION 
In adults with alcohol misuse, what is the clinical efficacy, cost-effectiveness, safety 
of and patient satisfaction associated with different systems for the organisation of 
care? 
5.5 INTRODUCTION 
This section presents reviews of the evidence for case management, ACT and 
stepped care. The reviews and evidence summaries are presented separately, but a 
combined section on evidence into recommendation is presented at the end of this 
section along with the recommendations developed by the GDG. In reviewing the 
evidence for the effectiveness of different service delivery models, the GDG initially 
decided to focus on RCTs. The use of this type of study design to evaluate service-
level interventions gives rise to a number of problems, including the definition of the 
interventions, the specification of the comparator and the interpretation of results of 
trials of complex healthcare interventions across different healthcare systems 
(Campbell et al., 2004). As demonstrated in the section below, the use of RCTs was 
further complicated by the limited number of studies identified. This led to the GDG 
including a range of observational studies in a review of the service delivery models, 
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both to increase the available evidence base and also because some observational 
studies may provide richer data on what services do, how they do it, and how they 
differ from alternative types of service and the standard care they hope to replace. 
Given the nature of the studies identified, a narrative synthesis of observational and 
RCT studies that were relevant to the intervention but could not be meta-analysed 
was conducted after the review of RCTs. 
5.6 CASE MANAGEMENT 
5.6.1 Introduction 
For the purposes of the guideline, case management is defined as the bringing 
together of the assessment, planning, coordination and monitoring of care under one 
umbrella. In a number of cases all four of these activities will be undertaken by one 
individual, but in other cases some of the above functions will be undertaken by 
other team members or health professionals and coordinated by one individual. In 
some case-management interventions the case manager adopts largely a brokerage 
role, while at other times they take on an active and direct clinical role. Where the 
case manager takes on an active clinical role using a specific intervention (for 
example, CBT), such interventions were excluded from the case management review 
and included in another relevant review within this guideline. Case management 
may also vary in its duration and intensity. For the purposes of this guideline, the 
GDG took the view that the intervention should be of sufficient duration to allow for 
all four functions to be undertaken.  
5.6.2 Clinical review protocol  
Information about the databases searched and the inclusion/exclusion criteria used 
for this section of the guideline can be found in Table 6. 
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Table 6: Databases searched and inclusion/exclusion criteria for clinical 
evidence 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO  
Date searched Systematic reviews from 1993 to March 2010; RCTs from database 
inception to March 2010; observational and quasi-experimental 
studies from database inception to October 2010 
Study design Systematic reviews, RCTs, observational studies, quasi-experimental 
studies 
Patient population Alcohol dependence or harmful drinking  
Interventions Case management versus other treatment 
Case management versus treatment as usual 
Outcomes Aftercare attendance; engagement in aftercare; abstinence; drinking 
frequency measures (for example, number of days drinking in the 
past month); quantity of alcohol consumption measures (for 
example, drinks per drinking day); number retained in treatment; 
relapse; lapse 
5.6.3 Studies considered10 
The review team conducted a new systematic search for RCTs and systematic 
reviews that assessed the benefits and downsides of case management and related 
health economic evidence. 
 
Five trials (three RCTs and two observational studies) relating to clinical evidence 
met the eligibility criteria set by the GDG, providing data on 1,261 participants. Of 
these trials, all five were published in peer-reviewed journals between 1983 and 
1999. In addition, 13 studies were excluded from the analysis. The most common 
reason for exclusion was no usable outcome data, or the intervention was aimed at a 
primarily drug misusing population rather than alcohol misuse. Summary study 
characteristics of the included studies are presented in Table 7 (further information 
about both included and excluded studies can be found in Appendix 16b). 
Case management versus treatment as usual  
There were three RCTs and two observational studies involving comparisons of case 
management and treatment as usual (AHLES1983, CONRAD1998, COX1998, 
MCLELLAN1999, PATTERSON1997). AHLES1983 compared case management with 
treatment as usual (standard aftercare arrangements), where the importance of 
attending aftercare was emphasised but not enforced. Patients were scheduled for 
one aftercare session at discharge, and aftercare consisted of individual problem-
oriented counselling. COX1998 compared case management with treatment as usual 
(there was no further description of treatment as usual). CONRAD1998 compared 
two types of residential inpatient care; the experimental group was case managed, 
whereas the control group participated in the residential care programme without 
case management.  
                                                 
10 Here and elsewhere in the guideline, each study considered for review is referred to using a study 
ID in capital letters (primary author and date of publication, except where a study is in press or only 
submitted for publication in which case a date is not used). 
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For the purposes of this guideline, two observational were also included in the 
review. PATTERSON1997 compared the addition of a community psychiatric nurse 
(CPN) to aftercare with standard hospital care. Standard hospital care consisted of 
an offer of review appointments every 6 weeks following discharge. Lastly, 
MCLELLAN1999 compared case management with treatment as usual (no case 
management). In the standard-care condition, participants received group 
abstinence-oriented outpatient drug-misuse counselling twice weekly. In the case-
management condition, participants received a clinical case manager to provide 
support for housing, medical care, legal advice and parenting classes, in addition to 
the drug counselling programme. For a graphical representation of the data, these 
two studies were inputted into the forest plots for comparison with the results of the 
RCTs; however, it should be noted that the outcomes and data were not pooled with 
the data found in the RCTs. 
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Table 7: Study information table for trials of case management 
 Case management versus treatment as usual 
Total no. of trials (total 
no. of participants) 
5 RCTs (N = 1262) 
Study ID (1) AHLES1983 
(2) COX1998 
(3) CONRAD1998 
(4) MCLELLAN1999 (observational) 
(5) PATTERSON1997 (observational) 
Baseline severity (mean 
[SD]) 
(1) 80% admitted to levels of drinking within the abusive range 
(2) Days of drinking (any alcohol use) in last 30 days: 
 CM: 23.6 (9.2) 
 Control: 23 8 (9.1) 
(3) Days of alcohol use in past 30 days: 18.4 for control group; 19.0 for experimental group 
(4) Whole sample on average reported 13.4 years of problem alcohol use (12.1) 
(5) Daily alcohol (units) (mean [SD]) 
 CPN aftercare: 39.4 (18.3) 
 Standard aftercare: 42.9 (16.6) 
Length of follow-up (1) 6- and 12-month  
(2) Assessed in 6-month intervals up to 2-year follow-up 
(3) At 3, 6 and 9 months during enrolment and 12, 18, and 24 months after completion of 
treatment.  
(4) 6-month 
(5) Assessed at 1, 2, 3, 4 and 5 years post-treatment 
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5.6.4 Clinical evidence for case management  
Evidence from the important outcomes and overall quality of evidence are presented 
in Table 7 and Table 8. The associated forest plots can be found in Appendix 17a.  
 
Table 8: Case management versus treatment as usual 
Outcome or subgroup k Total 
N 
Statistics Effect (95% 
CI) 
Quality of 
the 
evidence 
(GRADE) 
Lapse (non-abstinence)   RR (M-H, random, 95% CI)   
At 6-month follow-up 1 36 RR (M-H, random, 95% CI) 0.27 (0.11,0.65) 
 
At 12-month follow-up (RCT) 1 36 RR(M-H, random, 95% CI) 0.75 (0.52,1.08) 
 
At 2-year follow-up (non-RCT) 1 122 RR(M-H, random, 95% CI) 0.88 (0.69,1.12) 
 
At 3-year follow-up 1 122 RR(M-H, random, 95% CI) 0.68 (0.53,0.85) 
   
At 4-year follow-up 1 122 RR(M-H, random, 95% CI) 0.57 (0.45,0.73) 
   
At 5-year follow-up 1 122 RR(M-H, random, 95% CI) 0.49 (0.37,0.63) 
   
Drinking frequency      
Mean days of alcohol 
intoxication (non-RCT) 
1 537 STD mean difference (IV, 
Random, 95% CI) 
-0.07 (-0.25,0.11) 
 
Days any alcohol use at 6-month 
follow-up 
2 551 STD mean difference (IV, 
Random, 95% CI) 
-0.10 (-0.40,0.20) 
 
Days using alcohol since last 
interview at 6-month follow-up 
1 193 STD mean difference (IV, 
Random, 95% CI) 
-0.34 (-0.63,-0.05) 
 
Days drinking any alcohol in 
last 30 days at 9-month follow-
up 
1 358 STD mean difference (IV, 
Random, 95% CI) 
-0.13 (-0.34,0.08) 
 
Days drinking any alcohol in 
last 30 days at 12-month follow-
up 
1 193 STD mean difference (IV, 
Random, 95% CI) 
-0.21 (-0.49,0.08) 
 
Days using any alcohol since 
last interview at 12-month 
follow-up 
1 193 STD mean difference (IV, 
Random, 95% CI) 
-0.30 (-0.59,-0.01) 
 
Days drinking any alcohol in 
last 30 days at 18-month follow-
up 
1 193 STD mean difference (IV, 
Random, 95% CI) 
-0.33 (-0.62,-0.05) 
 
Days using alcohol since last 
interview at 18-month follow-up 
1 193 STD mean difference (IV, 
Random, 95% CI) 
-0.49 (-0.78,-0.20) 
 
5.6.5 Evidence summary 
Case management versus treatment as usual  
There was a significant difference in lapse (non-abstinence) at 6-month follow-up, in 
favour of case management, with a small effect size; however, this effect was not 
significant at 12-month follow-up. There was a significant difference favouring case 
management found at 3-, 4- and 5-year follow-up, with the largest effect size 
occurring at 3-year follow-up and decreasing to a moderate effect size at 4- and 5-
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year follow-up, respectively. It is important to note that these results are based on 
one observational study (PATTERSON1997). 
 
On measures of drinking frequency, when considering the number of days drinking 
any alcohol (in the last 30 days) or mean days of intoxication, there were no 
significant differences between case management or treatment as usual at either 6-, 
9- or 12-month follow-up. Interestingly, there was a significant effect observed at 18-
month follow-up in favour of case management (very small effect size) based on the 
results of one study (COX1998).  
 
When considering the number of days using alcohol since the last interview 
(COX1998), there was a significant difference observed, favouring case management 
over treatment as usual at all follow-up points (small to moderate effect sizes): 6-
month, 12-month and 18-month follow-up. 
 
Based on the GRADE methodology outlined in Chapter 3, the quality of this 
evidence is moderate, therefore further research is likely to have an important 
impact on our confidence in the estimate of the effect (see Table 8). 
 
Due to the heterogeneous nature of studies within case management, it was not 
possible to combine the outcome data provided across studies. As a result, there are 
a number of useful RCT studies which add value to the meta-analysis presented. For 
the purpose of this guideline and to obtain a better overview of the available 
literature, four RCT studies (Chutuape et al., 2001; Gilbert, 1988; Krupski et al., 2009; 
Sannibale et al., 2003; Stout et al., 1999), which met methodological criteria but did 
not have outcomes which could be used in meta-analyses for this review, are 
described below. 
 
Gilbert (1988) conducted an RCT comparing case management, a home visit and 
treatment as usual for those with alcohol dependence. After receiving inpatient or 
outpatient treatment, patients were scheduled to be assigned a case manager or have 
a home visit, which consisted of appointments scheduled not at the hospital but at a 
convenient location for the patient. Patients in the home visit condition were 
contacted with follow-up letters to reschedule aftercare appointments. In the 
traditional treatment (treatment as usual), no active attempts were made to improve 
attendance at aftercare appointments. On appointment keeping measures, results 
from an ANOVA revealed a significant group by time interaction F=4.56 (6,240), 
p<0.01, and post-hoc Tukey‘s HSD test revealed significant differences between 
home visit and case manager groups at 6- (p<0.05), 9- and 12-month follow-up 
(p<0.01). Both active treatment groups showed a decline in appointment keeping 
rates after the therapists stopped making active attempts to encourage the patient to 
attend therapy. On drinking outcomes, there were no significant differences between 
groups at any follow-up point.  
 
Stout and colleagues (1999) conducted an RCT comparing case monitoring versus 
treatment as usual for those with alcohol dependence. The results indicated a 
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significant difference on percentage of days heavy drinking at 3-year follow-up, 
wherein the frequency of heavy drinking was twice as high in the controls as in the 
case monitored participants. In addition, survival analysis indicated that case 
monitoring was significantly better at prolonging time to lapse and relapse (p=0.05), 
as well as in reducing the severity of the relapse. There was no significant difference 
between the two groups for time to first heavy drinking day (p=0.1). It should be 
noted that 66% of this sample had a comorbid Axis 1 diagnosis.  
 
Chutuape and colleagues (2001) looked at the transition from an assisted-
withdrawal programme to aftercare. Participants were randomly assigned to one of 
three conditions: incentive and escort to aftercare, incentive only, or standard 
treatment. Standard treatment participants only received referral instructions and 
were told to go to aftercare following discharge. Results from a logistic regression 
analysis indicated that aftercare contact rates differed significantly by referral 
condition (p=0.001). Post hoc tests indicated that participants in the escort and 
incentive and incentive only conditions completed intake at aftercare more (p<0.05) 
than those receiving standard treatment.  
 
When comparing a structured aftercare programme with an unstructured aftercare 
programme, Sannibale and colleagues (2003) found that structured programmes had 
a fourfold increase in aftercare attendance (odds ratio [OR] 4.3, 95% CI 1.7 to 11.2) 
and a reduced rate of uncontrolled substance use at follow-up (OR 0.3, 95% CI 0.1 to 
0.9). Further, participants in either aftercare condition relapsed later than those who 
attended no aftercare programme; however, this significant difference did not 
emerge for time to lapse.  
 
More recently, Krupski and colleagues (2009) evaluated the impact of recovery 
support services (including case management) provided through an access to 
recovery programme in the US for clients undergoing substance-misuse treatment. 
Standard treatment consisted of ‗chemical dependency treatment‘. The comparison 
group was a multi-modal programme entitled Access to Recovery (ATR), which 
included a case management component. They found that, in comparison with 
standard care, the ATR programme was associated with increased length of stay in 
treatment and completion of treatment (42.5 days longer). Furthermore, multivariate 
survival analysis indicated the risk of ending treatment was significantly lower 
(hazard ratio = 0.58, p<0.05) among the ATR clients. 
5.6.6 Special populations 
No studies that evaluated the efficacy of case management for children and young 
people or older people and met inclusion criteria were identified.  
5.6.7 Health economic evidence 
No studies were identified in the systematic literature review that considered the 
cost effectiveness of case management in the treatment of alcohol misuse. Details on 
the methods used for the systematic review of the health economics literature for 
this guideline are described in Chapter 3.
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5.7 ASSERTIVE COMMUNITY TREATMENT  
5.7.1 Introduction 
ACT is a method of delivering treatment and care which was originally developed 
for people with serious mental illness in the community (Thompson et al., 1990). The 
intention is to prevent or reduce admission to hospital. The model of care has been 
defined and validated, based upon the consensus of an international panel of experts 
(McGrew et al., 1994; McGrew & Bond, 1995). Over time, the focus has shifted to 
provide for effective support in the community to those with severe, long-term 
mental illness who may previously have spent many years as hospital inpatients. 
ACT now aims to support continued engagement with services, reduce the extent 
(and cost) of hospital admissions and improve outcomes (particularly quality of life 
and social functioning).  
 
The evidence for effectiveness in the international literature is strong for severe 
mental illness (Marshall & Lockwood, 2002), although this may in part be due to the 
comparator used (essentially poor quality standard care). For example, ACT has 
been shown to be effective in the US (Marshall & Lockwood, 2002), but less so in the 
UK where standard care is of a better quality (Killaspy et al., 2006). There is little 
evidence for the effectiveness of ACT in alcohol disorders and the evidence from the 
field of dual diagnosis (psychosis and substance misuse) is currently rather weak 
(NICE, 2011a). 
5.7.2 Clinical review protocol 
Information about the databases searched and the inclusion/exclusion criteria used 
for this section of the guideline can be found in Table 9. 
 
Table 9: Databases searched and inclusion/exclusion criteria for clinical evidence 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Systematic reviews from 1993 to March 2010; RCTs from database 
inception to March 2010; observational and quasi-experimental studies 
from database inception to October 2010. 
Study design Systematic reviews, RCTs, observational studies, quasi-experimental 
studies 
Patient population Diagnosed with an alcohol use disorder (alcohol dependence) or 
alcohol misuse 
Interventions ACT versus other active interventions 
ACT versus treatment as usual  
Outcomes None specified 
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5.7.3 Studies considered11 
For the purposes of this guideline the GDG adopted the definition of ACT used by 
Marshall and Lockwood (2002), which identified the following key elements:  
 
 care is provided by a multidisciplinary team (usually involving a 
psychiatrist with dedicated sessions) 
 care is exclusively provided for a defined group of people (those with 
severe and chronic problem)  
 team members share responsibility for clients, so that several members 
may work 
 with the same client, and members do not have individual caseloads 
(unlike case management) 
 the team attempts to provide all psychiatric and social care for each 
service user, rather than making referrals to other agencies 
 care is provided at home or in the workplace, as far as possible 
 treatment and care are offered assertively to individuals who are 
uncooperative or reluctant (‗assertive outreach‘) 
 medication concordance is emphasised. 
 
The review team conducted a new systematic search for RCTs and systematic 
reviews that assessed the benefits and downsides of ACT methods. 
 
Four trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on 706 participants. Of these, none were unpublished and three were 
published in peer-reviewed journals between 1991 and 2008. In addition, two studies 
were excluded. The most common reason for exclusion was due to a comorbid 
sample population of psychosis (where this was the primary diagnosis) and alcohol 
dependence/misuse. Summary study characteristics of the included studies are 
presented in Table 10 (further information about both included and excluded studies 
can be found in Appendix 16b). 
 
A meta-analysis was not performed as there was only one non-randomised study 
which concerned people who misuse alcohol as the primary group (PASSETTI2008). 
The three RCTs, Drake and colleagues (1998), Bond and McDonel (1991) and Essock 
and colleagues (2006), include populations with co-existing and primary diagnosis 
psychosis and substance misuse, and thus have been covered in another NICE 
guideline currently in development on psychosis and substance misuse (NICE, 
2011a). It is important to note that in the Bond and McDonel (1991) study, 70% had a 
primary diagnosis of schizophrenia or schizoaffective disorder and 61% reported 
their primary substance misuse problem was with alcohol. Conversely, in the Essock 
and colleagues‘ (2006) study, 76% had a primary diagnosis of schizophrenia or 
schizoaffective disorder, and 74% misused alcohol while 81% used other substances. 
                                                 
11 Here and elsewhere in the guideline, each study considered for review is referred to by a study ID 
in capital letters (primary author and date of study publication, except where a study is in press or 
only submitted for publication, then a date is not used). 
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In the Drake and colleagues‘ (1998) study, 53.4% had a primary diagnosis of 
schizophrenia, 22.4% of schizoaffective disorder, 24.2% of bipolar, and 72.6% of the 
sample misused alcohol. No differences were reported in any of the three trials on 
relapse outcomes, and there were no significant differences reported on 
hospitalisation or relapse rates in the Essock and colleagues‘ (2006) or Drake and 
colleagues‘ (1998) trials, both comparing ACT with case management. In the Bond 
and McDonel (1991) trial, there were significant differences in treatment engagement 
and completion of assessment, but no significant differences between groups on 
drinking outcomes.  
5.7.4 Evidence summary  
PASSETTI2008 conducted a parallel cohort trial comparing a flexible access clinic 
(based on ACT principles) with a usual care clinic. Treatment as usual (usual care 
clinic) consisted of two specialist alcohol community nurses and social workers. 
Medical cover was provided by a consultant, an associate specialist, and a junior 
doctor. Care coordinators had a relatively large caseload and there was limited 
integration of health and social care staff, along with less community-based 
assessments and case discussions. The trial found that participants in the flexible 
access clinic were significantly more likely to complete withdrawal (Pearson‘s Chi 
square test, 2 =4.43 p=0.05) and enter an aftercare programme earlier (Student‘s t-
test, t = 2.61, p=0.02). No significant difference between the two groups was found 
on completion of assessment and drinking outcomes were not measured. 
5.7.5 Special populations 
No studies evaluating the efficacy of ACT for children and young people or older 
people which met inclusion criteria could be identified.  
5.7.6 Health economic evidence 
No studies were identified in the systematic literature review that considered the 
cost-effectiveness of ACT for alcohol misuse. Details on the methods used for the 
systematic review of the health economics literature for this guideline are described 
in Chapter 3.
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Table 10: Characteristics of studies evaluating assertive methods 
Study Study 
design 
Comparis
ons 
Outcomes  Baseline 
severity  
Treatment characteristics Results  
PASSETTI2008 
(UK) 
Non-
randomised 
parallel 
cohort pilot 
study 
Flexible 
access clinic 
(ACT 
methods) 
 
Usual care 
clinic 
% 
completed 
assessment 
 
% 
completed 
aftercare 
 
% 
completed 
medically 
assisted 
withdrawal 
Alcohol 
units per 
week (mean 
[SD]): 
 
Flexible 
access:  
143 (111) 
 
Usual care:  
177 (120) 
Flexible access clinic (n=188): two walk-in weekly 
slots, each of 3 hours; two full-time CPNs, social 
workers, clinical psychologists and medical cover 
provided by staff of community alcohol team. 
Offered community-based assessments whenever 
patients had failed to attend. Modelled on ACT in 
the sense that it targeted patients with a history of 
disengagement; maintained a small case load; 
operated proactively and engaged assertively; it 
offered flexible access including assessment and 
treatment in the community where required; run 
by a CPN care coordinator working within a 
multidisciplinary team that met frequently, 
typically after each assessment or review. 
 
Usual care clinic (n=223): two full-time specialist 
CPNs and two social workers. Full time medical 
staff; large caseload (25 to 30), multidisciplinary 
case discussion took place once weekly or less, 
community-based assessments were not offered 
and limited integration of health and social care 
staff work. 
No significant 
differences between 
the two groups on % 
completing 
assessment.  
 
Significant 
differences found 
between two groups 
on % completed 
withdrawal 
programmes, p<0.05 
(in favour of flexible 
access clinic) and % 
entered aftercare, 
p<0.02. 
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5.8 STEPPED CARE 
5.8.1 Introduction 
The stepped care approach to care is based on two key principles (Davison, 2000; 
Sobell & Sobell, 2000): 
 The provision of the least restrictive and least costly intervention that will be 
effective for a person‘s presenting problems. 
 The use of a self-correcting mechanism which is designed to ensure that if an 
individual does not benefit from an initial intervention, a system of monitoring is 
in place to identify a more appropriate and intensive intervention is provided. 
 
Stepped-care models, which have their origins in the treatment of tobacco addiction 
(Sobell & Sobell, 2000), provide for escalating levels of response to the complexity or 
severity of the disorder and are an explicit attempt to formalise the delivery and 
monitoring of patient flow through the system. In establishing a stepped-care 
approach, consideration should be given not only to the degree of restrictiveness 
associated with a treatment, and its costs and effectiveness, but also to the likelihood 
of its uptake by a patient and the likely impact that an unsuccessful intervention will 
have on the probability of other interventions being taken up. Despite the origins in 
the field of addiction, stepped-care systems have not been the subject of much 
formal evaluation in the area.  
 
A useful review by Bower and Gilbody (2005) of the evidence for the use of stepped 
care in the provision of psychological therapies generally was unable to identify a 
significant body of evidence. However, they set out three assumptions which they 
argue a stepped-care framework should be built on and which should be considered 
in any evaluation of stepped care. These assumptions concern the equivalence of 
clinical outcomes (between minimal and more intensive interventions, at least for 
some patients), the efficient use of resources (including healthcare resources outside 
the immediate provision of stepped care) and the acceptability of low-intensity 
interventions (to both patients and professionals). They reviewed the existing 
evidence for stepped care against these three assumptions and found some evidence 
to suggest that stepped care may be a clinically and cost-effective system for the 
delivery of psychological therapies, but no evidence that strongly supported the 
overall effectiveness of the model. 
 
In the field of alcohol misuse there are well-developed brief interventions which are 
suitable for use in a stepped-care system (see NICE, 2010a, for a comprehensive 
review) such as brief motivational interventions, but other low-intensity 
interventions which are less dependent on the availability of professional staff and 
focus on patient-initiated approaches to treatment are also available and include self-
help materials such as books and computer programmes (Bennet-Levey et al., 2010). 
In addition, many alcohol treatment services already operate forms of stepped care 
and they are implicit in current national policy guidance (MoCAM; Department of 
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Health, 2006a) but as yet there has been little formal evaluation or systematic review 
of the area.  
Definition 
For the purposes of this review, stepped care is defined as a system for the 
organisation and delivery of care to people with harmful or dependent drinking 
which: 
a) provides to the majority, if not all harmful or dependent drinkers, the least 
restrictive and least costly brief interventions that will be effective for a 
person‘s presenting problems 
b) has a system of built-in monitoring that ensures that those who have not 
benefited from the initial intervention will be identified 
c) has the referral systems and capacity to ensure that more intensive 
interventions are provided to those who have not benefited from a low 
intensity intervention. 
5.8.2 Clinical review protocol 
Information about the databases searched and the inclusion/exclusion criteria used 
for this section of the guideline can be found in Table 11 (further information about 
the search for health economic evidence can be found in Section 5.8.6). 
 
Table 11: Databases searched and inclusion/exclusion criteria for 
clinical evidence 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, 
PsycINFO 
Date searched Systematic reviews from 1993 to March 2010. All 
other searches from database inception to March 2010 
Study design RCTs, Systematic reviews 
Patient population Those with alcohol dependence or alcohol misuse  
Interventions Stepped-care approach versus treatment as usual 
Outcomes Any drinking outcome; engagement or attendance in 
aftercare sessions or programmes 
5.8.3 Studies considered12 
The review team conducted a new systematic search for RCTs and systematic 
reviews that assessed the efficacy of stepped-care approaches. 
 
Three trials relating to clinical evidence that potentially met the eligibility criteria set 
by the GDG were found, providing data on 496 participants. Of these, three 
(BISCHOF2008; BRESLIN2009; DRUMMOND2009) were published in peer-
reviewed journals between 1999 and 2009. The trials are listed below in Table 12 and 
the outcomes of the studies are described in the text below. The GDG considered 
                                                 
12 Here and elsewhere in the guideline, each study considered for review is referred to by a study ID 
in capital letters (primary author and date of study publication, except where a study is in press or 
only submitted for publication, then a date is not used). 
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these studies very carefully and concluded that, despite the claims of individual 
studies (for example, labelling the intervention as stepped care), none of these 
studies delivered a form of stepped care that was fully consistent with the definition 
of a stepped care approach adopted for this guideline.  
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Table 12: Characteristics of studies evaluating stepped-care approaches 
Study Study 
design 
Comparisons Outcomes  Baseline 
severity  
Treatment characteristics Results  
DRUMMOND 
2009 
(UK) 
RCT Stepped care 
intervention 
Minimal 
intervention 
(Control)  
Total alcohol 
consumed in 
180 days 
 
Drinks per 
drinking day 
 
PDA 
Total alcohol 
consumed in 180 
days (mean [SD]) 
 
Intervention: 
1699.6 (194.8) 
 
Control:  
1423 (113.3) 
 
DDD 
Intervention:  
15.2 (1.1) 
 
Control: 12.9 (0.8) 
 
PDA 
intervention:  
37.9 (3.8) 
 
Control: 36.6 ( 3.4) 
Intervention: (n=39): Sequential series of 
interventions according to need/response.  
 
Step 1: 40-minute session of behaviour-
change counselling from a nurse with follow-
up 28 days after initial session. Patients 
consumed >21 units of alcohol in any 1 week 
or >10 units per day were referred to Step 2.  
 
Step2: Four 50-minute sessions of MET 
(trained alcohol counsellor); follow-up 28 
days. If consumed same as in Step 1, referred 
to Step 3.  
 
Step 3: Referral to local community alcohol 
team for specialist intervention. No limit on 
duration/intensity of treatment; where 
necessary, assisted withdrawal, inpatient 
treatment, outpatient counselling, relapse 
prevention and drug therapy given. 
 
Control: (n=52): 5-minute directive advice 
session from practice nurse addressing 
alcohol consumption reduction. Received 
self-help booklet.  
Greater reduction in 
stepped-care group than 
control in total alcohol 
consumed (-408.6 g 
versus -238.8 g) and 
DDD (-2.4 versus -1.0), 
with an adjusted mean 
difference of 145.6 (95% 
CI -101.7 to 392.9) and 
1.1 (-0.9 to 3.1) but not 
significant.  
BRESLIN1999 
(CANADA) 
RCT Stepped-care 
approach 
(treatment non-
responders 
assigned to 
three groups 
PDA 
 
DDD 
Alcohol 
Dependence Scale 
score: 
 
Range: 11.3–12.8 
Initial treatment: Four sessions of 
motivationally based outpatient treatment. 
Treatment non-responders who consumed 
more than 12 drinks per week between 
assessment and third session were 
considered to be ‗drinking heavily during 
No significant 
differences between 
groups for PDA or DDD 
due to having a 
supplemental 
intervention. 
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based on 
whether they 
were heavily 
drinking or not)  
treatment‘ an additional ‗step‘, which 
consisted of additional readings, written 
exercises and a personalised progress report. 
N=67 responded to initial treatment 
 
N=33 received supplemental intervention 
 
N=36 did not respond to initial treatment 
 
Multivariate analysis of 
variance (MANOVA) 
indicated a significant 
effect of time for PDA, F 
(2,116 = 35.89, p<0.0001, 
for all groups)  
 
DDD F (2,115) = 26.91, 
p<0.0001.  
 
BISCHOF2008 
(GERMANY) 
RCT Stepped care 
 
Full care 
 
Untreated 
control group 
Grams of 
alcohol per 
day at 
follow-up 
 
Grams of alcohol 
per day 
 
Control group: 
Overall:  
41.0 (50.3)  
 
Stepped care: 
 46.9 (49.3) 
 
Full care: 
49.0 (41.3) 
Full care: (n=131) Received computerised 
feedback. Received brief counselling sessions 
based on motivational interviewing and 
behavioural change counselling, each session 
30 minutes 
 
Stepped care: (n=138) Computerised 
intervention and maximum of three brief 
counselling sessions at 1, 3 and 6 months 
after baseline. 30 to 40 minutes each.  
 
If a participant within the SC group reported 
a reduction of alcohol consumption below 
the study criteria for at risk drinking and 
binge drinking within the last 3 weeks and 
also indicated a high self-efficacy to keep the 
acquired behavioural change up, the 
intervention was discontinued and no further 
contact made until 12-month follow-up.  
 
Control: (n=139) Received a booklet on 
health behaviour.  
No significant 
differences except when 
split by severity, where 
at-risk drinkers were 
significantly different 
from the control group 
on difference in grams 
alcohol per day baseline 
to follow-up (Mann-
Whitney U test, p=0.002) 
and binge criteria at FU, 
Mann-Whitney U test, 
p=0.039) 
 
OLS-regression: no 
significant difference, 
overall, (R2 change 
=0.006, p=0.124) 
 
A significant difference 
for people at risk/who 
misuse alcohol (R2 
change = 0.039, p=0.036) 
but not for alcohol 
dependence (R2 change 
= 0.002, p=0.511) or 
heavy episodic driving 
(R2 change = 0.000, 
p=0.923) 
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5.8.4 Evidence Summary 
Breslin and colleagues (1997) evaluated the contribution of pre- and within 
treatment predictors with 212 problem drinkers who initially completed a brief 
cognitive behavioural motivational outpatient intervention. The analyses revealed 
that in the absence of the ability to systematically monitor within treatment drinking 
outcomes and goals, therapist prognosis ratings can be used in making stepped-care 
treatment decisions. These prognosis ratings improve predictions of outcomes even 
after pre-treatment characteristics are controlled. In a later study, BRESLIN1999 
evaluated a stepped-care model (but which the GDG considered might be more 
accurately described as an evaluation of sequenced as opposed to stepped care13) for 
harmful drinkers, with the initial treatment consisting of four sessions of 
motivationally-based outpatient treatment. The design split participants into 
treatment responders and non-responders, with treatment non-responders defined 
as those having consumed >12 drinks per week between assessment and the third 
session of the intervention. There was also a third group of non-responders who did 
not respond to initial treatment, but received a supplemental intervention consisting 
of post-treatment progress reports. A repeated measures ANOVA indicated a 
significant effect of time for per cent days abstinent (PDA), F (2,116) = 35.89, 
p<0.0001, for all groups) and for drinks per drinking day (DDD), F (2,115) = 26.91, 
p<0.0001. F results from follow-up contracts revealed that those who received a 
supplemental intervention showed no additional improvements on drinking 
outcome measures in comparison with those who did not receive a supplemental 
intervention (no significant differences on PDA or DDD). Furthermore, treatment 
responders and non-responders sought additional help at the same rate. It must be 
noted that this intervention and approach was aimed at problem drinkers and not at 
severely dependent drinkers. Furthermore, it is possible that the lack of effect in this 
study was due to the intensity of the ‗stepped‘ intervention, as it only consisted of a 
progress report. It is possible that we could increase our confidence in the effect if 
the supplemental intervention provided to treatment non-responders from the initial 
intervention was more intensive and alcohol-focused.  
 
BISCHOF2008 compared two types of stepped-care interventions (but which the 
GDG consider to be a comparison of two different models of brief interventions) 
with a control group. The stepped-care group received a computerised feedback 
programme after assessment and a maximum of three brief counselling sessions 
delivered by telephone, lasting 30 to 40 minutes each. The counselling was delivered 
based on the success of the previous intervention, the computerised feedback 
programme. If a participant reported a reduction of alcohol consumption, the 
intervention was discontinued. Those in the full care group received a fixed number 
of four telephone-based brief counselling sessions at 30 minutes each, in addition to 
the computerised feedback system. The control group received a booklet on health 
                                                 
13 ‗Stepped care ‗is a system for the organisation of care in which the least intrusive and most effective 
intervention is offered first. ‗Sequenced care‘ refers to a process of care where intervention often of 
equivalent intensity is offered in sequence if there is no response to the first intervention.  
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behaviour. An ordinary least squares (OLS) regression analysis indicated that there 
was no significant difference overall, in terms of efficacy of the intervention (r2 
change =0.006, p=0.124). A significant difference was found for at risk/alcohol 
misuse at 12-month follow-up (r2 change = 0.039, p=0.036), but not for alcohol 
dependence (r2 change = 0.002, p=0.511) or heavy episodic driving (r2 change = 
0.000, p=0.923). Thus stepped-care and full-care groups did not differ on drinking 
outcomes, but when compared with the control group the intervention showed 
small to medium effect size for at-risk drinkers only. It should be noted that this 
intervention does not fit with the definition of stepped care used for this guideline, 
because the approach employed in this study represents more intensive levels of the 
same interventions, rather than ‗stepped‘-up care if the participant does not respond 
to the initial intervention.  
 
More recently, an RCT pilot study was conducted (DRUMMOND2009) to evaluate a 
stepped-care intervention in primary care primarily for hazardous and harmful 
drinkers (and, in the view of the GDG, not a stepped care model with much 
relevance to the population which is the focus of this guideline), compared with a 
minimal intervention. Participants received either a 3 stage stepped care 
intervention, or a 5 minute of brief advice delivered by a practice nurse. Participants 
in the stepped care intervention received a single session of behaviour change 
counselling (delivered by a practice nurse), four 50-minute sessions of MET 
provided by an alcohol counsellor and, lastly, referral to a community alcohol 
treatment agency. At 6-month follow-up, there was a reduction on drinking outcome 
measures in both groups and a slight trend favouring the stepped-care intervention 
for total alcohol consumed (adjusted mean difference = 145.6, 95% CI, -101.7 to 392.9, 
effect size difference = 0.23) and drinks per drinking day (adjusted mean difference 
= 1.1, 95% CI, -0.9 to 3.1, effect size difference = 0.27). These differences were not 
significant.  
5.8.5 Special populations 
No studies evaluating the efficacy of a stepped-care approach for children and 
young people or older people which met inclusion criteria were identified.  
5.8.6 Health economic evidence 
The study by DRUMMOND2009 included a cost-effectiveness analysis of a stepped-
care alcohol intervention compared with minimal intervention in the primary care 
setting. The study population consisted of UK males with a diagnosis of an alcohol 
use disorder and follow-up was 6 months post-randomisation. The primary outcome 
measure used in the economic analysis was the quality-adjusted life year (QALY), 
estimated from EQ-5D utility scores obtained from the study participants. A societal 
perspective was adopted for the analysis which included costs relating to staff 
training, specific psychological interventions, and other healthcare, social care and 
criminal justice services. In the intervention group, mean total treatment costs were 
£216 at baseline and total mean service costs were £2,534 at follow-up, compared 
with £20 and £12,637 in the control group. These differences in 6-month follow-up 
costs were largely explained by criminal justice services utilisation in the control 
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group (£8,000 versus £0). At 6 months, the intervention group gained a mean 0.3849 
QALYs compared with 0.3876 in the control group. Therefore, the control group was 
both more costly and more effective in comparison with the intervention group, 
although the difference in both costs and QALYs were not statistically significant. 
The authors did not present the incremental cost effectiveness ratio (ICER) for the 
control group versus the intervention group but calculated that, at a UK cost-
effectiveness threshold range of between £20,000 to £30,000 per QALY, stepped care 
had a 98% probability of being the most cost-effective option. The results from this 
study are directly applicable to UK clinical practice and the primary outcome 
measure ensures comparability across healthcare interventions. However, potential 
limitations include the small sample size which limits the ability to detect 
statistically significant differences in costs and outcomes, and the short time horizon 
of the study. In addition, no sensitivity analyses were carried out to test the 
robustness of the cost-effectiveness results. 
5.8.7 Health economics summary 
Only one study was identified that considered the cost-effectiveness of a stepped 
care approach to the management of alcohol use disorders (DRUMMOND2009). The 
initial results of this short-term pilot study suggest that stepped care may offer 
significant cost savings without any significant impact on health outcomes over 6 
months. However, the GDG expressed the opinion that the study described a 
stepped-care model that was not of much relevance to the population that is the 
focus of this guideline. In addition, longer term trial based evidence is required to 
confirm the cost-effectiveness of stepped care beyond 6 months. 
5.9 CLINCIAL EVIDENCE SUMMARY 
The five studies (three RCTs and two observational) reviewed for case management 
indicate that when case management is compared with standard treatment, it is 
significantly better in reducing lapse and days using alcohol. All other outcomes 
assessing drinking frequency and measures of abstinence did not reach significance. 
The five studies reviewed narratively to support the results of the meta-analysis all 
found significant improvements in favour of case management on aftercare 
attendance, those attending intake sessions and completion of treatment. Only one of 
these additional studies (Stout et al., 1999) reported a significant difference on any 
drinking outcome, lapse and relapse in favour of case management. The overall 
quality of the evidence is moderate and therefore more studies would help increase 
our confidence in the estimate of the effect of case management. 
 
One observational study assessing ACT methods versus standard care found that 
ACT improved rates of completion and attendance in medically-assisted withdrawal 
and aftercare programmes.  
 
Four studies assessing stepped care methods found that there may be a small effect 
in favour of stepped care, for hazardous drinkers. There were no significant 
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differences found on alcohol outcomes for more harmful and dependent drinkers, 
which are the population covered by this guideline.  
5.10  FROM EVIDENCE TO RECOMMENDATIONS  
5.10.1  Case management 
The GDG reviewed the evidence for the clinical efficacy of case management as an 
intervention to promote abstinence and reduce alcohol consumption, as well as 
improving client engagement, treatment adherence and use of aftercare services. 
Evidence from both randomised trials and observational studies indicates that when 
case management is compared with standard treatment, case management had 
significant benefit over treatment as usual for certain drinking-related outcomes (for 
example, lapse and frequency/quantity of alcohol use), and outcomes evaluating 
engagement and completion of treatment and aftercare. It must be noted, however, 
that the overall quality of the evidence base was limited – the results of the meta-
analysis had to be supported by additional evidence that could not be included in 
meta-analyses. In terms of aftercare, the components of aftercare and outcome 
measures vary widely across studies. There are many ways of motivating a patient 
to engage in aftercare programmes, and of structuring an aftercare programme in an 
attempt to retain the patient. These include the use of incentives, having access to an 
escort for aftercare sessions, being prompted and contacted by an aftercare therapist, 
and having structured aftercare programmes. The GDG considered case 
management to be an effective but relatively intensive intervention for people who 
misuse alcohol. The GDG felt that case management should be targeted at those with 
moderate and severe dependence, and in particular those who have a history of 
difficulty in engaging with services. The GDG were also aware that case 
coordination is part of routine care (see the introduction to this chapter) in all 
specialist alcohol services, but were concerned that the focus of case management is 
only on the more severely alcohol dependent and that, as a consequence, the 
coordination of care for harmful alcohol misuse and those with mild alcohol 
dependence were at risk of the coordination of their care being neglected. This was a 
particular concern, given the considerable number of agencies involved in the 
delivery of alcohol misuse services. To address this issue, the GDG made a 
recommendation for the delivery of case coordination.  
5.10.2  Assertive community treatment 
Although assertive community interventions have been reviewed in another NICE 
guideline under development for the treatment of individuals with a diagnosis of 
psychosis and a history of substance misuse (NICE, 2011a), the narrative review of 
these studies in this guideline identified a very limited evidence base. In this review, 
one trial assessing ACT versus standard care suggested that assertive methods may 
be beneficial in improving rates of completion and attendance in medically-assisted 
withdrawal and aftercare programmes. On the basis of this single trial, there is 
insufficient evidence to support any clinical recommendation. However, the GDG 
did develop a research recommendation because it considered that the ACT might 
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have value in ensuring more effective care and treatment for severely alcohol 
dependent people who have significant problems in engaging with services.  
5.10.3 Stepped care 
None of the studies reviewed directly addressed stepped care either as defined in 
the guideline or for the populations covered by this guideline. The GDG therefore 
has no recommendations to make that might suggest changes to or developments of 
the current, well-established system for stepped care that structure the provision of 
alcohol misuse services in the NHS and related services. 
5.11  RECOMMENDATIONS  
Care coordination and case management 
5.11.1.1 Care coordination should be part of the routine care of all service users in 
specialist alcohol services and should: 
 be provided throughout the whole period of care, including aftercare 
 be delivered by appropriately trained and competent staff working in 
specialist alcohol services 
 include the coordination of assessment, interventions and monitoring 
of progress, and coordination with other agencies.  
5.11.1.2 Consider case management to increase engagement in treatment for people 
who have moderate to severe alcohol dependence and who are considered 
at risk of dropping out of treatment or who have a previous history of poor 
engagement. If case management is provided it should be throughout the 
whole period of care, including aftercare. 
 
5.11.1.3 Case management should be delivered in the context of Tier 3 interventions14 
by staff who take responsibility for the overall coordination of care and 
should include:  
 a comprehensive assessment of needs 
 development of an individualised care plan in collaboration with the 
service user and relevant others (including families and carers and 
other staff involved in the service user‘s care) 
 coordination of the care plan to deliver a seamless multiagency and 
integrated care pathway and maximisation of engagement, including 
the use of motivational interviewing approaches 
 monitoring of the impact of interventions and revision of the care plan 
when necessary. 
 
                                                 
14 See Figure 4. 
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5.12  RESEARCH RECOMMENDATION 
5.12.1.1 For which service users who are moderately and severely dependent on 
alcohol is an assertive community treatment model a clinically and cost-
effective intervention compared with standard care?  
 
This question should be answered using a randomised controlled design in which 
participants are stratified for severity and complexity of presenting problems. It 
should report short- and medium-term outcomes (including cost-effectiveness 
outcomes) of at least 18 months‘ duration. Particular attention should be paid to the 
reproducibility of the treatment model, and  to the training and supervision of 
those providing the intervention, to ensure that the results are robust and 
generalisable. The outcomes chosen should reflect both observer and service user-
rated assessments of improvement (including personal and social functioning) and 
the acceptability of the intervention. The study needs to be large enough to 
determine the presence or absence of clinically important effects, and mediators 
and moderators of response should be investigated. 
 Why this is important? 
Many people, in particular those with severe problems and complex comorbidities, 
do not benefit from treatment and/or lose contact with services. This leads to poor 
outcomes and is wasteful of resources. ACT models have been shown to be 
effective in retaining people in treatment in those with serious mental illness who 
also misuse alcohol and drugs, but the evidence for an impact on outcomes in not 
proven. A number of small pilot studies suggest that an assertive community 
approach can bring benefit in both service retention and clinical outcomes in 
alcohol misuse. Given the high morbidity and mortality associated with chronic 
severe alcohol dependence, the results of this study will have important 
implications for the structure and provision of alcohol services in the NHS. 
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SECTION 3 – THE ASSESSMENT OF 
HARMFUL DRINKING AND ALCOHOL 
DEPENDENCE 
5.13  INTRODUCTION 
The purpose of this section is to identify best practice in the diagnosis and 
assessment of alcohol misuse across a range of clinical settings; NHS provided and 
funded services, including primary care and non-statutory alcohol services. Previous 
reviews of assessment procedures (for example, Raistrick et al., 2006; Allen & Wilson, 
2003) have outlined the role of clinical interview procedures, identification 
questionnaires and investigations in developing an assessment of needs. In order to 
obtain a comprehensive overview of the range and variety of assessment procedures 
this chapter should be read in conjunction with the reviews and recommendations 
on identification and assessment contained in two other NICE guidelines on alcohol 
misuse (NICE, 2010a; NICE, 2010b).  
 
A key aim of the assessment process should be to elicit information regarding the 
relevant characteristics of alcohol misuse as outlined in the current diagnostic 
systems for alcohol use disorders; that is, the ICD–10 (WHO, 1992) and the DSM–IV 
(APA, 1994). Although diagnosis is an important aspect of most assessments, the 
focus of assessment should not only be on diagnosis and alcohol consumption but 
should also consider physical, psychological and social functioning. The range and 
comprehensiveness of any assessment will vary depending on the setting in which it 
is undertaken and the particular purpose of the assessment, but in all cases the 
central aim is to identify a client‘s need for treatment and care. The 
comprehensiveness of the assessment should be linked to the intended outcomes 
(for example, onward referral of an individual or offering treatment interventions). 
The range and depth of the components of assessment should reflect the complexity 
of tasks to be addressed and the expertise required to carry out the assessment. 
Crucial to the effective delivery of any assessment process is the competence of the 
staff who are delivering it, including the ability to conduct an assessment, interpret 
the findings of the assessment and use these finding to support the development of 
appropriate care plans and where necessary, risk management plans.  
 
Current practice in the assessment of alcohol misuse is very varied across England 
and Wales, including the range of assessments in specialist alcohol services 
(MoCAM; Department of Health, 2006a). To some extent this reflects the different 
aims and objectives of the services (including specialist alcohol services) in which 
assessments are undertaken but it also reflects the lack of clear guidance and 
subsequent agreement on what constitutes the most appropriate assessment 
methods for particular settings (MoCAM; Department of Health, 2006a). Given the 
high prevalence of alcohol misuse and comorbidity with a wide range of other 
physical and mental disorders, effective diagnosis and assessment can have major 
implications for the nature of any treatment provided and the likely outcome of that 
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treatment. In an attempt to address some of these concerns the National Treatment 
Agency (NTA) developed MoCAM (Department of Health, 2006a), which outlined a 
four-tiered conceptual framework for treatment and describes three levels of 
assessment that should be considered in different clinical settings: a screening 
assessment, a triage assessment and a comprehensive assessment. However, the 
extent to which this framework has led to improvements in the nature and quality of 
assessments provided remains unclear (but it has been more influential in 
determining the structure of services). The importance of MoCAM for this chapter 
(and for the guideline in general) is that it provides a conceptual framework in 
which to place the recommendations on assessment and which also link with the 
recommendation on assessment in the other NICE guidelines on alcohol (NICE, 
2010a; NICE, 2010b). With this in mind, the GDG decided to develop a set of 
recommendations for assessment that supported the development of clinical care 
pathways to promote access to effective care, where possible integrating with the 
existing service structure. Where this is not possible, the GDG has developed 
recommendations which suggest changes in existing service structures.  
5.14  CLINICAL QUESTIONS 
The clinical questions that the GDG addressed, and from which the literature 
searches were developed were: 
 
a) What are the most effective (i) diagnostic and (ii) assessment tools for alcohol 
dependence and harmful alcohol use? 
b)  What are the most effective ways of monitoring clinical progress in alcohol 
dependence and harmful alcohol use? 
c) To answer these questions, what are the advantages, disadvantages and 
clinical utility of: 
 the structure of the overall clinical assessment, 
 biological measures, 
 psychological/behavioural measures, 
 neuropsychiatric measures (including cognitive impairment), 
 and physical assessment? 
5.15 AIM OF REVIEW OF DIAGNOSTIC AND 
ASSESSMENT TOOLS FOR ALCOHOL DEPENDENCE 
AND HARMFUL ALCOHOL-USE 
5.15.1 Introduction 
This review aims to identify the most appropriate tools for assessing the presence of 
alcohol dependence or harmful drinking, the severity of dependence, alcohol 
consumption/frequency of use, motivation and readiness to change, alcohol 
withdrawal and alcohol-related problems in adults. (The issue of assessment in 
special populations is dealt with in Sections 5.21 and 5.22.) The GDG were also 
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tasked with identifying all the potential components of a clinical assessment (and 
their respective places in the care pathway) that would facilitate the most effective 
delivery of any assessment. This section sets out the criteria for a quantitative 
analysis of the assessment tools included in the review, and the subsequent synthesis 
of the characteristics and psychometric properties of the tools. Please note, the GDG 
was not tasked with evaluating assessment tools used for screening of alcohol 
dependence and harmful alcohol use as this is outside the scope of the guideline. See 
the NICE public health guideline (NICE, 2010a) for a review of screening tools.  
5.15.2 Clinical review protocol 
Information about the databases searched and the inclusion/exclusion criteria used 
for this section of the guideline can be found in Table 13. 
 
Table 13: Clinical review protocol for the evaluation of tools for assessing 
alcohol dependence and harmful alcohol use 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Systematic reviews from 1993 to March 2010. All other searches 
from database inception to March 2010  
Study design RCTs, systematic reviews  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Assessment domains Dependence (and severity of dependence); 
consumption/frequency; alcohol withdrawal; motivation and 
readiness to change; physical, psychological and social 
problems; clinical interview; physical examination; blood, breath 
and urine testing 
Critical outcomes Critical outcomes for quantitative review: sensitivity, specificity, 
area under the curve, positive predictive value, negative 
predictive value 
For quantitative meta-analyses calculating the diagnostic 
accuracy of an assessment tool, raw data (true positive, true 
negative, false positive, false negative) is needed. See methods, 
Chapter 3, for a definition of these terms 
 
5.16 QUANTITATIVE REVIEW OF ASSESSMENT TOOLS 
5.16.1 Aim of a quantitative review of assessment tools  
The initial aim of this review was to assess the pooled diagnostic accuracy of the 
assessment tools using meta-analytic receiver operating characteristic (ROC) curve 
analyses. ROC analyses would therefore provide the pooled sensitivity and 
specificity of each assessment tool, and give an indication of positive predictive 
value and negative predictive value. For a definition and explanation of these terms, 
see Chapter 3. 
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5.16.2 Evaluating assessment tools for use in a review to assess 
diagnostic accuracy 
The review team conducted a systematic review of studies that assessed the 
psychometric properties of all alcohol related assessments tools. From these, 
references were excluded by reading the title and/or abstract. At this stage of the 
sifting process, studies were excluded if they did not address the diagnostic accuracy 
of an assessment tools and hence were not relevant for this section of the review. 
Furthermore, the focus of this review was on assessment and not screening or case 
identification (latter issues are covered in the NICE [2010a] guideline on preventing 
hazardous and harmful drinking). Therefore, tools developed solely for those 
purposes were excluded from the review. The remaining references were assessed 
for eligibility for use in meta-analyses on the basis of the full text using certain 
inclusion criteria and papers excluded if they did not meet those criteria. The 
inclusion criteria were as follows: 
 The study meets basic guideline inclusion criteria (see Chapter 3). 
 The population being assessed in the study reflects the scope of this 
guideline (see Table 13).  
 Extractable data is available to perform pooled sensitivity and specificity 
analyses (see methods Chapter 3).  
 The assessment tool is tested against a validated gold standard diagnostic 
instrument (for example, DSM–IV, ICD–10, Composite International 
Diagnostic Interview [CIDI] [APA, 1994; WHO, 1992]). 
5.16.3 Outcome of study search for quantitative review  
Following the sifting process as outlined above, 33 studies assessing the diagnostic 
accuracy of a wide range of assessment tools were identified for possible inclusion in 
meta-analyses. Twenty-seven studies were excluded and could not be used for a 
quantitative review. The main reason for this was that the population being assessed 
were outside the scope of this guideline (for example, pregnant women, hazardous 
drinkers, or less than 80% of the sample were alcohol dependent or harmful 
drinkers). Studies were further excluded because they did not report sensitivity and 
specificity data in an extractable format. 
 
After all exclusion criteria were applied, there were only six studies remaining 
which could have been used for a quantitative review. This number of studies was 
insufficient to perform an unbiased and comprehensive diagnostic accuracy meta-
analyses of all the assessment tools identified in the review for alcohol misuse. 
Although there were a wide range of tools initially identified for the meta-analyses, 
most studies did not provide appropriate psychometric information and the majority 
of studies reported the results of their own sensitivity and specificity analyses. As 
outlined above, the actual number of participants identified as true positive, true 
negative, false positive, false negative (see Chapter 3 for definition) is needed to run 
pooled sensitivity and specificity analyses.  
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In view of the limitations of the data, it was decided by the GDG that a narrative 
synthesis of assessment tools should be undertaken. Therefore, all papers were 
reconsidered for use in a narrative review. 
5.17 NARRATIVE SYNTHESIS OF ASSESSMENT TOOLS  
5.17.1 Aim of narrative synthesis 
The main aim of the narrative synthesis was to identify tools that could inform 
clinical decision making and treatment planning in the following areas: the 
assessment of alcohol dependence; the severity of alcohol dependence and the 
associated harms; and motivation for change. This guideline did not aim to review 
assessment tools to aid in the measurement of alcohol withdrawal as these tools 
have already been reviewed in the accompanying NICE guideline on management 
of alcohol-related physical complications (NICE, 2010b), which recommends the use 
of the Clinical Institute Withdrawal Assessment Scale for Alcohol (CIWA-Ar) 
(Sullivan et al., 1989). To facilitate understanding and use of the CIWA-Ar, its 
characteristics can be seen in Table 14 and Table 15.  
5.17.2 Evaluating assessment tools for use in a narrative synthesis 
The inclusion and exclusion criteria of the initial sifting process were reapplied to 
the available literature and involved identifying assessment tools which were 
applicable to the population of interest in this guideline. The literature was 
evaluated for a number of important study characteristics and assessment 
tools/literature were excluded on this basis. Firstly, the patient population was 
required to meet inclusion criteria for alcohol misuse, that is, harmful or dependent 
drinkers. Furthermore, the psychometric data for the study was required to 
adequately distinguish between alcohol misuse and substance misuse in an adult 
dual-diagnosed sample. The context in which the tool is used was also evaluated, 
that is, to ascertain if the tool is used for opportunistic screening in non-treatment 
seeking populations (see the NICE [2010a] guideline on preventing hazardous and 
harmful drinking) or can be used for assessment of dependence and outcome 
monitoring in a treatment-seeking population.  
 
The second stage of the review was to identify tools for a narrative that could be 
recommended for use in assessing alcohol misuse in a clinical setting. In the absence 
of a formal quantitative review, the decision to include assessment tools in a 
narrative synthesis was made using the three criteria outlined below. These criteria 
were developed and agreed by the GDG, and informed by the National Institute on 
Alcohol Abuse and Alcoholism guide for assessing alcohol misuse (Allen & Wilson, 
2003).  
Clinical utility 
This criterion required the primary use of the assessment tool to be feasible and 
implementable in a routine clinical care. The tool should contribute to the 
identification of treatment needs and therefore be useful for treatment planning.  
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Psychometric data 
Reported findings for sensitivity, specificity, area under the curve, positive 
predictive value, negative predictive value, reliability and validity of the assessment 
tools were considered. Although sensitivity and specificity are important outcomes 
in deciding on the usefulness of an assessment tool, particularly for diagnostic 
purposes, for other clinical purposes reliability and validity are also important. See 
Chapter 3 for a description of diagnostic test accuracy terms. The tool should be 
applicable to a UK population, for example by being validated in either a UK 
population or one that is similar to the UK population.  
Tool characteristics and administrative properties 
The assessment tool should have well-validated cut-offs in the patient population of 
interest. Furthermore, and dependent on the practitioner skill-set and the setting, 
tools were evaluated for the time needed to administer and score them as well as the 
nature of the training (if any) required for administration or scoring. Lastly, the cost 
of the tool and copyright issues were also considered.  
5.17.3 Outcome of the narrative synthesis 
The studies initially identified were the result of the original quantitative review 
search and sift. A total of 73 tools were identified and 34 were excluded from the 
review, leaving 39 assessment questionnaires and clinical interview tools that were 
considered for a narrative review.  
 
The clinical interview tools identified did not form a part of the narrative review of 
assessment questionnaires. Most (n=5) were excluded as being not feasible for 
routine use in a UK NHS setting (see criteria above).  
 
The outcome of the initial sift and the exclusion criteria applied was discussed with 
the GDG, and the preliminary list of 39 assessment tools were put forward for 
possible inclusion in the narrative synthesis. Using the additional criteria (that is, 
clinical utility, psychometric data and characteristics of the tool), this discussion 
resulted in a subset of five questionnaires (excluding the CIWA-Ar) being included 
in the subsequent narrative synthesis. Of these, three questionnaires measure the 
domain of alcohol dependence, one assesses alcohol-related problems, and one 
assesses motivation. These assessment tools are described below accordingly. Table 
14 displays information pertaining to the questionnaires which met criteria for a 
narrative review. These tables provide information of the domain the tool assesses 
(for example, dependence, problems and so on) and indicates if the tool is 
appropriate for the assessment of young people or adults (see Section 5.22 for a 
review of the assessment of children and young people). Additionally, Table 15 
displays the characteristics of the assessment questionnaires included in the 
narrative review. This table gives more extensive information, such as the scale and 
cut-offs, number of items, time to administer and score, whether training is required 
for use, copyright/cost of the tool, and the source reference. 
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Table 16 identifies the questionnaires and clinical interview tools identified in the 
original sift but excluded for the reasons outlined above. 
 
In developing this review the GDG were mindful of the need for all assessments and 
interventions to be carried out by competent individuals (for example, Krisnamurthy 
et al., 2004; MoCAM; Department of Health, 2006a), and thus this chapter should be 
read with this clear expectation in mind. It should also be noted that the accuracy of 
the assessment of alcohol consumption from self-reported alcohol consumption can 
be enhanced (Sobell & Sobell, 2003) by interviewing individuals who are not 
intoxicated, giving written assurances of confidentiality, encouraging openness and 
honesty, asking clearly-worded questions and providing memory aids to recall 
drinking (such as drinking diaries). 
5.18 THE ASSESSMENT OF ALCOHOL DEPENDENCE  
From the initial review, and using the criteria outlined in Section 5.16.2, the GDG 
identified three measures for inclusion in the narrative review of tools to measure 
alcohol dependence. These were the AUDIT (Babor et al., 2001); the SADQ (Stockwell 
et al., 1979); and the Leeds Dependence Questionnaire (LDQ) (Raistrick et al., 1994). 
Information on the characteristics of these three questionnaires is summarised in 
Table 14 and Table 15.  
5.18.1 Alcohol Use Disorders Inventory Test 
The AUDIT questionnaire was developed by WHO and designed to identify people 
who have an alcohol use disorder. Although the AUDIT was not primarily 
developed as a measure of alcohol dependence, and indeed contains items from a 
three domains (alcohol consumption, alcohol dependence and alcohol related 
problems), it may have utility in assessment of alcohol dependence, particularly by 
staff who are not working in specialist alcohol treatment services (for example, GPs 
and acute hospital and mental healthcare staff). Unlike many of the other published 
assessment questionnaires, previous literature assessing the psychometric properties 
of the AUDIT is extensive. The AUDIT has ten items constructed across three 
domains: consumption (items 1 to 3); dependence (items 4 to 6); and problems (items 
7 to 10). The development of the AUDIT revealed that a score of 16 or more 
represented high levels of alcohol misuse. In a UK primary-care sample the AUDIT, 
with a cut off of at least 8, using CIDI as the gold standard, was found to identify 
alcohol dependent patients with a sensitivity of 84% and specificity of 83% (Coulton 
et al., 2006). The AUDIT has a maximum score of 40 with the following categories 
being defined: 1 to 7, low-risk drinking; 8 to 15, hazardous drinking; 16 to 19, 
harmful drinking; and 20 or more, possible alcohol dependence (Room et al., 2005). 
However, for cut-offs higher than 8 (which could be used to identify harmful or 
dependent drinkers as opposed to hazardous drinkers), the specificity remains much 
the same, but the sensitivity of the AUDIT appears to reduce drastically. For 
example, at a cut-off score of 15, sensitivity for DSM–III diagnosed abuse or 
dependence was 49% (Fleming et al., 1991). Even at a much lower cut-off of 12 
points, Barry and Fleming (1993) reported a sensitivity of 21% (lifetime diagnosis) 
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and 36% (current diagnosis). At a cut-off of 11 points, Schmidt and colleagues (1995) 
reported a sensitivity of 11% for diagnosed abuse or dependence. 
 
The AUDIT has been found in a number of studies in various settings and 
populations to have high internal consistency (Barry & Fleming, 1993; Fleming et al., 
1991; Hays et al., 1995; Schmidt et al., 1995; Thomas & McCambridge, 2008). 
However, data is not readily available on test–retest reliability except from a study 
in a young adult population (mean age 20.3 years) in which the authors report high 
test–retest reliability (Thomas & McCambridge, 2008). 
 
The correlation between AUDIT score and severity of dependence has been 
investigated in a severely dependent sample of participants (n=1134, 84.9%) scoring 
in the higher range of AUDIT scores (20 to 40 points) (Donovan et al., 2006). 
Correlation analyses results revealed that an AUDIT score of 8 to 15 was mostly 
correlated with mild (53.3%) and moderate (41.7%) severity, a score of 16 to 19 was 
mostly correlated with moderate (55.7%) and mild (37.1%) severity, and a score of 20 
to 40 points was mostly correlated with moderate (55.7%) and severe (29.5%) 
dependence. The authors conclude that AUDIT may therefore be applicable in a 
clinical setting, for assessing severity of alcohol dependence in a treatment-seeking 
population. 
 
The AUDIT score categories described relate to adults. Professional judgement as to 
whether to revise scores downwards should be considered for; women (including 
those who are or planning to become pregnant), young people (under 18 years), 
people aged 65 years or over, and those with significant mental health problems 
(O‘Hare et al., 2006).  
 
The AUDIT is predominantly used for opportunistic screening purposes in non-
treatment seeking populations (for example, primary care). However, it has some 
clinical utility because it can be used either as the basis for a brief intervention or as a 
referral to specialist services. The AUDIT is routinely used for screening in the UK 
and is freely available to download. Furthermore, although it requires minimal 
training for administration and scoring by trained personnel, it is quick and easy to 
use. The AUDIT manual (Babor et al., 2001) states that clinical judgement should be 
exercised when using the proposed cut-offs if other evidence presented is contrary to 
the AUDIT score, especially for those who have a history of alcohol dependence. 
5.18.2 Severity of Alcohol Dependence Questionnaire 
The SADQ was developed by Stockwell and colleagues (1979). It is a 20-item 
questionnaire with a maximum score of 60. Five elements of the alcohol dependence 
syndrome (Edwards & Gross, 1976) examined are: 
 Physical withdrawal (items 1 to 4) 
 Affective withdrawal (items 5 to 8) 
 Withdrawal relief drinking items (9 to 12) 
 Alcohol consumption items (13 to 16) 
 Rapidity of reinstatement items (17 to 20). 
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Stockwell and colleagues (1983) reported that the SADQ (Stockwell et al., 1979; 1983) 
has: high test–retest reliability (correlation coefficient ranged from 0.55 to 0.82 across 
individual questions); good content, criterion and construct validity; and is 
correlated with physician and self-reported ratings of withdrawal severity, and the 
quantity of medication to be prescribed during alcohol withdrawal. However, the 
SADQ questions assessing consumption and frequency of drinking did not correlate 
with liver function and blood tests. This may be more an indication of the limited 
sensitivity and specificity of the liver function tests than a reflection on the 
performance of the SADQ (Coulton et al., 2006). 
 
SADQ scores of at least 31 indicate severe alcohol dependence (Stockwell et al., 
1983), with higher scores predicting increased severity of alcohol withdrawal 
symptoms (Shaw  et al., 1998; Stockwell et al., 1983). Severe dependence, because of 
the risk of severe alcohol withdrawal symptoms is often used as a clinical decision 
aid in deciding on the need for inpatient assisted alcohol withdrawal programmes 
and an inclusion criterion for inpatient care.  
 
Severe alcohol dependence (SADQ >= 31) particularly in those with comorbid 
problems or who lack social support (see below), may require inpatient assisted 
withdrawal programme (Raistrick et al., 2006). The professional will need to consider 
if the severity of alcohol dependence and associated alcohol withdrawal symptoms 
identified before considering a prescribing strategy. Current clinical practice, in the 
experience of the GDG, suggests that those identified as scoring less than 15 on the 
SADQ usually do not require medication to assist alcohol withdrawal. 
 
The SADQ identifies not just dependence but indicates the severity of dependence 
and hence has utility in a clinical setting. It is routinely used in the UK and is freely 
available to download or from the author. The SADQ takes very little time to 
administer and does not require training for administration or scoring. 
5.18.3 Leeds Dependence Questionnaire 
The LDQ (Raistrick et al., 1994) is a ten-item questionnaire that is based on a 
psychological understanding of dependence and has applicability to the 
measurement of dependence for any substance. A score greater than 21 out of a 
possible 30 indicates severe dependence. The LDQ has been reported to have 
acceptable concurrent validity when compared with other instruments such as the 
SADQ (R=0.69, p<0.0001), is independent of other possible covariates such as gender 
and age, has high internal consistency (one factor accounted for 64.2% of the 
variance), and had high test–retest reliability in a variety of populations (0.95) 
(Raistrick et al., 1994). 
 
Furthermore, in a sample of patients attending the Leeds Addiction Unit, the LDQ 
was also found to have high internal consistency (Heather et al., 2001). It has also 
been found to be sensitive to change over the course of treatment in alcohol 
dependent adults (Tober et al., 2000). However, the LDQ appears to show a ceiling 
effect and does not reflect those at the more severe end of dependence (Heather et al., 
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2001). Ford (2003) evaluated the use of the LDQ in a psychiatric population and 
reported excellent internal reliability and acceptable concurrent validity with clinical 
opinion. The authors conclude that the LDQ is a sensitive to the degree of substance 
dependence and applicable to a population with severe mental health problems in 
an inpatient setting. The LDQ has also been found to have high internal consistency 
in a ‗juvenile delinquent‘ sample (Lennings, 1999). 
 
In a young adult population (18 to 25 years old) undergoing residential treatment for 
substance dependence, the LDQ was reported to have high internal consistency, 
acceptable (but lower than expected) concurrent validity when compared with 
DSM–IV dependence criteria and PDA (Kelly et al., 2010). Additionally, in a young 
adult population (mean age 20.3 years), the LDQ had satisfactory test–retest 
reliability and internal consistency (Thomas & McCambridge, 2008).  
 
The LDQ is an applicable diagnostic measure of severity of alcohol dependence and 
hence can be used for other purposes in a clinical setting, such as for setting 
treatment goals and outcome monitoring. Furthermore, it is brief and does not 
require training for administration and scoring. It was developed and validated in 
the UK, and is free to use.  
5.19 THE ASSESSMENT OF PROBLEMS ASSOCIATED 
WITH ALCOHOL MISUSE 
5.19.1 Introduction 
The causal relationship between alcohol consumption and alcohol-related problems 
such as adverse social consequences, physical disease and injury is well established 
(Rehm et al., 2009; Drummond, 1990). The extent to which problems are attributable 
to alcohol means that those presenting for clinical interview may experience 
considerable problems that are diagnostically important in helping to establish if the 
patient is experiencing harmful alcohol use or alcohol dependence.  
 
From the initial review, the GDG identified one measure for inclusion in the 
narrative review of tools for measuring problems associated with alcohol misuse; 
this is the Alcohol Problems Questionnaire (APQ) (Drummond, 1990). Several other 
questionnaires were identified that included alcohol related problem items, but these 
were mixed with other conceptual content (for example, dependence symptoms). 
Information on the characteristics of the APQ are summarised in Table 14 and Table 
15. 
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Table 14: Assessment tools included in narrative review 
Assessment instruments included in narrative 
review 
Population Assessment category 
Adult  
Young 
people 
(>10 years)  
Dependence 
Consumption 
and 
frequency 
Alcohol 
withdrawal 
Motivation 
and 
readiness to 
change 
Harm and 
alcohol 
problems 
APQ •      •1 
AUDIT • • •1 • •1   • 
CIWA-Ar •    •1    
LDQ • • (>16 years) •1      
SADQ •  •1 • •    
Readiness to Change Questionnaire (treatment version) 
(RCQ–TV) 
• •    •1  
•Tool used; 1 Primary use        
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Table 15: Characteristics of assessment tools included in narrative review 
Assessment instrument Number of items & format Time taken to 
administer and by 
whom 
Time to score 
and by whom 
Copyright and cost of test 
Scale and cut-offs  Training required for 
administration 
Alcohol Problems Questionnaire 
(APQ) 
44 items (eight subscales), pencil and paper self-
administered 
3 to 5 minutes; respondent Minimal; minimally 
trained technician 
No; free to use 
Maximum score = 23 No training 
Alcohol Use Disorders 
Identification Test (AUDIT) 
Ten items (three subscales), pencil and paper or computer 
self-administered 
2 minutes; trained personnel  1 minute; trained 
personnel 
Yes; test and training manual free to use, 
training costs $75 
Scale: 0 to 40. Cut-offs: 8 to 15 = hazardous; 16 to 19 = 
harmful, mild or moderate dependence; ≥20 = severe 
dependence  
Minimal training 
Clinical Institute Withdrawal 
Assessment (CIWA-Ar) 
Eight items, observation format 2 minutes; trained personnel 4 to 5 minutes; 
trained personnel 
Yes; free to use 
Total score ranges from; 0 to 9 = minimal/absent 
withdrawal; 10 to 19 = mild/moderate withdrawal; ≥20 = 
severe withdrawal  
Training required for 
administration 
Leeds Dependence Questionnaire 
(LDQ)  
Ten items, paper and pencil self-administered 2 to 5 minutes; respondent 
or personnel 
Half a minute; non-
trained personnel  
No; free to use 
Scale: 0 to 30. Cut-offs: 0 = no dependence; 1 to 10 = 
low/moderate dependence; 11 to 20 = moderate/high 
dependence; 21 to 30 = high dependence  
No training 
Readiness to Change 
Questionnaire – treatment version 
(RCQ–TV) 
15 items (three subscales). Most up-to-date version has 12 
items, pencil and paper self-administered 
2 to 3 minutes; respondent 
 
 
No training 
1 minute; non-
trained personnel 
Yes; free to use 
Original total score range: -10 to +10; current version total 
score range: -8 to +8 
Severity of Alcohol Dependence 
Questionnaire (SADQ) 
20 (five subscales), pencil and paper self-administered 5 minutes; respondent 1 minute; trained 
personnel or 
clinician  
No; free to use 
Scale: 0 to 60; Cut-offs: <15 = mild dependence; 16 to 30 = 
moderate dependence; ≥31 = severe dependence 
 
No training 
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Table 16: Assessment tools excluded from narrative review  
Assessment tools excluded from narrative 
review 
Population Assessment category  
Adult  Young 
people 
(>10 
years)  
Depende
nce 
Consum
ption 
and 
frequenc
y 
Alcohol 
withdra
wal 
Motivati
on and 
readines
s to 
change 
Harm 
and 
alcohol 
problem
s 
Clinical 
intervie
w tool 
Reference 
Adolescent Alcohol Involvement Scale (AAIS)  • •1, 2 •1     Mayer and Filstead (1979) 
Adolescent Drinking Index (ADI)  • •1, 2      Harrell andWirtz (1990) 
Alcohol Dependence Scale (ADS) •  •1  •    Skinner and Horn (1984) 
Alcohol Withdrawal Syndrome Scale (AWS) •        Wetterling and colleagues (1997) 
Clinical Institute Withdrawal Assessment (CIWA-
AD) 
•    •1    Sullivan and colleagues (1989) 
Cognitive Lifetime Drinking History (CLDH) •   •1     Russell and colleagues (1997) 
Composite International Diagnostic Interview 
(CIDI) Version 2.1 
•  • • •   •1 Robins and colleagues (1989) 
Comprehensive Addiction Severity Inventory for 
Adolescents (CASI-A)3 
 •(>16 
years) 
•1, 2     •1 
Meyers and colleagues (1995) 
Customary Drinking and Drug Use Record 
(CDDR)3 
 • •1, 2  •  • •1 Brown et al., 1998 
Diagnostic Interview Schedule for DSM–IV (DIS–
IV) – Alcohol Module 
•  •     •1 No source reference 
Drinker Inventory of Consequences (DrInC) •      •1  Miller et al., 1995 
Drinking Problems Index (DPI) •      •1  Finney and colleagues (1991) 
Drinking Self–Monitoring Log (DSML) • •  •
1     Sobell and colleagues (1993); 
Sobell et al., 1997 
Ethanol Dependence Syndrome (EDS) Scale •  •1  •    Babor (1996) 
Form 90-AQ (Alcohol Questionnaire) 
• •  •1     
No source reference 
1 Primary use; 2 Assesses dependence or abuse. Continued 
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Table 16: (Continued) 
Assessment tools excluded from the narrative 
review 
Population Assessment category  
Adult  Young 
people 
(>10 years)  
Dependenc
e 
Consumpti
on and 
frequency 
Alcohol 
withdrawal 
Motivation 
and 
readiness 
to change 
Harm and 
alcohol 
problems 
Clinical 
interview 
tool 
Reference 
Global Appraisal of Individual Needs (GAIN) • • •   • • •1 Dennis and colleagues (2002) 
Lifetime Drinking History (LDH) •   •1     Skinner and Sheu (1982) 
Mini International Neuropsychiatric Interview 
– Clinician Rated (MINI-CR) 
•  •     •1 Sheehan and colleagues (1998) 
Motivational Structure Questionnaire (MSQ) • •    •1   Cox and Klinger (2004) 
Personal Experience Inventory (PEI)3  • •2    •1  Winters and Henly (1989) 
Psychiatric Research Interview for Substance 
and Mental Disorders (PRISM) 
•  •  •  • •1 Hasin and colleagues (1996) 
Quantity–Frequency (QF) Methods • •  •1     No source reference 
Rutgers Alcohol Problem Index (RAPI)  • •1, 2    •1  White and Labouvie (1989) 
Semi–Structured Assessment for the Genetics 
of Alcoholism (SSAGA–II) 
•  •     •1 Bucholz and colleagues (1994) 
Short Alcohol Dependence Data (SADD) •  •1      Raistrick et al., 1983 
Stages of Change Readiness and Treatment 
Eagerness Scale (SOCRATES) - Version 8 
•     •1   Miller and Tonigan (1996) 
Structured Clinical Interview for the DSM –
Substance Use Disorders Module (SCID 
SUDM) 
 • •1, 2     •1 Martin and colleagues (1995a) 
Substance Use Disorders Diagnostic Schedule 
(SUDDS-IV)3 
 •(>16 
years) 
•1,2     •1 Hoffman and Harrison (1995) 
Timeline Followback (TLFB) • •  •1     Sobell and colleagues (1979) 
University of Rhode Island Change 
Assessment (URICA) 
•     •1   DiClemente and Hughes (1990) 
1 Primary use; 2 Assesses dependence or abuse
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5.19.2  Alcohol Problems Questionnaire 
The APQ (Drummond, 1990) was developed for use as a clinical instrument and 
assesses problems associated with alcohol alone, independent of dependence. The 
APQ is a 44-item questionnaire (maximum possible score of 44) which assesses eight 
problem domains (friends, money, police, physical, affective, marital, children and 
work). The first five domains make up 23 items that are common to all individuals. 
The maximum score of 23 is derived from these items to arrive at a common score 
for all individuals.  
 
In the original validation study of the APQ, Drummond (1990) reported that the 
APQ common score (based on the common items) was significantly highly 
correlated with total SADQ score (R = 0.63) and drinking quantity as indicated by 
the alcohol consumption items of the SADQ (R = 0.53). Partial correlations, however, 
(which control for each item included in the analyses) revealed that there was a 
highly significant relationship between alcohol-related problems and alcohol 
dependence that is independent of the quantity of alcohol consumed (Drummond, 
1990). Williams and Drummond (1994) similarly reported a highly significant 
correlation between the APQ common score and the SADQ (R = 0.51), and a 
significant partial correlation between the APQ common score and SADQ 
(controlling for alcohol consumption) (R = 0.37). However, when controlling for 
dependence, the partial correlation between alcohol problems as measured by the 
APQ and alcohol consumption was low, which suggests that dependence may 
mediate the relationship between these two variables (Williams & Drummond, 
1994). The results of these two studies indicate that the APQ has high reliability and 
validity for assessing alcohol-related problems in an alcohol dependent population. 
The APQ is quick and easy to administer.  
5.20  THE ASSESSMENT OF MOTIVATION 
Self-awareness, with respect to the adverse consequences of drinking, levels of 
motivation and readiness to change drinking behaviour, vary enormously across the 
population presenting for alcohol treatment. The need to assess such issues is widely 
accepted. For example, Raistrick and colleagues (2006) noted that ‗an understanding 
of the service user's motivation to change drinking behaviour is a key to effective 
treatment and can be used to decide on the specific treatment offered‘. A number of 
methods have been developed to aid the assessment of motivational status, these are 
usually linked to the cycle of change developed by Williams and DiClemente (1983) 
are designed to site drinkers at specific stages within the cycle. The key stages of 
change are pre-contemplation (seemingly unaware of any problem), contemplation 
(aware and considering change), preparation (decision to change taken, planning 
what to do), action (doing it) and maintenance (working to secure the change). 
 
From the initial review, the GDG identified two related measures for possible 
inclusion in the narrative synthesis of tools to measure motivation in people with 
alcohol misuse problems; these are the RCQ (Rollnick et al., 1992) and the RCQ-TV 
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(Heather et al., 1999). The original RCQ is for a harmful and hazardous non-
treatment seeking population, and hence is not described in this narrative review.  
5.20.1 Readiness to Change Questionnaire – treatment version 
The RCQ-TV (Heather et al., 1999) was developed from the original RCQ for use in a 
treatment-seeking alcohol misuse population. Both versions refer to drinking 
reduction. However, the treatment version also refers to abstinence from drinking. 
The RCQ-TV has 15 items and three subscales (pre-contemplation, contemplation 
and action). The items are scored from -2 (strongly disagree) to +2 (strongly agree), 
with a maximum of +10 and minimum of -10.  
 
Heather and colleagues (1999) found low item–total correlations for the pre-
contemplation, contemplation and action scale of the RCQ-TV. Internal consistencies 
were low to moderate (Cronbach‘s α ranged from 0.60 to 0.77 across subscales). Test–
retest reliability was adequate (R = 0.69 to 0.86 across subscales). With regard to 
concurrent validity, those in the contemplation group reported drinking more than 
those in the action group, had less desire to stop drinking and reported less 
confidence in being able to stop drinking. The various subscales on the RCQ-TV 
correlated significantly with their URICA equivalents (that is, pre-contemplation, 
contemplation and action), although correlations were small in magnitude (for 
example, R = 0.39 to 0.56).  
 
Participants who had been in treatment for more than 6 months or who had had any 
treatment were more likely to be in the action group than those treated for less than 
6 months or those who had had no treatment(x2 = 8.75, p<0.005). Similarly, those 
initially assigned to the action group were more likely than those in the 
contemplation group to have a good outcome at follow-up. This result remained 
when re-classifying participants at follow-up.  
 
Heather and Hönekopp (2008) examined the properties of the standard 15-item 
version as well as a new 12-item version of the RCQ-TV in the UKATT sample of 
participants. The authors reported that there was little difference between the two 
versions. For example, the internal consistency of the 15-item version ranged from α 
= 0.64 to 0.84 across subscales and for the 12-item version α = 0.66 to 0.85 across 
subscales. Both versions showed adequate consistency over time when assessed at 3- 
and 12-month follow-up. Heather and Hönekopp (2008) also assessed the construct 
validity of both versions of the RCQ-TV by analysing their correlation with other 
important variables, namely PDA, DDD and alcohol problems (using the APQ). Both 
versions showed a low correlation with these items at baseline but high correlations 
at 3- and 12-month follow-up, indicating that the RCQ-TV may have good predictive 
value. However, the shorter version was better able to predict outcome (unsigned 
predictive value of 12-item version varied between R = 0.19 to 0.43). 
 
Because the RCQ-TV has seen specifically developed for a treatment-seeking 
population, it has value for both treatment planning and monitoring. Furthermore, it 
is short and requires no training for administration. Although it is copyrighted, it is 
 132 
 
available for no cost by contacting the original developers. However, the RCQ-TV 
adopts a very narrow focus on motivation and does not add much value to what 
could be obtained from a well-structured clinical interview. 
5.20.2 Evidence summary  
The above narrative review identifies a number of tools used in the assessment of 
several domains and that met the criteria set out at the beginning of this section and 
which the GDG considered to be feasible and appropriate to use in a NHS or related 
healthcare setting. They are: 
 
 The Alcohol Use Disorders Inventory Test (AUDIT) – for case identification and 
initial assessment of problem severity. 
 The Severity of Alcohol Dependence Questionnaire (SADQ) – to assess the 
presence and severity of alcohol dependence. 
 The Leeds Dependence Questionnaire (LDQ) – to assess the presence and severity 
of alcohol dependence. 
 The Alcohol Problems Questionnaire (APQ) – to assess the nature and extent of 
the problems associated with of alcohol misuse. 
 The Readiness to Change Questionnaire – Treatment Version (RCQ-TV) – to assess 
the motivation to change their drinking behaviour. 
 
The assessment tools above can only be fully effective when they are used as part of 
a structured clinical assessment, the nature and purpose of which is clear to both 
staff and client. The nature and purpose of the assessment will vary according to 
what prompts the assessment (for example, a request for help from a person who is 
concerned that they are dependent on alcohol or further inquiries following the 
diagnosis of liver disease which is suspected to be alcohol related).  
 
The following section of the guideline aims to review the structures for the delivery 
of assessment services. The following review will then provide the context in which 
the recommendations for assessment are developed.  
5.21 SPECIAL POPULATIONS – OLDER PEOPLE 
No assessment tools specifically developed for treatment-seeking older people who 
misuse alcohol were identified. A number of assessment tools for screening in an 
older population have been developed. However, screening tools are outside the 
scope of this guideline. Please see the public health guideline (NICE, 2010a) for a 
review of screening tools. 
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5.22 SPECIAL POPULATIONS – CHILDREN AND YOUNG 
PEOPLE 
5.22.1 Introduction  
A number of instruments that aid in the identification and diagnosis of alcohol 
misuse in children and young people are available. In considering the development 
of the assessment tools for children and young people, the GDG considered the 
framework set out within the Models of Care for Alcohol Misusers (National Treatment 
Agency for Substance Misuse, 2006), but felt that the service structures for children 
and adolescent services, the nature of the problems presented by children, and the 
need for an integrated treatment approach with child and adolescent services, meant 
that this service model needed significant modification. After consideration, the 
GDG decided to concentrate on two key areas for assessment tools: 
 
1) Case identification/diagnostic assessment 
2) Comprehensive assessment. 
 
The remainder of this review is therefore structured around these two areas. The 
clinical questions set out below relate specifically to these two areas.  
5.22.2 Clinical questions 
The clinical questions which the GDG addressed, and from which the literature 
searches were developed were: 
 
a) What are the most effective (i) diagnostic and (ii) assessment tools for alcohol 
dependence and harmful alcohol use in children and young people (aged 10 
to 18 years)? 
b)  What are the most effective ways of monitoring clinical progress in alcohol 
dependence and harmful alcohol use in children and young people (aged 10 
to 18 years)? 
 
5.22.3 Definition and aim of review of diagnostic and assessment 
tools for alcohol dependence and harmful alcohol use  
This section was developed in conjunction with the review of assessment tools, and 
the structure and format for the delivery assessment of alcohol services for adults. 
The strategy for identifying potential tools was the same as adopted for adults. See 
Section 5.15.2 for databases searched and clinical review protocol, and procedure for 
evaluating assessment tools for inclusion in diagnostic accuracy meta-analyses.  
 
As was the case with the review of adult assessment tools, the original intention was 
to conduct a quantitative review assessing the sensitivity, specificity and positive 
predictive value of the instruments for case identification, diagnosis, assessment and 
alcohol related problems in children and young people. However, the search failed 
 134 
 
to identify sufficient data to allow for a quantitative review. As a result, a narrative 
synthesis of the tools was undertaken and the conclusions are presented below. The 
identification and subsequent criteria necessary for inclusion in the narrative review 
of assessment tools were that: 
 
  the tool assesses primarily alcohol and not drugs 
 the tool has either been developed for use in children and young people or 
has been validated in this population 
 the tool has established and satisfactory psychometric data (for example, 
validity/reliability and sensitivity/specificity) 
 the tool assesses a wide range of problem domains (for example, dependence, 
quantity/frequency of alcohol consumed, alcohol-related problems and so 
on) 
 the tool has favourable administrative properties (for example, copyright, 
cost, time to administer and so on).  
5.22.4 Narrative synthesis of assessment tools for children and young 
people 
Case identification/diagnosis 
From the review of the literature, using the stipulated inclusion and exclusion 
criteria and properties outlined above, the GDG identified three tools for case 
identification in children and young people. These were the AAIS (Mayer & Filstead, 
1979), the ADI (Harrell & Wirtz, 1985) and AUDIT (Babor et al., 2001). Both the AAIS 
and ADI have both been developed for use in an adolescent population. However, 
the AAIS has not been adequately validated and the ADI, although claiming 
adequate reliability and validity data, is not routinely used in the UK. As was the 
case in the review of adult assessment tools, the AUDIT questionnaire was found to 
be the most appropriate and suitable for use as a case identification/diagnostic 
instrument. For a review of the psychometric properties and characteristics of the 
AUDIT, see Section 5.18.1. We also evaluated the need for a revised cut-off in young 
people using the AUDIT questionnaire. Chung and colleagues (2000) recommends 
modification of the AUDIT to be more appropriate to young people. Two studies 
using representative populations suggest a cut off score of 4 or more (Chung et al., 
2000; Santis et al., 2009).  
Comprehensive assessment instruments 
As part of the systematic review and associated search strategies, a number of 
clinical interview tools which provide a comprehensive assessment of alcohol 
misuse in children and young people specifically were identified. These are: the ADI 
(Winters & Henly, 1993); the CASI-A (Meyers et al., 1995); the CDDR (Brown et al., 
1998); the Diagnostic Interview Schedule for Children (DISC; Piacentini et al., 1993); 
the SCID SUDM (Martin et al., 1995a); the SUDDS-IV (Hoffman & Harrison, 1995); 
and the Teen Addiction Severity Index (T-ASI; Kaminer et al., 1991). Based on the 
criteria outlined above, the clinical interview tools which met inclusion criteria and 
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are included in this narrative review are the ADI, DISC and T-ASI (see Table 17 
below for characteristics of these tools). The GDG made a consensus-based decision 
to exclude the CASI-A, CDDR, SCID SUDM and SUDDS-IV from the narrative 
review because these tools have been developed for the use in adolescents over the 
age of 16 years old population only, and hence may be inappropriate for use with 
children under that age. See 
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Table 16 for characteristics of these excluded tools.  
 
Adolescent Drinking Index 
The ADI is a comprehensive assessment instrument which provides a DSM–III-R-
based psychiatric diagnosis of alcohol abuse or dependence in 12- to 18-year-olds. As 
well as substance and alcohol abuse/dependence, the ADI also assesses a variety of 
other problems such as psychosocial stressors, cognitive impairment, and school and 
interpersonal functioning. The ADI as a clinical instrument has been reported to 
have good inter-rater reliability (alcohol abuse = 0.86; alcohol dependence = 0.53); 
test–retest reliability (0.83); significant concurrent validity among all variables (range 
= 0.58 to 0.75); adequate criterion validity assessed by agreement with a clinician 
rating (alcohol abuse k=0.71; alcohol dependence k=0.82); and high sensitivity and 
specificity for alcohol abuse (both 0.87) and dependence (0.90 and 0.95, respectively) 
(Winters & Henly, 1989; Winters et al., 1993). The ADI takes 50 minutes to complete 
and can be obtained at a cost from the developer.  
Diagnostic Interview Schedule for Children 
The DISC provides a diagnosis of alcohol dependence or abuse based on DSM–IV 
criteria. It has been found to be highly sensitive in identifying young people who 
have previously been diagnosed as having a substance use disorder (sensitivity = 
75%) (Fisher et al., 1993). However, although the DISC has been found to have 
acceptable reliability and validity data, this has been for non-substance specific 
psychiatric disorders (see Schwab-Stone et al., 1996; Piacentini et al., 1993; Schaffer et 
al., 1996; Jensen et al., 1995). It is also relatively lengthy (1 to 2 hours), and 
copyrighted.  
Teen Addiction Severity Index 
The T-ASI is a semi-structured clinical interview designed to provide a reliable and 
valid measure in the evaluation of substance abuse in adolescents. It has 126 items 
that provide severity ratings for psychoactive substance use, school or employment 
status, family function, peer-social relationships, legal status and psychiatric status. 
The T-ASI has satisfactory inter-rater reliability (R = 0.78) and has been found to 
have utility in both the clinical identification of alcohol dependence or harmful 
alcohol use, as well as in the assessment of changes of severity over time as a 
response to treatment, and hence may be applicable as an outcome monitoring tool 
(Kaminer et al., 1991). Kaminer and colleagues (1993) also established that the T-ASI 
could adequately distinguish between 12- to 17-year-olds with and without 
substance-use disorders as defined by the DSM–III-R. The T-ASI has an added 
benefit as it can be administered in less than 30 minutes, it is free to use and not 
copyrighted. 
 
No measures of alcohol problems, such as the APQ for adults, was identified and 
nor was any specific instrument, such as the RCQ-TV for motivation, identified. 
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Table 17: Characteristics of clinical interview tools for children and adolescents 
included in the narrative review 
Assessment instrument Number of items and format 
Time to administer and by 
whom 
Training required for 
administration; time to score; by 
whom  
Adolescent Diagnostic 
Interview (ADI) 
213 items (not all asked), 
structured interview 
Approximately 50 minutes 
(depends on number of 
substances used), trained 
personnel 
Yes; 15 to 20 minutes; trained 
personnel  
Diagnostic Interview 
Schedule for Children 
(DISC) 
Variable depending on module 
assessed, structured interview 
1 to 2 hours; trained personnel 
Scoring algorithms are provided 
by National Institute of Mental 
Health – DISC 
No; immediate; computer 
program 
Teen Addiction Severity 
Index (T-ASI) 
154 items (seven subscales), 
structured interview 
20 to 45 minutes; trained 
personnel 
Yes; 10 minutes; non-trained 
personnel  
 
Use of biological markers  
The review of adult alcohol misuse identified that no particular biological markers 
were of value in achieving a diagnosis of harmful or dependent drinking. Given that 
clinically significant changes in liver enzymes are rare in adults, even in those with 
established alcohol dependence (Clark et al., 2001), it seems unlikely that the routine 
use of such biological markers is of value in children and young people. However, 
the use of urine analysis or breath testing to determine the presence during 
treatment and/or assessment of drug or alcohol misuse may be of value in assessing 
the veracity in the overall assessment, but should not be used as a diagnostic marker.  
5.22.5 Evidence summary  
The GDG identified that the AUDIT is appropriate for case identification of alcohol 
misuse in children and young people, but with the proviso that the cut-offs are 
adjusted downwards to a score of 4 or more. Also, modification of AUDIT items to 
make them relevant to adolescents should be considered. The advantages identified 
for adults – that it is brief, and easy to administer and score – remain the same.  
 
The review of tools to aid a comprehensive assessment in children and young people 
identified three possible tools – the ADI, the DISC and the T-ASI. The review 
identified some problems with the DISC including population in which it was 
standardised, its duration and its cost. The other two instruments (the ADI and the 
T-ASI) met the criteria chosen by the GDG and therefore both could be used as part 
of a comprehensive assessment of alcohol misuse. However, although the T-ASI is 
free to use, the ADI can only be obtained at a monetary cost. Furthermore, the T-ASI 
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has utility as an outcome monitoring tool and, although perhaps too long for routine 
use (30 minutes), it may have value as an outcome measure for periodic reviews. As 
with the adult assessment, these tools should be used and interpreted by trained 
staff. The comprehensive interview should not only assess the presence of an alcohol 
use disorder, but also other comorbid and social problems, development needs, 
educational and social progress, motivation and self-efficacy, and risk. A 
child/young person may be competent to consent to a treatment; this depends on 
the age and capacity of the child and assessment of competence. Where appropriate, 
consent should be obtained from parents or those with parental responsibility. The 
aim of the assessment should be, wherever possible, to set a treatment goal of 
abstinence. 
5.23 THE STRUCTURE AND CONTENT OF THE 
ASSESSMENT INTERVIEW 
5.23.1 Introduction 
In developing this section of the chapter, the GDG drew from publications on the 
structuring and settings for the delivery of alcohol services (MoCAM; Department of 
Health, 2006a) and also the two recent NICE guidelines on the treatment and 
management of alcohol related problems (NICE, 2010a; NICE, 2010b). The NICE 
guidelines were particularly important in setting the context for and limits of this 
review. A number of authors have set out the aims and components of an 
assessment for alcohol misuse including Edwards and colleagues (2003), MoCAM 
(Department of Health, 2006a) and Raistrick and colleagues (2006). The common 
aims for assessment of alcohol misuse that emerge from these authoritative reviews 
are: 
 
 establishing the presence of an alcohol-use disorder  
 the level of alcohol consumption 
 determining whether the alcohol-use disorder is best characterised as harmful 
drinking or alcohol dependence 
 establishing the presence of acute risks (for example, self-harm, harm to 
others, medical/mental health emergenciesand  safeguarding children) 
 establishing the capacity to consent to treatment or onward referral  
 experience and outcome of previous intervention(s) 
 establishing the willingness to engage in further assessment and/or treatment 
 establishing the presence (but not necessarily diagnosing) of possible co-
existing common problems features (for example, co-occurring substance 
misuse, medical, mental health and social problems) 
 determining the urgency of referral and/or an assessment for alcohol 
withdrawal. 
The following sections describe in some detail the key aspects of alcohol misuse. The 
extent to which they are addressed in the description of the different assessment 
systems that follow will vary according to the needs of the individual, the service in 
which the assessment is delivered, the specific purpose of the assessment and the 
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competence of the staff undertaking the assessment. Nevertheless all staff 
undertaking an assessment of alcohol misuse will need to be familiar with the issues 
described below.  
5.23.2 Alcohol use and related consequences 
For harmful alcohol use or alcohol dependence to be identified, three domains need 
to be addressed: alcohol consumption, features of alcohol dependence and alcohol 
problems (Edwards et al., 2003; Allen, 2003). It should be remembered that to arrive 
at a diagnosis of harmful alcohol use, alcohol dependence needs to be excluded and 
therefore dependence features need to be considered for all those undergoing 
diagnostic clinical interview (ICD–10; WHO, 1992). Baseline alcohol consumption 
and severity of alcohol dependence have been identified as potentially significant 
predictors of treatment outcome (Adamson et al., 2009).  
Consumption  
Harmful effects of alcohol use have been found to be influenced by both the amount 
and pattern of alcohol consumption (Rehm et al., 2004). Assessing typical daily and 
weekly alcohol consumption and comparing findings with recommended levels of 
alcohol consumption is therefore a useful starting point.  
 
Individuals may present at different stages of a drinking cycle, so it is important to 
acknowledge that the absence of current alcohol use does not exclude the patient 
from being diagnosed with an alcohol-use disorder (WHO, 1992). Therefore an 
overview of the patient‘s current drinking status, preferred type of alcohol/brand 
consumed, the setting in which this occurs and general amount consumed is an 
important part of a assessment (Edwards et al., 2003; MoCAM; Department of 
Health, 2006a). Usually the assessment of consumption and frequency relies on the 
evaluation of self-reported alcohol consumption. Sobell and Sobell (2003) considered 
previous reviews of the validity and reliability of self-reported alcohol consumption 
and found that there is enhanced accuracy from individuals who are: (i) alcohol free 
when interviewed; (ii) given written assurances of confidentiality; (iii) interviewed 
in a setting that encourages openness and honesty; (iv) asked clearly worded 
questions; and (v) provided with memory aids to recall drinking (that is, drink 
diaries), because those interviewed with alcohol in their system tending to 
underestimate their consumption. Previous reviews support the concept of 
enquiring about the patient‘s typical drinking day (Rollnick et al., 1999; Edwards et 
al., 2003). The notion of focusing on the typical drinking day allows staff to 
concentrate on what may normally occur in the absence of other factors that may 
influence large variations in alcohol consumption (such as stress, finances and life 
events) that may be misleading. Regular high-level alcohol consumption may 
indicate tolerance to alcohol that has a significant relationship to alcohol dependence 
and consequent alcohol withdrawal.  
The evolution of the patient‘s current alcohol consumption over time needs to be 
considered in order to identify significant patterns of alcohol use that are 
diagnostically important. In a more detailed assessment, the concept of drinking 
milestones may help to identify significant drinking-related instances from the time 
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of first drink through to present alcohol consumption patterns. Edwards and 
colleagues (2003) suggests the inclusion of milestones such as age at first alcoholic 
drink, first drinking most weekends, first drinking daily and when they commenced 
drinking at the current levels. Additionally, it is important to document when the 
patient recognises the following: when they first felt alcohol was a problem; the 
heaviest period of alcohol consumption; and significant periods where they have 
experienced being alcohol free. Seeking clarification with regard to typical quantities 
of alcohol consumed at significant milestones will help establish the development of 
potential alcohol misuse.  
Dependence  
People who are dependent on alcohol develop adjustments to alcohol being present 
or absent in the body. Regular alcohol consumption can result in central nervous 
system changes that adapt to and compensate for the depressant effects of alcohol on 
the body. If this adaptation occurs, these changes may also result in the central 
nervous system being hyper-excited when alcohol levels are reduced, presenting 
characteristic alcohol withdrawal symptoms. Sensitive exploration of the six 
individual alcohol dependence criteria will confirm a diagnosis and help the 
individual to understand and acknowledge the condition that they are experiencing 
(Edwards et al., 2003). It is generally accepted that a number of aspects of 
dependence should be covered in a comprehensive assessment, including tolerance, 
neglecting activities and interests, compulsion, physiological withdrawal and 
drinking despite problems (Maisto et al., 2003). 
Tolerance 
Regular alcohol drinkers become tolerant to the central nervous system effects of 
alcohol (Kalant, 1996). There appears to be a number of individual factors that 
influence the development of tolerance to alcohol including metabolic, 
environmental and learned factors (Tabakoff et al., 1986). There is no simple clinical 
tool to directly measure alcohol tolerance. However increasing consumption levels 
and a reduced effect of the same amount of alcohol over time are indicative of 
tolerance. The effect of blood alcohol concentration (BAC) on an individual will 
decrease as tolerance develops (Hoffman & Tabakoff, 1996) but even in tolerant 
individuals high level alcohol consumption will still impair functioning and 
judgement. Nevertheless people with very high alcohol tolerance will be able to 
tolerate a high BAC that would be fatal to a non-tolerant individual. 
Alcohol withdrawal  
Staff will need to understand and recognise the features of alcohol withdrawal to 
accurately arrive at a diagnosis of alcohol dependence. Alcohol withdrawal 
symptoms need to be differentiated from other clinical characteristics and conditions 
that may present similarly.  
Alcohol withdrawal symptoms include:  
 Tremor 
 Nausea 
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 Sweating 
 Mood disturbance including agitation and anxiety 
 Disturbed sleep pattern  
 Hyperacusis – sensitivity to sound 
 Hyperthermia – increased body temperature 
 Tachycardia – increased pulse rate 
 Increased respiratory rate 
 Tactile and/or visual disturbances – itching, burning and so on. 
 
Severe alcohol withdrawal symptoms include:  
 Hallucinations – auditory, visual and/or tactile  
 Alcohol withdrawal seizures – grand mal type seizures 
 Delirium tremens (DTs) – coarse tremor, agitation, fever, tachycardia, 
profound confusion, delusions and hallucinations. 
 
People who are moderately or severely alcohol dependent will develop an acute 
alcohol withdrawal syndrome when they abruptly stop or substantially reduce their 
alcohol consumption. People who are mildly dependent may experience some 
milder symptoms of alcohol withdrawal including sweating, nausea, and mild 
tremor but generally do not require medical treatment. Withdrawal symptoms 
develop as early as 6 to 8 hours after abrupt reduction or cessation of alcohol intake.  
 
Table 18 provides an illustration of alcohol withdrawal symptoms against a timeline 
since last drink. The time from last drink to onset of withdrawal symptoms reduces 
with increasing severity of dependence, such that people who are severely alcohol 
dependent may begin to experience withdrawal within a few hours of the last drink. 
 
Table 18: Timeline for the emergence of alcohol withdrawal symptoms 
Timeline from last drink Alcohol withdrawal symptoms 
Onset: 6 to 8 hours 
Peak: 10 to 30 hours 
Subsides: 40 to 50 hours 
Generalised hyperactivity, tremor, sweating, nausea, 
retching, mood fluctuation, tachycardia, increased 
respirations, hypertension and mild pyrexia 
Onset: 0 to 48 hours  Withdrawal seizures 
Onset: 12 hours 
Duration: 5 to 6 days 
Auditory and visual hallucinations may develop which are 
characteristically frightening  
Onset: 48 to 72 hours DTs: coarse tremor, agitation, fever, tachycardia, profound 
confusion, delusions and hallucinations 
 
The individual may describe the use of alcohol to avoid or relieve the effects of 
alcohol withdrawal, which would further demonstrate dependence to alcohol. 
Compulsion  
An individual‘s compulsion to consume alcohol is commonly reported when an 
alcohol-dependent drinker attempts to control or stop use. This has been described 
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as urges or cravings (Drummond & Phillips, 2002). The intensity of craving is highly 
correlated with the severity of dependence. Certain situations and emotional states 
(cues) that influence the presence and intensity of alcohol craving, as these may be 
an important factor in precipitating future drinking episodes (Drummond, 2000). 
Not everyone who is alcohol dependent reports alcohol craving, and craving per se 
does not inevitably lead to relapse. However, for some service users it can be an 
unpleasant and troubling symptom. 
Neglecting activities and interests  
Individuals who are dependent on alcohol may describe a reduction or change in 
their participation in activities they hold as important (Edwards & Gross, 1976). As 
alcohol becomes increasingly more salient to the drinker, the need to obtain, 
consume and/or recover from excessive alcohol consumption takes higher priority 
in their lives relative to usual obligations and interests. Identifying the salience 
alcohol has for the individual – exploring past and current interests with the 
individual is important to establish. 
Drinking despite  problems associated with alcohol  
Alcohol-related problems can occur in the absence of alcohol dependence (that is, 
accidents, legal problems and so on). However, a person who is dependent on 
alcohol may maintain drinking behaviour despite experiencing harmful effects of 
alcohol such as harm to the liver and depressed mood (Edwards & Gross, 1976). The 
individual may continue to drink despite criticisms from family, friends and work 
colleagues. This can be difficult to establish because the individual may not make a 
connection between their drinking and the consequences, or be embarrassed about 
discussing problems related to their drinking. Part of the process of the assessment is 
to help the individual make these causal connections through motivational 
interviewing techniques. 
Other substances of misuse 
The assessment of alcohol misuse is often complicated by the presence of co-
occurring conditions, these, along with the implications for assessment, are outlined 
below. 
Comorbid opioid and alcohol dependence 
 In treatment services for opioid dependency, about a quarter to a third of patients 
will have problems with alcohol (Department of Health, 2007). In addition, 
prognosis for this group can be poor with many showing limited changes in 
drinking behaviour. A recent systematic review about whether alcohol consumption 
is affected during the course of methadone maintenance treatment concluded that 
alcohol use is not likely to reduce by just entering such programmes, with most 
studies reporting no change (Srivastava et al., 2008). In the UK National Treatment 
Outcome Research Study, 25% of people misusing opiates were drinking heavily 
(>10 units per day) at the start of the study and 4 to 5 years later about a quarter 
were continuing to do so (Gossop et al., 2003).  
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Comorbid cocaine and alcohol dependence  
Cocaine use is increasing in England (NHS Information Centre & National Statistics, 
2009), and comorbid cocaine and alcohol dependence is commonly seen and can be 
challenging to treat. There is little known in the UK about the level of this 
comorbidity in alcohol treatment services. In the US Epidemiological Catchment 
Area study, 85% of cocaine-dependent patients were also alcohol dependent (Regier 
et al., 1990). In a sample of 298 treatment-seeking cocaine users, 62% had a lifetime 
history of alcohol dependence (Carroll et al., 1993). In a sample of people in contact 
with drug treatment agencies (mainly for opiate addiction and in the community 
abusing cocaine), heavy drinking was common. Those using cocaine powder were 
more likely to drink heavily than those using crack cocaine (Gossop et al., 2006).  
 
When taken together, cocaine and alcohol interact to produce cocaethylene, an active 
metabolite with a half-life three times that of cocaine. In addition, alcohol inhibits 
some enzymes involved in cocaine metabolism, so can increase its concentration by 
about 30% (Pennings et al., 2002). Due to the presence of cocaethylene which has 
similar effects to cocaine and a longer half-life, this leads to enhanced effects. For 
instance, taken together cocaine and alcohol result in greater euphoria and increased 
heart rate compared with either drug alone (McCance-Katz et al., 1993; see Pennings 
et al., 2002).  
Comorbid alcohol and benzodiazepine dependence  
Benzodiazepine use is more common in patients with alcohol misuse than in the 
general population, with surveys reporting prevalence of around 10 to 20% (Ciraulo 
et al., 1988; Busto et al., 1983). In more complex patients it can be as high as 40%, 
which is similar to that seen in psychiatric patients. Not all use will necessarily be by 
misusers. For some individuals, their growing dependence on benzodiazepines 
began when a prescription for withdrawal from alcohol was extended and then 
repeatedly renewed. For others the prescription may have been initiated as a 
treatment for anxiety or insomnia, but then was not discontinued in line with 
current guidelines.  
Comorbid alcohol and nicotine dependence  
Many patients with alcohol misuse smoke cigarettes, which leads to an extra burden 
of morbidity and mortality in addition to the alcohol misuse. The prevalence of 
smoking has been estimated at around 40% in population-based studies of alcohol-
use disorder and as much as 80% in people with alcohol dependence who are 
seeking treatment (Grant et al., 2004b; Hughes, 1995). Comorbidity is higher in men 
than women and in younger compared with older people (Falk et al., 2006). 
Comorbid nicotine and alcohol dependence has been comprehensively reviewed 
recently by Kalman and colleagues (2010).  
Motivation and self-efficacy 
The assessment of an individual‘s willingness to engage in treatment can vary 
considerably and has been the subject of considerable debate. Assessment can be 
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effective as an intervention in itself and has been shown to influence behaviour 
change (McCambridge & Day, 2008), increasing an individual‘s confidence towards 
change that may prompt reductions in alcohol consumption (Rollnick et al., 1999). 
Being sensitive to the individual‘s needs, developing rapport and a therapeutic 
alliance have all been identified as important aspects in the effective engagement of 
an individual who drinks excessively (Najavits & Weiss, 1994; Raistrick et al., 2006; 
Edwards et al., 2003). Indeed, there is evidence to suggest that a premature focus on 
information gathering and completion of the assessment process may have a 
negative impact on the engagement of the patient (Miller & Rollnick, 2002). Where 
this approach is adopted, there is some evidence to suggest that initial low levels of 
motivation are not necessarily a barrier to an effective assessment and the future 
uptake of treatment (Miller & Rollnick, 2002).  
 
An openness to discussion aimed at understanding a person‘s reasons for seeking 
help and the goals they wish to attain has also been positively associated with 
engagement in assessment and treatment (Miller, 1996). The individual‘s personal 
drinking goals can then be acknowledged and used as a basis for negotiation once 
the assessment is completed (Adamson et al., 2010).  
 
Alcohol-related problems present in a number of different settings, often 
concurrently (for example, a person may present as depressed in primary care 
subsequent to a brief admission for acute pancreatitis, both related to excessive 
alcohol intake). Therefore, effective assessment systems need to be linked to equally 
effective communication between those involved in the care and treatment of people 
with alcohol related problems (Maisto et al., 2003). Sharing of information between 
agencies should be encouraged to maximise safety and effectiveness of treatment 
(MoCAM; Department of Health, 2006a). 
5.24 FRAMEWORK FOR ASSESSMENT OF ALCOHOL 
MISUSE  
As noted above, the presentation of alcohol-related problems are rarely 
straightforward and can span a wide range of settings and organisations. This 
complexity of presentation is often matched by equally complex assessment or 
treatment responses. It is therefore important that clear structures are in place to 
identify and assess the presenting problems, to determine the most appropriate 
treatment option and, where necessary, to make an appropriate referral. This section 
reviews the evidence, albeit limited, for the organisation and delivery of assessment 
systems. In doing so it not only draws on the evidence that relates directly to the 
organisation and delivery of care (see Section 2 of this chapter) but also on the 
evidence reviewed in the two other NICE guidelines on prevention and early 
detection of hazardous and harmful drinking  (NICE, 2010a) and on management of 
alcohol-related physical complications (NICE, 2010b). This section also draws on 
other parts of this guideline that consider evidence which is relevant to a framework 
for the assessment of alcohol misuse. It should be noted that the framework of 
assessment in this guideline is not specifically concerned with the opportunistic 
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screening for hazardous and harmful drinking that is covered by the NICE (2010a) 
guideline on prevention and early detection. However, it is important that the 
assessment framework considers both those who seek treatment and those who do 
not respond to brief interventions.  
 
In developing the framework for assessment, the evidence for the discussion of 
stepped-care systems in Section 2 of this chapter was particularly influential. The 
evidence review provided no convincing evidence to suggest a significant variation 
for the stepped-care framework set out in the Models of Care for Alcohol Misusers 
(MoCAM; Department of Health, 2006a) developed by the National Treatment 
Agency. Building on the framework in MoCAM, a four-level strategy for the 
assessment (and management) of harmful drinking and alcohol dependence 
emerges15. This is set out below: 
 
1. Case identification/diagnosis  
2. Withdrawal assessment 
3. Triage assessment 
4. Comprehensive assessment. 
 
These four levels, which are defined below, take account of the broad approach to 
the delivery of assessment and interventions across different agencies and settings 
including primary healthcare, third sector providers, criminal justice settings, acute 
hospital settings and specialist alcohol service providers. It should be noted, 
however, that this does not follow a strictly stepped-care model because an 
assessment for withdrawal could follow from a triage and a comprehensive 
assessment. Withdrawal assessment was not included in the MoCAM assessment 
framework as a separate assessment algorithm, but was considered by the GDG to 
merit separate inclusion in these guidelines. Alcohol withdrawal assessment is an 
area of clinical management that often requires immediate intervention. This is 
particularly apparent where an alcohol dependent individual may experience acute 
alcohol withdrawal as a consequence of an admission to an acute hospital ward 
(NICE, 2010b) due to an acute health problem, or has been recently committed to 
prison.  
 
The framework for assessment (seeFigure 4) sits alongside the four-tiered conceptual 
framework described in MoCAM (Department of Health, 2006a) and assumes that 
only appropriately skilled staff will undertake the assessment elements. The Drug 
and Alcohol National Occupational Standards (DANOS; Skills for Health [2002] and 
Skills for Care16) set out the skills required to deliver assessment and interventions 
under the four-tiered framework. The different levels of assessment will require 
varying degrees of competence, specialist skills and expertise to undertake the more 
complex assessments. 
                                                 
15 The terms levels and tiers are adopted from the MoCAM (Department of Health, 2006a) to facilitate 
ease of understanding and implementation.  
16 See www.skillsforcare.org.uk. 
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Level 1: 
Case identification/diagnosis  
Trained and competent staff in all services 
providing Tier 1 to 4 interventions 
 
Level 2: 
Withdrawal assessment  
Trained and competent staff in all services 
providing Tier 1 to 4 interventions 
 
Level 3: 
Triage assessment  
Trained and competent staff in all services 
providing Tier 2 to 4 interventions 
 
Level 4: 
Comprehensive assessment  
Trained and competent staff in all services 
providing Tier 3 to 4 interventions (and some 
Tier 2 interventions) 
 
Figure 4: Assessment levels. 
 
5.25 THE FRAMEWORK FOR ASSESSMENT OF 
ALCOHOL MISUSE 
5.25.1 Case identification and diagnosis 
Aims 
Case identification and, following on from that, diagnosis seek to identify 
individuals who are in need of intensive care-planned treatment because of possible 
alcohol dependence, those with harmful alcohol use who are in need of or have not 
responded to brief interventions and those experiencing comorbid problems which 
may complicate the treatment of the alcohol misuse. Given the overall stepped 
framework in which the assessment takes place, it is anticipated that this level 
would have two main objectives:  
 
a) To identify those individuals who need an intervention (see Chapters 6 and 7) 
for harmful or alcohol dependence  
b) To identify those who may need referral for a comprehensive assessment 
and/or withdrawal assessment including those who:  
 have not responded to an extended brief intervention 
 have moderate to severe alcohol dependence or otherwise may need 
assisted alcohol withdrawal 
 those that show signs of clinically significant alcohol-related impairment 
(for example, liver disease or significant alcohol related mental health 
problems).  
 
Settings 
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Case identification and diagnosis are activities that should be available across the 
whole range of healthcare and related services (for example, GPs, accident and 
emergency departments, children and families social services, and specialist alcohol 
treatment agencies).  
Method 
This level of assessment should consider:  
 establishing the probable presence of an alcohol-use disorder  
 the level of alcohol consumption (as units17 of alcohol per day or per week)  
 where an alcohol-use disorder is suggested, distinguish harmful drinking 
from alcohol dependence  
 establishing the presence of risks (for example, self-harm, harm to others, 
medical/mental health emergencies and safeguarding children) 
 establishing the capacity to consent to treatment or onward referral  
 experience and outcome of previous intervention(s) 
 establishing the willingness to engage in further assessment and/or treatment 
 establishing the presence of possible co-existing common problems features 
(for example, additional substance misuse, medical, mental health and social 
problems) 
 determining the urgency of referral and/or an assessment for alcohol 
withdrawal. 
 
The treatment options that follow immediately on from this initial assessment, 
the exception of assisted withdrawal, will focus on harmful or dependent 
A significant number of individuals may already have received brief intervention 
and not benefited from them; if this is the case then the individual will need to be 
referred for a comprehensive assessment. See Figure 5: Care pathway: case 
identification and possible diagnosis for adults 
for an outline of the care pathway for the case identification and possible diagnosis 
for adults.
                                                 
17 The UK unit definition differs from definitions of standard drinks in some other countries. For 
example, a UK unit contains two thirds of the quantity of ethanol compared with a US ‗standard 
drink‘. 
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Figure 5: Care pathway: case identification and possible diagnosis for adults 
 
 Screen (PAT, FAST, SASQ and so on) 
indicates possible alcohol-use 
disorder  
Administer AUDIT  
AUDIT score <8: 
Low-risk drinking –
no further action 
AUDIT score 16–19:  
Harmful drinking 
AUDIT score 8–15:  
Hazardous drinking 
AUDIT score 20+: 
Probable alcohol 
dependence  
Referral to specialist 
assessment/withdrawal 
assessment 
Referral to specialist 
assessment where no 
improve maintained 
Extended brief 
intervention(s)  
Review of progress  
Consider Tier 2 interventions 
Consider Tier 2 or 3/  
Immediate withdrawal 
assessment for acute 
inpatients settings and 
prisons  
Brief intervention 
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5.25.2 Level 2: withdrawal assessment 
Aims 
Assessment of the need for a medically managed withdrawal, the potential risks (for 
example, DTs or seizures), and the most appropriate setting in which to manage 
withdrawal. A key factor will be determining whether the withdrawal management 
should take place in a community or an inpatient or residential setting. This section 
of the guideline should be read in conjunction with the section on planned assisted 
alcohol withdrawal in this guideline and the reader should also refer to the guideline 
on the management of unplanned acute withdrawal (NICE, 2010b). It should be 
noted that assisted withdrawal from alcohol should not be seen as a stand-alone 
treatment for alcohol dependence but rather as an often essential initial intervention 
within a broader care plan including psychosocial or pharmacological therapies to 
prevent relapse. Specifically the withdrawal assessment should aim: 
 
a) to identify those individuals who need an assisted withdrawal because of 
alcohol dependence  
b) to identify:  
 the severity of the dependence 
 the level of alcohol consumption 
 the presence of comorbid factors such as substance misuse, severe 
psychiatric disorders, significant physical illness or disability 
 the availability of personal and social support and housing support 
c) to identify in which setting a withdrawal can be most clinically, cost-
effectively and safely managed  
d) to determine the urgency with which the assisted withdrawal should be 
provided 
e) to provide sufficient information to properly integrate the assisted 
withdrawal programme into a wider care plan. 
Settings  
Withdrawal assessments take place in a number of healthcare settings; the 
management of those presenting in a state of unplanned withdrawal in acute 
medical settings is dealt with in NICE (2010b). However, although this guideline‘s 
recommendations are focused primarily on the management of planned withdrawal, 
a number of the recommendation in this guideline will be relevant to the assessment 
of all individuals who are alcohol dependent and at risk of developing withdrawal 
symptoms. Primary care, prisons, police custody, general hospitals, secondary care 
mental health services, and specialist drug and alcohol services are all settings in 
which the need for a withdrawal assessment may arise. These varied settings mean 
that the nature of the assessment will vary depending on the resources and skills 
available in those settings. However, as described in Section 4 of this chapter there is 
evidence that assisted withdrawal from alcohol can be safely and effectively 
delivered in all those settings provided that an assessment has been performed to 
determine the most appropriate environment in which to undertake the withdrawal 
 150 
 
and the regimen required (Maisto et al., 2003). The impact of comorbid conditions 
and their implications for the choice of withdrawal setting is described more fully in 
Section 4. A number of reviews (for example, Raistrick et al., 2006; NICE, 2010b) 
highlight factors which suggest the need for residential or inpatient withdrawal 
programmes. These include: those who are at high risk18 of developing alcohol 
withdrawal seizures or DTs; those with a history of polydrug use; significant 
cognitive impairment; the homeless; and those with an illness that requires 
medical/surgical or psychiatric treatment.  
Methods 
Those who experience a significant degree of alcohol dependence will typically 
exhibit alcohol withdrawal symptoms 6 to 8 hours after their last drink, with peak 
effect of alcohol withdrawal symptoms occurring after between 10 to 30 hours (see 
guideline on management of alcohol-related physical complications; NICE, 2010b). 
However the onset of withdrawal varies with severity of dependence such that 
people who are severely dependent will experience withdrawal earlier after 
stopping drinking than those who are less dependent. Early diagnosis of alcohol 
dependence will help to initiate proactive management strategies for the individual 
and reduce risks to the patient.  
The NICE guideline on management of alcohol-related physical 
complications 
(NICE, 2010b) reviewed the tools for the assessment and monitoring of patients who 
are alcohol dependent and at risk of developing alcohol withdrawal. The guideline 
recommends the use of a validated tool to support clinical judgement in the 
assessment of alcohol withdrawal. Furthermore, the guideline recommended the use 
of an assessment tool in situations particularly where staff are less experienced with 
the assessment and management of alcohol withdrawal. The guideline identified the 
CIWA-Ar as a valuable tool for measuring alcohol withdrawal symptoms. The 
guideline also noted that a delay in assessment and treatment of withdrawal of more 
than 24 hours is associated with greater withdrawal complications.  
 
After establishing the possibility of alcohol misuse it is important to establish first 
whether or not dependence is present; in all settings this is a two stage process. The 
first stage involves the identification of those at risk of dependence and withdrawal. 
The preferred aid to a clinical assessment is the AUDIT questionnaire. An AUDIT 
score greater than 20 is an indication of likely alcohol dependence and the need for 
withdrawal assessment (Babor et al., 2001). If it is not possible to complete an AUDIT 
questionnaire then regular consumption of alcohol of 15 to 20 or greater units per 
day suggests likely dependence. Although there is no absolute level of daily or 
weekly alcohol consumption which indicates the likelihood of alcohol dependence, 
the SADQ score (a measure of the severity of dependence – see above) correlates 
with high-level alcohol consumption (Stockwell et al., 1979). Others support the view 
                                                 
18 There is a higher risk of developing DTs in people with a history of seizures or DTs and/or signs of 
autonomic over-activity with a high blood alcohol concentration.  
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that typical drinks per drinking day is a useful indicator of the severity of alcohol 
dependence and need for alcohol withdrawal management (Shaw et al., 1998). There 
are a number of methods to establish alcohol quantity and frequency, including 
direct patient report, drinking diaries and retrospective recording systems (Sobell & 
Sobell, 2003), although previous reviews have identified that such techniques vary in 
accuracy (Raistrick et al., 2006). However it should be noted that both of AUDIT 
scores and typical drinks per day should be adjusted for gender (Dawe, 2002) age 
(both for older adults (Beullens & Aertgeerts, 2004) and adolescents (McArdle, 2008) 
and people with established liver disease (Gleeson et al., 2009).  
 
The second stage involves an assessment of the severity of alcohol dependence. 
Again a formal assessment tool is the preferred means to identify the severity of 
dependence in this guideline. The review of such tools for this guideline revealed 
that the SADQ (Stockwell et al., 1979; 1983) has broad clinical utility as it identifies 
the presence and severity of alcohol dependence, predicts withdrawal severity and 
acts as a useful guide for the quantity of medication to be prescribed during alcohol 
withdrawal.  
5.25.3 Withdrawal assessment in children and young people 
As has already been noted, the diagnosis and identification of withdrawal symptoms 
in children and young people is difficult. This means that the potential for harm 
through under-identification of alcohol withdrawal on young people is considerable. 
Unfortunately, there is little direct evidence to guide the process of withdrawal 
management, including both its identification and treatment in young people. In the 
development of this section the GDG drew extensively on the review of assisted 
withdrawal for adults, contained both in the NICE guideline for acute withdrawal 
(NICE, 2010b) and for planned withdrawal within this guideline. In essence, the data 
used to support much of this review is an extrapolation from a data set developed 
from the management of withdrawal in adults. The principle that the GDG 
approached this data with is one of considerable caution and a desire to, as far as 
possible, reduce any significant harm arising from withdrawal symptoms in young 
people.  
Identification of need for assisted alcohol withdrawal  
Identification of withdrawal should be based on careful assessment of the pattern, 
frequency and intensity of drinking. The limited data available for review, the 
evidence from adults and the greater vulnerability of young people to the harmful 
effects of alcohol led the GDG to conclude that they should be a significant reduction 
in the threshold for young people for initiating withdrawal management. The 
threshold that has been established for adults of an AUDIT score of more than 20, an 
SADQ score of more than 20 or the typical consumption of 15 units per day is not 
appropriate for adolescents. In adolescents binge drinking is common (defined as 
more than five units of alcohol on any one occasion) and a pattern of frequent binge 
drinking (for example, a pattern of two or more episodes of binge drinking in a 
month) or an AUDIT score of 15 should alert the clinician to possible dependence 
and trigger a comprehensive assessment. The presence of any potential withdrawal 
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symptoms should be taken seriously and a comprehensive assessment initiated. A 
range of factors including age, weight, previous history of alcohol misuse and the 
presence of co-occurring disorders will also influence the threshold for initiating a 
comprehensive assessment and withdrawal management. See Figure 6 for a 
summary of the care pathway for withdrawal assessment.  
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AUDIT >20 
Consider need for alcohol 
withdrawal  
Assess the presence of one or more of the following: 
 Dependence severity: SADQ/units per typical drinking 
day 
 Comorbid problems 
Outcome of assessment 
 SADQ <15 
 Typical drinks per day <15 
 SADQ 15-30 
 Typical drinks per day <30 units 
 Absence of comorbid features 
 SADQ >30  
 Typical drinks per day >30 units 
 Comorbid features present 
Consider Tier 2 or 3 interventions 
 Psychological and pharmacological 
interventions 
 Comprehensive assessment where comorbid 
features present 
Outpatient (Tier 3 interventions): 
 Assisted alcohol withdrawal 
Inpatient (Tier 4 interventions):  
 Assisted alcohol withdrawal 
Comprehensive assessment (Tier 3/4 interventions) 
 Interventions to prevent relapse 
AUDIT <20 
 
AUDIT  
 
Figure 6: Care pathway: withdrawal assessment. 
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5.25.4 Level 3: brief triage assessment 
Aims 
A brief triage assessment should be undertaken when an individual first contacts a 
specialist alcohol service, and it has the aim of developing an initial plan of care 
(MoCAM; Department of Health, 2006a). Failure to identify clinical and/or social 
priorities may result in an individual being directed to inappropriate services or lost 
to any form of care. Typically people presenting for a triage assessment may be 
harmful drinkers who have not benefitted from an extended brief intervention (see 
NICE, 2010a) and/or those with an AUDIT score of more than 20, or have been 
referred to or have self-referred to a specialist alcohol services.  
 
A brief triage assessment is not simply a brief assessment of alcohol misuse only. The 
focus is equally on the management risk, identification of urgent clinical or social 
problems to be addressed, and accessing the most appropriate pathways of care for 
alcohol misuse. The triage assessment therefore incorporates the common elements 
of assessment identified above with the aim of establishing the severity of the 
individual‘s problems, the urgency to action required and referral to the most 
appropriate treatment interventions and service provider.  
 
Specifically the triage assessment should establish:  
 the need for emergency or acute interventions, for example referral to 
accident and emergency for an acute medical problem or to a crisis team for a 
mental health emergency  
 presence and degree of risks of harms to the person, others including 
children, due to alcohol, substance misuse, and related problems (medical, 
mental health, social and criminal)  
 the appropriate alcohol treatment intervention(s) and setting(s) for the 
problems assessed  
 an appropriate level of communication and liaison with all those involved in 
the direct care and management of the individual  
 the need for a further comprehensive specialist assessment (see Section 5.25.5 
below)  
 the need to agree follow-up plans. 
Settings  
All specialist alcohol services (including those that provide combined drug and 
alcohol services) should operate a triage assessment according to agreed local 
procedures. This level of assessment is not intended to be a full assessment of an 
individual‘s needs on which to base a care plan. The Triage Assessment should 
identify immediate plans of care through the use of standardised procedures to 
ensure that all clinically significant information and risk factors are captured in one 
assessment. Incorporating tools and questionnaires as an adjunct to the clinical 
interview will help improve consistency of decision making.  
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Methods 
The triage assessment should include: 
 alcohol use history including: 
- typical drinking; setting, brand, and regularity 
- alcohol consumption using units of alcohol consumed on a Typical 
Drinking Day 
- features of alcohol dependence  
- alcohol-related problems 
- adjunctive assessment tools (including the AUDIT and SADQ) to 
inform the assessment of risk and the immediate and future clinical 
management plan  
 co-occurring problems (medical, mental health, substance misuse, social 
and criminal) 
 risk assessment 
 readiness and motivation to change. 
Risk assessment  
The increasing importance of risk assessment in the clinical decision making process 
has led to a number of tools being developed to systematically screen for high risk 
problems and behaviours which draw on a common framework for risk assessment 
systems in mental health (Department of Health, 2006a) . In the NHS it is expected 
that local protocols are agreed that specify the elements and tools for risk assessment 
to be applied (MoCAM; Department of Health, 2006a). Establishing these protocols 
and standards will also identify the competencies required for the collation and 
interpretation of risk to develop a risk management plan.  
 
The risk assessment process should review all aspects of the information collected 
during the clinical interview, and where appropriate consider results from; 
investigations, questionnaire items, correspondence and records, liaison with other 
professionals, family and carers, to formulate an assessment of risks to the 
individual, to others and to the wider community. The risk assessment should 
consider the interaction between comorbid features to arrive at an informed opinion 
of the severity of risk and the urgency to act.  
 
MoCAM (Department of Health, 2006a) identifies that risk assessment should 
consider the following domains:  
 risks associated with alcohol use or other substance use (such as physical 
damage, alcohol poisoning) 
 risk of self-harm or suicide  
 risk of harm to others (including risks of harm to children and other 
domestic violence, harm to treatment staff and risks of driving while 
intoxicated) 
 risk of harm from others (including being a victim of domestic abuse) 
 risk of self-neglect 
 safeguarding children procedures must be included. 
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Where risks are identified, a risk management plan that considers monitoring 
arrangements, contingency plans and information sharing procedures, needs to be 
developed and implemented (MoCAM; Department of Health, 2006a). Guidance 
developed for those working with patients with mental health problems indicates 
that the most effective risk assessments and risk management plans are developed 
by multi-disciplinary teams and in collaboration between health and social care 
agencies (Department of Health, 2007).  
Urgency to act  
The urgency to act will be linked to the severity and level of risks identified from all 
the information gathered and should consider: 
 The individual‘s intentions to carry out act of self harm or harm to others 
 The state of distress being experienced by the individual 
 The severity of comorbid medical or mental health conditions and the 
sudden deterioration of the individual‘s presentation 
 The safeguarding needs of child/young person 
5.25.5 Level 4: comprehensive assessment 
Aims 
A comprehensive assessment should be undertaken where individual experiences 
significant comorbidity, moderate or severe alcohol dependence or presents a high 
level of risk to self or others. This group will often require structured and/or 
intensive interventions and are often involved with multiple agencies. Those 
presenting with complex problems will require their care to be planned and co-
ordinated.  
 
The comprehensive assessment aims: 
 to determine the exact nature of problems experienced by the individual 
across multiple domains 
 to specify needs to inform development of a care plan 
 to identify planned outcomes to be achieved and methods to assess these 
outcomes  
Settings  
Comprehensive assessment is undertaken by specialist alcohol services that provide 
tier 3 and 4 interventions although some tier 2 services with sufficiently experienced 
staff may also offer comprehensive assessments, as outlined by MoCAM 
(Department of Health, 2006a).  
Methods 
Comprehensive assessment should not be seen as a single event conducted by one 
member of the multidisciplinary team, although coordination of the assessment 
process may bring real benefit (see Section 5.3 for a review of case coordination and 
case management). The complex nature of the problems experienced by an 
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individual with long-standing alcohol misuse or dependence suggests that the 
comprehensive assessment may need to be spread across a number of appointments 
and may typically involve more than one member of the multidisciplinary team. A 
range of expertise will often be necessary to assess the nature of problems. 
Comprehensive assessment may require specific professional groups to undertake 
tasks such as; physical examination, prescribing needs, social care needs, psychiatric 
assessment, and a formal assessment of cognitive functioning. Specialist alcohol 
services conducting comprehensive assessments therefore need to have access to: 
GPs and specialist physicians, addiction psychiatrists, nurses, psychologists and 
specialist social workers.  
 
The comprehensive assessment should include an in-depth consideration and 
assessment of the following domains: 
 alcohol use and related consequences 
- alcohol consumption 
- alcohol dependence  
- alcohol-related problems 
 motivation  
 self-efficacy 
 co-occurring problems 
- substance misuse 
- physical health history and problems 
- mental health history and problems 
- social functioning and problems 
 risk assessment 
 treatment goals 
 assessment of the service user‘s capacity to consent to treatment 
 formulation a plan of care and risk management plan. 
5.25.6 Methods of physical investigation  
Breath /blood alcohol level 
Alcohol is excreted in the breath, and its concentration in breath is correlated with 
blood alcohol concentration. On average it takes approximately one hour to 
eliminate one unit of alcohol from the body, however the elimination rate varies 
between individuals and is more rapid in people who are alcohol dependent than 
those who are not (Ugarte et al., 1977; Allen et al., 2004). Breath alcometers reliably 
measure the breath alcohol concentration in a non-invasive way. Blood/breath 
alcohol concentration may be a useful part of the clinical assessment in the following 
areas:  
  
 Although self report has been found to be a reliable indicator of levels of 
alcohol consumption in treatment seeking populations, patients with 
alcohol in their system at the time of assessment are more likely to 
underestimate their levels of alcohol consumption (Sobell & Sobell, 2003).  
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 Clinicians have a responsibility to discuss drink driving concerns with 
patients and their responsibilities in reporting this to the DVLA (DVLA, 
2010). Service users who have driven on the way to an assessment and 
who are over the legal limit for driving (80 mg/100 ml) need to be 
advised not to drive until they are legally able to do so. 
Blood investigations  
There are a number of biomarkers suggested to be clinically useful in the assessment 
of alcohol related physical harm (Allen et al., 2003), monitoring of clinical outcome, 
and as a motivational enhancement strategy (Miller et al., 1992). However, in people 
who are seeking treatment for alcohol misuse, biomarkers do not offer any 
advantage over self-report measures in terms of accuracy of assessing alcohol 
consumption (Allen et al., 2003; Sobell & Sobell, 2003), and are less sensitive and 
specific than the AUDIT in screening for alcohol misuse (Drummond & Ghodse, 
1999).  
 
Gamma Glutamyl Transferase has a sensitivity of 50 to 70% in the detection of high 
levels of alcohol consumption in the last 1 to 2 months and a specificity of 75 to 85% 
(Drummond & Ghodse, 1999). Reasons for false positive results including hepatitis, 
cirrhosis, cholestatic jaundice, metastatic carcinoma, treatment with simvastatin, 
obesity. 
 
Mean corpuscular volume (MCV) has a sensitivity of 25 to 52% and specificity of 85 
to 95% in the detection of alcohol misuse. It remains elevated for 1 to 3 months after 
abstinence. Reasons for false positives include B12 and folate deficiency, pernicious 
anaemia, pregnancy and phenytoin (Drummond & Ghodse, 1999; Allen et al., 2004). 
 
Carbohydrate-deficient transferrin (CDT) has greater specificity (80 to 98%) than 
other biomarkers for heavy alcohol consumption, and there are few causes of false 
positive results (severe liver disease, chronic active hepatitis) (Schwan et al., 2004). 
However routine CDT monitoring is not routinely available, and there remains some 
debate about how best to measure it. Evidence suggests that the test is less sensitive 
in women (Anton & Moak, 1994). CDT increases and recovers more rapidly than 
gamma-glutamyl transferase (GGT) in response to a drinking binge, within one 
week of onset of heavy drinking, and recovery typically in 1 to 3 weeks, compared 
with 1 to 2 months with GGT (Drummond & Ghodse, 1999).  
 
Advantages of blood investigations as part of the initial assessment include: 
 screening for alcohol related physical conditions that may need further 
investigation and onward referral 
 Provide baseline measures of alcohol related damage (in some patients) against 
which to measure improvement and act as motivational enhancement strategy 
 Objective measurement of outcome, particularly when combined (eg CDT and 
GGT; Allen et al., 2003) and in conjunction with other structured outcome 
measures (Drummond et al., 2007).  
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Hair and sweat analysis 
As alcohol is rapidly excreted from the body, there is currently no reliable or 
accurate way of measuring alcohol consumption in the recent past, and the mainstay 
of outcome measurement is self-report (Sobell & Sobell, 2003).This is less useful for 
regulatory monitoring purposes and so there is a growing interest by manufacturers 
in the design biomarkers for recent alcohol consumption. Studies to date focus on 
hair and skin sweat analysis, but there is currently a lack of evidence to recommend 
their use in routine clinical care (Pragst & Balikova, 2006)  
Assessment of alcohol-related physical harm  
The assessment of alcohol related physical harm is an important component of a 
specialist service (Edwards et al., 2003). The aims of such an assessment are to: 
 identify physical health problems which require immediate attention and 
onward referral to appropriate acute medical care 
 identify physical health problems which are a consequence of the alcohol misuse, 
and require monitoring, and potential future referral 
 
The relationship between alcohol related physical health problems and level of 
alcohol consumption is complex (Morgan & Ritson, 2009), as is the presence of 
physical signs in relation to underlying pathology. Consequently patients presenting 
with longstanding, severe alcohol dependence may have few overt physical signs, 
but significant underlying organ damage (for example, liver disease). Others may 
present with significant symptoms (for example, gastritis) or signs (for example, 
hypertension) which may resolve without active treatment once the service user 
abstains. 
Liver/ gastrointestinal problems  
Alcohol related liver disease often develops ‗silently‘ over a 10 to 15 year period and 
blood tests of liver function (alanine amino transferase - ALT) may only become 
abnormal at quite advanced stages of disease and so a test that is within the normal 
range does not exclude liver damage (Prati et al., 2002). Equally raised ALT may be 
the result of induction of liver enzymes by alcohol rather than an indication of liver 
pathology (Drummond & Ghodse, 1999). Other laboratory tests including gamma 
glutamyl transferase (GGT) and serum aspartate amino transferase (AST) may be 
raised in people who misuse alcohol, but do not necessarily indicate the presence of 
significant organ damage as a result of enzyme induction (Bagrel et al., 1979). 
Patients with signs of severe (decompensated) liver disease (for example, presenting 
with jaundice, fluid retention; spontaneous bruising, hepatic encephalopathy) will 
need urgent specialist medical care from a hepatology service. Symptoms of 
anorexia, nausea, vomiting and diarrhoea and malabsorption syndromes are 
common in people who misuse alcohol. In many cases these symptoms resolve with 
treatment of the underlying alcohol misuse, but people with significant pain, or 
evidence of gastrointestinal blood loss will need referral for further investigation. 
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Cardiovascular 
Alcohol has a dose related effect on blood pressure, in addition to being elevated 
during alcohol withdrawal (Xin et al., 2001). Patients who present with hypertension, 
or who are already prescribed anti-hypertensive medication will need to have this 
reviewed as treatment progresses.  
Neurological 
Wernicke‘s Syndrome classically presents with a triad of symptoms (ataxia, 
confusion and nystagmus), but in practice this triad only occurs in a minority of 
cases (Thomson & Marshall, 2006). Given the severity of brain damage (Wernicke-
Kosakoff Syndrome) that may occur if the condition is untreated, clinicians need to 
have a high index of suspicion particularly in those patients who are malnourished 
and have any of the following clinical signs: ataxia, ophthalmoplegia, nystagmus, 
acute confusional state, or (more rarely) hypotension or hypothermia. Patients 
presumed to have a diagnosis of Wernicke‘s encephalopathy will need immediate 
treatment or onward referral (NICE, 2010b). 
 
Symptoms of peripheral neuropathy are common (30 to 70%) in people who misuse 
alcohol (Monteforte et al., 1995). The symptoms are predominantly sensory (although 
muscle weakness is also seen) and include numbness, pain and hyperaesthesia in a 
‗glove and stocking‘ distribution primarily in the legs. Symptoms should be 
monitored and will require referral if they do not improve with alcohol abstinence. 
5.25.7 Mental health: comorbidity and cognitive functioning 
Alcohol is strongly associated with a wide range of mental health problems, 
particularly depression, anxiety, and self-harm (Weaver et al., 2003). In addition, 
many patients have deficits in cognitive function, and which may not be identified 
without systematic investigation (Evert & Oscar-Berman, 1995). The presence of 
psychological distress and/or comorbid psychiatric diagnoses, particularly if 
undetected may have a substantial impact on treatment engagement and progress, 
leading to suboptimal treatment outcomes (Weaver et al., 2003). 
 
There are significant challenges in the assessment and diagnosis of mental health 
comorbidity. Some symptoms may be the direct result of excessive alcohol 
consumption, or withdrawal, and these tend to reduce once abstinence has been 
achieved (Brown et al., 1995). The same symptoms may however, also be the result of 
a comorbidity which requires parallel treatment, but the presence of which may also 
worsen the alcohol misuse. Finally there are comorbid conditions (for example, 
social anxiety, some forms of cognitive impairment) which are not apparent whilst 
the person is drinking, but which emerge following abstinence and may have an 
impact on retention in treatment. 
Depression and anxiety 
Although many symptoms of depression or anxiety may be directly attributable to 
alcohol misuse, many people still reach the threshold for a diagnosis of a psychiatric 
 161 
 
disorder. For instance, 85% of patients in UK alcohol treatment services had one or 
more comorbid psychiatric disorders including 81% with affective and/or anxiety 
disorders (34% severe depression; 47% mild depression, 32% anxiety) and 53% had a 
personality disorder (Weaver et al., 2003). Such high levels of comorbidity are not 
surprising given that the underlying neurobiology of depression or anxiety and 
alcoholism have many similarities, particularly during withdrawal (Markou & Koob, 
1991). In addition there are shared risk factors since twin studies reveal presence of 
one increase the risk for the other disorder (Davies et al., 2008).  
 
There is a high prevalence of comorbidity between anxiety and alcohol misuse both 
in the general and clinical populations. Anxiety disorders and alcohol dependence 
demonstrate a reciprocal causal relationship over time, with anxiety disorders 
leading to alcohol dependence and vice versa (Kushner et al., 1990). Panic disorder 
and generalised anxiety disorder can emerge during periods of alcohol misuse, 
however the association with obsessive compulsive disorder is less robust.  
 
Social phobia and agoraphobia often predate the onset of alcohol misuse. The 
prevalence of social anxiety ranges from 8 to 56% in people who misuse alcohol, 
which makes it the most prevalent psychiatric comorbidity. People who are alcohol 
dependent and have comorbid social anxiety disorder show significantly more 
symptoms of alcohol dependence, higher levels of reported depression, and greater 
problems and deficits in social support networks as compared with alcohol 
dependent patients without social anxiety (Thevos et al., 1999).  
 
The relationship between alcohol and depression is also reciprocal in that depression 
can increase consumption, but depression also can also be caused or worsened by 
alcohol misuse (Merikangas et al., 1996).  
Sleep disorders 
Sleep disorders, commonly insomnia, increase the risk of alcohol misuse and also 
contribute to relapse (Brower, 2003; Krystal et al., 2008). Whilst many people believe 
that alcohol helps them to sleep, this is not the case. Although onset of sleep may be 
reduced after drinking alcohol, disruption to sleep patterns occur later in the night 
such as REM rebound and increased dreaming, as well as sympathetic arousal 
(Krystal et al., 2008). Abstinence may reveal a sleep disorder that the person has not 
been entirely aware of since they have always used alcohol to sleep. Insomnia is also 
a prominent feature of both acute and protracted alcohol withdrawal syndromes, the 
latter of which can last for 3 to 12 months. 
Eating disorders 
There is substantial evidence that alcohol misuse and eating disorders commonly co-
occur (Sinha & O‘Malley, 2000). In specialist alcohol inpatient treatment the 
prevalence of eating disorders can be as high as 40%. Commonly an eating disorder 
exists together with other psychiatric disorders such as depression. In people with 
an eating disorder, up to half have been reported to misuse alcohol (Danksy et al., 
2000). A number of studies have found the strongest relationship for bulimia 
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nervosa, followed by patients suffering from binge eating disorder and eating 
disorder not otherwise specified (EDNOS) (Gadalla & Piran, 2007). No association 
has been reported between anorexia nervosa and alcohol misuse. In study of 
European specialist eating disorder services, alcohol consumption was higher in 
patients with EDNOS and bulimia nervosa than anorexia nervosa, but a greater 
lifetime prevalence of alcohol misuse was not found (Krug et al., 2009).  
Psychosis 
Patients with psychotic disorders (including schizophrenia and bipolar disorder) are 
vulnerable to the effects of alcohol and at increased risk of alcohol misuse (Weaver et 
al., 2003). Approximately 50% of patients requiring inpatient psychiatric treatment 
for these disorders will also misuse alcohol (Barnaby et al., 2003; Sinclair et al., 2008). 
However, a smaller proportion of patients will present without a diagnosis of an 
underlying psychotic or mood disorder, which will need to be identified as part of a 
comprehensive assessment. For a more thorough review of this area see the NICE 
guideline on psychosis and substance misuse (forthcoming NICE, 2011a) 
Self-harm and suicide 
There is a significant, but complex association between alcohol misuse and self-harm 
and suicide. Approximately 50% of all patients presenting to hospital following an 
episode of self-harm have consumed alcohol immediately before or as part of the act 
of self-harm (Hawton et al., 2007). The mortality by suicide in patients who present 
following an episode of self-harm is significantly increased in the next 12 months (66 
times that of the general population) (Zahl & Hawton, 2004) and this risk remains 
high after many years (Owens et al., 2002). However recent data from a long-term 
follow-up suggests that the mortality of self-harm patients appears to be caused by 
alcohol related conditions as much as suicide (Sinclair et al., 2009). For people whose 
self-harm occurs only when intoxicated, abstinence from alcohol was recognised as 
the effective intervention (Sinclair & Green, 2005). Alcohol dependence has been 
shown to increase the risk of suicide by five to 17 times, with the RR being greatest 
in women (Wilcox et al., 2004).  
Cognitive impairment 
Between 75 and 100% of patients admitted for inpatient treatment for alcohol 
perform below on age standardised tests of alcohol function (Alcohol Strategy 
Review 2003). Cognitive impairments frequently improve significantly once 
abstinence has been achieved and so should be reassessed after 2 to 3 weeks of 
abstinence (Loeber et al., 2009). 
 
A number of assessment tools can be used to assess cognitive function in people who 
misuse alcohol have been identified. These include the Mini-Mental Status 
Examination (MMSE; Folstein et al., 1975); the Cognitive Capacity Screening 
Examination (CCSE; Jacobs et al., 1977); the Neuropsychological Impairment Scale 
(NIS; O‘Donnell & Reynolds, 1983); and the Cognitive Laterality Battery (CLB; 
Gordon, 1986).  
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The Mini-Mental Status Examination (MMSE; Folstein et al., 1975) is a cognitive 
screening instrument that is widely used in clinical practice and has been established 
as a valid and reliable test of cognitive function (Folstein et al., 1975). It measures 
orientation, registration, short term memory, attention and calculation, and 
language. A score of 17 or less is considered to be severe cognitive impairment, 18 – 
24 mild to moderate impairment, and 25 - 30 normal or borderline impairment. It has 
the advantage of being brief, requiring little training in administration and 
interpretation, free to use, and is designed to assess specific facets of cognitive 
function (Small et al., 1997). The MMSE has been found to have high sensitivity for 
detecting moderate to severe cognitive impairment as well as satisfactory reliability 
and validity (see Nelson et al., 1986 for a review). The MMSE can be utilised as a 
brief screening tool as well as for assessing changes in cognitive function over time 
(Brayne et al., 1997).  
 
It must be noted however that the MMSE has been found to be sensitive to 
educational level in populations where educational levels are low (Liu et al., 1994; 
Escobar et al., 1986). Therefore, the cut-offs used to identify cognitive impairment 
may need to be adjusted for people who misuse alcohol with few years of formal 
education (Crum et al., 1993; Cummings, 1993). Furthermore, the MMSE has been 
criticised for not being sensitive enough for those in various cultures where the 
education levels are low and participants may fail to respond correctly to specific 
items (Iype et al., 2006; Liu et al., 1994; Katzman et al., 1988; Escobar et al., 1986). 
Because of this, it is necessary (and often practised) to amend and adjust aspects of 
the MMSE in order to increase applicability to a particular cultural setting. For 
example, a Hindi version of the MMSE, the Hindi Mental Status Examination 
(HMSE) (Ganguli et al., 1995) was designed to address some of the cultural problems 
with the MMSE and to make it more applicable to an Indian cultural setting.  
 
Most research evaluating the accuracy, reliability and validity of the MMSE has been 
in the assessment of age-related cognitive impairment and dementia whereas 
research in the field of alcohol and substance misuse is limited. However, the MMSE 
has been utilised in substance misuse research (Smith et al., 2006). Additionally, it 
has been highlighted that the MMSE mainly assesses verbal cognitive function and is 
limited in assessing non-dominant hemisphere skills and executive functions (Bak & 
Mioshi, 2007). This could lead to frontal-dysexecutive and visuospatial symptoms 
going undetected. 
 
The Cognitive Capacity Screening Examination (CCSE; Jacobs et al., 1977) was 
designed to screen for diffuse organic mental syndromes. The CCSE has 30 items 
which provide information on the areas of orientation, digit span, concentration, 
serial sevens, repetition, verbal concept formulation, and short term verbal memory. 
A score of less than 19 has been suggested as indicative of organic dysfunction 
(Haddad & Coffman, 1987; Hershey et al., 1987; Jacobs et al., 1977). As with most 
cognitive screening instruments, the CCSE has been studied extensively in people 
with dementia (Nelson et al., 1986). It has been found to have adequate reliability 
and validity in detecting cognitive impairment (Foreman, 1987; Villardita & Lomeo, 
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1992). However, the CCSE has been found to be sensitive to age and education 
(Luxenberg & Feigenbaum, 1986; Omer et al., 1983) and has been found to have a 
high false negative rate and hence low sensitivity (Nelson et al., 1986; Schwamm et 
al., 1987). Furthermore, Gillen and colleagues (1991) and Anderson and Parker (1997) 
reported that the CCSE did not adequately distinguish between cognitively impaired 
and non-impaired people who misuse substances. 
 
The Neuropsychological Impairment Scale (NIS) is a 50-item scale which has been 
designed to identify brain damage. The reliability and validity of the NIS has been 
previously reported in normal and neuropsychiatric populations (O‘Donnell et al., 
1984a; 1984b) as well as having a sensitivity of between 68% and 91% and a 
specificity of between 43% and 86% (O‘Donnell et al., 1984b). Errico and colleagues 
(1990) further reported predictive validity, and test–retest reliability in a sample of 
people undergoing assisted alcohol withdrawal.  
 
The Cognitive Lateral Battery (CLB) was developed to measure visuospatial and 
verbosequential functioning with tests administered on a sound/sync projector and 
takes 80 minutes for administration. However, the CLB has been reported to have 
limited clinical utility in the assessment of cognitive function in an alcohol 
dependent population (Errico et al., 1991).  
 
Addenbrooke‘s Cognitive Evaluation (ACE; Mathuranath et al., 2000) was developed 
as a brief test of key aspects of cognition which expanded on the MMSE by assessing 
memory, language and visuospatial abilities in greater depth, as well as including 
assessment of verbal fluency. ACE is designed to be sensitive to the early stages of 
dementia (Moishi et al, 2006) and was found to detect dementia earlier and to 
discriminate more highly between different subtypes of dementia than the MMSE 
(Mathuranath, 2006). In order to comprehensively assess cognitive impairment, the 
ACE can be used in a cognitive test battery along with tests which assess other 
cognitive domains (Lezak, 1995; Spreen & Strauss, 1998), such as the Trail-Making 
Test, Part B (Army Individual Test Battery, 1944) or the Block Design subtest of the 
Wechsler Adult Intelligence Scale (WAIS-R) (Wechsler D., 1981). Mioshi and 
colleagues (2006) developed a revised version of the test, ACE-R, which addressed 
previously identified weaknesses in the original test and made it easier to administer 
(Mioshi et al 2006). Bak and colleagues (2007) found that ACE-R has a good 
specificity for the detection of dementia (94%) with a specificity of 89% (at a cut-off 
score of 88/100). The ACE-R is administered as a bed-side test and takes 
approximately 16 minutes to complete and consists of five sections, each designed to 
assess a specific cognitive domain (Mioshi et al, 2006). Although the ACE-R takes 
longer to administer than some other tests for cognitive impairment, such as the 
MMSE, it has been found to have a high level of patient acceptability and can be 
administered without specialist training (Larner, 2007). The ACE and ACE-R tests 
are published in 19 languages, although no evidence was found regarding the effect 
of cultural or educational differences on testing outcomes. 
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The ACE has been used in screening for cognitive dysfunction in people who misuse 
alcohol (Gilchrist & Morrison, 2004), although no research in this field using ACE-R 
could be identified. Additionally, research into the efficacy and sensitivity of ACE-R 
in assessing substance induced cognitive impairment is negligible. It has been 
suggested however, that it is possible to extrapolate the validity of the ACE as an 
instrument to assess age-related cognitive impairment and apply it in assessing 
cognitive impairment in people who misuse alcohol. The increased sensitivity of 
ACE in relation to the MMSE may mean that it is subtle enough to identify people 
who misuse alcohol that have mild cognitive impairment who are able to function 
successfully in the community but have a history of non-engagement with alcohol 
services (personal communication, Ken Wilson, October, 2010). 
Childhood abuse 
A history of physical and/ or sexual abuse is common in patients seeking treatment 
for alcohol misuse, particularly women (Moncrieff et al., 1996). Patients identified 
with childhood trauma who wish for further intervention should be referred to 
appropriate services once they have reached a degree of stability in terms of their 
alcohol use (NCCMH, 2005, guideline on PTSD). 
Family and relationships 
Relationships with partners, parents, children and significant others are often 
affected by alcohol misuse (Copello et al., 2005). Families and carers also suffer 
significantly in their own right with an increased incidence of mental disorder 
(Dawson et al., 2007). Involvement of partners or family can help identify the needs 
of the help seeking individual. The prevalence of alcohol misuse in the victims and 
perpetrators of domestic violence provides an important rationale for the 
exploration of these issues. 
Employment 
The status of the individual‘s occupation is significant in terms of the individual‘s 
ability to remain economically active. Past employment history may indicate the 
individual‘s capacity to obtain and retain employment. Employment history might 
provide insights into factors that maintain the individuals drinking status that need 
to be explored. Those assessing employed individuals will need to consider potential 
risks to the person, colleagues and the public because of excessive drinking (for 
example when the individual has responsibility for the safety of others). 
Criminality and offending  
Assessment of criminality and offending behaviour should encompass a number of 
factors; presence and onset of criminal activity, the severity of offending behaviour, 
relationship of offending to alcohol consumption and/or alcohol withdrawal and the 
presence of violence and aggressive behaviour, and hence risks to others. Liaison 
with criminal justice services is necessary to ensure appropriate co-ordination of care 
and effective communication and information sharing protocols are in place.  
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Fitness to drive 
For people who misuse alcohol and continue to drive a motor vehicle clinical staff 
have a duty to advise the individual that it is the duty of the license holder or license 
applicant to notify DVLA of any medical condition, which may affect safe driving. 
There are circumstances in which the license holder cannot, or will not notify the 
DVLA. Clinicians will need to consult the national medical guidelines of fitness to 
drive in these circumstances (DVLA, 2010). 
5.25.8 Goals for drinking behaviour 
The information collated from the comprehensive assessment will identify the type 
and severity of the alcohol misuse experienced, and the presence and significance of 
comorbid problems. This information should be considered alongside the 
individual‘s preferred drinking goals as basis for a negotiated care plan with 
drinking goals specified. Previous reviews and studies (Raistrick et al., 2006; Heather 
et al., 2010; Adamson et al., 2010) have identified that: 
 
 Individuals seeking abstinence from alcohol should be supported in their aim 
regardless of their severity of problems. 
 
 Individuals with comorbid problems for which continued drinking is clearly 
contraindicated should be strongly advised that abstinence should be 
considered. 
 
 Individuals who seek non-abstinence goals (that is, moderation or controlled 
drinking) usually experience less severe problems and should be supported. 
However, where a practitioner identifies that abstinence should be promoted 
but the individual seeks non-abstinence as a goal, a negotiated approach 
should be supported where abstinence is considered if moderation goals 
prove unsuccessful. 
 
 If the individual is uncertain as to which goal to pursue, further motivational 
interventions should be considered to arrive at a consensus approach. 
 
 Treatment goals need to be regularly reviewed and changed where indicated. 
Staff should adopt a flexible approach to goal setting that recognises the 
above parameters.  
5.25.9 Formulating a care plan and risk management plan 
The intention of any assessment whether triage, withdrawal or comprehensive is to 
arrive at a care plan that takes into account the individual‘s views and preferences 
and those of their family and carer‘s where indicated, and any safeguarding issues. 
The development of a care plan needs to address the presenting alcohol misuse and 
consider the impact of treatment on existing problems (MoCAM, Department of 
Health, 2006a). It should take account of the presence, severity and complexity of 
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problem areas that in turn will influence the choice of treatment interventions, 
medications and/or settings that are offered.  
 
The care plan should be developed in negotiation with the individual (National 
Treatment Agency for Substance Misuse, 2006). The care plan may include short, 
intermediate and long-term objectives, in addition to any contingency planning 
needed where risk increases. Care plans need to be shared with those also involved 
in providing care to the individual as planned treatment interventions and 
medications may have significant interactions with existing or planned care for other 
problems or conditions.  
5.25.10 Outcome monitoring  
Outcome monitoring is important in assessing how treatment for alcohol misuse is 
progressing. The main aim of outcome evaluation should be to assess whether there 
has been a change in the targeted behaviour following treatment. Outcome 
monitoring aids in deciding whether treatment should be continued, or if further 
evaluation and a change of the care plan is needed. There are three important areas 
of outcome monitoring; deciding what outcome to measure, how to measure it (the 
appropriate tools), and when to measure outcome. Routine outcome monitoring 
(including feedback to staff and patients) has been shown to be effective in 
improving outcomes (Lambert et al., 2002). Routine session by session measurement 
provides a more accurate assessment of overall patient outcomes (Clark et al., 2009)  
What outcome should be measured? 
Assessment of alcohol consumption (for example, intensity and frequency of 
drinking) is a basic component of outcome monitoring. For example Emrick (1974) 
states that monitoring abstinence post-treatment is a significant predictor of 
psychosocial functioning. as Alcohol related problems or harm have also been 
suggested to be important in outcome monitoring. Longabaugh and colleagues 
(1994) state outcome measurement should contain a range of assessment domains 
and include life functioning (such as physical health and social functioning). Alcohol 
problems are the only assessment domain which is significantly associated with 
drinking outcome measures (PDA, DDD, first drink) (Project MATCH Research 
Group, 1997; 1998). This suggests that alcohol-related problem outcome measures 
should be assessed in addition to alcohol consumption.  
How should outcome be measured?  
When selecting a suitable tool for outcome monitoring, there are a number of factors 
that need to be considered as suggested in a review of by Raistrick and colleagues 
(2006). An outcome monitoring tool should be:-  
 universal and not constrained by any particular substance or social group 
 have proven validity and reliability and have published psychometric properties 
 sensitive to change 
 easy readable and in a neutral language 
 either practitioner-completed, self completed, or a combination of both 
 appropriate for the clinical population.  
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The outcome measure that is applicable to all tiers of services is assessing the level of 
alcohol consumption by interviewing the patient about their quantity and frequency 
of alcohol consumption, but the use of a formal measure will improve the reliability 
and validity of measurement (Sobell et al., 1979). The most valid and reliable 
measures of alcohol consumption include a diary method to obtain drinking data 
(Sobell & Sobell, 2003). However, measures such as the time-line follow-back 
questionnaire (Sobell & Sobell, 2003) are more feasible to administer in the research 
setting rather than a routine clinical setting. Some clinical services in the UK use 
prospective weekly drinking diaries which are self completed by service users but 
their reliability and validity is unknown. 
 
A number of assessment tools have been designed specifically for outcome 
measurement in addiction treatment. They all measure multiple domains of 
functioning but their comprehensiveness, utility and specificity to alcohol treatment 
vary. The most widely used tools for outcome measurement are the Addiction 
Severity Index (ASI; McLellan et al., 1980), AUDIT (Babor et al., 2001), the Maudsley 
Addiction Profile (MAP; Marsden et al., 1998), the Christo Inventory for Substance 
Misuse Services (CISS; Christo et al., 2000), the Comprehensive Drinker Profile (CDP; 
Miller & Marlatt, 1987), RESULT (Raistrick and Tober, 2003), and the Treatment 
Outcomes Profile (TOP; Marsden et al., 2007). The GDG evaluated the clinical utility 
of these tools in alcohol treatment on the extent to which each tool has sufficient 
validity and reliability data in an alcohol dependent population and if the tool has 
high usability (that is, it is easy to read and understand, it does not require extensive 
training for use and it is brief). Table 19 describes the characteristics of the outcome 
measurement tools identified.  
 
Table 19: Characteristics of routine outcome monitoring tool 
Outcome monitoring tool 
Is there adequate 
psychometric data in 
primarily alcohol 
dependent population?  
Does the tool have high 
usability (for example, 
readable, short time to 
administer, limited training 
required)? 
Source reference 
Addiction Severity Index 
(ASI) 
Yes (but validity and 
reliability is questionable) 
No - requires a trained 
interviewer and takes 50 to 60 
minutes to complete  
McLellan, A. T., Luborsky, L., Woody, G. & O‘Brien, C. 
(1980). An improved diagnostic instrument for substance 
abuse patients: The Addiction Severity Index. Journal of 
Nervous and Mental Disease, 168, 26–33. 
AUDIT Yes - extensive data that 
supports reliability and 
validity 
Yes - takes 2 minutes to 
complete 
Babor, T. F., Higgins-Biddle, J. C., Saunders, J. B., et al. (2001). 
AUDIT – The Alcohol Use Disorders Identification Test: Guidelines for 
Use in Primary Care (2nd edition). Geneva: WHO. 
Maudsley Addiction 
Profile (MAP) 
No Yes - takes 20 minutes Marsden, J., Gossop, G., Stewart, D., et al. (1998). The 
Maudsley Addiction Profile (MAP): A brief instrument 
for assessment treatment outcome. Addiction, 93, 1857–
1867. 
Christo Inventory for 
Substance Misuse Services 
(CISS) 
No Yes - takes 10 minutes Christo, G., Spurrell, S. & Alcorn, R. (2000). Validation of 
the Christo Inventory for Substance-misuse Services 
(CISS): A simple outcome evaluation tool. Drug and 
Alcohol Dependence, 59, 189–197. 
Comprehensive Drinker 
Profile (CDP) 
No No - requires a trained 
interviewer and takes 2 hours to 
complete  
Miller, W. R. & Marlatt, G. A. (1987) Manual Supplement 
for the Brief Drinker Profile, Follow-up Drinker Profile, and 
Collateral Interview Form. Odessa, FL: Psychological 
Assessment. 
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RESULT No Yes - takes 30 minutes Raistrick, D. & Tober, G. (2003). Much more than 
outcomes. Drug & Alcohol Findings, 8, 27–29. 
Treatment Outcomes 
Profile (TOP) 
No - primarily in drug 
misuse population 
Yes - one page, 20 items Marsden J; Farrell M; Bradbury C; Dale-Perera A; 
Eastwood B; Roxburgh M; Taylor S. The Treatment 
Outcomes Profile (TOP): A structured interview for the 
evaluation of substance misuse treatment. London: 
National Treatment Agency for Substance Misuse, 2007. 
 
The GDG excluded the ASI as it was excluded in our earlier review of primary 
outcome tools and also is too lengthy for use as an outcome monitoring tool. The 
CISS, CDP, MAP and RESULT were also excluded as they have not been adequately 
validated in an alcohol dependent clinical sample in the UK. Lastly, the TOP is 
primarily used in a drug misusing population with only limited psychometric data 
for alcohol dependent clinical samples. The protocol for reporting TOP (2010) states 
explicitly that ‗the reporting of the TOP for adult primary alcohol users is not 
required‘ and therefore the TOP is not being applied in routine practice.  
 
Based on these criteria, a GDG consensus-based decision was made that the AUDIT 
has the greatest utility as a routine outcome monitoring tool to evaluate drinking-
related outcomes. The AUDIT questionnaire is already widely used. It contains 
several relevant drinking domains in addition to alcohol consumption (problems 
and dependence). The time taken to complete the AUDIT (less than 2 minutes) also 
lends itself to use in routine practice. The AUDIT-C (Bush et al., 1998) is a three-item 
version of the AUDIT which measures only alcohol consumption; that is, frequency 
of drinking, quantity consumed on a typical occasion and the frequency of heavy 
episodic drinking (six or more standard drinks on a single occasion). Bush and 
colleagues (1998) reported that the AUDIT-C performed better than the full AUDIT 
in detecting heavy drinking and was just as effective as the full AUDIT in identifying 
active alcohol misuse or dependence. The study also found that using a cut-off of 3 
out of a possible 12 points, the AUDIT-C correctly identified 90% of active alcohol 
abuse/dependence, and 98% of patients drinking heavily. However, other studies 
have reported that a cut-off of 5 or more for men and 4 or more for women results in 
the optimal sensitivity and specificity for detecting any alcohol use disorders (Gual 
et al., 2002; Dawson et al., 2005b). In addition, the AUDIT-C has been found to be 
equally effective in detecting alcohol use disorders across ethnic groups (Frank et al., 
2008). However, it should be noted that the AUDIT-C has been reported to have a 
high false positive rate when used as a screening tool (Nordqvist et al., 2004). 
Nevertheless, the ease of use, and already established relationship between 
frequency and quantity of drinking with alcohol misuse and dependence give the 
AUDIT-C credence for the use of outcome monitoring.  
 
The APQ has been widely used in alcohol treatment outcome studies as a measure of 
alcohol-related problems in the UK (for example, Drummond, 1990; UKATT 
research group, 2005; DRUMMOND2009). Furthermore, it is quick and easy to 
administer. Therefore, the APQ can be used to measure alcohol-related problems, in 
conjunction with a drinking-related outcome tool such as the AUDIT-C. However 
the ten-item AUDIT still has the advantage of measuring a wider range of domains 
 170 
 
in one simple validated questionnaire, and therefore more readily lends itself to 
routine clinical outcome monitoring.  
When should outcome be measured?  
Most changes in drinking behaviour and the largest reduction in severity of drinking 
occurs in the first 3 months of treatment (Babor et al., 2003; Weisner et al., 2003). 
Initial benefits in drinking related outcomes may be more apparent at 3 months but 
other nondrinking domains such as social functioning and global health may need 
longer to show improvements following treatment. As there is a high attrition rate in 
many alcohol services this can result in poor response rates in routine outcome 
monitoring. This underlines the importance of routine session by session 
measurement and the utility of a brief measure such as the AUDIT or a prospective 
weekly drinking diary. The latter requires considerable cooperation of service users 
and is of unknown reliability and validity.  
5.25.11 Special Populations 
A framework for assessment for children and young people with alcohol 
problems 
As with the adult assessment, the use of any assessment tool needs to be set in 
context. The context here is that all children who are beyond initial identification 
should be offered an assessment within specialist CAMHS. Although 
recommendations are made below for the use of specific measures to assess the 
nature and extent of the alcohol misuse and related problems, it was also the view of 
the GDG that the assessment should take place in the context of a comprehensive 
overall assessment of the mental health, educational, and social care needs of the 
children and young people, in line with current best practice (DfES, 2007). In 
common with good assessment practice in CAMHS Services the involvement of 
parents, carers, and others (for example, schools) is an essential part of any 
assessment. It should also be noted that parents not only have a key role as 
informants, advisors and participants in the process of assessment, but they also 
have a key role to play in the development of any future treatment plans. It is 
therefore important that wherever possible they are involved from the beginning.  
 
The overall structure of assessment (at least for the assessment of alcohol misuse) is 
provided, by the assessment tools reviewed above. However, whatever assessment 
tool is used both from the child and adult literature, (Harrington et al., 1999 and see 
Chapter 5) suggest that the following domains need to be considered as part of any 
assessment of alcohol related problems in children and young people: 
 Alcohol use – consumption, dependence features and associated problems 
 Co-morbid substance misuse– consumption, dependence features and 
associated problems 
 Motivation 
 Self efficacy  
 Other problem domains 
- Physical history and problems 
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- Mental health and problems 
- Social functioning 
- Educational attainment and attendance 
- Peer relationships 
- History of abuse and trauma 
- Family functioning and relationships 
 Risk assessment 
 Developmental needs of the young person 
 Treatment goals 
 Obtaining consent to treatment 
 Formulation of a care plan and risk management plan 
 
Additional points to bear in mind, is the use of further informants. For example, in 
terms of the assessment of consumption, the use of other informants such as parents, 
carers or schools may assist in detailing the history of consumption and clarifying 
the level and veracity of use.  
 
As was identified in the introduction, the presentation of alcohol misuse or 
dependence does not typically follow the pattern seen in adults. More often, a 
pattern of binge drinking is observed often accompanied by drug misuse. It is 
important, therefore, to detail this both the pattern of drinking and the comorbid 
drug misuse. It should also be noted that adolescents may have lower prevalence of 
withdrawal symptoms along with a lower tolerance. Both these factors may 
contribute to continued high alcohol intake, particularly of binge drinking, with 
consequent serious implications for psychological and physical health, but without 
the ‗warning signs‘ of emerging withdrawal symptoms. 
History of trauma and abuse 
It has already been noted that comorbidity of substance misuse is significantly 
higher in adolescents who misuse alcohol. It is also important to note that alcohol 
misusing adolescents have a significant increased rate of physical abuse (by a factor 
of 6 to 12) and a significant increased rate of sexual abuse (by up to a factor of 20) 
(Clark et al., 1997a). Given that it is possible that these histories may have a 
significant etiological role in the development of alcohol misuse, it is important that 
these issues are part of assessment. It is also likely that a history of trauma has an 
impact for the likely comorbidity, for example, the existence of PTSD (Clark et al., 
2003) and also that it may be associated with poor response to treatment and the 
need for more complex treatment interventions. 
5.25.12 Evidence summary  
Content of the clinical assessment 
The literature review identified a number of components of a structured clinical 
interview. These included assessment of the current extent and history of drinking, 
associated potential for withdrawal, the likelihood of withdrawal, the need for 
review of associated physical health problems, the examination of mental health and 
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the impact of alcohol on social, personal and occupational and educational 
functioning. It also identified that the impact of alcohol on the family would be an 
important issue also to be considered. Considerable emphasis on the literature 
reviewed was placed on the importance of engaging people with alcohol related 
problems in treatment and negotiating appropriate goals. It is clear from the 
literature that for people who are moderately and severely dependent drinkers, the 
initial goal should be one of abstinence. For others who are harmful and mildly 
dependent drinkers, it may be possible to consider a reduction in drinking as a 
reasonable treatment goal. However, past history of unsuccessful attempts to 
moderate drinking should be born in mind when making these assessments.  
There is little evidence which indicates the identification and assessment methods 
needed for assisted withdrawal in children and young people. Therefore, the GDG 
makes a consensus-based decision to extrapolate from the review of the adult 
literature and combine this with expert opinion. The group concluded that a 
comprehensive assessment and assessment for assisted withdrawal should be 
offered to all children and young people with an established drinking of binge 
drinking, an AUDIT score of more than 15 and this who consume above five units 
per day but this decision should also take into consideration other factors such as 
age, weight, previous history of alcohol misuse and the presence of co-occurring 
disorders.  
 
The review of formal assessment measures also considered a number of measures of 
motivation (readiness to change). It was not felt by the group that the quality of 
these measures (in part because of impracticality of these measures which were 
designed primarily for use in research) warranted their use in standard clinical care. 
However, a consideration of a patient‘s readiness and/or motivation for change is a 
vital part of assessment.  
Physical investigations 
An awareness of, and inquiry into the nature of commonly presenting physical 
health problems with alcohol misuse are important. This guideline, and other related 
NICE guidelines (NICE, 2010a; 2010b), considered the value of biomarkers, for 
example, liver function tests as indicators for diagnosis of alcohol related disorders. 
From the reviews conducted for this and the other NICE guidelines it was concluded 
that these measures have insufficient sensitivity and specificity compared with 
validated assessment methods such as the AUDIT. However, for people with specific 
physical health problems, for those whom regular feedback on a particular biological 
marker may act as a motivational tool, and those for whom pharmacological 
treatments may require liver function tests (for example, naltrexone and disulfiram), 
then these measures may have an important part to play in the ongoing treatment 
and management of alcohol misuse. No evidence was identified in this or the other 
NICE guidelines (2010a; 2010b) to support the use of other biomarkers (for example, 
hair analysis) for routine clinical use in assessment or outcome monitoring of alcohol 
misuse.  
 
 173 
 
Assessment of comorbid substance misuse  
It is recognised that smoking, drinking and drug taking behaviours cluster together 
(Farrell et al., 2001) and that excessive drinkers with high AUDIT scores are more 
likely to have used drugs in the past (Coulthard et al., 2002). Therefore the evidence 
suggests that co-existing substance misuse should be assessed. Clinical assessment 
should include the type of drug and its route of administration, the quantity and the 
frequency with which it is used.  
Assessment of comorbid mental health problems 
Mental health problems which co-exist with alcohol misuse can have a significant 
impact, both on the treatment and long-term outcome of the alcohol related problem. 
However, depression and anxiety can often develop as a consequence of alcohol 
misuse. At assessment there is no reliable way of determining whether a comorbid 
mental health problem is primary or secondary to alcohol misuse. This means that 
symptoms of comorbid mental disorders need to be monitored throughout the 
course of assessment and treatment. A common presentation in alcohol misuse is 
suicidal ideation. This needs to be assessed and actively managed as part of an 
overall risk management process. The GDG considered that as, a minimum, the re-
assessment of common mental disorders should occur three to four weeks following 
abstinence from alcohol. At this point, consideration may be given to treatment. 
NICE guideline for the management of these disorders should be consulted.  
Cognitive impairment 
Cognitive impairment is present in most people who misuse alcohol presenting for 
treatment. These impairments, which may be transitory, are, however, often missed 
in the initial assessment. The evidence reviewed suggested that the MMSE has 
reasonable validity as an initial identification tool, and should be supplemented with 
specific questions to detect duration extent or functional impairment. There is also 
evidence to suggest that the ACE-R has good sensitivity for diagnosing mild 
cognitive impairment. However, it does not assess all aspects of cognitive function 
and should be used as a part of a specialist comprehensive assessment test battery in 
conjunction with an executive test such as the Block Design subtest of the Wechsler 
Adult Intelligence Scale (WAIS-III) (Wechsler, 2007) or the Trail-making test, Part B 
(Army Individual Test Battery, 1944). It is not possible to conduct an effective 
cognitive assessment in people who misuse alcohol who are actively drinking. 
Unless there is evidence of gross cognitive impairment, which may require further 
and immediate investigation, the GDG took the view that adequate assessment of 
cognitive impairment is best left until 3 to 4 weeks following abstinence from 
alcohol. At this point if significant cognitive impairment persists it should be subject 
to more formal assessment including conducting a more detailed history and 
neuropsychological testing. Those patients presenting acutely with a confused state 
and significant memory loss, may be suffering from Wernicke‘s encephalopathy and 
should be assessed and treated accordingly (see NICE guideline 2010b).  
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Organisation and delivery of assessment  
The evidence for the organisation and delivery of the range of assessment was 
reviewed. This included a review of the currently recommended assessment systems 
in England and, in particular, the MoCAM stepped are framework. This approach 
begins with an initial case identification/diagnostic assessment. Here the emphasis 
is on brief assessments which can be administered by staff in a range of services in 
healthcare and related settings. There is good evidence from the assessment tools 
reviewed above that scores on measures such as the AUDIT and SADQ provide a 
useful indication of the appropriate level of intervention needed. There is also 
evidence that people who misuse alcohol can be assessed in a relatively brief triage 
assessment. The guideline also reviewed the evidence for the factors to be 
considered in a withdrawal assessment. Finally the indications for and content of 
comprehensive assessment was reviewed. In summary the GDG felt that a stepped 
approach to assessment in line with that set out in MoCAM (Department of Health, 
2006a) was appropriate.  
Outcome monitoring 
The GDG reviewed the evidence for the use of routine outcome monitoring. A range 
of assessment tools were considered as part of the overall view of assessment tools. 
Although these measures are effective at identifying the presence or severity of the 
disorder most were felt unsuitable or impractical for routine outcome measurement. 
The evidence suggested that the AUDIT questionnaire provides a valid, reliable and 
feasible method to monitor outcome in routine clinical care. Prospective weekly 
drinking diaries whilst widely used in clinical services are of unknown reliability 
and validity. The routine use of breath alcohol concentration measurement was not 
supported by the evidence either in initial assessment or routine outcome 
monitoring, although it has a useful place in monitoring abstinence in the context of 
an assisted withdrawal programme. The GDG therefore favoured the AUDIT 
(specifically the first three questions from the questionnaire with subsequent 
questions only used for 6-month follow-up) as a routine measure but recognised that 
in some services, especially Tier 3 and 4 specialist services an additional, more 
detailed assessment measure may also be used. The GDG also favoured the APQ as 
an outcome monitoring tool when assessing alcohol-related problems. 
5.26 FROM EVIDENCE TO RECOMMENDATIONS 
Assessment tools  
The review of assessment tools identified a number of measures which had 
sufficiently robust psychometric properties to be used in routine clinical care. In 
addition to these factors, the GDG also used expert knowledge to assess the benefit 
and feasibility of their use in routine care. As an initial case identification tool, that is 
one which would indicate whether or not further treatment was required, the 
AUDIT questionnaire is the most appropriate instrument. On occasions where the 
AUDIT questionnaire was not available and/or not practical, then a simple typical 
daily alcohol consumption measure could also be used as an indicator of potential 
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need for treatment. For people suspected of having alcohol dependence, the use of 
the SADQ or the Leeds Dependence Questionnaire (LDQ), were supported by the 
GDG as effective instruments to measure the severity of alcohol dependence in order 
to guide further management. For assessing the extent of problems associated with 
alcohol misuse the Alcohol Problems Questionnaire (APQ) was identified as meeting 
all the necessary criteria. In addition, on the basis of the NICE guideline on the 
management of alcohol-related physical complications review (NICE, 2010b), the 
CIWA-Ar was judged to be the most appropriate instrument to measure alcohol 
withdrawal symptoms.  
Content of the clinical assessment and the organisation and delivery of 
assessment systems 
It is important to recognise that the use of individual assessment tools alone, such as 
those identified above, does not constitute a comprehensive assessment. The 
evidence suggested that, in addition to a historical and recent history of drinking, 
the associated physical and mental health problems and the impact on health and 
social and economic problems should also be assessed. This section also identified 
the importance of the impact on family (including importantly children). It is also 
important to recognise that a key aspect of effective assessment is the process of 
engaging people and identifying treatment goals. For example, determining whether 
abstinence, which is the initial preferred goal for moderately and severely dependent 
drinkers, or moderation of alcohol consumption is the preferred goal. The GDG 
therefore decided to provide detail on the content of the range of assessment 
domains. The GDG also reviewed the evidence for the organisation and delivery of 
assessment systems and supported the established system recommended within 
MoCAM (Department of Health, 2006a). This may require additional specialist 
assessment resources and systems to ensure that individuals have the capacity and 
competency deliver these assessments.  
Physical investigations 
The review for this guideline (based in significant part on parallel work undertaken 
on other NICE guidelines , NICE ; 2010b) established that physical investigations in 
particular, blood tests including measures of liver function are not sufficiently 
sensitive or specific measures for routine use in specialist alcohol services. However, 
biomarkers can have added benefit as motivational tools by providing feedback on 
progress and in assessing suitability for some pharmacological interventions (for 
example, naltrexone and disulfiram). The GDG also considered that the 
measurement of breath alcohol is a useful, objective part of the clinical monitoring in 
the management of assisted alcohol withdrawal.  
Assessment of comorbid substance misuse  
The presence of comorbid substance misuse is associated with poorer outcomes for 
those with alcohol misuse the GDG reviewed evidence on this along with the 
recommendation in the NICE (2007a) guideline on psychosocial management of 
substance misuse. It was agreed that assessment of comorbid drug misuse should 
therefore be a part of routine assessment of alcohol misuse. Consideration should be 
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given to the use of use biological testing (for example, of urine or saliva samples) as 
part of a comprehensive assessment of drug misuse, but clinicians should not rely on 
it as the sole method of diagnosis and assessment. 
Assessment of comorbid mental health problems  
Comorbid mental health problems are a common presentation in people who misuse 
alcohol. It is important that this is assessed at initial presentation. However, it should 
be noted that for most clients‘ symptoms of, for example, depression and anxiety 
will remit following 3 to 4 weeks of abstinence from alcohol. It is therefore often not 
appropriate or necessary to instigate treatment for the disorder at the point of the 
initial assessment. Careful monitoring and reassessment of mental health symptoms 
following abstinence are an important part of the assessment procedure. Treatment 
of mental health disorders persisting beyond 3 to 4 weeks after abstinence should be 
considered.  
Routine outcome monitoring  
Routine outcome monitoring is an essential part of any effective healthcare system 
provision. The AUDIT questionnaire was identified as the most reliable and feasible 
measure for routine outcome monitoring. Prospective drinking diaries are of 
unknown reliability and validity. The APQ was also identified as beneficial for the 
assessment of alcohol-related problems when monitoring treatment outcome.  
Competence of staff 
It is essential that clinicians performing assessments of people who misuse alcohol 
should be fully competent to do so.  
Children and young people 
Due to the lack of sufficient evidence, the GDG decided to adopt a modified version 
of the assessment framework adopted for adults. As with the adult review the GDG 
favoured the use of the AUDIT tool as a case identification/screening tool and this is 
consistent with the approach adopted the NICE prevention and brief intervention 
guideline (NICE, 2010a) However, the GDG decided to adjust the threshold for 
AUDIT in light of evidence that this increased the sensitivity for adolescent alcohol 
misuse. For a more comprehensive assessment the GDG recommended two possible 
assessment tools and the integration of any assessment of alcohol misuse into a 
comprehensive assessment of the needs of the child or young person.  
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5.26.1 Recommendations  
Identification and assessment 
General principles 
5.26.1.1 Staff working in services provided and funded by the NHS who care for 
people who potentially misuse alcohol should be competent to identify 
harmful drinking and alcohol dependence. They should be competent to 
initially assess the need for an intervention or, if they are not competent, 
they should refer people who misuse alcohol to a service that can provide an 
assessment of need. [KPI] 
 
5.26.1.2 Make sure that assessment of risk is part of any assessment, that it informs 
the development of the overall care plan, and that it covers risk to self 
(including unplanned withdrawal, suicidality and neglect) and risk to 
others.  
5.26.1.3 When conducting an initial assessment, as well as assessing alcohol misuse, 
the severity of dependence and risk, consider the:  
 extent of any associated health and social problems 
 need for assisted alcohol withdrawal. 
5.26.1.4 Use formal assessment tools to assess the nature and severity of alcohol 
misuse, including the: 
 AUDIT for identification and as a routine outcome measure 
 SADQ or LDQ for severity of dependence  
 Clinical Institute Withdrawal Assessment of Alcohol Scale, revised 
(CIWA-Ar) for severity of withdrawal  
 APQ for the nature and extent of the problems arising from alcohol 
misuse. 
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5.26.1.5 When assessing the severity of alcohol dependence and determining the 
need for assisted withdrawal, adjust the criteria for women, older people, 
children and young people19, and people with established liver disease who 
may have problems with the metabolism of alcohol. 
5.26.1.6 Staff responsible for assessing and managing assisted alcohol withdrawal 
(see Section 5.30.2) should be competent in the diagnosis and assessment of 
alcohol dependence and withdrawal symptoms and the use of drug 
regimens appropriate to the settings (for example, inpatient or community) 
in which the withdrawal is managed.  
5.26.1.7 Staff treating people with alcohol dependence presenting with an acute 
unplanned alcohol withdrawal should refer to ‗Alcohol use disorders: 
diagnosis and clinical management of alcohol-related physical 
complications‘ (NICE clinical guideline 100). 
Assessment in all specialist alcohol settings  
Treatment goals  
5.26.1.8 In the initial assessment in specialist alcohol services of all people who 
misuse alcohol, agree the goal of treatment with the service user. Abstinence 
is the appropriate goal for most people with alcohol dependence, and people 
who misuse alcohol and have significant psychiatric or physical comorbidity 
(for example, depression or alcohol-related liver disease). When a service 
user prefers a goal of moderation but there are considerable risks, advise 
strongly that abstinence is most appropriate, but do not refuse treatment to 
service users who do not agree to a goal of abstinence. 
5.26.1.9 For harmful drinking or mild dependence, without significant comorbidity, 
and if there is adequate social support, consider a moderate level of drinking 
as the goal of treatment unless the service user prefers abstinence or there 
are other reasons for advising abstinence. 
5.26.1.10 For people with severe alcohol dependence, or those who misuse 
alcohol and have significant psychiatric or physical comorbidity, but are 
unwilling to consider a goal of abstinence or engage in structured treatment, 
consider a harm reduction programme of care. However, ultimately the 
service user should be encouraged to aim for a goal of abstinence. 
5.26.1.11 When developing treatment goals, consider that some people who 
misuse alcohol may be required to abstain from alcohol as part of a court 
order or sentence. 
 
 
 
 
 
                                                 
19
 See section 5.22 for assessment of children and young people. 
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Brief triage assessment 
5.26.1.12 All adults who misuse alcohol who are referred to specialist alcohol 
services should have a brief triage assessment to assess: 
 the pattern and severity of the alcohol misuse (using AUDIT) and 
severity of dependence (using SADQ)  
 the need for urgent treatment including assisted withdrawal  
 any associated risks to self or others 
 the presence of any comorbidities or other factors that may need 
further specialist assessment or intervention. 
Agree the initial treatment plan, taking into account the service user‘s 
preferences and outcomes of any previous treatment. 
Comprehensive assessment  
5.26.1.13 Consider a comprehensive assessment for all adults referred to 
specialist alcohol services who score more than 15 on the AUDIT. A 
comprehensive assessment should assess multiple areas of need, be 
structured in a clinical interview, use relevant and validated clinical tools 
(see Section 5.16), and cover the following areas:  
 alcohol use, including:  
- consumption: historical and recent patterns of drinking (using, for 
example, a retrospective drinking diary), and if possible, additional 
information (for example, from a family member or carer) 
- dependence (using, for example, SADQ or LDQ) 
- alcohol-related problems (using, for example, APQ) 
 other drug misuse, including over-the-counter medication 
 physical health problems  
 psychological and social problems 
 cognitive function (using, for example, the Mini-Mental State 
Examination [MMSE])20 
 readiness and belief in ability to change. [KPI] 
                                                 
20 Mini-Mental State Examination: Folstein, M. F., Folstein, S. E. & McHugh, P. R. (1975) ‗Mini-mental 
state‘. A practical method for grading the cognitive state of patients for the clinician. Journal of 
Psychological Research, 12, 189–198. 
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5.26.1.14 Assess comorbid mental health problems as part of any comprehensive 
assessment, and throughout care for the alcohol misuse, because many 
comorbid problems (though not all) will improve with treatment for alcohol 
misuse. Use the assessment of comorbid mental health problems to inform 
the development of the overall care plan. 
5.26.1.15 For service users whose comorbid mental health problems do not 
significantly improve after abstinence from alcohol (typically after 3–4 
weeks), consider providing or referring for specific treatment (see the 
relevant NICE guideline for the particular disorder). 
5.26.1.16 Consider measuring breath alcohol as part of the management of 
assisted withdrawal. However, breath alcohol should not usually be 
measured for routine assessment and monitoring in alcohol treatment 
programmes.  
5.26.1.17 Consider blood tests to help identify physical health needs, but do not 
use blood tests routinely for the identification and diagnosis of alcohol use 
disorders.  
5.26.1.18 Consider brief measures of cognitive functioning (for example, MMSE) 
to help with treatment planning. Formal measures of cognitive functioning 
should usually only be performed if impairment persists after a period of 
abstinence or a significant reduction in alcohol intake.  
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SECTION 4 – DETERMINING THE 
APPROPRIATE SETTING FOR THE DELIVERY 
OF EFFECTIVE CARE 
5.27 INTRODUCTION  
This section is concerned with identifying the settings in which to deliver clinical 
care for people who misuse alcohol. It begins with a review of planned assisted 
withdrawal, which is linked to and draws heavily on the review conducted for the 
NICE guideline on management of alcohol-related physical complications (NICE, 
2010b). It then considers the range of settings in which assisted withdrawal and the 
interventions covered in Chapters 6 and 7 of this guideline may be best provided, 
including community, residential and inpatient settings.  
 
The majority of services provide treatment for alcohol misuse in community or 
outpatient settings, whereby a patient is visited at home by a health or social care 
professional or attends a clinic or a day hospital. There are also approximately 200 
voluntary or independent sector providers of residential rehabilitation treatment for 
drug or alcohol misuse in England (National Treatment Agency, 2009b). The services 
that they offer can be differentiated according to factors such as the principal aims of 
treatment, patient group and length of stay. Residential rehabilitation services may 
offer medically assisted withdrawal from alcohol, but usually only as a prelude to 
longer-term rehabilitation or aftercare. Finally, medically-managed inpatient 
facilities are usually run by the NHS, and a review of national provision in 2004 
highlighted 77 NHS hospitals that admitted patients for drug or alcohol withdrawal, 
and a further 28 non-statutory or private providers (Day et al., 2005).  
 
Current practice in the management of assisted withdrawal, and the general 
provision of alcohol treatment services, tends to follow MoCAM (Department of 
Health, 2006a) guidance that suggested community settings were preferred for the 
treatment of the majority of people who misuse alcohol, as they are seen as more cost 
effective and more likely to promote change in their drinking behaviour in a normal 
social environment. However, it was noted that some people would require 
treatment in hospital or in supported residential accommodation, including those 
who are severely dependent, have a history of withdrawal complicated by seizures 
or DTs, are in poor physical or psychological health, are at risk of suicide, or misuse 
drugs. Homeless people, those who lack social support or stability or those who 
have had previous unsuccessful attempts at withdrawal in the community may also 
require inpatient treatment. MoCAM also stipulated that inpatient assisted 
withdrawal should lead seamlessly into structured care-planned treatment and 
support, whether delivered in the community or in residential rehabilitation 
services. However, it should also be noted, as discussed at the beginning of this 
chapter, that there is considerable variation in practice (including in the settings) in 
which services are provided.  
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A number of authors have considered the possible benefits of treatment in a 
residential setting (Gossop, 2003; Mattick & Hall, 1996; McKay et al., 1995; Weiss, 
1999). In considering the potential benefits of any setting it is useful to distinguish 
between the provision of withdrawal management and the provision of further 
treatment and rehabilitation. Residential settings provide a high level of medical 
supervision and safety for individuals who require intensive physical and/or 
psychiatric monitoring, and the possibility of more intensive treatment may also 
help patients who do not respond to interventions of lower intensity. Residential 
settings may also offer the patient respite from their usual social milieu (that is, the 
people and places associated with alcohol use) and improved continuity of care. 
However, the protectiveness of a residential unit may also be one of its main 
disadvantages—it may limit opportunities for the patient to develop new coping 
strategies (Annis, 1996). Time away from work or study, reduced family contact and 
the stigmatisation associated with some residential service settings may also be 
potential disadvantages of residential care (Strang et al., 1997). Finally, residential 
settings are considerably more expensive than non-residential alternatives.  
 
Previous reviews of studies of residential treatment for alcohol misuse conducted in 
the 1980s concluded that residential/inpatient treatment had no advantages over 
outpatient treatment (Annis, 1996; Miller & Hester, 1986). Furthermore, every 
controlled study of length of inpatient treatment found no advantage in longer over 
shorter stays, or in extended inpatient care over assisted withdrawal alone (Annis, 
1996; Miller, 1986). However, the authors noted a variety of methodological 
problems with the studies, not least that the nature of the treated populations varied 
substantially, from general psychiatric patients assessed for alcohol misuse and 
outpatient problem drinkers to inpatient alcoholics (Miller, 1986). Miller also noted 
that a course of outpatient treatment averaged less than 10% of the cost of inpatient 
treatment. Therefore, even if residential settings afforded a modest advantage in 
overall effectiveness, preference might still be given to non-residential treatment 
based on cost effectiveness.  
 
Further research conducted since the mid-1980s has challenged some of these 
conclusions. In a review of the literature, Finney and colleagues (1996) found 14 
studies in which setting effects might have been detected. Of these studies, seven 
found significant setting effects on one or more drinking-related outcomes, with five 
favouring inpatient over outpatient treatment and a further two favouring day 
hospital over inpatient treatment (Finney et al., 1996). In all but one instance in which 
a significant effect emerged, patients in the more effective setting received more 
intensive treatment, and participants were not ‗pre-selected‘ for their willingness to 
accept random assignment. Other potential methodological problems were also 
identified. As mentioned above, it is often thought that an inpatient or residential 
setting will benefit patients from social environments where heavy drinking is 
common and encouraged, by allowing the patient a period of respite. However, 
some studies randomised participants to inpatient or outpatient treatment after an 
initial period of inpatient treatment for medically-assisted withdrawal. Finney and 
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colleagues (1996) commented that this treatment setting contamination might bias 
studies toward no-difference findings.  
5.28 CLINICAL QUESTIONS  
 
1. In adults in planned alcohol withdrawal, what is the clinical efficacy, cost 
effectiveness, safety of, and patient satisfaction associated with: 
 preparatory work before withdrawal 
 different drug regimens  
 the setting (that is, community , residential or inpatient)?  
 
2. In adults in planned alcohol withdrawal what factors influence the choice of 
setting in terms of clinical and cost effectiveness including: 
 severity of the alcohol disorder  
 physical comorbidities 
 psychological comorbidities 
 social factors? 
 
3. In adults with harmful or dependent alcohol use what are the preferred 
structures for and components of community-based and residential specialist 
alcohol services to promote long-term clinical and cost-effective outcomes?  
5.29 ASSISTED ALCOHOL WITHDRAWAL 
5.29.1 Introduction 
This section is concerned with planned assisted alcohol withdrawal. It should be 
read in conjunction with the NICE guideline on management of alcohol-related 
physical complications (NICE, 2010b); the reviews conducted for that guideline 
informed the decisions of the GDG. Previous research assessing the settings for 
assisted withdrawal from alcohol has yielded a considerable amount of debate about 
the safety, efficacy and cost effectiveness of the various options available. Settings 
for assisted withdrawal include the community, where assisted withdrawal may be 
delivered in a day hospital setting, in specialist community alcohol teams or in 
primary care, specialist inpatient and specialist residential settings. In addition, 
assisted withdrawal programmes are also provided in the prison healthcare system, 
police custody, and in a range of acute general medical settings. This section is also 
concerned with the indications for inpatient assisted withdrawal. Some further 
details about the settings in which assisted withdrawal can take place are given 
below. Special populations or patient groups who may be at risk of complications 
are considered separately in sections 5.29.6 and 5.30.7. 
Community settings 
In a community setting a person undergoing assisted withdrawal lives in their own 
accommodation throughout the treatment. A spectrum of treatment intensity is also 
possible. Day hospital treatment (sometimes known as ‗partial hospitalisation‘; see 
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ASAM guidelines above) may involve the patient attending a treatment facility for 
up to 40 hours per week during working hours, Monday to Friday, and returning 
home in the evening and weekends. This facility may be located within an inpatient 
or residential rehabilitation unit, or may be stand-alone. It is likely to be staffed by a 
multidisciplinary team, with input from medical and nursing staff, psychologists, 
occupational therapists, social workers, counsellors, and other staff specialising in 
debt, employment or housing issues. Other community assisted withdrawal 
programmes may invite the patient to attend for appointments with a similar range 
of multidisciplinary staff, but at a much lower frequency and intensity (for example, 
once or twice a week), or they may be provided by GPs often with a special interest 
in treating alcohol-related problems. Alternatively, staff may visit the patient in their 
own home to deliver interventions. Between these two options are most intensive 
community-based options, where an increased frequency of community visits and 
some limited use of office or team-based treatment may form part of an intensive 
community programme.  
Inpatient and residential settings 
In inpatient and residential settings, the service user is on-site for 24 hours a day for 
the duration of assisted withdrawal. Inpatient and residential settings encompass a 
spectrum of treatment intensity. At one end lie specialist units within either acute 
medical or psychiatric hospitals, dedicated to the treatment of alcohol or drug 
problems (known as ‗inpatient units‘). Such units have specialist medical and 
nursing input available 24 hours a day, and are staffed by a multidisciplinary team 
that may also include psychologists, occupational therapists, social workers, 
counsellors, and other staff specialising in debt, employment or housing issues. At 
the other end of the spectrum are facilities usually known as ‗residential 
rehabilitation‘ units, which are usually provided by the non-statutory sector and not 
sited within hospital premises. Although the goal of such units is usually the 
provision of longer-term treatment (3 to 12 months) aimed at enhancing the patient‘s 
ability to live without using alcohol, increasingly they also provide an initial period 
of assisted withdrawal. Such units may also have access to medical and nursing 
input over the full 24-hour period, but this is usually at a lower level of intensity and 
more likely to utilise non-specialist staff (for example, GPs). Such units are more 
likely to adopt a ‗social model‘ rather than a ‗medical model‘, and may be staffed by 
both professionals and individuals in recovery. In addition, a number of prisons may 
offer a high level of medical supervision including, where necessary, admission to 
the hospital wing of the prison.  
5.29.2 Aim of review and review protocol 
The initial aim of this review was to perform a systematic meta-analysis of RCT data 
that addressed the clinical question. However, only one well-designed RCT 
assessing the benefits and harms of different settings for assisted withdrawal has 
been published (Hayashida et al., 1989). Therefore, the GDG made a consensus-based 
decision to assess all available studies and provide a narrative review. The review 
team assessed the literature identified from the search conducted by the NICE 
guideline on management of alcohol-related physical complications (NICE, 2010b); 
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full details of the search strategies can be found in that guideline. Studies were 
considered for inclusion in a narrative review for this guideline if they met the 
inclusion criteria (see Chapter 3) and if the population being assessed in the study 
reflected the scope of this guideline (see Appendix 1). Furthermore, studies were 
considered for inclusion in the narrative review using the clinical review protocol in 
Table 20. The key outcomes of interest were: the efficacy of the setting for assisted 
withdrawal (for example, the patient successfully completed the programme and 
remained abstinent during the period assisted withdrawal); the safety profile (for 
example, the development of complications, and hence the patient factors that 
indicate that a non-residential setting for assisted withdrawal is unsuitable or 
unsafe); and participation in consequent rehabilitation treatment. Other outcomes of 
interest are patient satisfaction and other patient and physician related factors.  
 
Table 20: Clinical review protocol for the evaluation of different settings 
for assisted withdrawal from alcohol  
Electronic Databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO; see 
the NICE guideline on management of alcohol-related physical 
complications (NICE, 2010b) for search strategies 
Date searched Systematic Reviews from 1993 to March 2010. All other searches 
from database inception to March 2010 
Study design RCTs; Systematic reviews 
Patient population Adults (over 18 years old)  
Patients with alcohol withdrawal syndrome 
Critical Outcomes Main outcomes: severity of withdrawal; completion rates; 
abstinence during assisted withdrawal; safety (development of 
complications); participation in further rehabilitation treatment 
after assisted withdrawal 
Other outcomes; patient and physician factors 
 
5.29.3 Studies considered 
Five studies comparing different settings for assisted withdrawal were identified. Of 
these, one was an RCT (Hayashida et al., 1989), three were retrospective matching 
studies (Stockwell et al., 1991; Bartu & Saunders, 1994; Parrott et al., 2006), and one a 
retrospective case study comparing patient characteristics in different settings (Allan 
et al., 2000). In addition, five open prospective studies (Collins et al., 1990; 
Drummond & Chalmers, 1986; Feldman et al., 1975; Soyka & Horak, 2004; Stinnett, 
1982) and an RCT assessing adding a brief psychological intervention to home-based 
assisted withdrawal (Alwyn et al., 2004) were also identified. These additional 
studies did not compare different settings for assisted withdrawal but reported 
treatment outcomes for a community setting for assisted withdrawal.  
 
The literature search also identified studies and systematic reviews evaluating 
circumstances in which inpatient admission for assisted withdrawal may be 
appropriate, as well as special populations and patient groups whom may require 
inpatient assisted withdrawal from alcohol. These studies are considered separately.  
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5.29.4 Narrative review of settings for assisted withdrawal  
Studies comparing different settings for assisted withdrawal 
Apart from the Hayashida and colleagues (1989) study, the studies discussed above 
were observational in design and participants were only matched for severity of 
alcohol dependence. Furthermore, although these studies indicated that it is feasible 
for assisted withdrawal to take place in a community setting for a severely 
dependent population, it is probable that a number of patients with significant 
comorbidities and previous history of seizures where excluded. As these patients 
form a significant proportion of those who are referred to and receive inpatient or 
residential assisted withdrawal, caution is needed when interpreting these results.  
 
Only one randomised trial (Hayashida et al., 1989), conducted in a US Veterans 
Administration medical centre, compared the effectiveness and safety of inpatient 
(n=77) and outpatient (n=87) assisted withdrawal. Patients with serious medical or 
psychiatric symptoms, predicted DTs and a very recent history of seizures were 
excluded from this study. The authors reported that more inpatients than 
outpatients completed assisted withdrawal. However, inpatient treatment was 
significantly longer and more costly than outpatient treatment. Additionally, both 
groups had similar reductions in problems post-treatment when assessed at 1- and 6-
month follow-up. Although abstinence was statistically significantly higher for the 
inpatient group at 1-month follow-up, these differences were not observed at 6-
month follow-up. The authors concluded that outpatient assisted withdrawal should 
be considered for people with mild-to-moderate symptoms of alcohol withdrawal.  
 
Stockwell and colleagues (1991) compared a retrospective inpatient sample (n=35) 
with a group receiving home-based assisted withdrawal (n=41). The two samples 
were matched for age, sex, and drinking severity. Patients undertaking home-based 
assisted withdrawal were severely dependent (SADQ score = 28.7; mean alcohol 
consumption 174.6 units per week) and had a high level of alcohol-related problems 
(APQ score = 4.6). The authors reported that home-based assisted withdrawal was as 
safe and effective for a severely dependent population as inpatient care. However, 
the matched inpatient sample did not include anyone with severe alcohol 
withdrawal syndrome or physical or psychiatric symptoms and, therefore, is not 
representative of an inpatient population.  
 
Bartu and Saunders (1994) also compared people undertaking home-based assisted 
withdrawal (n=20) with patients in an inpatient specialist unit (n=20). Patients were 
matched for age, sex, presence of social support, absence of medical complications, 
and severity of withdrawal symptoms. It was reported that home-based assisted 
withdrawal was as beneficial as inpatient assisted withdrawal. It should be noted, 
however, that the matched inpatient sample was not representative of a typical 
inpatient, who may be severely dependent and have several complications.  
 
Parrott and colleagues (2006) compared alcohol-focused outcomes and cost of 
residential (n=54) and any day (n=49) settings for assisted withdrawal in the UK and 
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reported similar alcohol-focused outcomes (PDA and DDD) for patients attending a 
residential treatment centre and a day treatment centre in the UK. This paper mainly 
discusses cost implications and is reviewed in the health economics section (5.29.7).  
 
In a comparison between home-based assisted withdrawal (n=29) and day hospital 
services (n=36), in severely dependent patients, Allan and colleagues (2000) in a UK-
based study evaluated the types of patients selected for home-based assisted 
withdrawal, its safety and efficacy, and patient satisfaction and involvement in 
further treatment. Participants in both groups were severely dependent (two thirds 
had a SADQ score of over 30), although the day hospital group drank significantly 
more at baseline (home-based group = 178 units, day hospital group = 194 units in 
the week before assisted withdrawal). Furthermore, although both groups had 
alcohol-related problems, as assessed by the APQ, the day hospital group had 
significantly more severe problems and social instability. The authors reported that 
there were no significant differences between the groups in the proportion of 
participants who completed assisted withdrawal, complication rates (which were 
low), and uptake of treatment post withdrawal. However, it should be noted that 
this study did not match participants in both settings but aimed to assess the 
characteristics of the patients who use home-based and day hospital assisted 
withdrawal.  
Prospective studies evaluating outpatient assisted withdrawal  
Further studies assessing the treatment outcomes and characteristics of patients in 
various settings were identified from the literature search. These studies were open 
prospective studies and aimed to evaluate the safety and efficacy of outpatient 
assisted withdrawal. Feldman and colleagues (1975) evaluated an outpatient 
treatment programme for alcohol withdrawal (n=564). The authors reported that 
only 47% required outpatient assisted withdrawal and 19% required inpatient 
assisted withdrawal. Outpatient assisted withdrawal was successful and had a low 
dropout rate of 14%. However, the authors attributed this success to the involvement 
of the family early on, the use of withdrawal medication and involvement in peer 
group therapeutic activity. The results of an earlier study reflected these findings 
(Alterman et al., 1988). The investigators reported that ambulatory assisted 
withdrawal was relatively successful for mild-to-moderate alcohol withdrawal 
symptomatology.  
 
Soyka and Horak (2004) assessed the efficacy and safety of outpatient assisted 
withdrawal in a German open prospective study. Alcohol dependent participants 
were excluded if they presented with severe alcohol-related disorders, such as 
seizures or psychosis, or major psychiatric and medical comorbidity. Some 
participants referred to the treatment clinic had to be admitted for inpatient care 
(n=348) leaving 331 patients being treated in an outpatient setting. The study 
reported very high completion rates (94%) for patients in an outpatient assisted 
withdrawal programme. Furthermore, outpatient assisted withdrawal was 
associated with increased participation in further treatment (91% of initial sample). 
Soyka and Horak (2004) additionally found that of those who completed assisted 
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withdrawal successfully, all entered either motivationally- or psychotherapy-based 
treatment.  
 
Stinnett (1982) evaluated the effectiveness and safety of 116 participants referred for 
outpatient assisted withdrawal in an alcoholism treatment centre. Fifty per cent 
completed treatment, and 89% of these completers went on to continue with follow-
up rehabilitation treatment. Collins and colleagues (1990) assessed the efficacy of a 
UK-based outpatient alcohol withdrawal programme. Of those deemed suitable for 
outpatient assisted withdrawal (n=76; 44% of all referrals), 79% successfully 
completed the treatment. These patients were severely alcohol dependent (91% had 
an SADQ score greater than 30). However, not all studies have reported such 
favourable completion rates. For example, in a severely dependent sample of 26 
patients (77% with a SADQ score greater than 31), Drummond and Chalmers (1986) 
reported that only 23% of patients completed assisted withdrawal and 19% attended 
a follow-up 1 month later.  
 
In a UK-based RCT, Alwyn and colleagues (2004) evaluated the addition of a brief 
psychological intervention to GP-managed home-based assisted withdrawal. The 
psychological intervention consisted of five 30-minute sessions with motivational, 
coping skills and social support approaches. The study reported that both the control 
and the psychological intervention group (total n=91) showed significant 
improvements in drinking outcomes from baseline to follow-up (3- and 12-month) 
indicating that home-based assisted withdrawal was effective. In addition, the 
psychological intervention group showed significantly greater improvements than 
the control group at and 12-month follow-up. These results suggest that there is 
benefit in adding brief psychological intervention to assisted withdrawal. 
 
From the patients‘ perspective, it has been suggested that gains made in inpatient 
assisted withdrawal may not be easily transferable to the patient‘s home and social 
environment (Bischof et al., 2003). Undertaking assisted withdrawal in a home or 
outpatient setting enables the patient to retain important social contacts that may 
facilitate their attempts to achieve abstinence as well as subsequent rehabilitation. 
Patients can continue in employment (if appropriate) and be in a familiar 
environment with family support, which may help to minimise stress and anxiety 
and help to motivate them. It has also been suggested that the home environment is 
also less stigmatising than an inpatient setting for assisted withdrawal (Allen et al., 
2005). In a study assessing patients‘ perceptions and fears of alcohol withdrawal, 
Allen and colleagues (2005) found that patients were fearful and concerned about 
the psychiatric residential setting for assisted withdrawal and expressed feelings of 
stigmatisation associated with being in an ‗institutional‘ setting. The authors also 
reported no difference in patient satisfaction between a home and outpatient setting 
for assisted withdrawal. Additionally, patient satisfaction with outpatient assisted 
withdrawal services have also been found to be high when administered in an 
intensive day programme (Strobbe et al., 2004). Stockwell and colleagues (1990) 
found that three quarters of patients preferred their home as the setting for assisted 
withdrawal, and two fifths and one third were unwilling to undergo withdrawal in, 
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respectively, a psychiatric hospital and a general hospital. The patients also 
emphasised the importance of support from the nurse supervising their assisted 
withdrawal, the breathalyser, medications, telephone support service and the 
involvement of supporters, familiar surroundings, privacy and confidentiality, and 
being able to stay with their family. 
 
Another factor that may be relevant to the provision of home or outpatient assisted 
withdrawal is availability of treatment capacity. An early report (Stockwell et al., 
1986) revealed that in the Exeter Health Authority, GPs arranged as many home-
based assisted withdrawals as hospital-based. However, of the home-based assisted 
withdrawals, two fifths were unsupervised. Approximately a third of GPs were 
reluctant to take medical responsibility for home-based assisted withdrawal, but of 
those who were happy to, they reported a preference for this setting. Winters and 
McGourty (1994) also surveyed GPs in Chester and Ellesmere Port. Approximately 
60% reported that they provided home-based assisted withdrawal from their 
practices. However, 10% believed specialist help was required. Additionally, they 
reported that unsuccessful home-based assisted withdrawal was usually due to lack 
of support at weekends and lack of patient motivation. Over 20% of 
Northumberland GPs reported carrying out home-based assisted withdrawals in the 
last year (Kaner & Masterson, 1996). Similar to Winters and McGourty (1994), most 
GPs stressed the importance of having daily supervision as well as more information 
about the process of assessing patients for suitability for home-based assisted 
withdrawal.  
5.29.5 Inappropriate admission for residential assisted withdrawal  
In services with ready access to inpatient facilities for assisted withdrawal, there is 
evidence to suggest that given the likelihood of medical complications more patients 
are admitted than is necessary. Whitfield (1980) reported than only 5% of people 
who misuse alcohol require hospitalisation for withdrawal management. Booth and 
colleagues (1996) assessed appropriate and inappropriate utilisation of inpatient 
services for assisted withdrawal for alcohol in the US. The study, which randomly 
sampled a number of patients admitted into Veterans Administration medical 
centres, found that only 16% of alcoholics undergoing inpatient assisted withdrawal 
were appropriately admitted, and that the majority of these had medical or 
neurological complications such as liver cirrhosis, chest pains, kidney failure, 
gastrointestinal bleeding and seizures, and therefore met admission criteria. 
However, 84% were admitted for the purpose of monitoring alone and did not meet 
Appropriateness Evaluation Protocol (AEP) criteria for inpatient admission. 
Furthermore, the majority of inappropriately admitted patients did not develop any 
serious complications that could have justified inpatient care. These patients had 
lengthy admission length of 11 days on average, which has serious cost implications. 
An earlier study (Booth et al., 1991) also reported similar findings, albeit with a 
higher percentage (55%) of appropriate admissions. 
 
The implementation of a standardised policy that guides the decision about inpatient 
admission or outpatient assisted withdrawal in a small community hospital resulted 
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in a significant reduction in the number of admissions (Asplund et al., 2004). 
Furthermore, no patients needed hospitalisation for withdrawal complications, 
which indicates that outpatient assisted withdrawal, is safe for the majority of 
patients without prior complications as identified by a thorough assessment. 
Outpatient assisted withdrawal may be more appropriate for a population with less 
severe problems. In a sample of male military veterans enrolled in outpatient 
withdrawal, Webb and Unwin (1988) reported that 54% successfully completed 
outpatient assisted withdrawal, 22% were admitted for inpatient care and 24% 
dropped out of the treatment. The group referred for inpatient care had a 
significantly higher level of dependence (measured by SADQ score) than those who 
successfully completed outpatient assisted withdrawal. This would suggest that 
inpatient assisted withdrawal may be more appropriate for patients with more 
severe alcohol dependence. 
5.29.6 Special Populations 
Medical or psychiatric comorbidities  
For the majority of people who misuse alcohol, outpatient or home-based assisted 
withdrawal appears to be safe, viable and effective (see above). However, for a 
minority of patients, a non-residential setting for assisted withdrawal may be 
inappropriate or unsafe. An inpatient setting may be more appropriate for the 
management of moderate to severe withdrawal symptoms such as DTs and seizures, 
comorbid medical, surgical and psychiatric problems (for example, suicidal 
ideation), pregnancy, or if the patient is not able to take medication by mouth 
(Bischof et al., 2003; Blondell et al., 2002; Blondell, 2005; Dukan et al., 2002; Ferguson 
et al., 1996; Kraemer et al., 1997; Saitz & O‘Malley, 1997). There is evidence to suggest 
that a history of multiple prior episodes of assisted withdrawal may lead to an 
increased risk of seizures and withdrawal problems (Booth & Blow, 1993; Brown et 
al., 1988; Lechtenberg & Worner, 1990), and so a number of previous unsuccessful 
attempts at outpatient assisted withdrawal may also suggest the need for referral to 
an inpatient setting. Dependence on drugs can increase the risks associated with 
withdrawal and also the duration and severity of withdrawal symptoms, therefore 
patients with comorbid drug misuse disorders may require treatment in an inpatient 
setting. In addition, Pettinati and colleagues (1993) found that those with high 
psychiatric comorbidity and/or poor social support benefited more from inpatient 
than outpatient treatment.  
Children and young people 
No evidence evaluating the safety and efficacy of different settings for withdrawal 
management is children and young people was identified. The GDG therefore drew 
from the adult literature with special consideration to the additional problems often 
associated with alcohol misuse in children and young people (for example, problems 
with school, the family, crime and mental health). A significant concern of the GDG 
for children and young people was with the identification of potential dependence 
and subsequent withdrawal. In formulating recommendations about the appropriate 
setting for assisted withdrawal, the GDG considered that the safety issues 
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concerning assisted withdrawal might differ for children (aged 10 to 15 years) and 
young people (aged 16 to 18 years).  
Older people 
The GDG did not identify any clinical evidence evaluating the efficacy and safety of 
different settings for assisted withdrawal specifically for older people. However, 
research suggests that older patients (aged 60 years and above) are more at risk of 
cognitive and functional impairment during withdrawal and hence should be 
considered for inpatient care (Kraemer et al., 1997).  
Homeless patients 
Homeless patients requiring assisted withdrawal may also require inpatient care 
unless other shelter and accommodation can be arranged. For example, in a large 
study assessing the effectiveness of an ambulatory assisted withdrawal programme 
in the Veterans Administration system in the US (Wiseman et al., 1997), half of the 
patients were homeless. The study reported that 88% of patients successfully 
completed assisted withdrawal and 96% of these successful completers were referred 
for further treatment on either an inpatient or an outpatient basis. However, the 
programme provided supported housing for the homeless during the period of 
assisted withdrawal. Although low socioeconomic status and homelessness may 
make outpatient assisted withdrawal more challenging, they are not necessarily 
contraindications for treatment failure and hence should be assessed on a more 
detailed individual basis. O‘Connor and colleagues (1991) reported that socially 
disadvantaged people were not at an increased risk of unsuccessful assisted 
withdrawal in an outpatient setting.  
5.29.7 Health economics evidence  
Systematic literature review 
The literature search identified only one economic study that assessed the cost 
effectiveness and cost utility of different settings for assisted withdrawal (Parrott et 
al., 2006). The study evaluated two UK-based withdrawal programmes for people 
dependent on alcohol. The first intervention was a 10-day assisted withdrawal in a 
22-bed facility in Manchester staffed by mental health nurses with support from a 
local GP. The first part of the intervention involved managing withdrawal safely 
whilst the second part involved social care interventions. The second intervention 
was a brief hospitalisation programme based at a Newcastle NHS inpatient unit. 
This involved 3-day inpatient assisted withdrawal, if required, followed by 
attendance at a day programme. Patients in this programme were also given 
counselling based on cognitive-behavioural principles, including motivational 
intervention prior to structured interventions aimed at abstinence or moderate 
drinking. Both programmes were compared with no intervention rather than with 
each other because baseline data was compared with clinical and economic outcome 
data collected at 6 months after implementation. The economic analysis adopted a 
societal perspective. It included costs to the NHS, other alcohol treatment services, 
social services and the criminal justice system. The outcome measures used were 
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QALYs for the cost-utility analysis and reduction in units of alcohol per day and 
reduction in percentage of drinking days in the cost-effectiveness analysis. QALYs 
were estimated using EQ-5D scores obtained from participants in the study. 
 
In the cost-effectiveness analysis, the cost per unit reduction in alcohol consumption 
was £1.87 in the Manchester sample and £1.66 in the Newcastle sample. The cost per 
reduction of one drink per day was £92.75 in the Manchester sample and £22.56 in 
the Newcastle sample. The cost per percentage point reduction in drinking was 
£30.71 in the Manchester sample and £45.06 in the Newcastle sample. In the cost-
utility analysis, the Incremental Cost Effectiveness Ratio (ICER) per QALY gained, 
compared with no intervention, was £65,454 (£33,727 when considering only 
treatment costs) in the Manchester sample and £131,750 (£90,375 treatment costs 
only) in the Newcastle sample. Overall, the authors concluded that both alcohol 
withdrawal programmes improved clinical outcomes at a reasonable cost to society. 
However, QALY differences were not significant over 6 months with both ICERs 
well above current NICE thresholds for cost-effectiveness. 
 
The validity of the study results is limited by the absence of a non-treatment group 
for both alcohol withdrawal programmes as changes in clinical outcomes may have 
occurred without the interventions. Also, the within-group before-and-after study 
design meant that time-dependent confounding variables could not be controlled 
for. Data for each programme were collected from single centres, which may limit 
generalisability of the study findings to other UK centres. The small patient sample 
size in both centres and substantial loss to follow-up also limits the robustness of the 
analysis. It should be noted that patients in the two centres were different in terms of 
severity of dependence, the number and severity of alcohol-related problems, and 
socioeconomic status, and therefore direct comparison of costs and outcomes 
associated with each intervention is not appropriate. No sensitivity analyses were 
performed to test the robustness of the base case results. 
Summary of existing economic evidence 
The findings of Parrott and colleagues (2006) suggest that both programmes may be 
cost effective in terms of reduction in alcohol consumption rather than QALYs 
gained. The settings, the costs reported and the measure of benefit adopted in the 
study make this study directly applicable. However, the effectiveness evidence is not 
without limitations: the comparator of no treatment may not be relevant and the 
robustness of the results was not fully explored in sensitivity analyses. 
Cost analysis of assisted withdrawal in different settings  
The cost effectiveness of assisted withdrawal across different settings was 
considered by the GDG as an area with potentially significant resource implications. 
As previously discussed, clinical evidence was derived from studies with different 
designs and therefore it was not possible to synthesise the clinical data in order to 
conduct a formal economic evaluation. Nevertheless, existing clinical evidence does 
not suggest that the effectiveness of home-based or outpatient assisted withdrawal 
attempted in outpatient/home settings differs significantly from that of assisted 
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withdrawal provided in inpatient/residential settings. Therefore, a simple cost 
analysis was undertaken to estimate costs associated with assisted withdrawal that 
are specific to the setting in which assisted withdrawal is provided. 
 
Three different assisted withdrawal settings were considered in the cost analysis: 
inpatient/residential, outpatient and home-based. The healthcare resource use 
estimates for each setting were based on descriptions of resource use in studies 
included in the systematic literature review of clinical evidence. Information was 
mainly sought in studies conducted in the UK, as clinical practice and respective 
resource use described in these studies is directly relevant to the guideline context. 
After reviewing the relevant literature, it was decided to utilise resource use 
estimates reported in Alwyn and colleagues (2004), which were then adapted 
according to the expert opinion of the GDG in order to reflect current routine clinical 
practice within the NHS. The estimated resource use was subsequently combined 
with national unit costs in order to provide a total cost associated with provision of 
assisted withdrawal in the three settings assessed. Unit costs were derived from 
national sources (Curtis, 2009; Department of Health, 2010) and reflected 2009 prices. 
It should be noted that the cost estimates reported below do not include the cost of 
drugs administered to people undergoing assisted withdrawal. However, such a cost 
is expected to be similar across all assisted withdrawal settings and therefore its 
omission is unlikely to significantly affect the relative costs between different options 
assessed. 
Inpatient/residential assisted withdrawal 
According to Alwyn and colleagues (2004), inpatient/residential assisted 
withdrawal lasts 2 weeks and requires an extra outpatient visit. The GDG estimated 
that inpatient assisted withdrawal may last longer, between 2 and 3 weeks. The unit 
cost of NHS adult acute mental health inpatient care is £290 per patient day 
(Department of Health, 2010). The unit cost of hospital outpatient consultant drug 
and alcohol services is £85 per face-to-face contact for a follow-up visit (Department 
of Health, 2010). By combining the above resource use estimates with the respective 
unit costs, the total cost of inpatient/residential assisted withdrawal is estimated to 
range between £4,145 and £6,175 per person treated. 
Outpatient assisted withdrawal 
Outpatient assisted withdrawal is estimated to require six outpatient attendances 
(Alwyn et al., 2004). The unit cost of a face-to-face contact with hospital outpatient 
consultant drug and alcohol services is £181 for the first visit and £85 for each 
follow-up visit (Department of Health, 2010). By combining these data, the total cost 
of outpatient assisted withdrawal is estimated at £606 per person treated. 
Home-based assisted withdrawal 
Alwyn and colleagues (2004) estimated that home-based assisted withdrawal 
requires six community psychiatry nurse (CPN) home visits, lasting 30 minutes each. 
The GDG were of the opinion that the first of these visits should be replaced by an 
outpatient visit to alcohol consultant services, so that appropriate assessment is 
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carried out before starting assisted withdrawal. Moreover, the GDG advised that the 
travel time of the healthcare professional providing home-based assisted withdrawal 
should be taken into account. Considering that home visits often take place in 
remote areas, the GDG estimated that the travelling time of the healthcare 
professional staff was likely to range between 1 and 2 hours per home visit. The unit 
cost of a face-to-face contact with outpatient consultant drug and alcohol services is 
£181 for the first visit (Department of Health, 2010). The unit cost of a CPN is not 
available for 2009. The total cost of home-based assisted withdrawal was therefore 
based on the unit cost of community nurse specialists (Band 6), as this type of 
healthcare professional is expected to provide home-based assisted withdrawal. The 
unit cost for community nurse specialists is £35 per working hour and £88 per hour 
of patient contact (Curtis, 2009). This unit cost includes salary (based on the median 
full-time equivalent basic salary for Agenda for Change Band 6 of the January to 
March 2009 NHS Staff Earnings estimates for qualified nurses), salary oncosts, 
capital and revenue overheads, as well as qualification costs. The unit cost per 
working hour was combined with the estimated travelling time, while the unit cost 
per hour of patient contact was combined with the estimated total duration of home 
visiting. A £4 travel cost was assumed for each visit. By combining all the above 
data, the total cost of home-based assisted withdrawal was estimated to range 
between £596 and £771. 
Summary 
The cost analysis indicates that, provided that the different assisted withdrawal 
settings have similar effectiveness, then outpatient and home-based assisted 
withdrawal are probably less costly (and thus potentially more cost effective) than 
inpatient assisted withdrawal, resulting in an estimated cost saving of 
approximately £3,400 to £5,600 per person treated. 
5.29.8 Clinical and health economic evidence summary 
The evidence indicates that a community setting for assisted withdrawal is as 
effective and safe for the majority of patients as an inpatient or residential assisted 
withdrawal as long as the patient is without serious medical contraindications. It is 
also likely to be more cost effective as cost savings of between £3,400 to £5,600 per 
person may be generated The evidence reviewed is limited as there is only one RCT, 
but it should be noted that it is extremely difficult to undertake an RCT in this area 
given the clinicians concerns about the relative safety for more severely dependent 
patients. The GDG (drawing on the evidence in the reviews conducted for this 
guideline) therefore decided that it was important to consider the following factors 
when determining whether a community or residential/ inpatient assisted 
withdrawal is the most appropriate:  
 a history of epilepsy or withdrawal-related seizures or DTs during 
previous assisted withdrawal 
 a significant psychiatric or physical comorbidity (for example, chronic 
severe depression, psychosis, malnutrition, congestive cardiac failure, 
unstable angina, chronic liver disease) 
  a significant learning disability 
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 significant cognitive impairment  
 homelessness 
 pregnancy  
 children and young people 
 older people 
5.30 EVALUATING DOSING REGIMES FOR ASSISTED 
WITHDRAWAL  
5.30.1 Introduction 
This section assesses the safety, efficacy, cost effectiveness and patient satisfaction 
associated with different medication regimens used in assisted withdrawal from 
alcohol. When undertaking assisted withdrawal, the patient is required to stop 
alcohol intake abruptly, and the ensuing withdrawal symptoms are treated with 
medication, usually benzodiazepines. Once the withdrawal symptoms are 
controlled, the medication can be gradually reduced and stopped at a rate that 
prevents withdrawal symptoms re-emerging but without creating over-sedation. 
Key elements of the process are to provide a large enough initial dose to prevent 
severe withdrawal symptoms including seizures, DTs, severe anxiety or autonomic 
instability, but to withdraw the medication at a rate which prevents re-emergence of 
symptoms or serious complications such as DTs or seizures. Special populations 
with indications for specific dosing regimens are discussed in Section 5.30.7.  
5.30.2 Definitions of dosing regimen methods 
Fixed-dose regimen  
A fixed dose regimen involves starting treatment with a standard dose determined 
by the recent severity of alcohol dependence and/or typical level of daily alcohol 
consumption, followed by reducing the dose to zero usually over 7 to 10 days 
according to a standard protocol.  
Table 21 gives an example of a titrated fixed-dose regimen (SWLSTG, 2010). Note 
that due to the gradual rate of reduction, with higher starting doses, the duration of 
treatment is longer than with lower starting doses. A common error in management 
of alcohol withdrawal is too rapid reduction of chlordiazepoxide which can result in 
emergence or re-emergence of severe alcohol withdrawal symptoms. Another 
common error is too low a starting dose of chlordiazepoxide. This can be avoided by 
taking account of typical daily alcohol consumption and/or SADQ score in 
determining the starting dose. In addition the response to fixed dose withdrawal 
regimes should be monitored using a validated tool such as the Clinical Institute 
Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar; Sullivan et al., 1989) 
and the dose of medication adjusted upwards or downwards accordingly in the 
early stages of withdrawal. In severe alcohol dependence the doses of 
chlordiazepoxide required may exceed the BNF prescribing range. It is more 
clinically effective to increase the dose of chlordiazepoxide to adequately control 
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alcohol withdrawal symptoms than to add another type of medication (for example, 
haloperidol). 
 
The first dose of medication should be given before withdrawal symptoms begin to 
emerge. Delay in initiating chlordiazepoxide treatment can result in withdrawal 
symptoms either becoming difficult to control or the emergence of complications 
such as DTs or seizures. Therefore in people with severe alcohol dependence the first 
dose should be given before the breath alcohol concentration falls to zero, as 
withdrawal will emerge during the falling phase of breath alcohol concentration. 
The more severe the alcohol dependence, the earlier withdrawal symptoms emerge 
after last alcohol intake. Some people who are severely alcohol dependent can 
experience withdrawal with a blood alcohol concentration of 100 mg/100 ml or 
more. 
 
Table 21: Titrated fixed-dose chlordiazepoxide protocol for treatment of alcohol 
withdrawal (SWLSTG, 2010) 
Typical recent daily 
consumption 
15 to 25 units 30 to 49 units 50 to 60 units 
 
Severity of alcohol 
dependence 
MODERATE 
SADQ score 15 to 
25 
SEVERE 
SADQ score 30 to 40 
VERY SEVERE 
SADQ score 40 to 60 
 
Starting doses of 
chlordiazepoxide 
15 to 25 mg q.d.s. 30 to 40 mg q.d.s 50 mg q.d.s. 
 
Day 1 (starting dose) 15 q.d.s. 25 q.d.s. 30 q.d.s. 40 q.d.s.* 50 q.d.s.* 
Day 2 10 q.d.s.1 20 q.d.s. 25 q.d.s. 35 q.d.s. 45 q.d.s. 
Day 3 10 t.d.s.2 15 q.d.s. 20 q.d.s. 30 q.d.s. 40 q.d.s. 
Day 4 5 t.d.s. 10 q.d.s. 15 q.d.s. 25 q.d.s. 35 q.d.s. 
Day 5 5 b.d.3 10 t.d.s. 10 q.d.s. 20 q.d.s. 30 q.d.s. 
Day 6  5 nocte4 5 t.d.s. 10 t.d.s. 15 q.d.s. 25 q.d.s. 
Day 7  5 b.d. 5 t.d.s. 10 q.d.s. 20 q.d.s. 
Day 8  5 nocte 5 b.d. 10 t.d.s. 10 q.d.s. 
Day 9   5 nocte 5 t.d.s. 10 q.d.s. 
Day 10    5 b.d. 10 t.d.s. 
Day 11    5 nocte 5 t.d.s. 
Day 12     5 b.d. 
Day 13     5 nocte 
 
* Doses of chlordiazepoxide in excess of 30 mg q.d.s. should only be prescribed in cases where severe withdrawal symptoms are 
expected and the patient‘s response to the treatment should always be regularly and closely monitored. Doses in excess of 40 
mg q.d.s. should only be prescribed where there is clear evidence of very severe alcohol dependence. Such doses are rarely 
necessary in women and never in the elderly or where there is severe liver impairment. 
1 Four times a day; 2 Three times a day; 3 Twice daily; 4 At night 
Symptom-triggered regimen  
A symptom-triggered approach involves tailoring the drug regimen according to the 
severity of withdrawal and complications the patient is displaying. The patient is 
monitored on a regular basis and pharmacotherapy is administered according to the 
patient‘s level of withdrawal symptoms. Pharmacotherapy only continues as long as 
the patient is displaying withdrawal symptoms and the administered dose is 
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dependent on the assessed level of alcohol withdrawal. Withdrawal symptoms are 
usually assessed by clinical assessment including observation and interview and/or 
with the use of a validated withdrawal measurement tool such as the CIWA-Ar. See 
Table 22 for an example of a symptom-triggered dosing regimen (NICE, 2010b).  
Front-loading regimen 
A front-loading regimen involves providing the patient with an initially high dose of 
medication and then using either a fixed dose or symptom-triggered dosing regimen 
for subsequent assisted withdrawal. See Table 22 for an example of a front-loading 
dosing regimen (NICE, 2010b). 
 
Table 22: Examples of symptom-triggered and front-loaded dosing regimens for 
treating alcohol withdrawal with chlordiazepoxide 
Dosing 
Regimen 
 
Day 1 Day 2 Day 3 Day 4 
Symptom-
triggered 
20 to 30 mg as needed up to hourly, based on symptoms1 
Front-loaded2 100 mg every 2 to 4 
hours until sedation 
is achieved; then 50 
to 100 mg every 4 to 
6 hours as needed 
50 to 100 mg 
every 4 to 6 
hours as 
needed 
50 to 100 mg 
every 4 to 6 
hours as needed 
None 
1 These symptoms include pulse rate greater than 90 beats per minute, diastolic blood pressure greater than 90 mm Hg or signs 
of withdrawal. 
2 Frequently, very little additional medication is necessary after initial loading. 
 
5.30.3 Aim of review and review protocol 
As stated above, this section is concerned with the safety, efficacy, cost effectiveness 
and patient satisfaction different dosing regimens for assisted withdrawal and their 
appropriateness in various treatment settings. Furthermore, this section aims to 
evaluate medication for assisted withdrawal that is not appropriate or safe in a 
setting without 24-hour monitoring. The GDG identified that there would be 
insufficient RCT literature available to answer the clinical question, therefore it was 
decided by consensus to include all available studies in a systematic narrative 
review of the evidence. The review team assessed the literature identified from the 
search conducted by the NICE guideline on management of alcohol-related physical 
complications (NICE, 2010b); full details of the search strategies can be found in that 
guideline. Studies were considered for inclusion in the narrative synthesis if they 
met the inclusion criteria (see Chapter 3) and if the population being assessed in the 
study reflected the scope of this guideline (see Appendix 1). Furthermore, studies 
were considered for inclusion in the narrative synthesis using the clinical review 
protocol described in Table 23. The outcomes of interest were the efficacy 
(management of alcohol withdrawal syndrome, duration of treatment and amount of 
medication required), safety (development of complications), as well as patient and 
physician satisfaction of the dosing regimens.  
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Table 23: Clinical review protocol for the evaluation of different dosing 
regimens for assisted withdrawal from alcohol  
Electronic Databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO; see 
the NICE guideline (NICE, 2010b) on management of alcohol-
related physical complications for search strategies 
Date searched Systematic Reviews from 1993 to March 2010. All other searches 
from database inception to March 2010 
Study design RCTs; Systematic reviews;  
Patient population Adults (>18 years); Patients with alcohol withdrawal syndrome 
Critical Outcomes Main outcomes: severity of withdrawal; duration of treatment; 
total amount of medication; incidence of seizures and DTs or 
other complications 
Other outcomes: patient and physician satisfaction; completion 
rates 
 
In addition the review team conducted a search for studies which evaluated patient 
indications for inpatient assisted withdrawal. The review team also reviewed the 
safety of using different types of medication for assisted withdrawal in a setting that 
does not have 24-hour clinical monitoring, which is the more typical situation in 
clinical practice. Due to the nature of the review question, the GDG identified that 
there would be a lack of RCT literature (confirmed by the original RCT search for 
this guideline) and hence a search was conducted for systematic reviews. The review 
team assessed the available literature identified from the search conducted by the 
NICE guideline on management of alcohol-related physical complications (NICE, 
2010b). 
5.30.4 Studies considered  
Twelve studies evaluating the efficacy and safety of different regimens for assisted 
withdrawal were identified. Nine of these studies compared a symptom-triggered 
(ST) regimen of administering alcohol withdrawal medication (with or without 
front-loading) to a fixed-dosing (FD) regimen (Saitz et al., 1994; Weaver et al., 2006; 
Manikant et al., 1993; Sullivan et al., 1991; Daeppen et al., 2002; Day et al., 2004; 
Wasilewski et al., 1996; Lange-Asschenfeldt et al., 2003; Hardern & Page, 2005), and 
three studies compared usual non-protocol routine based hospital care to a ST 
regimen (DeCaroulis et al., 2007; Reoux & Miller, 2000; Jaeger et al., 2001). The 
characteristics and settings of the included studies can be found in Table 24. 
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Table 24: Characteristics of studies evaluating dosing regimen methods 
Study Study design Setting Comparison 
Method of assessing alcohol withdrawal 
syndrome 
Daeppen2002 Randomised placebo 
controlled trial 
Inpatient alcohol treatment 
unit 
1. ST (n=56) CIWA-Ar administered half an hour after 
placebo dose 2. FD (n=61) 
Day2004 RCT  Inpatient alcohol treatment 
unit 
1. ST front loading (n=11) CIWA-Ar administered every 90 minutes 
2. FD (n=12) 
DeCarolis2007 Retrospective audit Inpatient intensive care unit 
(Veterans Administration 
medical centre) 
1. ST (n=21) Minnesota Detoxification Scale (MIND) 
2. Routine hospital FD (n=16) 
Hardern2005 Retrospective audit General hospital inpatient 
ward  
1. ST (n-23) CIWA-Ar (when administered not reported) 
2. Regular dosing (n=28) 
Jaeger2001 Retrospective chart analyses General hospital inpatient 
ward  
1. ST (n=84) CIWA-Ar administered every 1 to 2 hours 
2. Usual Care: FD or as needed 
at discretion of medical staff 
(n=132) 
Lange-
Asschenfeldt2003 
Retrospective chart analysis General hospital inpatient 
ward  
1. ST (n=33) Modified German CIWA-Ar administered at: 
initial assessment; first day of admission and 
days 1 to 3 (every 2 hours); days 4 and 5 
(every 4 hours); day 6 (4 times daily); day 7 
(three times daily); days 8 and 9 (twice daily) 
2. FD (n=32) 
Manikant1993 RCT Psychiatric inpatient ward 1. ST front loading (n=20) CIWA-Ar administered every 90 minutes 
2. FD (n=21) 
Reoux2000 Retrospective chart analysis ST = Inpatient specialist 
alcohol unit (Veterans 
Administration medical 
centre); Routine care = 
General Medical Ward or 
Inpatient psychiatry unit 
1. ST (n=26) CIWA-Ar administered 1 hour after being 
medicated 2. Routine hospital alcohol 
withdrawal practice (varied and 
non-protocol based) (n=14) 
Saitz1994 Randomised placebo 
controlled trial 
Inpatient specialist alcohol 
unit (Veterans 
Administration medical 
centre) 
1. ST (n=51) CIWA-Ar administered hourly 
2. FD (n=50) 
Sullivan1991 Retrospective case series General hospital inpatient 
ward  
1. ST front loading (n=133) CIWA-Ar administered hourly and then as 
needed (clinical judgement) 
2. FD front loading (n=117) 
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Wasilewski1996 Prospective cohort Psychiatric inpatient ward 1. ST front loading (n=51) CIWA-Ar administered every 1 to 2 hours 
2 FD (n=45) 
Weaver2006 Quasi-randomised General hospital inpatient 
ward  
1. ST (n=91) CIWA-Ar at initial assessment and then 
every 4 hours 2. FD (n=92) 
 
Study  Outcomes  Results 
Daeppen2002 Total amount of medication required ST (95.4 [107.7] mg) significantly less than FD (231.4 [29.4] mg) (Mann-Whitney U = 5.84; p<0.001)  
Number using medication ST (39.3%) significantly fewer patients than FD (100%) (χ2 = 52.2; p<0.001) 
Duration of treatment Subgroup analyses (n=19) with history of complications: ST (22.7 [26.68] hours) significantly 
shorter than FD (62.1 [6.18] hours) (Mann-Whitney U = 2.87, p=0.004)  
Patient well-being No significant difference between groups in health concerns, anxiety, energy or depression  
Incidence of complications  No significant difference in number of seizures, hallucinations or DTs 
Day2004 Total amount of medication required ST (222 mg) significantly less than FD(700 mg) (p<0.001) 
Duration of treatment ST (8 hours) significantly shorter than FD (242 hours) (p<0.001) 
Severity of alcohol withdrawal No significant difference between groups 
Incidence of complications  No significant difference between groups 
Patient satisfaction No significant difference in self-perceived adverse symptoms or patient satisfaction with regimens 
DeCaroulis2007 Time to reach symptom control ST (7.7 [4.9] hours) significantly shorter time than routine FD (19.4 [9.7]) (p=0.002) 
Total amount of medication required ST (1044 [534] mg) significantly less than routine FS (1677 [937]) (p=0.014) 
Duration of treatment No significant difference between groups 
Hardern2005 Total amount of medication required No significant difference between groups  
Duration of treatment No significant difference between groups  
Time from first to last administration ST (48 hours) significantly shorter than regular dosing (110 hours) (p=0.086)  
Jaeger2001 Duration of treatment No significant difference between groups 
Total amount of medication required No significant difference between groups 
Incidence of complications  No significant difference in incidence of complications overall; ST had significantly less incidence 
of DTs (p=0.04) (ST = 20.5%; Usual care = 6.9%) 
Lange-
Asschenfeldt2003 
Total amount of medication required ST (median 4352 [4589]) significantly less than FD (median 9921 [6599]) (p=0.0004) 
Duration of treatment ST (median 4.2 [2.9]) significantly less than FD (median 7.5 [3.3]) (p=0.0003) 
Incidence of complications  No significant difference between groups  
Use of co-medication No significant difference between groups  
Manikant1993 Total amount of medication required No statistical data provided: ST = 67 mg; FD = 200 mg 
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Severity of alcohol withdrawal No significant difference between groups 
 
 
 
Study Outcomes Results 
Reoux2000 Total amount of medication required ST (82.7 [153.6] mg) significantly less than routine practice (367.5 [98.2] mg) (p=0.004) 
Number of doses required ST (1.7 [3.1]) significantly less than routine practice (10.4 [7.9]) (p=0.001) 
Duration of medication use ST (10.7[20.7]) significantly less than routine practice (64.3[60.4]) (p=0.006) 
Adverse effects None present in both groups 
Saitz1994 Duration of treatment ST (median = 9 hours) significantly shorter than FD (median 68 hours) (Wilcoxon z =5.68; p<0.001) 
Total amount of medication required ST (100 mg) significantly less than FD (425 mg) (Wilcoxon z = 5.30, p<0.001) 
Severity of alcohol withdrawal No significant difference between groups (p=0.73) 
Incidence of complications  No significant difference between groups in incidence of DTs (p=0.36); hallucinations (p=0.62); 
seizures (none); lethargy (p=0.42); leaving the hospital against medical advice (p=0.68); readmission 
within 30 days (p=0.72) 
Participation in further rehabilitation 
treatment after assisted withdrawal 
ST (69%) greater than FD (50%) (non-significant) (p=0.06) 
Sullivan1991 Total amount of medication required ST (50 mg) significantly less than FD (75 mg) (p=0.04) 
Duration of treatment No significant difference between groups 
Number of patients requiring <20 mg 
of medication 
ST (33%) significantly more than FD (12.8%) (p=0.05) 
Rate of discharge against medical 
advice 
No significant difference between groups 
Rates of complication No significant difference between groups 
Wasilewski1996 Total amount of medication required SD (87 [47.2] mg) significantly less than FD (1784 [1800] mg) (p<0.00001)  
Duration of delirium ST (6.9 [4.8]) significantly less than FD (33.8 [25.7]) (Mann-Whitney U = 265.0, p<0.001) 
Abnormalities and somatic disorders  No significant difference between groups 
Weaver2006 Total amount of medication required ST (29 mg) significantly less than FD (100 mg) (p<0.0001) 
Severity of alcohol withdrawal No significant difference between groups in first 2 days  
Protocol errors ST (17.6%) significantly more than FD (7.6%) (χ2 = 4.14; p=0.042) 
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5.30.5 Narrative summary of findings 
Medication use and duration of treatment  
The results of most studies favoured the use of ST over FD regimens for outcomes 
assessing medication use and duration of treatment. The ST approach resulted in 
lower medication needed (Daeppen et al., 2002; Day et al., 2004; DeCarolis et al., 2007; 
Lange-Asschenfeldt et al., 2003; Reoux & Miller, 2000; Saitz et al., 1994; Sullivan et al., 
1991; Wasilewski et al., 1996; Weaver et al., 2006), lower frequency of administration 
(Daeppen et al., 2002; Reoux & Miller, 2000), and a shorter duration of treatment 
(Daeppen et al., 2002; Day et al., 2004; Lange-Asschenfeldt et al., 2003; Reoux & Miller, 
2000; Saitz et al., 1994; ). However, not all studies assessing these outcomes reported 
results favouring an ST approach. Sullivan and colleagues (1991) and Jaeger and 
colleagues (2001) found no difference between ST front loading and FD front loading 
regimens in terms of length of stay, and Jaeger and colleagues (2001) reported no 
significant difference between groups in total dose of medication required. Hardern 
and Page (2005) found no difference in dose administered and length of stay 
between ST and regular FD regimens. 
Severity of withdrawal symptoms 
DeCarolis and colleagues (2007) reported significantly less time to reach symptom 
control in the ST protocol group when compared with an FD regimen. Saitz and 
colleagues (1994) found no difference between an ST and FD regimen in time taken 
from admission to achieving a CIWA-Ar score of less than 8. Manikant and 
colleagues (1993) and Day and colleagues (2004) also found no significant difference 
in severity of withdrawal (using the CIWA-Ar) between an ST front loading and an 
FD regimen. 
Rates of complications or adverse effects 
Jaeger and colleagues (2001) reported significantly fewer episodes of DTs in the ST 
regimen group when compared with routine care but found no difference in overall 
complication rates. Other studies, however, reported no difference between ST and 
other FD regimens/routine care in rates of complications and adverse effects (for 
example, incidence of seizures, DTs and hallucinations) (Lange-Asschenfeldt et al., 
2003; Reoux and Miller, 2000; Saitz et al., 1994; SULLIVAN1991). In Wasilewski and 
colleagues‘ (1996) study, although patients in the ST front loading group had a 
significantly shorter duration of delirium than the FD group, no significant 
difference was observed in somatic disorders and abnormalities. Additionally, Day 
and colleagues (2004) did not find a significant difference between ST front loading 
and FD regimens in self-reported adverse symptoms. 
Other outcomes 
Other outcomes, including patient satisfaction, discharge against medication advice, 
use of co-medication and protocol errors, were reported in the reviewed studies. 
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Daeppen and colleagues (2002)21 and Sullivan and colleagues (1991) reported that 
there were no significant differences in patient comfort level between groups, and 
Day and colleagues (2004) reported no significant difference between ST front 
loading and FD regimens in terms of patient satisfaction. Two studies (Sullivan et al., 
1991; Saitz et al., 1994) reported no difference between ST and FD regimens in terms 
of rates of discharge against medical advice, and Lange-Asschenfeldt and colleagues 
(2003) found no difference in use of co-medication. Weaver and colleagues (2006) 
reported significantly more protocol errors in the ST group as opposed to the FD 
regimen group. 
Symptom-triggered assisted withdrawal in a general medical setting  
The studies reviewed above are probably not reflective of patients with complex 
problems who typically are admitted to a general hospital ward for medical 
treatment and present with withdrawal symptoms, that is, they are undergoing 
unplanned withdrawal (Hecksel et al., 2008). For example, although the Jaeger and 
colleagues‘ (2001) study found fewer episodes of DTs in the ST regimen group, 
patients were excluded from the study if they presented with medical comorbidities. 
In a general admissions unit, this in effect would exclude any post-surgical patients 
(Hecksel et al., 2008). Additionally, Reoux and Miller (2000) excluded any patients 
with complex medical histories, and Sullivan and colleagues (1991) did not take into 
account medical comorbidity. Therefore, Hecksel and colleagues (2008) suggest that 
in these studies, which have assessed an ST approach in a non-specialist general 
medical setting, patients that are most likely to develop complications such as DTs 
have not been investigated using the CIWA-Ar tool and therefore some uncertainty 
about its value with this population remains (Ferguson et al., 1996).  
 
The majority of the ST studies were conducted in addiction specialist inpatient 
settings or psychiatric hospitals, which have highly trained specialist staff familiar 
with the ST dosing regimen and methods (Daeppen et al., 2002; Day et al., 2004; 
Lange-Asschenfeldt et al., 2003; Manikant et al., 1993; Reoux & Miller, 2000; Saitz et 
al., 1994; Wasilewski et al., 1996). When dosing regimens were compared in non-
alcohol specialist settings, that is, in general hospital medical wards, extensive 
training was delivered to staff (Jaeger et al., 2001; Sullivan et al., 1991; Weaver et al., 
2006). For example, in the study by Sullivan and colleagues training was delivered 
over a 6-month period with the assistance of clinical nurse specialist in alcohol and 
substance misuse. In the Hardern (2005) study a retrospective audit compared the 
use of an ST regime (which had been introduced in the medical admissions unit) 
with regular fixed dosing. However, nurses who were trained to use the scoring tool 
were frequently unavailable when the patient was admitted. This is reflective of the 
competing demands on staff in a non-addiction treatment setting. This variability 
can also be observed in different non-specialist departments such as emergency 
departments (Kahan et al., 2005).  
 
                                                 
21 In Daeppen and colleagues‘ (2002) study, 60.3% of patients did not require pharmacological assisted 
withdrawal.  
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Nurses, whether in a specialist unit, psychiatric ward, general medical ward, or in 
the community, play a vital role in successful assisted withdrawal. Stockwell and 
colleagues (1990) found both patients and family members rated the support from 
community nurses as more important than medication for assisted withdrawal. 
Nursing staff in specialist addiction treatment centres are highly skilled and trained 
in all aspects of the medical management of alcohol withdrawal (Cooper, 1994) and 
have a working knowledge of current working practices and liaise with other staff 
and services (Choudry, 1990). This may well have an impact on the efficacy of the ST 
programmes in the studies above.  
 
Most physicians and nurses working in general medical wards are not specialists in 
the management of alcohol dependence. This is a concern, as the first point of 
contact for many alcohol dependent people is not a specialist addiction unit, but 
more usually a general physician in a non-specialist treatment setting such as a 
general medical ward (O‘Connor & Schottenfeld, 1998). Nurses in general medical 
practice may also lack specialised knowledge and education about addiction and 
assisted withdrawal (Coffey, 1996; Happell & Taylor, 1999; Ryan & Ottlinger, 1999). 
Even if training were provided, the obstacles to ensuring comprehensive training in 
a general medical setting also needs consideration (Schmacher et al., 2000).  
 
Bostwick and Lapid (2004) reported on the use of a symptom-triggered approach by 
psychiatrists at the Mayo Clinic in Rochester, Minnesota. A CIWA-Ar controlled 
protocol was not effective in managing alcohol withdrawal and patients deteriorated 
with use of an ST approach. In these specific cases reported by Bostwick and Lapid 
(2004), patients were assumed to be presenting with pure alcohol withdrawal 
syndrome. However, as no thorough clinical interview was utilised and the patients 
could not communicate effectively, medical staff did not ascertain whether the 
apparent presenting alcohol withdrawal symptoms were a result of other acute 
medical conditions such as sepsis, pain and shock. In another study of admissions in 
Mayo Clinics, Hecksel and colleagues (2008) found that half of patients receiving ST 
assisted withdrawal did not meet criteria using the CIWA-Ar. The investigators 
reported that 44% of patients given this protocol had not been drinking, and 23% 
were unable to communicate effectively. Surprisingly, of those who could 
communicate, 64% were not currently drinking but were still receiving ST 
medication. Again, and reflective of Bostwick and Lapid‘s (2004) study, medical 
histories were overlooked by physicians with a slight hint at alcohol use in the 
patient‘s history informing a decision to use this approach. Physicians also regularly 
assumed that autonomic hyperactivity and psychological distress were a result of 
alcohol withdrawal and hence a high CIWA-Ar score was attained, resulting in 
unnecessary benzodiazepine treatment. The investigators concluded that in patients 
with a history of alcohol dependence who are likely to develop adverse effects (DTs 
and seizures), a CIWA-Ar based ST approach is not appropriate and a more patient-
centred, personalised approach to medication management that goes beyond the 
CIWA-Ar is needed. Furthermore, in medical and surgical patients with a history of 
drinking, the ST approach to medication management has not been proven. 
Bostwick and Lapid (2004) and Hecksel and colleagues (2008) also conclude that an 
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ST approach is not appropriate for patients with complex medical and surgical 
comorbidities and hence may not be suitable for many patients presenting with 
alcohol withdrawal syndrome in a general medical setting.  
Medication not appropriate for use in a setting without 24-hour 
monitoring 
The use of certain medications for assisted withdrawal may not be appropriate in 
non-residential settings such as an outpatient clinic or the patient‘s home. Outpatient 
medication should be administered orally, have low potential for misuse or 
overdose, and have few side effects (O‘Connor et al., 1994).  
 
Contraindications for benzodiazepines and chlormethiazole in non-residential 
settings identified in the literature are set out below.  
Benzodiazepines 
Although long-acting benzodiazepines (such as chlordiazepoxide and diazepam) are 
preferred for patients with alcohol withdrawal syndrome, short-acting 
benzodiazepines (such as oxazepam) may be preferred in those for whom over-
sedation must be avoided, in people with liver disease who may not be able to 
metabolise long-acting agents efficiently, and in people with chronic obstructive 
pulmonary disease (COPD) (Blondell, 2005; Mayo-Smith et al., 2004). However, apart 
from patients with liver failure and those with COPD (who may well be managed as 
inpatients [see above]), short-acting benzodiazepines may not be suitable for 
outpatient assisted withdrawal due to the risk of breakthrough seizures (Mayo-
Smith, 1997). Furthermore, short-acting benzodiazepines (such as diazepam, 
chlordiazepoxide, alprazolam and lorazepam) may have a greater potential for 
misuse than longer-acting benzodiazepines such as oxazepam and halazepam 
(Griffiths & Wolf, 1990; McKinley, 2005; Soyka & Horak, 2004).  
Chlormethiazole 
Chlormethiazole is used in inpatient care as it has a short half-life (Majumdar, 1990). 
However, it requires close medical supervision and is therefore not recommended 
for non-residential settings such as outpatient clinics, patients‘ homes and prisons. 
Furthermore, it is addictive (although this is unlikely to develop in the short time 
period of an assisted withdrawal) and, more importantly, it can have fatal 
consequences in overdose resulting from coma and respiratory depression, 
especially when taken with alcohol (Gregg & Akhter, 1979; Horder, 1978; McInnes et 
al., 1980; McInnes, 1987; Stockwell et al., 1986).  
5.30.6 Assisted withdrawal in the prison setting  
Research evaluating assisted withdrawal in custodial settings such as police custody 
and the prison setting is scarce. Individuals taken into police custody are often under 
the influence of alcohol and some of these individuals may be alcohol dependent 
(Naik & Lawton, 1996). Deaths in UK police custody have been associated with 
alcohol intake (Yoshida et al., 1990) and 86% of fatalities in police custody are 
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associated with recent alcohol consumption and alcohol dependence (Giles & 
Sandrin, 1990). However, there is little guidance on the assessment and management 
of alcohol withdrawal in police custody or prison settings but also evidence to 
suggest that any such guidance is not always followed (Ghodse et al., 2006).  
 
People received into prison carry a heightened risk of suicide in the early days of 
their custody; one third of all prison suicides happen within the first week of 
imprisonment (Shaw et al., 2003). This phase coincides with alcohol withdrawal for 
around one in five prisoners, and the above study found an association between 
alcohol dependence and risk of suicide. Alcohol dependence is commonplace among 
people entering prison: the most recent national study of prisoners to be conducted 
found that 6% of all prisoners returned AUDIT scores of 32 and above (Singleton et 
al., 1998). (It should be noted that screening with AUDIT now forms part of the 
assessment of alcohol misuse in the prison service). The break in consumption that 
begins with arrest means that many alcohol dependent people arrive in prison in 
active states of withdrawal. This position is further complicated by the high levels of 
comorbid drug (including opiates, benzodiazepines and cocaine) misuse in the 
prison population (Ramsay, 2003). Due to the increased risk of suicide, severity of 
alcohol dependence and high risk of developing withdrawal effects, clinical 
management of alcohol withdrawal should begin on the day of reception into 
custody. The preferred agent of assisted withdrawal in the prison service is 
chlordiazepoxide (Department of Health, 2006c).  
 
Following alcohol withdrawal, there is some evidence that alcohol treatment 
programmes addressing offending behaviour can reduce rates of re-offending 
(Hollis, 2007; McCulloch & McMurran, 2008), but these studies both lack a well-
matched control group. A comparative study of a modified therapeutic community 
and a standard mental health intervention for the treatment of male prisoners with 
both mental health and substance misuse problems found evidence that the 
therapeutic community group re-offended at a significantly reduced rate (Sacks et 
al., 2004). Because alcohol is prohibited in prison, the majority of alcohol-dependent 
people will remain alcohol-free prior to their release. 
5.30.7 Assisted alcohol withdrawal dosing regimens for special 
populations 
Children and young people 
The use of the same drug regimens as for adults should be used, with doses 
appropriately adjusted for age and alcohol consumption. The evidence for favouring 
either symptom triggered or fixed dose regimens with children and young people 
remains uncertain as there are no trials which have investigated this issue. 
Nevertheless whichever regimen is chosen there is a clear requirement for very close 
monitoring of withdrawal symptoms. Given the uncertainty identified in this 
guideline about the capacity of staff to manage symptom triggered withdrawal, 
where symptoms are easily identifiable, it was suggested that a cautious approach to 
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the management of symptoms in young people is a fixed dose regimen but with very 
close symptom monitoring using a validated rating scale such as the CIWA-Ar.  
Older people 
As noted earlier older people can have higher levels of physical comorbidity, 
cognitive impairment, a lower capacity to metabolise alcohol and medications, and 
be in receipt of a larger number of medications than younger people. In addition 
older people can be more frail and prone to accidents and falls. Therefore it is 
prudent to have a lower threshold for admission for inpatient assisted alcohol 
withdrawal in older people who misuse alcohol. Further, doses of benzodiazepines 
may need to be reduced in older people compared with guidelines for younger 
adults. 
5.30.8 Clinical evidence summary  
There is some evidence to suggest that for assisted withdrawal, an ST regimen 
reduces medication use and duration of treatment and, therefore, is preferred in 
settings where 24-hour monitoring is available and the staff are highly trained in the 
use of this regimen. However, the evidence is not conclusive and some previous 
research has found no difference between ST and FD regimens in efficacy as well as 
for other outcomes such as rates of complication and patient experience. 
Furthermore, the studies that have evaluated this question were conducted in 
settings where 24-hour monitoring from trained staff is available and in the majority 
of cases these are specialist addiction units and where this was not the case, the staff 
involved in these studies were extensively trained (for periods up to 6 months) for 
the purpose of the study.  
 
Due to the skill required to treat alcohol withdrawal with an ST regimen, there is a 
higher possibility of protocol errors where staff are not highly trained. This suggests 
that in a non-specialist inpatient setting, the ST approach may not be feasible, as staff 
in general medical settings may not the training, expertise and resources to conduct 
an ST regimen. Therefore, in non-specialist general settings, a tapered FD regimen 
may be more appropriate for assisted withdrawal.  
 
 There are currently no RCTs that assess the efficacy of an ST regimen for assisted 
withdrawal in an outpatient setting. This may be because the use of an inpatient or 
specialist ST dosing regimen in a community setting is unpractical as 24-hour is not 
possible, or ad hoc monitoring is not appropriate. The gradual tapering FD regimen 
is therefore more appropriate for outpatient assisted withdrawal as it involves 
providing medication in specified doses for a predetermined number of days. The 
medication dose is gradually reduced until cessation as in inpatient FD regimes. The 
evidence also indicates that chlormethiazole is not appropriate for use in outpatient 
assisted withdrawal because there is a high risk of misuse and overdose.  
 
It is common for people who are alcohol dependent who are taken into police 
custody may develop alcohol withdrawal syndrome. However, previous research 
suggests that the alcohol withdrawal syndrome is not always detected in this setting. 
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Staff should be aware of the importance of identifying potential or possible alcohol 
withdrawal and be trained in the use of tools to detect alcohol dependence (for 
example, the AUDIT). Furthermore, due to the risk of suicide and medical 
complications that could develop as a consequence of alcohol withdrawal, the 
management of the alcohol withdrawal syndrome should be instituted immediately 
upon entry into custody.  
 
There is no direct evidence that suggests added benefit of a symptom-triggered 
regimen over a fixed-dosing regimen for children and young people. However, as 
the GDG believe that all assisted withdrawal for children and young people should 
take place in an inpatient setting which should have 24-hour monitoring and care, 
and a tapered fixed-dose approach should be used.  
 
There should be a lower threshold for admission for inpatient assisted withdrawal in 
older people. Further, doses of benzodiazepine medication for assisted withdrawal 
may need to be reduced compared with guidelines for younger adults. 
5.31 FROM EVIDENCE TO RECOMMENDATIONS: 
ASSISTED WITHDRAWAL 
This section draws on the preceding reviews of assisted withdrawal settings and 
drug regimens; the summaries of these reviews can be found in Sections 5.29 and 
5.30.  
 
The evidence indicated that a community setting for assisted withdrawal is as 
clinically effective and safe for the majority of patients as an inpatient or residential 
setting and it is also likely to be more cost effective. The GDG agreed that both 
efficacy and safety outcomes were of critical importance for this review. The GDG 
therefore decided that community-based assisted withdrawal should be the first 
choice for most patients. However, the GDG was aware that some of the more 
severely alcohol dependent patients, often with complex comorbidities, were often 
excluded from the studies reviewed. Consequently, the severity and complexity of 
the population in these studies was not representative of those who would typically 
require inpatient withdrawal management. The GDG considered this, as well as 
other evidence presented that might inform this issue, and identified a number of 
factors that would indicate that a residential or inpatient setting may be preferred to 
a community setting. They also considered which of the factors would suggest that 
assisted withdrawal should be managed in an inpatient setting with access to 24-
hour specialist doctors and nurses with expertise in managing alcohol withdrawal in 
the context of significant comorbidity. The factors the GDG considered important are 
as follows:  
 a history of epilepsy or withdrawal-related seizures or DTs during previous 
assisted withdrawal 
 significant psychiatric or physical comorbidity (for example, chronic severe 
depression, psychosis, malnutrition, congestive cardiac failure, unstable 
angina, chronic liver disease) 
 209 
 
  significant learning disability 
 significant cognitive impairment  
 a history of poor adherence and previous failed attempts 
 homelessness 
 pregnancy  
 children and young people 
 older people.  
 
The review of drug regimens for assisted withdrawal drew on the NICE guideline 
on management of alcohol-related physical complications (NICE, 2010b) for both the 
initial review of the medication regimens and in order to ensure that there was a 
comprehensive and coherent approach to assisted withdrawal across both 
guidelines. The GDG was, therefore, concerned to build on the other guideline and 
develop recommendations that were feasible for use in a range of settings, both 
specialist and non-specialist in inpatient, residential and community (including 
primary care) services. After carefully considering the evidence, the GDG came to 
the conclusion that symptom triggered assisted withdrawal was only practical in 
those inpatient settings that contained 24-hour medical monitoring and high levels 
of specially trained staff. The GDG therefore took the view that the preferred method 
for assisted withdrawal was a fixed dose regimen for community and residential 
settings. In addition the GDG also considered how some of the complex 
comorbidities often encountered in specialist alcohol services may be best managed. 
In particular the GDG were concerned to provide advice on the management of 
comorbid alcohol, and benzodiazepine misuse. This was of concern as the GDG 
recognised the need to go above recommended BNF dosages for people who were 
dually dependent in order to reduce the likelihood of seizures. In the absence of any 
evidence from the studies reviewed, the GDG reached agreement on this issue by 
consensus.  
 
Given the uncertainty about the severity of withdrawal symptoms and the potential 
negative consequences for children and young people of withdrawal, the GDG felt 
that there should be a lower threshold in the admission criteria for children and 
young people who misuse alcohol than for adults and specialist advice should be 
made available to the healthcare professional. The GDG also felt that it was prudent 
that all assisted withdrawal for children aged 10 to 15 years take place in an acute 
inpatient or residential setting with significant medical and nursing staff availability 
on a 24-hour basis. For young people aged 16 to 18 years, if withdrawal management 
is conducted in a community setting (that is, non-residential setting where the young 
person does not sleep in the unit), particular care needs to be taken in monitoring the 
young person. 
 
The GDG did not identify any evidence evaluating different dosing regimens for 
children and young people. The GDG suggest an inpatient setting with 24-hour 
monitoring for 10- to 15-year-olds for assisted withdrawal. There is a lack of clinical 
evidence suggesting the appropriate dose of medication for assisted withdrawal for 
children and young people as well as older people. However the GDG felt that the 
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dose should be lower than that provided for an adult taking into consideration the 
age, size, and gender of the individual. 
 
Dose regimes for older people undergoing assisted withdrawal may need to be 
reduced compared with guidelines for younger adults. 
5.31.1 Recommendations  
Assessment and interventions for assisted alcohol withdrawal 
[Refer to 5.31.1.19 – 5.31.1.22 for assessment for assisted withdrawal in children and 
young people] 
5.31.1.1 For service users who typically drink over 15 units of alcohol per day 
and/or who score 20 or more on the AUDIT, consider offering: 
 an assessment for and delivery of a community-based assisted 
withdrawal, or  
 assessment and management in specialist alcohol services if there are 
safety concerns (see 5.29) about a community-based assisted 
withdrawal. [KPI] 
5.31.1.2 Service users who need assisted withdrawal should usually be offered a 
community-based programme, which should vary in intensity according to 
the severity of the dependence, available social support and the presence of 
comorbidities. 
 For people with mild to moderate dependence, offer an outpatient-
based withdrawal programme in which contact between staff and the 
service user averages 2–4 meetings per week over the first week. 
 For people with mild to moderate dependence and complex needs22, or 
severe dependence, offer an intensive community programme 
following assisted withdrawal in which the service user may attend a 
day programme lasting between 4 and 7 days per week over a 3-week 
period.  
 
5.31.1.3 Outpatient-based community assisted withdrawal programmes should 
consist of a drug regimen  (see 5.31.1.7 – 5.31.1.18) and psychosocial support 
including motivational interviewing (see 6.23.1.1).  
 
                                                 
22 For example, psychiatric comormbidity, poor social support or homelessness. 
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5.31.1.4 Intensive community programmes following assisted withdrawal  should 
consist of a drug regimen (see 7.15.1.1 – 7.15.1.3) supported by psychological 
interventions including individual treatments (see 7.15.1.1 – 7.15.1.3), group 
treatments, psychoeducational interventions, help to attend self-help groups, 
family and carer support and involvement, and case management (see 
5.11.1.2). 
5.31.1.5 Consider inpatient or residential assisted withdrawal if a service user meets 
one or more of the following criteria. They:  
 drink over 30 units of alcohol per day 
 have a score of more than 30 on the SADQ 
 have a history of epilepsy, or experience of withdrawal-related seizures 
or delirium tremens during previous assisted withdrawal programmes 
 need concurrent withdrawal from alcohol and benzodiazepines  
 regularly drink between 15 and 20 units of alcohol per day and have: 
- significant psychiatric or physical comorbidities (for example, 
chronic severe depression, psychosis, malnutrition, congestive 
cardiac failure, unstable angina, chronic liver disease) or 
- a significant learning disability or cognitive impairment. 
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5.31.1.6 Consider a lower threshold for inpatient or residential assisted withdrawal 
in vulnerable groups, for example, homeless and older people. 
Drug regimens for assisted withdrawal 
5.31.1.7 When conducting community-based assisted withdrawal programmes, use 
fixed-dose medication regimens23.  
5.31.1.8 Fixed-dose or symptom-triggered medication regimens24 can be used in 
assisted withdrawal programmes in inpatient or residential settings. If a 
symptom-triggered regimen is used, all staff should be competent in 
monitoring symptoms effectively and the unit should have sufficient 
resources to allow them to do so frequently and safely. 
5.31.1.9 For service users having assisted withdrawal, particularly those who are 
more severely alcohol dependent or those undergoing a symptom-triggered 
regimen, consider using a formal measure of withdrawal symptoms such as 
the CIWA-Ar.  
5.31.1.10 Prescribe and administer medication for assisted withdrawal within a 
standard clinical protocol. The preferred medication for assisted withdrawal 
is a benzodiazepine (chlordiazepoxide or diazepam). 
5.31.1.11 In a fixed-dose regimen, titrate the initial dose of medication to the 
severity of alcohol dependence and/or regular daily level of alcohol 
consumption. In severe alcohol dependence higher doses will be required to 
adequately control withdrawal and should be prescribed according to the 
SPC. Make sure there is adequate supervision if high doses are 
administered. Gradually reduce the dose of the benzodiazepine over 7-10 
days to avoid alcohol withdrawal recurring (see Table 21). 
5.31.1.12 Be aware that benzodiazepine doses may need to be reduced for 
children and young people25, older people, and people with liver 
impairment (see 5.31.1.13).  
5.31.1.13 If benzodiazepines are used for people with liver impairment, consider 
one requiring limited liver metabolism (for example, lorazepam); start with 
a reduced dose and monitor liver function carefully. Avoid using 
benzodiazepines for people with severe liver impairment. 
                                                 
23 A fixed dose regimen involves starting treatment with a standard dose, not defined by the level of 
alcohol withdrawal, and reducing the dose to zero over 7 - 10 days according to a standard protocol.  
24
 A symptom-triggered approach involves tailoring the drug regimen according to the severity of 
withdrawal and any complications. The service user is monitored on a regular basis and 
pharmacotherapy only continues as long as the service user is showing withdrawal symptoms.  
25 At the time of publication (February 2011), benzodiazepines did not have UK marketing 
authorisation for use in children and young people under 18. Informed consent should be obtained 
and documented. 
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5.31.1.14 When managing withdrawal from co-existing benzodiazepine and 
alcohol dependence increase the dose of benzodiazepine medication used 
for withdrawal. Calculate the initial daily dose based on the requirements 
for alcohol withdrawal plus the equivalent regularly used daily dose of 
benzodiazepine26. This is best managed with one benzodiazepine 
(chlordiazepoxide or diazepam) rather than multiple benzodiazepines. 
Inpatient withdrawal regimens should last for 2–3 weeks or longer, 
depending on the severity of co-existing benzodiazepine dependence. When 
withdrawal is managed in the community, and/or where there is a high 
level of benzodiazepine dependence, the regimen should last for longer than 
3 weeks, tailored to the service user‘s symptoms and discomfort. 
5.31.1.15 When managing alcohol withdrawal in the community, avoid giving 
people who misuse alcohol large quantities of medication to take home to 
prevent overdose or diversion27. Prescribe for installment dispensing, with 
no more than 2 days‘ medication supplied at any time.  
5.31.1.16 In a community-based assisted withdrawal programme, monitor the 
service user every other day during assisted withdrawal. A family member 
or carer should preferably oversee the administration of medication. Adjust 
the dose if severe withdrawal symptoms or over-sedation occur.  
5.31.1.17 Do not offer clomethiazole for community-based assisted withdrawal 
because of the risk of overdose and misuse. 
5.31.1.18 For managing unplanned acute alcohol withdrawal and complications 
including delirium tremens and withdrawal-related seizures, refer to NICE 
clinical guideline 100. 
                                                 
26 At the time of publication (February 2011), benzodiazepines did not have UK marketing 
authorisation for this indication or for use in children and young people under 18. Informed consent 
should be obtained and documented. This should be done in line with normal standards of care for 
patients who may lack capacity (see www.publicguardian.gov.uk or www.wales.nhs.uk/consent) or 
in line with normal standards in emergency care. 
27 When the drug is being taken by someone other than for whom it was prescribed.  
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Special considerations for children and young people who misuse alcohol  
– assessment and referral 
5.31.1.19 If alcohol misuse is identified as a potential problem, with potential 
physical, psychological, educational or social consequences, in children and 
young people aged 10–17 years, conduct an initial brief assessment to assess: 
 the duration and severity of the alcohol misuse (the standard adult 
threshold on the AUDIT for referral and intervention should be 
lowered for young people aged 10–16 years because of the more 
harmful effects of a given level of alcohol consumption in this 
population) 
 any associated health and social problems 
 the potential need for assisted withdrawal. 
5.31.1.20 Refer all children and young people aged 10–15 years to a specialist 
child and adolescent mental health service (CAMHS) for a comprehensive 
assessment of their needs, if their alcohol misuse is associated with physical, 
psychological, educational and social problems and/or comorbid drug 
misuse. 
5.31.1.21 When considering referral to CAMHS for young people aged 16-17 
years who misuse alcohol, use the same referral criteria as for adults (see 
section 1.2.2). 
5.31.1.22 A comprehensive assessment for children and young people 
(supported if possible by additional information from a parent or carer) 
should assess multiple areas of need, be structured around a clinical 
interview using a validated clinical tool (such as the Adolescent Diagnostic 
Interview [ADI] or the Teen Addiction Severity Index [T-ASI]), and cover 
the following areas: 
 consumption, dependence features and patterns of drinking  
 comorbid substance misuse (consumption and dependence features) 
and associated problems 
 mental and physical health problems  
 peer relationships and social and family functioning 
 developmental and cognitive needs, and educational attainment and 
attendance 
 history of abuse and trauma 
 risk to self and others 
 readiness to change and belief in the ability to change  
 obtaining consent to treatment 
 developing a care plan and risk management plan. 
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5.32 RESIDENTIAL AND COMMUNITY SETTINGS FOR 
THE DELIVERY OF INTERVENTIONS FOR 
ALCOHOL MISUSE 
5.32.1  Introduction  
This section assesses the settings that are most clinically and cost effective in the 
delivery of interventions to reduce alcohol consumption, promote abstinence and 
reduce relapse. In the UK most such interventions are provided in community 
settings usually by a specialist alcohol team. However, some services are provided in 
residential settings usually following a period of residential assisted withdrawal. 
There is also considerable debate in the UK regarding the value of residential 
treatment and specifically for which alcohol-related problems a residential unit is 
most appropriate.  
 
As with the previous reviews, caution is needed in the assessment and interpretation 
of the evidence as it is possible that some of the most severely dependent patients 
may have been excluded from the studies (for example, Pettinati et al., 1993). In 
addition, as others have identified, it is possible to confuse the setting with treatment 
intensity and duration (for example, Finney et al., 1996; Mosher et al., 1975). Another 
problem arises when separating the benefits of a period of inpatient or residential 
assisted withdrawal from the effects of continued residential psychosocial treatment 
(see Walsh et al., 1991). Also, as is the case when evaluating many complex 
interventions, it is difficult to identify which elements of the intervention are 
mutative; for example McKay and colleagues (1995) and Rychtarik and colleagues 
(2000a) evaluated the same treatment in both residential and non-residential settings 
and reported that the milieu (that is, living in the residential setting for 24 hours a 
day) added little to the likelihood of a positive outcome of treatment. Relatively few 
studies in the area report differential outcomes based on patient characteristics, but 
the picture that does emerge is reasonably consistent. The most commonly studied 
predictor variables in the treatment of alcohol dependence have been measures of 
alcohol problem severity and social stability. More severe and less socially stable 
patients who misuse alcohol seem to fare better in inpatient (or more intensive 
treatment), whereas among married patients with stable accommodation, fewer 
years of problem drinking, and less history of treatment, outpatient (and less 
intensive) treatment yields more favourable outcomes than inpatient treatment 
(Kissin et al., 1970; McLellan et al., 1983; Orford et al., 1976; Smart et al., 1977; Stinson, 
1970; Willems et al., 1973). Finally, some studies provide limited descriptions of the 
interventions (in particular the comparator interventions) and this, along with the 
different healthcare systems in which the studies took place, makes interpretation of 
the evidence challenging.  
5.32.2 Clinical review protocol  
Information about the databases searched and the inclusion/exclusion criteria used 
for this section of the guideline can be found in Table 25 (further information about 
the search for health economic evidence can be found in Chapter 3). 
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Table 25: Databases searched and inclusion/exclusion criteria for clinical evidence 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCTs; Systematic Reviews. Systematic reviews from 1993 to 
March 2010. All other searches from database inception to 
March 2010 
Patient population Diagnosed with having an alcohol use disorder (alcohol 
dependence or harmful alcohol use)  
Interventions Residential treatment settings versus community treatment 
settings; 
duration of residential treatment (long versus short) 
Outcomes Relapse; lapse (non-abstinence); number of participants 
consuming alcohol; PDA; drinking frequency measures (for 
example, mean number of drinking days, number of intoxicated 
days, number drinking daily); quantity of alcohol measures (for 
example, DDD) 
 
5.32.3 Studies considered28 
The review team conducted a new systematic search for RCTs that assessed the 
beneficial and detrimental effects of different settings for the delivery of alcohol 
treatment interventions after an assisted withdrawal programme and related health 
economic evidence (see Section 5.29.7).  
 
A variety of different treatment settings are described in the research literature. 
Services were designated as inpatient units; residential units; day hospitals (also 
known as partial hospitalisation or day centres), or outpatient based interventions of 
differing intensity and duration (involving attendance at an outpatient clinic, home 
visits, a combination of both, or containing some limited elements of a day 
programme). These are in line with the definitions set out in section 1 of this 
chapter). 
 
It is also important to note that most of the studies included in this review are North 
American, with few studies conducted in the UK or Europe. They cover a diverse 
range of populations, including some very specific samples (that is, employment 
schemes, Veterans Administration populations), which may limit generalisability to 
the UK treatment population. 
 
Fourteen trials met the eligibility criteria set by the GDG, providing data on 2679 
participants. All of the studies were published in peer-reviewed journals between 
1972 and 2005. Summary study characteristics of the included studies are presented 
in Table 26. (Further information about both included and excluded studies can be 
found in Appendix 16c).  
                                                 
28 Here and elsewhere in the guideline, each study considered for review is referred to by a study ID 
in capital letters (primary author and date of study publication, except where a study is in press or 
only submitted for publication, then a date is not used). 
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A meta-analyses was conducted for an adult population only as there was not 
enough evidence to perform a meta-analysis for children and young people.  
Residential units versus outpatient treatment  
Of the 14 included trials, three involved a comparison of residential units versus 
outpatient treatment. RYCHTARIK2000A compared a residential unit versus an 
outpatient setting; CHAPMAN1988 compared a 6-week inpatient programme with a 
6 week outpatient programme. WALSH1991 compared compulsory inpatient 
treatment versus compulsory attendance at AA, this study was atypical in that the 
sample consisted of workers at an industrial plant in the US who were part of an 
employee assistance programme, whose jobs were at risk should they fail to attend 
treatment. A 3-week period of residential treatment was followed by a year of job 
probation, during which attendance at AA meetings at least three times per week, 
sobriety at work, and weekly checks with the programme staff were compulsory if 
the person wanted to keep their job. The outpatient treatment group were referred 
and offered an escort to a local AA meeting, which they were advised to continue 
attending at least three times a week for a year. They were treated in the same way 
as participants in the residential group for the following year. 
Residential units versus day hospital  
Of the 14 included trials, seven (BELL1994; LONGABAUGH1983; MCKAY1995; 
MCLACHLAN1982; RYCHTARIK2000A; WEITHMANN2005; WITBRODT2007) involved a 
comparison of residential rehabilitation units versus day hospital. All seven trials had a 28-
day length of stay in treatment. Both MCKAY1995 and WITBRODT2007 looked at day 
hospital versus residential rehabilitation treatment, with the populations being split into a 
self-selected arm and a randomised arm.  
Day hospital versus outpatient treatment 
Two trials out of the 14 involved a comparison of day hospital versus outpatient treatment 
(MORGENSTERN2003; RYCHTARIK2000A).  
Residential unit versus residential unit  
Of the 14 included trials, one (KESO1990) involved a comparison of two different 
types of residential treatment, assessing the efficacy of two different therapeutic 
approaches. The Kalliola programme was based on the Hazelden or Minnesota 
model, with a focus on AA 12-step principles with abstinence as the designated 
treatment goal, whereas the Jarvenpaa programme was a more traditional approach 
to residential rehabilitation without the focus on AA 12-step principles.  
Short versus long duration inpatient treatment 
Three of the 14 trials involved a comparison of different lengths of admission to 
inpatient treatment. MOSHER1975 compared a 9-day versus a 30-day inpatient stay. 
STEIN1975 compared a 9-day residential inpatient stay with a 9-day stay with an 
additional 25 days of residential rehabilitative care. PITTMAN1972 compared a 
group receiving 7 to 10 days of inpatient care only with 3 to 6 weeks of inpatient care 
with an additional option of further outpatient aftercare.  
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5.32.4 Clinical evidence for residential and community settings for 
the delivery of alcohol treatment interventions  
Evidence from the important outcomes and overall quality of evidence are presented 
in Table 27, 
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Table 28, Table 29, Table 30 and Table 31. The associated forest plots are in Appendix 
17b. 
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Table 26: Study characteristics table for residential settings 
 Residential unit versus 
outpatient treatment 
Residential unit versus 
day hospital 
Day hospital versus 
outpatient treatment 
Residential unit versus 
residential unit 
Short duration versus 
longer duration 
inpatient 
Total no. of 
trials (total no. 
of participants) 
 3 RCTs (N = 334) 7 RCTs (N = 1453) 1 RCT (N = 382) 1 RCT (N = 141) 3 RCTs (N = 493) 
Study ID (1) CHAPMAN1988 
(2) RYCHTARIK2000A 
(3) WALSH1991 
(1) BELL1994 
(2) 
LONGABAUGH1983 
(3) MCKAY1995 
(4) MCLACHLAN1982 
(5) RYCHTARIK2000A 
(6) WEITHMANN2005 
(7) WITBRODT2007 
(1) 
MORGENSTERN2003 
(2) RYCHTARIK2000A 
(1) KESO1998 (1) MOSHER1975 
(2) PITTMAN1975 
(3) STEIN1975 
 
Baseline 
severity: mean 
(SD)(only for 
studies that had 
baseline 
severity 
information 
available ) 
(1) Average daily 
absolute alcohol (g):  
Inpatient: 256.3 
Outpatient: 202.2 
Confrontational 
interview: 226.2 
(2) DDD (mean [SD]) 
Inpatient (n=62) 
10.95 (8.14) 
Intensive outpatient 
(n=69) 
10.24 (6.62) 
Standard outpatient 
(n=61) 
10.66 (6.77) 
 
(3) Averaged 6.3 drinks 
a day and 19.8 drinking 
days in the month 
preceding interview; 
(2) Mean number of 
days of abstinence in 
preceding 6 months 
Inpatient: 7.51 
Day:8.28 
 
(3) No. of days of 
alcohol intoxication (in 
previous 30 days): 
(mean [SD]) 
Random assignment 
Day hospital: 16.79 
(7.29) 
Inpatient: 12.96 (7.64) 
 
(4) Consumed alcohol 
on an average of 295 of 
the previous 365 days 
Consumed an average 
of 18 1.5-fluid-ounce 
(1) Baseline PDA (mean 
[SD]):  
Inpatient: 48.1 
Intensive outpatient: 
54.4 
Outpatient: 61.8 
 
(2) (refer to first 
column) 
 
(1) Consumption of 
alcohol 2-month 
average in grams per 
day (mean [SD]) 
Kalliola AA-type : 
(Hazelden/ Minnesota 
model): 
112.2(80.3)  
Jarvenpaa traditional 
type treatment: 
98.3(72.8) 
 
 
(2) 92.3% intoxicated 
upon admission to 
treatment, all 
alcoholism diagnosis  
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 21% had been drink 
daily and 45% weekly 
in previous month 
drinks (17 ml) of 40% 
ethanol per day 
 
(5) (refer to first 
column) 
 
(6) Drinks per drinking 
day (30 days prior to 
admission) (mean [SD]) 
Inpatient: 12.3 (6.9) 
Day hospital: 26.6(32.2) 
PDA (mean [ SD]) 
Inpatient: 26.6 (32.) 
Day hospital: 28.6 (28.9)  
Treatment 
length  
(1) 6 weeks 
(2) 28 days 
(3) 3 weeks 
 
 
 
(1), (3)–(6) Range: 28 to 
31 days  
(2) Range: 2 to 3 weeks  
(7) Day hospital: Range 
2 to 3 weeks 
Residential – up to 60 
days 
(1) Ranged from 22.77 
days – 12 weeks 
(2) (see left) 
(1) 28 days (1) 9 day versus 21 day  
(2) 7 to 20 days versus 3 
to 6 weeks 
(3) 9 day versus 21 day 
Length of 
follow-up (if 
available) 
(1) 6, 18 months 
(2) 6, 9, 12, 15, 18 
months 
(3) 1, 3, 6, 12, 18, 24 
months post-treatment  
 
(2) 6, 12, 18, 24 months 
(3) 3, 6, 12 months  
(4) 12 months  
(5) 6, 9, 12, 15, 18 
months 
(6) 3, 6, 9, 12 months  
(7) 6, 12 months 
(1) 3, 6, 9 months (1) 12 months (1) 3, 6 months  
(2) 3, 12 months 
(3) 2, 4, 7, 10, 13 months  
 
 
Abstinent or 
non-abstinent 
prior to trial 
 (3) Non-abstinent 
(6) Combined with 
initial inpatient assisted 
withdrawal  
   
Country (1) New Zealand 
(2), (3) US 
 
(1)–(3), (5), (7) US 
(4) Canada  
(6) Germany 
(1) US (1) Finland (1), (2) (3) US 
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Table 27: Residential unit versus outpatient treatment 
Outcome or subgroup k Total N Statistics Effect (95% CI) Quality of the 
evidence (GRADE) 
1. Abstinence      
 1.1 PDA at 3-month follow-up 1 119 SMD (IV, random, 95% CI) 0.22 (-0.14, 0.58) 
 
2. DDD at 3-month follow-up 1 119 SMD (IV, random, 95% CI) 0.02 (-0.34, 0.38) 
 
3. Lapse (number of participants non-abstinent)       
 3.1. Lapse at 6-month follow-up 1 46 RR (M-H, random, 95% CI) 0.92 (0.64,1.32) 
 
 3.2. Lapse at 18-month follow-up 1 48 RR (M-H, random, 95% CI) 1.30 [0.87, 1.95] 
 
 3.3. Lapse (number of participants non-
abstinent) at 2-year follow-up 
1 156 RR (M-H, random, 95% CI) 0.76 (0.61, 0.94) 
 
4. Number drinking <60 g absolute alcohol on a 
drinking day at 6-month follow-up 
1 46 RR (M-H, random, 95% CI) 0.66 (0.26,1.66) 
 
5. Number drinking <60 g absolute alcohol on a 
drinking day at 18-month follow-up 
1 48 RR (M-H, random, 95% CI) 0.66 [0.29, 1.48] 
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Table 28: Residential unit versus day hospital 
Outcome or subgroup k Total N Statistics Effect (95% CI) Quality of the 
evidence (GRADE) 
1. Abstinence       
1.1. PDA at 3-month follow-up 1 121 SMD (IV random, 95% CI) 0.23 (-0.13,0.59) 
 
1.2. Alcohol consumption outcomes 2 169 SMD (IV random, 95% CI) Subtotals only  
1.3. Drinks per drinking day at 3-month follow-
up 
1 121 SMD (IV random, 95% CI) 0.01 (-0.34,0.37) 
 
1.4. Mean number of drinking days at 3-month 
follow-up 
1 48 SMD (IV random, 95% CI) 0.33 [-0.24, 0.90] 
 
1.5. Mean number of drinking days at 6-month 
follow-up 
1 48 SMD (IV random, 95% CI) 0.76 (0.17,1.35) 
 
1.6. Mean number of drinking days at 12-month 
follow-up 
1 48 SMD (IV random, 95% CI) 0.51 (-0.06,1.09) 
 
2. Relapse 2 209 RR (M-H, random, 95% CI)  Total events  
2.1. Post-treatment 1 109 RR (M-H, random, 95% CI) 0.51 (0.16,1.59) 
 
2.2. At 12-month follow-up 1 100 RR (M-H, random, 95% CI) 1.20 (0.69,3.68) 
 
3. Lapse (non-abstinence) 5 722 RR (M-H, random, 95% CI) Subtotals only  
3.1. Number of participants non-abstinent at 6-
month follow-up 
2 467 RR (M-H, random, 95% CI) 1.05 (0.82,1.34) 
 
3.2. Number of participants non-abstinent at 12-
month follow-up 
2 393 RR (M-H, random, 95% CI) 1.05 (0.88,1.25) 
 
3.3. Number of participants non-abstinent 
throughout 12-month follow-up 
1 109 RR (M-H, random, 95% CI) 1.04 (0.86,1.26) 
 
4. Drinking frequency 3 260 RR (M-H, random, 95% CI) Subtotals only 
 
4.2. Number of participants drinking daily at 6-
month follow-up 
1 174 RR (M-H, random, 95% CI) 0.24 (0.03,1.85) 
 
5. Number not retained in treatment 1 646 RR (M-H, random, 95% CI) 0.67 (0.52,0.85) 
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Table 29: Day hospital versus outpatient treatment 
Outcome or subgroup k Total N Statistics Effect (95% CI) Quality of the evidence 
(GRADE) 
1. Abstinence 2 376 SMD (IV, random, 95% CI)  Subtotals only  
1.1. PDA 2 376 SMD (IV, random, 95% CI) -0.05 [-0.26,0.15] 
 
2. DDD at 3-month follow-
up 
1 124 SMD (IV, random, 95% CI) 0.01 [-0.34,0.36] 
 
 
Table 30: Residential unit versus residential unit (two different models of treatment) 
Outcome or subgroup k Total N Statistics Effect (95% CI) Quality of the evidence 
(GRADE) 
1. Relapse 1 109 RR (M-H, random, 95% CI) Subtotals only  
 1.1. Number relapsed at 4- 
to 8-month follow-up 
1 109 RR (M-H, random, 95% CI) 0.79 (0.58,1.08) 
 
 1.2. Number relapsed at 8 
to 12-month follow-up  
1 109 RR (M-H, random, 95% CI) 0.87 (0.67,1.13) 
 
 
Table 31: Short versus longer duration inpatient treatment  
Outcome or subgroup k Total N Statistics Effect (95% CI) Quality of the evidence 
(GRADE) 
1. Lapse (non-abstinence)  3 513 RR (M-H, random, 95% CI) Subtotals only  
 1.1. Post-treatment 3 513 RR (M-H, random, 95% CI) 0.94 (0.84,1.05) 
 
 1.2. At 6-month follow-up 1 200 RR (M-H, random, 95% CI) 1.05 (0.91,1.21) 
 
 1.3. At 7-month follow-up  1 58 RR (M-H, random, 95% CI) 0.86 (0.60,1.23) 
 
 1.4. At 10-month follow-
up 
1 58 RR (M-H, random, 95% CI) 0.82 (0.58,1.16) 
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 1.5. At 13-month follow-
up 
1 58 RR (M-H, random, 95% CI) 0.95 (0.64,1.40) 
 
2. Number consuming 
alcohol 60 to 90% of the 
time at 3-month follow-up 
1 200 RR (M-H, random, 95% CI) 0.95 (0.78,1.14) 
 
3. Number consuming 
alcohol 60 to 90% of time at 
6-month follow-up 
1 200 RR (M-H, random, 95% CI) 1.09 (0.91,1.30) 
 
4. Number consuming 
alcohol less than 60% of 
time at 3-month follow-up 
1 200 RR (M-H, random, 95% CI) 1.01[0.82,1.24] 
 
3. Number consuming 
alcohol less than 60% of 
time at 6-month follow-up 
1 200 RR (M-H, random, 95% CI) 0.82[0.61,1.09] 
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5.32.5 Clinical evidence summary 
Residential unit versus outpatient treatment 
Residential unit treatment was no more effective than an outpatient treatment in 
maintaining abstinence or in reducing the number of drinks per drinking day at 3-
month follow-up (RYCHTARIK2000A). Furthermore, there was no significant 
difference observed between treatment in a residential unit and a day hospital in 
reducing the number of participants drinking more than 60 g of alcohol per drinking 
day at 6-month follow-up (CHAPMAN1988).  
 
A residential unit setting was significantly more effective than an outpatient setting 
in increasing the number of participants abstinent at 2-year follow-up in only one 
study (WALSH1991). This study population was atypical and is unlikely to be 
representative of patients attending UK alcohol treatment services, and the study 
included treatment elements that would be difficult to replicate in the UK.  
 
Based on the GRADE method outlined in Chapter 3, the quality of this evidence is 
moderate and further research is likely to have an important impact on our 
confidence in the estimate of the effect and may change the estimate (for further 
information, see Table 27). 
Residential unit versus day hospital  
On measures of alcohol consumption, there was no significant difference between a 
residential unit and a day hospital on drinks per drinking day at 3-month follow-up. 
At 6-month follow-up, there was a significant difference between the two groups 
favouring day hospital treatment on mean number of drinking days, based on the 
results of the MCKAY1995 study. This effect did not remain at 12-month follow-up, 
however there was a trend (p=0.08) slightly favouring day hospital treatment. It 
should be noted that this study had both a randomised and self-selected sample, and 
since inclusion into this analysis was restricted to RCTs, only the randomised 
population was used. However, the results from the self-selected sample parallel the 
results from the randomised arm. The self-selected participants did not do any better 
on drinking outcomes than those who were randomly assigned at 6- or 12-month 
follow-up. Any differences that did emerge from the self-selected group, tended to 
favour the partial hospitalisation group (day hospital), as found in the randomised 
sample.  
 
On rates of relapse or lapse to alcohol at 6 and 12 months post-treatment, there were 
no significant differences between residential unit and day hospital treatment. 
Additionally, there were no significant differences in the number of participants 
drinking daily at 6-month follow-up (LONGABAUGH1983), or in the PDA at 3-
month follow-up (RYCHTARIK2000A).  
 
One study found that more participants were retained in treatment in the residential 
setting than the day hospital setting (BELL1994). However, this study included a 
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mixture of participants with primary drug and alcohol misuse problems, and so the 
results may not be representative of individuals presenting to an alcohol treatment 
service. 
 
Based on the GRADE methodology outlined in Chapter 3, the quality of this 
evidence is moderate and further research is likely to have an important impact on 
our confidence in the estimate of the effect and may change the estimate (for further 
information see 
 228 
 
Table 28). 
Day hospital versus outpatient treatment 
A day hospital was not found to be any more effective than a less intensive 
outpatient setting in terms of PDA or DDD at 3-month follow-up. However, it is 
important to consider that the MORGENSTERN2003 study contained a mixture of 
both primary drug and alcohol users, so these results may not be generalisable to the 
wider population presenting for treatment of alcohol problems. 
 
Based on the GRADE methodology outlined in Chapter 3, the quality of this 
evidence is moderate to high and further research is likely to have an important 
impact on our confidence in the estimate of the effect and may change the estimate 
(for further information, see Table 29).  
Residential unit versus residential unit  
When analysing two different therapeutic approaches to residential treatment, no 
difference was found between the two different residential treatment models 
(Kalliolla and Jarvenpaa) on reducing the number of participants who relapsed from 
4- through 12-month follow-up.  
 
Based on the GRADE methodology outlined in Chapter 3, the quality of this 
evidence is moderate and further research is likely to have an important impact on 
our confidence in the estimate of the effect and may change the estimate (for further 
information, see Table 30). 
Short duration versus longer duration level (inpatient)  
There was no significant difference between a 21-day inpatient stay and an extended 
9-day inpatient stay at reducing the number of participants consuming alcohol post-
treatment, or at 3- or 6-month follow-up (MOSHER1975). A longer duration in an 
inpatient setting was no more effective in preventing lapse (non-abstinence) than a 
shorter duration in an inpatient setting. No effect remained at 6-, 7-, 10- and 13-
month follow-up.  
 
Based on the GRADE methodology outlined in Chapter 3, the quality of this 
evidence is moderate and further research is likely to have an important impact on 
our confidence in the estimate of the effect and may change the estimate (for further 
information, see Table 31). 
5.32.6 Additional trials assessing different treatment settings  
Randomised controlled trials 
There are several additional studies that were well-conducted trials but could not be 
included in meta-analyses did not evaluate the treatment settings as defined above. 
These studies nevertheless found similar results that support this meta-analysis. 
Chick (1988) compared simple advice with amplified advice (simple advice plus one 
session of motivational interviewing) with extended treatment, which included the 
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offer of further outpatient appointments, inpatient, or day treatment. There were no 
differences between the advice groups or the extended treatment on abstinence 
outcomes at 2- year follow-up, nor on drinking frequency outcomes. There were no 
significant differences found on alcohol consumed in 7 days prior to follow-up, 
frequency of drinking over 200 g per day in the past year, period of abstinence in the 
past year, or on other measures such as employment or marital situation. Edwards 
and Guthrie (1967) assigned participants to an average of 9 weeks of inpatient or 
outpatient treatment, and found no significant differences on measures of drinking 
at 6- and 12-month follow-up. Lastly, Eriksen (1986a) assigned 17 alcoholics post-
assisted withdrawal to either immediate inpatient treatment or a 4-week waiting list 
control. Results indicated no significant differences between groups on outcomes of 
days drinking, or on other outcomes such as sick leave or institutionalisation.  
Predictor studies 
Even in the absence of overall differences in treatment outcomes between residential 
and outpatient settings, it is possible that certain types of patients derive differential 
benefits or harms from being treated in these alternative settings. This is the central 
issue in matching patients to optimal treatment approaches. Relatively few of the 
above studies report differential outcome based on patient characteristics but a 
reasonably consistent picture does emerge, although it should be pointed out this is 
often based on post hoc analysis of non-randomised populations and so should be 
treated with caution. The GDG consider this issue, the main evidence points which 
are summarised below; in doing so the GDG drew on the existing systematic review 
developed by the Specialist Clinical Addiction Network (Specialist Clinical 
Addiction Network, 2006) for the consensus statement on in-patient treatment.  
 
The most commonly studied predictor variables in the treatment of alcohol 
dependence have been measures of problem severity and social stability. More 
severe and less socially stable patients who misuse alcohol seem to fare better in 
inpatient or more intensive treatment (possibly outpatient based), whereas among 
married patients with stable accommodation, fewer years of problem drinking, and 
less history of treatment, outpatient (and less intensive) treatment yields more 
favourable outcomes than inpatient treatment (Kissin, 1970; McLellan et al., 1983; 
Orford et al., 1976; Smart, 1977; Stinson, 1979; Willems, 1973). When heterogeneous 
populations of people who misuse alcohol are averaged together, the consistent 
finding is of comparable (or better) outcomes from outpatient as opposed to 
residential treatment (McLellan et al., 1983). Moos and colleagues (1999) found in an 
effectiveness trial of inpatient treatment of different theoretical orientations within 
the Veterans Administration treatment system that longer lengths of stay were 
associated with better outcomes. Likewise, in Project MATCH, patients who 
received inpatient treatment prior to 12 weeks of outpatient care had better drinking 
outcomes than those who went directly into outpatient care (Project MATCH 
Research Group, 1997). 
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5.32.7 Special Populations 
No clinical evidence evaluating the efficacy of different settings for the treatment of 
alcohol misuse were identified for children, young people or older populations.  
5.32.8 Health economic evidence 
Systematic literature review 
One study was identified in the systematic search of the economic literature that 
considered the cost effectiveness of different settings for rehabilitation treatment for 
people with an alcohol use disorder (alcohol dependence or harmful alcohol use) 
(Pettinati et al., 1999). Details of the methods used for the systematic search of the 
economic literature are described in Chapter 3. 
 
The study by Pettinati and colleagues (1999) assessed the cost-effectiveness of 
inpatient versus outpatient treatment of people with alcohol dependence. Both 
inpatient and outpatient treatment programmes followed the same multi-modal 
clinical approach based on the traditional 12-step programme of AA. This involved 
individual, marital, family, and group counselling provided in the intensive 
treatment period, including 4 weeks of inpatient and 6 weeks of outpatient 
treatment. The primary difference between the inpatient and outpatient programmes 
was the amount of treatment hours and attendance at support groups. Inpatients 
attended educational and therapy sessions from 9 a.m. to 5 p.m. and attended an AA 
meeting in the evening whilst outpatients were expected to attend individual and/or 
group sessions approximately one to two evenings a week, AA meetings on the 
evenings they did not attend therapy sessions, and a family educational programme 
at the weekends. The study population consisted of 173 patients with a formal 
diagnosis of alcohol dependence but no other substance dependence. The primary 
outcome measure used in the study was the probability of returning to significant 
drinking over 12 months. This was defined as 3 or more alcoholic drinks in one 
sitting, admission to an inpatient or detoxification centre or incarceration due to 
alcohol-related disorders. A US healthcare payer perspective was adopted for the 
analysis. Resource use and cost items included the total number of treatment service 
hours attended during the intensive treatment programme each week via interviews 
with the subject. A weighted cost-to-charge ratio was applied to the billing charges 
for services to adjust for geographic- or institution-specific charges. 
 
Rather than calculate ICERs, the authors presented cost-effectiveness ratios by 
dividing treatment costs by the probability of returning to significant drinking. For 
treatment responders, the inpatient:outpatient cost-effectiveness ratio was calculated 
for the 3-month follow-up as 4.5:1, at the 6-month follow-up as 5.3:1 and at the 12-
month follow-up as 5.6:1. For treatment responders, the mean (SD) cost of 
successfully completing inpatient treatment was $9,014 ($2,986) versus $1,420 ($619), 
(p<0.01); a ratio of 6.5:1. The validity of the study findings are limited it was based 
on a non-randomised study design within the US healthcare system which may not 
be generalisable to the UK setting. Only the costs of treatment were included in the 
cost analysis, with no consideration of any subsequent healthcare and very little 
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detail was given by the authors on resource use and cost estimation. Finally, health 
outcomes, which were not formally combined with cost differences in order to 
compute ICERs. 
Cost analysis of rehabilitation treatment in different settings 
The cost effectiveness of rehabilitation treatment for people with an alcohol use 
disorder in different settings was considered by the GDG as an area with potentially 
significant resource implications. A formal economic evaluation comparing different 
rehabilitation settings was not attempted due to time constraints and problems in 
synthesising relevant clinical evidence. Nevertheless, a cost analysis was undertaken 
to estimate costs associated with rehabilitation treatment of people who misuse 
alcohol in different settings in the UK. The results of this analysis were considered 
by the GDG alongside the findings of the clinical effectiveness review, in order to 
make a judgement regarding the cost effectiveness of different settings for 
rehabilitation treatment. 
 
Two different settings for rehabilitation treatment were considered in the analysis: 
residential settings and day hospital (partial hospitalisation) settings. The healthcare 
resource use estimates for each setting were based on descriptions of resource use in 
studies included in the systematic literature review of clinical evidence. Studies 
conducted in the UK were limited in this review. Therefore, resource use estimates 
from studies conducted outside the UK were refined using the expert opinion of the 
GDG in order to reflect current routine clinical practice within the NHS. The 
estimated resource use was subsequently combined with national unit costs in order 
to provide a total cost associated with rehabilitation treatment in the three settings 
assessed. Unit costs were derived from national sources (Curtis, 2009; Department of 
Health, 2010) and reflected 2009 prices.  
Residential treatment unit  
The duration of treatment in this setting has been reported to vary from 4 weeks 
(Sannibale et al., 2003) to 60 days (Zemore & Kaskutas, 2008). Both studies were 
conducted outside the UK. The GDG estimated that residential treatment typically 
lasts 12 weeks (3 months) in the UK setting. No unit costs for residential treatment 
for people with an alcohol use disorder provided within the NHS are available. 
Residential units for people who misuse drugs/alcohol provided by the voluntary 
sector cost £808 per resident week (Curtis, 2009). By combining estimated duration 
of residential treatment with the respective unit cost, the total cost of residential 
rehabilitation treatment is estimated at £9,696. 
 
Day hospital treatment 
According to Zemore and Kaskutas (2008) and McKay and colleagues (1995), the 
duration of rehabilitation treatment taking place in day hospitals ranges between 2 
and 4 weeks. The GDG considered 4 weeks to be a reasonable duration of day 
hospital rehabilitation in the UK. McKay and colleagues (1995) reported that 
participants in their study attended a day hospital 5 days per week. The GDG 
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estimated that frequency of attendance in day hospital rehabilitation should be 
between 5 and 7 days per week. UK unit costs of such services are not available. The 
NHS unit cost of mental health day care is £102 per attendance (Department of 
Health, 2010). However, this facility is likely to provide, on average, non-specialist 
services and therefore this unit cost is expected to be somewhat lower than the cost 
of a day hospital rehabilitation service. On the other hand, Parrott and colleagues 
(2006) reported a local unit cost of a day hospital assisted withdrawal and 
rehabilitation service for people who are alcohol dependent of £129 per day (uplifted 
from the originally reported cost of £109 per day in 2004 prices, using the Hospital 
and Community Health Services pay and prices inflation indices provided in Curtis 
[2009]). Using the range of these two unit costs, and combining them with the 
estimated resource use, the total cost of a day hospital rehabilitation treatment for 
people who misuse alcohol is estimated to range from £2,040 (for a 5-day per week 
programme, using the lower unit cost) to £3,612 (for a 7-day per week programme, 
using the higher unit cost). 
Summary 
The cost analysis indicates that, as expected, day hospital treatment is less costly 
than residential rehabilitation.  
5.32.9  Clinical and health economic evidence summary  
A range of treatment settings were reviewed for treatment taking place after an 
assisted withdrawal programme. These included: inpatient facilities, residential 
units, outpatient treatment, and day hospital treatment. For all the treatment 
settings, the evidence in support of them was assessed to be of a high or moderate 
quality using GRADE profiles. 
 
Overall, inpatient settings were not seen as any more effective than outpatient, or 
day hospital settings. The exception to this was that day hospital settings were 
favoured over inpatient settings in one study on improving drinking outcomes at 6- 
and 12-month follow-up. Additional time in an inpatient setting did not improve 
outcomes, and a standard, shorter, inpatient stay seemed to be equally as effective.  
 
Furthermore, three studies (BELL1994, MORGENSTERN2003, WITBRODT2007) 
included people who misused both drugs and alcohol and it can be difficult to 
disentangle the effects for those with a primary alcohol misuse problem. However, 
alcohol data were reported separately from other substances and it was possible to 
use these data in this review.  
 
The studies also include a wide range of different programmes. For example, the 
nature of the outpatient programmes in these studies varied considerably in content, 
duration and intensity. However, he results of the meta-analysis are in line with the 
findings of previous reviews assessing the effectiveness of residential versus non 
residential treatment (for example, Finney et al., 1996). A cost analysis undertaken 
for this guideline indicated that day hospital treatment incurs considerably lower 
costs than residential treatment. 
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Taking both cost and clinical effectiveness evidence into account, these results 
suggest that once an assisted withdrawal programme has been completed; a 
psychosocial treatment package delivered in a non-residential day hospital or 
community treatment programme29 is likely to be the more cost-effective option.  
5.32.10 From evidence to recommendations 
The GDG conducted a systematic review evaluating the efficacy of residential and 
community settings for the delivery of interventions for alcohol misuse. A meta-
analyses was conducted evaluating drinking related critical outcomes identified by 
the GDG such as relapse, lapse, drinking frequency, drinking quantity. The evidence 
from this review suggests that community settings are at least as effective as 
residential units and less costly in providing effective treatment alcohol misuse. The 
evidence did not show any additional benefit of residential-based interventions. The 
GDG therefore recommend a community setting as the preferred setting for 
delivering effective treatment. For some of the more severely dependent patients 
there is some evidence to suggest that more intensive programme are more effective, 
but the GDG took the view that these intensive programme can also be provided in 
the community in the form of day hospital or similarly intensive community-based 
programmes. The GDG believe that a small number of people who are alcohol 
dependent may benefit from residential treatment after assisted withdrawal and 
identified the homelessness as such a group. It should be noted that the evidence 
base is this topic areas is limited for a number of reasons. Firstly, the clinical studies 
use varied descriptions of the settings evaluated. Secondly, outcomes assessed across 
studies were also heterogeneous, which meant that not all studies could be included 
in a systematic meta-analysis. Thirdly, a great majority of studies included in the 
review are based in the US, covering a diverse range of populations (for example, 
employment schemes, Veterans Administration populations), thus limiting the 
generalisability to a UK setting. The GDG considered these limitations in the 
interpretation of the results of the systematic review and when making 
recommendations.  
 
 
 
5.32.11 Recommendations 
Interventions to promote abstinence and relapse prevention   
                                                 
29 The costs of such a programme are likely to be lower than a day hospital programme given its 
reduced intensity. 
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5.32.11.1 For people with alcohol dependence who are homeless, consider 
offering residential rehabilitation for a maximum of 3 months. Help the 
service user find stable accommodation before discharge. 
5.32.11.2 For all children and young people aged 10 – 17 years who misuse 
alcohol, the goal of treatment should usually be abstinence in the first 
instance. 
 
5.32.12 Research Recommendations  
5.32.12.1 For people who are moderately and severely dependent on alcohol and 
have significant comorbid problems, is an intensive residential rehabilitation 
programme clinically and cost effective when compared with intensive 
community-based care?  
This question should be answered using a prospective cohort study of all people 
who are moderately and severely dependent on alcohol entering residential and 
intensive community rehabilitation programmes in a purposive sample of alcohol 
treatment services in the UK. It should report short- and medium-term outcomes 
(including cost-effectiveness outcomes) of at least 18 months‘ duration. Particular 
attention should be paid to the characterisation of the treatment environment and 
the nature of the interventions provided in order to inform the analysis of 
moderators and mediators of treatment effect. The outcomes chosen should reflect 
both observer and service user-rated assessments of improvement (including 
personal and social functioning) and the acceptability of the intervention. The study 
needs to be large enough to determine the presence or absence of clinically 
important effects, and mediators and moderators of response should be investigated. 
A cohort study has been chosen as the most appropriate design as previous studies 
in this area that have attempted to randomise participants to residential or 
community care have been unable to recruit clinically representative populations.  
Why this is important? 
Many people, in particular those with severe problems and complex comorbidities, 
do not benefit from treatment and/or lose contact with services. One common 
approach is to offer intensive residential rehabilitation and current policy favours 
the provision of such care. However, the research on the effectiveness of residential 
rehabilitation is uncertain with a suggestion that intensive community services may 
be as effective. The interpretation of this research is limited by the fact that many of 
the more severely ill people are not entered into the clinical trials because some 
clinicians are unsure of the safety of the community setting. However, clinical 
opinion is divided on the benefits of residential rehabilitation, with some suggesting 
that those who benefit are a motivated and self-selected group who may do just as 
well with intensive community treatment, which is currently limited in availability. 
Given the costs associated with residential treatment and the uncertainty about 
outcomes, the results of this study will have important implications for the cost 
effectiveness and provision of alcohol services in the NHS. 
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6 PSYCHOLOGICAL AND 
PSYCHOSOCIAL INTERVENTIONS  
6.1 INTRODUCTION 
This chapter is concerned with structured psychological interventions used to help 
people who experience alcohol dependence or harmful alcohol use. These 
approaches have been the focus of much research and debate over the years.  
 
Psychological interventions for people experiencing alcohol misuse or dependence 
have traditionally made use of the interaction between the service user and a 
therapist, worker, helper or counsellor (the latter terminologies may vary depending 
on services and settings). In addition, more recently, there has been some growth 
and expansion in the use of self help based interventions that involve the use of 
DVDs, books, computer programmes or self-help manuals. 
 
Psychological approaches vary depending on the theoretical models underpinning 
them. Broadly, psychological interventions can be classified into behavioural, 
cognitive, psychodynamic, humanistic, systemic, motivational, disease, and social 
and environmental. The emphasis of each therapy is different, depending on the 
theoretical underpinning of the approach. Behavioural approaches for example are 
based on the premise that excessive drinking is a learned habit and therefore 
influenced by principles of behaviour. The latter can hence be used to teach the 
individual a different behavioural pattern that will reduce the harm emerging from 
excessive drinking. Cognitive approaches, on the other hand, emphasise the role of 
thinking and cognition either prior to engaging in drinking behaviour or in order to 
prevent or avoid lapse or relapse. Social approaches focus the work on the social 
environment, for example, families or wider social networks. In some instances, a 
combination of approaches is used and described under the term of ‗multimodal‘ 
treatment, guided by the rationale that a combination of approaches is more 
powerful than each individual component. Each category of intervention is 
discussed in more detail later in this chapter within sub-sections describing the 
studies reviewed that are relevant to each type of approach.  
 
Whilst the rationale and theoretical frameworks for treatments have been clearly 
articulated in the various research studies, the evidence for the superiority of one 
form of treatment over another in the field of alcohol has been difficult to find 
(Miller & Wilbourne, 2002). This has led to the general view in the field that whilst 
psychological interventions are better than no intervention, no one approach is 
superior to another. In this chapter, where available, the evidence for each 
psychological intervention is assessed in relation to three comparators: (i) is the 
intervention superior to treatment as usual or a control condition? (ii) is the 
intervention superior to other interventions? and (iii) is the intervention superior to 
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other variants of the same type of approach (for example, behavioural cue exposure 
versus behavioural self-control training)? 
 
The review of this literature is of significant importance, given the potential wide use 
of psychological interventions in NHS and non-statutory services and the need to 
provide an evidence base to inform and guide the implementation and use of these 
approaches. It is important to note that previous influential reviews of alcohol 
treatment (for example, ‗Mesa Grande‘ Miller & Wilbourne, 2002) have combined 
findings from a large number of trials that included a wide range of populations (for 
example, opportunistic versus help-seeking; mild versus severe dependence). In the 
current review, only studies that involved treatment seeking populations 
experiencing harmful drinking or alcohol dependence were included and therefore 
the number of trials meeting these criteria was reduced in order to make them 
relevant to the population addressed in this guideline. 
 
Finally, psychological treatments can also be used to help people experiencing 
harmful alcohol use or dependence in order to address coexisting problems such as 
anxiety and depression. Psychological treatments can also be used to help people 
who misuse alcohol address coexisting disorders such as anxiety and depression. 
These approaches are not covered within this review and the reader is referred to the 
separate NICE guidelines that address psychological interventions for specific 
mental health problems. Healthcare professionals should note that, although the 
presence of alcohol misuse may impact, for example, on the duration of a formal 
psychological treatment, there is no evidence supporting the view that psychological 
treatments for common mental disorders are ineffective for people who misuse 
alcohol. A number of NICE mental health guidelines have specifically considered the 
interaction between common mental health problems and drug and alcohol use. For 
example, NICE guidelines such as for anxiety (NICE, 2004) or obsessive-compulsive 
disorder (NICE, 2006) provide advice on assessment and the impact that drug and 
alcohol misuse may have on the effectiveness or duration of treatment. There is also 
some evidence to suggest that the active treatment of comorbid mental health 
problems may improve drug and alcohol substance misuse outcomes (Charney et al., 
2001; Hesse, 2004; Watkins et al., 2006). This may be particularly important for 
service users who have achieved abstinence (note that symptoms of depression and 
anxiety may remit following successful treatment of the alcohol problem), but whose 
alcohol use is at risk of returning or escalating due to inadequately treated anxiety or 
depression.  
6.1.1 Current practice 
Services for people who are alcohol dependent and harmful drinkers are commonly 
delivered by statutory and non-statutory providers. The field is undergoing rapid 
change across different areas of the country due to the impact of the commissioning 
process. Traditionally services have been provided by teams where the 
detoxification and counselling aspects of treatment have been fairly clearly 
separated. Within the NHS, teams tend to consist of different disciplines including 
nurses, counsellors, medical practitioners and less often other professions such as 
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psychologists and occupational therapists. Teams are commonly under-resourced 
with practitioners having high caseloads and limited access to supervision. Most 
practice involves an eclectic approach that combines strategies from various 
psychological approaches. A more recent development involves contracts between 
commissioners and providers that may determine for example the number of 
sessions to be delivered yet this is rarely informed by the evidence and tends to be 
driven by pragmatic or resource issues (Drummond et al., 2005). 
 
Whilst the research literature to date, has concentrated mostly on the comparison of 
well defined treatment interventions commonly incorporated into treatment 
manuals, this stands in contrast to what is normally delivered in routine practice. 
Despite the research on psychological treatments, current UK practice is not 
underpinned by a strong evidence base and there is wide variation in the uptake and 
implementation of psychological approaches to treatment across services 
(Drummond et al., 2005). 
 
A number of factors may contribute to the low implementation of evidence based 
psychological interventions. First, there is a lack of availability of reviews of the 
current evidence in a clear and practical format that can be accessible to 
practitioners, managers and commissioners. This has led to a weak dissemination of 
the evidence base concerning psychological interventions for alcohol misuse within 
routine service provision. Second the varied composition of the workforce with a 
range of training experiences, not all of which include training in the delivery of 
psychological interventions. Furthermore as noted by Tober and colleagues (2005) 
training programmes for the management of substance misuse vary widely in 
content with no consensus on methods to provide and evaluate such training or to 
maintain its effects. Supervision of psychological interventions is equally varied and 
not always available. Finally, there is a tendency in the field to eclecticism fuelled by 
the perception that all approaches are either equally valid or equally ineffective.  
6.2 THERAPIST FACTORS 
Several therapist factors that could potentially affect treatment have been 
considered, including demographics, professional background, training, use of 
supervision and competence. Two related aspects are dealt with below, namely the 
therapeutic alliance and therapist competence.  
6.2.1 The therapeutic alliance  
There are various definitions of the therapeutic alliance, but in general terms it is 
viewed as a constructive relationship between therapist and client, characterised by 
a positive and mutually respectful stance in which both parties work on the joint 
enterprise of change. Bordin (1979) conceptualised the alliance as having three 
elements comprising the relationship between therapist and patient: agreement on 
the relevance of the tasks (or techniques) employed in therapy, agreement about the 
goals or outcomes the therapy aims to achieve, and the quality of the bond between 
therapist and patient.  
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There has been considerable debate about the importance of the alliance as a factor 
in promoting change, with some commentators arguing that technique is 
inappropriately privileged over the alliance, a position reflected in many humanistic 
models where the therapeutic relationship itself is seen as integral to the change 
process, with technique relegated to a secondary role (for example, Rogers, 1951). 
The failure of some comparative trials to demonstrate differences in outcome 
between active psychological therapies (for example, Elkin, 1994; Miller & 
Wilbourne, 2002) is often cited in support of this argument and is usually referred to 
as ‗the dodo-bird hypothesis‘ (Luborsky et al., 1975). However, apart from the fact 
that dodo-bird findings may not be as ubiquitous as is sometimes claimed this does 
not logically imply that therapy technique is irrelevant to outcome. Identifying and 
interpreting equivalence of benefit across therapies remains a live debate (for 
example, Ahn & Wampold, 2001; Stiles et al., 2006) but should also include a 
consideration of cost effectiveness as well as clinical efficacy (NICE, 2008a).  
 
Meta-analytic reviews report consistent evidence of a positive association of the 
alliance with better outcomes with a correlation of around 0.25 (for example, 
Horvath & Symonds, 1991; Martin et al., 2000), a finding that applies across a 
heterogeneous group of trials (in terms of variables such as type of therapy, nature 
of the disorder, client presentation, type of measures applied and the stage of 
therapy at which measures are applied). However, it is the consistency, rather than 
the size of this correlation, which is most striking, since a correlation of 0.25 would 
suggest it could account for only 6% of the variance in the outcome. Specific studies 
of the role of the alliance in drug and alcohol treatment programmes have been 
conducted. Luborsky and colleagues (1985), Connors and colleagues (1997) and Ilgen 
and colleagues, (2006) reported a relationship between treatment outcomes but 
others (for example, Ojehagen et al., 1997) have not. Ojehagen and colleagues suggest 
that this discrepancy between the various studies may have arisen from 
methodological differences between the studies; in contrast to Luborsky and 
colleagues and Connors and colleagues and Ilgen and colleagues, in Ojehagen and 
colleagues, ratings of the alliance were made by an independent rater from video 
tapes as opposed to rating made by the therapist early in treatment. This is 
consistent with other studies; for example Feeley and colleagues (1999) reported that 
alliance quality was related to early symptom change. Therefore, it seems reasonable 
to debate the extent to which a good alliance is necessary for a positive outcome of 
an intervention, but it is unlikely to be sufficient to account for the majority of the 
variance in outcome.  
6.2.2 Therapist competence  
Studies of the relationship between therapist competence and outcome suggest that 
all therapists have variable outcomes, although some therapists produce consistently 
better outcomes (for example, Okiishi et al., 2003). There is evidence that more 
competent therapists produce better outcomes (Barber et al., 1996, 2006; Kuyken & 
Tsivrikos, 2009). This is also the case for psychological interventions in the alcohol 
field, the Project MATCH Research Group (1998) report therapist differences which 
impact on outcome. A number of studies have also sought to examine more precisely 
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therapist competence and its relation to outcomes; that is, what is it that therapists 
do in order to achieve good outcomes? A number of studies are briefly reviewed 
here. 
 
This section, draws on a more extensive review of the area by Roth and Pilling (2010) 
which focused on CBT as this area had the most extensive research. In an early 
study, Shaw and colleagues (1999) examined competence in the treatment of 36 
patients treated by eight therapists offering CBT as part of the National Institute of 
Mental Health trial of depression (Elkin et al., 1989). Ratings of competence were 
made on the Cognitive Therapy Scale (CTS). Although the simple correlation of the 
CTS with outcome suggested that it contributed little to outcome variance, 
regression analyses indicated a more specific set of associations; specifically, when 
controlling for pre-therapy depression scores, adherence and the alliance, the overall 
CTS score accounted for 15% of the variance in outcome. However, a subset of items 
on the CTS accounted for most of this association.  
 
Some understanding of what may account for this association emerges from three 
studies by DeRubeis's research group (Feeley et al., 1999; Brotman et al., 2009). All of 
the studies made use of the Collaborative Study Psychotherapy Rating Scale (CSPRS: 
Hollon et al., 1988), subscales of which contained items specific to CBT. On the basis 
of factor analysis, the CBT items were separated into two subscales labelled 
‗cognitive therapy – concrete‘ and ‗cognitive therapy – abstract‘. Concrete techniques 
can be thought of as pragmatic aspects of therapy (such as establishing the session 
agenda, setting homework tasks or helping clients identify and modify negative 
automatic thoughts). Both DeRubeis and Feeley (1990) and Feeley and colleagues 
(1999) found some evidence for a significant association between the use of 
‗concrete‘ CBT techniques and better outcomes. The benefits of high levels of 
competence over and above levels required for basic practice has been studied in 
most detail in the literature on CBT for depression. In general, high severity and 
comorbidity, especially with Axis II pathology, have been associated with poorer 
outcomes in therapies, but the detrimental impact of these factors is lessened for 
highly competent therapists. DeRubeis and colleagues (2005) found that the most 
competent therapists had good outcomes even for patients with the most severe 
levels of depression. Kuyken and Tsivrikos (2009) found that therapists who are 
more competent have better patient outcomes regardless of the degree of patient 
comorbidity. In patients with neurotic disorders (Kingdon et al., 1996) and 
personality disorders (Davidson et al., 2004), higher levels of competence were 
associated with greater improvements in depressive symptoms. Although 
competence in psychological therapies is hard to measure in routine practice, 
degrees of formal training (Brosan et al., 2007) and experience in that modality 
(James et al., 2001) are associated with competence and are independently associated 
with better outcomes (Burns & Nolen-Hoeksema, 1992). All therapists should have 
levels of training and experience adequate to ensure a basic level of competence in 
the therapy they are practicing, and the highest possible levels of training and 
experience are desirable for those therapists treating patients with severe, enduring 
or complex presentations. In routine practice in services providing psychological 
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therapies for depression, therapists should receive regular supervision and 
monitoring of outcomes. Roth and colleagues, (2010) reviewed the training 
programmes associated with clinical trials as part of a programme exploring 
therapist competence (Roth & Pilling, 2008). They showed that clinical trials are 
associated with high levels of training, supervision and monitoring; factors which 
are not always found in routine practice. This is part due the inadequate description 
of training programmes in the trial reports. However, there is an increasing 
emphasis on describing the process of training in clinical trials, the report by Tober 
and colleagues (2005) being a notable recent publication describing the training 
programme for UKATT.  
 
Trepka and colleagues (2004) examined the impact of competence by analysing 
outcomes in Cahill and colleagues' (2003) study. Six clinical psychologists (with 
between 1 and 6 years post-qualification experience) treated 30 clients with 
depression using CBT, with ratings of competence made on the CTS. In a completer 
sample (N=21) better outcomes were associated with overall competence on the CTS 
(r= 0.47); in the full sample this association was only found with the ‗specific CBT 
skills‘ subscale of the CTS. Using a stringent measure of recovery (a BDI score no 
more than one SD from the non-distressed mean), nine of the 10 completer patients 
treated by the more competent therapists recovered, compared with four of the 11 
clients treated by the less competent therapists. These results remained even when 
analysis controlled for levels of the therapeutic alliance.  
 
Miller and colleagues (1993) looked at the relationship of therapist behaviour in a 
brief (two-session) ‗motivational check-up‘; they identified one therapist behaviour 
(a confrontational approach) which was associated with increased alcohol intake. 
Agreeing and monitoring homework is one of the set of ‗concrete‘ CBT skills 
identified above. All forms of CBT place an emphasis on the role of homework 
because it provides a powerful opportunity for clients to test their expectations. A 
small number of studies have explored whether compliance with homework is 
related to better outcomes, although rather fewer have examined the therapist 
behaviours associated with better client ‗compliance‘ with homework itself. 
Kazantzis and colleagues (2000) report a meta-analysis of 27 trials of cognitive 
and/or behavioural interventions that contained data relevant to the link between 
homework assignment, compliance and outcome. In 19 trials clients were being 
treated for depression or anxiety; the remainder were seen for a range of other 
problems. Of these, 11 reported on the effects of assigning homework in therapy and 
16 on the impact of compliance. The type of homework varied, as did the way in 
which compliance was monitored, although this was usually by therapist report. 
Overall there was a significant, although modest, association between outcome and 
assigning homework tasks (r = 0.36), and between outcome and homework 
compliance (r = 0.22). While Kazantzis and colleagues (2000) indicate that homework 
has greater impact for clients with depression than anxiety disorders, the number of 
trials on which this comparison is made is small and any conclusions must therefore 
be tentative.  
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Bryant and colleagues (1999) examined factors leading to homework compliance in 
26 clients with depression receiving CBT from four therapists. As in other studies, 
greater compliance with homework was associated with better outcome. In terms of 
therapist behaviours, it was not so much therapists' CBT-specific skills (such as 
skilfully assigning homework or providing a rationale for homework) that were 
associated with compliance, but ratings of their general therapeutic skills, and 
particularly whether they explicitly reviewed the homework assigned in the 
previous session. There was also some evidence that compliance was increased if 
therapists checked how the client felt about the task being set and identified 
potential difficulties in carrying it out.  
6.3 MATCHING EFFECTS/SEVERITY  
One of the main challenges in providing services for alcohol treatment is to increase 
the effectiveness of the interventions offered. The concept of tailoring treatments to 
particular types of clients in order to increase effectiveness has been appealing to 
researchers both in terms of its logical plausibility and as a possible explanation for 
the reason that no one intervention has universal effectiveness. However, despite 
this, there is limited evidence to date that matching alcohol misusing or alcohol 
dependent clients to treatment approaches demonstrates effectiveness. 
 
In 1989 the National Institute on Alcohol Abuse and Alcoholism (NIAAA) began the 
largest national multisite RCT of alcoholism treatment matching entitled Matching 
Alcoholism Treatments to Client Heterogeneity (Project MATCH). This study 
outlined matching hypotheses which were investigated across both ‗outpatient‘ and 
‗aftercare‘ settings following inpatient or day hospital treatment. Clients were 
randomly allocated to one of three manual guided treatment approaches 
individually offered, namely, Cognitive Behavioural Coping Skills Therapy, MET or 
12-Step Facilitation Therapy (Project MATCH Research Group, 1997). However, tests 
of the primary matching hypotheses over the 4- to 15-month follow-up period 
revealed few matching effects. Of the variables considered, psychiatric severity was 
considered an attribute worthy of further consideration as this alone appeared to 
influence drinking at 1-year follow-up. A UK trial later explored client treatment 
matching in the treatment of alcohol misuse comparing MET with Social Behaviour 
Network Therapy (UKATT Research Team, 2007), the findings of which strongly 
supported those of Project MATCH in that none of the five matching hypotheses 
was supported at either follow-up point on any outcome measure.  
 
Despite the limited findings from these major trials, other studies have detected 
more positive conclusions which have highlighted methodological considerations 
associated with matching. Several studies have acknowledged the usefulness of 
matching treatment approaches for individuals who are experiencing severe 
psychiatric co-morbidity. In a trial comparing alcohol dependent clients with a range 
of psychiatric impairments, more structured coping skills training yielded lower 
relapse rates at 6-month follow-up (Kadden et al., 1989). Studies which looked 
specifically at matching in the context of psychiatric disturbance have acknowledged 
that the severity of the psychiatric presentation has a negative impact upon the 
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relapse rates (Brown et al., 2002) although matching appears to have assisted in 
retaining individuals in treatment (McLellan et al., 1997). Although in some cases no 
significant differences have been detected between overall relapse rates when 
matching treatments at 2 years follow-up, relapse to alcohol was found to have 
occurred more slowly where high psychiatric co-morbidity is matched with more 
structured coping skills training (Cooney et al., 1991). 
 
The importance of service user choice in relation to self-matching treatments has 
been associated with more positive outcomes in two studies (Brown et al., 2002; 
UKATT, 2007), whilst other trials have emphasised the negative consequences of 
‗mismatching‘ including earlier relapse (Cooney et al., 1991), poorer outcomes 
(Karno & Longabaugh, 2007) and increased need of support services (Conrod et al., 
2000). 
 
Treatment providers are now required to consider not only treatment efficacy but 
cost effectiveness and for this reason, treatment matching has remained an appealing 
option (Moyer et al., 2000). However, for the findings of matching trials to be 
meaningful, one must consider a variety of methodological issues. Many of the 
recent studies considered have involved small samples, comparing a diverse range 
of variables both in terms of sample characteristics and treatment process factors 
(McLellan & Alterman, 1991). It has been suggested that for trials to provide more 
meaningful findings, there is a need for a clearer focus on matching questions which 
then focus upon well-specified treatments that have clear goals with specific patient 
populations. In this way, such designs may be more likely to provide interpretable 
results as well as a clearer understanding of the processes likely to be responsible for 
such findings. 
 
Despite the steady development of patient-treatment matching studies in relation to 
alcohol dependence, the outcomes to date indicate that there is no one single 
treatment that is effective for all clients. There continue to be many obstacles to 
matching clients to specific treatment programmes in real world settings and for 
many organisations patient-treatment matching remains impractical. Research 
would appear to indicate that the nature and severity of co-morbid and complex 
presentations such as, psychiatric disturbance do have a negative impact upon 
treatments for addiction and this is arguably an area for further research (McLellan 
et al., 1997). It has been suggested that given the diversity of presentations and the 
large number of variables implicated in such research, the development of reliable 
and generalisable measures will be important for both the effective training and 
evaluation of treatment-matching efficacy (McLellan & Alterman, 1991). 
6.4 SETTING THE CONTEXT FOR TWELVE-STEP 
FACILITATION AND ALCOHOLICS ANONYMOUS 
The 12-step principles were first set out in a publication by Alcoholics Anonymous 
(AA) in the 1950s. AA describes itself as a ‗Fellowship‘ and AA groups are widely 
available in the UK as support networks for people who are alcohol dependent. AA 
is a self-help movement with the 12-step principles at the core. The 12 steps lay out a 
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process that individuals are recommended to follow, based on an assumption that 
dependence on alcohol is a disease and therefore a goal of lifelong abstinence should 
be promoted. Membership is entirely voluntary and free of charge, there is a 
spiritual element to participation and life-long membership is encouraged. 
Attendance has been associated with successful abstinence from alcohol in a number 
of studies (see Ferri et al., 2006, for a systematic review).  
 
Most 12-step treatment is predicated on the understanding that the treatment would 
fail without subsequent attendance at 12-step fellowship meetings. However, a 
common problem in the treatment of alcohol dependence with AA or 12-step groups 
is that people who misuse alcohol frequently discontinue AA involvement at the end 
of their designated treatment period and usually do not continue with aftercare 
treatment (Kaskutas et al., 2005; Kelly et al., 2003; Moos et al., 2001; Tonigan et al., 
2003). As a result, manual guided Twelve-Step Facilitation (TSF) has been developed 
as an active stand-alone or adjunctive intervention which involves: introducing the 
person who misuses alcohol to the principles of AA and the 12 steps of treatment 
(for example, Project MATCH Research Group, 1993), providing information on AA 
facilitates in the geographical area, and engaging with the client in setting goals for 
attendance and participation in the meetings. The aim of TSF is to maintain 
abstinence whilst in treatment and to sustain gains made after treatment concludes. 
This guideline is concerned with the use of TSF as an active intervention in the 
treatment of alcohol dependence and harmful alcohol use. An evaluation of the 
classic AA approach is outside the scope of this guideline.  
6.5 REVIEW OF PSYCHOLOGICAL THERAPIES  
6.5.1 Aim of review 
This section aims to review the evidence for psychological interventions without 
pharmacological interventions for the treatment of alcohol dependence and harmful 
alcohol use. The literature reviewed in this Section is focused on a reduction or 
cessation of drinking and hence assesses any outcomes pertaining to this. Most of the 
literature in the field is focused on adults over the age of 18 years. However, for 
young people under the age of 18 years old, literature assessing the clinical efficacy 
of psychological therapies for alcohol misuse alone (without comorbid drug misuse) 
is limited. The psychological evidence below is for an adult population only and a 
review of the evidence for the treatment of young people is described in Section 6.22. 
 
Psychological interventions were considered for inclusion in the review if they were: 
 Planned treatment 
 For treatment-seeking participants only (of particular importance for the brief 
interventions as our scope did not cover opportunistic brief interventions – 
see scope Appendix 1) 
 Manual-based or in the absence of a formal manual, the intervention should 
be well-defined and structured 
 Ethical and safe 
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The following psychological therapies used in the treatment of alcohol misuse were 
considered for inclusion in this guideline:- 
 Brief interventions (planned only) 
- for example, psychoeducational and motivational techniques 
 Self-help based treatments 
- Brief self-help interventions (including guided self help/bibliotherapy) 
 Twelve-step facilitation 
 Cognitive behavioural based therapies 
- Standard cognitive behavioural therapy 
- Coping skills 
- Social skills training 
- Relapse prevention 
 Behavioural therapies 
- Cue exposure 
- Behavioural self-control training  
- Contingency management 
- Aversion therapy 
 Motivational enhancement therapy 
 Social network and environment based therapies 
- Social behaviour and network therapy  
- The community reinforcement approach  
 Counselling 
- Couples therapy (including including behavioural couples therapy and 
other variants of couples therapy) 
 Family-based interventions 
- Functional family therapy 
- Brief strategic family therapy 
- Multi-systematic therapy 
- Five-step family interventions 
- Multidimensional family therapy  
- Community reinforcement and family training  
 Psychodynamic therapy 
- Short-term psychodynamic intervention 
- Supportive expressive psychotherapy 
 
In addition, physical therapies such as meditation and acupuncture are also covered 
in this review.  
 
Good quality RCT evidence for the clinical efficacy of some of the psychological 
therapies listed was not always available. Therefore, the evidence summaries in this 
chapter describe the psychological therapies for which evidence of sufficient quality 
(see methods Chapter 3 for methodological criteria) was available. There are a 
number of useful studies which add value to the RCT data presented and they are 
included in this review. For the purpose of this guideline, and in order to obtain an 
overview of the available literature, studies that have met other methodological 
criteria are described in the evidence summaries of the individual therapies.  
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Full characteristics of included studies, forest plots and GRADE profiles can be 
found in Appendix 16d, 17c & 18c respectively as they were too extensive to place 
within this chapter. 
6.5.2 Clinical questions  
Primary clinical questions addressed in this chapter 
1. For people who are alcohol dependent or harmful drinkers, is psychological 
treatment x, when compared with y, more clinically and cost-effective and does 
this depend on: 
 Presence of comorbidities 
 Subtypes (matching effects) 
 Therapist-related factors (quality, therapeutic alliance, competence, training, 
etc.) 
6.6 OUTCOMES 
There were no consistent critical outcomes across studies and outcomes were mainly 
continuous in nature. This variability in outcomes poses some difficulties in pooling 
data from different studies. Therefore, continuous outcomes were grouped into three 
categories:- 
 Abstinence, for example, 
- Percentage/proportion days abstinent  
- Abstinent days per week/month 
- Longest duration abstinent 
 Rates of consumption, for example, 
- Percentage/proportion days heavy drinking 
- Drinking days per month 
- Days drinking greater than X drinks per week 
 Amount of alcohol consumed, for example, 
- Drinks per drinking day 
- Mean number of drinks per week 
- Grams of alcohol per drinking day 
- Number of drinks per drinking episode 
 
Dichotomous outcomes included: 
 Abstinence (number of participants abstinent) 
 Lapse (number of participants who have drank at all) 
 Relapse (number of participants who have drank more than X number of 
drinks) 
 Attrition (the number of participants leaving the study for any reason) 
 
Studies varied in their definition of these dichotomous terms. For example, the 
number of drinks defined as constituting a relapse varied. 
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6.7 MOTIVATIONAL TECHNIQUES 
6.7.1 Definition  
MET is the most structured and intensive motivational-based intervention. It is 
based on the methods and principles of motivational interviewing (Miller et al., 
1992). It is patient-centred and aims to result in rapid internally motivated changes 
by exploring and resolving ambivalence towards behaviour. The treatment strategy 
of motivational interviewing is not to guide the client through recovery step by step, 
but to use motivational methods and strategies to utilise the patient‘s resources. A 
more specific manualised and structured form of motivational interviewing based 
on the work of Project MATCH is usually utilised (Project Match Research Group, 
1993).  
 
Brief motivational interventions include the computerised Drinker‘s Check Up 
which assesses symptoms of dependence, alcohol related problems and motivation 
for change, and ‗feedback, responsibility, advice, menu, empathy, self-efficacy‘ 
(FRAMES; Bien et al., 1993).  
6.7.2 Clinical review protocol (Motivational Techniques) 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this Section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21 of this 
Chapter). See Table 32 below for a summary of the clinical review protocol for the 
review of Motivational Techniques. 
 
Table 32: Clinical review protocol for the review of motivational 
techniques 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per 
week 
Pregnant Women 
Interventions Motivational Techniques 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants 
who have relapsed) 
Lapse (time to first drink or number of participants who 
have lapsed) 
Attrition (leaving the study early for any reason) 
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6.7.3 Studies considered for review30 
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of motivational techniques in the treatment of alcohol 
dependence or harmful alcohol use. See Table 33 for a summary of the study 
characteristics. It should be noted that some trials included in analyses were three- 
or four-arm trials. In order to avoid double-counting, the number of participants in 
treatment conditions used in more than one comparison was divided (by half in a 
three-arm trial, and by three in a four-arm trial). 
 
Eight trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on 4209 participants. All eight studies were published in peer-
reviewed journals between 1997 and 2007. A number of studies identified in the 
search were initially excluded because they were not relevant to this  
guideline. Studies were excluded because they did not meet methodological criteria 
(see methods Chapter 3). When studies did meet basic methodological inclusion 
criteria, the main reason for exclusion was not meeting drinking quantity/diagnostic 
criteria, that is, participants were not drinking enough to be categorised as harmful 
or dependent drinkers or less than 80% of the sample meet criteria for alcohol 
dependence or harmful alcohol use. Other reasons were that treatment was 
opportunistic as opposed to planned, the study was not directly relevant to the 
clinical questions, or no relevant alcohol-focused outcomes were available. A list of 
excluded studies can be found in Appendix 16d.  
Motivational techniques versus minimal intervention control  
Of the eight included trials, three involved a comparison of motivational techniques 
versus control met criteria for inclusion. HESTER2005 assessed the drinker‘s check-
up versus waiting list control; ROSENBLUM2005b investigated MET plus relapse 
prevention versus information and referral only; and SELLMAN2001 assessed MET 
versus feedback only. The included studies were conducted between 2001 and 2005. 
The 5-year follow-up outcomes were obtained from Adamson and Sellman (2008). 
Motivational techniques versus other active intervention  
Of the eight included trials, six assessed motivational techniques versus another 
active intervention met criteria for inclusion. DAVIDSON2007 investigated MET 
versus cognitive behavioural broad spectrum therapy; MATCH1997 assessed MET 
versus both CBT and TSF; SELLMAN2001 compared MET with non-directive 
reflective listening (counselling); SHAKESHAFT2002 assessed FRAMES with CBT; 
SOBELL2002 compared motivational enhancement/personalised feedback with 
psychoeducational bibliotherapy/drinking guidelines; and lastly UKATT2005 
investigated MET versus SBNT. The included studies were conducted between 1997 
and 2007. 
 
                                                 
30 Here and elsewhere in the guideline, each study considered for review is referred to by a study ID 
in capital letters (primary author and date of study publication, except where a study is in press or 
only submitted for publication, then a date is not used). 
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Table 33: Summary of study characteristics for motivational techniques 
 Motivational versus minimal 
intervention control 
Motivational versus other 
active intervention 
K(total N) 3 RCTs (N = 433) 6 RCTs (N = 3818) 
Study ID (1) HESTER2005  
(2) ROSENBLUM2005b  
(3) SELLMAN2001  
 
(1) DAVIDSON2007  
(2) MATCH1997  
(3) SELLMAN2001  
(4) SHAKESHAFT2002  
(5) SOBELL2002  
(6) UKATT2005  
Diagnosis (when 
reported) 
(1) AUDIT score 8+ 
(2) DSM alcohol 
dependent/abuse 
(3) DSM alcohol dependent  
(1), (3) DSM alcohol dependent 
(2), (6) DSM alcohol 
dependent/abuse 
 
Baseline severity 
(when reported) 
(1) Drinks per drinking day: 
approximately 7 
(3) Mild/moderate dependence 
Unequivocal heavy drinking 6+ 
times (in 6 months prior to 
treatment): 90.2% 
 
 
 
 
(1) Percent days abstinence: 
approximately 30%, percent 
days heavy drinking: 
approximately 63% 
(2) Percent days abstinent: 
approximately 30%, drinks per 
drinking day: approximately 
16 
(3) Unequivocal heavy 
drinking 6+ times  
in 6 months prior to treatment: 
90.2% 
(4) Weekly Australian units 
per week: approximately 32 
units 
(5) Number of drinking days 
per week: approximately 5.5 
days, drinks per drinking day: 
approximately 5 
(6) Percent days abstinent: 
29.5%, 
number of drinks per drinking 
day: 26.8 drinks 
Number of 
sessions 
Range: 1 to 12 sessions Range: 1 to 12 sessions 
Length of 
treatment 
Range: 1 to 6 weeks Range: 1 to 12 weeks 
Length of follow-
up  
Range: 1 month to 5 years Range: 6 months to 5 years  
Setting (1) Computer based intervention 
(2) Homeless soup-kitchen 
(3) Outpatient treatment centre 
 
(1), (3), (4), (6) Outpatient 
treatment centre 
(2) Clinical research unit 
(5) Mail information 
Treatment goal (1) Abstinence or drinking 
reduction/moderation 
(2) Drinking 
reduction/moderation 
(3) Not explicitly stated 
(1)–(2) Abstinence or drinking 
reduction/moderation 
(3)–(5) Not explicitly stated 
(6) Abstinence or drinking 
reduction/moderation 
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Country (1), (2) US 
(3) New Zealand 
(1)–(2) US 
(3) New Zealand 
(4) Australia 
(5) US 
(6) UK 
6.7.4 Evidence summary31 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Motivational techniques versus minimal intervention control  
One computerised session of MET (drinker‘s check up) was significantly better than 
control in reducing average drinks per day at 1-month follow-up (moderate effect 
size). However, this finding as based on the results of a single study. Furthermore, 
no significant difference in average drinks per day and drinks per drinking day was 
observed between the drinker‘s check up and control at 2- and 12-month follow-up.  
 
MET (with relapse prevention) (ROSENBLUM2005b) was significantly more 
effective than control at reducing heavy alcohol use when assessed at 5-month 
follow-up (moderate effect size). This was further supported by the SELLMAN2001 
study which favoured MET over control in the number of people who drank 
excessively and frequently (10 or more drinks, 6 or more times) at 6-month follow-
up (large effect size). However, this effect was not observed at long follow-up 
assessment (5 years). Although no significant difference was observed between 
groups in reducing the days ANY alcohol was drank, the analyses showed a trend 
favouring MET with relapse prevention over control (p=0.07). No significant 
difference in attrition rates were observed between MET and control groups across 
studies.  
 
The quality of this evidence is moderate and further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 34. 
Motivational techniques versus other active intervention  
The clinical evidence showed that no significant difference could be found between 
motivational techniques and other active interventions in maintaining abstinence at 
up to 15-month follow-up. Furthermore, no difference between groups was observed 
in reducing the number of participants who had lapsed or reducing heavy drinking 
at all follow-up points.  
 
Other therapies (namely CBT and TSF) were more effective than motivational 
techniques in reducing the quantity of alcohol consumed when assessed post-
                                                 
31 Sensitivity analyses were conducted to assess the effect of combining studies investigating brief 
motivational techniques with structured MET studies. The findings were found to be robust in 
sensitivity analysis and the effects found were not determined by the intensity and duration the 
motivational intervention.  
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treatment. However, the effect size was small (0.1) and was no longer seen at longer 
follow-up points of 3 to 15 months. 
 
No significant difference was observed between groups in attrition rates post-
treatment or at 3-month follow-up. However, other therapies were more effective at 
retaining participants at 6-month follow-up (low effect size). Follow-up periods 
longer than 6 months did not indicate any significant difference between groups. 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 35. 
 
Table 34: Motivational techniques versus control evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method 
Effect 
estimate 
Lapse or relapse       
Lapsed up until 6-month follow-up     
  at 6-months 82 
RR (M-H, Random, 95% 
CI) 
0.90 [0.77, 
1.06] 
Lapsed >12-month follow-up     
  at 5-year follow-up 56 
RR (M-H, Random, 95% 
CI) 
1.03 [0.77, 
1.37] 
Amount of alcohol consumed       
Amount of alcohol consumed up to 6-
month follow-up 
    
  Average drinks per day (log transformed) 
over entire assessment period at 1-month 
follow-up 
61 
SMD (IV, Random, 95% 
CI) 
-0.67 [-1.20, -
0.15] 
  Average drinks per day (log transformed) 
over entire assessment period at 2-month 
follow-up 
61 
SMD (IV, Random, 95% 
CI) 
-0.46 [-0.97, 
0.06] 
  Drinks per drinking day (log 
transformed) at 1-month follow-up 
61 
SMD (IV, Random, 95% 
CI) 
-0.17 [-0.68, 
0.34] 
  Drinks per drinking day (log 
transformed) at 2-month follow-up 
61 
SMD (IV, Random, 95% 
CI) 
0.21 [-0.30, 
0.72] 
Amount of alcohol consumed 7- to 12-
month follow-up 
    
  Average drinks per day (log transformed) 
over entire assessment period at 12-month 
follow-up 
61 
SMD (IV, Random, 95% 
CI) 
-0.20 [-0.71, 
0.31] 
  Drinks per drinking day (log 
transformed) at 12-month follow-up 
61 
SMD (IV, Random, 95% 
CI) 
0.36 [-0.15, 
0.88] 
Rates of consumption        
Rates of consumption up to 6-month 
follow-up 
    
  Days any alcohol use at 5-month follow-
up 
139 
SMD (IV, Random, 95% 
CI) 
-0.31 [-0.64, 
0.03] 
  Days heavy alcohol use (>4 drinks) at 5-
month follow-up 
46 
SMD (IV, Random, 95% 
CI) 
-0.70 [-1.30, -
0.11] 
Rate of consumption up to 6-month 
follow-up 
    
  Exceeded national drinking guidelines at 
least once at 6-month follow-up 
82 
RR (M-H, Random, 95% 
CI) 
0.89 [0.66, 
1.19] 
  Exceeded national drinking guidelines 6 
or more times at 6-month follow-up 
82 
RR (M-H, Random, 95% 
CI) 
0.89 [0.66, 
1.19] 
  Drank 10+ standard drinks at least once 
at 6-month follow-up 
82 
RR (M-H, Random, 95% 
CI) 
0.77 [0.58, 
1.03] 
  Drank 10+ or more drinks 6 or more 
times at 6-month follow-up 
82 
RR (M-H, Random, 95% 
CI) 
0.66 [0.43, 
1.00] 
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Rates of consumption >12-month follow-
up 
    
  Exceeded national drinking guidelines at 
least once at 5-year follow-up 
56 
RR (M-H, Random, 95% 
CI) 
0.90 [0.60, 
1.36] 
  Exceeded national drinking guidelines 6 
or more times at 5-year follow-up 
56 
RR (M-H, Random, 95% 
CI) 
0.92 [0.52, 
1.62] 
  Drank 10+ standard drinks at least once 
at 5-year follow-up 
56 
RR (M-H, Random, 95% 
CI) 
0.64 [0.34, 
1.22] 
  Drank 10+ or more drinks 6 or more 
times at 5-year follow-up 
56 
RR (M-H, Random, 95% 
CI) 
0.72 [0.29, 
1.74] 
Attrition (dropout)     
Attrition (dropout) post-treatment 290 
RR (M-H, Random, 95% 
CI) 
1.09 [0.76, 
1.57] 
Attrition (dropout) up to 6-month follow-
up 
82 
RR (M-H, Random, 95% 
CI) 
Not 
estimable 
  at 6-month follow-up 82 
RR (M-H, Random, 95% 
CI) 
Not 
estimable 
Attrition (dropout) at 7- to 12-month 
follow-up 
61    
  at 12 months 61 
RR (M-H, Random, 95% 
CI) 
0.89 [0.30, 
2.61] 
Attrition (dropout) >12-month follow-up 82 
RR (M-H, Random, 95% 
CI) 
1.30 [0.68, 
2.48] 
  at 5-year follow-up 82 
RR (M-H, Random, 95% 
CI) 
1.30 [0.68, 
2.48] 
 
Table 35: Motivational techniques versus other intervention evidence summary  
Outcome or subgroup 
Number of 
participants  Statistical method 
Effect 
estimate 
Abstinence     
Abstinent post-treatment 1801 SMD (IV, Random, 95% CI) 
0.08 [-0.02, 
0.18] 
Abstinence up to 6-month follow-up 2476 SMD (IV, Random, 95% CI) 
0.02 [-0.06, 
0.10] 
  at 3-month follow-up 835 SMD (IV, Random, 95% CI) 
0.09 [-0.12, 
0.30] 
  at 6-month follow-up 1641 SMD (IV, Random, 95% CI) 
-0.01 [-0.11, 
0.10] 
Abstinence - 7- 12-month follow-up     
  at 9-month follow-up 1616 SMD (IV, Random, 95% CI) 
0.05 [-0.06, 
0.15] 
  at 12-month follow-up 1672 SMD (IV, Random, 95% CI) 
0.04 [-0.07, 
0.15] 
Abstinence >12-month follow-up     
  at 15-month follow-up 1573 SMD (IV, Random, 95% CI) 
0.06 [-0.05, 
0.16] 
Lapse or Relapse     
Lapsed up to 6-month follow-up     
  at 6 months 82 RR (M-H, Random, 95% CI) 
0.93 [0.78, 
1.10] 
Lapsed >12-month follow-up     
  at 5 year follow-up 48 RR (M-H, Random, 95% CI) 
1.02 [0.75, 
1.40] 
Rates of consumption      
Rate of consumption post-treatment     
  Percent heavy drinking days 149 SMD (IV, Random, 95% CI) 
0.05 [-0.27, 
0.37] 
Rate of consumption up to 6-month 
follow-up 115 SMD (IV, Random, 95% CI) 
0.02 [-0.35, 
0.38] 
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  Binge consumption (occasions in 
prior 30 days where at least 7 (males) 
or 5 (females) drinks consumed at 6 
months 115 SMD (IV, Random, 95% CI) 
0.02 [-0.35, 
0.38] 
Rate of consumption up to 6-month 
follow-up     
  Exceeded national drinking 
guidelines at least once at 6-month 
follow-up 82 RR (M-H, Random, 95% CI) 
0.83 [0.63, 
1.10] 
  Exceeded national drinking 
guidelines 6 or more times at 6-
month follow-up 82 RR (M-H, Random, 95% CI) 
0.83 [0.63, 
1.10] 
  Drank 10+ standard drinks at least 
once at 6-month follow-up 82 RR (M-H, Random, 95% CI) 
0.80 [0.60, 
1.07] 
  Drank 10+ or more drinks 6 or 
more times at 6-month follow-up 82 RR (M-H, Random, 95% CI) 
0.69 [0.45, 
1.05] 
Rate of consumption – 7- to 12-
month follow-up     
  Number of days drinking per week 
at 12-month follow-up 657 SMD (IV, Random, 95% CI) 
0.00 [-0.15, 
0.15] 
  Days >5 drinks at 12 months 657 SMD (IV, Random, 95% CI) 
-0.08 [-0.23, 
0.08] 
Rates of consumption >12-month 
follow-up     
  Exceeded national drinking 
guidelines at least once at 5-year 
follow-up 48 RR (M-H, Random, 95% CI) 
0.96 [0.61, 
1.51] 
  Exceeded national drinking 
guidelines 6 or more times at 5-year 
follow-up 48 RR (M-H, Random, 95% CI) 
0.85 [0.47, 
1.53] 
  Drank 10+ standard drinks at least 
once at 5-year follow-up 48 RR (M-H, Random, 95% CI) 
0.88 [0.41, 
1.88] 
  Drank 10+ or more drinks 6 or 
more times at 5-year follow-up 48 RR (M-H, Random, 95% CI) 
1.17 [0.38, 
3.61] 
 
Amount of alcohol consumed      
Amount of alcohol consumed post-treatment     
  Drinks per drinking day 1652 
SMD (IV, Random, 95% 
CI) 
0.10 [-0.00, 
0.20] 
Amount of alcohol consumed up to 6-month 
follow-up 2380 
SMD (IV, Random, 95% 
CI) 
0.05 [-0.04, 
0.13] 
  Drinks per drinking day at 3-month follow-up 624 
SMD (IV, Random, 95% 
CI) 
-0.04 [-0.20, 
0.12] 
  Drinks per drinking day at 6-month follow-up 1641 
SMD (IV, Random, 95% 
CI) 
0.08 [-0.02, 
0.18] 
  Drinks per week at 6 months 115 
SMD (IV, Random, 95% 
CI) 
0.09 [-0.27, 
0.46] 
Amount of alcohol consumed 7- to 12-month 
follow-up     
  Drinks per drinking day at 9-month follow-up     
  Drinks per drinking day at 12-month follow-up 2771 
SMD (IV, Random, 95% 
CI) 
0.01 [-0.07, 
0.08] 
  Drinks per week at 12 months 657 
SMD (IV, Random, 95% 
CI) 
-0.01 [-0.16, 
0.14] 
Amount of alcohol consumed >12-month 
follow-up     
  Drinks per drinking day at 15-month follow-up 1573 
SMD (IV, Random, 95% 
CI) 
0.05 [-0.05, 
0.16] 
Attrition (dropout)      
Attrition (dropout) post-treatment 2022 
RR (M-H, Random, 95% 
CI) 
0.70 [0.31, 
1.59] 
Attrition (dropout) up to 6 months follow-up 2719 
RR (M-H, Random, 95% 
CI) 
1.37 [1.05, 
1.80] 
  at 3-month follow-up 762 
RR (M-H, Random, 95% 
CI) 
1.36 [0.84, 
2.18] 
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  at 6-month follow-up 1957 
RR (M-H, Random, 95% 
CI) 
1.38 [1.00, 
1.92] 
Attrition (dropout) at 7- to 12-months follow-up     
  at 9-month follow-up 1641 
RR (M-H, Random, 95% 
CI) 
1.85 [0.83, 
4.11] 
  at 12-month follow-up 3130 
RR (M-H, Random, 95% 
CI) 
1.15 [0.87, 
1.52] 
Attrition (dropout) >12-month follow-up 1676 
RR (M-H, Random, 95% 
CI) 
0.86 [0.55, 
1.35] 
  at 15-month follow-up 1594 
RR (M-H, Random, 95% 
CI) 
1.27 [0.52, 
3.08] 
  at 5-year follow-up 82 
RR (M-H, Random, 95% 
CI) 
0.75 [0.45, 
1.27] 
 
6.8 TWELVE-STEP FACILITATION 
6.8.1 Definition  
Twelve-Step Facilitation (TSF) is based on the 12-step or Alcoholics Anonymous 
(AA) concept that alcoholism is a spiritual and medical disease (see Section 6.4 for a 
discussion of AA). As well as a goal of abstinence, this intervention aims to actively 
encourage commitment to and participation in AA meeting. Participants are asked to 
keep a journal of AA attendance and participation and are given AA literature 
relevant to the ‗step‘ of the programme the client patient has reached. TSF is highly 
structured and manualised (Nowinski et al., 1992) and involves a weekly session in 
which the patient is asked about their drinking, AA attendance and participation, 
given an explanation of the themes of the current sessions, and goals for AA 
attendance are set.  
6.8.2 Clinical review protocol (twelve-step facilitation) 
Information about the databases searched and the inclusion/exclusion criteria used 
for this section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21). See Table 36 
below for a summary of the clinical review protocol for the review of twelve-step 
facilitation (TSF). 
 
Table 36: Clinical review protocol for the review of twelve-step facilitation (TSF) 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions TSF 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
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Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
Notes. 
6.8.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of TSF in the treatment of alcohol dependence or harmful 
alcohol use. See Table 37 for a summary of the study characteristics. It should be 
noted that some trials included in analyses were three- or four-arm trials. In order to 
avoid double-counting, the number of participants in treatment conditions used in 
more than one comparison was divided (by half in a three-arm trial, and by three in 
a four-arm trial). 
 
Six trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on n=2556 participants. All six studies were published in peer-
reviewed journals between 1997 and 2009. A number of studies identified in the 
search were initially excluded because they were not relevant to this guideline. 
Studies were excluded because they did not meet methodological criteria (see 
methods Chapter 3). When studies did meet basic methodological inclusion criteria, 
the main reason for exclusion was the studies were assessing the efficacy of twelve-
step groups (that is, AA) directly (not twelve-step facilitation) and hence were also 
naturalistic studies. Other reasons included a drug and not alcohol focus, secondary 
analysis and not being directly relevant to the current guideline. A list of excluded 
studies can be found in Appendix 16d. 
TSF versus other active intervention 
Of the six included trials, five compared TSF with another active intervention. The 
comparator against TSF was CBT (EASTON2007), couples therapy and 
psychoeducational intervention (FALSSTEWART2005; FALSSTWEART2006), MET 
and CBT (MATCH1997), and coping skills (WALITZER2009). 
 
Comparing different formats of TSF 
Two included studies assessed one form of TSF versus another. TIMKO2007 
evaluated intensive TSF versus standard TSF. In the standard TSF condition, people 
who misuse alcohol were given an AA schedule and encouraged to attend sessions. 
Counsellors and patients reviewed relapse prevention, but treatment was more 
focused on psychoeducation. In the intensive TSF condition, standard treatment was 
provided and counsellors actively arranged AA meeting attendance. Participants 
were encouraged to keep an AA attendance journal. WALITZER2009 assessed a 
directive approach to TSF versus a motivational approach to TSF in addition to 
treatment-as-usual (coping skills).  
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Table 37: Summary of study characteristics for Twelve-Step Facilitation (TSF) 
 TSF versus other active 
intervention 
Different formats of 
TSF 
K(total N) 5 RCTs (N = 1221) 2 RCTs (N = 456) 
Study ID (1) EASTON2007 
(2) FALSSTEWART2005 
(3) FALSSTWEART2006 
(4) MATCH1997 
(5) WALITZER2009 
(1) TIMKO2007  
(2) WALITZER2009  
 
Diagnosis (when reported) (1), (2) DSM alcohol 
dependent 
(3), (4) DSM IV alcohol 
dependent/abuse 
 
Baseline severity (when 
reported) 
(1) Approximately 19 years 
of alcohol use, 
alcohol use in past 28 days: 
approximately 6 days 
(2) Percentage day heavy 
drinking: 56 to 59% across 
treatment groups 
(3) Percentage days 
abstinent: 40 to 44% across 
treatment groups 
(4) Percentage days 
abstinent: approximately 
30, drinks per drinking day: 
approximately 16 drinks 
(5) Percentage days 
abstinent: 35.4%, 
percentage days heavy 
drinking: 32.7% 
(1) ASI alcohol 
score: 
approximately 0.28 
(2) Percentage days 
abstinent: 35.4%, 
percent days heavy 
drinking: 32.7% 
Number of sessions Range: 12 to 32 sessions (1) 1 session  
(2) 12 sessions in 
which TSF was in 
addition to other 
treatment 
Length of treatment 12 weeks Unclear 
Length of follow-up Range: 3 to 15 months Range: 3 to 12 
months 
Setting (1)–(3) Outpatient 
treatment centre 
(4) Clinical research unit 
(5) Outpatient treatment 
centre 
Outpatient 
treatment centre 
  
Treatment goal (1) Drinking 
reduction/moderation 
(2) Not explicitly stated 
(3) Abstinence 
(4) Abstinence or drinking 
reduction/moderation 
(5) Not explicitly stated 
Not explicitly 
stated 
 
Country (1)–(5) US US 
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6.8.4 Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
TSF versus other active intervention 
The clinical evidence revealed no significant difference between TSF and other active 
interventions in maintaining abstinence, reducing heavy drinking episodes when 
assessed post-treatment and various at follow-up points up to 12 months. TSF was 
significantly better than other active intervention in reducing the amount of alcohol 
consumed when assessed at 6-month follow-up. However, the effect size was small 
(SMD=-0.09) and no significant difference between groups was observed for any 
other follow-up points. 
 
No significant difference in attrition rates were observed between TSF and other 
active interventions in attrition post-treatment and up to 6-month follow-up. 
However, those receiving TSF were more likely to be retained at 9-month follow-up, 
although his difference was not observed at 12- and 15-month follow-up. 
 
The quality of this evidence is high therefore further research is unlikely to change 
our confidence in the estimate of the effect. An evidence summary of the results of 
the meta-analyses can be seen in Table 38. 
Comparing different formats of TSF 
Directive TSF was more effective at maintaining abstinence than motivational TSF 
up to 12-month follow-up (RR = -0.41 to -0.81 across follow-up points). However, no 
difference between groups was observed in reducing heavy drinking episodes.  
 
In addition, intensive TSF was significantly more effective than standard TSF in 
maintaining abstinence at 12-month follow-up (RR = 0.81). 
 
No significant difference between TSF methods was observed in attrition post-
treatment or at various follow-up points up to 12 months.  
 
Additionally, KAHLER2004 was identified as assessing brief advice to facilitate AA 
involvement versus a motivational enhancement approach to facilitate AA 
involvement. This study could not be included in analyses as data could not be 
extracted. However, the study reported that although AA attendance was associated 
with better drinking outcomes, the more intensive motivational enhancement format 
of facilitating involvement did not improve involvement in AA and hence did not 
result in better alcohol outcomes. 
 
The quality of this evidence is moderate and further research is likely to have an 
important impact on our confidence in the estimate of the effect and may change the 
estimate (see Appendix 18c). An evidence summary of the results of the meta-
analyses can be seen in Table 39. 
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Table 38: Twelve-Step Facilitation versus other intervention evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence       
Abstinence post-treatment 1860 SMD (IV, Random, 95% CI) 0.04 [-0.10, 0.18] 
Abstinence up to 6-month follow-up     
  % days abstinent at 3-month follow-up 340 SMD (IV, Random, 95% CI) -0.05 [-0.41, 0.31] 
  % days abstinent at 6-month follow-up 1975 SMD (IV, Random, 95% CI) -0.03 [-0.23, 0.16] 
Abstinence 7- to 12-month follow-up     
  % days abstinent at 9-month follow-up 1942 SMD (IV, Random, 95% CI) 0.00 [-0.18, 0.18] 
  % days abstinent at 12-month follow-up 1911 SMD (IV, Random, 95% CI) -0.01 [-0.21, 0.19] 
Abstinence >12-month follow-up     
 At 15-month follow-up 1573 SMD (IV, Random, 95% CI) -0.01 [-0.12, 0.09] 
Rates of consumption        
Rate of alcohol consumption post-
treatment 
    
 % days heavy drinking at post-treatment 99 SMD (IV, Random, 95% CI) -0.01 [-0.47, 0.45] 
Rate of alcohol consumption up to 6-
month follow-up 
    
  % days heavy drinking at 3-month 
follow-up 
301 SMD (IV, Random, 95% CI) -0.13 [-0.43, 0.17] 
  % days heavy drinking at 6-month 
follow-up 
296 SMD (IV, Random, 95% CI) -0.08 [-0.42, 0.26] 
Rate of alcohol consumption - 7- to 12-
month follow-up 
    
  % days heavy drinking at 9-month 
follow-up 
288 SMD (IV, Random, 95% CI) 0.13 [-0.14, 0.40] 
  % days heavy drinking at 12-month 
follow-up 
282 SMD (IV, Random, 95% CI) 0.15 [-0.28, 0.58] 
Amount of alcohol consumed       
Amount of alcohol consumed post-
treatment 
1651 SMD (IV, Random, 95% CI) 0.01 [-0.13, 0.15] 
Amount of alcohol consumed up to 6-
month follow-up 
    
  at 6-month follow-up 2194 SMD (IV, Random, 95% CI) -0.09 [-0.17, -0.00] 
Amount of alcohol consumed 7- to 12-
month follow-up 
    
  at 9-month follow-up 1615 SMD (IV, Random, 95% CI) -0.04 [-0.15, 0.06] 
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  at 12-month follow-up 1594 SMD (IV, Random, 95% CI) -0.09 [-0.20, 0.01] 
  at 6-month follow-up 1640 SMD (IV, Random, 95% CI) -0.09 [-0.19, 0.01] 
Amount of alcohol consumed >12-month 
follow-up 
    
  at 15-month follow-up 1573 SMD (IV, Random, 95% CI) -0.04 [-0.14, 0.07] 
Attrition (dropout)      
Attrition (dropout) post-treatment 1864 RR (M-H, Random, 95% CI) 1.11 [0.73, 1.70] 
Attrition (dropout) up to 6-month follow-
up 
    
  at 3-month follow-up 227 RR (M-H, Random, 95% CI) 0.57 [0.19, 1.73] 
  at 6-month follow-up 1853 RR (M-H, Random, 95% CI) 1.21 [0.29, 5.11] 
Attrition (dropout) 7- to 12-month follow-
up 
    
  at 9-month follow-up 1837 RR (M-H, Random, 95% CI) 0.37 [0.15, 0.88] 
  at 12-month follow-up 1930 RR (M-H, Random, 95% CI) 1.21 [0.55, 2.65] 
Attrition (dropout) >12-month follow-up     
  at 15-month follow-up 1594 RR (M-H, Random, 95% CI) 0.46 [0.16, 1.37] 
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Table 39: Comparing different formats of twelve-step facilitation evidence 
summary  
Outcome or subgroup 
Number of 
participants  
Statistical method 
Effect 
estimate 
Abstinence        
PDA up to 6 months follow-up     
  at 3-month follow-up 102 
SMD (IV, Random, 95% 
CI) 
-0.40 [-
0.79, -0.00] 
  at 6-month follow-up 97 
SMD (IV, Random, 95% 
CI) 
-0.41 [-
0.81, -0.01] 
PDA 7- to 12-month follow-up     
 at 9-month follow-up 95 
SMD (IV, Random, 95% 
CI) 
-0.57 [-
0.98, -0.16] 
 at 12-month follow-up 95 
SMD (IV, Random, 95% 
CI) 
-0.58 [-
0.99, -0.17] 
Lapse or relapse        
Number of participants lapsed 7- to 12-
month follow-up 
    
 at 12-month follow-up 307 
RR (M-H, Random, 95% 
CI) 
0.81 [0.66, 
1.00] 
Rates of consumption        
Percentage of days heavy drinking up to 6-
month follow-up 
    
 at 3-month follow-up 102 
SMD (IV, Random, 95% 
CI) 
-0.20 [-
0.59, 0.19] 
 at 6-month follow-up 97 
SMD (IV, Random, 95% 
CI) 
-0.07 [-
0.47, 0.33] 
Percentage of days heavy drinking at 7- to 
12-month follow-up 
    
 at 9-month follow-up 95 
SMD (IV, Random, 95% 
CI) 
-0.20 [-
0.60, 0.20] 
 at 12-month follow-up 95 
SMD (IV, Random, 95% 
CI) 
-0.09 [-
0.50, 0.31] 
Attrition (dropout)      
Attrition (dropout) post-treatment 345 
RR (M-H, Random, 95% 
CI) 
1.01 [0.55, 
1.84] 
Attrition (dropout) up to 6-month follow-up     
 at 3-month follow-up 111 
Odds ratio (M-H, Fixed, 
95% CI) 
0.29 [0.06, 
1.44] 
 at 6-month follow-up 102 
Odds ratio (M-H, Fixed, 
95% CI) 
1.53 [0.24, 
9.57] 
Attrition (dropout) 7- to 12-month follow-up     
 at 9-month follow-up 97 
RR (M-H, Random, 95% 
CI) 
1.02 [0.07, 
15.86] 
 at 12-month follow-up 440 
RR (M-H, Random, 95% 
CI) 
1.04 [0.52, 
2.06] 
 
6.9 COGNITIVE BEHAVIOURAL THERAPY 
6.9.1 Definition  
CBT encompasses a range of therapies in part derived from the cognitive 
behavioural model of affective disorders, in which the patient works collaboratively 
with a therapist using a shared formulation to achieve specific treatment goals. Such 
goals may include recognising the impact of behavioural and/or thinking patterns 
on feeling states and encouraging alternative cognitive and/or behavioural coping 
skills to reduce the severity of target symptoms and problems. Cognitive 
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behavioural therapies include standard CBT, relapse prevention, coping skills and 
social skills training. 
Standard cognitive behavioural therapy 
Standard CBT is a discrete, time-limited, structured psychological intervention, 
derived from a cognitive model of drug misuse (Beck et al., 1993). There is an 
emphasis on identifying and modifying irrational thoughts, managing negative 
mood and intervening after a lapse to prevent a full-blown relapse.  
Relapse-prevention  
A CBT adaptation based on the work of Marlatt, this incorporates a range of 
cognitive and behavioural therapeutic techniques to identify high risk situations, 
alter expectancies and increase self-efficacy. This differs from standard CBT in the 
emphasis on training people who misuse alcohol to develop skills to identify 
situations or states where they are most vulnerable to alcohol use, to avoid high-risk 
situations, and to use a range of cognitive and behavioural strategies to cope 
effectively with these situations (Annis, 1986; Marlatt & Gordon, 1985). 
Coping and Social Skills Training 
Coping and social skills training is a variety of CBT that is based on social learning 
theory of addiction and the relationship between drinking behaviour and life 
problems (Marlatt & Gordon, 1985; Kadden et al., 1992). Treatment is manual-based 
(Marlatt & Gordon, 1985) and involves increasing the individual‘s ability to cope 
with high-risk social situations and inter-personal difficulties.  
6.9.2 Clinical review protocol (cognitive behavioural therapies) 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this Section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21). See Table 40 
below for a summary of the clinical review protocol for the review of cognitive 
behavioural therapies. 
 
 Table 40: Clinical review protocol for the review of cognitive behavioural 
therapies 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Cognitive behavioural therapies 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
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Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
6.9.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of cognitive behavioural therapies in the treatment of alcohol 
dependence or harmful alcohol use. See Table 41 for a summary of the study 
characteristics. It should be noted that some trials included in analyses were three- 
or four-arm trials. In order to avoid double-counting, the number of participants in 
treatment conditions used in more than one comparison was divided (by half in a 
three-arm trial, and by three in a four-arm trial).  
 
Twenty RCT trials relating to clinical evidence met the eligibility criteria set by the 
GDG, providing data on n=3970 participants. All twenty studies were published in 
peer-reviewed journals between 1986 and 2009. A number of studies identified in the 
search were initially excluded because they were not relevant to this guideline. 
Studies were excluded because they did not meet methodological criteria (see 
methods Chapter 3). When studies did meet basic methodological inclusion criteria, 
the main reasons for exclusion were not having alcohol-focused outcomes that could 
be used for analysis, and not meeting drinking quantity/diagnosis criteria, that is, 
participants were not drinking enough to be categorised as harmful or dependent 
drinkers or less than 80% of the sample meet criteria for alcohol dependence or 
harmful alcohol use. Other reasons were that the study was outside the scope of this 
guideline, presented secondary analyses, and was drugs focused or did not 
differentiate between drugs and alcohol and were focused on aftercare. A list of 
excluded studies can be found in Appendix 16d.  
Cognitive behavioural therapies versus treatment-as-usual or control32 
Three studies compared CBT versus TAU or control. BURTSCHEIDT2002 assessed 
CBT versus coping skills versus TAU (unstructured, non-specific support and 
therapy). MONTI1993 investigated cue exposure with coping skills against control 
(unspecified TAU and daily cravings monitoring). ROSENBLUM2005b assessed 
relapse prevention with MET versus control (information and referral only). 
Cognitive behavioural therapies versus other active intervention 
Thirteen studies assessed CBT versus another active intervention. CONNORS2001 
was complex in design and investigated alcohol-focused coping skills, with/without 
the addition of life coping skills, with/without the addition of psychoeducational 
intervention at different intensities. Additionally, the study investigated the 
                                                 
32 Treatment as usual (TAU) and control were analysed together because TAU was unstructured, 
unspecified and brief and similar to what would be classified as control in other studies.  
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difference between low and high intensity treatment of these conditions. The results 
of the 30-month follow-up were obtained from Walitzer and Connors (2007). The 
other studies included in this analyses were DAVIDSON2007 (broad-spectrum 
treatment versus MET); EASTON2007 (CBT versus TSF); ERIKSEN1986B and 
LITT2003 (both assessed coping skills versus group counselling); LAM2009 (coping 
skills versus BCT with/without parental skills training); MATCH1997 (CBT versus 
both MET and TSF); MORGENSTERN2007 (coping skills with MET versus MET 
alone); SANDAHL1998 (relapse prevention versus psychodynamic therapy); 
SHAKESHAFT2002 (CBT versus FRAMES); SITHARTHAN1997 (CBT versus cue 
exposure); VEDEL2008 (CBT versus BCT); and WALITZER2009 (coping skills versus 
TSF).  
Comparing different formats of cognitive behavioural therapy  
Six studies investigated one form of CBT versus another form of CBT. 
BURTSCHEIDT2001 investigated CBT versus coping skills; MARQUES2001 assessed 
group versus individual cognitive behavioural psychotherapy; CONNORS2001 
investigated different intensities of alcohol-focused coping skills; LITT2009B 
assessed a packaged CBT program versus an individual assessment treatment 
program which was cognitive behavioural in nature; MONTI1990 investigated 
communication skills training (both with and without family therapy) as well as 
cognitive behavioural mood management training. ROSENBLUM2005a investigated 
relapse prevention versus relapse prevention with motivational enhancements.  
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 Table 41: Summary of study characteristics for cognitive behavioural therapies 
 Cognitive behavioural 
therapies versus TAU or 
control 
Cognitive behavioural therapies versus other active 
intervention 
Different formats of cognitive 
behavioural therapies 
K(total N) 3 RCTs (N = 450) 13 RCTs (N = 2956) 6 RCTs (N = 771) 
Study ID (1) BURTSCHEIDT2001  
(2) MONTI1993  
(3) ROSENBLUM2005b  
 
(1) CONNORS2001  
(2) DAVIDSON2007  
(3) EASTON2007  
(4) ERIKSEN1986B  
(5) LAM2009 
(6) LITT2003  
(7) MATCH1997  
(8) MORGENSTERN2007  
(9) SANDAHL1998  
(10) SHAKESHAFT2002  
(11) SITHARTHAN1997 
(12) VEDEL2008  
(13) WALITZER2009  
(1) BURTSCHEIDT2001  
(2) MARQUES2001  
(3) CONNORS2001  
(4) LITT2009B  
(5) MONTI1990  
(6) ROSENBLUM2005a 
 
 
Diagnosis (when 
reported) 
(1), (2) DSM alcohol dependent 
 
(1)–(3), (9) DSM alcohol dependent 
(5)–(8), (12) DSM dependent/abuse 
(1)–(3), (5) DSM /ICD alcohol 
dependent 
(4), (6) DSM alcohol 
dependent/abuse 
Baseline severity 
(when reported) 
(2) ADS score: 20.7 
SMAST score: 9.97 
Drinks per drinking day: 12.1 
drinks, PDA: 47% 
Percent days heavy drinking: 
45% 
 
 
(1) Percent of sample severe dependence: 8.3% 
Percent of sample moderate dependence: 66% 
Percent of sample mild dependence: 18.1% 
(2) PDA: approximately 30% 
Percent days heavy drinking: approximately 63% 
(3) Approximately 19 years of alcohol use 
Alcohol use in past 28 days: approximately 6 days 
(4) Previous alcoholism inpatient status: 66.7% 
(5) PDA: approximately 37% 
(6) Drinking days 6 months prior to intake: 72% 
(7) PDA: approximately 30% 
Drinks per drinking day: approximately 16 drinks 
(8) DDD: 9.5 drinks 
(2) Number of drinking days-in 
last 90 days: 49 days 
Number of heavy drinking days 
in last 90 days : 34.5 days  
Number of problem drinking 
days in last 90 days: 16.5 days  
Mean weekly consumption: 36.5 
drinks  
SADD score abstinence/ 
moderate rates: 17 
(3) Percentage of sample severe 
dependence: 8.3% 
Percentage of sample moderate 
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ADS core: 12.2 
(9) Duration of alcohol dependence: 11 years 
Reported morning drinking:75.5% 
(10) Weekly Australian units per week: approximately 32 units 
(11) SADQ-C score: 18.81 
ICQ score: 13.05 
CDSES score: 35.93 
Drinking days/ month: 20.2 days 
Consumption/ occasion: 8.82 drinks 
(12) 62% alcohol dependent 
50% when drinking drank 7+ units 
57% drank daily or nearly daily 
(13) PDA: 35.4% 
Percentage of days heavy drinking: 32.7% 
dependence: 66% 
Percentage of sample mild 
dependence: 18.1% 
Average monthly abstinent 
days: 10.1 days 
Average monthly light days: 6.1 
days 
Average monthly moderate 
days: 8 days 
Average monthly heavy days: 
5.7 days 
(4) Proportion days abstinence: 
0.19 days 
Proportion days heavy drinking: 
approximately 0.59 days 
(5) Percentage of possible 
drinking days abstinent: 
approximately 43% 
Number of possible DDD: 11 
drinks 
Number of actual DDD: 17 
drinks 
Percent possible drinking days 
in which heavy drinking: 45% 
(6) Number of days abstinent in 
past 30 days: 14 days 
ASI alcohol score: 
approximately 0.47 
Number of 
sessions 
Range: 6 to 26 sessions Range: 6 to 26 sessions Range: 12 to 23 sessions 
Length of 
treatment 
Range: 2 weeks to  6 months Range: 10 weeks to 6 months Range: 6 to 10 weeks 
Length of follow-
up  
Range: 0 to 6 months Range: 3 to 18-month  Range: 3 to 18 months  
Setting (1) Outpatient treatment centre 
(2) Inpatient 
Inpatient  
ERIKSEN1986B  
Inpatient  
MONTI1990  
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(3) Homeless soup-kitchen 
 
JOHN2003 
 
Outpatient treatment centre 
WALITZER2009  
 
Outpatient research unit 
LITT2003 
 
Outpatient treatment centre 
BURTSCHEIDT2001  
MARQUES2001  
LITT2009B  
 
Outpatient research unit 
CONNORS2001 
ROSENBLUM2005a 
 
Treatment goal 
 
Not explicitly stated 
BURTSCHEIDT2001  
MONTI1993  
ROSENBLUM2005b  
 
Drinking reduction/moderation 
CONNORS2001  
EASTON2007  
MORGENSTERN2007  
SANDAHL1998  
SITHARTHAN1997 
 
Abstinence or drinking reduction/moderation 
DAVIDSON2007  
ERIKSEN1986B  
MATCH1997  
VEDEL200833 
 
Not explicitly stated 
LAM2009 
LITT2003  
SHAKESHAFT2002  
WALITZER2009 
 
 
 
 
Drinking reduction/moderation 
CONNORS2001 
 
Not explicitly stated 
BURTSCHEIDT2001  
MARQUES2001  
LITT2009B  
MONTI1990  
ROSENBLUM2005a 
 
Country BURTSCHEIDT2001 (Germany) CONNORS2001 (US) BURTSCHEIDT2001 (Germany) 
                                                 
33 Guidelines were stipulated for controlled drinking. 
 267 
 
MONTI1993 (US) 
ROSENBLUM2005b (US) 
  
 
DAVIDSON2007 (US) 
EASTON2007 (US) 
ERIKSEN1986B (Norway) 
LAM2009 (US) 
LITT2003 (US)  
MATCH1997 (US)  
MORGENSTERN2007 (US)  
SANDAHL1998 (Sweden) 
SHAKESHAFT2002 (Australia) 
SITHARTHAN1997 (Australia 
VEDEL2008 (Netherlands 
WALITZER2009 (US) 
MARQUES2001 (Brazil) 
CONNORS (US) 
LITT2009B (US)  
MONTI1990 (US) 
ROSENBLUM2005a (US) 
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6.9.4 Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Cognitive behavioural therapies versus TAU or control 
Cognitive behavioural therapies were significantly better than control at reducing 
heavy drinking episodes but no significant difference between groups was observed 
for a reduction in days any alcohol is used (assessed post-treatment) or the number 
of participants who have lapsed and relapsed (assessed at 3-month follow-up) when 
compared with TAU. However, resulting in a moderate effect size, cognitive 
behavioural therapies were significantly better than TAU in reducing the number of 
participants who lapsed and relapsed when assessed at 6-month follow-up. No 
difference between groups was observed in attrition rates post-treatment or at 6-
month follow-up. 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect and may change the 
estimate (see Appendix 18c for full GRADE profile). 
 
One study assessing cognitive behavioural therapies versus control could not be 
added to the meta-analyses. KÄLLMÉN2003 could not be included as the data was 
presented in an unusable format. The study reported that the control group 
(unstructured discussion) drank significantly less alcohol at 18-month follow-up 
than the group receiving coping skills. An evidence summary of the results of the 
meta-analyses can be seen in Table 42. 
Cognitive behavioural therapies versus other active intervention 
Meta-analyses results revealed no significant difference between cognitive 
behavioural therapies and other therapies in maintaining abstinence both post-
treatment and up to 15-month follow-up. A single study however did favour coping 
skills over counselling in the number of sober days at 12-month follow-up, and 
another single study favouring relapse prevention over psychotherapy at 15-month 
follow-up. However, these single outcomes do not reflect the meta-analyses results 
described above. In addition, cognitive behavioural therapies were found to be more 
effective at maintaining abstinence/light days when assessed up to 18-month follow-
up (based on data by CONNORS2001). No significant difference was observed 
between groups in reducing heavy drinking episodes and the amount of alcohol 
consumed both post-treatment and up to 18-month follow-up. A single study 
outcome (ERIKSEN1986B ) favoured coping skills over counselling in reducing the 
amount of alcohol consumed, but again, this single study was not reflective of other 
analyses with similar variables.  
 
The VEDEL2008 study assessed severity of relapse in their sample. The results 
indicated that other active intervention (namely CBT) was more effective than 
couples therapy (namely BCT) in reducing occasions in which participants lapsed 
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drank over six drinks on one occasion) or relapsed (drank more than six drinks most 
days of the week, but no significant difference was observed in the number of 
participants who relapsed on a regular basis (a few times a month). It must be noted 
that effect sizes were small and the results of a single study cannot be generalised. 
 
No significant difference was observed between CBT and other active therapies in 
attrition rates.  
 
The quality of this evidence is high therefore further research is unlikely to change 
our confidence in the estimate of the effect. An evidence summary of the results of 
the meta-analyses can be seen in Table 43 and Table 44. 
Comparing different formats of cognitive behavioural therapies  
For maintaining abstinence, an individual assessment treatment programme was 
significantly more effective than a packaged CBT program when assessed post-
treatment (moderate effect size based on a single study). However, for the same 
comparison, no significant difference was observed between groups in reducing 
heavy drinking episodes. The addition of motivational enhancement to relapse 
prevention did not reduce the number of possible drinking days (at 6-month follow-
up) and analyses favoured standard relapse prevention (moderate effect size). 
Furthermore, the addition of family therapy to coping skills did not show any 
significant benefit. Also, no significant difference in various drinking outcomes was 
observed between coping skills and other types of cognitive behavioural therapies 
(for example, CBMMT) when assessed at 6-month follow-up. No difference between 
CBT and coping skills were observed in the number of participants who had lapsed 
or relapsed at 6-month follow-up. No difference in attrition rates were observed 
between the various types of CBT.  
 
More intensive coping skills was significantly better than standard coping skills at 
maintaining abstinent/light drinking at 12-month follow-up (moderate effect size) 
but this benefit was no longer significant at 18-month follow-up. Individual CBT was 
significantly more effective than group CBT in reducing the number of heavy 
drinkers at 15-month follow-up.    
 
The quality of this evidence is moderate and further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 45 and Table 46. 
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Table 42: Cognitive behavioural therapies versus treatment as usual or control 
evidence summary  
Outcome or subgroup 
Number of 
participants  Statistical method Effect estimate 
Rates of consumption        
Rates of consumption post-
treatment     
 Number of days any alcohol 
use 139 SMD (IV, Random, 95% CI) -0.31 [-0.64, 0.03] 
 Number of days heavy 
alcohol use (>4 drinks) 46 SMD (IV, Random, 95% CI) -0.70 [-1.30, -0.11] 
Lapse or relapse       
Lapsed - up to 6 months 
follow-up     
 at 3-month follow-up 34 RR (M-H, Random, 95% CI) 1.27 [0.64, 2.54] 
 at 6-month follow-up 137 RR (M-H, Random, 95% CI) 0.75 [0.57, 0.99] 
Relapse up to 6-month follow-
up     
 at 3-month follow-up 30 RR (M-H, Random, 95% CI) 1.57 [0.69, 3.59] 
 at 6-month follow-up 133 RR (M-H, Random, 95% CI) 0.55 [0.38, 0.80] 
Attrition (dropout)      
Attrition (dropout) post-
treatment 324 RR (M-H, Random, 95% CI) 1.07 [0.74, 1.53] 
Attrition (dropout) up to 6-
month follow-up     
 at 3-month follow-up 32 RR (M-H, Random, 95% CI) Not estimable 
 at 6-month follow-up 135 RR (M-H, Random, 95% CI) 0.53 [0.18, 1.54] 
 
 
Table 43: Cognitive behavioural therapies versus other interventions evidence 
summary (1) 
Outcome or subgroup 
Number of 
participants  Statistical method 
Effect 
estimate 
Abstinence     
Abstinence post-treatment     
 Days abstinent 1901 SMD (IV, Random, 95% CI) 
-0.09 [-0.21, 
0.03] 
Abstinence up to 6-month follow-up     
 PDA at 3-month follow-up 280 SMD (IV, Random, 95% CI) 
0.14 [-0.23, 
0.51] 
 PDA at 6-month follow-up 1946 SMD (IV, Random, 95% CI) 
0.02 [-0.12, 
0.17] 
Abstinence from 7- to 12-month 
follow-up     
 PDA at 9 months 1886 SMD (IV, Random, 95% CI) 
-0.01 [-0.14, 
0.13] 
 PDA at 12 months 1887 SMD (IV, Random, 95% CI) 
0.01 [-0.12, 
0.15] 
 Number of sober days at 12-month 
follow-up 23 SMD (IV, Random, 95% CI) 
-1.67 [-2.65, -
0.70] 
Abstinence >12-month follow-up     
 PDA at 15-month follow-up 1702 SMD (IV, Random, 95% CI) 
-0.06 [-0.16, 
0.04] 
 Number of days abstinent at 15-
month follow-up 44 SMD (IV, Random, 95% CI) 
0.64 [0.03, 
1.24] 
 PDA at 18-month follow-up 128 SMD (IV, Random, 95% CI) 
-0.22 [-0.57, 
0.13] 
Abstinent/light (1 to 3 standard 
drinks) up to 6-month follow-up     
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 at 6-month follow-up 61 SMD (IV, Random, 95% CI) 
-0.94 [-1.48, -
0.40] 
Abstinent/light (1 to 3 standard 
drinks) 7 to 12-month follow-up     
 at 12-month follow-up 61 SMD (IV, Random, 95% CI) 
-0.84 [-1.40, -
0.27] 
Abstinent/light (1 to 3 standard 
drinks) >12-month follow-up     
 at 18-month follow-up 61 SMD (IV, Random, 95% CI) 
-0.74 [-1.26, -
0.21] 
Lapse or relapse     
Days to first drink at 18-month 
follow-up 128 SMD (IV, Random, 95% CI) 
0.15 [-0.20, 
0.50] 
Days to first heavy drinking day at 
18-month follow-up 128 SMD (IV, Random, 95% CI) 
-0.09 [-0.44, 
0.26] 
Relapse (>6 units most days of the 
week) post-treatment 48 RR (M-H, Random, 95% CI) 
0.39 [0.18, 
0.86] 
Regular relapse (>6 units a few times 
a month) post-treatment 48 RR (M-H, Random, 95% CI) 
1.56 [0.44, 
5.50] 
Severe lapse (>6 units on one 
occasion) post-treatment 48 RR (M-H, Random, 95% CI) 
2.33 [1.01, 
5.38] 
Rates of consumption     
Rates of consumption post-
treatment     
 % heavy drinking days 149 SMD (IV, Random, 95% CI) 
-0.05 [-0.37, 
0.27] 
Rate of consumption up to 6-month 
follow-up     
 Proportion days heavy drinking at 
3-month follow-up 280 SMD (IV, Random, 95% CI) 
0.18 [-0.21, 
0.57] 
 Proportion days heavy drinking at 
6-month follow-up 275 SMD (IV, Random, 95% CI) 
0.15 [-0.26, 
0.55] 
 Drinking days per month at 6-
month follow-up 42 SMD (IV, Random, 95% CI) 
0.61 [-0.01, 
1.23] 
 Binge consumption (occasions in 
prior 30 days where at least 7 
(males) or 5 (females) drinks 
consumed at 6-month follow-up 115 SMD (IV, Random, 95% CI) 
-0.02 [-0.38, 
0.35] 
Rate of consumption – 7- to 12-
month follow-up     
 Proportion days heavy drinking at 
9-month follow-up 271 SMD (IV, Random, 95% CI) 
-0.04 [-0.29, 
0.20] 
 Proportion days heavy drinking at 
12-month follow-up 267 SMD (IV, Random, 95% CI) 
0.03 [-0.25, 
0.30] 
Rate of consumption >12-month 
follow-up     
 Days >80 g of absolute alcohol at 
15-month follow-up 44 SMD (IV, Random, 95% CI) 
0.06 [-0.53, 
0.65] 
 Proportion days heavy drinking at 
15 months 
128 SMD (IV, Random, 95% CI) 
-0.07 [-0.42, 
0.27] 
 Proportion days heavy drinking at 
18 months 
190 SMD (IV, Random, 95% CI) 
-0.20 [-0.50, 
0.10] 
 
 
Table 44: Cognitive behavioural therapies versus other interventions evidence 
summary (2) 
Outcome or subgroup 
Number of 
participants  
Statistical method 
Effect 
estimate 
Amount of alcohol consumed       
Amount of alcohol consumed post-treatment 1788 SMD (IV, Random, 95% CI) 
0.02 [-0.19, 
0.22] 
Amount of alcohol consumed up to 6-month follow-up     
 Number of participants consuming at 
hazardous/harmful levels weekly - at 6-month follow-
295 RR (M-H, Random, 95% CI) 
1.09 [0.80, 
1.49] 
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up 
 Number of participants binge drinking had at least 12 
binge episodes in previous 30 days - at 6-month 
follow-up 
295 RR (M-H, Random, 95% CI) 
1.12 [0.84, 
1.49] 
 Number of participants binge drinking at all (at least 1 
binge episode in previous 30 days) at 6-month follow-
up 
295 RR (M-H, Random, 95% CI) 
0.95 [0.87, 
1.05] 
 Units of alcohol per week at 5-month follow-up 48 SMD (IV, Random, 95% CI) 
0.20 [-0.37, 
0.77] 
 Units of alcohol per week at 6-month follow-up 45 SMD (IV, Random, 95% CI) 
0.16 [-0.42, 
0.75] 
 Drinks per occasion/drinking day at 6 months 1683 SMD (IV, Random, 95% CI) 
0.07 [-0.13, 
0.26] 
 Drinks per week at 6-months 115 SMD (IV, Random, 95% CI) 
-0.09 [-0.46, 
0.27] 
Amount of alcohol consumed - 7- to 12-month follow-
up 
    
 Alcohol consumption (cl pure alcohol) at 12-month 
follow-up 
24 SMD (IV, Random, 95% CI) 
-1.15 [-2.02, -
0.27] 
 Drinks per drinking day at 9-month follow-up 1615 SMD (IV, Random, 95% CI) 
-0.03 [-0.13, 
0.08] 
 Drinks per drinking day at 12-month follow-up 1683 SMD (IV, Random, 95% CI) 
0.07 [-0.04, 
0.17] 
Amount of alcohol consumed >12-month follow-up 1618 SMD (IV, Random, 95% CI) 
-0.02 [-0.12, 
0.08] 
 grams absolute alcohol per drinking day at 15-month 
follow-up 
44 SMD (IV, Random, 95% CI) 
-0.07 [-0.66, 
0.53] 
 Drinks per drinking day at 15-month follow-up 1574 SMD (IV, Random, 95% CI) 
-0.02 [-0.12, 
0.09] 
Attrition (dropout)       
Attrition (dropout) post-treatment 2267 RR (M-H, Random, 95% CI) 
1.05 [0.61, 
1.80] 
Attrition (dropout) - up to 6-month follow-up     
 at 3-month follow-up 200 RR (M-H, Random, 95% CI) 
1.29 [0.60, 
2.78] 
 at 6-month follow-up 2296 RR (M-H, Random, 95% CI) 
0.93 [0.59, 
1.48] 
Attrition (dropout) - 7 -12-month follow-up     
 at 9-month follow-up 1788 RR (M-H, Random, 95% CI) 
1.61 [0.76, 
3.40] 
 at 12-month follow-up 1988 RR (M-H, Random, 95% CI) 
1.27 [0.47, 
3.41] 
Attrition (dropout) - >12-month follow-up 1773 RR (M-H, Random, 95% CI) 
1.75 [0.84, 
3.64] 
 at 15-month follow-up 1643 RR (M-H, Random, 95% CI) 
1.65 [0.77, 
3.52] 
 at 18-month follow-up 130 RR (M-H, Random, 95% CI) 
4.29 [0.21, 
85.82] 
 
 
Table 45: Comparing different formats of CBT evidence summary  
Outcome or subgroup 
Number 
of 
participan
ts  
Statistical method Effect estimate 
Abstinence       
Abstinence post-treatment 110 SMD (IV, Random, 95% CI) 0.39 [0.01, 0.77] 
Abstinence up to 6-month follow-up     
 at 15 week follow-up 186 SMD (IV, Random, 95% CI) -0.31 [-0.60, -0.02] 
 % possible drinking days (any day not in 
inpatient treatment or jail) abstinent at 6-
month follow-up 
94 SMD (IV, Random, 95% CI) -0.10 [-0.52, 0.32] 
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Table 46: Comparing different formats of CBT evidence summary 
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Lapse or relapse/ other outcomes       
Number of participants lapsed - up to 6-month 
follow-up 
63 
RR (M-H, Random, 95% 
CI) 
1.09 [0.70, 1.70] 
 at 6 months 63 
RR (M-H, Random, 95% 
CI) 
1.09 [0.70, 1.70] 
Number of participants relapse - up to 6-month 
follow-up 
63 
RR (M-H, Random, 95% 
CI) 
1.03 [0.53, 2.03] 
 at 6 months 63 
RR (M-H, Random, 95% 
CI) 
1.03 [0.53, 2.03] 
Number of days to 1st drink (lapse) up until 6-
month follow-up 
94 
SMD (IV, Random, 95% 
CI) 
0.19 [-0.23, 0.61] 
 at 6-month follow-up 94 
SMD (IV, Random, 95% 
CI) 
0.19 [-0.23, 0.61] 
Number of days to first heavy drink (relapse) up 
until 6-month follow-up 
94 
SMD (IV, Random, 95% 
CI) 
0.11 [-0.31, 0.53] 
 at 6-month follow-up 94 
SMD (IV, Random, 95% 
CI) 
0.11 [-0.31, 0.53] 
Number heavy drinkers >20 drinks/wk and >10% 
heavy days (>=5 drinks/occasion) at 15-month 
follow-up 
100 
RR (M-H, Random, 95% 
CI) 
2.86 [1.26, 6.48] 
Attrition (dropout)       
Attrition (dropout) post-treatment 204 
RR (M-H, Random, 95% 
CI) 
0.87 [0.44, 1.71] 
Attrition (dropout) up to 6-month follow-up 515 RR (M-H, Random, 95% 1.07 [0.69, 1.68] 
Abstinent/light (1 to 3 standard drinks) 
Drinking Days up to 6-month follow-up 
   
 at 6-month follow-up 61 SMD (IV, Random, 95% CI) -0.39 [-0.90, 0.12] 
Abstinent/light (1 to 3 standard drinks) 
Drinking Days 7- to 12-month follow-up 
    
 at 12-month follow-up 61 SMD (IV, Random, 95% CI) -0.65 [-1.21, -0.09] 
Abstinent/light (1 to 3 standard drinks) 
Drinking Days >12-month follow-up 
   
 at 18-month follow-up 61 SMD (IV, Random, 95% CI) -0.38 [-0.96, 0.20] 
Rates of consumption        
Rates of consumption post-treatment    
 Proportion of heavy drinking days (men>6, 
women>4 drinks) 
110 SMD (IV, Random, 95% CI) 0.34 [-0.04, 0.72] 
Rates of Consumption up to 6-month follow-
up 
   
 % of possible days (any day not in inpatient 
treatment or jail) heavy (>6) drinking at 6-
month follow-up 
94 SMD (IV, Random, 95% CI) -0.22 [-0.65, 0.20] 
Rates of consumption >12-month follow-up     
 Number of drinking days at 15-month follow-
up 
106 SMD (IV, Random, 95% CI) -0.03 [-0.41, 0.35] 
 Number of problem drinking days at 15-
month follow-up 
106 SMD (IV, Random, 95% CI) 0.24 [-0.14, 0.62] 
 Number of heavy drinking days at 15-month 
follow-up 
106 SMD (IV, Random, 95% CI) 0.37 [-0.01, 0.75] 
Amount of alcohol consumed       
Amount of alcohol consumed up until 6-
month follow-up 
    
 Number of drinks per possible drinking day 
(any day not in inpatient treatment or jail) at 6-
month follow-up 
94 SMD (IV, Random, 95% CI) -0.30 [-0.73, 0.13] 
 Number of drinks per actual drinking day at 
6-month follow-up 
94 SMD (IV, Random, 95% CI) -0.49 [-1.44, 0.47] 
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CI) 
 at 15 week follow-up 230 
RR (M-H, Random, 95% 
CI) 
1.11 [0.65, 1.90] 
 at 6 months 285 
RR (M-H, Random, 95% 
CI) 
0.99 [0.44, 2.23] 
Attrition (dropout) 7- to 12-month follow-up 132 
RR (M-H, Random, 95% 
CI) 
0.89 [0.06, 13.57] 
 at 12-month follow-up 132 
RR (M-H, Random, 95% 
CI) 
0.89 [0.06, 13.57] 
Attrition (dropout) >12-month follow-up 285 
RR (M-H, Random, 95% 
CI) 
0.99 [0.42, 2.35] 
 at 15-month follow-up 155 
RR (M-H, Random, 95% 
CI) 
0.87 [0.55, 1.39] 
 at 18-month follow-up 130 
RR (M-H, Random, 95% 
CI) 
4.43 [0.22, 88.74] 
 
6.10 BEHAVIOURAL THERAPIES (EXCLUDING 
CONTINGENCY MANAGEMENT)34  
6.10.1 Definition  
Behavioural interventions use behavioural theories of conditioning to help achieve 
abstinence from drinking by creating negative experiences/events in the presence of 
alcohol, and positive experiences/events in alcohols absence. Behavioural therapies 
considered for review included cue exposure, behavioural self-control training, 
aversion therapy and contingency management. Variants of two therapies (cue 
exposure and behavioural self-control training) which were based on a similar 
theoretical understanding of the nature of alcohol misuse were considered as single 
entity for the purposes of the review. Contingency management, although a 
behavioural intervention, was analysed separately because it is based on classic 
reinforcement model and has no alcohol specific formulation (see section 6.11 for 
evidence review). Aversion therapy was excluded because it is no longer routinely 
used in alcohol treatment in the UK.  
Cue exposure 
Cue exposure treatment for alcohol misuse is based on both learning theory models 
and social learning theory and suggests that environmental cues associated with 
drinking can elicit conditioned responses which can in turn lead to a relapse (Niaura 
et al., 1988). The first case study using cue exposure treatment for excessive alcohol 
consumption was reported by Hodgson and Rankin (1976). Treatment is designed to 
reduce craving for alcohol by repeatedly exposing the service user to alcohol-related 
cues until they ‗habituate‘ to the cues and can hence maintain self-control in a real-
life situation where these cues are present. 
Behavioural self-control training 
Behavioural self-control training is also referred to as ‗behavioural self-management 
training‘ and is based on the techniques described by Miller and Muńoz (1976). 
Patients are taught to set limits for drinking, self-monitor drinking episodes, refusal 
                                                 
34 See section 6.11 for a review of contingency management  
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skills training and training for coping behaviours in high-risk relapse situations. 
Behavioural self-control training is focused on a moderation goal rather than 
abstinence.  
6.10.2 Clinical review protocol (behavioural therapies) 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this section of the guideline can be found in Appendix 16d (further information 
about the search for health economic evidence can be found in Section 6.21). See 
Table 47 below for a summary of the clinical review protocol for the review of 
behavioural therapies. 
 
Table 47: Clinical review protocol for the review of behavioural therapies 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Behavioural Self-Management, Behavioural Self-Management 
Training, Behavioural Self-Control Training, Cue Exposure 
(alone or with CBT or Coping Skills), Moderation-Oriented Cue 
Exposure 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
Notes. 
6.10.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of behavioural therapies in the treatment of alcohol 
dependence or harmful alcohol use. SeeTable 48 for a summary of the study 
characteristics. It should be noted that some trials included in analyses were three- 
or four-arm trials. In order to avoid double-counting, the number of participants in 
treatment conditions used in more than one comparison was divided (by half in a 
three-arm trial, and by three in a four-arm trial). 
 
Six RCT trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on n=527 participants. All six studies were published in peer-
reviewed journals between 1988 and 2006. A number of studies identified in the 
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search were initially excluded because they were not relevant to this guideline. 
Studies were excluded because they did not meet methodological criteria (see 
Chapter 3). When studies did meet basic methodological inclusion criteria, the main 
reasons for exclusion were not having alcohol-focused outcomes that could be used 
for analysis, and not meeting drinking quantity/diagnosis criteria, that is, 
participants were not drinking enough to be categorised as harmful or dependent 
drinkers or less than 80% of the sample meet criteria for alcohol dependence or 
harmful alcohol use. A list of excluded studies can be found in Appendix 16d. 
Table 48: Summary of study characteristics for behavioural therapies 
 Behavioural therapies 
versus control/TAU 
Behavioural therapies 
versus other active 
intervention 
Different formats 
of behavioural 
therapy 
K(total N) 2 RCTs (N = 134) 4 RCTs (N = 3420) 2 RCTs (N = 199) 
Study ID (1) ALDEN1988  
(2) MONTI1993  
(1) ALDEN1988 
(2) KAVANAGH2006  
(3) SITHARTHAN1997  
(4) WALITZER2004  
(1) HEATHER2000  
(2) 
KAVANAGH2006  
 
Diagnosis (when 
reported) 
(2) DSM alcohol dependent 
 
(2) DSM alcohol 
dependent 
(4) 85% had low level 
alcohol dependence and 
15% had moderate 
levels 
(2) DSM alcohol 
dependent 
 
Baseline severity 
(when reported) 
(1) Consuming >84 
standard ethanol units per 
week 
(2) ADS score: 20.7 
SMAST score: 9.97 
Drinks/drinking day: 12.1; 
abstinent days: 47%; heavy 
drinking days: 45% 
 
(1) Consuming >84 
standard ethanol units 
per week 
(2) SADQ-C score: 
approximately 13.7 
AUDIT score: 
approximately 28 
Weekly alcohol 
consumption: 
approximately 37 
(3) SADQ-C score: 18.81 
ICQ score: 13.05 
CDSES score: 35.93 
Drinking days/ month: 
20.2; consumption/ 
occasion: 8.82 
(4) ADS score: 8.4 
Abstinent days/month: 
11.0; Frequency of >6 
drink per drinking 
period per month: 5.1  
(1) SADQ-C score: 
18.7 
APQ: 10.1 
Drinks/drinking 
day: 19.96; 
abstinent days: 
19.14% 
(2) SADQ-C score: 
approximately 13.7 
AUDIT score: 
approximately 28 
Weekly alcohol 
consumption:  
approximately 37 
 
Number of sessions Range: 6 to 12 Range: 6 to 12 8 sessions 
Length of treatment Range: 6 to 12 weeks Range: 6 to 12 weeks 8 weeks 
Length of follow-up  Range: 6 to 24 months Range: 3 to 12 months Range: 3 to 12 
months 
Setting (1) Outpatient clinical 
research unit 
(2) Inpatient VA medical 
(1)–(4) Outpatient 
clinical research unit 
(1), (2) Outpatient 
clinical research 
unit 
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Behavioural therapies versus control  
Of the six included trials, there were two involving a comparison of behavioural 
therapies versus control which met criteria for inclusion. ALDEN1988 assessed 
behavioural self-management training versus waiting list control, and MONTI1993 
assessed cue exposure with coping skills versus control (treatment-as-usual and 
daily cravings monitoring). The included studies were conducted between 1988 and 
1993.  
Behavioural Therapies versus other active intervention  
 Of the six included trials, four trials which evaluated behavioural therapies versus 
other active interventions met criteria for inclusion. Behavioural and other active 
therapies were as follows: ALDEN1988 (behavioural self-management versus 
developmental counselling); KAVANAGH2006 (cue exposure plus CBT versus 
emotional cue exposure plus CBT); SITHARTHAN1997 (cue exposure versus CBT); 
WALITZER2004 (behavioural self management versus behavioural couples therapy 
with alcohol focused spousal involvement and alcohol focused spousal involvement 
alone). The included studies were conducted between 1988 and 2006. 
Comparing different formats of behavioural therapy 
Of the six included trials, two trials which assessed one type of behavioural therapy 
versus another met criteria for inclusion. The behavioural therapies in the 
HEATHER2000 study were moderation-oriented cue exposure and behavioural self-
control training. In the KAVANAGH2006 study, they were cue exposure (plus CBT) 
and emotional cue exposure (plus CBT). The included studies were conducted 
between 2000 and 2006. 
 
 
6.10.4 Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Behavioural therapies versus control/TAU 
The review evidence indicated behavioural therapies were more effective than 
control in reducing the amount of alcohol consumed (SMD=-0.97, large effect size) 
and maintaining controlled drinking (SMD=-0.60, medium effect size) when 
assessed post-treatment. However, it must be noted that this was based on a single 
study. 
centre  
Treatment goal (1) Drinking 
reduction/moderation 
(2) Not explicitly stated 
(1)–(4) Drinking 
reduction/moderation 
(1), (2) Drinking 
reduction/moderat
ion 
Country (1) Canada 
(2) US 
(1)–(3) Australia 
(4) US 
(1) UK 
(2) Australia 
 
 278 
 
No significant difference was observed between behavioural therapies and control in 
maintaining abstinence when assessed post-treatment. Furthermore, no significant 
difference could be found between behavioural therapies and control in the number 
of participants who lapsed or relapsed up to 6-month follow-up. In addition, there 
was no significant difference between behavioural therapies and control in attrition 
rates.  
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 49. 
Behavioural therapy versus other active intervention  
The review evidence indicated that behavioural therapies were not as effective as 
other interventions (in this case couples-based therapies) in maintaining 
abstinent/light drinking days up to 12-month follow-up. In addition to this, there 
was no significant difference between behavioural therapies and counselling in 
maintaining abstinence both post-treatment and up to 24-month follow-up. 
 
No difference was observed between behavioural therapies and other active 
interventions (for example, CBT) in reducing the amount of alcohol consumed up to 
24-month follow-up. However, one study (SITHARTHAN1997) showed a medium 
effect size favouring cue exposure over CBT in reducing drinks per occasion at 6-
month follow-up. 
 
Behavioural therapies were not as effective as other active interventions (namely 
couples therapies) in reducing heavy drinking days. Medium to high effects 
favouring couples therapy were found at all assessment points up to 12-month 
follow-up.  
 
The review results revealed that other therapies (that is, CBT and counselling) had 
significantly less post-treatment attrition than behavioural therapies. However, no 
significant difference was observed between treatments at follow-up (3 to 24 
months). 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 50. 
 
Comparing different formats of behavioural therapy 
The clinical evidence indicates that there was no significant difference between cue 
exposure and behavioural self-control training in maintaining abstinence post-
treatment or at 6-month follow-up. Furthermore, no significant difference was 
observed between cue exposure and emotional cue exposure in reducing the amount 
of alcohol consumed at six to 12-month follow-up. In line with this, no significant 
difference was observed between moderation-oriented cue exposure and behaviour 
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self-control training in reducing alcohol consumption when assessed at 6-month 
follow-up. 
 
No difference was observed between behavioural therapies in attrition both at post-
treatment and 6-month follow-up. 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 51. 
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Table 49: Behavioural therapy versus TAU or control evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence       
Abstinent days per week post-treatment 94 SMD (IV, Random, 95% CI) -0.37 [-0.79, 0.04] 
Amount of alcohol consumed       
Total weekly consumption post-
treatment 
94 SMD (IV, Random, 95% CI) -0.97 [-1.40, -0.54] 
Lapse or relapse       
Lapse up to 6-month follow-up     
  at 0 to 3 months 34 RR (M-H, Random, 95% CI) 1.27 [0.64, 2.54] 
  at 3 to 6 months 34 RR (M-H, Random, 95% CI) 0.57 [0.29, 1.10] 
Relapse up to 6-month follow-up     
  at 0 to 3 months 34 RR (M-H, Random, 95% CI) 1.60 [0.68, 3.79] 
  at 3 to 6 months 34 RR (M-H, Random, 95% CI) 0.63 [0.25, 1.61] 
Rates of consumption       
Controlled (<= 3 standard drinks) per 
week at post-treatment 
94 SMD (IV, Random, 95% CI) -0.60 [-1.02, -0.18] 
Attrition (dropout)       
Attrition (dropout) post-treatment 34 RR (M-H, Random, 95% CI) 0.44 [0.04, 4.45] 
Attrition (dropout) up to 6-month 
follow-up 
    
  at 3 months 32 RR (M-H, Random, 95% CI) Not estimable 
  at 6 months 32 RR (M-H, Random, 95% CI) 3.95 [0.20, 76.17] 
 
Table 50: Behavioural therapy versus other intervention evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method 
Effect 
estimate 
Abstinence       
Abstinence post-treatment     
 PDA per week 73 SMD (IV, Random, 95% CI) 
0.11 [-0.35, 
0.57] 
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 Controlled (<=3 standard drinks) per week post-treatment 73 SMD (IV, Random, 95% CI) 
0.00 [-0.46, 
0.47] 
Abstinence up to 6-month follow-up     
 PDA/light per month at 3-month follow-up 63 SMD (IV, Random, 95% CI) 
0.77 [0.23, 
1.31] 
 PDA/light per month at 6-month follow-up 83 SMD (IV, Random, 95% CI) 
0.49 [0.06, 
0.93] 
Abstinence 7- to 12-month follow-up     
 PDA/light per month at 9-month follow-up 61 SMD (IV, Random, 95% CI) 
0.60 [0.05, 
1.15] 
 PDA/light per month at 12-month follow-up 61 SMD (IV, Random, 95% CI) 
0.54 [-0.01, 
1.09] 
Abstinent days per week at 12-month follow-up 105 SMD (IV, Random, 95% CI) 
0.22 [-0.17, 
0.60] 
 Controlled (<=3 standard drinks) per week at 12-month follow-up 105 SMD (IV, Random, 95% CI) 
0.19 [-0.19, 
0.57] 
Abstinence >12-month follow-up     
 Abstinent days per week at 24-month follow-up 93 SMD (IV, Random, 95% CI) 
0.14 [-0.26, 
0.55] 
 Controlled (<=3 standard drinks) per week at 24-month follow-up 93 SMD (IV, Random, 95% CI) 
0.28 [-0.13, 
0.69] 
Amount of alcohol consumed       
Amount of alcohol consumed post-treatment 73 SMD (IV, Random, 95% CI) 
-0.12 [-0.59, 
0.34] 
Total weekly alcohol consumption (standard drinks) post assessment 73 SMD (IV, Random, 95% CI) 
-0.12 [-0.59, 
0.34] 
Amount of alcohol consumed up to 6-month follow-up     
Total weekly alcohol consumption at 3-month follow-up 164 SMD (IV, Random, 95% CI) 
0.12 [-0.21, 
0.44] 
Drinks per occasion at 6-month follow-up 42 SMD (IV, Random, 95% CI) 
-0.66 [-1.29, -
0.04] 
Total weekly alcohol consumption at 6-month follow-up 164 SMD (IV, Random, 95% CI) 
0.14 [-0.19, 
0.46] 
Amount of alcohol consumed per week 7- to 12-month follow-up     
Total weekly alcohol consumption at 9-month follow-up 164 SMD (IV, Random, 95% CI) 
0.05 [-0.28, 
0.37] 
Total weekly alcohol consumption at 12-month follow-up 269 SMD (IV, Random, 95% CI) 
0.18 [-0.07, 
0.42] 
Amount of alcohol consumed per week >12-month follow-up 105 SMD (IV, Random, 95% CI) 
0.08 [-0.31, 
0.46] 
Total weekly alcohol consumption at 24 months follow-up 105 SMD (IV, Random, 95% CI) 
0.08 [-0.31, 
0.46] 
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Rates of consumption       
Rates of consumption up to 6-month follow-up     
 Percentage of days heavy drinking (>6 drinks per day) at 3-month 
follow-up 
64 SMD (IV, Random, 95% CI) 
0.96 [0.42, 
1.51] 
 Percentage of days heavy drinking (>6 drinks per day) at 6-month 
follow-up 
63 SMD (IV, Random, 95% CI) 
0.59 [0.06, 
1.13] 
 Drinking days per month at 6-month follow-up 42 SMD (IV, Random, 95% CI) 
-0.61 [-1.23, 
0.01] 
Rates of consumption up to 7- to 12-month follow-up     
  Percentage of days heavy drinking (>6 drinks per day) at 9-month 
follow-up 
62 SMD (IV, Random, 95% CI) 
0.85 [0.30, 
1.41] 
  Percentage of days heavy drinking (>6 drinks per day) at 12-month 
follow-up 
62 SMD (IV, Random, 95% CI) 
0.66 [0.12, 
1.21] 
2.11 Attrition (dropout) post-treatment 306 RR (M-H, Random, 95% CI) 
1.73 [1.13, 
2.63] 
2.12 Attrition (dropout) up to 6-month follow-up     
 2.12.1 at 3 months 64 RR (M-H, Random, 95% CI) 
0.61 [0.03, 
13.87] 
 2.12.2 at 6 month 110 RR (M-H, Random, 95% CI) 
1.55 [0.35, 
6.82] 
Attrition (dropout) 7- to 12-month follow-up 251 RR (M-H, Random, 95% CI) 
1.49 [0.72, 
3.07] 
 at 9 months 63 RR (M-H, Random, 95% CI) 
3.10 [0.41, 
23.61] 
 at 12 months 188 RR (M-H, Random, 95% CI) 
1.34 [0.61, 
2.90] 
Attrition (dropout) >12-month follow-up 105 RR (M-H, Random, 95% CI) 
0.98 [0.34, 
2.85] 
 at 24 months 105 RR (M-H, Random, 95% CI) 
0.98 [0.34, 
2.85] 
 
Table 51: Comparing various formats of behavioural therapy evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence       
Abstinent post-treatment (MOCE versus BSCT) 77 SMD (IV, Random, 95% CI) -0.23 [-0.68, 0.22] 
Abstinence up to 6-month follow-up    
 at 6-month follow-up (MOCE versus BSCT) 91 RR (M-H, Random, 95% CI) 0.90 [0.19, 4.21] 
Amount of alcohol consumed       
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Amount of alcohol consumed up to 6-month follow-up     
 at 3-month follow-up (CE versus ECE) 108 SMD (IV, Random, 95% CI) -0.02 [-0.40, 0.36] 
 at 6-month follow-up (CE versus ECE)  108 SMD (IV, Random, 95% CI) -0.05 [-0.43, 0.33] 
Amount of alcohol consumed 7- to 12-month follow-up     
 Drinks per drinking day at 6-month follow-up (MOCE versus 
BSCT) 
77 SMD (IV, Random, 95% CI) 0.41 [-0.04, 0.86] 
 Amount of alcohol consumed at 9 months (CE versus ECE) 108 SMD (IV, Random, 95% CI) -0.01 [-0.39, 0.37] 
 Amount of alcohol consumed at 12-month follow-up (CE versus 
ECE)  
108 SMD (IV, Random, 95% CI) -0.02 [-0.40, 0.36] 
Attrition (dropout)       
Attrition (dropout) post-treatment (CE versus ECE) 108 RR (M-H, Random, 95% CI) 0.75 [0.50, 1.14] 
Attrition (dropout) up to 6-month follow-up    
 at 6-month follow-up (MOCE versus BSCT)  91 RR (M-H, Random, 95% CI) 1.61 [0.59, 4.44] 
 284 
 
6.11 CONTINGENCY MANAGEMENT 
6.11.1 Definition  
Contingency management provides a system of reinforcement designed to make 
continual alcohol use less attractive and abstinence more attractive. There are four 
main methods of providing incentives: 
 Voucher-based reinforcement: People who misuse alcohol receive vouchers 
with various monetary values (usually increasing in value after successive 
periods of abstinence) for providing biological samples (usually urine) that 
are negative for alcohol. These vouchers are withheld when the biological 
sample indicates recent alcohol use. Once earned, vouchers are exchanged for 
goods or services that are compatible with an alcohol-free lifestyle. 
 Prize-based reinforcement: This is more formally referred to as the ‗variable 
magnitude of reinforcement procedure‘ (Prendergast et al., 2006). Participants 
receive draws, often from a number of slips of paper kept in a fishbowl, for 
providing a negative biological specimen. Provision of a specimen indicating 
recent alcohol use results in the withholding of draws. Each draw has a 
chance of winning a ‗prize‘, and the value of which varies. Typically, about 
half the draws say ‗Good job!‘. The other half results in the earning of a prize, 
which may range in value from £1 to £100 (Prendergast et al., 2006). 
 Cash incentives: people who misuse alcohol receive cash (usually of a 
relatively low value, for example, £1.50 to £10) for performing the target 
behaviour, such as submitting a urine sample negative for alcohol or 
compliance with particular interventions. Cash incentives are withheld when 
the target behaviour is not performed. 
 Clinic privileges: participants receive clinic privileges for performing the 
target behaviour, for example, providing a negative biological sample. But 
these privileges are withheld when the target behaviour is not performed. An 
example of a clinic privilege is a take-home methadone dose (for example, 
Stitzer et al., 1992). This incentive is appropriate for drug treatment for 
substances such as heroin but is not applicable to alcohol treatment.  
6.11.2 Clinical review protocol (Contingency Management) 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this Section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21). See Table 52 
below for a summary of the clinical review protocol for the review of contingency 
management). 
 
Table 52: Clinical review protocol for the review of contingency 
management 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
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Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Contingency Management 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
 
6.11.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of contingency management in the treatment of alcohol 
dependence or harmful alcohol use. See Table 53 for a summary of the study 
characteristics.  
 
Three trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on n=355 participants. All three studies were published in peer-
reviewed journals between 2000 and 2007. A number of studies identified in the 
search were initially excluded because they were not relevant to this guideline. 
Studies were excluded because they did not meet methodological criteria (see 
methods Chapter 3). When studies did meet basic methodological inclusion criteria, 
the main reason for exclusion was that the participants in the study did not meet 
drinking quantity/diagnosis criteria, that is, participants were not drinking enough 
to be categorised as harmful or dependent drinkers or less than 80% of the sample 
meet criteria for alcohol dependence or harmful alcohol use. Another reason was 
that the study was drugs focused or did not differentiate between drugs and alcohol. 
A list of excluded studies can be found in Appendix 16d.  
Contingency management versus control  
Of the three included trials, there was only one involving a comparison of 
contingency management versus control which met criteria for inclusion. LITT2007 
assessed contingency management with network support versus case management 
(an active control). 
Contingency management versus TAU 
 Of the three included trials, two trials evaluating contingency management versus 
treatment-as-usual (standard care) met criteria for inclusion. Both ALESSI2007 and 
PETRY2000 assessed contingency management with standard care versus standard 
care alone. The included studies were conducted between 2000 and 2007. 
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Contingency management versus other active intervention  
Of the three included trials, one trial which assessed contingency management 
versus another active intervention met criteria for inclusion. The treatment 
conditions in LITT2007 were contingency management with network support versus 
network support alone.  
 
Table 53: Summary of study characteristics for contingency management 
 Contingency 
management versus 
control 
Contingency 
management versus 
treatment as usual 
Contingency 
management versus 
other active 
intervention 
K(total N) 1 RCTs (N = 139) 2 RCTs (N = 145) 1 RCTs (N = 141) 
Study ID (1) LITT2007 (1) ALESSI2007  
(2) PETRY2000  
(1) LITT2007  
Diagnosis (when 
reported) 
(1) DSM alcohol 
dependent/abuse 
(1) DSM alcohol 
dependent/abuse  
(2) DSM alcohol 
dependent 
(1) DSM alcohol 
dependent/abuse 
Baseline severity 
(when reported) 
(1) Drinking days in 
past 3 months: 72% 
 (2) Years of alcohol 
dependence: 23.5 years 
(1) Drinking days in 
past 3 months: 72% 
Number of  
sessions 
12 sessions (1), (2) rewards for 
negative sample  
(1) rewards for 
attendance 
12 sessions 
Length of  
treatment 
12 weeks N/A 12 weeks 
Length of follow-
up 
27 months Range: Post-Treatment 
only 
27 months 
Setting (1) Outpatient 
treatment centre 
(1), (2) Outpatient 
treatment centre 
(1) Outpatient 
treatment centre 
Treatment goal (1) Not explicitly 
stated 
(1), (2) Abstinence (1) Not explicitly 
stated 
Country (1) US (1), (2) US (1) US 
 
6.11.4 Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Contingency management versus control 
The review evidence indicated that contingency management (with network 
support) was more effective at maintaining abstinence than control post-treatment 
(large effect size) and up to 15-month follow-up (medium effect size). However, no 
significant differences were observed between contingency management with 
network support and control for follow-up periods greater than 15 months. It should 
be noted that this analyses was based on the LITT2007 study only. 
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Contingency management (with network support) was more effective than control 
(low to medium effect size) at reducing drinking quantity when assessed at 6, 9 and 
21-month follow-up. However, no significant difference was found between 
treatment conditions post-treatment, at 12-, 15-, 18-, 24- and 27-month follow-up. 
 
No significant difference was observed between conditions in attrition post-
treatment and at all follow-up points up to 27 months. 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 54. 
Contingency management versus TAU (standard care) 
The clinical review revealed no significant beneficial effect of adding contingency 
management to standard care in maintaining abstinence when assessed post-
treatment. However, the addition of contingency management to standard care was 
beneficial in reducing the number of participants who relapsed to heavy drinking. 
Furthermore, the addition of contingency management to standard care was 
beneficial in reducing attrition rates. 
 
The quality of this evidence is moderate therefore further research is likely to have 
an important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in  
Table 55. 
Contingency management versus other active intervention 
The addition of contingency management to network support was not beneficial in 
maintaining abstinence both post-treatment and up to 9-month follow-up. However, 
network support without contingency management was more effective at 
maintaining abstinence at 12- to 24-month follow-up. 
 
The quality of this evidence is moderate therefore further research is likely to have 
an important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in  
Table 56. 
 
Table 54: Contingency management versus control evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence       
Abstinence post-treatment     
 PDA post-treatment 114 SMD (IV, Random, 95% CI) -0.80 [-1.18, -0.42] 
Abstinence up to 6-month follow-up     
 at 6-month follow-up 114 SMD (IV, Random, 95% CI) -0.68 [-1.06, -0.31] 
Abstinence 7- to 12-month follow-up     
 at 9-month follow-up 114 SMD (IV, Random, 95% CI) -0.58 [-0.96, -0.21] 
 at 12-month follow-up 114 SMD (IV, Random, 95% CI) -0.39 [-0.76, -0.02] 
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Abstinence >12-month follow-up     
 at 15-month follow-up 114 SMD (IV, Random, 95% CI) -0.50 [-0.87, -0.12] 
 at 18-month follow-up 114 SMD (IV, Random, 95% CI) 0.10 [-0.27, 0.47] 
 at 21-month follow-up 114 SMD (IV, Random, 95% CI) -0.15 [-0.52, 0.22] 
 at 24-month follow-up 114 SMD (IV, Random, 95% CI) -0.24 [-0.61, 0.12] 
 at 27-month follow-up 114 SMD (IV, Random, 95% CI) 0.09 [-0.27, 0.46] 
Amount of alcohol consumed       
Amount of alcohol consumed (DDD) post-treatment 114 SMD (IV, Random, 95% CI) -0.25 [-0.61, 0.12] 
Amount of alcohol consumed (DDD) up to 6-month 
follow-up 
114    
 at 6-month follow-up 114 SMD (IV, Random, 95% CI) -0.66 [-1.04, -0.28] 
Amount of alcohol consumed (DDD) 7- to 12-month 
follow-up 
    
 at 9-months 114 SMD (IV, Random, 95% CI) -0.38 [-0.75, -0.01] 
 at 12-month follow-up 114 SMD (IV, Random, 95% CI) -0.10 [-0.47, 0.26] 
Amount of alcohol consumed (DDD) >12-month follow-
up 
    
 at 15-month follow-up 114 SMD (IV, Random, 95% CI) -0.11 [-0.48, 0.26] 
 at 18-month follow-up 114 SMD (IV, Random, 95% CI) -0.26 [-0.63, 0.11] 
 at 21-month follow-up 114 SMD (IV, Random, 95% CI) -0.53 [-0.90, -0.16] 
 at 24-month follow-up 114 SMD (IV, Random, 95% CI) -0.10 [-0.47, 0.27] 
 at 27-month follow-up 114 SMD (IV, Random, 95% CI) 0.13 [-0.23, 0.50] 
Attrition (dropout)       
Attrition (dropout) post-treatment 139 RR (M-H, Random, 95% CI) 1.23 [0.35, 4.40] 
Attrition (dropout) up to 6-month follow-up     
 at 6-months 130 RR (M-H, Random, 95% CI) 2.00 [0.19, 21.52] 
Attrition (dropout) 7- to 12-month follow-up     
 at 9-months 127 RR (M-H, Random, 95% CI) 7.11 [0.37, 134.89] 
 at 12-months 124 RR (M-H, Random, 95% CI) Not estimable 
Attrition (dropout) >12-month follow-up     
 at 18-months 123 RR (M-H, Random, 95% CI) 1.08 [0.07, 16.95] 
 at 27-months 117 RR (M-H, Random, 95% CI) 2.18 [0.20, 23.37] 
 
Table 55: Contingency management versus standard care (TAU) evidence 
summary  
Outcome or subgroup 
Number of 
participants 
Statistical method 
Effect 
estimate 
Abstinence       
Abstinence post-treatment    
 Longest duration abstinent (weeks) post-treatment 103 SMD (IV, Random, 95% CI) 
-0.27 [-0.66, 
0.12] 
Lapse or relapse       
 Number relapsed to heavy drinking at end of treatment 42 RR (M-H, Random, 95% CI) 
0.43 [0.19, 
0.98] 
 Number lapsed (non-abstinent) at the end of treatment 42 RR (M-H, Random, 95% CI) 
0.52 [0.25, 
1.09] 
Attrition (dropout)       
Attrition (dropout) abstinence post-treatment 145 RR (M-H, Random, 95% CI) 
0.19 [0.07, 
0.52] 
 
Table 56: Contingency management versus other intervention evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
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Abstinence        
Abstinence post-treatment     
 PDA post-treatment 112 SMD (IV, Random, 95% CI) -0.12 [-0.49, 0.25] 
Abstinence up to 6-month follow-up     
 at 6-month follow-up 112 SMD (IV, Random, 95% CI) 0.13 [-0.24, 0.50] 
Abstinence 7- to 12-month follow-up     
 at 9-month follow-up 112 SMD (IV, Random, 95% CI) 0.19 [-0.18, 0.56] 
 at 12-month follow-up 112 SMD (IV, Random, 95% CI) 0.37 [-0.00, 0.75] 
Abstinence >12-month follow-up     
 at 15-month follow-up 112 SMD (IV, Random, 95% CI) 0.35 [-0.02, 0.72] 
 at 18-month follow-up 112 SMD (IV, Random, 95% CI) 0.70 [0.32, 1.08] 
 at 21-month follow-up 112 SMD (IV, Random, 95% CI) 0.37 [-0.01, 0.74] 
 at 24-month follow-up 112 SMD (IV, Random, 95% CI) 0.48 [0.11, 0.86] 
 at 27-month follow-up 112 SMD (IV, Random, 95% CI) 0.84 [0.45, 1.22] 
Amount of alcohol consumed       
Amount of alcohol consumed (DDD) post-treatment 114 SMD (IV, Random, 95% CI) -0.36 [-0.73, 0.01] 
Amount of alcohol consumed (DDD) up to 6-month 
follow-up 
    
 at 6-month follow-up 114 SMD (IV, Random, 95% CI) -0.25 [-0.62, 0.12] 
Amount of alcohol consumed (DDD) 7- to 12-month 
follow-up 
    
 at 9-months 114 SMD (IV, Random, 95% CI) -0.05 [-0.42, 0.31] 
 at 12-month follow-up 114 SMD (IV, Random, 95% CI) 0.32 [-0.05, 0.69] 
Amount of alcohol consumed (DDD) >12-month 
follow-up 
    
 at 15-month follow-up 114 SMD (IV, Random, 95% CI) 0.49 [0.12, 0.87] 
 at 18-month follow-up 114 SMD (IV, Random, 95% CI) 0.17 [-0.20, 0.54] 
 at 21-month follow-up 114 SMD (IV, Random, 95% CI) -0.21 [-0.57, 0.16] 
 at 24-month follow-up 114 SMD (IV, Random, 95% CI) 0.03 [-0.34, 0.40] 
 at 27-month follow-up 114 SMD (IV, Random, 95% CI) 0.15 [-0.22, 0.52] 
Attrition        
Attrition (dropout) post-treatment 141 RR (M-H, Random, 95% CI) 0.85 [0.27, 2.64] 
Attrition (dropout) up to 6-month follow-up     
 at 6 months 130 RR (M-H, Random, 95% CI) 5.00 [0.24, 102.16] 
Attrition (dropout) 7- to 12-month follow-up     
 at 9 months 128 RR (M-H, Random, 95% CI) 3.10 [0.33, 28.97] 
 at 12 months 124 RR (M-H, Random, 95% CI) Not estimable 
Attrition (dropout) >12-month follow-up     
 at 18 months 122 RR (M-H, Random, 95% CI) 3.20 [0.13, 77.04] 
 at 27 months 117 RR (M-H, Random, 95% CI) 0.73 [0.13, 4.19] 
 
6.12 SOCIAL NETWORK AND ENVIRONMENT BASED 
THERAPIES 
6.12.1 Definition  
Social network and environment based therapies use the individual‘s social 
environment as a way to help achieve abstinence or controlled drinking. These 
therapies include SBNT and the community reinforcement approach (CRA).  
Social behaviour and network therapy 
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SBNT comprises a range of cognitive and behavioural strategies to help clients build 
social networks supportive of change which involve the patient and members of the 
patient‘s networks (for example, friends and family) (Copello et al., 2002). The 
integration of these strategies has the aim of helping the patient to build ‗positive 
social support for a change in drinking‘. 
The Community Reinforcement Approach (CRA) 
 In the community reinforcement approach (Hunt & Azrin, 1973; Meyers & Miller, 
2001; Sisson & Azrin, 1989), emphasis is placed on maintaining abstinence through 
the development of activities that do not promote alcohol use, for example, 
recreational and social activities, employment and family involvement.  
6.12.2 Clinical review protocol (Social Network and Environment 
Based Therapies) 
Information about the databases searched and the inclusion/exclusion criteria used 
for this Section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21). See Table 57 
below for a summary of the clinical review protocol for the review of social network 
and environment based therapies. 
 
Table 57: Clinical review protocol for the review of social network and 
environment based therapies 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Social Network and Environment Based Therapies 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
 
6.12.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of social network and environment based therapies in the 
treatment of alcohol dependence or harmful alcohol use. See Table 58 for a summary 
of the study characteristics. It should be noted that some trials included in analyses 
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were three- or four-arm trials. In order to avoid double-counting, the number of 
participants in treatment conditions used in more than one comparison was divided 
(by half in a three-arm trial, and by three in a four-arm trial). 
 
Three trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on n=1058 participants. All three studies were published in peer-
reviewed journals between 1999 and 2007. A number of studies identified in the 
search were initially excluded because they were not relevant to this guideline. 
Studies were excluded because they did not meet methodological criteria (see 
Chapter 3). When studies did meet basic methodological inclusion criteria, the main 
reason for exclusion was not having alcohol-focused outcomes that could be used for 
analysis. A list of excluded studies can be found in Appendix 16d. 
Social network and environment based therapies versus control  
Of the three included trials, there was only one involving a comparison of social 
network and environment based therapies versus control which met criteria for 
inclusion. LITT2007 assessed network support (both with and without contingency 
management) versus a case management active control. In this study, network 
support involved encouraging the participant to change their social network form 
one that promotes drinking to one that encourages abstinence as well as encouraging 
the use of established social support networks such as alcoholics anonymous (AA). 
Social network and environment based therapies versus other active 
intervention 
Two of the three included trials which met criteria for inclusion assessed social 
network and environment based therapies versus another active intervention. 
LEIGH1999 investigated a volunteer support condition (a volunteer was part of most 
treatment sessions and spent a substantial amount of time with the participant 
whilst in the community) versus an unspecified office-based individual intervention. 
UKATT2005 investigated social behaviour and network therapy (see Section 6.12.1 
for definition) versus MET. 
 
Table 58: Summary of study characteristics for social network and 
environment based therapies 
 Social network and environment 
based therapies versus control 
Social network and environment 
based therapies versus other 
active intervention 
K(total N) 1 RCT (N = 210) 2 RCTs (N = 989) 
Study ID (1) LITT2007 (1) LEIGH2009 
(2) UKATT2005  
Diagnosis (when 
reported) 
(1) DSM alcohol 
dependent/abuse 
(2) DSM alcohol 
dependent/abuse  
Baseline severity 
(when reported) 
(1) Drinking days in past 3 
months: 72% 
Prior treatment for alcohol 
dependence: 1.3  
 
(1) Outpatient alcoholics 
drinking 5.5 days per week 
Drinks per week: Range 73 to 89 
(2) Days abstinent: 29.5% per 
month 
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Number of drinks per drinking 
day: 26.8 
Number of sessions 12 sessions 8 sessions 
Length of treatment 12 weeks Range: 8 to 16 weeks 
Length of follow-up  6- to 27-month Range: 1- to 12-month 
Setting (1) Outpatient treatment centre 
 
(1), (2) Outpatient treatment 
centre 
Treatment goal (1) Not explicitly stated (1), (2) Abstinence or drinking 
reduction/moderation 
Country (1) US (1) Canada 
(2) UK 
 
 
6.12.4 Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Social network and environment based therapies versus control  
The clinical evidence showed that social network and environment based therapies 
were significantly better than control at maintaining abstinence (moderate effect 
size) when assessed post-treatment, and at 6-, 9-, 12-, 15- and 24-month follow-up. 
However, no significant difference was observed at 18-, 21- and 27-month follow-up. 
 
Social network and environment based therapies were not significantly better than 
control in reducing drinking at post-treatment or at 12-, 15-, 24- and 27-month 
follow-up. However, a significant benefit (low to moderate effect size) was observed 
for social network and environment based therapies over control in reducing the 
quantity of alcohol consumed when assessed at 6-, 9-, 18- and 21-month follow-up. 
 
No significant difference was observed between treatment conditions in attrition 
either post-treatment or at all follow-up points. It must be noted that the comparison 
between social network and environment based therapies versus control was based 
on a single study. 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 59. 
Social network and environment based therapies versus other active 
intervention 
The clinical evidence did not reveal any significant difference between social 
network and environment based therapies and other active interventions in 
maintaining abstinence, reducing the quantity of alcohol consumed, reducing the 
number of drinking days and attrition. 
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The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 60. 
 
Table 59: Social network/environment based therapies versus control evidence 
summary 
Outcome or subgroup 
Number of 
participants  
Statistical method 
Effect 
estimate 
Abstinence        
Abstinence post-treatment     
 % days abstinent post-treatment 172 SMD (IV, Random, 95% CI) 
-0.76 [-1.08, -
0.43] 
Abstinence up to 6-month follow-
up 
    
 at 6-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.75 [-1.08, -
0.43] 
Abstinence 7- to 12-month follow-
up 
    
 at 9-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.70 [-1.03, -
0.38] 
 at 12-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.59 [-0.99, -
0.19] 
Abstinence >12-month follow-up     
 at 15-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.68 [-1.03, -
0.32] 
 at 18-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.28 [-1.02, 
0.46] 
 at 21-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.35 [-0.74, 
0.05] 
 at 24-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.49 [-0.96, -
0.01] 
 at 27-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.31 [-1.12, 
0.49] 
Amount of alcohol consumed       
Drinks per drinking day post-
treatment 
172 SMD (IV, Random, 95% CI) 
-0.07 [-0.41, 
0.28] 
Drinks per drinking day up to 6-
month follow-up 
    
 at 6-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.54 [-0.86, -
0.22] 
Drinks per drinking day 7- to 12-
month follow-up 
    
 at 9 months 172 SMD (IV, Random, 95% CI) 
-0.37 [-0.68, -
0.05] 
 at 12-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.25 [-0.57, 
0.06] 
Drinks per drinking day >12-month 
follow-up 
    
 at 15-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.35 [-0.83, 
0.12] 
 at 18-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.34 [-0.66, -
0.03] 
 at 21-month follow-up 172 SMD (IV, Random, 95% CI) -0.43 [-0.75, -
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0.11] 
 at 24-month follow-up 172 SMD (IV, Random, 95% CI) 
-0.11 [-0.43, 
0.20] 
 at 27-month follow-up 172 SMD (IV, Random, 95% CI) 
0.06 [-0.26, 
0.37] 
Attrition (dropout)       
Attrition (dropout) post-treatment 211 RR (M-H, Random, 95% CI) 
1.36 [0.45, 
4.13] 
Attrition (dropout) up to 6-month 
follow-up 
    
 at 6 months 196 RR (M-H, Random, 95% CI) 
0.54 [0.08, 
3.59] 
Attrition (dropout) 7- to 12-month 
follow-up 
    
 at 9-months 192 RR (M-H, Random, 95% CI) 
2.41 [0.28, 
20.76] 
 at 12 months 188 RR (M-H, Random, 95% CI) Not estimable 
Attrition (dropout) >12-month 
follow-up 
365 RR (M-H, Random, 95% CI) 
0.78 [0.22, 
2.79] 
 at 18-months 186 RR (M-H, Random, 95% CI) 
0.33 [0.04, 
2.64] 
 at 27-months 179 RR (M-H, Random, 95% CI) 
1.31 [0.26, 
6.61] 
 
Table 60: Social network/environment based therapies versus other intervention 
evidence summary   
Outcome or subgroup 
Number of 
participants  
Statistical method 
Effect 
estimate 
Abstinence        
Abstinence up to 6-month follow-up     
 PDA at 3-month follow-up 686 SMD (IV, Random, 95% CI) 
-0.02 [-
0.17, 0.13] 
Abstinence 7- to 12-month follow-up     
 PDA at 12-month follow-up 612 SMD (IV, Random, 95% CI) 
-0.02 [-
0.18, 0.14] 
Rates of consumption        
Rate of consumption up to 6-month 
follow-up 
    
 Number drinking days at 1-month 
follow-up 
79 SMD (IV, Random, 95% CI) 
-0.03 [-
0.47, 0.41] 
 Number of drinking days 6-month 
follow-up 
79 SMD (IV, Random, 95% CI) 
0.09 [-0.35, 
0.54] 
Rate of consumption at 7- to 12-month 
follow-up 
    
 Number of drinking days 12-month 
follow-up 
79 SMD (IV, Random, 95% CI) 
0.15 [-0.29, 
0.60] 
Amount of alcohol consumed       
Amount of alcohol consumed up to 6-
month follow-up 
    
 Mean quantity per day at 1-month 
follow-up 
79 SMD (IV, Random, 95% CI) 
0.02 [-0.42, 
0.46] 
 Mean quantity per day 6 months 
follow-up 
79 SMD (IV, Random, 95% CI) 
0.43 [-0.02, 
0.87] 
 Number drinks per drinking day at 3- 624 SMD (IV, Random, 95% CI) 0.04 [-0.12, 
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month follow-up 0.20] 
Amount of alcohol consumed 7- to 12-
month at follow-up 
599 SMD (IV, Random, 95% CI) 
0.07 [-0.09, 
0.23] 
 Mean quantity per day 12-month 
follow-up 
79 SMD (IV, Random, 95% CI) 
0.13 [-0.31, 
0.57] 
 Number of drinks per drinking day at 
12-month follow-up 
520 SMD (IV, Random, 95% CI) 
0.06 [-0.11, 
0.23] 
Attrition (dropout)      
Attrition (dropout) post-treatment 193 RR (M-H, Random, 95% CI) 
0.93 [0.68, 
1.28] 
Attrition (dropout) up to 6-month 
follow-up 
    
 at 3-month follow-up 762 RR (M-H, Random, 95% CI) 
0.68 [0.42, 
1.08] 
Attrition (dropout) 7- to 12-month 
follow-up 
    
 at 12-month follow-up 689 RR (M-H, Random, 95% CI) 
1.00 [0.65, 
1.56] 
 
6.13 COUPLES THERAPY 
6.13.1 Definition  
The content and definition of couples therapy can vary and reflect different 
approaches, for example, cognitive behavioural or psychodynamic. Couples-based 
interventions (including behavioural couples therapy [BCT]) involve the spouse or 
partner expressing active support for the person who misuses alcohol in reducing 
alcohol use, including via the use of behavioural contracts. Couples are helped to 
improve their relationship through more effective communication skills, and 
encouraged to increase positive behavioural exchanges through acknowledgement 
of pleasing behaviours and engagement in shared recreational activities (Fals-
Stewart et al., 2005). Standard BCT is manual based and structured (Fals-Stewart et 
al., 2004) and combines cognitive-behaviour treatment strategies with methods that 
address relationship issues arising from alcohol misuse as well as more general 
relationship problems with the aim of reducing distress.  
6.13.2 Clinical review protocol (Couples Therapy) 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this Section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21). See Table 61 
below for a summary of the clinical review protocol for the review of couples 
therapy. 
 
Table 61: Clinical review protocol for the review of couples therapy 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
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At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Couples Therapy 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
 
6.13.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the 
or detrimental effects of couples therapies in the treatment of alcohol dependence 
harmful alcohol use. See 
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Table 62: Summary of study characteristics for couples therapy 
 for a summary of the study characteristics. It should be noted that some trials 
included in analyses were three- or four-arm trials. In order to avoid double-
counting, the number of participants in treatment conditions used in more than one 
comparison was divided (by half in a three-arm trial, and by three in a four-arm 
trial). 
 
Eight trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on n=602 participants. All eight studies were published in peer-
reviewed journals between 1988 and 2009. A number of studies identified in the 
search were initially excluded because they were not relevant to this guideline. 
Studies were excluded because they did not meet methodological criteria (see 
methods Chapter 3). When studies did meet basic methodological inclusion criteria, 
the main reason for exclusion was not having alcohol-focused outcomes that could 
be used for analysis. Other reasons were not meeting drinking quantity/diagnosis 
criteria, that is, participants were not drinking enough to be categorised as harmful 
or dependent drinkers or less than 80% of the sample meet criteria for alcohol 
dependence or harmful alcohol use, the study was outside the scope of this 
guideline, or the study was drugs focused or did not differentiate between drugs 
and alcohol. A list of excluded studies can be found in Appendix 16d.  
Couples therapy versus other active intervention  
Of the eight included RCT trials, seven compared couples therapy with another 
active intervention met criteria for inclusion. In the FALSSTEWART2005 study, 
participants received one of two methods of couples therapy (BCT and brief 
relationship counselling) or individually based TSF or psychoeducational 
intervention. All groups also had group counselling as standard. 
FALSSTEWART2006 assessed BCT (with individual TSF) versus individual TSF or 
psychoeducational intervention alone. LAM2009 investigated BCT (both with and 
without parental skills training) versus individually-based coping skills. 
OFARRELL1992 assessed two methods of couples therapy (interactional couples 
therapy and behavioural marital therapy) versus counselling. SOBELL2000 
compared couples therapy in the form of direct social support with natural social 
support. VEDEL2008 compared BCT with CBT. WALITZER2004 investigated BCT 
with and without alcohol-focused spousal involvement with behavioural self-
management.  
Behavioural couples therapy versus other couples therapy  
Three studies assessed BCT versus other methods of couples therapy. Studies that 
could be included in these analyses compared BCT to the following; brief 
relationship therapy (FALSSTEWART2005), interactional couples therapy 
(OFARRELL1992), and alcohol focused spousal involvement (WALITZER2004). 
Intensive behavioural couples therapy versus brief couples therapy  
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Two studies were included to assess the possible difference in outcome between 
more intensive and less intensive couples therapy. FALSSTEWART2005 assessed 
BCT (plus counselling) versus brief relationship therapy plus counselling (brief 
BCT). ZWEBEN1988 assessed eight sessions of conjoint therapy versus one session of 
couples advice counselling.  
Parental skills & behavioural couples therapy versus behavioural couples 
therapy alone 
This analyses involved a single study (LAM2009) which assessed BCT with and 
without the addition of parental skills training. 
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Table 62: Summary of study characteristics for couples therapy 
 Couples therapy versus other active 
intervention 
BCT versus other couples therapy  Intensive versus BCT Parental skills & 
BCT versus BCT 
alone 
K (total N) 7 RCTs (N = 486) 3 RCTs (N = 114) 2 RCTs (N = 216) 1 RCT (N = 20) 
Study ID (1) FALSSTEWART2005  
(2) FALSSTEWART2006  
(3) LAM2009  
(4) OFARRELL1992  
(5) SOBELL2000  
(6) VEDEL2008  
(7) WALITZER2004  
(1) FALSSTEWART2005 
(2) OFARRELL1992 
(3) WALITZER2004 
 
(1) FALSSTEWART2005  
(2) ZWEBEN1988  
 
(1) LAM2009 
Diagnosis 
(when 
reported) 
(1) DSM alcohol dependent 
(2), (3), (6) DSM dependent/abuse 
(1) DSM alcohol dependent 
 
(1) DSM alcohol dependent (1) DSM 
dependent/ abuse 
Baseline 
severity 
(when 
reported) 
(1) Percent days heavy drinking: 56 to 59% 
across groups 
(2) PDA: 40 to 44% across groups 
(3) PDA: approximately 37% 
(4) MAST score >7 
Years of problem drinking: 15.79 years 
Previous alcohol hospitalisations: 2.09 
(5) ADS score: 12.6 
Proportion days abstinent: 0.22 approximately 
 Proportion days 1 to 4 drinks: 0.35 
approximately 
 Proportion days 5 to 9 drinks: 0.32 
approximately 
 Proportion days 10+ drinks: 0.12 approximately 
Mean number of drinks per drinking day: 6 
drinks approximately 
(6) 62% alcohol dependent 
50% when drinking drank 7+ units 
57% drank daily or nearly daily 
(7) Abstinent days per month: 11 days 
(1) Percent days heavy drinking: 56 to 
59% across groups 
(2) MAST score >7 
Years of problem drinking: 15.79 
years 
Previous alcohol hospitalisations: 2.09 
(3) Abstinent days per month: 11 days 
Frequency of drinking >6 drinks per 
drinking period per month: 5.1 
ADS score: 8.4 
85% low dependence; 15% moderate 
dependence 
 
(1) Percent days heavy 
drinking: 56 to 59% across 
groups 
(2) ADS core: 8.4 
MAST score: approximately 
20 
44% heavy drinking in past 
year 
36.5% abstinent in the past 
year 
 
(1) PDA: 
approximately 
37% 
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Frequency of drinking >6 drinks per drinking 
period per month: 5.1 
ADS score: 8.4 
85% low dependence; 15% moderate 
dependence 
Number of 
sessions 
Range: 4 to 18 sessions Range: 10 to 12 sessions Range: 1 to 12 sessions 12 sessions 
Length of 
treatment 
Range: 4 to 12 weeks Range: 10 to 12 weeks Range: 1 to 12 weeks 12 weeks 
Length of 
follow-up  
Range: 2 to 24 months Range: 2 to 24 months  Range: 2 to 24 months 6 & 12 months  
Setting (1)–(4), (6), (7) Outpatient treatment centre 
(5) Outpatient research unit 
(1)–(3) Outpatient treatment centre (1), (2) Outpatient treatment 
centre 
 
(1) Outpatient 
treatment centre 
Treatment 
goal 
(1), (3) Not explicitly stated 
(2), (4) Abstinence 
(5), (7) Drinking reduction/moderation 
(6) Abstinence or controlled drinking  
(1) Not explicitly stated 
(2) Abstinence 
(3) Drinking reduction/ moderation 
 
 
(1) Not explicitly stated 
(2) Abstinence or drinking 
reduction/moderation 
 
(1) Not explicitly 
stated 
 
Country (1)–(4), (7) US 
(5) Canada 
(6) Netherlands 
(1)–(3) US 
 
 
(1) US 
(2) Canada 
 
(1) US 
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6.13.4 Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Couples therapy versus other active intervention 
Not significant difference was observed between couples therapy (all types) and 
other active interventions in maintaining abstinence at post-treatment and 2-month 
follow-up assessment. However, over longer periods, couples therapy was 
significantly more effective than other therapies in maintaining abstinence and/or 
light drinking (moderate effect size) when assessed up to 12-month follow-up. This 
difference was not observed in follow-up periods longer than 12 months. An 
additional randomised study (MCCRADY2009) could not be included in these 
analyses as no extractable data was provided. The study reported the BCT was more 
effective than individual coping skills treatment in maintaining abstinence and 
reducing heavy drinking days.  
 
Couples therapy was significantly more effective than other active interventions in 
reducing heavy drinking episodes when assessed up to 12-month follow-up. 
However, there was no difference between couples therapy and other active 
interventions post-treatment. 
 
The VEDEL2008 study assessed severity of relapse in their sample. The results 
indicated that other active intervention (namely CBT) was more effective than 
couples therapy (namely BCT) in reducing occasions in which participants lapsed 
drank over six drinks on one occasion) or relapsed (drank more than six drinks most 
days of the week, but no significant difference was observed in the number of 
participants who relapsed on a regular basis (a few times a month). It must be noted 
that effect sizes were small and from a single study. 
 
No difference in attrition rates was observed between groups post-treatment and at 
3-month follow-up. Couples therapy had less attrition than other therapies at 6-
month follow-up (large effect size), and other therapies had less attrition than 
couples therapy at 12-month follow-up (large effect size).  
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 63. 
BCT versus other couples therapy 
No significant difference was observed between BCT and other forms of couples 
therapy in maintaining abstinence when assessed post-treatment and up to 24-
month follow-up. Similarly no difference between these groups was observed in 
reducing heavy drinking and attrition rates post-treatment and up to 12-month 
follow-up. 
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The quality of this evidence is moderate and further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 64. 
Intensive versus standard couples therapy 
At 1-month follow-up, brief couples therapy was more effective than more intensive 
couples therapy in maintaining abstinence (moderate effect size). However, this 
difference was not maintained up to 18-month follow-up. Furthermore, no 
significant benefit of more intensive couples therapy over brief couples therapy in 
reducing heavy drinking was observed up to 18-month follow-up. Those who 
received more intensive couples therapy were more likely to be retained for follow-
up assessment at 12 months than brief couples therapy (small effect size). 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 65. 
Parental skills & BCT versus BCT alone 
The addition of parental skills training to BCT did not significant improve abstinence 
rates both post-treatment and up to 12-month follow-up. 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect, An evidence 
summary of the results of the meta-analyses can be seen in Table 66. 
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Table 63: Couples therapy versus other intervention evidence summary 
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence        
Abstinence (% or proportion) post-treatment 214 SMD (IV, Random, 95% CI) -0.16 [-0.44, 0.13] 
Abstinence (% or proportion) up to 6-month follow-up     
  PDA at 2-month follow-up 34 SMD (IV, Random, 95% CI) -0.42 [-1.14, 0.29] 
  PDA at 3-month follow-up 138 SMD (IV, Random, 95% CI) -0.37 [-0.72, -0.01] 
  PDA/light (no alcohol or 1 to 3 drinks) at 3-month 
follow-up 
63 SMD (IV, Random, 95% CI) -0.77 [-1.31, -0.23] 
  PDA at 6-month follow-up 202 SMD (IV, Random, 95% CI) -0.47 [-0.77, -0.18] 
  PDA/light (no alcohol or 1 to 3 drinks) at 6-month 
follow-up 
63 SMD (IV, Random, 95% CI) -0.52 [-1.04, 0.01] 
Abstinence (% or proportion) 7- to 12-month follow-up     
  PDA abstinent at 9-month follow-up 138 SMD (IV, Random, 95% CI) -0.60 [-0.96, -0.24] 
  PDA/light (no alcohol or 1 to 3 drinks) at 9-month 
follow-up 
61 SMD (IV, Random, 95% CI) -0.60 [-1.15, -0.05] 
  PDA at 12-month follow-up 245 SMD (IV, Random, 95% CI) -0.54 [-0.81, -0.27] 
  PDA/light (no alcohol or 1 to 3 drinks) at 12-month 
follow-up 
61 SMD (IV, Random, 95% CI) -0.54 [-1.09, 0.01] 
Abstinence (% or proportion) >12-month follow-up     
   at 18 months 34 SMD (IV, Random, 95% CI) -0.26 [-0.97, 0.45] 
   at 24 months 34 SMD (IV, Random, 95% CI) -0.34 [-1.05, 0.37] 
Lapse or relapse       
Relapse (>6 units most days of the week) post-treatment 48 RR (M-H, Random, 95% CI) 2.57 [1.16, 5.71] 
Regular relapse (>6 units a few times a month) post-
treatment 
48 RR (M-H, Random, 95% CI) 0.64 [0.18, 2.27] 
Severe lapse (>6 units on one occasion) post-treatment 48 RR (M-H, Random, 95% CI) 1.71 [1.06, 2.78] 
Rates of consumption      
Rates of consumption post-treatment     
  Percentage of days heavy drinking post-treatment 152 SMD (IV, Random, 95% CI) 0.01 [-0.33, 0.35] 
Rates of consumption up to 6-month follow-up     
  Percentage of days heavy drinking(>6 drinks per day) at 215 SMD (IV, Random, 95% CI) -0.50 [-0.79, -0.22] 
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3-month follow-up 
  Percentage of days heavy drinking (>6 drinks per day) at 
6-month follow-up 
215 SMD (IV, Random, 95% CI) -0.57 [-0.86, -0.29] 
 Rates of consumption 7- to 12-month follow-up     
  Days light drinking (proportion) at 12-month follow-up 43 SMD (IV, Random, 95% CI) -0.08 [-0.68, 0.52] 
  Percentage of days heavy drinking (>6 drinks per day) at 
9-month follow-up 
213 SMD (IV, Random, 95% CI) -0.70 [-0.99, -0.41] 
  Percentage of days heavy drinking (>6 drinks per day) at 
12-month follow-up 
213 SMD (IV, Random, 95% CI) -0.71 [-1.01, -0.42] 
  Days drinking 5 to 9 drinks (proportion) at 12-month 
follow-up 
43 SMD (IV, Random, 95% CI) 0.05 [-0.56, 0.65] 
  Days drinking >= 10 drinks(proportion) at 12-month 
follow-up 
43 SMD (IV, Random, 95% CI) -0.25 [-0.86, 0.35] 
Amount of alcohol consumed        
Amount of alcohol consumed post-treatment     
  Units per week 48 SMD (IV, Random, 95% CI) -0.38 [-0.95, 0.20] 
Amount of alcohol consumed up to 6-month follow-up     
  Units per week at 6-month follow-up 45 SMD (IV, Random, 95% CI) -0.16 [-0.75, 0.42] 
Amount of alcohol consumed at 7- to 12-month follow-up     
 Mean number of DDD at 12-month follow-up 43 SMD (IV, Random, 95% CI) -0.11 [-0.71, 0.49] 
Attrition (dropout)     
Attrition (dropout) post-treatment 313 RR (M-H, Random, 95% CI) 1.22 [0.74, 2.02] 
Attrition (dropout) up to 6-month follow-up     
 at 3-month follow-up 64 RR (M-H, Random, 95% CI) 1.64 [0.07, 37.15] 
 at 6-month follow-up 111 RR (M-H, Random, 95% CI) 0.05 [0.00, 0.75] 
Attrition (dropout) 7- to 12-month follow-up     
 at 9-month follow-up 63 RR (M-H, Random, 95% CI) 0.19 [0.03, 1.17] 
 at 12-month follow-up 242 RR (M-H, Random, 95% CI) 2.26 [1.33, 3.84] 
 
Table 64: Behavioural couples therapy (BCT) versus other couples therapy evidence summary 
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence        
Abstinence (% or proportion) post-treatment 22 SMD (IV, Random, 95% CI) -0.67 [-1.54, 0.20] 
 305 
 
Abstinence (% or proportion) up to 6-month follow-up     
 at 2-month follow-up 22 SMD (IV, Random, 95% CI) -0.17 [-1.01, 0.67] 
  PDA/light (no alcohol or 1 to 3 drinks) at 3-month 
follow-up 
41 SMD (IV, Random, 95% CI) -0.13 [-0.74, 0.48] 
 at 6-month follow-up 22 SMD (IV, Random, 95% CI) 0.11 [-0.73, 0.95] 
  PDA/light (no alcohol or 1 to 3 drinks) at 6-month 
follow-up 
41 SMD (IV, Random, 95% CI) -0.05 [-0.67, 0.56] 
abstinence (percentage or proportion) 7– to 12-month 
follow-up 
    
  PDA or light (no alcohol or one to three drinks) at 9-
month follow-up 
41 SMD (IV, Random, 95% CI) -0.17 [-0.78, 0.44] 
  PDA at 12-month follow-up 22 SMD (IV, Random, 95% CI) 0.11 [-0.73, 0.95] 
  PDA or light (no alcohol or 1 to 3 drinks) at 12-month 
follow-up 
41 SMD (IV, Random, 95% CI) -0.40 [-1.02, 0.22] 
  PDA (or proportion) >12-month follow-up     
  at 18 months follow-up 22 SMD (IV, Random, 95% CI) 0.10 [-0.74, 0.94] 
  at 24-month follow-up 22 SMD (IV, Random, 95% CI) 0.26 [-0.58, 1.10] 
Rates of consumption        
Rates of consumption post-treatment     
  Percentage of days heavy drinking 50 SMD (IV, Random, 95% CI) 0.02 [-0.54, 0.57] 
Rates of consumption up to 6-month follow-up     
  Percentage of days heavy drinking (>6 drinks per day) at 
3-month follow-up 
91 SMD (IV, Random, 95% CI) -0.07 [-0.48, 0.34] 
  Percentage of days heavy drinking (>6 drinks per day) at 
6-month follow-up 
91 SMD (IV, Random, 95% CI) 0.08 [-0.33, 0.49] 
Rates of consumption 7 - 12-month follow-up     
  Percentage of days heavy drinking (>6 drinks per day) at 
9-month follow-up 
91 SMD (IV, Random, 95% CI) -0.02 [-0.43, 0.39] 
  Percentage of days heavy drinking (>6 drinks per day) at 
12-month follow-up 
91 SMD (IV, Random, 95% CI) 0.07 [-0.34, 0.49] 
Attrition (dropout)     
Attrition (dropout) post-treatment 22 RR (M-H, Random, 95% CI) Not estimable 
Attrition (dropout) up to 6-month follow-up     
 at 3-month follow-up 42 RR (M-H, Random, 95% CI) 3.00 [0.13, 69.70] 
 at 6-month follow-up 41 RR (M-H, Random, 95% CI) Not estimable 
 at 9-month follow-up 42 RR (M-H, Random, 95% CI) 1.00 [0.07, 14.95] 
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Attrition (dropout) 7 - 12-month follow-up 41 RR (M-H, Random, 95% CI) Not estimable 
 at 12-month follow-up 41 RR (M-H, Random, 95% CI) Not estimable 
 
Table 65: Intensive couples therapy versus brief couples therapy evidence summary 
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence        
Abstinence (% or proportion) up to 6-month follow-up     
 at 1-month follow-up 116 SMD (IV, Random, 95% CI) 0.64 [0.26, 1.02] 
 at 2-month follow-up 116 SMD (IV, Random, 95% CI) 0.22 [-0.15, 0.60] 
 at 6-month follow-up 116 SMD (IV, Random, 95% CI) 0.17 [-0.21, 0.54] 
Abstinence (% or proportion) 7– to 12-month follow-up     
 at 12-month follow-up 116 SMD (IV, Random, 95% CI) 0.26 [-0.11, 0.63] 
Abstinence (% or proportion) >12-month follow-up     
 at 18-month follow-up 116 SMD (IV, Random, 95% CI) 0.15 [-0.22, 0.52] 
Rates of Consumption        
Rates of consumption post-treatment     
 Percentage of days heavy drinking 50 SMD (IV, Random, 95% CI) 0.02 [-0.54, 0.57] 
Rates of consumption up to 6-month follow-up     
 Percentage of days heavy drinking (>6 drinks per day) at 
1-month follow-up 
116 SMD (IV, Random, 95% CI) 0.36 [-0.02, 0.73] 
 Percentage of days heavy drinking (>6 drinks per day) at 
2-month follow-up 
116 SMD (IV, Random, 95% CI) -0.14 [-0.51, 0.23] 
 Percentage of days heavy drinking (>6 drinks per day) at 
3-month follow-up 
50 SMD (IV, Random, 95% CI) -0.01 [-0.57, 0.54] 
 Percentage of days heavy drinking (>=5 drinks per day) 
at 6-month follow-up 
166 SMD (IV, Random, 95% CI) 0.02 [-0.29, 0.32] 
 % Moderate drinking days (1 to 4 drinks per day) at 1-
month follow-up 
116 SMD (IV, Random, 95% CI) -0.57 [-0.95, -0.20] 
 % Moderate drinking days (1 to 4 drinks per day) at 2-
month follow-up 
116 SMD (IV, Random, 95% CI) -0.34 [-0.71, 0.04] 
 % Moderate drinking days (1 to 4 drinks per day) at 6-
month follow-up 
116 SMD (IV, Random, 95% CI) -0.15 [-0.52, 0.22] 
Rates of consumption 7 - 12-month follow-up     
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 % Moderate drinking days (1 to 4 drinks per day) at 12-
month follow-up 
116 SMD (IV, Random, 95% CI) -0.30 [-0.67, 0.07] 
 Percentage of days heavy drinking (>6 drinks per day) at 
9-month follow-up 
50 SMD (IV, Random, 95% CI) -0.01 [-0.57, 0.54] 
 Percentage of days heavy drinking (>=5 drinks per day) 
at 12-month follow-up 
166 SMD (IV, Random, 95% CI) -0.03 [-0.34, 0.27] 
Rates of consumption >12-month follow-up     
 % Moderate drinking days (1 to 4 drinks per day) at 18-
month follow-up 
116 SMD (IV, Random, 95% CI) -0.23 [-0.60, 0.14] 
 Percentage of days heavy drinking (>=5 drinks per day) 
at 18-month follow-up 
116 SMD (IV, Random, 95% CI) -0.04 [-0.42, 0.33] 
Attrition (dropout)     
Attrition (dropout) post-treatment 218 RR (M-H, Random, 95% CI) 
63.43 [3.97, 
1012.92] 
Attrition (dropout) >12-month follow-up     
 at 1- to 18-month follow-up 163 RR (M-H, Random, 95% CI) 0.40 [0.23, 0.69] 
 
 
Table 66: Parental skills + BCT versus BCT alone evidence summary 
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence        
PDA post-treatment 20 SMD (IV, Random, 95% CI) 0.12 [-0.75, 1.00] 
PDA at 6-month follow-up 20 SMD (IV, Random, 95% CI) 0.04 [-0.84, 0.91] 
PDA abstinent at 12-month follow-up 20 SMD (IV, Random, 95% CI) -0.04 [-0.92, 0.84] 
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6.14 COUNSELLING 
6.14.1 Definition  
The British Association for Counselling and Psychotherapy defines counselling as ‗a 
systematic process which gives individuals an opportunity to explore, discover and 
clarify ways of living more resourcefully, with a greater sense of well-being‘ (British 
Association of Counselling, 1992). This definition, which has been used in other 
NICE guidelines, was adopted for this review but in the included studies 
counselling for alcohol treatment was not often well-defined or manual-based 
making decisions about inclusion difficult, where there was uncertainty this was 
resolved in discussion with the GDG.  
6.14.2 Clinical review protocol (Counselling) 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this Section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21). See Table 67: 
Clinical review protocol for the review of counselling below for a summary of the 
clinical review protocol for the review of counselling. 
 
Table 67: Clinical review protocol for the review of counselling 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Counselling 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
Notes. 
6.14.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of counselling in the treatment of alcohol dependence or 
harmful alcohol use. See Table 68 for a summary of the study characteristics. It 
should be noted that some trials included in analyses were three- or four-arm trials. 
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In order to avoid double-counting, the number of participants in treatment 
conditions used in more than one comparison was divided (by half in a three-arm 
trial, and by three in a four-arm trial). 
 
Five trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on n=630 participants. All five studies were published in peer-
reviewed journals between 1986 and 2003. A number of studies identified in the 
search were initially excluded because they were not relevant to this guideline. 
Counselling studies were mainly excluded for not being randomised trials. When 
studies did meet basic methodological inclusion criteria, the main reason for 
exclusion were that treatment was opportunistic as opposed to planned, the study 
was not directly relevant to the clinical questions, or no relevant alcohol-focused 
outcomes were available. A list of excluded studies can be found in Appendix 16d. 
Counselling versus control  
Of the five included trials, there was only one involving a comparison of counselling 
versus control which met criteria for inclusion. SELLMAN2001 assessed counselling 
(non-directive reflective listening) versus control (no further treatment – feedback 
only). 
Counselling versus other active intervention 
All five included trials assessed counselling versus another active intervention and 
met criteria for inclusion. ERIKSEN1986B assessed counselling (group) versus social 
skills training (coping skills), JOHN2003 assessed counselling (individual) versus 
multi-modal standard intervention (see Appendix 16d for more information), 
LITT2003 assessed counselling (group) versus coping skills, O‘FARRELL1992 
assessed counselling (individual) versus both interactional couples therapy and 
behavioural marital therapy, and SELLMAN2001 assessed counselling (non-
directive reflective listening) versus MET. The included studies were conducted 
between 1986 and 2003. 
 
Table 68: Summary of study characteristics for counselling 
 Counselling versus 
control 
Counselling versus other active 
intervention 
K(total N) 1 RCT (N = 80) 5 RCT (N = 590) 
Study ID (1) SELLMAN2001 (1) ERIKSEN1986B  
(2) JOHN2003 
(3) LITT2003 
(4) O‘FARRELL1992 
(5) SELLMAN2001  
Diagnosis (1) DSM alcohol 
dependent 
 
(2) ICD–10 alcohol dependent  
(3) DSM alcohol dependent/abuse 
(5) DSM alcohol dependent 
Baseline severity (when 
reported) 
(1) Unequivocal heavy 
drinking 6+ times in 6-
month follow-up period: 
90.2% 
 
(1) Previous alcoholism inpatient 
status: 66.7% 
(3) Drinking days 6-months prior to 
intake: 72% 
(4) MAST Score: >7 
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(5) Unequivocal heavy drinking 6+ 
times in 6-month follow-up period: 
90.2% 
Number of sessions 4 sessions Range: 8 to 26 
Length of treatment 6 weeks Range: 3 to 26 weeks 
Length of follow-up (only 
including papers 
reporting follow-up 
measures) 
6-month and 5-year Range: 2-months – 5 years  
Setting (1) Outpatient treatment 
centre 
 
(1), (2) Inpatient  
(3) Outpatient research unit 
(4), (5) Outpatient Treatment 
Centre 
Treatment goal (1) Not explicitly stated 
 
(1) Drinking reduction/moderation 
(2), (4) Abstinence 
(3), (5) Not explicitly stated 
Country (1) New Zealand (1) Norway 
(2) Germany 
(3), (4) US 
(5) New Zealand 
 
6.14.4 Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Counselling versus Control 
Based on the SELLMAN2001 study, no significant difference was observed between 
treatment groups, hence, the clinical evidence does not support the benefits of 
counselling over control in maintaining abstinence or reducing heavy drinking. 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 69. 
Counselling versus other active intervention 
In maintaining abstinence, no significant difference was observed between 
counselling and other therapies when assessed up to 6-month follow-up. However, 
bar the 6-month follow-up, these results are based on a single study 
(O‘FARRELL1992) whereas in the analyses assessing couples therapies versus other 
active therapies, more studies were included in the analyses for this outcome. Other 
therapies (namely couples therapies and coping skills) showed significant benefits 
over counselling in maintaining abstinence at longer follow-up periods of up to 18 
months.  
 
Overall, no significant difference was observed between counselling and other 
therapies up to 18-month follow-up in time to first drink (lapse), time to first heavy 
drink (relapse) and reducing heavy drinking episodes. These analyses were based on 
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data from a single study (LITT2003). However, other therapies (coping skills) were 
more effective than counselling in reducing amount of alcohol consumed when 
assessed at 12-month follow-up. Again, this result was based on a single study 
(ERIKSEN1986B ) limiting the ability to generalise the findings.  
 
Lastly, no significant difference was observed between counselling and other 
therapies in attrition rates. 
 
The quality of this evidence is moderate therefore further research is likely to have 
an important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in  
Table 70. 
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Table 69: Counselling versus control evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Rates of consumption        
Rates of consumption up to 6-month follow-up     
 Exceeded national guidelines at least once (at 6 
months) 
80 RR (M-H, Random, 95% CI) 1.07 [0.83, 1.38] 
 Exceeded national guideline >=6 times (at 6 
months) 
80 RR (M-H, Random, 95% CI) 1.07 [0.83, 1.38] 
 Drank >=10 standard drinks at least once (at 6 
months) 
80 RR (M-H, Random, 95% CI) 0.97 [0.77, 1.22] 
 Drank >=10 standard drinks >= 6 times (at 6 
months) 
80 RR (M-H, Random, 95% CI) 0.96 [0.69, 1.34] 
Rates of consumption >12-month follow-up     
 Exceeded national guidelines at least once (at 5 
years) 
50 RR (M-H, Random, 95% CI) 0.94 [0.62, 1.45] 
 Exceeded national guidelines >= 6 times (at 5 
years) 
50 RR (M-H, Random, 95% CI) 1.09 [0.62, 1.89] 
 Drank >=10 standard drinks at least once (at 5 
years) 
50 RR (M-H, Random, 95% CI) 0.74 [0.38, 1.41] 
 Drank >=10 standard drinks >=6 times (at 5 
years) 
50 RR (M-H, Random, 95% CI) 0.61 [0.22, 1.73] 
Lapse or relapse       
Lapse up to 6-month follow-up     
 Broke abstinence (lapse) at 6 months 80 RR (M-H, Random, 95% CI) 0.97 [0.85, 1.11] 
Lapse >12-month follow-up     
 Broke abstinence (lapse) at 5 years 50 RR (M-H, Random, 95% CI) 1.00 [0.73, 1.38] 
Attrition (dropout)        
Attrition (dropout) post-treatment 80 RR (M-H, Random, 95% CI) Not estimable 
Attrition (dropout) >12-month follow-up     
 at 5-year follow-up 80 RR (M-H, Random, 95% CI) 1.73 [0.95, 3.15] 
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Table 70: Counselling versus other intervention evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence        
Abstinence (%) post-treatment 34 SMD (IV, Random, 95% CI) 0.31 [-0.86, 1.47] 
Abstinence (% or proportion) up to 6 months     
 % days abstinent at 2-month follow-up 34 SMD (IV, Random, 95% CI) 0.42 [-0.29, 1.14] 
 % days abstinent at 3-month follow-up 128 SMD (IV, Random, 95% CI) 0.12 [-0.23, 0.47] 
 % days abstinent at 6-month follow-up 162 SMD (IV, Random, 95% CI) 0.25 [-0.06, 0.56] 
Abstinence (% or proportion) at 7- to 12-month 
follow-up 
    
 Sober days at 12-month follow-up 23 SMD (IV, Random, 95% CI) 1.67 [0.70, 2.65] 
 % days abstinent at 9-months follow-up 128 SMD (IV, Random, 95% CI) 0.24 [-0.11, 0.58] 
 % days abstinent at 12-month follow-up 162 SMD (IV, Random, 95% CI) 0.28 [-0.03, 0.59] 
Abstinence (% or proportion) >12-month follow-
up 
    
 % days abstinent at 15-month follow-up 128 SMD (IV, Random, 95% CI) 0.28 [-0.07, 0.63] 
 % days abstinent at 18-month follow-up 162 SMD (IV, Random, 95% CI) 0.30 [-0.01, 0.61] 
 % days abstinent at 24-month follow-up 34 SMD (IV, Random, 95% CI) 0.34 [-0.37, 1.05] 
Lapse or relapse       
Lapse up to 6-month follow-up     
 Broke abstinence (lapse) at 6-month follow-up 404 RR (M-H, Random, 95% CI) 1.15 [1.01, 1.32] 
Lapsed - 7- to 12-month follow-up     
 at 12-month follow-up 322 RR (M-H, Random, 95% CI) 0.92 [0.81, 1.05] 
Lapse >12-month follow-up     
 Broke abstinence (lapse) at 5-year follow-up 48 RR (M-H, Random, 95% CI) 0.98 [0.72, 1.34] 
Rates of consumption        
Rates of consumption up to 6-month follow-up     
 Proportion days heavy drinking (>= 6 men, 4 
women) at 3-months follow-up 
128 SMD (IV, Random, 95% CI) 0.14 [-0.21, 0.49] 
 Proportion days heavy drinking (>= 6 men, 4 
women) at 6 months follow-up 
128 SMD (IV, Random, 95% CI) 0.20 [-0.15, 0.55] 
Rates of consumption 7- to 12-month follow-up     
 Proportion days heavy drinking (>= 6 men, 4 
women) at 9-month follow-up 
128 SMD (IV, Random, 95% CI) 0.10 [-0.24, 0.45] 
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 Proportion days heavy drinking (>= 6 men, 4 
women) at 12 months follow-up 
128 SMD (IV, Random, 95% CI) 0.17 [-0.18, 0.52] 
Rates of consumption >12-month follow-up     
 Proportion days heavy drinking (>= 6 men, 4 
women) at 15-months follow-up 
128 SMD (IV, Random, 95% CI) 0.07 [-0.27, 0.42] 
 Proportion days heavy drinking (>= 6 men, 4 
women) at 18 months follow-up 
128 SMD (IV, Random, 95% CI) 0.20 [-0.15, 0.55] 
Rates of consumption up to 6-month follow-up     
 Exceeded national guidelines at least once (at 6 
months) 
82 RR (M-H, Random, 95% CI) 1.21 [0.91, 1.60] 
 Exceeded national guideline >=6 times (at 6 
months) 
82 RR (M-H, Random, 95% CI) 1.21 [0.91, 1.60] 
 Drank >=10 standard drinks at least once (at 6 
months) 
82 RR (M-H, Random, 95% CI) 1.25 [0.94, 1.67] 
 Drank >=10 standard drinks >= 6 times (at 6 
months) 
82 RR (M-H, Random, 95% CI) 1.46 [0.95, 2.23] 
Rates of consumption >12 months follow-up     
 Exceeded national guidelines at least once (at 5 
years) 
48 RR (M-H, Random, 95% CI) 1.04 [0.66, 1.65] 
 Exceeded national guidelines >= 6 times (at 5 
years) 
48 RR (M-H, Random, 95% CI) 1.18 [0.66, 2.12] 
 Drank >=10 standard drinks at least once (at 5 
years) 
48 RR (M-H, Random, 95% CI) 1.14 [0.53, 2.45] 
 Drank >=10 standard drinks >=6 times (at 5 
years) 
48 RR (M-H, Random, 95% CI) 0.86 [0.28, 2.65] 
Amount of alcohol consumed       
Amount of alcohol consumed at 7- to 12-month 
follow-up 
    
 cl pure alcohol at 12-month follow-up 23 SMD (IV, Random, 95% CI) 1.15 [0.26, 2.05] 
 Time to first drink assessed at 18-month follow-
up 
128 SMD (IV, Random, 95% CI) 0.15 [-0.20, 0.50] 
 Time to first heavy drink assessed at 18-month 
follow-up 
128 SMD (IV, Random, 95% CI) 0.09 [-0.26, 0.44] 
Attrition (dropout)     
Attrition (dropout) post-treatment 128 RR (M-H, Random, 95% CI) Not estimable 
Attrition (dropout) up to 6 months follow-up     
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 at 3- to 6-month follow-up 322 RR (M-H, Random, 95% CI) 1.02 [0.74, 1.42] 
Attrition (dropout) 7- to 12-month follow-up     
 at 12-month follow-up 247 RR (M-H, Random, 95% CI) 0.85 [0.67, 1.08] 
Attrition (dropout) >12-month follow-up     
 at 5-year follow-up 82 RR (M-H, Random, 95% CI) 1.33 [0.79, 2.24] 
 
FINAL DRAFT 
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6.15 PSYCHODYNAMIC THERAPY  
6.15.1 Definition  
Short-term psychodynamic therapy is a derived from a psychodynamic/ 
psychoanalytic model in which: a) therapist and patient explore and gain insight into 
conflicts and how these are represented in current situations and relationships, 
including the therapy relationship; b) service users are given an opportunity to 
explore feelings and conscious and unconscious conflicts originating in the past, 
with the technical focus on interpreting and working through conflicts; c) therapy is 
non-directive and service users are not taught specific skills such as thought 
monitoring, re-evaluation or problem solving. Treatment typically consists of 16 to 
30 sessions (Leichsenring et al., 2004) but there are interventions which offer more or 
less than this range. 
6.15.2 Clinical review protocol (psychodynamic therapy) 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this Section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21). See Table 71 
below for a summary of the clinical review protocol for the review of 
psychodynamic therapy). 
 
Table 71: Clinical review protocol for the review of psychodynamic 
therapy 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Psychodynamic therapy 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
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6.15.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of psychodynamic therapies in the treatment of alcohol 
dependence or harmful alcohol use. See Table 72 for a summary of the study 
characteristics.  
 
One trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on n=49 participants. The study was published in peer-reviewed 
journals in 1998. A number of studies identified in the search were initially excluded 
because they were not relevant to this guideline. Studies were further excluded 
because they did not meet methodological criteria (see Chapter 3). When studies did 
meet basic methodological inclusion criteria, the main reasons for exclusion were 
that the study was not directly relevant to the clinical questions, or no relevant 
alcohol-focused outcomes were available. A list of excluded studies can be found in 
Appendix 16d.  
Psychodynamic therapy versus other active intervention  
The single trial which was suitable for inclusion was SANDAHL1998 and it 
investigated group-based time-limited group psychotherapy (or a short-term 
psychodynamic therapy as described above) versus another active intervention 
which in this case was relapse prevention. 
 
Table 72: Summary of study characteristics for psychodynamic therapy 
 Psychodynamic therapy versus other active intervention 
K(total N) 1 RCT(N = 49) 
Study ID (1) SANDAHL1998 
Diagnosis (when available) DSM III-R alcohol dependence 
Baseline severity (when 
reported) 
Duration of alcohol misuse: 11 years 
Reported morning drinking:75.5% 
Number of sessions 15 sessions 
Length of treatment 15 weeks 
Length of follow-up  15-month 
Setting Outpatient treatment centre 
Treatment goal Drinking reduction/moderation 
Country Sweden 
 
6.15.4 Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Psychodynamic therapy versus other active intervention  
At 15-month follow-up, psychodynamic therapy was significantly more effective 
than other therapies (in this case cognitive behavioural relapse prevention) in 
maintaining abstinence, although the effect size was moderate. However, no 
significant difference was observed between psychodynamic therapy and other 
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therapies in reducing the quantity of alcohol consumed, heavy drinking rate or 
attrition. It must be noted that this analysis was based on a single study. 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 73. 
 
Table 73: Psychodynamic therapy versus other intervention evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence       
Days abstinent at 15-month 
follow-up 
44 
SMD (IV, Random, 95% 
CI) 
-0.64 [-1.24, -
0.03] 
Rates of consumption        
Days >80 g absolute alcohol 
(heavy drinking) at 15-month 
follow-up 
44 
SMD (IV, Random, 95% 
CI) 
-0.06 [-0.65, 
0.53] 
Amount of alcohol consumed       
Grams absolute alcohol per 
drinking day at 15-month 
follow-up 
44 
SMD (IV, Random, 95% 
CI) 
0.07 [-0.53, 
0.66] 
Attrition (dropout)        
 at 15-month follow-up 49 
RR (M-H, Random, 95% 
CI) 
0.64 [0.12, 
3.50] 
 
6.16 MULTI-MODAL TREATMENT 
6.16.1 Definition 
Multi-modal treatment for alcohol misuse involves a combination of a number of 
interventions which have been developed and evaluated as standalone interventions 
for alcohol misuse. Components of a multi-modal treatment could include 
motivational aspects (such as MET), TSF, AA or self-help group participation, group 
counselling, CBT based relapse-prevention training and psychoeducational sessions. 
The intention is that by combining a number of effective interventions the combined 
treatment will be greater than any one individual treatment.  
6.16.2 Clinical review protocol (Multi-Modal Treatment) 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this Section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21).  
 
Table 74: Clinical review protocol for the review of multi-modal treatment 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
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At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Multi-Modal Treatment 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
 
6.16.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of multi-modal therapies in the treatment of alcohol 
dependence or harmful alcohol use. See Table 75 for a summary of the study 
characteristics.  
 
Two trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on n=427 participants. Both studies were published in peer-reviewed 
journals between 2002 and 2003. A number of studies identified in the search were 
initially excluded because they were not relevant to this guideline. Studies were 
excluded because they did not meet methodological criteria (see Chapter 3). When 
studies did meet basic methodological inclusion criteria, the main reason for 
exclusion was that no relevant alcohol-focused outcomes were available. A list of 
excluded studies can be found in Appendix 16d.  
Multi-Modal Treatment versus other active intervention  
Both included trials which met criteria for inclusion assessed multi-modal treatment 
versus another active intervention. DAVIS2002 assessed standard multi-modal 
outpatient treatment versus psychoeducational intervention. Standard multi-modal 
treatment included a three week orientation period which consisted of six group 
therapy sessions, three alcohol education and three leisure education films, three 
community meetings, and a minimum of six AA meetings. After orientation, 
participants were assigned to a permanent therapist for a mixture of individual and 
group therapy sessions tailored to the needs of the participant. JOHN2003 assessed 
multi-modal standard inpatient and outpatient treatment versus individual 
counselling. Standard treatment was based on the principles of motivational 
interviewing, relapse prevention, and psychoeducational films with a focus to 
support the motivation to seek help for substance-use problems.  
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Table 75: Summary of study characteristics for multi-modal treatment  
 Multi-modal treatment versus other active intervention 
K (total N) 2 RCTs (N = 427) 
Study ID (1) DAVIS2002 
(2) JOHN2003 
Diagnosis (when available) (1) DSM treatment-seeking alcohol abuse or dependent 
(2) ICD–10 alcohol dependent 
Baseline severity (when 
reported) 
(1) Days drinking in last 6 months: approximately 110 
days 
Number of sessions Variable (see description of treatment modalities) 
Length of treatment Variable from 14 days inpatient (JOHN2003) to 6 months 
inpatient and outpatient (DAVIS2002) 
Length of follow-up  Range: 6- to 12-month 
Setting (1) Outpatient treatment centre 
(2) Inpatient 
Treatment goal (1) Drinking reduction/moderation 
(2) Abstinence 
Country (1) US 
(2) Germany 
 
6.16.4 Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Multi-modal versus other active intervention 
A small effect was observed favouring other therapies (that is, psychoeducational) 
over multi-modal treatment in maintaining abstinence when assessed post-
treatment. In additional other therapies (that is, counselling) were significantly better 
than multi-modal treatment in reducing the number of participants who had lapsed 
(small effect size). However, this was not the case at 12 months follow-up as no 
difference between groups was observed. Furthermore, no difference was observed 
between multi-modal treatment and other therapies in reducing the number of days 
drinking, the quantity of alcohol consumed, and attrition up to 12-month follow-up.  
 
The quality of this evidence is low therefore further research is very likely to have an 
important impact on our confidence in the estimate of the effect and is likely to 
change the estimate. An evidence summary of the results of the meta-analyses can be 
seen in Table 76. 
 
Table 76: Multimodal intervention versus other intervention evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method Effect estimate 
Abstinence        
Length of sobriety (in months) 
post-treatment 
77 
SMD (IV, Random, 
95% CI) 
0.48 [0.02, 
0.93] 
Lapse or relapse       
Lapsed post-treatment 84 RR (M-H, Random, 0.79 [0.60, 
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95% CI) 1.03] 
Lapsed up to 6-month follow-up     
 at 6 months 322 
RR (M-H, Random, 
95% CI) 
1.23 [1.04, 
1.45] 
Lapsed - 7- to 12-month follow-up     
 at 12-month follow-up 322 
RR (M-H, Random, 
95% CI) 
0.92 [0.81, 
1.05] 
Rates of consumption        
Days drinking post-treatment 80 
SMD (IV, Random, 
95% CI) 
-0.41 [-0.85, 
0.04] 
Amount of alcohol consumed       
 Fluid ounces per day post-
treatment  
75 
SMD (IV, Random, 
95% CI) 
-0.25 [-0.71, 
0.21] 
Attrition (dropout)     
Attrition (dropout) post-treatment 89 
RR (M-H, Random, 
95% CI) 
1.05 [0.43, 
2.57] 
Attrition (dropout) up to 6 months 
follow-up 
    
 at 6-month follow-up 322 
RR (M-H, Random, 
95% CI) 
1.02 [0.74, 
1.42] 
Attrition (dropout) at 7- to 12-
month follow-up 
    
 at 12-month follow-up 223 
RR (M-H, Random, 
95% CI) 
0.86 [0.67, 
1.09] 
 
6.17 SELF-HELP BASED TREATMENT 
6.17.1 Definition  
A self-help intervention is where a healthcare professional (or para-professional) 
would facilitate the use of the self-help material by introducing, monitoring and 
reviewing the outcome of such treatment. The intervention is limited in nature, 
usually no more than three to five sessions some of which may be delivered by 
telephone. Self-administered intervention are designed to modify drinking 
behaviour and makes use of a range of books, web pages, CD-ROMs or a self-help 
manual that is based on an evidence-based intervention and designed specifically for 
the purpose. An example is Guided Self Change (GSC) (Sobell & Sobell, 1993). This 
treatment is manual-based and uses the principles of CBT and MET. The patient has 
an initial assessment followed by four treatment sessions and two follow-up 
telephone calls.  
6.17.2 Clinical review protocol (Self-help based treatment) 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this Section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21). See Table 77 
below for a summary of the clinical review protocol for the review of self-help based 
treatment. 
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Table 77: Clinical review protocol for the review of self-help based 
treatment 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Self-Help Based Treatment 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
Notes. 
6.17.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of self-help based treatment in the treatment of alcohol 
dependence or harmful alcohol use. See Table 78 for a summary of the study 
characteristics.  
 
One trial relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on n=93 participants. The included study was published in a peer-
reviewed journal in 2002. A number of studies identified in the search were initially 
excluded because they were not relevant to this guideline. Studies were excluded 
because they did not meet methodological criteria (see methods Chapter 3). A 
particular problem for self-helped based treatments is that they usually fall under 
the grouping of ‗brief interventions‘ Therefore, the main reasons for exclusions were 
the population assessed were hazardous drinkers (outside the scope of this 
guideline), the population were not treatment seeking, or no relevant alcohol-
focused outcomes were available. A list of excluded studies can be found in 
Appendix 16d.  
Guided self-help based treatment (guided) versus non-guided self-help 
based treatment  
The single trial include in this analyses involved a comparison of guided self-help 
based treatment (guided) versus non-guided self-help based treatment. 
ANDREASSON2002 assessed guided self change versus self-help manual and advice 
only (non-guided). 
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Table 78: Summary of study characteristics for self-help based treatment 
 Self-help based treatment (guided) versus self-help based 
treatment (non-guided) 
K(total N) 1 RCT (N = 93) 
Study ID (1) ANDREASSON2002 
Diagnosis (when available) SADD score of 12.1 indicating a medium level of alcohol 
dependence 
Baseline severity (when 
reported) 
Number of drinks per week: 24.3 drinks 
Number of drinks per drinking day: 5.7 
Number of sessions Guided self-help 
Assessment = 1 session 
Treatment = 4 sessions 
Follow-up = 2 telephone calls 
 
Non-guided self-help 
Assessment = 1 session 
Treatment = 1 session 
Length of treatment N/A 
Length of Follow-up 9- and 23-month 
Setting Outpatient treatment centre 
Treatment Goal Not explicitly stated 
Country Sweden 
 
6.17.4 Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Guided self-help based treatment (guided) versus non-guided self-help 
based treatment  
Guided self-help was significantly more effective than non-guided self-help in 
reducing the quantity of drinks consumed per week when assessed at 9-month 
follow-up. However, no significant difference was observed between group for the 
same variable at 23-month follow-up as we as the number of drinks per drinking day 
(at 9- and 23-month follow-up) or attrition at 23-month follow-up. 
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 79. 
 
Table 79: Comparing different formats of self-help based treatment evidence 
summary  
Outcome or subgroup 
Number of 
participants  
Statistical method 
Effect 
estimate 
Amount of alcohol consumed       
Amount of alcohol consumed at 7- to 12-
month follow-up 
    
 Number standard drinks per week at 9-
month follow-up 
59 SMD (IV, Random, 95% CI) 
-0.54 [-
1.06, -0.02] 
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 Number of drinks per drinking day at 9-
month follow-up 
59 SMD (IV, Random, 95% CI) 
-0.19 [-
0.70, 0.32] 
Amount of alcohol consumed >12-month 
follow-up 
    
 Number of standard drinks per week at 23-
month follow-up 
59 SMD (IV, Random, 95% CI) 
-0.45 [-
0.97, 0.07] 
 Number of drinks per drinking day at 23-
month follow-up 
59 SMD (IV, Random, 95% CI) 
-0.10 [-
0.61, 0.41] 
Attrition (dropout)      
Attrition at 23-month follow-up 93 
RR (M-H, Random, 95% 
CI) 
0.91 [0.53, 
1.55] 
 
6.18 PSYCHOEDUCATIONAL INTERVENTIONS 
6.18.1 Definition  
A psychoeducational intervention involves an interaction between an information 
provider and service user, which has the primary aim of offering information about 
the condition and providing support and management strategies. Psychoeducational 
intervention for alcohol misuse involves the use of education videos, literature and 
lectures which highlight the health and lifestyle risks of excessive alcohol 
consumption. It is not usually used as a formal method of treatment, but an adjunct 
to conventional treatment methods. Psychoeducational attention control treatment 
(PACT) is a form of manual-based psychoeducational therapy developed by Fals-
Stewart and Klostermann (2004) and used in some alcohol treatment trials.  
6.18.2 Clinical review protocol (psychoeducational interventions) 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this Section of the guideline can be found in Chapter 3 (further information about 
the search for health economic evidence can be found in Section 6.21). See Table 80 
below for a summary of the clinical review protocol for the review of 
psychoeducational intervention). 
 
Table 80: Clinical review protocol for the review of psychoeducational 
intervention 
Electronic databases COCHRANE, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm)  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Psychoeducational Intervention 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
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Rates of Consumption 
Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
Notes. 
6.18.3 Studies considered for review  
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of behavioural therapies in the treatment of alcohol 
dependence or harmful alcohol use. See Table 50 for a summary of the study 
characteristics. It should be noted that some trials included in analyses were three- 
or four-arm trials. In order to avoid double-counting, the number of participants in 
treatment conditions used in more than one comparison was divided (by half in a 
three-arm trial, and by three in a four-arm trial). 
 
Five trials relating to clinical evidence met the eligibility criteria set by the GDG, 
providing data on n=1312 participants. All five studies were published in peer-
reviewed journals between 2001 and 2006. A number of studies identified in the 
search were initially excluded because they were not relevant to this guideline. 
Studies were excluded because they did not meet methodological criteria (see 
methods Chapter 3). When studies did meet basic methodological inclusion criteria, 
the main reason for exclusion was not meeting drinking quantity/diagnosis criteria, 
that is, participants were not drinking enough to be categorised as harmful or 
dependent drinkers or less than 80% of the sample meet criteria for alcohol 
dependence or harmful alcohol use. A list of excluded studies can be found in 
Appendix 16d.  
Psychoeducational intervention versus other active intervention 
All five included trials assessed psychoeducational therapy versus another active 
intervention inclusion. CONNORS2001 was complex in design and investigated 
psychoeducational therapy plus alcohol-focused coping skills versus life skills plus 
alcohol-focused coping skills. Additionally, the study investigated the difference 
between low and high intensity treatment of these conditions. The results of the 30-
month follow-up were obtained from Walitzer and Connors (2007). DAVIS2002 
assessed psychoeducational therapy versus standard multi-modal treatment. 
FALSSTEWART2005 investigated psychoeducational therapy (used as an attentional 
control) versus behavioural couples therapy (plus group counselling), brief 
relationship therapy (plus group counselling) and individually based TSF (plus 
group counselling). FALSSTEWART2006 investigated psychoeducational therapy (as 
an attentional control) versus behavioural couples therapy (plus individually-based 
TSF) as well as individually-based twelve-step facilitation alone. SOBELL2002 
investigated psychoeducational (bibliotherapy/drinking guidelines) versus 
motivational enhancement/personalised feedback.  
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Table 81: Summary of study characteristics for psychoeducational intervention 
 
 
 
 
 Psychoeducational versus other active 
intervention 
K(total N) 5 RCTs (N = 1312) 
Study ID (1) CONNORS2001 
(2) DAVIS2002 
(3) FALSSTEWART2005 
(4) FALSSTEWART2006 
(5) SOBELL2002 
Diagnosis (when available) 
 
(1), (3), (4) DSM alcohol dependent2) DSM alcohol 
dependent/abuse 
Baseline severity (when 
reported) 
(1) Percent of sample severe dependence: 8.3% 
Percent of sample moderate dependence: 66% 
Percent of sample mild dependence: 18.1% 
Average monthly abstinent days: 10.1 days 
Average monthly light days: 6.1 days 
Average monthly moderate days: 8 days 
Average monthly heavy days: 5.7 days 
(2) Days drinking over 6 months: 110 days 
(3) Percent day heavy drinking: 56 to 59% across 
treatment groups 
(4) Percent days abstinent: 40 to 44% across 
treatment groups 
(5) Drinking days per week: 5.5 days 
Drinks per drinking day: 5 drinks 
Number of sessions Range: 1 to 26 sessions 
Length of treatment Range: 1 to 26 weeks 
Length of follow-up  Range: 3 to 18 months 
Setting (1) Outpatient clinical research unit 
(2)–(4) Outpatient treatment centre 
(5) Community level mail intervention 
Treatment goal (1), (2) Drinking reduction/moderation 
(3), (5) Not explicitly stated 
(4) Abstinence 
Country (1)–(5) US 
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Evidence summary 
The GRADE profiles and associated forest plots for the comparisons can be found in 
Appendix 18c and 17c respectively. 
Psychoeducational versus other active intervention  
The clinical findings for this comparison are mixed whether in favour of other active 
therapies over a psychoeducational intervention or finding no clinically significant 
difference between psychoeducational and other therapies. Other therapies were 
significant better than psychoeducational therapy in increasing length of sobriety 
(post-treatment), and the percentage of abstinent/light drink days at 6 and 12-month 
follow-up. 
 
No significant difference was observed been a psychoeducational intervention and 
other active therapies in attrition rates and other drinking related variables.  
 
The quality of this evidence is moderate therefore further research is likely to have an 
important impact on our confidence in the estimate of the effect. An evidence 
summary of the results of the meta-analyses can be seen in Table 82.
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Table 82: Psychoeducational intervention versus other intervention evidence summary  
Outcome or subgroup 
Number of 
participants  
Statistical method 
Effect 
estimate 
Abstinence        
Length of sobriety (months) post-treatment 77 SMD (IV, Random, 95% CI) 
0.48 [0.02, 
0.93] 
Abstinence post-treatment     
 Percentage of days abstinent post-treatment 138 SMD (IV, Random, 95% CI) 
0.03 [-0.32, 
0.38] 
Abstinence up to 6-month follow-up     
 at 3-month follow-up 138 SMD (IV, Random, 95% CI) 
0.12 [-0.26, 
0.50] 
 at 6-month follow-up 138 SMD (IV, Random, 95% CI) 
0.30 [-0.23, 
0.84] 
Abstinence 7- to 12-month follow-up     
 at 9-month follow-up 138 SMD (IV, Random, 95% CI) 
0.28 [-0.35, 
0.92] 
 at 12-month follow-up 138 SMD (IV, Random, 95% CI) 
0.26 [-0.43, 
0.96] 
Abstinent/light (1 to 3 standard drinks) up to 6-
month follow-up 
    
 at 6-month follow-up 61 SMD (IV, Random, 95% CI) 
0.94 [0.40, 
1.48] 
Abstinent/light (1 to 3 standard drinks) 7- to 12-
month follow-up 
    
 at 12-month follow-up 61 SMD (IV, Random, 95% CI) 
0.84 [0.27, 
1.40] 
Abstinent/light (1 to 3 standard drinks) >12-month 
follow-up 
    
 at 18-month follow-up 61 SMD (IV, Random, 95% CI) 
0.74 [0.21, 
1.26] 
Number lapsed (non-abstinent) post-treatment     
 at 6-month follow-up 84 RR (M-H, Random, 95% CI) 
1.27 [0.97, 
1.66] 
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Rates of consumption        
Rate of alcohol consumption post-treatment 179 SMD (IV, Random, 95% CI) 
0.21 [-0.11, 
0.53] 
 % days heavy drinking at post-treatment 99 SMD (IV, Random, 95% CI) 
-0.00 [-0.46, 
0.46] 
 Days drinking (over last 6 months) post-treatment 80 SMD (IV, Random, 95% CI) 
0.41 [-0.04, 
0.85] 
Rate of alcohol consumption up to 6-month follow-
up 
    
 % days heavy drinking at 3 months 99 SMD (IV, Random, 95% CI) 
0.19 [-0.27, 
0.65] 
 % days heavy drinking at 6 months 99 SMD (IV, Random, 95% CI) 
0.37 [-0.10, 
0.83] 
Rate of alcohol consumption - 7- to 12-month follow-
up 
    
 days drinking per week at 12-month follow-up 657 SMD (IV, Random, 95% CI) 
0.00 [-0.15, 
0.15] 
 days drinking five or more drinks at 12-month 
follow-up 
657 SMD (IV, Random, 95% CI) 
0.08 [-0.08, 
0.23] 
 % days heavy drinking at 9-months 99 SMD (IV, Random, 95% CI) 
0.38 [-0.09, 
0.84] 
 % days heavy drinking at 12-months 99 SMD (IV, Random, 95% CI) 
0.50 [-0.04, 
1.04] 
Amount of alcohol consumed       
Amount of alcohol consumed post-treatment     
 Fluid ounces per day 75 SMD (IV, Random, 95% CI) 
0.25 [-0.21, 
0.71] 
Amount of alcohol consumed 7- to 12-month follow-
up 
    
 drinks per drinking day at 12-month follow-up 657 SMD (IV, Random, 95% CI) 
0.00 [-0.15, 
0.15] 
 drinks per week at 12-month follow-up 657 SMD (IV, Random, 95% CI) 
0.01 [-0.14, 
0.16] 
Attrition (dropout)      
Attrition (dropout) post-treatment 227 RR (M-H, Random, 95% CI) 0.93 [0.46, 
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1.87] 
Attrition up to 6-month follow-up     
 at 6 months 144 RR (M-H, Random, 95% CI) 
1.01 [0.32, 
3.19] 
Attrition (dropout) 7- to 12-month follow-up     
 at 12-month follow-up 1082 RR (M-H, Random, 95% CI) 
0.83 [0.64, 
1.07] 
Attrition (dropout) >12-month follow-up     
 at 18 months 130 RR (M-H, Random, 95% CI) 
0.23 [0.01, 
4.67] 
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6.19 MINDFULNESS MEDITATION 
6.19.1 Definition 
Mindfulness meditation is rooted in the principles of Buddhism and is characterised 
by having a non-judgemental approach to experiences that result in the practitioner 
acting reflectively rather than impulsively on these experiences (Chiesa, 2010). 
Mindfulness mediation has a goal of developing a non-judgemental attitude and 
relationship to thoughts, feelings and actions as they experienced by the practitioner 
and not necessarily to change the content of thoughts as in CBT for example 
(Teasdale et al., 1995).  
 
Mindfulness-based meditation has been suggested as a method of improving 
physical and mental health (for a review, see Allen et al., 2006). However, the quality 
of this research is generally poor, not focused on alcohol as the substance of misuse, 
and few in number. 
6.19.2 Clinical review protocol 
In the current review, the role of meditation in maintaining abstinence and drinking 
reduction was investigated. Their application to other aspects usually associated 
with alternative therapies in this topic area (such as craving and withdrawal 
symptoms) was beyond the scope of this guideline and hence was not investigated. 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this Section of the guideline can be found in Chapter 3. See Table 83 below for a 
summary of the clinical review protocol for the review of Meditation). 
 
Table 83: Clinical review protocol for the review of meditation 
Electronic databases COCHRANE, AMED, CINAHL, EMBASE, 
MEDLINE, PsycINFO 
Date searched Systematic Reviews from 1993 to March 2010. All 
other searches from database inception to March 2010 
Study design RCTs (≥ 10 participants per arm); systematic reviews  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for 
alcohol dependence or harmful alcohol use (clinical 
diagnosis or drinking >30 drinks per week) 
Excluded 
populations 
Hazardous drinkers and those drinking <30 drinks 
per week 
Pregnant women 
Interventions Meditation 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of consumption 
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Relapse (>X number of drinks or number of 
participants who have relapsed) 
Lapse (time to first drink or number of participants 
who have lapsed) 
Attrition (leaving the study early for any reason) 
 
6.19.3 Studies considered for review 
The review team conducted a systematic search of RCTs and systematic reviews that 
assessed the beneficial or detrimental effects of meditation in the treatment of 
alcohol dependence or harmful alcohol use. Following the literature search, there 
was an insufficient number of studies remaining to perform an unbiased and 
comprehensive meta-analysis of meditation for the treatment of AUDs. Therefore, 
the GDG consensus was that a narrative summary of these studies would be 
conducted and observational studies would be included in the review. See Table 84 
for a summary of the study characteristics.  
 
Two trials (Bowen et al., 200635; Zgierska et al., 2008) relating to clinical evidence 
providing data on n=320 participants were identified by the search. Both studies 
were published in peer-reviewed journals between 2006 and 2008. To our 
knowledge, no other studies which evaluated meditation for an AUD population 
with alcohol-focused outcomes have been published.
                                                 
35 A secondary analyses of this ample was conducted by Bowen et al. (2007).  
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Table 84: Summary of study characteristics for mindfulness meditation  
Study (country) Treatment conditions & 
number of participants 
Baseline severity & diagnosis Setting, treatment characteristics 
& assessment points 
BOWEN2006 
(US) 
1. Mindfulness meditation 
(n=63) 
*No indication of level of 
dependence 
Setting: Prison 
2. Treatment as usual 
(n=242) 
*Baseline drinks per week 
Meditation group = 64.83 
(SD=73.01); TAU = 43.98 (SD=55.61) 
Treatment characteristics: 
meditation: 10-day course, TAU: 
chemical dependency treatment, 
psychoeducational intervention 
Assessment point: at 3 months 
after release from prison 
ZGIERSKA2008 
(US) 
1. Mindfulness meditation 
(n=19). Participants 
continued usual outpatient 
treatment 
*DSM–IV alcohol-dependent 
graduates from an intensive 
outpatient treatment program 
Setting: Alcohol Treatment 
Centre 
Treatment characteristics: 8-
week course, 2-hour weekly 
sessions; Course involved both 
meditation training and relapse 
prevention using cognitive 
behavioural techniques.  
Assessment points: 4, 8, 12, 16 
week post-baseline 
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6.19.4 Evidence Summary 
Bowen and colleagues (2006) investigated the effectiveness of mindfulness 
meditation on substance use outcomes in an incarcerated population. The study 
compared mindfulness meditation with treatment-as usual (chemical dependency 
program and psychoeducational intervention). The authors reported that 
mindfulness meditation was significantly more effective than treatment as usual in 
the amount of alcohol consumed at 3-month follow-up (p<0.005). However, 
adherence to the therapy was not assessed and therefore the authors were unclear as 
to whether participants correctly followed the principles of mindfulness meditation. 
Furthermore, the level of alcohol dependence in this sample was unclear.  
 
In a feasibility pilot prospective case series study, Zgierska and colleagues (2008) 
evaluated the efficacy of mindfulness meditation in increasing abstinence and 
reducing the quantity of alcohol consumed. Alcohol dependent participants whom 
had recently completed an intensive outpatient treatment program were recruited. 
The study found that participants reported significantly fewer heavy drinking days 
at 4, 8 and 12 week follow-up (all p<0.005) but not 16 week follow-up. Furthermore, 
participants were drinking significant less when assessed at 4 and 8 week follow-up 
(p<0.005) but no significant difference was observed at 12 and 16 week follow-up. 
No significant difference over time was observed in increasing percent days 
abstinent. It must be noted however, that meditation in this study was not used as an 
active intervention but an after treatment intervention. Furthermore, the sample size 
was small and the study had no control group.  
 
These studies reported a significant effect of mindfulness meditation on alcohol 
consumption Overall, there is limited and poor quality evidence which does not 
support the use of mindfulness-based meditation for treating alcohol dependence 
and harmful alcohol use.  
6.20 CLINICAL EVIDENCE SUMMARY 
A range of psychological interventions to prevent relapse or promote abstinence in 
harmful and dependent alcohol misuse were reviewed. The participant populations 
of the studies included in this review were either harmful drinkers or mildly 
dependent on alcohol. There was very limited evidence of low to moderate quality 
to support the efficacy of counselling, psychodynamic therapy, multi-modal 
treatment, self-help based treatment, psychoeducational interventions and 
mindfulness meditation. Evidence for efficacy showed an advantage for behavioural 
couples therapy both over treatment as usual, active controls and other active 
interventions. In the cases of the other psychological interventions there was 
evidence that CBT, social behaviour and networks therapy and behavioural 
therapies were better than treatment as usual or control. The evidence for the 
efficacy of the addition of contingency management to standard care was limited 
and contradictory overall, which was made more complicated as contingency 
management was not a stand-alone intervention and was added to standard care or 
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network support. In the case of twelve-step facilitation and motivational techniques, 
although there was evidence to equivalents to other interventions, there was no 
evidence to show that these interventions were, for harmful and dependent drinkers, 
more effective than the other interventions. Importantly there was a lack of evidence 
for their effectiveness compared with treatment as usual or control. For all the above 
interventions the evidence was judged to be of a high or moderate quality on the 
GRADE profiles.  
 
The duration of treatment and number of sessions across the treatment trials 
included in the review was also considered. The duration of treatment for 
motivational techniques was 1 to 6 weeks, TSF was 12 weeks, cognitive behavioural 
therapies was 2 weeks to 6 months with most ending at 12 weeks, behavioural 
therapies was 6 to 12 weeks, social network and environment based therapies 
ranged from 8 to 16 weeks, and couples therapies ranged from 4 to 12 weeks. Taking 
into consideration the intensity of the treatments in these trials, for those with a high 
intensity (that is, not including the lower intensity motivational technique 
interventions, cognitive behavioural therapies and behavioural therapies), the 
duration of treatment was on average 12 weeks.  
 
In addition, the GDG felt that both motivational techniques and twelve-step 
facilitation were best seen as components of any effective psychosocial intervention 
delivered in be alcohol services with the assessment and enhancing of motivation 
forming a key element of the assessment process. It should also be noted that 
facilitation of uptake of community support (for example, Alcoholics Anonymous) is 
also seen as a key element of case coordination and case management (see Chapter 
5). It should also be noted that the individual psychological interventions form a 
required component part of any pharmacological intervention and in developing 
these recommendations this was also borne in mind.  
6.21 HEALTH ECONOMIC EVIDENCE  
6.21.1 Review overview 
The literature search identified six studies that assessed the cost-effectiveness of 
psychological interventions for the treatment of alcohol dependence or harmful 
alcohol use (Alwyn et al., 2004; Fals-Stewart et al., 2005; Holder et al., 2000; Mortimer 
& Segal 2005; Slattery et al., 2003; UKATT study, 2005;). Full references, 
characteristics and results of all studies included in the economic review are 
presented in the form of evidence tables in the appendices. 
 
The study by Alwyn and colleagues (2004) considered the cost-effectiveness of 
adding a psychological intervention (PI) to a conventional home detoxification 
programme for the treatment of problem drinkers. The home detoxification 
programme comprised five home visits of 30 minutes duration delivered by CPNs. 
The study population consisted of 91 heavy drinkers in the UK who fulfilled 
inclusion criteria for home detoxification. A number of outcome measures were 
assessed in the study including: number of drinks per drinking day; total number of 
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days abstinent; total number of alcohol units consumed; abstinence or moderate 
drinking and severity of dependence. The number-needed-to-treat (NNT) to produce 
one extra non-drinker was also calculated. An NHS perspective was used for the 
economic analysis. Resource use data included inpatient days, outpatient care 
(including CPN visits) and medications. As clinical outcomes were left 
disaggregated and no summary outcome measure was used in the economic 
analysis, a cost-consequences analysis was used. 
 
The authors made no formal attempt to compare the total costs of PI in addition to 
home detoxification versus home detoxification alone. Instead the authors calculated 
total costs per patient of inpatient treatment (£2,186 to £3,901), outpatient treatment 
(£581 to £768) and home detoxification plus PI (£231). Therefore, the extra cost of a PI 
programme was substantially lower than the cost of inpatient treatment and 
outpatient visits. In terms of clinical outcomes, significantly better results were 
observed in patients treated with home detoxification plus PI. The authors 
concluded that, due to the low NNT to obtain an extra non-drinker, it is likely that 
the implementation of a PI would lead to cost savings to the NHS. Although the 
results of this study are highly relevant to the UK context, there are a number of 
methodological limitations. Firstly, no attempt was made to combine costs and 
effectiveness with an array of effectiveness measures used in the study. The 
measures of effectiveness used are of limited usefulness to policy-makers when 
assessing the comparative cost-effectiveness of healthcare interventions. The clinical 
effectiveness study compared PI in addition to home detoxification versus home 
detoxification alone. However, in the cost-analysis, home detoxification was 
compared with other detoxification programmes, such as inpatient and outpatient 
programmes. Therefore, the study did not directly assess the cost-effectiveness of 
adding PI to home detoxification. 
 
The study by Fals-Stewart and colleagues (2005) considered the cost-effectiveness of 
brief relationship therapy (BRT) compared with standard behavioural couples 
therapy (S-BCT), individual-based treatment (IBT) and psychoeducational attention 
control treatment (PACT for alcoholic male patients and their nonsubstance-abusing 
female partners. BRT, IBT and PACT consisted of 18 therapy sessions over 12 weeks 
whilst S-BCT consisted of 24 sessions over 12 weeks with patients randomised to one 
of the four groups and followed up for 12 months. A societal perspective was taken 
for the analysis with costs including those associated with the four treatment 
programmes and costs of patients and their partners travel time. The primary 
measure of effectiveness for the economic analysis was the change in percentage 
days of heavy drinking from baseline to 12 months. Rather than calculating ICERs, 
the authors calculated mean change in PDHD over 12 months divided by mean cost 
of treatment delivery (in $100 units), with higher ratios indicating greater cost-
effectiveness. Overall, BRT had the highest mean ratio (4.61) of the four treatment 
programmes considered, suggesting this was the most cost-effective treatment. The 
findings of this study have limited applicability to this guideline as it is based within 
the US health system, outcomes were not expressed as QALYs and a societal 
perspective was taken for the cost analysis (both outside the NICE reference case). 
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Furthermore, no formal attempt at an incremental analysis, in terms of differences in 
costs and outcomes, was attempted by the authors. 
 
The study by Holder and colleagues (2000) compared the healthcare costs of three 
treatment modalities: 12-session CBT, 4-session MET and 12-session TSF, over three 
years follow-up. The study participants were a sample (65%) of patients with alcohol 
dependency symptoms taken from the US Project MATCH study (Project MATCH 
Research Group, 1998). The perspective of the cost analysis was from US health care 
providers. Resource use data included the three treatments and any subsequent 
inpatient or outpatient care over three years. The authors calculated mean monthly 
costs for the three treatments rather than total costs over three years and no 
incremental or statistical analyses were presented. Overall, mean monthly costs were 
$186 for CBT, $176 for MET and $225 for TSF, suggesting that MET had the largest 
potential healthcare savings over three years. The major limitations of this analysis 
were the lack of descriptive detail on the resource use and costs considered whilst no 
incremental analysis was presented. The findings have limited applicability to this 
guideline as it was based on the US healthcare system and no formal attempt was 
made by the authors to combine cost and clinical outcomes data, which were 
collected in the study and reported elsewhere (Project MATCH Research Group, 
1998). 
 
The study by Mortimer and Segal (2005) conducted separate, mutually exclusive 
model-based economic analyses of interventions for problem drinking and alcohol 
dependence. A lifetime horizon was used for all of the analyses considered. The first 
analysis compared three brief motivational interventions with different levels of 
intensity (simple = 5 minutes, brief = 20 minutes, extended = four sessions of 120 to 
150 minutes) versus no active treatment in a population of heavy drinkers within the 
Australian healthcare setting. The outcome measure used in the analysis were 
QALYs calculated from disability weights derived from a single published source 
(Stouthard et al., 1997). Clinical effectiveness data was taken from published studies 
evaluating interventions targeting heavy drinkers at lower severity levels. This data 
was used to estimate how patients would progress between specific drinking states 
(problem, moderate or dependent) within the model. The authors did not specify the 
resource use and cost components included in the model within the article although 
a health service perspective was adopted for the analysis. The results of the analysis 
suggested that brief motivational interventions were cost-effective compared with 
no active treatment. The incremental cost-effectiveness ratios (ICERs) ranged from 
under $AUD 82 (£61) per QALY for the simple intervention to under $AUD 282 
(£179) per QALY for the extended intervention. 
 
The second analysis compared psychotherapies for mild to moderate alcohol 
dependence. The comparators were moderation-oriented cue exposure (MOCE) 
versus behavioural self-control training (BSCT) and MET or non-directive reflective 
listening (NDRL) versus no further counselling after initial assessment (NFC), again 
within the Australian healthcare setting. Again, the outcome measure used in the 
analysis were QALYs calculated from disability weights derived from a single 
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published source (Stouthard et al., 1997). Clinical effectiveness data was taken from 
published studies evaluating interventions for mild to severely dependent drinkers. 
This data was used to estimate how patients would progress between specific 
drinking states (problem, moderate or dependent) within the model. No resource 
use and cost components were specified within the article. The results of the analysis 
suggested that MOCE was cost-effective in comparison with BSCT, resulting in an 
ICER of $AUD 2145 (£1,589) per QALY. NDRL was dominated by NFC, resulting in 
higher costs but lower QALYs. However, the results of the analysis suggested that 
MET was cost-effective compared with NFC, resulting in an ICER $AUD 3366 
(£2,493) per QALY. 
 
There are several limitations with the results of the study by Mortimer and Segal 
(2005) that reduce their applicability to any UK-based recommendations. In the 
second analysis of interventions for mild to moderate alcohol dependence, a 
common baseline comparator was not used in the analyses of MOCE, MET and 
NDRL, limiting their comparability in terms of cost-effectiveness. Ideally, indirect 
comparisons of the three interventions would have provided additional information 
about their relative effectiveness. Little explanation was given in the article as to how 
the clinical effectiveness data, which was taken from various sources, was used to 
inform the health states used in the economic models. The article did not specify the 
resource use and costs that were included in the analyses although a health 
perspective was used. The analyses all used QALYs as the primary outcome 
measure, which allows for comparison across interventions, although again there 
was insufficient description of the utility weights that were applied to the health 
states within the model.  
 
The study by Slattery and colleagues (2003) developed an economic model to assess 
the cost-effectiveness of four psychological interventions in comparison with 
standard care within the Scottish health service: coping/social skills training; 
behavioural self-control training (BSCT); MET and marital/family therapy. The 
population examined were 45-year-old men and women with a diagnosis of alcohol 
dependence. The outcome measures used in the economic model were the number 
of patients who have abstained and number of patient deaths averted. The clinical 
effectiveness data was based on a methodologically diverse selection of trials which 
were not described within the study. Most studies included a treatment arm in 
which the intervention was thought likely to have little or no effect and this was 
used as the comparator arm when available. Resource use involved in the delivery of 
psychosocial therapies was estimated from expert clinical opinion and included the 
number and duration of sessions; staff and educational materials. Unit costs were 
taken from Scottish health service estimates. Other healthcare costs included in the 
model were those associated with alcohol-related disease endpoints such as stroke, 
cancer, cirrhosis and alcohol-related psychoses. Costs were applied according to 
inpatient length of stay taken from Scottish medical records. 
 
For each intervention, the costs of psychosocial treatment and any disease endpoints 
for a hypothetical cohort of 1000 patients were compared with standard care over a 
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20 year time horizon, to determine any net healthcare cost savings. All four therapies 
demonstrated net savings ranging from £274,008 (Coping/Social Skills Training) to 
£80,452 (BSCT) in comparison with standard care. All four interventions resulted in 
lower costs per additional abstinent patient and lower costs per death averted in 
comparison with standard care. Whilst the results of the study, based on a 
hypothetical cohort of patients within the Scottish health service, may be applicable 
to a UK setting, there are several problematic methodological issues with the study. 
Firstly, the sources of the effectiveness data used in the model were not explicitly 
described by the authors who suggested that the data was taken from a 
methodologically diverse selection of trials, thus suggesting a high level of 
heterogeneity. Secondly, no attempt was made to translate intermediate clinical 
endpoints such as abstinence rates into QALYs, which are useful to decision makers 
when assessing the comparative cost-effectiveness of healthcare interventions. 
 
The UKATT study (2005) evaluated the cost effectiveness of MET versus social 
behaviour and network therapy amongst a population comprising people who 
would normally seek treatment for alcohol misuse at UK treatment sites. The 
outcome measure used in the economic analysis were QALYs which were estimated 
by using the EQ-5D questionnaire completed by patients at baseline, 3 and 12 
months. The primary measures of clinical effectiveness were changes in alcohol 
consumption, alcohol dependence and alcohol-related problems over the 12-month 
period. A societal perspective was taken for the analysis. Resource use data that was 
collected during the study included training and supervision and materials related 
to treatment, hospitalisation, outpatient visits, GP and CPN visits, rehabilitation and 
consultation in alcohol agencies, social service contacts and court attendances. Unit 
cost estimates were derived from a variety of UK published sources. 
 
At 12 months, the total mean costs were higher in the MET group, resulting in a 
mean difference of £206 per patient (95% CI -£454 to £818) versus social behaviour 
and network therapy. After adjusting for baseline differences, the MET group 
achieved slightly higher QALYs than social behaviour and network therapy, 
resulting in a mean difference of 0.0113 QALYs (95% CI: -0.0532 to 0.0235). 
Combining costs and QALYs, the MET group had an incremental cost-effectiveness 
ratio of £18,230 in comparison with social behaviour and network therapy. Cost-
effectiveness acceptability curves showed that, at a cost-effectiveness threshold of 
£30,000 per QALY, MET had a 57.6% probability of being more cost-effective than 
social behaviour and network therapy. The results of the study are applicable to a 
UK setting and the outcome measure used enables comparison across healthcare 
interventions. However, as the authors note, the analysis had a short time horizon 
and the longer term effects of a reduction in drinking were not taken into 
consideration. 
 
6.21.2 Health economic summary 
The systematic search of the health economics literature did not identify evidence on 
the cost effectiveness of all of the psychological interventions considered in this 
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guideline. Three of the studies identified were UK-based (Alwyn et al., 2004; Slattery 
et al., 2003; UKATT study, 2005), two were US-based (Fals-Stewart et al., 2005; Holder 
et al., 2000) and one was Australian (Mortimer & Segal, 2005). The study by Alwyn 
and colleagues (2004) suggested that adding psychological intervention to a home 
detoxification programme may offer NHS cost savings in problem drinkers. The 
study by Slattery and colleagues (2003) showed that four psychological 
interventions, including coping/social Skills training; behavioural self-control 
training (BSCT); MET and marital/family therapy offered significant healthcare cost 
savings compared with standard care for alcohol-dependent patients. The UKATT 
study (2005) suggested that MET was cost effective in patients who misuse alcohol, 
at current UK thresholds, in comparison with social behaviour and network therapy 
(but note it was not identified as a clinically effective intervention in this guideline). 
Fals-Stewart and colleagues (2005) concluded that brief relationship therapy was 
significantly more cost effective compared with standard behavioural couples 
therapy, individual-based treatment and psychoeducational control treatment. 
Holder and colleagues (2000) suggested that MET offered the largest potential 
healthcare cost savings over 3 years when compared with CBT or TSF. Mortimer and 
Segal (2005) concluded that brief motivational interventions were cost effective 
compared with no active treatment among problem drinkers whilst moderation-
oriented cue exposure (MOCE) and MET were cost-effective treatments for alcohol 
dependency, although no common comparators were used in either analysis. 
 
Providing an adequate summary of the health economics evidence presented here is 
difficult, due to the differences across the studies in terms of the interventions and 
comparators considered, study populations, costs and outcomes considered and 
other methodological differences. Overall, the health economics review does not 
provide evidence of superior cost effectiveness for any particular psychological 
therapy. 
6.21.3 Economic considerations 
Of all the psychological interventions included in the systematic effectiveness review 
and then found suitable for recommendation in the NHS, only a few of these have 
supporting economic evidence.  
 
A potential solution to this problem would be to undertake economic modelling to 
determine the most cost effective psychological intervention. However, certain 
aspects of the effectiveness evidence made it difficult to do so that is, there was a 
lack of common comparators and interventions were usually compared with other 
active interventions, a ‗no treatment/usual care/placebo‘ arm was rarely identified. 
 
Furthermore, the meta-analyses showed that there were small if any differences in 
effect between active treatments, and only a few of these showed much evidence a 
consistent positive effect for example, behavioural couples therapy, particularly 
against other therapies. . 
 
Therefore the following costing exercise was undertaken for the possible 
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recommended psychological interventions. 
Behavioural Couples Therapy 
The clinical effective studies in the guideline systematic literature review described 
this intervention being delivered in a variety of ways. The GDG were of the opinion 
that the number of sessions and duration of these sessions as described by Lam and 
colleagues (2009) that is, 12 weekly session of 60 minutes duration under the 
supervision of a competent practitioner, were considered to be reflective of what 
should be delivered in the UK NHS. 
 
It is very likely that these sessions would be conducted by a clinical psychologist. 
The unit cost of a clinical psychologist is £75 per hour of patient contact in 2008/09 
prices (Curtis, 2009). This cost includes salary, salary on-costs, overheads and capital 
overheads plus any qualification costs.  
 
Based on these estimates the average cost of a behavioural couples therapy 
intervention would be £900 per couple. 
Cognitive behavioural therapy 
No evidence on the cost effectiveness of CBT in this population was identified by the 
systematic search of the health economics literature. 
 
The clinical evidence in the guideline systematic literature review described CBT 
interventions being delivered in a variety of sessions and durations either 
individually or in structured groups under the supervision of a competent 
practitioner. The clinical evidence was taken in consideration and the GDG agreed 
that a CBT programme would typically involve weekly sessions of 1 hour duration 
over a 12 week period.  
 
These sessions would be conducted by a clinical psychologist. The unit cost of a 
clinical psychologist is £75 per hour of patient contact in 2008/09 prices (Curtis, 
2009). This cost includes salary, salary oncosts, overheads and capital overheads plus 
any qualification costs.  
 
Based on these estimates the average cost of an individual based CBT intervention 
would be £900 per patient. 
 
The GDG were of the opinion that group interventions although likely to be more 
cost effective per patient, they were unlikely to be delivered successfully in an 
outpatient setting because of the expected high attrition/low retention rates. They 
were also of the opinion that group interventions would potentially be more suitable 
to inpatient/residential settings as the likelihood of patients attending all treatment 
sessions would be higher. It was unclear from the literature what the optimal 
number of patients per group would be. Obviously, if the number and duration of 
sessions as well as the number of staff delivering the service remained the same, the 
total costs per person would be expected to decrease significantly. 
FINAL DRAFT 
 342 
 
Social Network & Environment Based Therapies  
The UKATT Research team described social behaviour and network therapy to 
comprise of up to eight 50-minute sessions (UKATTstudy, 2005). This particular 
intervention can be delivered by a range of mental health professionals. The GDG 
highlighted that it is likely that the sessions would be supervised by a nurse (or a 
NHS professional who is trained to deliver this intervention). It was assumed that 
such workers would be on Agenda for Change (AfC) salary scale 6 which would 
likely to be comparable to the salary scales of a community nurse. The unit cost of an 
AfC Band 6 community nurse is £70 per hour of patient contact in 2008/09 prices 
(Curtis, 2009). This cost includes salary, salary oncosts, overheads and capital 
overheads plus any qualification costs. Based on these estimates the average cost of 
such a therapy would be £467 per patient. 
Behavioural Therapies 
The clinical evidence in the guideline systematic literature review described a 
variety of interventions that were considered to be behavioural therapies. They were 
delivered in a variety of sessions and durations either individually or in structured 
groups under the supervision of a competent practitioner. The clinical evidence was 
taken in consideration and the GDG agreed that behavioural therapies would 
typically involve weekly sessions of 1 hour duration over a 12 week period.  
 
Behavioural therapies can also be delivered by a range of mental health 
professionals. The GDG highlighted the following professionals: a clinical 
psychologist or a nurse or a NHS professional who is trained to deliver this 
intervention. It was assumed that such workers would be on Agenda for Change 
(AfC) salary scale 6 which would likely to be comparable to the salary scales of a 
community nurse. The unit cost of an AfC Band 6 community nurse is £70 per hour 
of patient contact and the unit cost of a clinical psychologist is £75 per hour of 
patient contact in 2007/08 prices (Curtis, 2009). These costs include salary, salary 
oncosts, overheads and capital overheads plus any qualification costs. Based on 
these estimates the average cost of a behavioural intervention would be £900 per 
patient if delivered by a clinical psychologist and £840 per patient if delivered by a 
mental health professional described above. 
A summary of the estimated resource use and costs involved in delivering these 
psychological interventions is presented in Table 85. 
 
Table 85: Summary of resource use and costs associated with psychological 
interventions  
Behavioural Couples Therapy £ 900 per couple 
12 weekly sessions 60 minutes long  this estimate based on LAM, 2009 (study 
included in clinical evidence review) 
Clinical Psychologist £75 per hour of client contact (Curtis, 2009) 
CBT £ 900 per patient 
12 weekly sessions 60 minutes long  GDG expert opinion and clinical evidence  
Delivered by clinical psychologist £75 per hour of client contact (Curtis, 2009) 
Social Network & Environment Based Therapies 
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8 sessions 50 minutes long  UKATT study, (2005) 
nurse(community) AfC Band 6 £70/hr spent 
with patient (£1.17/min) 
£467 per patient 
Behavioural Therapies 
12 weekly sessions 60 minutes long GDG expert opinion and clinical evidence 
 Clinical Psychologist £75 per hour of client 
contact (Curtis, 2009) 
£ 900 per patient 
nurse(community) AfC Band 6 £68/hr 
spent with patient 
£1.13/min 
£816 per patient 
 
6.22 SPECIAL POPULATIONS – CHILDREN AND YOUNG 
PEOPLE 
6.22.1 Introduction 
In the development of the adult treatments sections of this guideline it was accepted 
for some people who misuse alcohol (in particular those with harmful use or mild 
dependence) the reduction in alcohol consumption might be an option. However, 
given the potential long-term harm experienced by children and young people who 
are alcohol dependent or harmful drinkers and the frequent presence of comorbid 
substance misuse and other psychiatric disorders, it is felt that the appropriate goal 
for children and young people should be achieving abstinence. However, it was 
recognised by the GDG that considerable difficulties are faced by some young 
people in trying to achieve abstinence and particularly if the support they receive 
from their families, carers and others in limited or non existent or they experience 
considerable peer pressure to drink alcohol. Therefore, for some young people the 
GDG accepted that that an initial reduction in alcohol misuse maybe the only 
achievable short-term objective. Nevertheless, the GDG‘s view was that given the 
considerable problems that young people face, that abstinence remained the 
preferred goal.  
 
A further important difference between the treatment of adults and young people 
concerns the presence of comorbidities. Although comorbid depressive and anxiety 
symptoms are common in adults with harmful drinking and alcohol misuse (Weaver 
et al., 2006), the extent and severity of the comorbidities often found in children is 
greater (Perepletchikova et al., 2008). Comorbid disorders such as conduct disorder 
and attention deficit and hyperactivity disorder significantly complicate the 
management alcohol misuse and concurrent treatment of them is to be considered. 
This problem is well known (Perepletchikova et al., 2008) and a number of 
treatments, for example, multi-systemic therapy (Henggeler et al., 1999) , or 
treatment such as brief strategic family therapy (Szapocznik et al., 2003) or 
multidimensional family therapy (Liddle et al., 1999) have been developed for 
conduct disorder explicitly to deal with the complexity of problems faced by 
children and young people including drug and alcohol misuse. The later two 
interventions have a very explicit focus on substance misuse. At the heart of all these 
interventions, lies the recognition of the considerable complexity of problems 
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presented by young people who misuse alcohol and drugs and the need often to 
develop a multi-systems, multi-level approach to deliver an integrated approach to 
treatment.  
6.22.2 Aim of review 
This section aims to review the evidence for psychological interventions for the 
treatment of alcohol dependence and harmful alcohol use in children and young 
people. However, although there are several published reviews on the efficacy of 
psychological interventions for adults and for the prevention of adolescent substance 
misuse, there are only a limited number of trials assessing the clinical efficacy of 
psychological interventions for alcohol misuse alone (without comorbid drug 
misuse) for children and young people under the age of 18 years old. In addition, the 
patient populations assessed in these trials more often than not have comorbid 
substance misuse. Therefore, a GDG consensus-based decision was agreed that the 
literature search would be for alcohol-specific primary studies as well as published 
systematic reviews to guide the overall strategy of a narrative synthesis of the 
evidence. 
 
Psychological therapies were considered for inclusion in the review if they were:- 
 Alcohol-focused only 
 Planned treatment (especially for brief interventions) 
 For treatment-seeking participants only (of particular importance for the brief 
interventions as our scope did not cover opportunistic brief interventions – see scope 
Appendix 1) 
 Manual-based or in the absence of a formal manual, the intervention should be well-
defined and structured 
 Ethical and safe 
6.22.3 Clinical questions 
The primary clinical question addressed in this section is: 
 
For children and young people who are alcohol dependent or harmful drinkers, is 
treatment x when compared with y more clinically and cost effective and does this 
depend on the presence of comorbidities?  
6.22.4 Clinical review protocol  
Table 86: Clinical review protocol for the review of psychological therapies for 
children and young people. 
Electronic databases CENTRAL, CINAHL, EMBASE, MEDLINE, PsycINFO 
Date searched Database inception to March 2010 
Study design RCT (≥ 10 participants per arm); Systematic reviews  
Patient population Children and young people (10 – 18 years) 
At least 80% of the sample meet the criteria for alcohol dependence or 
harmful alcohol use (clinical diagnosis) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Interventions Individual or group interventions; multi-component interventions  
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Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
Relapse (>X number of drinks or number of participants who have 
relapsed) 
Lapse (time to first drink or number of participants who have lapsed) 
Attrition (leaving the study early for any reason) 
 
 
As part of the overall search for effective individual, group and multi-component 
psychosocial interventions for children and young people, the review team 
conducted a systematic review of published systematic reviews (in part to take 
account of the complex comorbidity) of interventions for young people who misuse 
drugs and alcohol and also RCTs of psychosocial interventions for children and 
young people for alcohol misuse specifically. The literature search identified a 
number of primary studies investigating the efficacy of psychological therapies for 
children and young people. However, the participant population in the majority of 
these studies did not reach inclusion criteria for drinking severity and could not be 
classified dependent/harmful. See Table 86 above for a summary of the clinical 
review protocol for the review of psychological therapies for children and young 
people). 
 
6.22.5 Narrative review 
This review of the effective psychosocial interventions for children and young 
people should be read in conjunction with the review of brief interventions 
contained in the NICE public health guidance (NICE, 2010a), and the review of 
psychological interventions for adults contained in within this guideline. A limited 
number of studies, specifically on alcohol focused interventions, have been 
undertaken for children and young people. However, a number of studies have 
considered the treatment of conduct disorder in the presence of drug or alcohol 
misuse. In light of this significant comorbidity, in addition to the two guidelines 
referred to above, the GDG also drew on other recent NICE guidelines, specifically 
the review of conduct disorders for adolescents contained within the NICE guideline 
on ASPD (NICE 2008) and three other systematic reviews (Waldron & Kaminer, 
2004); Perepletchikova et al., 2008; Tripodi et al., 2010). Individual and group based 
therapies and multi-component interventions used in the treatment of alcohol 
dependence and harmful alcohol use in children and young people were considered 
in the review of the evidence.  
Individual and group psychological interventions  
The public health guidelines on the prevention of alcohol related problems in adults 
and young people (NICE 2010a) and also the NICE public health guidance on 
community interventions for vulnerable young adults (NICE, 2007b) , recognise the 
value of individual and/or group CBT. A number of studies which assess the use of 
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individual or group based psychological therapies have been identified and 
reviewed (Waldron &Kaminer, 2004; Perepletchikova et al., 2008; Tripodi et al., 2010).  
 
In a recent systematic review, Tripodi and colleagues (2010) conducted a meta-
analysis of experimental studies (including RCTs) evaluating both individual/group 
based interventions collectively (brief interventions, MET and CBT) as well as 
family-based therapies with a focus on reducing alcohol misuse. However, of these 
studies, only a limited number of trials evaluated the use of CBT (with an emphasis 
on relapse prevention) and MET in a sample of children or young people identified 
with harmful or dependent drinking, the specific focal point of this guideline. The 
review consisted of 16 studies (14 RCTs, 2 were quasi-experimental) assessing both 
individual/group treatment and multi-component therapies. Ten of these included 
studies assessed individual/group treatment. However, of the studies included in 
the meta-analysis, the main issues encountered were that the included studies are 
concerned with individuals who did not meet criteria for harmful drinking or 
alcohol dependence (n=1); were with a participant population with a significant 
comorbid psychiatric disorder (n=2); and in the majority of cases, the focus was not 
specifically on alcohol misuse, but rather on substance misuse more generally (n=7). 
The results of this meta-analyses showed a significantly large effect in drinking 
reduction for individual interventions (Effect Size = -0.75; 95% CI, -1.10 to -0.40) 
However, the meta-analyses did not distinguish between different types of 
individual interventions in pooled analyses therefore other reviews which focused 
on specific interventions were considered.  
Brief interventions and motivational interviewing  
Both the NICE prevention of alcohol related problems in adults and young people 
(NICE 2010a) and also the NICE public health guidance on community interventions 
for vulnerable young adults consider the evidence for brief motivational techniques 
(motivational interviewing and motivational enhancing techniques). Motivational 
interviewing and other brief interventions may serve to heighten motivation, 
increase self-efficacy, and provide personalised feedback and education tailored to 
specific substances and comorbid problems such as psychiatric disorders. The 
evidence for this is mainly from the adult literature though there is an emerging 
albeit still limited literature for adolescents where modifications of motivational 
interviewing or motivational enhancement techniques for adolescents have shown 
promise for both evaluation and treatment (Colby et al., 1998; Monti et al., 1999). 
However, a more recent review by Perepletchikova and colleagues (2008) reported 
uncertain outcomes for MET when used alone for alcohol use disorders (this is 
consistent with the approach to harmful and dependent alcohol misuse identified for 
adults in this guideline). There is some evidence to suggest that motivational 
techniques when combined with CBT may be effective, for example in the Cannabis 
Youth Trial (CYT; Dennis et al., 2004), although this population were predominately 
diagnosed as dependent on cannabis. 
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Cognitive behavioural therapy  
Waldron and Kaminer (2004) in a review of CBT approaches to substance use 
disorders (more broad than just alcohol misuse) concluded that individual CBT 
treatment may be effective in reducing substance misuse as well as other related 
problems. They also made a number of suggestions about the adaptation of CBT 
approaches to young people, addressing developmental stages and levels of 
maturity. This review reported that CBT in group format was as effective as 
individual therapy. CBT has been applied both in individual and group modalities 
in combination with family approaches and MET. Interventions with the adolescent 
alone (for example, CBT or CBT plus MET) have been reported as effective (Dennis 
et al., 2004; Kaminer & Burleson, 1999; Kaminer et al., 1998). However, much of the 
evidence base is from approaches dealing with comorbidity such as conduct 
disorders, and anxiety and affective disorders where information on the extent and 
severity of alcohol misuse specifically is lacking. Perepletchikova and colleagues 
(2008) in a subsequent review considered 5 studies looking at the effectiveness of 
CBT in the reduction of alcohol use disorders, three of which were of CBT alone, one 
evaluated an integrated family and group CBT approach and one looked at efficacy 
of CBT on reduction of substance use in those with comorbid conduct disorder. 
Again it appears that the data is primary concerned with children and young people 
who did not have a high severity of alcohol misuse.  
 
Kaminer and colleagues (2002) in one of the few studies that had a more substantial 
proportion of participants with alcohol dependence randomised participants to CBT 
or a psychoeducational therapy. Of 88 included participants, 12.5% (n=11) had an 
alcohol use disorder only and 60% (n=53) had an alcohol disorder as well as 
marijuana use disorder. Of these 64 participants with an alcohol use disorder, 58% 
met criteria for abuse and 42% for dependence (DSM III-R; American Psychiatric 
Association, 1987). The authors reported that there were reductions across both 
therapies in alcohol use. At three months alcohol use had improved significantly and 
to 9 months showed continued improvement. Substance use also showed a positive 
trend towards improvement. Kaminer and colleagues (2008) only included 
participants who meet DSM–IV criteria for alcohol dependence, although 81.8% of 
the sample also used marijuana. However, all participants received CBT and the 
focus on the study was on aftercare.  
 
Although the primary focus of comorbidity has been on individuals with conduct 
disorder, a few studies have also examined the problems presented by co-occurring 
common mental health disorders, such as depression and anxiety. One study 
evaluated the efficacy of an integrated 20-week programme of CBT with case 
management in a population of substance abusing young people (aged between 15 
and 25 years). Sixty-three percent of the sample met criteria for alcohol dependence. 
Treatment resulted in a significant improvement in abstinence rates as well as a 
reduction in the number or participants meeting diagnostic thresholds for 
dependence. These positive effects were also observed at 44 week follow-up. This 
study (like others) evaluates the effectiveness of psychological interventions for 
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young people include participants whom are over the age of 18 years. However, this 
age-range makes interpretation of data sets such as this difficult.  
 
Twelve Step Facilitation (TSF) 
The development of Twelve Step Facilitation (TSF), which grew out of the initial 
work of Alcohol Anonymous has been developed in to a treatment intervention for 
adults (ProjectMATCH, 1993; 1997) but has not been tested as an individual 
treatment in adolescents with harmful and dependent drinking. There have been no 
programmes for adolescents built around the 12 step model, and as far as the GDG 
were aware (or were able to identify), no evaluation of the effectiveness of a 12-step 
model for children and young people. It should be noted that some residential 
treatment centres for adolescents have refined the TSF resulting in the development 
of residential treatment models, for example, the Minnesota model (Winters et al., 
2000). However, no formal evaluations in alcohol dependent adolescents were 
identified.  
6.22.6 Evidence summary 
The evidence reviewed using these systematic reviews and primary studies suggests 
that although there has been recent progress in the development of individual or 
group psychological treatment of alcohol dependence and harmful alcohol use in 
children and young people no individual treatment has a convincing evidence base 
for harmful use of dependence. In some respect is in line with the adult literature 
and findings of our own meta-analyses where a number of structured treatments 
including CBT, behaviour therapy and social network behaviour therapy had some 
benefits for harmful and mildly dependent drinkers but it was not possible to 
distinguish between them on the basis of the current available evidence. The issue is 
further complicated by the fact that many of the trials evaluating the efficacy of these 
intervention, and representative of this population, involved participants with 
comorbid substance misuse.  
6.22.7 Multi-component psychological interventions 
Components of a multi-component intervention  
The need to involve family members, particularly parents has been recommended in 
policy guidance, for example Every Parent Matters (DfES, 2007) and in Supporting and 
Involving Carers (NTA, 2008). Family involvement has been shown to be positively 
associated with improved outcomes on domains and level of engagement of the 
young person (Dakof et al., 2001). This involvement is multi-fold and aims:_ 
 to obtain (depending on consent of the child and capacity) any necessary 
consent to treatment 
 to engage the support of the family in the treatment process 
 to obtain more information on the assessment of the child‘s alcohol use and 
general functioning 
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 to ascertain possible family involvement in parent training, coping skills and 
problem solving approaches to parenting, and more formal involvement in 
specific family programmes.  
 
Common elements identified for review in these programmes include:- 
 comprehensive assessment and monitoring 
 a focus on engagement of individuals (and usually their families) in treatment 
 an explicit linking of goals and interventions at all levels of the system 
 a goal-focused approach to treatment of family substance misuse,  
 the involvement of the family aimed at improving family communication 
problem solving and parenting skills 
 the provision of individual interventions, again often focused on coping skills 
identified for the child or young person.  
The programmes also require staff who are experienced and highly trained clinicians 
(all were graduates, most had masters or doctoral degrees).  
 
Although there are many approaches to family intervention for substance misuse 
treatment, they have common goals: providing education about alcohol and drug 
misuse; improve motivation and engagement; assisting in achieving and 
maintaining abstinence; setting consistent boundaries and structure; improving 
communication, and providing support. Family interventions are the most evaluated 
modality in the treatment of adolescents with substance use disorders. Among the 
forms of family based interventions are functional family therapy (Alexander et al., 
1990); brief strategic family therapy (Szapocznik et al., 1988), multisystemic therapy 
(Henggeler et al., 1992) and multidimensional family therapy (Liddle et al., 1999). An 
integrated behavioural and family therapy model that combines a family systems 
model and CBT has also been developed (Waldron et al., 2001).These interventions 
fall broadly under what would be called a systemic approach. They do not focus 
explicitly on the provision of specified individual interventions but rather it is for the 
therapist, in conjunction with their supervisor, to develop the specific therapeutic 
approach in light of the identified needs of the young person. Some trials, such as 
the large trial of cannabis misuse and dependence (Dennis et al., 2004), have focused 
on the provision of a systemic approach (in this case MDFT) but have also provided 
a specified range of psychological interventions such as MET, the development of a 
family support network including parental education, and the development of 
conditioning models from children in the community.  
Definitions of interventions 
Functional family therapy is a psychological intervention that is behavioural in 
focus. The main elements of the intervention include engagement and motivation of 
the family in treatment, problem-solving and behaviour change through parent 
training and communication training, and seeking to generalise change from specific 
behaviours to have an impact on interactions both within the family and with 
community agencies such as schools (see for example Gordon et al., 1995).  
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Brief strategic family therapy is a psychological intervention that is systemic in focus 
and is influenced by other approaches such as structural family therapy. The main 
elements of this intervention include engaging and supporting the family, 
identifying maladaptive family interactions and seeking to promote new more 
adaptive family interactions (see for example, Szapocznik et al., 1989). 
 
Multi-systematic therapy involved using strategies from family therapy and 
behaviour therapy to intervene directly in systems and processes related to antisocial 
behaviour (for example, parental discipline, family affective relations, peer 
associations, and school performances) for children or adolescents (Henggeler et al., 
1992). 
Effectiveness of multi-component interventions 
The GDG used the NICE ASPD guideline (NICE, 2009) review of family 
interventions and multi-systematic therapies for the treatment of conduct disorder in 
evaluating the effectiveness of multi-component interventions for children and 
adolescents. The primary focus of the ASPD review was on a reduction in offending 
behaviour but all the interventions, in particular BSFT and MDFT, had an explicit 
focus on substance misuse. The current guideline utilises the definitions from the 
ASPD guideline. 
 
In the ASPD guideline, the meta-analysis of 11 trials assessed the effectiveness of 
family interventions. The results of the meta-analysis showed that family 
interventions are more effective than control for reducing both behavioural 
problems (SMD -0.75; -1.19 to -0.30) and offending (RR -0.67; 0.42 to 1.07). 
Furthermore, 10 trials on multisystemic therapy that met the inclusion criteria for the 
review were analysed. There was significant heterogeneity for most outcomes; 
however, there was consistent evidence of a medium effect on reduction in 
offending outcomes including number of arrests (SMD -0.44; -0.82 to -0.06) and being 
arrested (RR 0.65; 0.42 to 1.00). 
 
In a recent meta-analysis, Tripodi and colleagues (2010) evaluated six trials of multi-
component and family-based interventions in the systematic review. However, none 
of these trials were focused specifically on alcohol misuse, and in two of the trials, 
only approximately 50% of the sample met criteria for alcohol dependence and 
harmful alcohol use. The overall findings were in line with the NICE ASPD 
guideline (NICE, 2009). The review did however reports that that multi-component 
family therapies were effective in reducing drinking in adolescents (Hedges g = -
0.46, 95% CI, -0.66 to -0.26). Perepletchikova and colleagues (2008) reviewed the 
evidence of family therapies specifically on alcohol use, although some of the family 
therapies did include substance use disorders. The types of family therapies 
evaluated included: multi systemic therapy, multidimensional therapy, brief family 
therapy, functional family therapy and strength oriented family therapy. The review 
reported that multi-component therapy again showed some benefits over standard 
group therapy for substance misuse and criminal activity outcomes.  
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6.22.8 Evidence summary  
The evidence for the use of multi-component interventions demonstrates clear 
benefits on offending behaviour and promising results for the reduction of alcohol 
and drug misuse. As was found with the individual- or group-based interventions, 
much of the research focuses on children and young people with substance use 
disorders and who are more likely have comorbid psychiatric disorders. Although 
not specifically focused on alcohol this does not significantly detract from their 
applicability to this guideline as comorbidity with conduct disorder and poly-drug 
use is a common feature amongst adolescents with significant alcohol misuse. The 
research to date does not however favour one particular multi-component 
intervention over another for the treatment for alcohol use disorders.  
6.22.9 From evidence to recommendations 
The GDG reviewed the evidence for the clinical effectiveness and cost effectiveness 
of various psychological interventions for the treatment of alcohol misuse. The GDG 
discussed and agreed that the main outcomes of interest related to drinking-focused 
outcomes. When considering the evidence presented, it must be noted that due to 
the lack of consistent critical outcomes assessed across studies, the number of studies 
evaluating the same outcomes within the included reviews was generally low. 
Outcomes had to be grouped according to more general outcomes which would 
indicate efficacy of treatment (for example, outcomes relating to abstinence, the 
amount of alcohol consumed, and the frequency or intensity of consumption). The 
GDG took the view that to be recommended, an active psychological intervention 
should show evidence of effectiveness against no treatment control/waitlist in the 
first instance, then treatment as usual, and preferably should be more effective than 
other active interventions. However, the evidence evaluating the effectiveness of an 
intervention against no treatment control/waitlist or standard care was not always 
available as most studies compared two or more active interventions with each 
other. The GDG considered this limitation of the evidence as well as individual 
treatment comparisons and the patient population evaluated in the trials during the 
process of making recommendations about the efficacy the interventions. The 
quality of the evidence overall was moderate and any limitations of the data 
addressed in the GRADE profiles were considered before making recommendations.  
 
As we can see from the above evidence summary, the strongest evidence for 
effectiveness in harmful and dependent drinking was for behavioural couples 
therapy. It is therefore recommended that behavioural couples therapy be 
considered as an effective intervention for individuals with harmful and mildly 
dependent alcohol misuse that had a partner, who was willing to engage in 
treatment. Behavioural couples therapy should be offered for mildly dependent and 
harmful drinkers as a standalone intervention. Consideration should also be given to 
giving behavioural couples therapy in combination with a pharmacological 
intervention for those individuals who meet the above criteria and have moderate or 
severe alcohol dependence (see Chapter 6).  
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The evidence for individual psychological interventions for harmful and mildly 
dependent drinkers was limited but stronger for CBT, social network and behaviour 
therapy and behaviour therapy than other therapies reviewed and are therefore 
recommended. The GDG considered the costings of the various psychological 
interventions (indications from this costings was that social network behaviour 
therapy was less costly than either CBT or behaviour therapy) but considered that, 
given the uncertainty about the relative cost-effectiveness of the interventions and 
the need to have available a range of interventions to meet the complexity of 
presenting problems that all three interventions should be recommended as 
standalone interventions. One of the three interventions should also used in 
combination with the drug treatments reviewed in Chapter 6.  
 
As can be seen from the clinical summary the GDG considered that appropriate 
elements of TSF and motivational-based interventions should be provided as a 
component of an assessment and subsequent intervention as the evidence, 
particularly against treatment as usual or similar controls was not strong enough to 
support their use as a standalone intervention for harmful and mildly dependent 
drinkers who seek treatment.  
Children and young people 
The evidence base is limited for the treatment of alcohol misuse in children and 
young people. As a consequence, the GDG were required to extrapolate from a 
number of datasets and sources that did not directly address the treatment of alcohol 
use disorders in children and young people. This included data on adults with 
alcohol use disorders, as well as children and young people with substance misuse, 
conduct disorder and ASPD. The GDG considered this to be justified approach as 
there is an urgent need to provide recommendations for the treatment of the 
increasing problem of alcohol misuse in children and young people. In extrapolating 
from these data sets the GDG adopted a cautious approach, recognising that as new 
evidence emerges the recommendations in this guideline will need revision.  
 
Despite limited evidence a reasonably clear picture emerged about the effectiveness 
of interventions to promote abstinence and prevent replace in children and young 
people. There was some evidence for individual interventions such as CBT and less 
so for MET. There was stronger evidence for the use of multi-component 
interventions such as MST, FFT, SBSFT, and MDFT but little evidence to determine 
whether one of other of the interventions had any advantage over the other. This 
evidence also mirrored the evidence for effectiveness in adults The GDG therefore 
decided that both types of intervention should be made available with CBT reserved 
for case where comorbidity is not present or of little significance but where it is 
present, multi-component interventions should be adopted.  
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6.23 RECOMMENDATIONS  
6.23.1.1 For all people who misuse alcohol, carry out a motivational intervention as 
part of the initial assessment. The intervention should contain the key 
elements of motivational interviewing including: 
 helping people to recognise problems or potential problems related to 
their drinking 
 helping to resolve ambivalence and encourage positive change and 
belief in the ability to change 
 adopting a persuasive and supportive rather than an argumentative 
and confrontational position. 
6.23.1.2 For all people who misuse alcohol, offer interventions to promote abstinence 
or moderate drinking as appropriate (see Sections 5.26.1.8–5.26.1.11) and 
prevent relapse, in community-based settings. 
 
6.23.1.3 Consider offering interventions to promote abstinence and prevent relapse 
as part of an intensive structured community-based intervention for people 
with moderate and severe alcohol dependence who have: 
 very limited social support (for example, they are living alone or have 
very little contact with family or friends) or 
 complex physical or psychiatric comorbidities or 
 not responded to initial community-based interventions (see 6.23.1.2). 
[KPI] 
6.23.1.4 All interventions for people who misuse alcohol should be delivered by 
appropriately trained and competent staff. Pharmacological interventions 
should be administered by specialist and competent staff36. Psychological 
interventions should be based on a relevant evidence-based treatment 
manual, which should guide the structure and duration of the intervention. 
Staff should consider using competence frameworks developed from the 
relevant treatment manuals and for all interventions should: 
 receive regular supervision from individuals competent in both the 
intervention and supervision 
 routinely use outcome measurements to make sure that the person who 
misuses alcohol is involved in reviewing the effectiveness of treatment  
 engage in monitoring and evaluation of treatment adherence and practice 
competence, for example, by using video and audio tapes and external audit 
and scrutiny if appropriate. [KPI] 
                                                 
36 If a drug is used at a dose or for an application that does not have UK marketing authorisation, 
informed consent should be obtained and documented. 
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6.23.1.5 All interventions for people who misuse alcohol should be the subject of 
routine outcome monitoring. This should be used to inform decisions about 
continuation of both psychological and pharmacological treatments. If there 
are signs of deterioration or no indications of improvement, consider 
stopping the current treatment and review the care plan.  
6.23.1.6 For all people seeking help for alcohol misuse: 
 give information on the value and availability of community support 
networks and self-help groups (for example, Alcoholics Anonymous or 
SMART Recovery) and 
 help them to participate in community support networks and self-help 
groups by encouraging them to go to meetings and arranging support 
so that they can attend. 
6.23.1.7 For children and young people aged 10–17 years who misuse alcohol offer: 
 individual cognitive behavioural therapy for those with limited 
comorbidities and good social support 
 multicomponent programmes (such as multidimensional family 
therapy, brief strategic family therapy, functional family therapy or 
multisystemic therapy) for those with significant comorbidities and/or 
limited social support. [KPI]  
6.23.1.8 Multidimensional family therapy should usually consist of 12–15 family-
focused structured treatment sessions over 12 weeks. There should be a 
strong emphasis on case coordination and, if necessary, crisis management. 
As well as family sessions, individual interventions may be provided for 
both the child or young person and the parents. The intervention should aim 
to improve: 
 alcohol and drug misuse 
 the child or young person‘s educational and social behaviour 
 parental well-being and parenting skills 
 relationships with the wider social system. 
6.23.1.9 Brief strategic family therapy should usually consist of fortnightly meetings 
over 3 months. It should focus on:  
 engaging and supporting the family 
 using the support of the wider social and educational system 
 identifying maladaptive family interactions 
 promoting new and more adaptive family interactions. 
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6.23.1.10 Functional family therapy should be conducted over 3 months by 
health or social care staff. It should focus on improving interactions within 
the family, including: 
 engaging and motivating the family in treatment (enhancing 
perception that change is possible, positive reframing and establishing 
a positive alliance) 
 problem solving and behaviour change through parent training and 
communication training 
 promoting generalisation of change in specific behaviours to broader 
contexts, both within the family and the community (such as schools). 
6.23.1.11 Multisystemic therapy should be provided over 3–6 months by a 
dedicated member of staff with a low caseload (typically between three and 
six cases). It should: 
 focus specifically on problem-solving approaches with the family 
 use the resources of peer groups, schools and the wider community. 
 Interventions for harmful drinking and mild alcohol dependence  
6.23.1.12 For harmful drinkers and people with mild alcohol dependence, offer a 
psychological intervention (such as cognitive behavioural therapies, 
behavioural therapies or social network and environment-based therapies) 
focused specifically on alcohol-related cognitions, behaviour, problems and 
social networks. [KPI] 
 
6.23.1.13 For harmful drinkers and people with mild alcohol dependence who 
have a regular partner who is willing to participate in treatment, offer 
behavioural couples therapy. 
 
6.23.1.14 For harmful drinkers and people with mild alcohol dependence who 
have not responded to psychological interventions alone, or who have 
specifically requested a pharmacological intervention, consider offering 
acamprosate37 or oral naltrexone38 in combination with an individual 
psychological intervention (cognitive behavioural therapies, behavioural 
therapies or social network and environment-based therapies) or 
behavioural couples therapy (see chapter 7 for pharmacological 
interventions).  
 
                                                 
37 Note that the evidence for acamprosate in the treatment of harmful drinkers and people who are 
mildly alcohol dependent is less robust than that for naltrexone. At the time of publication (February 
2011), acamprosate did not have UK marketing authorisation for this indication. Informed consent 
should be obtained and documented.  
38 At the time of publication (February 2011), oral naltrexone did not have UK marketing 
authorisation for this indication. Informed consent should be obtained and documented. 
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 Delivering psychological interventions  
6.23.1.15 Cognitive behavioural therapies focused on alcohol-related problems 
should usually consist of one 60-minute session per week for 12 weeks. 
6.23.1.16 Behavioural therapies focused on alcohol-related problems should 
usually consist of one 60-minute session per week for 12 weeks. 
6.23.1.17 Social network and environment-based therapies focused on alcohol-
related problems should usually consist of eight 50-minute sessions over 12 
weeks. 
6.23.1.18 Behavioural couples therapy should be focused on alcohol-related 
problems and their impact on relationships. It should aim for abstinence, or 
a level of drinking predetermined and agreed by the therapist and the 
service user to be reasonable and safe. It should usually consist of one 60-
minute session per week for 12 weeks. 
6.23.2 Research recommendation 
6.23.2.1 Is contingency management compared with standard care effective in 
reducing alcohol consumption in people who misuse alcohol? 
 
This question should be answered using a randomised controlled design that reports 
short-and medium-term outcomes (including cost-effectiveness outcomes) of at least 
18 months‘ duration. Particular attention should be paid to the reproducibility of the 
treatment model and training and supervision of those providing the intervention to 
ensure that the results are robust and generalisable. The outcomes chosen should 
reflect both observer and service user-rated assessments of improvement and the 
acceptability of the intervention. The study needs to be large enough to determine 
the presence or absence of clinically important effects, and mediators and 
moderators of response should be investigated. 
Why is this important? 
Psychological interventions are an important therapeutic option for people with 
alcohol related problems. However, even with the most effective current treatment 
(for example, cognitive behavioural therapies and social network and environment-
based therapies), the effects are modest at best and the treatments are not effective 
for everyone. Contingency management has a considerable and compelling evidence 
base in the treatment of substance misuse (for example, opioid misuse) but there is 
only a limited, if promising, evidence base for contingency management in the 
treatment of alcohol- related problems. The results of this research will have 
important implications for the provision of psychological treatment for alcohol 
misuse in the NHS. 
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6.24 ACUPUNCTURE  
Introduction  
Acupuncture is a form of Chinese medicine which has been practiced for over 3000 
years (Jordan, 2006). It involves inserting fine needles at selected points on the skin 
to balance the body‘s energy (chi), with the aim of treating and preventing disease. 
Acupuncture was introduced specifically for use in the treatment of substance-
related disorders approximately 30 years ago (Kao, 1974; Leung, 1977; Sacks, 1975; 
Wen et al., 1973). However, research has predominantly been for drug addictions for 
example, opiate dependence (Jordan, 2006), cocaine dependence (Gates et al., 2006; 
Mills et al., 2005) as well as nicotine dependence (White et al., 2006). Research for the 
use of acupuncture in alcohol use disorders is rather more limited and to date there 
are only two systematic reviews of acupuncture for alcohol dependence (Cho & 
Whang, 2009; Kunz et al., 2007). Addiction-specific auricular acupuncture involves 
inserting five small needles on each ear at points regarded to be specific to chemical 
dependence (shenmen, ‗sympathetic‘, ‗kidney‘, ‗liver‘ and ‗lung‘) (Smith & Khan, 
1988; Wen, 1979). 
6.24.1 Clinical review protocol  
In the current review, the role of acupuncture in maintaining abstinence and 
drinking reduction was investigated. It‘s application to other aspects usually 
associated with alternative therapies in this topic area (such as craving and 
withdrawal symptoms) was beyond the scope of this guideline and hence was not 
considered. Information about the databases searched and the inclusion/ exclusion 
criteria used for this section of the guideline can be found in Chapter 3. The GDG 
were of the opinion that a search for RCT studies alone may result in an insufficient 
number of studies to perform a review, therefore a consensus-based decision was 
made to also search for systematic reviews. See Table 87 below for a summary of the 
clinical review protocol for the review of Acupuncture. 
 
Table 87: Clinical review protocol for the review of acupuncture 
Electronic databases COCHRANE, AMED, CINAHL, EMBASE, MEDLINE, 
PsycINFO 
Date searched Systematic Reviews from 1993 to March 2010. All other searches 
from database inception to March 2010 
Study design RCTs (≥ 10 participants per arm); Systematic Reviews  
Patient population Adults (>18 years)  
At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant Women 
Interventions Acupuncture (all types) 
Comparator  Control or other active intervention 
Critical Outcomes Abstinence 
Amount of alcohol consumed 
Rates of Consumption 
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Relapse (>X number of drinks or number of participants who 
have relapsed) 
Lapse (time to first drink or number of participants who have 
lapsed) 
Attrition (leaving the study early for any reason) 
 
6.24.2 Studies considered for review  
The review team conducted a systematic search of RCTs and published systematic 
reviews that assessed the beneficial or detrimental effects of acupuncture in the 
treatment of alcohol dependence or harmful alcohol use. Following the literature 
search, 11 primary studies were identified. Of these studies, 4 investigated the effects 
of acupuncture on withdrawal symptoms, and 2 assessed its use for the management 
of cravings. These studies were excluded as the outcomes are outside the scope of 
this guideline. Therefore, five studies (4 RCTs, 1 observational study) were identified 
for inclusion in a review. However, the review team could not perform an unbiased 
and comprehensive meta-analysis as there were inconsistent outcomes measures 
across studies. Therefore, the GDG consensus was that a narrative summary of these 
studies would be conducted. The studies included for review were Bullock and 
colleagues (1987) (addiction-specific versus non-specific acupuncture); Bullock and 
colleagues (1989) (addiction-specific versus non-specific acupuncture); Worner 
(1992) (addiction specific acupuncture versus sham transdermal stimulations versus 
standard care control); Rampes (1997) (addiction-specific versus non-specific 
acupuncture versus no treatment control); and Bullock et al. (2002) (addiction specific 
acupuncture versus symptom-based acupuncture versus non-specific acupuncture 
versus standard care control). These studies were conducted between 1987 and 2002 
and provided data on n=752 participants. See Table 88 for characteristics of these 
studies. All included studies were RCTS bar Bullock and colleagues (1989).  
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Table 88: Summary of study characteristics for acupuncture 
Study 
(country) 
Treatment conditions & number of 
participants 
Baseline severity & diagnosis Setting, treatment characteristics & assessment 
points 
Bullock et al., 
1987 (US) 
1. Addiction specific acupuncture (n=27) * 98.1% of sample indicated 
alcohol as single substance of 
misuse 
Setting: alcohol treatment centre 
2. Non-addiction specific acupuncture 
(control) (n=27) 
 
*Auricular and hand acupuncture 
* Mean years of alcohol misuse: 
Treatment group = 21.6; Control 
group = 18.5 
Treatment characteristics: 45 day standard 
acupuncture treatment  
* 68.5% of sample drink daily; 
27.7% binge drink 
Assessment points: No follow-up, assessing 
during different phases of treatment 
Bullock et al., 
1989 (US) 
1. Addiction specific acupuncture (n=40) *Alcohol dependent participants Setting: Alcohol Treatment Centre 
2. Non-addiction specific acupuncture 
(control) (n=40) 
 
*Auricular and hand acupuncture 
* Mean years of alcohol misuse: 
Treatment group = 23.2; Control 
= 20.8 
Treatment characteristics: Patients received 
treatment after 3 to 5 day withdrawal 
management  
* 71% of the sample drink daily; 
21% binge drink 
Assessment points: 1-, 3- and 6-month follow-up 
Worner et al., 
1992 (US) 
1. Addiction specific acupuncture (n=19) *Alcohol dependent participants Setting: alcohol treatment centre 
2. Needleless transdermal stimulation 
(control) (n=21) 
* Daily intake approx 253.6 g per 
day 
Treatment characteristics: 3-month treatment; all 
participants received standard care (individual 
and group counselling, AA, task-oriented group 
activities) 
3. Standard care control (n=16) 
 
*Acupuncture at various body parts 
Assessment points: 3-month follow-up 
Rampes et al., 
1997 (UK) 
1. Addiction specific electro auricular 
acupuncture (n=23) 
* DSM–III–R alcohol dependent 
or abuse 
Setting: alcohol treatment centre 
2. Non-addiction specific electro auricular 
acupuncture (control) (n=20) 
* SADQ score approximately 32 
across groups 
Treatment characteristics: 30 minutess per week 
for 6 weeks;  
3. No Treatment Control (n=16) 
 
*Auricular acupuncture 
Assessment Points: 2- and 6-month follow-up 
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Bullock et al., 
2002 (US) 
1. Addiction specific auricular acupuncture 
(n=132) 
*Alcohol dependent participants 
in a residential treatment facility 
Setting: Alcohol Treatment Centre 
2. Symptom-based auricular acupuncture 
(n=104) 
Treatment Characteristics: 3 cycles of 6 
treatments for 3 weeks 
3. Non-addiction specific acupuncture 
(control) (n=133) 
Assessment points: 3-, 6- and 12-month follow-
up  
4. Standard care only – Minnesota model 
(control) (n=134) 
 
*Auricular acupuncture 
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6.24.3 Evidence summary 
Bullock and colleagues (1987) investigated acupuncture at addiction specific points 
versus non-specific points for reducing craving and maintaining abstinence. The 
authors report that the treatment group had significantly fewer drinking episodes 
than the control group (p=0.007) after the second (28 days) and third (45 days) phase 
of treatment but not after the first phase (5 days).  
 
Bullock and colleagues (1989) also investigated acupuncture at addiction-specific 
points versus non-specific points for craving reduction, maintaining abstinence and 
drinking reduction in people with chronic alcohol misuse. The study found that 
there was no significant difference between the treatment group and control group 
at 1-month follow-up in the number of drinking episodes (consumption of more 
than 3 drinks in one period). However at both three and six-month follow-up, the 
treatment group reported significantly less drinking episodes than the control group 
(p<0.001). Furthermore, the treatment group was significantly more effective than 
control at maintain abstinence and controlled drinking goals when assessed at 1-
month (p<0.01), 3- and 6-month follow-up (both p<0.05). This study was not 
randomised however; hence the results must be viewed with caution.  
 
Worner (1992) evaluated at addiction specific points versus needleless transdermal 
stimulation as well as a standard care group who receive no acupuncture. This study 
found no significant difference between groups in the number of participants who 
relapsed or needed further withdrawal management at three-month follow-up.  
 
Rampes (1997) assessed addiction specific electro-acupuncture versus non-specific 
electro-acupuncture and no treatment (control). The main outcome of interest was 
craving reduction which is outside the scope of this guideline. However, the authors 
also reported no significant difference between groups in amount of alcohol 
consumed at 2- and 6-month follow-up.  
 
Bullock and colleagues (2002) investigated specific and non-specific acupuncture as 
well as symptom-based acupuncture and standard care (based on the Minnesota 
Model). The authors found no significant difference in alcohol consumption at 3, 6 
and 12-month follow-up. Overall, the evidence suggests that acupuncture is not 
effective in drinking reduction and maintaining abstinence. 
 
The results of these studies are conflicting and show both a benefit of addiction-
specific acupuncture as well as no difference between addiction-specific acupuncture 
and other control conditions. Additionally, the treatments across studies are not 
comparable as the studies used different body parts for acupuncture treatment, 
different types of control group, different length of treatment and follow-up and 
varied significantly in sample size. Although the quality of these trials are acceptable 
in the most part, the number of studies are limited and there is not enough evidence 
to confirm the benefit of acupuncture in maintaining abstinence or reducing the 
amount of alcohol consumed. Therefore no recommendations are made. 
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6.24.4 Research recommendation 
6.24.4.1 Is acupuncture compared with usual care effective in reducing alcohol 
consumption? 
This question should be answered using a randomised controlled design that 
reports short-and medium-term outcomes (including cost-effectiveness 
outcomes) of at least 12 months‘ duration. Particular attention should be paid 
to the reproducibility of the treatment model and training and supervision of 
those providing the intervention to ensure that the results are robust and 
generalisable. The outcomes chosen should reflect both observer and service 
user-rated assessments of improvement and the acceptability of the treatment. 
The study needs to be large enough to determine the presence or absence of 
clinically important effects, and mediators and moderators of response should 
be investigated. 
Why this is important? 
Non-pharmacological treatments are an important therapeutic option for 
people with alcohol- related problems. There is an evidence base for 
acupuncture in reducing craving but not alcohol consumption in a number of 
small trials. The evidence for pharmacological treatments (for example, 
acamprosate or naltrexone) and psychological treatments (for example, 
cognitive behavioural therapies and social network and environment-based 
therapies) is modest at best and the treatments are not effective for everyone. 
Anecdotal evidence suggests that acupuncture, like psychological treatment, 
is valued by service users both in alcohol misuse and substance misuse 
services (although the evidence base for effectiveness is weak). The results of 
this study will have important implications for increased treatment choice for 
people who misuse alcohol in the NHS. 
6.25 PSYCHOLOGICAL INTERVENTIONS FOR CARERS 
Introduction 
There is an increasing recognition that alcohol misuse affects the entire family and 
the communities in which these families live but what constitutes best practice in the 
area is not well understood (Copello et al., 2006). What is not in doubt is the 
considerable suffering and hardship experienced by many families where a family 
member has a significant alcohol misuse problem (Orford et al., 2004). 
 
In developing this guideline the GDG drew on a previous review of psychological 
interventions for carers which had been undertaken for the NICE guideline on 
Psychosocial Interventions for Drug Misuse (NCCMH, 2008). This was a pragmatic 
decision as the previous review had drawn on literature covering both drug misuse 
and alcohol misuse and searches conducted for this guideline had failed to find any 
substantial new evidence from interventions to support family members and carers. 
The outcome of the NCCMH (2008) review is summarised below in narrative form.  
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The NCCMH (2008) guideline identified a number of interventions in the drug and 
alcohol field that had been developed and tested in formal trials. They are listed 
below  
 5-step intervention 
The 5-Step intervention seeks to help families and carers in their own right, 
independent of relatives who misuse drugs or alcohol. It focuses on three key areas: 
stress experienced by relatives, their coping responses and the social support 
available to them. Step 1 consists of listening and reassuring the carer, Step 2 
involves providing relevant information, Step 3 counselling about coping, Step 4 
counselling about social support and Step 5 discussion of the need for other sources 
of specialist help. This intervention consists of up to five sessions. 
Community reinforcement and family training  
Community reinforcement and family training is a manualised treatment 
programme that includes training in domestic violence precautions, motivational 
strategies, positive reinforcement training for carers and their significant other, and 
communication training. However, the primary aim of the treatment appears to be 
encouraging the person who misuses drugs or alcohol to enter treatment. This 
intervention again consists of up to five sessions. 
Self-help support groups 
A group of families and carers of people who misuse drugs meets regularly to 
provide help and support for one another. 
Guided self-help 
A professional offers a self-help manual (for example, based on the 5-step 
intervention), provides a brief introduction to the main sections of the manual and 
encourages the families and/or carers of people who misuse drugs to work through 
it in their own time at home. 
6.25.1 Summary of the 2008 review  
The review identified a total of three RCTs including two trials (Kirby et al., 1999; 
Meyers et al., 2002) for community reinforcement and family training (CRFT) 
compared with 12-step self-help groups and one trial (Copello et al., 200939) of the 5-
Step intervention in which 5-Step interventions of various intensities were 
compared.  
 
Neither Kirby and colleagues 1999, or Meyers and colleagues found any significant 
different between CRFT and 12-step self-help groups for reported levels of drug or 
alcohol use40. However, Kirby and colleagues (1999) found statistically significant 
changes from baseline for both groups in relation to carer problems and 
                                                 
39 Note this trial was identified prior to publication in 2008 but the reference to the published trial is 
used here.  
40 For both family members‘ report of person misusing alcohol or drugs and self-report measures. 
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psychological functioning. In contrast, Meyers and colleagues (2002) found no 
statistically significant differences (after Bonferroni corrections for multiple testing) 
in changes from baseline at 12-month follow-up. In the case of the 5-step 
intervention Copello and colleagues (2009) on two primary outcomes related to 
physical and psychological health and coping, no statistically significant differences 
were found between the full intervention and the guided self-help conditions for 
both physical and psychological health (WMD - 0.23; 95% CI, -4.11 to 3.65) and 
coping (WMD -0.12; 95% CI, -5.42 to 5.19). 
6.25.2 Clinical summary 
For both community reinforcement and family training and 5-step intervention, 
there were no statistically significant differences found between these more intensive 
interventions and self-help (that is, 12-step self-help groups and guided self-help). It 
appears that self-help interventions are as effective as more intensive psychological 
interventions in reducing stress and improving psychological functioning for carers 
and families of people who misuse drugs and alcohol. 
6.25.3 From evidence to recommendations  
In developing the recommendations for this section the guideline the GDG also took 
into account the reviews of family members, experience in Chapter 4 of this 
guideline which confirmed the view that families typically have considerable unmet 
needs. This meant that despite the limited evidence the GDG felt that the provision 
of information and the use of a range of self-help interventions (with relatively low 
cost) should be offered to families. The GDG also felt that where families could not 
make use of or have not benefitted from the use of the self-help materials that an 
offer of -a structured intervention as set out in the 5-step intervention should be 
made.  
6.25.4 Recommendations 
6.25.4.1 When the needs of families and carers of people who misuse alcohol have 
been identified:  
 offer guided self-help, usually consisting of a single session, with the 
provision of written materials  
 provide information about, and facilitate contact with, support groups 
(such as self-help groups specifically focused on addressing the needs 
of families and carers). 
6.25.4.2 If the families and carers of people who misuse alcohol have not benefited, 
or are not likely to benefit, from guided self-help and/or support groups 
and continue to have significant problems, consider offering family 
meetings. These should:  
 provide information and education about alcohol misuse  
 help to identify sources of stress related to alcohol misuse 
 explore and promote effective coping behaviours  
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 usually consist of at least five weekly sessions. 
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7 PHARMACOLOGICAL 
INTERVENTIONS  
7.1 INTRODUCTION 
Pharmacological interventions can be involved in different stages of treating alcohol 
misuse and its consequences. Medication is recognised as an adjunct to psychosocial 
treatment to provide an optimum treatment package to improve physical and 
mental health (Casswell & Thamarangsi, 2009). Prescribed medications are not a 
stand-alone treatment option and are only recommended as part of care-planned 
treatment (MoCAM, Department of Health, 2006a; Woody, 2003; Berglund, 2005; 
Raistrick et al., 2006). This chapter aims to detail the utility and efficacy of 
pharmacological interventions in the treatment of alcohol misuse. The chapter 
focuses on the use of pharmacological interventions in the promotion of abstinence 
and the reduction in alcohol consumption, and the treatment of comorbid disorders. 
For the use of pharmacological interventions in a planned withdrawal programme 
see Chapter 5 and for the use of pharmacological interventions in an unplanned 
withdrawal programme see NICE guideline on management of alcohol-related 
physical complications (NICE, 2010b).  
7.1.1 Current practice 
Pharmacotherapy is most frequently used to facilitate withdrawal from alcohol in 
dependent drinkers; many fewer individuals receive medication for relapse 
prevention such as acamprosate, disulfiram or naltrexone. Indeed some people may 
be reluctant to take medication and traditionally many residential rehabilitation 
units been not been prepared to accept or support people taking such medication, 
although this is slowly changing. A US survey revealed that only about 9% of people 
needing treatment for alcohol dependence received medication for relapse 
prevention; prescriptions of disulfiram declined by 3% between 2003 and 2007 while 
prescriptions for naltrexone rose by 3% and for acamprosate by 10% (Mark et al., 
2009). The level of prescribing is likely to be a similar or even lower in the UK. One 
estimate from data on prescriptions shows in 2008 that there were almost 135,000 
prescriptions for acamprosate or disulfiram from primary care or NHS settings, with 
the majority (62%) for acamprosate (The NHS Information Centre, Lifestyles 
Statistics, 2009). In NHS hospitals, the use of disulfiram has increased and now 
slightly more (54%) prescriptions are issued than for acamprosate. There are regional 
variations with London issuing 104 prescriptions per 100,000 population and North 
East, 417. Some doctors can be reluctant to prescribe pharmacological interventions 
such as acamprosate, naltrexone and disulfiram, due to lack of knowledge or 
familiarity (Mark et al., 2003). Barriers to prescribing naltrexone in the US have been 
described as including a ‗lack of awareness, a lack of evidence of efficacy in practice, 
side effects, time for patient management, a reluctance to take medications, 
medication addiction concerns, Alcoholics Anonymous (AA) philosophy, and price‘ 
(Mark et al., 2003). Nevertheless there are a variety of medications with proven 
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effectiveness and others with emerging efficacy that deserve due consideration as 
part of any individual treatment package. 
 
For relapse prevention, both acamprosate and disulfiram are licensed for relapse 
prevention in the UK, much of Europe, Australasia and North America. Naltrexone 
is used in the UK but licensed elsewhere (for example, in the US).  
 
In this guideline some pharmacotherapies described do not have a UK license for the 
indication discussed. It is important to realise that in this area of medicine, the 
absence of a license can mean that a license has not been applied for, rather than that 
the pharmacotherapy is not safe or appropriate. The terms 'unlicensed' and 'off-label' 
should not necessarily be taken to automatically imply disapproval, nor incorrect or 
improper use. There is no contra-indication to prescribing a drug off-license 
provided there is a body of evidence that supports its efficacy and safety (Healy & 
Nutt, 1998; Royal College of Psychiatrists, 2007), and often evidence of safety may 
come from its use in other disorders where a license may have been granted. In 
particular, many drugs will not have a license for use in adolescents/children or in 
the elderly but this is does not mean they necessarily lack efficacy or are unsafe. 
Nevertheless, when prescribing in these populations due care must be taken in terms 
of dosage and monitoring of side effects, as well as potential interactions with other 
medications or physical morbidity. 
7.1.2 The effects of alcohol on brain chemistry and how this relates 
to medication. 
As described in Chapter 2, alcohol affects many of the brain‘s chemical systems. The 
pharmacology of most of the medications commonly used such as benzodiazepines 
for alcohol withdrawal and disulfiram, acamprosate and naltrexone for relapse 
prevention, is well characterised and provides a potential neurobiological rationale 
for their effectiveness. Understanding more about how alcohol interacts with the 
brain has revealed many potential targets of interest, for example, to reduce drinking 
or craving. In many cases, medication already exists with the desired pharmacology 
but is used for another indication, for example, baclofen for muscle spasm. Most new 
medication is being developed to prevent relapse rather than for use in alcohol 
withdrawal, or to improve cognition or prevent toxicity.  
7.1.3 Brain chemistry and medication for relapse prevention 
Dopamine 
The pleasurable effects of alcohol are principally mediated by an increase in activity 
in the mesolimbic dopaminergic system. This dopaminergic system is regarded as 
the ‗reward‘ pathway and is involved in ‗natural‘ pleasures and motivations or 
drives such as food, sex and also responses to stress (Koob & Volkow, 2010).  
 
As dependence develops to any substance, this dopaminergic system is involved in 
responding to significant or salient cues and motivation to take more (Schultz, 2007). 
Therefore, increases in dopaminergic activity arise when a ‗cue‘ such as a pub or 
FINAL DRAFT 
 368 
 
glass of favourite drink appears, which drives the person to seek alcohol. Some 
individuals may describe this as craving though for many they may not be 
consciously aware of it. Therefore the role of dopamine switches from signalling 
pleasure to ‗alcohol-seeking or motivation‘ in response to a cue. In addition, activity 
is reduced in the dopaminergic system in alcohol dependence and is associated with 
greater risk of relapse as well as symptoms of dysphoria (Heinz, 2002). 
 
Since increases in dopamine mediate reward or motivation, blocking or antagonising 
the dopaminergic system, for example, with antipsychotics has been tried as a 
strategy to reduce drinking. However, these drugs have not shown clinical 
widespread effectiveness. Alternatively, since dependence is associated with 
reduced dopaminergic activity, boosting the dopamine system would be a 
reasonable strategy. Bromocriptine, a dopamine agonist, has shown promise in a 
clinical trial associated with a particular polymorphism of one of the dopamine 
receptors (Lawford et al., 1995) but not in all studies (Naranjo et al., 1997). It is 
possible for a drug to act like an agonist when there is low activity in the tissue and 
act like an antagonist when there is high activity – these are called partial agonists. 
One example is aripiprazole which is an antipsychotic. Preliminary studies have 
shown limited promise in relapse prevention (Anton et al., 2008b; Martinotti et al., 
2009). 
 
Disulfiram may be one medication that has some effects through the dopaminergic 
system in the brain. The effect of disulfiram is to block an enzyme (aldehyde 
dehydrogenase) in the liver that is involved in metabolising or getting rid of alcohol. 
Blocking this enzyme causes an unpleasant reaction involving flushing, nausea, 
palpitations etc. However, the enzyme in the brain that turns dopamine into 
noradrenaline is from the same family as the liver enzyme and so is also blocked by 
disulfiram leading to an increase in dopamine (Gaval-Cruz & Weinshenker, 2009). 
Whether this increase is linked to disulfiram‘s effectiveness remains unproven.  
Opioid system 
Alcohol increases levels of endorphins or opiates in the brain, which in turn increase 
dopaminergic activity. The main opiate receptor involved in ‗alcohol-liking‘ is mu, 
but the other opiate receptors, kappa and delta, also appear to have some role in 
alcohol liking and dependence (Herz, 1997).  
 
Consequently opiate antagonists or blockers, such as naltrexone or nalmefene, have 
been used to try and treat alcohol problems. Naltrexone is a non-specific opiate 
antagonist, blocking mu, kappa and delta receptors, whilst nalmefene is a mu 
antagonist and possibly a kappa partial agonist (Bart et al., 2005). Both of these 
medications, though naltrexone is more widely used, can reduce the pleasurable 
effects of alcohol (Drobes et al., 2004). A polymorphism of the mu opioid receptor has 
been reported to be predictive of treatment response to naltrexone in some studies 
(Anton et al., 2008c).  
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GABA – glutamate systems 
The GABA system is the brain‘s inhibitory or calming chemical system. Stimulation 
of one of its receptors, the GABA-B, reduces dopaminergic activity in the so-called 
reward pathway and therefore drugs that boost this system have been shown to 
reduce drug-liking and seeking (Cousins et al., 2002). Baclofen is a medication that 
has long been used to treat muscle spasms and acts as a GABA-B agonist, for 
example it will boost activity. This mechanism is proposed to underlie baclofen‘s 
recently reported efficacy in relapse prevention for alcohol dependence (Addolorato 
et al., 2007).  
 
The glutamatergic system is the brain‘s excitatory system and is involved in 
modulating the dopaminergic reward pathway. Acamprosate is a drug used for 
maintaining abstinence and has been shown to primarily reduce glutamatergic 
activity in the brain with some effect on increasing GABA-ergic activity. Since 
alcohol dependence is associated with hyperactivity in the glutamatergic system and 
reduced GABA-ergic activity, acamprosate may also improve abstinence rates by 
‗normalising‘ this imbalance (Littleton, 2000). It is also suggested that in abstinence, 
conditioned withdrawal (a withdrawal-like state such as anxiety induced by an 
object or place previously associated with drinking) is associated with a similar 
GABA-glutamatergic imbalance. Such conditioned withdrawal may be experienced 
as craving and acamprosate is proposed to also ‗correct‘ this imbalance (Littleton, 
2000). More recently roles in relapse prevention for other glutamatergic receptor 
subtypes for example, mGLuR2/3 and mGLuR5 have begun to be characterised 
(Olive, 2009). To reduce glutamatergic activity, memantine, a blocker or antagonist 
of one of glutamate‘s receptors, NMDA, has been investigated but not shown 
efficacy in preventing relapse (Evans et al., 2007).  
  
Anticonvulsants such as topiramate, can also reduce glutamatergic activity and 
boost GABA activity. In addition they can alter ion (calcium, sodium, potassium) 
channel activity thus further reducing brain activity. Several anticonvulsants are 
being studied for efficacy in treating alcohol misuse with currently the most 
evidence for topiramate (Johnson et al., 2007). Of the newer anticonvulsants, 
gabapentin and its analogue pregabalin have received some attention since they 
appear to have some efficacy in treating a variety of disorders commonly seen in 
those with alcohol problems such as depression, anxiety or insomnia. Both 
medications are licensed for use in epilepsy, neuropathic pain, and pregabalin for 
generalised anxiety disorder. Despite their names, they have not been shown to have 
any effect on the GABA system. Although, there is some limited inconsistent 
evidence that pregabalin may interact with the GABA-B receptor (Landmark, 2007). 
Both gabapentin and pregabalin interact with the alpha2delta voltage-activated 
calcium channel subunits resulting in inhibition of excitatory neurotransmitter 
release, mostly glutamate (Landmark, 2007).  
 
Hydroxybutyric acid (GHB) is a short-chain fatty acid which naturally occurs in the 
brain and GABA is its precursor. It has been used as an anaesthetic drug and to treat 
narcolepsy. Together with its pro-drug, butyrolactone (GBL), however, it is also a 
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drug of abuse and is used as a club drug or by body-builders. The exact mechanisms 
of action in the brain are not clear, particularly around how it modulates reward 
pathways, but it has been suggested that it mimics alcohol. 
 
Serotonergic system 
The acute and chronic effects of alcohol on the serotonin system are complex and not 
fully understood. One consistent demonstration has been of reduced serotonergic 
activity in so-called ‗early onset alcoholism‘ which describes individuals who 
become dependent before the age of 25 years old, have impulsive or antisocial 
personality traits, have a family history of alcoholism and are often male (Cloninger 
et al., 1981). In addition, many disorders which are commonly seen in individuals 
with alcohol problems are also proposed to have serotonergic dysfunction, for 
example, bulimia, depression, anxiety, OCD.  
 
Since a dysfunctional serotonergic system is implicated in alcohol misuse, drugs that 
can modulate this system have been studied as treatments for preventing relapse. 
These include selective serotonin reuptake inhibitor (SSRI) antidepressants and the 
anxiolytic, buspirone, a 5HT1A partial agonist. Such an approach is separate from 
any effect these drugs might have in treating any comorbid depression or anxiety for 
which they are licensed. Both SSRIs and buspirone have been found to reduce 
alcohol consumption in animal models (Johnson, 2008). However, for both SSRIs and 
buspirone, clinical efficacy in preventing relapse has been hard to demonstrate.  
 
One particular serotonin receptor subtype, 5HT3, modulates the dopaminergic 
reward pathway. Blockers or antagonists of 5HT3 receptors reduce dopaminergic 
activity, which results in reduced alcohol drinking in animal models. Therefore, 
ondansetron, a 5HT3 antagonist used to treat nausea, has been studied and clinical 
efficacy has been shown for some doses, more so in early-onset alcoholism (Johnson 
et al., 2000). Critical roles for the other serotonin receptors in alcohol use and 
dependence have not been demonstrated. 
 
7.1.4 Brain chemistry and medication for alcohol withdrawal 
A significant number of alcohol‘s effects on the brain involve interacting with the 
inhibitory GABA system. In addition to the GABA-B system described above, there 
is a GABA-A or GABA-benzodiazepine system that plays several important roles in 
mediating effects of alcohol on the brain.  
 
The GABA-A receptor is made of different subunits on which there are various 
binding sites, for benzodiazepines, barbiturates, neurosteroids, some anaesthetics as 
well as for GABA. Alcohol interacts with the GABA-benzodiazepine receptor and 
increases its inhibitory activity, resulting in reduced anxiety and sedation, and can 
contribute to ataxia, slurred speech and respiratory depression. Thus alcohol has a 
similar effect to benzodiazepines such as diazepam. Alcohol is often used for its 
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anxiolytic or sedative effects rather than pleasurable effects and anxiety and sleep 
disorders are associated with vulnerability to alcohol misuse. 
  
Tolerance is the need to drink more alcohol to get the same or desired effect 
develops in those drinking more heavily and regularly. A reduced sensitivity of the 
GABA system to alcohol underlies tolerance. It is thought that changes in the 
subunit profile of the GABA-A receptor complex are involved (Krystal et al., 2006). In 
alcohol withdrawal, benzodiazepines such as chlordiazepoxide (Librium) or 
diazepam (Valium) will boost this reduced GABAergic function to increase the 
inhibitory activity in the brain. This is important to control symptoms such as 
anxiety, tremor and to reduce the risk of complications such as seizures, delirium 
tremens.  
 
In addition to boosting the inhibitory GABA system, alcohol antagonises the 
excitatory neurotransmitter system, glutamate and particularly the NMDA receptor. 
To overcome this blockade, the number of NMDA receptors increase in response to 
continued drinking. This increase has been associated with memory impairment in 
animal models and may therefore underlie amnesia or blackouts, which can be 
experienced by people who drink heavily (Krystal et al., 2003). In alcohol 
withdrawal, therefore the increased glutamatergic activity significantly contributes 
to the associated symptoms and risk such tremor and seizures. Anticonvulsants 
which reduce glutamatergic activity as well as increasing GABA-ergic activity, can 
therefore be used to treat alcohol withdrawal. In addition to this GABA-glutamate 
activity, anticonvulsants will also inhibit voltage-activated sodium channels and, 
consequently, further excitatory activity.  
 
Another consequence of increased glutamatergic and calcium channel activity is cell 
death. Therefore a potential advantage of antagonising this increased activity in 
withdrawal is neuroprotection or preventing cell death. In animal models, 
acamprosate has been shown to reduce increased glutamatergic activity in 
withdrawal but robust clinical evidence is lacking. Whether it occurs with 
anticonvulsants has not been systematically studied. 
 
7.2 REVIEW OF PHARMACOLOGICAL INTERVENTIONS  
7.2.1 Aim of Review 
The focus of this chapter is on the effectiveness and cost-effectiveness of 
pharmacological interventions to prevent relapse or reduce alcohol consumption. 
The use of drugs alone or in combination with a range of other psychosocial 
interventions where considered. The drugs considered for inclusion in the review 
are set out in Table 89.  
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Table 89: Pharmacology of medications for the treatment of alcohol misuse  
Medication Main target - 
system and action  
Other relevant 
targets 
Use in which stage 
Acamprosate Antagonises 
glutamatergic 
function (NMDA, 
mGLuR5) 
Increases GABA-
ergic function 
Relapse prevention 
 
Naltrexone Opiate antagonist  Relapse prevention 
Disulfiram Blocks aldehyde 
dehydrogenase in 
liver increasing 
acetaldehyde 
Blocks dopamine-
B-hydroxylase in 
brain, increasing 
dopamine 
Relapse prevention 
Antipsychotics – variety of 
‗first or second 
generation‘. 
Dopamine DRD2 
antagonists (eg 
olanzapine, 
quetiapine); partial 
agonist (eg 
aripiprazole) 
 Relapse prevention, 
antipsychotic 
Benzodiazepines Increases GABA-
benzodiazepine 
function 
 Medically assisted 
withdrawal, possible 
role in relapse 
prevention. 
Baclofen  
GABA-B agonist 
 Relapse prevention,  
Gabapentin Ca channel 
antagonist 
 Relapse prevention 
and withdrawal 
Pregabalin Ca channel  Relapse prevention 
Topiramate Increases GABA-
ergic function and 
antagonises some 
glutamate. 
Reduces 
excitatory ion 
channel activity 
Relapse prevention 
Memantine NMDA antagonist  Relapse prevention. 
Odansetron 5HT3 antagonist  Relapse prevention 
Antidepressants: SSRI eg 
sertraline 
5HT reuptake 
inhibitor 
 Relapse prevention, 
antidepressant, 
anxiolytic 
Buspirone 5HT1A partial 
agonist 
 Relapse prevention, 
anxiolytic 
 
The review aimed to evaluate all available pharmacological interventions for relapse 
prevention. This was conducted for adults and, where evidence was available, 
separately for special populations such as children and young people and older 
people. The GDG decided to conduct a meta-analysis only on the drugs that were 
licensed for alcohol use in the UK or drugs that are in common usage with a large 
amount of clinical evidence of efficacy. From these criteria, the drugs identified for 
review were acamprosate, naltrexone and disulfiram. For naltrexone and disulfiram, 
only the oral delivery preparations of these drugs was considered for meta-analysis 
due the lack of available evidence and the uncommon usage of the extended-release 
and subcutaneous implantation preparations of these drugs. These drugs are 
evaluated in the first instance for both adults and for special populations. The 
narrative review of the available literature for the use of pharmacological 
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interventions for special populations (for example, children and young people or 
older people) can be found in Section 7.3. For other pharmacological interventions 
which are not licensed for used in the UK for the treatment of alcohol misuse, meta-
analyses were not conducted. The reasons for this and the narrative synthesis of the 
evidence can be found in Section 0. 
 
Literature evaluating pharmacological interventions for less severely dependent and 
non-dependent drinkers is limited and a meta-analysis could not be conducted. A 
narrative synthesis of the available literature is provided in section 7.16. Similarly, 
trials where the participant sample included a very high prevalence of comorbid 
mental health disorders were excluded from the meta-analysis and are reviewed 
separately in section 7.17. See chapter 3 for a further discussion of the review 
methods used in this chapter. Lastly, a review of the long term management of 
Wernicke-Korsakoff syndrome (WKS) can be found in section 7.18. 
 
7.2.2 Clinical Questions 
The clinical question which the GDG addressed, and from which the literature 
searches were developed is:- 
 
For people with alcohol dependence or harmful alcohol, what pharmacological 
interventions are more clinically and cost-effective? In addition:- 
(a) What are the impacts of severity and comorbidities on outcomes? 
(b) When should pharmacological treatments be initiated and for what 
duration should they be prescribed? 
 
7.3 CLINICAL REVIEW PROTOCOL FOR 
PHARMACOLOGICAL INTERVENTIONS FOR 
RELAPSE PREVENTION  
The drugs identified for this review have been listed in Table 89. Information about 
the databases searched and the inclusion/ exclusion criteria used for this section of 
the guideline can be found in Appendix 16e (further information about the search for 
health economic evidence can be found in Chapter 3). See Table 90 for the clinical 
review protocol followed for this review. The clinical and economic reviews of the 
pharmacological interventions licensed for use for alcohol in the UK (acamprosate, 
naltrexone, and disulfiram) can be found in section 7.4 to 7.12. The pharmacological 
interventions not licensed for use in the UK are reviewed in Section 7.14. 
 
Table 90: Clinical review protocol for pharmacological interventions for 
relapse prevention  
Electronic databases MEDLINE, EMBASE, CINAHL, PsycINFO, Cochrane Library  
Date searched Database inception to March 2010 
Study design RCTs 
Patient population At least 80% of the sample meet the criteria for alcohol 
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dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week) 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant women 
Interventions Any pharmacological intervention 
Comparator  Any other intervention 
Critical Outcomes Discontinuing treatment for any reason 
Discontinuing treatment due to adverse events 
Lapsing (returning to a drinking state) 
Relapsing (returning to a heavy drinking state) 
% days abstinent 
Cumulative abstinence duration 
Drinks per drinking day 
Total drinks consumed during treatment period 
Total days of heavy drinking during treatment 
Time to first drink 
Time to heavy drinking day 
 
7.4 ACAMPROSATE  
7.4.1 Studies considered for review41 
The review team conducted a systematic search for RCTs that assessed the benefits 
and disadvantages of acamprosate for relapse prevention. The clinical review 
protocol for this section can be found in Section 7.3. Study characteristics are 
summarised in Table 91. For the related health economic evidence see section 7.10.  
 
There were a total of 19 trials (including 1 study still awaiting translation) comparing 
acamprosate with placebo. These were typically large, high quality studies, of which 
10 were sponsored by the drug company. A number of psychosocial interventions 
were used in addition to the trial medication, in line with the drug licensing 
agreement, which included alcohol counselling, medication management and 
relapse prevention as well as high intensity alcohol treatment programs. Data on 
participants lapsing to alcohol consumption was acquired from the authors of two 
meta-analyses (Mann, 2004; Rosner et al., 2008), who had access to unpublished data 
and therefore allowed for the development of a more complete data set. Both the 
PAILLE1995 and PELC1997 studies were three armed trials where two different 
doses of acamprosate were compared with placebo (1.3 g and 2 g). To avoid the 
double counting of the control data, we only used the data for the groups taking 2 g 
of acamprosate, as this is the dose recommended by the BNF. Reasons for exclusion 
of studies from this review included not providing an acceptable diagnosis of 
alcohol dependence, not being an RCT, having less than 10 participants per group, 
not double blind and not reporting any relevant outcomes. Further information 
about both included and excluded studies can be found in Appendix 16e. 
 
                                                 
41 Here and elsewhere in the guideline, each study considered for review is referred to by a study ID 
in capital letters (primary author and date of study publication, except where a study is in press or 
only submitted for publication, then a date is not used). 
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The population within these trials was typically presenting with moderate to severe 
dependence on alcohol, either indicated through alcohol consumption or 
dependency scale show at baseline. These studies were mainly conducted in Europe, 
with only one (CHICK2000A) being conducted in the UK. Acamprosate was started 
after the participant completed medically assisted withdrawal (if required) in all 
trials except one, GUAL2001, when it was started during assisted withdrawal. 
 
Table 91: Summary of study characteristics for acamprosate versus 
placebo 
 Acamprosate versus placebo  
Total no. of trials (total no. of 
participants) 
19 RCTs (N = 4629) 
Study ID (1)ANTON2006 
(2)BALTIERI2003 
(3) BARRIAS1997 
(4)BESSON1998 
(5) CHICK2000A 
(6) GEERLINGS1997 
(7) GUAL2001 
(8) KIEFER2003 
(9) LADEWIG1993 
(10) MORLEY2006 
(11) NAMKOONG2003 
(12) PAILLE1995 
(13) PELC1992 
(14) PELC1997 
(15)POLDRUGO1997 
(16)ROUSSAUX1996 
(17) SASS1996 
(18)TEMPESTA2000 
(19)WHITWORTH1996 
Diagnosis DSM or ICD diagnosis of alcohol dependence 
Baseline severity: Units consumed per week 
Mean: 145.15 
Range: 90 – 314.37 
   
Mean dosage 1998 mg per day. 
Length of  
treatment 
Range: 8 weeks – 52 weeks 
Length of follow-up  
(only including papers 
reporting follow-up  
measures) 
(1) Up to 12 months 
(4) Up to 12 months 
(6) Up to 12 months 
(12) Up to 12 months and up to 18 months 
(15) Up to 12 months 
(17) Up to 12 months 
(19) Up to 12 months and up to 24 months 
Setting  (1)–(2) Outpatient 
(4)–(7) Outpatient 
(8)–(9) Inpatient/outpatient 
(10)–(12) Outpatient 
(14)–(18) Outpatient 
(19) Inpatient/outpatient 
Treatment goal (if (7), (8), (15) Abstinence 
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mentioned)  
 
7.4.2 Evidence summary 
Evidence from the important outcomes and overall quality of evidence are presented 
in Table 92. The full evidence profiles and associated forest plots can be found in 
Appendix 18d and Appendix 17d respectively. 
 
There was a significant but small effect of acamprosate in promoting abstinence in 
participants when compared with placebo (RR = 0.83, 95% CI = 0.77 to 0.88). The 
effect was most pronounced at 6 months, but remained significant up to 12 months. 
In the one trial that continued up to two years (WHITWORTH1996) this small effect 
continued for up to 12 months after the termination of treatment. The number of 
individuals relapsing to heavy drinking was also significantly less in the 
acamprosate group. This effect was also small (RR = 0.90, 95% CI = 0.81 to 0.99) but 
suggests participants were more likely to stay in treatment if randomised to 
acamprosate instead of placebo. However, more participants left the trials due to 
adverse events in the acamprosate group, although this was not statistically 
significant.  
 
The quality of the evidence for acamprosate is of high quality, therefore further 
research is unlikely to have an important impact on our confidence in the estimate of 
the effect. An evidence summary of the results of the meta-analyses can be seen in 
Table 92. 
 
Table 92: Evidence summary table for trials of acamprosate versus placebo 
 Acamprosate versus placebo 
Total number of studies 
(number of participants) 
19 RCTs (N = 4629) 
Study ID (1) ANTON2006 
(2) BALTIERI2003 
(3) BARRIAS1997 
(4) BESSON1998 
(5) CHICK2000A 
(6) GEERLINGS1997 
(7) GUAL2001 
(8) KIEFER2003 
(9) LADEWIG1993 
(10) MORLEY2006 
(11) NAMKOONG2003 
(12) PAILLE1995 
(13) PELC1992 
(14) PELC1997 
(15) POLDRUGO1997 
(16) ROUSSAUX1996 
(17) SASS1996 
(18) TEMPESTA2000 
(19) WHITWORTH1996 
Benefits  
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Lapsed (participants returning 
to any drinking) 
At 2 months: 
RR = 1.19 (0.76, 1.88) 
K=1, N=142 
 
At 3 months: 
RR = 0.88 (0.75, 1.04) 
K=1, N=350 
 
At 6 months: 
RR = 0.83 (0.77, 0.88) 
K=17, N=3964 
 
At 12 months: 
RR = 0.88 (0.80, 0.96) 
K=4, N=1332 
 
At 18 months: 
RR = 0.94 (0.87, 1.02) 
K=1, N=350 
 
At 24 months: 
RR = 0.92 (0.87, 0.98) 
K=1, N=448 
Relapsed to heavy drinking At 3 months: 
RR = 0.95 (0.86, 1.05) 
K=1, N=612 
 
At 6 months: 
RR = 0.81 (0.72, 0.92) 
K=10, N=2654 
 
At 12 months: 
RR = 0.96 (0.89, 1.04) 
K=1, N=612 
% days abstinent At 2 months: 
SMD = -0.10 (--0.43, 0.23) 
K=1, N=142 
 
At 3 months: 
SMD = 0.00 (-0.16, 0.15) 
K=1, N=612 
 
At 12 months: 
SMD = 0.00 (-0.20, 0.20) 
K=1, N=612 
Cumulative abstinence duration  At 3 months: 
SMD = -2.75 (-7.51, 2.01) 
K=2, N=241 
 
At 6 months: 
SMD = -0.29 (-0.41, -0.17) 
K=4, N=1134 
 
At 9 months: 
SMD = -0.24 (-0.46, -0.03) 
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K=1, N=330 
 
At 12 months: 
SMD = -0.35 (-0.46, -0.24) 
K=4, N=1316 
 
At 24 months: 
SMD = -0.34 (-0.66, -0.03) 
K=2, N=720 
Time to first drink SMD = -0.26 (-0.45, -0.06) 
K=3, N=738 
Drinks per drinking day SMD = -0.05 (-0.29, 0.20) 
K=2, N=258 
% days without heavy drinking SMD = -0.06 (-0.38, 0.27) 
K=1, N=142 
Harms  
Discontinuation for any reason 
 
RR = 0.90 (0.81, 0.99) 
K=15, N=4037 
Discontinuation due to adverse 
events 
RR = 1.36 (0.99, 1.88) 
K=12, N=3774 
 
7.5 NALTREXONE 
7.5.1 Studies considered 
The review team conducted a systematic review of RCTs that assessed the beneficial 
or detrimental effects of naltrexone for relapse prevention. See Section 7.2 for the aim 
of the review and the clinical questions. The clinical review protocol for this section 
can be found in Section 7.3. See Table 93 for a summary of the study characteristics 
of the included studies.  
 
There were a total of 27 trials comparing oral naltrexone with placebo and 4 trials 
comparing naltrexone with acamprosate. In addition, there were two studies 
comparing naltrexone with naltrexone plus sertraline and one trial comparing 
naltrexone with topiramate. The majority of the trials were large, high quality 
studies with five trials sponsored by drug companies. 26 of the trials (LATT2002 
being the exception) included one of a number of different psychosocial intervention 
in addition to either naltrexone or placebo, which included alcohol counselling, 
coping skills or relapse prevention as well as high intensity alcohol treatment 
programs. Unpublished data on individuals relapsing to heavy drinking was 
acquired from the authors of a meta-analysis (Rosner et al., 2008), who had access to 
unpublished data. Reasons for exclusion of studies from this review included not 
providing an acceptable diagnosis of alcohol dependence, not being an RCT, having 
less than 10 participants per group, not double blind and not reporting any relevant 
outcomes. Further information about both included and excluded studies can be 
found in Appendix 16e.  
 
One additional study including naltrexone by Petrakis and colleagues (2005), 
although a high quality trial, was excluded as the whole participant sample was 
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comorbid with a range of axis I disorders, with many participants having multiple 
co-existing disorders. This was unusual when compared the included trials, where 
comorbidity was usually grounds for exclusion. This study is described more fully in 
the comorbidity in Section 7.17.  
 
The participant population included in these trials ranged from mild to severe 
dependence based on baseline alcohol consumption and dependency scale scores. 
This is in contrast to the studies included in the acamprosate review whether 
participants generally presented with more severe dependence. The majority of 
these trials were conducted in North America, and recruitment was most commonly 
through advertisements or referrals. If assisted withdrawal was required, then 
naltrexone was started after this was completed in these trials. 
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Table 93: Summary of study characteristics for naltrexone 
 Oral naltrexone versus 
placebo 
Oral naltrexone 
versusacamprosate 
Oral naltrexone + 
sertraline versus oral 
naltrexone 
Oral naltrexone versus 
topiramate 
Total no. of trials (total 
no. of participants) 
 27 RCTs (N = 4296) 4 RCTs (N = 957) 2 RCTs (N = 178 ) 1 RCT (N = 101 ) 
Study ID (1) AHMADI2002 
(2) ANTON1999 
(3) ANTON2005 
(4) ANTON2006 
(5) BALLDIN2003 
(6) BALTIERI2008 
(7) CHICK2000B 
(8) GASTPAR2002 
(9) GUARDIA2002 
(10) HEINALA2001 
(11) HUANG2005 
(12) KIEFER2003 
(13) KILLEEN2004 
(14) KRANZLER2000 
(15) KRYSTAL2001 
(16) LATT2002 
(17) LEE2001 
(18) MONTI2001 
(19) MORLEY2006 
(20) MORRIS2001 
(21) OMALLEY1992 
(22) OMALLEY2003 
(23) OMALLEY2008 
(24) OSLIN1997 
(25) OSLIN2008 
(26) VOLPICELLI1992 
(27) VOLPICELLI1997 
(1) ANTON2006 
(2) KIEFER2003 
(3) MORLEY2006 
(4) RUBIO2001 
(1) FARREN2009 
(2) OMALLEY2008 
(1) BALTIERI2008 
Diagnosis DSM or ICD diagnosis DSM or ICD diagnosis DSM or ICD diagnosis DSM or ICD diagnosis 
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of alcohol dependence of alcohol dependence of alcohol dependence of alcohol dependence 
Baseline severity: 
mean/range 
Units consumed per 
week 
Mean: 98.6 
Range:  70.56 to  223 
Units consumed per 
week 
Mean: 128.1 
Range: 74.3 to 223 
Units consumed per 
week 
Mean: 83.75 
Range: 60 to 107.5 
Units consumed per 
week 
Mean: 263.64 
 
Mean dosage Naltrexone: 50 mg daily Naltrexone: 50 mg daily 
Acamprosate: 1998 mg 
daily 
Naltrexone: 50 mg daily 
Sertraline: 100 mg daily 
Naltrexone: 50 mg daily 
Topiramate: 300 mg 
daily 
Length of  
treatment 
Range: 12 to 24 weeks Range: 12 to 52 weeks Range: 12 to 16 weeks 12 weeks 
Length of follow-up  
(only including papers 
reporting follow-up  
measures) 
(2) Up to 6 months 
(4) Up to 12 months(12) 
Up to 6 months 
(21) Up to 6 months 
(4) Up to 12 months 
(12) Up to 6 months 
 
  
Setting (1)–(7) Outpatient 
(8) Inpatient/outpatient 
(9)–(11) Outpatient 
(12) Inpatient/ 
outpatient 
(13)–(16) Outpatient 
(17) Inpatient/ 
outpatient 
(18)–(27) Outpatient 
(1) Outpatient 
(2) Inpatient/outpatient 
(3)–(4) Outpatient 
(1)–(2) Outpatient (1) Outpatient 
 
Treatment goal (if 
mentioned) 
(4), (9), (14), (15), (17), 
(21), (24) Abstinence 
(10) Abstinence and 
drinking 
reduction/moderation  
(1), (4) Abstinence 
 
Not reported in any 
trials 
Not reported in any 
trials 
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7.5.2 Evidence summary 
Evidence from the important outcomes and overall quality of evidence are presented 
in (XX). The full evidence profiles and associated forest plots can be found in 
Appendix 18d and Appendix 17d respectively. 
 
The comparison of oral naltrexone versus placebo showed a small but significant 
effect favouring naltrexone on rates of relapse to heavy drinking (RR = 0.83, 95% CI 
= 0.75 to 0.91). The mean drinks per drinking day within the trial duration was less 
in the naltrexone group when compared with placebo with a small but significant 
effect (SMD = -0.28, 95% CI = -0.44 to -0.11). A significant but small effect favouring 
naltrexone was also found on days of heavy drinking during the trial (SMD = -0.43, 
95% CI = -0.82 to -0.03). Although overall discontinuation rates favoured naltrexone 
over placebo, there was no significant difference between the two groups. However, 
participants were significantly more likely to leave treatment due to adverse events 
in the naltrexone group, with significantly fewer adverse events reported in the 
placebo group. 
 
When comparing oral naltrexone and acamprosate, the four trials reviewed showed 
no significant difference in discontinuation for any reason or due to adverse event 
between the two interventions. On critical outcomes, there were no significant 
differences between naltrexone and acamprosate except for number of individuals 
returning to any drinking (RR = 0.71, 95% CI = 0.57 to 0.88) and drinks per drinking 
days (SMD = -0.76, 95% CI = -1.09 to -0.44). However, these findings were based only 
on one study (RUBIO2001) which found participants in the naltrexone group were 
significantly less likely to return to any drinking and consumed significantly less 
drinks per drinking day during the trial period. When comparing naltrexone with 
topiramate, the analysis showed no significant differences between the groups on 
any outcomes except number of participants continuously abstinent and weeks until 
first relapse, both outcomes favouring naltrexone. The analysis of naltrexone versus 
naltrexone plus sertraline showed no significant differences between the groups on 
any outcomes. However, discontinuation rates were less in the combination group. 
 
The quality of the evidence reviewed for oral naltrexone versus placebo was of high 
quality, therefore further research is unlikely to an important impact on our 
confidence in the estimate of the effect. The quality of the evidence for naltrexone 
versus acamprosate was also high. However, the quality for the evidence for the 
naltrexone plus sertraline combination intervention versus naltrexone alone and for 
naltrexone versus topiramate is moderate, therefore further research is likely to have 
an important impact on our confidence in the estimate of these effects.  
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Table 6: Evidence summary table for trials of naltrexone 
 Oral naltrexone versus 
placebo 
Oral naltrexone versus 
acamprosate 
Oral naltrexone + 
sertraline versus oral 
naltrexone 
Oral naltrexone versus 
topiramate 
Total number of studies 
(number of 
participants) 
27 RCTs (N = 4164) 4 RCTs (N = 957) 2 RCTs (N = 178 ) 1 RCT (N = 101) 
Study ID (1) AHMADI2002 
(2) ANTON1999 
(3) ANTON2005 
(4) ANTON2006 
(5) BALLDIN2003 
(6) BALTIERI2008 
(7) CHICK2000B 
(8) GASTPAR2002 
(9) GUARDIA2002 
(10) HEINALA2001 
(11) HUANG2005 
(12) KIEFER2003 
(13) KILLEEN2004 
(14) KRANZLER2000 
(15) KRYSTAL2001 
(16) LATT2002 
(17) LEE2001 
(18) MONTI2001 
(19) MORLEY2006 
(20) MORRIS2001 
(21) OMALLEY1992 
(22) OMALLEY2003 
(23) OMALLEY2008 
(24) OSLIN1997 
(25) OSLIN2008 
(26) VOLPICELLI1992 
(27) VOLPICELLI1997 
(1) ANTON2006 
(2) KIEFER2003 
(3) MORLEY2006 
(4) RUBIO2001 
(1) FARREN2009 
(2) OMALLEY2008 
(1) BALTIERI2008 
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Benefits     
Lapsed (participants 
returning to any 
drinking) 
At 3 months: 
RR = 0.92 (0.86, 1.00) 
K = 17, N = 1893 
 
At 6 months 
(maintenance 
treatment): 
RR = 0.79 (0.60, 1.05) 
K = 1, N = 113 
 
At 6 months (follow-
up) 
RR = 0.90 (0.69, 1.17) 
K = 1, N = 84 
At 12 months: 
RR = 0.71 (0.57, 0.88) 
K = 1, N = 157 
 
At 3 months: 
RR = 1.08 (0.77, 1.51) 
K=1, N=67 
At 1 month: 
RR = 1.44 (0.88, 2.35) 
K = 1, N = 101 
 
At 2 months: 
RR = 1.54 (1.02, 2.33) 
K = 1, N = 101 
 
At 3 months: 
RR = 1.48 (1.11, 1.97) 
K = 1, N = 101 
Relapsed to heavy 
drinking 
At 3 months: 
RR = 0.83 (0.76, 0.91) 
K = 22, N = 3320 
 
At 6 months 
(endpoint): 
RR = 0.96 (0.79, 1.17) 
K = 1, N = 240 
 
At 6 months (follow-
up): 
RR = 0.74 (0.60, 0.90) 
K = 3, N = 284 
 
At 6 months 
(maintenance 
treatment): 
RR = 0.46 (0.24, 0.89) 
K = 1, N = 113 
 
At 9 months 
At 3 months: 
RR = 0.96 (0.87, 1.06) 
K = 3, N = 800 
 
At 6 months: 
RR = 0.95 (0.64, 1.43) 
K = 1, N = 80 
 
At 12 months: 
RR = 0.99 (0.91, 1.08) 
K = 1, N = 612 
RR = 1.03 (0.73, 1.46) 
K = 1, N = 67 
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(endpoint): 
RR = 0.74 (0.56, 0.98) 
K = 1, N = 116 
 
At 12 months (follow-
up): 
RR = 0.95 (0.88, 1.03) 
K = 1, N = 618 
% days abstinent At 3 months: 
SMD = -0.22 (-0.37, -
0.07) 
K = 9, N = 1607 
 
At 6 months: 
SMD = -0.25 (-0.51, 
0.00) 
K = 1, N = 240 
 
At 12 months: 
SMD = -0.11 (-0.42, 
0.20) 
K = 1, N = 618 
At 3 months: 
SMD = 0.04 (-0.21, 0.29) 
K = 2, N = 720 
 
At 12 months: 
SMD = -0.11 (-0.27, 
0.04) 
K = 1, N = 612 
 
At 3 months: 
SMD = -0.12 (-0.79, 
0.56) 
K = 2, N = 178 
 
Time to first drink SMD = -0.07 (-0.21, 
0.08) 
K = 5, N = 730 
SMD = -0.09 (-0.34, 
0.15) K = 2, N = 265 
  
Time to first heavy 
drinking episode 
SMD = -0.32 (-0.68, 
0.03) 
K = 8, N = 1513 
SMD = -0.39 (-081, 0.03) 
K = 2, N = 265 
 SMD = 0.43 (0.04, 0.83) 
K = 1, N = 101 
Cumulative abstinence 
duration 
SMD = -0.12 (-0.39, 
0.15) 
K = 2, N = 217 
  SMD = 0.34 (-0.06, 0.73) 
K = 1, N = 101 
Drinks per drinking 
day during study 
period 
SMD = -0.28 (-0.44, -
0.11) 
K = 10, N = 1639 
SMD = -0.76 (-1.09, -
0.44) 
K = 1, N = 157 
SMD = -0.95 (-2.94, 
1.04) 
K = 2, N = 178 
 
Heavy drinking SMD = -0.43 (-0.82, -  SMD = -0.23 (-0.71, SMD = 0.33 (-0.064, 
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episodes during study 
period 
0.03) 
K = 7, N = 797 
0.25) 
K = 1, N = 67 
0.72) 
K = 1, N = 101 
Total drinks consumed 
during study period 
SMD = -0.32 (-0.70, 
0.06) 
K = 2, N = 257 
   
Harms     
Discontinuation for any 
reason 
RR = 0.94 (0.84, 1.05) 
K = 25, N = 3926 
RR = 0.85 (0.72, 1.01) 
K=4, N=957 
RR = 1.55 (1.00, 2.42) 
K = 2, N = 178 
RR = 1.12 (0.68, 1.83) 
K = 1, N = 101 
Discontinuation due to 
adverse events 
RR = 1.79 (1.15, 2.77) 
K = 12, N = 1933 
RR = 1.44 (0.63, 3.29) 
K = 2, N = 769 
RR = 2.92 (0.82, 10.44) 
K = 2, N = 178 
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7.6 ACAMPROSATE + NALTREXONE (COMBINED 
INTERVENTION) 
7.6.1 Studies considered  
The review team conducted a systematic review of RCTs that assessed the beneficial or 
detrimental effects of acamprosate plus naltrexone for relapse prevention. See Section 
7.2 for the aim of the review and the clinical questions. The clinical review protocol for 
this section can be found in Section 7.3. See Table 94 for a summary of the study 
characteristics of included studies.  
 
There were two trials comparing the combination of acamprosate and naltrexone with 
placebo, acamprosate alone and naltrexone alone. Both were large, multiple armed 
trials designed specifically to test the effects of the drugs in isolation and together. The 
KIEFER2003 trial included a population of severely dependent drinkers recruited from 
inpatient facilities; their mean preadmission consumption of alcohol was 223 units per 
week. Each participant received relapse prevention intervention in addition to 
pharmacological therapy. The ANTON2006 study included a less severe population of 
dependent drinkers who were recruited through advertisements or clinical referrals; 
their mean preadmission consumption of alcohol was 97 units per week. In addition to 
being randomised to one of four pharmacological interventions, participants were also 
randomised to a cognitive-behavioural intervention with medication management or 
medication management alone. Reasons for exclusion of studies from this review 
included not providing an acceptable diagnosis of alcohol dependence, not being an 
RCT, having less than 10 participants per group, not double blind and not reporting any 
relevant outcomes. Further information about both included and excluded studies can 
be found in Appendix 16e. 
 
Table 94: Summary of study characteristics for naltrexone + 
acamprosate 
 Naltrexone + 
acamprosate versus 
placebo 
Naltrexone + 
acamprosate versus 
acamprosate 
Naltrexone + 
acamprosate versus 
naltrexone 
Total no. of 
trials (total 
no. of 
participants) 
2 RCTs (N = 694) 2 RCTs (N= 688) 2 RCTs (N=694)  
Study ID (1) ANTON2006 
(2) KIEFER2003 
(1) ANTON2006 
(2) KIEFER2003 
(1) ANTON2006 
(2) KIEFER2003 
 
Diagnosis DSM or ICD 
diagnosis of alcohol 
dependence 
DSM or ICD 
diagnosis of alcohol 
dependence 
DSM or ICD 
diagnosis of alcohol 
dependence 
 
Baseline 
severity: 
Units consumed 
per week 
Units consumed per 
week 
Units consumed per 
week 
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mean (SD) Mean – 160.05 
Range: 97.1 – 223 
Mean – 160.05 
Range: 97.1 - 223 
Mean – 160.05 
Range: 97.1 - 223 
Mean dosage (1) Acamprosate =  
3 g per day 
Naltrexone = 100 
mg per day 
 
(2) Acamprosate =  
1998 mg per day 
Naltrexone = 50 mg 
per day 
(1) Acamprosate =  
3 g per day 
Naltrexone = 100 mg 
per day 
 
(2) Acamprosate =  
1998 mg per day 
Naltrexone = 50 mg 
per day 
(1) Acamprosate =  
3 g per day 
Naltrexone = 100 mg 
per day 
 
(2) Acamprosate =  
1998 mg per day 
Naltrexone = 50 mg per 
day 
Length of  
treatment 
12 weeks 12 weeks 12 weeks 
Length of 
follow-up 
(only 
including 
papers 
reporting 
follow-up 
measures) 
(1) Up to 12 months 
(2) Up to 6 months 
 
 (1) Up to 12 months 
(2) Up to 6 months 
 
(1) Up to 12 months 
(2) Up to 6 months 
 
 
Setting (1) Outpatient 
(2) Inpatient/ 
outpatient 
(1) Outpatient 
(2) Inpatient/ 
outpatient 
(1) Outpatient 
(2) Inpatient/ 
outpatient 
Treatment 
goal (if 
mentioned) 
(1) Abstinence 
 
 
(1) Abstinence 
 
(1) Abstinence 
 
 
7.6.2 Evidence summary  
Evidence from the important outcomes and overall quality of evidence are presented in 
. 
 
The full evidence profiles and associated forest plots can be found in Appendix 18d and 
Appendix 17d respectively. 
 
There was no significant difference between the combination of acamprosate and 
naltrexone than either drug alone at reducing the likelihood of returning to heavy 
drinking at three months (combination versus acamprosate: RR = 0.93, 95% CI = 0.74 to 
1.17 ; combination versus naltrexone: RR = 1.03 (0.90 to 1.17) and the one trial 
continuing up to 12 months showed a no effect. In addition, there were no significant 
differences on any other outcomes between the combination group and either drug. The 
combined drug group were also equivalent to the placebo group on discontinuation 
rates and percentage days abstinent. Relapse rates at 6 months were significantly 
different with a moderate effect in favour of the combined intervention group (RR = 
0.44, 95% CI = 0.28 to 0.69), however there was no difference between the groups in 
relapse rates at 3 months or 12 months. 
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The quality of the evidence is high; therefore further research is unlikely to an 
important impact on our confidence in the estimate of the effect. It was also noted that 
there was significant heterogeneity between comparisons of the KIEFER2003 and the 
ANTON2006 studies, which is very likely to be due to the differences in the populations 
baseline drinking level and where they were recruited from (inpatient facility versus 
advertisement or referral). 
 
Table 8: Evidence summary table for trials of acamprosate + naltrexone 
 Acamprosate + 
naltrexone versus 
placebo 
Acamprosate + 
naltrexone versus 
acamprosate 
Acamprosate + naltrexone 
versus naltrexone 
Total number of 
studies (number 
of participants) 
2 RCTs (N = 694) 2 RCTs (N= 688) 2 RCTs (N = 694) 
Study ID (1) ANTON2006 
(2) KIEFER2003 
(1) ANTON2006 
(2) KIEFER2003 
(1) ANTON2006 
(2) KIEFER2003 
Benefits    
Relapsed to 
heavy drinking 
At 3 months: 
RR = 0.78 (0.56, 1.09) 
K = 2, N = 694 
 
At 6 months: 
RR = 0.44 (0.28, 0.69) 
K = 1, N = 80 
 
At 12 months: 
RR = 0.97 (0.90, 1.05) 
K = 1, N = 614 
At 3 months: 
RR = 0.93 (0.74, 
1.17)K = 2, N = 688 
 
At 6 months: 
RR = 0.64 (0.38, 1.06) 
K = 1, N = 80 
 
At 12 months: 
RR = 1.02 (0.94, 1.10) 
K = 1, N = 608 
At 3 months: 
RR = 1.03 (0.90, 1.17) 
K = 2, N = 694 
 
At 6 months: 
RR = 0.67 (0.40, 1.12) 
K = 2, N = 80 
 
At 12 months: 
RR = 1.02 (0.94, 1.10) 
K = 1, N = 612 
% days abstinent At 3 months: 
SMD = -0.09 (-0.42, 
0.25) 
K = 1, N = 614 
 
At 12 months: 
SMD = -0.09 (-0.25, 
0.06) 
K = 1, N = 614 
At 3 months: 
SMD = -0.08 (-0.29, 
0.13) 
K = 1, N = 608 
 
At 12 months: 
SMD = -0.11 (-0.27, 
0.05) 
K = 1, N = 608 
At 3 months: 
SMD = -0.04 (-0.20, 0.12) 
K = 1, N = 614 
 
At 12 months: 
SMD = 0.02 (-0.18, 0.21) 
K = 1, N = 614 
Harms    
Discontinuation 
for any reason 
RR = 1.00 (0.53, 1.90) 
K = 2, N = 694 
RR = 0.92 (0.65, 1.32) 
K = 2, N = 687 
RR = 1.09 (0.87, 1.37) 
K = 2, N = 694 
Discontinuation 
due to adverse 
events 
RR = 3.16 (1.03, 9.76) 
K = 1, N = 614 
RR = 1.39 (0.34, 5.71) 
K = 1, N = 608 
RR = 1.10 (0.50, 2.40) 
K = 1, N = 614 
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7.7 ORAL DISULFIRAM 
7.7.1 Studies considered 
The review team conducted a systematic review of RCTs that assessed the beneficial or 
detrimental effects of disulfiram for relapse prevention. See Section 7.2 for the aim of 
the review and the clinical questions. The clinical review protocol for this section can be 
found in Section 7.3. See Table 9 for the characteristics of the included studies. Unlike 
the reviews of acamprosate and naltrexone, there was much less high quality evidence 
available on the efficacy and effectiveness of disulfiram, and for this reason the GDG 
decided to use open label trials in the meta-analysis of disulfiram.  
 
The reason for this was that due to the disulfiram-ethanol reaction, a number of the 
studies had to be open-label for ethical reasons so that participants were aware that 
they were taking a substance that can cause potentially dangerous side effects when 
taken with alcohol. This also contributes to the psychological effect of disulfiram, where 
the fear of the chemical reaction is believed to be as important as the pharmacological 
effects of the drug in determining the efficacy of the intervention. The FULLER1979 and 
FULLER1986 trials adapted their trials for this purpose and randomised participants to 
either the full dose of disulfiram (250 mg per day) or to 1 mg of disulfiram with a 
placebo agent which has been judged to have no clinical effect.  
 
Due to the age of some of the trials, inclusion criteria for diagnosis was also relaxed to 
include papers that did not explicitly mention the diagnosis tool used to determine 
eligibility to the trial. The Petrakis and colleagues (2005) trial was also excluded from 
the meta-analysis as many participants had a range of axis I disorders.  
  
There were a total of three trials comparing oral disulfiram to placebo (FULLER1979; 
FULLER1986; CHICK1992), one trial comparing oral disulfiram to acamprosate 
(LAAKSONEN2008), two trials comparing to naltrexone (DESOUSA2004; 
LAAKSONEN2008) and one trial comparing oral disulfiram to topiramate 
(DESOUSA2008). In addition, there was also one trial comparing disulfiram with 
counselling to counselling alone with no pharmacological intervention (GERREIN1973).  
 
The severity of the participants included in these trials was not reported for the older 
trials, however in the more recent studies, dependency indicated through baseline 
consumption and dependency scales suggested that these participants were of 
moderate to severe dependency. The trials varied in country conducted in, with 
CHICK1992 being the only trial conducted in the UK. Three studies were conducted in 
America (FULLER1979; FULLER1986; GERREIN1973), two were conducted in India 
(DESOUSA2004 ; DESOUSA2008) and the last in Finland (LAAKSONEN2008). 
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Table 9: Summary of study characteristics for oral disulfiram 
 
 
 
 Oral disulfiram 
versus placebo 
Oral disulfiram 
versus acamprosate 
Oral disulfiram 
versus naltrexone 
Oral disulfiram 
versus topiramate 
Oral disulfiram + counselling 
versus counselling 
Total no. of trials 
(total no. of 
participants) 
 3 RCTs (N =859) 1 RCT (N=243 ) 2 RCTs (N=343 ) 1 RCT (N=100) 1 RCT (N=26) 
Study ID (1) CHICK1992 
(2) FULLER1979 
(3) FULLER1986 
(1) 
LAAKSONEN2008 
(1) DESOUSA2004 
(2) 
LAAKSONEN2008 
(1) DESOUSA2008 (1) GERREIN1973 
Diagnosis National Council on 
alcoholism 
diagnostic criteria or 
by an undefined 
diagnosis tool. 
ICD diagnosis of 
alcohol dependence 
DSM or ICD 
diagnosis of alcohol 
dependence 
DSM diagnosis of 
alcohol dependence 
Undefined diagnosis tool 
Baseline severity: 
mean (SD) 
Units consumed per 
week 
Mean – 198.5 
Range: 190 - 207 
Units consumed per 
week 
Mean – 136.25 
 
Units consumed per 
week 
Mean – 111.35 
Range: 86.45 – 136.25 
Units consumed per 
week 
Mean – 70 
No details 
Mean dosage Disulfiram = 250 mg 
daily 
Disulfiram = 150 mg 
daily 
Acamprosate = 1998 
mg daily 
Disulfiram= 200 mg 
daily 
Naltrexone = 50 mg 
daily 
Disulfiram = 250 mg 
daily 
Topiramate = 150 
mg daily 
Disulfiram = 250 mg daily 
Length of  
treatment 
Range: 24 weeks – 
52 weeks. 
52 weeks 52 weeks 36 weeks 8 weeks 
Length of follow-up 
(only including 
papers reporting 
follow-up 
measures) 
No follow-up data 
recorded 
No follow-up data 
recorded 
No follow-up data 
recorded 
No follow-up data 
recorded 
No follow-up data recorded 
Setting (1)–(2) Outpatient 
(3) Inpatient/ 
outpatient  
(1) Outpatient  
 
(1)–(2) Outpatient (1) Inpatient/ 
outpatient 
(1) Outpatient  
Treatment goal (if 
mentioned) 
(3) Abstinence 
 
(1) Abstinence 
 
(1)–(2) Abstinence 
 
(1) Abstinence 
 
Not mentioned 
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7.7.2 Evidence summary  
Evidence from the important outcomes and overall quality of evidence are presented 
in Table 10. The full evidence profiles and associated forest plots can be found in 
Appendix 18d and Appendix 17d, respectively.  
 
Oral disulfiram was not significantly different from placebo in preventing 
participants lapsing to alcohol consumption (RR = 1.05, 95% CI = 0.96 to 1.15). There 
was also no difference in rates of discontinuation between the two groups. However, 
LAAKSONEN2008 showed that, in comparison with acamprosate, disulfiram was 
significantly more likely to increase the time until participants first drank any 
alcohol (SMD = -0.84, 95% CI = -1.28 to -0.40) and drank heavily (SMD = -1.17, 95% 
CI = -1.66 to -0.68) and also decreased the amount of alcohol consumed and the 
number of drinking days. In comparison with naltrexone, disulfiram was also 
significantly more likely to increase the time to first heavy drinking day and the 
number of abstinent days. Participants in the naltrexone group were significantly 
more likely to return to any drinking (RR = 0.18, 95% CI = 0.08 to 0.42) or relapse to 
heavy drinking (RR = 0.28, 95% CI = 0.13 to 0.59) when compared with the oral 
disulfiram group, although this was based on two open label studies 
(DESOUSA2004; LAAKSONEN2008). 
 
The comparison of disulfiram and topiramate also showed a significant difference in 
the number of participants relapsing to heavy drinking (RR = 0.23, 95% CI = 0.09 to 
0.55), time to first drink and time to first relapse in favour of disulfiram, but this was 
based on just one open label study (DESOUSA2008). It may be that the psychological 
effects of knowing they were taking disulfiram may have contributed significantly to 
the results. The comparison of disulfiram with counselling versus counselling alone 
showed no significant differences between the groups on numbers of participants 
returning to drinking (RR = 0.86, 95% CI = 0.55 to 1.34).  
 
The quality of the evidence was moderate; therefore further research is likely to have 
an important impact on our confidence in the estimate of the effect. The main reason 
for the lower quality of the evidence was that the studies reviewed were generally 
not conducted in a double blind trial. 
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Table 10: Evidence summary table for trials of oral disulfiram 
 Oral disulfiram 
versus placebo/ 1 
mg disulfiram 
Oral disulfiram 
versus acamprosate 
Oral disulfiram 
versus naltrexone 
Oral disulfiram 
versus topiramate 
Oral disulfiram + 
counselling versus 
counselling 
Total number of 
studies (number of 
participants) 
 3 RCTs (N = 859)  1 RCT (N = 243 ) 2 RCTs (N = 343 ) 1 RCT (N = 100) 1 RCT (N = 26) 
Study ID (1) CHICK1992 
(2) FULLER1979 
(3) FULLER1986 
(1) 
LAAKSONEN2008 
(1) DESOUSA2004 
(2) 
LAAKSONEN2008 
(1) DESOUSA2008 (1) GERREIN1973 
Benefits      
Lapsed 
(participants 
returning to any 
drinking) 
At 12 months: 
RR = 1.05 (0.96, 
1.15) 
K = 2, N = 492 
 At 12 months: 
RR = 0.18 (0.08, 
0.42) 
K = 1, N = 100 
 At 2 months: 
RR = 0.86 (0.55, 
1.34) 
K = 1, N = 49 
Relapsed to heavy 
drinking 
  At 12 months: 
RR = 0.28 (0.13, 
0.59) 
K = 1, N = 100 
At 12 months: 
RR = 0.23 (0.09, 
0.55) 
K = 1, N = 100 
 
Abstinent days (per 
week or total days) 
Total days change 
score: 
SMD = -0.45 (-0.86, -
0.04) 
 
K = 1, N = 93 
 
Abstinent days per 
week up to week 12: 
SMD = -1.11 (-1.52, -
0.70) 
 
K = 1, N = 106 
 
Abstinent days per 
week from week 12 
to 52: 
SMD = -0.74 (-1.17, -
0.31) 
 
K = 1, N = 91 
 
Total days: 
SMD = -0.41 (-0.81, -
0.02) 
 
K = 1, N = 100 
 
Abstinent days per 
week up to week 12: 
SMD = -1.09 (-1.50, -
0.68) 
 
K = 1, N = 107 
 
Abstinent days per 
week from week 12 
Total days: 
SMD = -0.30 (-0.70, 
0.09) 
 
K = 1, N = 100 
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to 52: 
SMD = -0.74 (-1.17, -
0.31) 
 
K = 1, N = 91 
Time to first drink  SMD = -0.84 (-1.28, -
0.40) 
 
K = 1, N = 89 
SMD = -1.22 (-2.47, 
0.02) 
 
K = 2, N = 189 
SMD = -3.16 (-3.75, -
2.56) 
 
K = 1, N = 100 
 
Time to first heavy 
drinking episode 
 SMD = -1.17 (-1.66, -
0.68) 
 
K = 1, N = 77 
SMD = -1.50 (-2.49, -
0.51) 
 
K = 2, N = 180 
SMD = -2.74 (-3.29, -
2.19) 
 
K = 1, N = 100 
 
Drinks per drinking 
day during study 
period 
  SMD = -0.11 (-0.50, 
0.28) 
 
K = 1, N = 100 
  
Alcohol consumed 
during study period 
Units consumed in 
last 4 weeks of trial 
– change score: 
SMD = -0.16 (-0.58, 
0.25) 
 
K = 1, N = 90 
 
Units consumed per 
week in last 6 
months of trial – 
change score: 
SMD = -0.35 (-0.75, 
0.05) 
 
K = 1, N = 97 
 
Total units 
consumed in last 6 
Grams per week up 
to week 12: 
SMD = -1.06 (-1.44, -
0.67) 
 
K = 1, N = 118 
 
Grams per week 
from week 12 to 52: 
SMD = -0.66 (-1.12, -
0.20) 
 
K = 1, N = 76 
 
Grams per week up 
to week 12: 
SMD = -0.93 (-1.31, -
0.56) 
 
K = 1, N = 124 
 
Grams per week 
from week 12 to 52: 
SMD = -0.74 (-1.20, -
0.28) 
 
K = 1, N = 78 
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months of trial – 
change score: 
SMD = -0.49 (-0.91, -
0.07) 
 
K = 1, N = 118 
Harms      
Discontinuation for 
any reason 
RR = 1.15 (0.43, 
3.12) 
 
K = 1, N = 406 
RR = 1.24 (0.71, 
2.16) 
 
K = 1, N = 162 
RR = 1.27 (0.73, 
2.19) 
 
K = 2, N = 262 
RR = 1.00 (0.26, 
3.78) 
 
K = 1, N = 100 
RR = 0.46 (0.08, 
2.56) 
 
K = 1, N = 49 
Discontinuation 
due to adverse 
events 
  RR = 3.00 (0.13, 
71.92) 
 
K = 1, N = 100 
RR = 0.20 (0.01, 
4.06) 
 
K = 1, N = 100 
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7.8 META-REGRESSION ON BASELINE ALCOHOL 
CONSUMPTION AND EFFECTIVENESS  
Whilst effectiveness has been established for acamprosate and Naltrexone for adults, 
and to some extent for disulfiram, not everyone benefits from these medications. In 
order to give medication to those most likely to benefit as well as reducing 
inappropriate prescribing, studies have been examined for predictors of outcome. 
No trials have been explicitly set up to define predictors, rather post-hoc analyses 
have been performed looking for relationships between outcome and clinical 
variables.  
 
Concerning acamprosate and naltrexone, it has been suggested that severity of 
dependence may influence outcome based on the type of patients in US (recruited by 
advert, do not generally require medication for assisted withdrawal) compared with 
European (recruited from treatment services, require medication for withdrawal) 
trials (Garbutt, 2009).  
 
A number of researchers have reported on the potential relationship between 
severity of alcohol dependence at baseline and effectiveness of both acamprosate 
and naltrexone (Monterosso, 2001; Richardson et al., 2008). The GDG decided to 
investigate whether baseline severity was associated with the effectiveness of either 
of these drugs. Craving has often been used as a measure of severity, but within the 
trials included the meta-analyses, the amount of alcohol consumed was much more 
frequently reported in the baseline demographics and therefore baseline severity 
was used in the analysis measured as the number of alcohol units consumed per 
week by the study sample. An alcohol unit was defined as 8 g or 10 ml of alcohol, as 
per UK classification. In studies published outside of the UK, the number of baseline 
‗drinks‘ was converted into UK alcohol units. 
 
A random-effects meta-regression was performed in Stata Version 9.2 (StataCorp, 
2007) using the revised meta-regression command with restricted maximum 
likelihood estimation and the improved variance estimator of Knapp and Hartung 
(2003). Covariates that were examined included: baseline severity (measured as the 
mean baseline consumption of alcohol in units per week); the setting of the trial 
(inpatient or outpatient); the year the study was published; the recruitment strategy 
of the trial and the trial was conducted in North America or the rest of the world. 
The regression coefficients are the estimated increase in the effect size (log RR) per 
unit increase in the covariate(s). Negative effect sizes indicate that the intervention 
had a better outcome than the control group. A random effects model (DerSimonian 
& Laird, 1986) was used in the analyses to incorporate the assumption that the 
different studies are estimating different, yet related, treatment effects, and to 
incorporate heterogeneity beyond that explained by the covariate(s) included in the 
model. 
 
Figure 7 shows the association between baseline alcohol consumption and 
effectiveness for the 20 trials of naltrexone versus placebo that included extractable 
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information on baseline drinking. There is a statistically significant association 
between baseline alcohol consumption and effectiveness (regression coefficient -.004, 
95% CI -.007 to -.0002), with 54.43% of the between-study variance explained by 
baseline severity (p = .04) (see Table 95). To control for variables that may act as 
confounders, the following variables were entered into a multivariate model: setting, 
recruitment, country, and year. The results suggest that baseline severity remains a 
significant covariate (regression coefficient-.004, 95% CI-.007 to -.001), with 97.61% of 
the between-study variance explained (see Table 96). 
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Figure 7: Association between baseline severity and effect size in naltrexone 
versus placebo trials (logRR). 
 
Table 95: Results of univariate meta-regression in naltrexone versus placebo trials 
Variables 
 
k (n) 
Coefficient 
(Standard 
error) 95% CI 
Adjusted 
Pa 
     
Baseline drinking 20 (3338) -0.003 (0.002) -0.007 to -0.001 0.04 
Constant  -0.19 (0.16) -0.15 to 0.53 0.25 
Abbreviations: k, number of studies; n, number of participants. 
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aCalculated using the Higgins and Thompson Monte Carlo permutation test (10000 permutations). 
 
Table 96: Results of multiple covariate meta-regression in naltrexone versus 
placebo trials 
Variables 
 
k (n) 
Coefficient 
(Standard 
error) 95% CI 
Adjusted 
Pa 
     
Baseline drinking 20 (3338) -.004 (.002) -0.007 to -0.001 0.02 
Setting (inpatient/outpatient) 20 (3338) -0.16 (.17) -0.51 to 0.19 0.35 
Recruitment strategy 20 (3338) 0.05 (.13) -0.22 to 0.31 0.73 
Country trial conducted 20 (3338) 0.11 (.12) -0.14 to 0.37 0.37 
Year published 20 (3338) 0.021 (.011) -0.001 to 0.043 0.07 
  Constant  -41.64 (21.51) -86.82 to 3.55 0.07 
Abbreviations: k, number of studies; n, number of participants. 
aCalculated using the Higgins and Thompson Monte Carlo permutation test (10000 permutations). 
 
Figure 8 shows the association between baseline alcohol consumption and 
effectiveness in the 11 trials of acamprosate versus placebo that included extractable 
information on baseline drinking. The results suggest that there is no important 
association between baseline severity and effectiveness (regression coefficient -.0001, 
95% CI -.0017 to .0015), with 0% of the between-study variance explained by baseline 
severity (p = .90) (see Table 97). Baseline drinking was also found to have no 
association when controlling for the setting of the trial or the year the study was 
published (see Table 98). Recruitment strategy and the country where the trial was 
conducted could not be tested as covariates as there was not enough variation on 
these areas in the studies to use these as covariates.  
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Figure 8: Association between baseline severity and effect size in acamprosate 
versus placebo trials (logRR). 
 
 
Table 97: Results of univariate meta-regression in acamprosate versus placebo 
trials 
Variables 
 
k (n) 
Coefficient 
(standard 
error) 95% CI 
Adjusted 
Pa 
     
Baseline drinking 11 (3476) -0.0001 
(0.0007) -0.002 to -0.001 0.9 
        Constant  -0.14 (.11) -0.38 to 0.09 0.2 
Abbreviations: k, number of studies; n, number of participants. 
aCalculated using the Higgins and Thompson Monte Carlo permutation test (10000 permutations). 
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Table 98: Results of multiple covariate meta-regression in acamprosate versus 
placebo trials. 
Variables 
 
k (n) 
Coefficient 
(Standard error) 95% CI 
Adjusted 
Pa 
     
Baseline drinking 11 (3476) -0.002 (0.0008) -0.002 to -0.001 0.82 
Setting 
(inpatient/outpatient) 
11 (3476) 
-0.03 (0.09) -0.18 to 0.25 0.72 
Year published 11 (3476) 0.01 (0.013) -0.02 to 0.04 0.47 
    Constant  -19.3 (25.32) -79.18 to 40.58 0.47 
Abbreviations: k, number of studies; n, number of participants. 
aCalculated using the Higgins and Thompson Monte Carlo permutation test (10000 permutations). 
 
7.9 PREDICTORS OF EFFICACY 
Acamprosate 
 Lesch and Walter (1996) reviewed outcomes in their trial with reference to their four 
typologies: Type I (social drinking develops into dependence, craving, relief 
drinking, family history); Type II (alcohol consumed to medicate sleep or anxiety; 
consumption varies with context, behaviour changes with alcohol); Type III (alcohol 
used to self-medicate a psychiatric disorder such as depression; family history 
positive for alcoholism or psychiatric disorder; impaired behaviours not always 
related to alcohol); and Type IV (brain damage and psychiatric disorders before 14 
years; seizures not related to alcohol; mild withdrawal symptoms). They reported 
that Types I and II, but not III and IV, responded to acamprosate.  
 
In the UK trial, Chick (2000) speculated whether the continuous rather than episodic 
drinker would be more likely to respond since their negative study had more 
participants with episodic drinking patterns. Kiefer and colleagues (2005) examined 
predictors in their original trial of acamprosate alone and with naltrexone and 
reported that acamprosate was mainly efficacious in patients with low baseline 
somatic distress, mainly effective in Type I, and that craving showed no predictive 
value.  
 
Mason and Lehert (2010) explored the first US acamprosate trial (Mason et al., 2010) 
and suggested that acamprosate may reduce the negative impact of subsyndromal 
anxiety or a past psychiatric history. 
 
In contrast, Verheul and colleagues (2005) examined pooled data from seven RCTs 
that included 1485 patients with alcohol dependence. Whilst ‗cumulative abstinence 
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duration (CAD)‘, or continuous abstinence, was predicted by higher levels of craving 
or anxiety at baseline, this was for all patients and acamprosate showed no 
differentially efficacy. Other variables that were investigated and showed no 
significant relationship with outcomes including severity of dependence which was 
non-linearly associated with CAD, family history, age of onset and gender. 
Therefore, they concluded that acamprosate is potentially effective for anyone with 
alcohol dependence.  
Naltrexone 
Monterosso and colleagues (2001) reported that those with a family history of 
alcoholism and high levels of craving were more likely to benefit from naltrexone. 
Rubio and colleagues (2005) similarly reported from their naltrexone trial that those 
with a family history of alcoholism benefited more, as well as those whose onset of 
alcohol abuse was before age 25, or those who had history of other substance abuse. 
Kiefer and colleagues (2005) reported that naltrexone was effective especially in 
patients with high baseline depression and in Type III and IV (Lesch & Walter, 2006). 
 
Several studies have investigated whether genetic variants of the opioid receptors, 
mu, kappa and delta, are related to naltrexone‘s efficacy. Several studies have 
reported an association between greater treatment response and A118G (OPRM1), a 
functional polymorphism of the µ-opioid receptor gene, (Oslin et al., 2003; Anton et 
al., 2008b; Oroszi et al., 2009; Kim et al., 2009) but not all (Gelenter et al., 2007). In a 
relatively small sample, Ooteman and colleagues (2009) explored other genotypes 
and reported effects of GABRA6, GABRA2, OPRM1 and dopamine D2 receptor 
genes moderated treatment response from acamprosate or naltrexone and subjective 
and physiological cue reactivity.  
 
It is not clear whether gender influences treatment outcome with studies of 
naltrexone in alcoholism reporting no gender differences (Anton et al., 2006). 
Pettinati and colleagues (2008b) reported that in comorbid cocaine/alcohol 
dependence naltrexone (150 mg per day), men reduced their cocaine and alcohol use 
whereas women did not, indeed their cocaine use increased. However, most have 
limited power to detect gender x treatment outcome. 
Disulfiram 
There is no systematic review and little indication from trials of disulfiram about 
which type of patient might be more likely to benefit from treatment.  
7.9.1  Compliance and adherence 
These are related to predictors of efficacy given that if a patient is not taking their 
medication as prescribed, then its effectiveness is likely to be reduced. Since 
acamprosate and naltrexone are generally well tolerated medications, problematic 
side effects are unlikely to contribute significantly to reduced compliance.  
 
This issue has only been studied with naltrexone where Rohsenow and colleagues 
(2000) found that compliance was better in those that believed that the medication 
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would help them stay sober and was not predicted by demographic or pre-treatment 
alcohol use variables, commitment to abstinence or self-efficacy about abstinence. 
 
For disulfiram, witnessing or supervision has been shown to be an important 
component of its effectiveness (Chick, 1992; Sereny et al., 1986). Those patients who 
might do better with unsupervised disulfiram are older (Baekeland et al., 1971; Fuller 
et al., 1986); more socially stable (Fuller et al., 1986); impulsive (Banys 1988); and 
higher in motivation (Baekeland et al., 1971).  
7.9.2 When to start pharmacological treatment 
We are giving advice regarding prescribing these medications for relapse prevention 
and therefore patients should be abstinent from alcohol at the time of starting 
medication. All medications should be used as an adjunct to psychosocial treatment 
and not prescribed in isolation.  
Acamprosate 
The SPC recommends that ‗treatment with acamprosate should be initiated as soon 
as possible after the withdrawal period and should be maintained if the patient 
relapses‘. Advice to start as soon as possible was made since studies that allowed 
more than a couple of weeks after assisted withdrawal resulted in more patients 
drinking again before initiating acamprosate with consequent reduced efficacy. 
Given that individuals are at particularly high risk of relapse in the first few days 
and given that it takes about 5 days for acamprosate to achieve steady state levels, 
starting it as soon as possible seems sensible (Mason et al., 2002).  
 
In addition, there is evidence from preclinical models that acamprosate can reduce 
glutamatergic hyperactivity associated with alcohol withdrawal leading to reduced 
cellular damage (Spanagel et al., 1996; Qatari et al., 2001). Preliminary data from man 
suggests that acamprosate during withdrawal may also reduce hyperactivity and 
improve sleep (Boeijinga et al., 2004; Staner et al., 2006). Consequently, some 
practitioners start the acamprosate for relapse prevention during or even before 
assisted withdrawal. Acamprosate has been started with assisted withdrawal with 
no reports of adverse events (Gual et al., 2001; Kampan et al., 2009). Acamprosate did 
not alter the course of alcohol withdrawal including CIWA-Ar score and amount of 
benzodiazepines taken. Unlike Gual and colleagues (2001), Kampan and colleagues 
(2009) found that acamprosate started during assisted withdrawal was associated 
with poorer drinking outcomes compared with those who had placebo. However, 
Gual and colleagues compared acamprosate with placebo for the entire treatment 
period whereas in Kampan and colleagues acamprosate was open label and without 
placebo in the relapse prevention phase.  
Naltrexone 
When using naltrexone for relapse prevention, patients should be abstinent. 
However, there is no information on the optimal time to start medication. Like 
acamprosate, it is safe to start naltrexone while patients are still drinking or during 
medically assisted withdrawal.  
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Disulfiram 
Given the reaction between alcohol and disulfiram, treatment should only be started 
at least 24 hours after the last alcoholic drink (SPC).  
7.9.3 How long to continue with pharmacological treatment 
Most trials of medication are between 3 to 6 months and show efficacy. However 
many patients relapse within months to years but there is very limited evidence to 
guide how long medication should be continued. Patients who are doing well may 
be best advised to remain on medication for at least 6 months. However, some of 
these patients may feel confident enough to stop medication earlier. Alternatively 
some would prefer to stay on medication for longer; continuation beyond a year 
would need to be justified. If a patient is not engaging with other aspects of 
treatment, for example, psychosocial and is drinking heavily, stopping the 
medication is appropriate until they engage with treatment. However if a patient is 
engaged but still drinking, a review of all of their treatment is indicated to assess 
whether this is optimal, including medication.  
 
There is no evidence currently that long-term use of any of the relapse prevention 
pharmacotherapy incurs additional adverse consequences particularly when relapse 
to heavy drinking will be associated with morbidity and mortality. However, 
medication is ideally used as an adjunct to support engagement with psychosocial 
approaches to alter behaviour and attitudes to alcohol.  
 
For acamprosate, Mann (2004) reported from their meta-analysis that the effect sizes 
increased with time (the effect sizes on abstinence at 3, 6, and 12 months were 1.33, 
1.50, and 1.95 respectively. This suggests that a clinically relevant benefit of 
treatment may be observed as early as 3 months which gradually increases up to 1 
year and possibly beyond. For naltrexone, there is evidence that its effects do not 
persist when it is stopped (O‘Malley et al., 1996).  
7.10 HEALTH ECONOMIC EVIDENCE  
7.10.1 Systematic review 
The literature search identified seven studies that assessed the cost-effectiveness of 
pharmacological agents for the maintenance phase of treatment of alcohol 
dependence (Annemans et al., 2000; Mortimer & Segal, 2005; Palmer et al., 2000; 
Rychlik et al., 2003; Schadlich & Brecht, 1998; Slattery et al., 2003; Zarkin et al., 2008). 
Full references, characteristics and results of all studies included in the economic 
review are presented in the form of evidence tables in the appendices. 
 
Annemans and colleagues (2000) modelled the healthcare costs of acamprosate 
compared with no treatment in the prevention of alcoholic relapse over a 24-month 
time horizon. The patient population started the model following assisted 
withdrawal in an ambulatory state. Effectiveness data used to populate the model 
was sourced from several published and unpublished studies. A Belgian health 
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payers‘ perspective was taken for the analysis. Therefore, only direct medical costs, 
relating to hospitalisations, psychiatric and GP consultations and medications, were 
included in the model. The total expected cost of the acamprosate strategy was 
€5,255 over the two-year time horizon compared with €5,783 in the no treatment 
arm. Therefore, despite the higher drug acquisition costs, acamprosate was shown to 
be a cost-saving intervention, in terms of reduced hospitalisations due to alcohol-
related complications. The major limitation of the study was that it was a cost-
analysis and did not consider the impact of the interventions on overall clinical 
effectiveness and patient quality of life. Furthermore, the study was from the Belgian 
health payer‘s perspective which may have limited applicability to the UK context. 
 
The study by Mortimer and Segal (2005) conducted a model-based economic 
analysis of naltrexone plus counselling versus counselling alone amongst detoxified 
patients with a history of severe alcohol dependence. A lifetime horizon was used 
for all of the analysis. Clinical effectiveness was measured using QALYs which were 
calculated from disability weights derived from a single published source (Stouthard 
et al., 1997). Clinical effectiveness data were taken from published studies evaluating 
interventions targeting heavy drinkers at lower severity levels. These data were used 
to estimate how patients would progress between specific drinking states (problem, 
moderate or dependent) within the model. The authors did not specify the resource 
use and cost components included in the model within the article although an 
Australian health service perspective was adopted for the analysis. The results of the 
analysis suggested that naltrexone was cost-effective in comparison with standard 
care resulting in an ICER of $ AUD 12,966.  
 
There are several limitations with the results of the study that reduce their 
applicability to any UK-based recommendations. Little explanation was given in the 
article as to how the clinical effectiveness data, which was taken from various 
sources, was used to inform the health states used in the economic models. The 
article did not specify the resource use and costs that were included in the analyses 
although a health perspective was used. The analysis used QALYs as the primary 
outcome measure, which allows for comparison across interventions, although again 
there was insufficient description of the utility weights that were applied to the 
health states within the model.  
 
Palmer and colleagues (2000) modelled the lifetime cost-effectiveness of adjuvant 
acamprosate therapy, in conjunction with standard counselling therapy, compared 
with standard counselling alone, in alcohol-dependent patients. The study 
population comprised men of an average age 41 years, who had been withdrawn 
from alcohol and had a mixture of alcohol-related complications. The model allowed 
patients to progress through various health states associated with important alcohol-
related complications including liver disease, gastrointestinal disease, alcoholic 
cardiomyopathy and other complications. Clinical effectiveness data was sourced 
from 28 published studies that were not formally meta-analysed and authors‘ 
assumptions. The outcome measure used for the economic analysis was the number 
of life-years gained with adjuvant acamprosate over standard therapy. The 
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perspective of the cost analysis was from German third-party payers. Costs, again 
reported in Deutschmarks, included those associated with drug acquisition and 
treatment of alcohol-related complications. 
 
The results of the cost-effectiveness analysis showed that adjuvant acamprosate 
therapy was the dominant treatment strategy, resulting in lower costs (DM 48,245 
versus DM 49,907) and greater benefits (15.9 versus 14.6 life-years gained) in 
comparison with standard therapy. Interpretation of the study results is subject to a 
number of methodological limitations. Firstly, a formal literature review was not 
undertaken in order to derive effectiveness estimates and no formal meta-analysis of 
summary data was performed, with the authors using data from studies selectively. 
Cost items used in the analysis were not reported adequately and unit costs and 
resources were not reported separately. Finally, as noted by the authors, no 
consideration was given to patients‘ quality of life in measuring the relative 
effectiveness of the treatments considered. 
 
The objective of the study by Rychlik and colleagues (2003) was to compare the 
healthcare costs over one year of psychosocial rehabilitation support either alone or 
with adjuvant acamprosate treatment. The cost-effectiveness analysis was conducted 
alongside a prospective cohort study across 480 centres in the German primary care 
setting. Patients who fulfilled DSM–IV criteria for alcohol dependence were included 
in the study. The primary measure of clinical effectiveness in the study was 
abstinence rates after one year. The perspective of the study was from the German 
health insurance. Direct healthcare costs included medications, hospitalisations, 
outpatient care and diagnostic and laboratory tests. Total one-year costs were 
analysed according to both per-protocol (PPA) and intention-to-treat (ITT) due to the 
expected patient attrition. Within both analyses, the adjuvant acamprosate treatment 
resulted in lower costs (€1225 to €1254 versus €1543 to €1592) and higher rates of 
abstinence (32 to 23% versus 20 to 21%) in comparison with no adjuvant treatment. 
The results of the economic analysis may be of limited applicability to the UK setting 
due to the cohort study design, the study setting and the short time horizon, as well 
as the effectiveness measure used. 
 
The study by Schadlich and Brecht (1998) was a model-based cost-effectiveness 
analysis comparing adjuvant acamprosate therapy (in addition to standard care) to 
standard care (placebo and counselling or psychotherapy) for alcohol dependence. 
The patient population were defined as being alcohol-dependent and abstinent from 
alcohol for up to 28 days prior to entering the study. Data were derived from a single 
double-blind RCT across 12 outpatient centres in Germany. The primary health 
outcome measure was the percentage of patients remaining abstinent at the end of 
48-weeks of medication-free follow-up. Transition probabilities to target events 
within the model were elicited from clinical expert opinion. The outcome measures 
used in the cost-effectiveness analysis were cases of target events avoided including 
cases of alcoholic psychoses, alcohol dependence syndrome, acute alcoholic hepatitis 
and alcoholic liver cirrhosis. A German healthcare system perspective was taken for 
the cost analysis. Costs (reported in Deutschmarks) included in the model related to 
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hospital treatment, acamprosate acquisition and patient rehabilitation for target 
events. 
 
The incremental cost-effectiveness ratio of acamprosate versus standard care was –
DM 2,602 (range: -DM406 to –DM 8,830) per additional abstinent alcoholic, thus 
resulting in a net saving in terms of direct medical costs. The results of the study, 
based on a single RCT in Germany, are of limited relevance to the UK setting. No 
attempt was made to translate the intermediate outcome of abstinence into final 
outcomes such as QALYs, which are of greater relevance to decision-makers. 
Another limitation of the study was that resource use quantities were not reported 
separately from the costs. Costing was also performed retrospectively and was not 
based on the same patient sample that was used in the effectiveness analysis, thus 
limiting the study‘s internal validity. 
 
The study by Slattery and colleagues (2003) developed an economic model to assess 
the cost-effectiveness of acamprosate, naltrexone and disulfiram compared with 
standard care within the Scottish health service setting. The population examined 
were 45-year-old men and women with a diagnosis of alcohol dependence. The 
outcome measures used in the economic model were the number of patients who 
have abstained and number of patient deaths averted. The clinical effectiveness data 
was based on a methodologically diverse selection of trials which were not described 
within the study. Resource use involved in the pharmacological interventions 
included drug acquisition as well as outpatient and GP consultations. Costs were 
applied from Scottish health service estimates. Other healthcare costs included in the 
model were those associated with alcohol-related disease endpoints such as stroke, 
cancer, cirrhosis and alcohol-related psychoses. Costs were applied according to 
inpatient length of stay taken from Scottish medical records. 
 
The total costs of pharmacological treatments and any disease endpoints for a 
hypothetical cohort of 1000 patients were compared with standard care over a 20 
year time horizon, to determine any net healthcare cost savings. Acamprosate 
resulted in net savings of £68,928 whilst naltrexone and disulfiram resulted in net 
economic costs of £83,432 and £153,189 respectively in comparison with standard 
care amongst a hypothetical cohort of 1000 patients. Whilst the results of the study, 
based on a hypothetical cohort of patients within the Scottish health service, may be 
applicable to a UK setting, there are several problematic methodological issues with 
the study. First, the sources of the effectiveness data used in the model were not 
explicitly described by the authors who suggested that the data was taken from a 
methodologically diverse selection of trials, thus suggesting a high level of 
heterogeneity. Secondly, no attempt was made to translate intermediate clinical 
endpoints such as abstinence rates into QALYs, which are useful to decision makers 
when assessing the comparative cost-effectiveness of healthcare interventions. 
 
Zarkin and colleagues (2008) evaluated the cost-effectiveness of the COMBINE study 
(Anton et al., 2006) interventions after 16 weeks of treatment. Within the study, 
patients with a primary diagnosis of alcohol dependence from across 11 US study 
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sites were randomised to nine intervention groups. In eight groups, all patients 
received medical management (MM) and were randomised to receive naltrexone, 
acamprosate, combination (naltrexone and acamprosate) or placebo or combined 
behavioural intervention (CBI) in addition to naltrexone, acamprosate, combination 
or placebo. The ninth treatment group received CBI only (without MM). Three 
clinical measures were used in the economic analysis: percentage of days abstinent, 
avoidance of heavy drinking and achieving a good clinical outcome (abstinent or 
moderate drinking without problems). Costs were analysed from the treatment 
provider perspective. Resource use included medications, staff time and laboratory 
tests.  
 
Each intervention was ranked in increasing order of mean total cost for each of the 
three effectiveness measures. Only three interventions – MM and placebo, MM and 
naltrexone and naltrexone and acamprosate – were included in the final comparative 
analysis. This is because the other six interventions were dominated (resulting in 
higher mean costs but lower effectiveness) by the aforementioned interventions. The 
ICERs for the comparison of MM and naltrexone versus MM and placebo were $42 
per percentage increase in days abstinent, $2,847 per patient avoiding heavy 
drinking and $1,690 per patient achieving a good clinical outcome. The ICERs for the 
comparison of naltrexone and acamprosate versus MM and naltrexone were $664 
per percentage point increase in days abstinent, $8,095 per patient avoiding heavy 
drinking and $7,543 per patient achieving a good clinical outcome. 
 
This study is the only cost-effectiveness study reviewed that considered 
combinations of pharmacological and psychosocial interventions. However, there 
are a number of limitations when interpreting the results of the study. The cost 
analysis relied on the trial investigators judgement of best clinical practice which 
specifically relates to the US healthcare system and may not be generalisable to the 
UK health service. Interpretation of the results is further reduced by the short time 
horizon and the choice of outcome measures used in the analysis. Translation of 
intermediate outcomes such as rates of abstinence or moderate drinking into final 
outcomes such as QALYs would also be more helpful to decision-makers. 
7.10.2 Summary of existing health economics evidence  
Of the seven cost-effectiveness studies identified in the literature, four compared 
acamprosate to standard care (Annemans et al., 2000; Palmer et al., 2000; Rychlik et 
al., 2003; Schadlich &Brecht, 1998), one compared naltrexone to standard care 
(Mortimer & Segal, 2005), one study compared naltrexone, acamprosate and 
disulfiram to standard care (Slattery et al., 2003). The remaining study compared 
nine possible treatment combinations including naltrexone, acamprosate, 
combination (naltrexone and acamprosate) or placebo either alone or in combination 
with combined behavioural intervention. Only one study was UK-based (Zarkin et 
al., 2008) whilst the other studies were based in Belgian, German or US populations. 
Nearly all of the studies were model-based economic analyses except for Rychlik 
and colleagues (2003), which was a cohort-based study and Zarkin and colleagues 
(2008), which was based on the COMBINE RCT (Anton et al., 2006). Within nearly all 
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of the studies, pharmacological treatments were provided as adjuvant treatments to 
standard care which differed across the studies considered. 
  
In summary, the results suggested that acamprosate was either cost saving or the 
dominant treatment strategy (offering better outcomes at lower costs) in comparison 
with standard care. Naltrexone plus counselling was cost-effective compared with 
counselling alone in patients with a history of severe alcohol dependence (Mortimer 
& Segal, 2005). The one UK study showed that acamprosate resulted in significant 
healthcare cost savings whilst naltrexone and disulfiram resulted in significant net 
economic costs in comparison with standard care (Slattery et al., 2003). Zarkin and 
colleagues (2008) showed that naltrexone in addition to medical management and 
combination therapy (naltrexone plus acamprosate) were cost-effective over a 16-
week period. 
 
Providing an adequate summary of the health economics evidence presented here is 
difficult, due to the differences across the studies in terms of the comparator 
treatments considered (that is, definitions of ‗standard care‘ differed across studies), 
study populations, costs and outcomes considered and other methodological 
differences. Overall, the f evidence reviewed is insufficient to support a single 
pharmacological treatment over any other. 
7.11 ECONOMIC MODEL  
This section considers cost-effectiveness of pharmacological interventions as an 
adjunctive treatment for the prevention of relapse in people who are in recovery 
from alcohol dependence 
7.11.1 Introduction 
The systematic search of the economic literature identified a number of studies 
assessing the relative cost-effectiveness of pharmacological treatments, either alone 
or as an adjunct to psychological therapy, in the prevention of relapse in people who 
are in recovery from alcohol dependence. The studies varied in terms of both 
methodological quality and applicability to the UK context. The results overall were 
inconsistent and did not support one pharmacological therapy over another. 
Therefore, an economic model was developed in order to answer this question. The 
objective of the economic model was to explore the relative cost-effectiveness of 
pharmacological treatments for the prevention of relapse in people who are in 
recovery from alcohol dependence. The aim of the analysis was to reflect current UK 
clinical practice, using the most relevant and up-to-date information on costs and 
clinical outcomes. Details on the guideline systematic review of the economic 
literature on pharmacological interventions for relapse prevention are provided in 
Section 7.10.1. 
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7.11.2 Methods 
Interventions assessed 
The choice of interventions assessed in the economic analysis was determined by the 
clinical data that was analysed within the guideline systematic literature review. 
Only pharmacological interventions licensed in the UK as first-line adjuvant 
treatments in the prevention of relapse in people in recovery from alcohol 
dependence were considered. As a result, both naltrexone and acamprosate were 
considered in the economic analysis. Disulfiram was not included in the economic 
analysis due to the scarcity of available clinical data: only one open-label trial, 
comparing disulfiram with naltrexone, considered relapse to alcohol dependence as 
an outcome measure (De Sousa et al., 2004). Trials comparing Disulfiram with other 
treatments were also open-label which also limited their comparability with trials 
naltrexone and acamprosate which were double-blinded The GDG acknowledged 
that this was a limitation of the analysis, in terms of providing a comprehensive 
consideration of the relative cost-effectiveness of all available pharmacological 
interventions that currently exist within the UK. The GDG decided that combination 
treatment (naltrexone and acamprosate) would also be excluded from the economic 
model due to uncertainty about the data, in particular the uncertainty about the risk 
of combined use of these drugs one of which is not licensed for use in the UK. The 
pair-wise meta-analyses showed no benefit of combination treatment versus 
naltrexone or acamprosate alone, in terms of relapse to heavy drinking, at 3, 6 or 12 
months follow-up. 
Model Structure 
A pragmatic decision model was constructed using Microsoft Excel 2007. Within the 
model a hypothetical cohort of 1000 patients who are in recovery from alcohol 
dependence can either relapse to heavy drinking (defined as 5+ drinks for males; 4+ 
drinks for females) or remain in recovery during a 12-month period. The structure of 
the decision tree is presented in Figure 9. The time horizon was chosen to reflect 
current UK guidance and recommendations, which recommend that patients should 
be maintained on pharmacological therapy for up to 12 months if patients are 
responding successfully to treatment. Three treatment groups were considered in the 
model: 1) Acamprosate and standard care; 2) Naltrexone and standard care and; 3) 
standard care alone. Standard care was defined as psychological therapy that 
patients would be receiving in order to prevent relapse to heavy drinking. The 
psychological therapy would be delivered by a community nurse over the 12-month 
period.  
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Figure 9: Schematic of model structure. 
Costs and outcomes 
The analysis adopted the perspective of the NHS and personal social services, as 
currently recommended by NICE. Costs relating to drug acquisition, blood tests, 
psychological interventions, outpatient secondary care and primary care were 
considered in the analysis. The outcome measured was the QALY. 
 
Clinical input parameters and overview of methods of evidence synthesis  
Clinical input parameters consisted of relapse rates associated with each intervention 
assessed: that is, naltrexone, acamprosate, or placebo. The economic analysis 
considered all relevant data reported in the studies included in the respective 
guideline systematic clinical review. To take all trial information into consideration, 
network (mixed treatment comparison) meta-analytic techniques were employed. 
Network meta-analysis is a generalisation of standard pair-wise meta-analysis for A 
versus B trials to data structures that include, for example, A versus B, B versus C 
and A versus C trials (Lu & Ades, 2004). A basic assumption of network meta-
analysis is that direct and indirect evidence estimate the same parameter; in other 
words, the relative effect between A and B measured directly from a A versus B trial, 
is the same with the relative effect between A and B estimated indirectly from A 
versus C and B versus C trials. Network meta-analytic techniques strengthen 
inference concerning the relative effect of two treatments by including both direct 
and indirect comparisons between treatments and, at the same time, allow 
simultaneous inference on all treatments examined in the pair-wise trial 
comparisons while respecting randomisation (Lu & Ades, 2004; Caldwell et al., 2005). 
Simultaneous inference on the relative effect a number of treatments is possible 
provided that treatments participate in a single ‗network of evidence‘, that is, every 
treatment is linked to at least one of the other treatments under assessment through 
direct or indirect comparisons. 
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Details on the methods and relapse data utilised in the network meta-analysis that 
was undertaken to estimate clinical input parameters for the economic analysis are 
presented in Appendix 15. Table 99 provides the mean probability of relapse (as well 
as the respective 95% credible intervals) at one year of treatment for naltrexone, 
acamprosate and placebo, as estimated by network meta-analysis. Overall, the 
results of the network meta-analysis are comparable with those obtained in the pair-
wise comparisons, reported as relative-risk of relapse to heavy drinking at 3, 6 and 
12 months. These comparisons showed small but significant differences favouring 
naltrexone and acamprosate versus placebo, but no significant differences between 
naltrexone and acamprosate over 12 months. The results of the network meta-
analysis suggest that acamprosate had the highest probability (63%) of being the best 
treatment at reducing the probability of relapse over 12 months. However, the wide 
credible intervals around the mean estimates are indicative of the uncertainty 
surrounding these mean estimates. 
 
Table 99: Results of network meta-analysis – probability of relapse at 12 months 
Treatment Mean Lower CrI Upper CrI Probability that treatment 
is best at reducing relapse 
over 12 months 
Placebo 0.8956 0.5509 1.0000 0.000 
Naltrexone 0.8253 0.4095 0.9997 0.369 
Acamprosate 0.8176 0.3894 0.9996 0.631 
 
Relapse data 
Data on rates of relapse to alcohol dependency were taken from 32 RCTs included in 
the guideline systematic review of pharmacological treatments for the prevention of 
relapse in people in recovery from alcohol dependence. All trials included 
pharmacological treatments as an adjunct to psychological treatment. Data on 
combination treatment (acamprosate and naltrexone) or disulfiram were excluded as 
it did not strengthen inference between the three comparators included in the 
economic model. The RCTs reported rates of relapse at three different time-points: 3 
months (n=20), 6 months (n=9) and 12 months (n=3). Data were extracted from the 
guideline systematic review, which adopted an intention-to-treat analysis. Therefore, 
it was assumed that study participants who discontinued treatment early were likely 
to have an unfavourable outcome (that is, relapse to alcohol dependence).The RCTs 
included in the MTC meta-analysis used different definitions of relapse and different 
baseline psychological therapies , a factor that may limit the generalisability of 
relapse rates across the studies considered. For studies that reported relapse rates at 
multiple timepoints, for example 3 and 6 months, relapse from the final endpoint, in 
this case 6 months, was used in the network meta-analysis. 
 
Within the economic model, it was assumed that an equal proportion of patients 
within each treatment group would relapse at any monthly time interval (from 1 to 
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12 months). Monthly probabilities were calculated using the following formula 
(Miller & Homan, 1994): 
 
 
 
Where n =1,2,..,11. 
Utility data and estimation of quality-adjusted life years 
To express outcomes in the form of QALYs, the health states of the economic model 
were linked to appropriate utility scores. Utility scores represent the health-related 
quality of life (HRQoL) associated with specific health states on a scale from 0 
(death) to 1 (perfect health). They are estimated using preference-based measures 
that capture people‘s preferences for the health states under consideration. The 
systematic search of the literature identified one study that reported utility scores for 
specific health states associated alcohol-related disorders (Kraemer et al., 2005). 
 
The study by Kraemer and colleagues (2005) directly measured utility scores for a 
spectrum of alcohol-related health states using different methods of utility 
measurement including visual analogue scale (VAS), time trade-off (TTO) and 
standard gamble (SG) techniques. The study was based on a cross-sectional 
interview of 200 adults recruited from one clinic (n=100) and one community sample 
(n=100) in the US. Study subjects completed computerised versions of the utility 
rating exercises for their current health and 6 hypothetical alcohol-related health 
state scenarios presented in random order. Utility ratings were scaled from 0 to 1 
and anchored by death (0) and perfect health (1). Table 100 summarises the mean 
utility scores for the six alcohol-related health states for the three techniques used. 
As the results in table show, for each of the techniques used, utility scores decreased 
as the severity of alcohol use increased. 
 
Table 100: Mean utility scores for alcohol-related health states and utility 
measurement technique (adapted from Kraemer et al., 2005) 
Alcohol-related health state 
scenario 
VAS 
Mean (SD) 
TTO 
Mean (SD) 
SG 
Mean (SD) 
Non-drinking 0.94 (0.09) 0.97 (0.13) 0.93 (0.15) 
Safe drinking 0.85 (0.17) 0.94 (0.20) 0.88 (0.22) 
At-risk drinking 0.72 (0.24) 0.84 (0.30) 0.82 (0.27) 
Alcohol abuse 0.52 (0.23) 0.72 (0.35) 0.75 (0.29) 
Alcohol dependence 0.36 (0.22) 0.54 (0.37) 0.67 (0.29) 
Alcohol dependence, in recovery 0.71 (0.24) 0.86 (0.25) 0.83 (0.24) 
 
NICE recommends the EQ-5D as the preferred measure of HRQoL in adults for use 
in cost-utility analyses. NICE also suggests that the measurement of changes in 
HRQoL should be reported directly from people with the condition examined, and 
the valuation of health states should be based on public preferences elicited using a 
choice-based method, such as TTO or SG, in a representative sample of the UK 
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population. At the same time, it is recognised that EQ-5D utility scores may not be 
available or may be inappropriate for the condition or effects of treatment (NICE 
2008a). The study by Kraemer and colleagues (2005) did not use the EQ-5D 
questionnaire to estimate utility scores and was based on a US population sample 
who did not experience the alcohol-related health states they were asked to rate. 
Furthermore, the patient sample was not randomly selected but were conveniently 
recruited either from clinic waiting rooms or self-selected within the community 
after responding to an advertisement. The low sample size (n=200) also limits the 
results of the study, contributing to the uncertainty around the mean utility score 
estimates. However, this was the only study identified in the literature review that 
applied utility scores to specific alcohol-related health states using appropriate 
measurement techniques (SG or TTO) as recommended by NICE. 
 
The two health states of interest in the economic model were: a) in recovery from 
alcohol dependence and b) relapse to alcohol dependence. For these health states, 
the utility scores for the ‗alcohol dependence‘ and ‗alcohol dependence, in recovery‘ 
health states were chosen from Kraemer and colleagues (2005). In the base-case 
analysis, the TTO utility scores were used whilst the SG utility scores were used in 
the sensitivity analysis. 
Resource use and cost data 
Costs associated with pharmacological interventions for relapse prevention in 
people in recovery from alcohol dependence were calculated by combining resource 
use estimates with appropriate UK national unit costs. Costs relating to the 
interventions consisted of the relevant drug acquisition costs, psychological 
treatment, outpatient and primary care. People who relapsed to alcohol dependency 
were assumed to discontinue pharmacological and psychological treatment and 
incur other healthcare costs, as described below. Where necessary, costs were 
uplifted to 2009 prices using the Hospital and Community Health Services (HCHS) 
Pay and Prices Index (Curtis, 2009). Discounting was not required as the time 
horizon of the analysis was 12 months. 
Drug acquisition costs 
Drug acquisition costs were taken from the latest edition of the British National 
Formulary (British Medical Association & The Royal Pharmaceutical Society of Great 
Britain, 2010). The recommended daily dosage for acamprosate was 1998 mg per day 
and for naltrexone was 50 mg per day. The drug acquisition costs and monthly costs 
for both drugs included in the analysis are presented in Table 101. 
 
Table 101: Drug acquisition costs and estimated monthly costs of pharmacological 
interventions included in the economic model 
Drug Daily Dosage Unit Cost (BNF 59, March 2010) Monthly cost 
Acamprosate 1998 mg Campral 333 mg, 168-tab = £24 £26.10 
Naltrexone 50 mg Nalorex 50 mg, 28-tab = £22.79 £24.76 
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Other costs of patient management 
Estimates on resource use associated with the psychological intervention, outpatient 
and primary care and blood laboratory tests were based on GDG expert opinion. It 
was assumed that patients in all three treatment arms would receive the same 
individual psychological intervention focused specifically on alcohol misuse (for 
example, CBT, behavioural therapy or social network and environment based 
therapy) delivered by a practice nurse. It was assumed that each patient would 
receive one session per month or 12 sessions over the entire 12-month period if they 
did not relapse. It was assumed that patients in the three treatment groups would all 
require one initial 30-minute outpatient consultation with a consultant psychiatrist 
prior to starting treatment. Patients receiving adjuvant pharmacological 
interventions would require an additional two visits as part of their medical 
supervision. The second visit would be a 15-minute outpatient visit with a 
consultant psychiatrist and the third would be a GP consultation at the end of the 12-
month period. At all three visits, it was assumed that patients would require blood 
tests (liver function test and urea and electrolytes) to monitor for any potential 
hepatotoxic effects. It was assumed that patients receiving standard care would not 
require any further monitoring. Further details of resource use and costs associated 
with patient management are provided in Table 102. 
 
Table 102: Resource use over 12 months and unit costs associated with patient 
management for people in recovery from alcohol dependence 
Service Usage per person Unit Cost 
(2008/09 
prices) 
Source of unit costs; 
comments Pharmacological 
Intervention 
Standard 
Care 
Psychological 
treatment 
12 12 £88 Curtis, 2009; Nurse 
specialist (community): £88 
per hour of patient contact 
Outpatient 
visit 
2  
(1 x 30 min; 1 x 
15 min) 
1 
(1 x 30 min) 
30 min: £161 
15 min: £81 
Curtis, 2009; Consultant 
Psychiatrist: £322 per hour 
of patient contact 
GP visits 1 0 £35 Curtis, 2009; GP per surgery 
consultation lasting 11.7 
minutes: £35 
Laboratory 
blood tests 
(LFT; U&E) 
3 0 LFT: £5.70 
U&E: £4.63 
Newcastle-upon-Tyne 
Hospitals NHS Foundation 
Trust – personal 
communication 
 
Monthly cost of relapse to alcohol dependence  
The monthly cost of relapse to alcohol dependence was based on estimates of the 
annual cost of alcohol misuse to the NHS in England by the Department of Health 
for 2007 (Department of Health, 2008). Cost components included hospital inpatient 
and day visits, outpatient visits, A&E and ambulance visits, primary care 
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consultations and prescribed medications. The report estimated the total annual cost 
of alcohol harm to be £2.7 billion in 2006/07 prices. These costs were based on the 
estimated number of higher-risk drinkers in England taken from mid-2006 estimates 
published by the Office for National Statistics (Office for National Statistics, 2006). 
Higher-risk drinkers were defined as men who consumed 50 or more drinks per 
week and women who consumed 35 or more drinks per week. The total number of 
higher-risk drinkers in England in 2006 was estimated to be 2,653,545. To attribute a 
proportion of these NHS costs to dependent drinkers, required calculating the ratio 
of the estimated prevalence of alcohol dependence (5.9%) to the prevalence of 
hazardous drinking (24.2%) which were taken from the recent survey for adult 
psychiatric morbidity in England for 2007 (McManus et al., 2009). Hazardous 
drinking was defined in the survey as a score of 8 or more on the AUDIT scale. It 
was assumed that this definition of hazardous drinking was equivalent to the 
definition of higher-risk drinkers in the Department of Health report (Department of 
Health, 2008). Multiplying this ratio by the total number of higher-risk drinkers 
produced an estimate of 646,939 dependent drinkers in England in 2006. 
 
The survey also estimated the proportion of healthcare service use by people 
identified as dependent or hazardous drinkers (McManus et al., 2009). It was 
estimated that 10% of hazardous drinkers (but not dependent) and 21% of 
dependent drinkers used healthcare services in England during 2007. Assuming a 
ratio of 2.1, it was possible to estimate the total annual and monthly NHS costs 
attributable to people who relapse to alcohol dependency. The costs were inflated 
from 2006/07 prices using the HCHS index (Curtis, 2009). Total annual costs 
attributable to alcohol dependency were estimated at £1,800, giving a monthly cost 
of £150. 
Data analysis and presentation of the results  
Two methods were used to analyse the input parameter data and present the results 
of the economic analysis. 
 
Firstly, a deterministic analysis was undertaken, where data are analysed as mean 
estimates and results are presented as mean total costs and QALYs associated with 
each treatment under consideration. Relative cost-effectiveness between alternative 
treatment options is estimated using incremental analysis: all options are first ranked 
from the most to the least effective; any options that are more costly than options 
that are more highly ranked are dominated (because they are also less effective) and 
excluded from further analysis. Subsequently, incremental cost-effectiveness ratios 
(ICERs) are calculated for all pairs of consecutive treatment options. ICERs express 
the additional cost pr additional unit of benefit associated with one treatment option 
relative to its comparator. Estimation of such a ratio allows for consideration of 
whether the additional benefit is worth the additional cost when choosing one 
treatment option over another. If the ICER for a given treatment option is higher 
than the ICER calculated for the previous intervention in the ranking of all 
interventions, this strategy is then excluded from further analysis on the basis of 
extended dominance. After excluding cases of extended dominance, ICERs are 
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recalculated. The treatment option with the highest ICER below the cost-
effectiveness threshold is the most cost-effective option. 
 
Several sensitivity analyses were conducted to explore the impact of the uncertainty 
characterising model input parameters on the results of the deterministic analysis. 
The following scenarios were explored: 
 Using utility scores from Kraemer and colleagues (2005) obtained from the standard 
gamble (SG) technique rather than time-trade-off. These mean utility scores were 0.67 
for ‗alcohol dependence‘ and 0.83 for ‗alcohol dependence, in recovery‘. 
 Increase the level and intensity of patient monitoring whilst on pharmacological 
treatment so that patients in recovery receive 6 outpatient visits (5 with a consultant 
psychiatrist; 1 with a GP) over the 12 month period 
 Vary the monthly cost of relapse, from £0 to £300 
In addition to a deterministic analysis, a probabilistic analysis was also conducted. 
For this, model input parameters were assigned probability distributions (rather 
than expressed as point estimates), to reflect the uncertainty characterising the 
available clinical and cost data. Subsequently, 10,000 iterations were performed, each 
drawing random values from the distributions fitted to each model input parameter. 
 
The probabilistic distribution of data on the probability of relapse over 12 months 
was based on the results of the MTC analysis with random values recorded for each 
of the 10,000 MTC iterations performed in WinBUGS. In order to maintain the 
correlation between the posterior estimates for the probability of relapse over 12 
months, data from each of the common MTC simulations for this parameter were 
exported jointly and fitted into the Excel file of the economic model where the 
probabilistic analysis was carried out. 
 
To account for likely high skewness and variability, all monthly cost inputs, 
including the monthly cost of relapse, were assigned a gamma distribution based on 
an assumed standard error of 30% of the mean value used in the deterministic 
analysis. Utility estimates were assigned beta distributions, based on the standard 
errors around the mean values reported in the study by Kraemer and colleagues 
(2005). 
 
Results of the probabilistic analysis are presented in the form of cost-effectiveness 
acceptability curves (CEACs), which demonstrate the probability of each treatment 
option being the most cost-effective among the strategies assessed at different levels 
of willingness-to-pay per unit of effectiveness (interpreted as different cost-
effectiveness thresholds set by the decision-maker).  
In addition, the cost effectiveness acceptability frontier (CEAF) is provided alongside 
CEACs, showing which treatment option among those examined offers the highest 
average net monetary benefit (NMB) at each level of willingness-to-pay (Fenwick et 
al., 2001). The NMB of a treatment option at different levels of willingness-to-pay is 
defined by the following formula: 
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NMB = E · λ – C 
 
Where E and C are the effectiveness (number of QALYs) and costs associated with 
each treatment option, respectively, and λ is the level of the willingness-to-pay per 
unit of effectiveness. 
7.11.3 Results of economic model 
Deterministic analysis 
Table 103 provides mean costs and QALYs per 1,000 people for the interventions 
under consideration as well as the results of the incremental analyses. The 
interventions were ranked from highest to lowest in terms of the number of QALYs 
gained over 12 months. Acamprosate was associated with the highest costs and the 
highest number of QALYs whilst standard care was associated with the lowest costs 
and the lowest number of QALYs. The ICER of acamprosate was £5,043 per QALY 
versus standard care and £1,899 per QALY versus naltrexone. The ICER of 
naltrexone versus standard care was £5,395 per QALY, meaning that naltrexone was 
extendedly dominated. AllICERs lie well below the cost-effectiveness threshold of 
£20,000 to £30,000 per QALY currently set by NICE (NICE, 2008b). 
 
Table 103: 12-month mean costs and QALYs per 1,000 patients and ICERs for 
pharmacological interventions used for relapse prevention in people in recovery 
from alcohol dependency 
Treatment QALYs Costs ICER 
Acamprosate 683 £1,802,982 £1,899 £5,043 (versus standard care) 
Naltrexone 680 £1,797,737 £5,395  Extendedly dominated 
Standard care 656 £1,664,382 -  
 
Table 104 shows that the cost-effectiveness results were fairly robust under the 
scenarios explored in the sensitivity analysis. The ICER of acamprosate versus 
standard care reached £10,000 per QALY, while naltrexone was extendedly 
dominated when utility scores estimated from the standard gamble technique were 
used. The ICER of naltrexone versus standard care was approximately £11,000 per 
QALY. When the intensity of patient monitoring was increased, then the ICER of 
acamprosate versus naltrexone was £13,323/QALY and of naltrexone versus 
standard care £10,789/QALY. When the monthly cost of relapse was £0, the ICER of 
acamprosate compared with standard care increased to approximately £10,000, and 
naltrexone was extendedly dominated (with an ICER versus standard care of £11,000 
per QALY. However, when the monthly cost of relapse was doubled to £300, both 
pharmacological interventions dominated standard care, resulting in lower costs and 
higher QALYs over 12 months; acamprosate dominated naltrexone under this 
scenario. It must be noted that under all scenarios explored in one-way sensitivity 
analysis, the ICERs of both drugs versus standard care were below the NICE lower 
cost effectiveness threshold of £20,000 per QALY. 
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Table 104: Results of deterministic sensitivity analyses 
Scenario tested ICERs 
1) Utility scores estimated from 
standard gamble instrument  
Acamprosate versus Standard care: 
£10,087 
Naltrexone extendedly dominated 
2) Increased intensity of patient 
monitoring over 12-month period 
Acamprosate versus Naltrexone: 
£13,323 
Naltrexone versus Standard care: 
£10,789 
3) Monthly cost of relapse is 
(a) £0; (b) £300 
(a) 
Acamprosate versus Standard care: 
£10,668 
Naltrexone extendedly dominated 
(b) 
Acamprosate is dominant 
Standard care is dominated by both 
other options 
 
Probabilistic analysis 
Results of the probabilistic analysis were very similar to those of the deterministic 
analysis – Acamprosate was associated with the highest costs and QALYs and 
standard care was associated with the lowest costs and QALYs. ICERs were very 
similar to those calculated in the deterministic analysis. Probabilistic analysis 
demonstrated that standard care had the highest probability of being cost-effective, 
as well as the highest net monetary benefit up to a willingness-to-pay (WTP) level of 
£6,000 per QALY. Above this figure, acamprosate had the highest probability of 
being the most cost-effective treatment option and the highest net monetary benefit. 
Using the current threshold of £20,000 to £30,000 per QALY set by NICE, the 
probability of acamprosate or naltrexone being the most-effective treatment option 
were approximately 52 to 53% and 44 to 45% respectively. 
 
Figure 10 shows the CEACs generated for the three interventions considered whilst 
Table 105 shows the net monetary benefit and probability of each intervention being 
cost-effective at various levels of willingness-to-pay per QALY gained. Figure 11 
shows the CEAF for the three options assessed. It can be seen that acamprosate 
provides the highest average net monetary benefit at any willingness to pay above 
£10,000 per QALY. 
 
Table 105: Net Monetary Benefit and probability of each intervention being cost-
effective at various levels of willingness-to-pay (WTP) per QALY gained 
WTP Acamprosate Naltrexone Standard care 
NMB Probability NMB Probability NMB Probability 
£0 -£1,803 0.062 -£1,798 0.071 -£1,664 0.867 
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£10,000 £5,027 0.457 £5,002 0.399 £4,896 0.144 
£20,000 £11,857 0.519 £11,802 0.440 £11,456 0.041 
£30,000 £18,687 0.527 £18,602 0.449 £18,016 0.024 
£40,000 £25,517 0.532 £25,402 0.449 £24,576 0.019 
£50,000 £32,347 0.533 £32,202 0.449 £31,136 0.018 
 
 
 
Figure 10: Cost-effectiveness acceptability curves for three treatment options over 
12 months. 
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Figure 11: Cost-effectiveness acceptability frontier for three treatment options over 
12 months. 
7.11.4 Discussion of economic model  
The results of the economic analysis suggest that acamprosate is potentially the most 
cost-effective pharmacological treatment, when used as an adjunct to a psychological 
intervention, for relapse prevention in people in recovery from alcohol dependence. 
Given the uncertainty characterising the model input parameters, in particular the 
12-month probability of relapse, the probability of either acamprosate or naltrexone 
being the most cost-effective option at the NICE cost-effectiveness threshold of 
£20,000, was 52% and 44% respectively. 
 
A major limitation of the analysis was the exclusion of disulfiram, a pharmacological 
intervention that is currently licensed in the UK for the treatment of relapse 
prevention in people in recovery from alcohol dependence. Only one open-label 
RCT was identified in the systematic review that compared disulfiram with 
naltrexone, which used relapse to alcohol dependence as an outcome measure (De 
Sousa et al., 2004). The GDG decided it would be inappropriate to include the results 
of an open-label study in the network meta-analysis. Another limitation was that the 
RCTs included in the MTC meta-analysis used different definitions of relapse and 
different baseline psychological therapies, a factor that may undermine the pooled 
relapse rates considered in both the pair-wise and network meta-analyses. 
 
Another possible limitation of the analysis is the relatively short time horizon of the 
economic model, although this reflected the time horizon of the RCTs that were 
included in the systematic review and meta-analyses. Indeed, the majority of the 
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trials included in the network meta-analysis measured rates of relapse up to 3 and 6 
months with only three studies actually measuring rates of relapse up to 12 months 
follow-up. Ideally, a more comprehensive economic analysis would attempt to 
model the long-term cost-effectiveness of the three interventions, in terms of 
exploring the longer term impact of relapse prevention on future alcohol-related 
complications and survival. Earlier economic models have attempted to explore the 
longer-term cost-effectiveness of adjuvant pharmacological therapies over the 
patients‘ lifetime, by translating relapse to alcohol dependency into alcohol-related 
diseases including liver disease, cardiomyopathy, pancreatitis and alcoholic 
psychoses as well as alcohol-related mortality (Schadlich & Brecht, 1998; Palmer et 
al., 2000). However, these models required assumptions, often based on limited 
clinical evidence, about the longer-term prognosis of patients who relapsed to 
alcohol dependence. 
 
The results of the network meta-analysis are undermined by the heterogeneity 
between studies in terms of the range of underlying psychological interventions and 
the study time horizons. All studies included in the analysis were RCTs of 
pharmacological treatment or placebo as an adjunct to psychological interventions 
for the prevention of relapse. The RCTs included a wide range of psychological 
interventions including coping skills, counselling, brief CBI, MET and group 
therapies. The results of the meta-analyses presented here, including the network 
meta-analysis, assume that any differences in effectiveness are entirely explained by 
the adjuvant pharmacological interventions as opposed to the underlying 
psychological interventions. Whilst the economic model adopted a 12-month time 
horizon, the majority of the RCTs included in the network meta-analysis, were either 
3 months (n=20) or 6 months (n=9) duration. The analysis attempted to extrapolate 
the majority of this data over a 12-month period. If the effectiveness of 
pharmacological interventions for relapse prevention actually declines over 12 
months, the analysis may have over-estimated the cost-effectiveness of acamprosate 
or naltrexone as an adjunct to psychological interventions. 
 
The analysis was based on the perspective of the NHS and personal social services, 
as recommended by NICE. Costs associated with the interventions considered were 
estimated from national sources and GDG expert opinion. The results suggested that 
drug acquisition costs did not determine the relative cost-effectiveness of the three 
interventions. However, the results of the sensitivity analyses suggest that results 
may be sensitive to the intensity of patient monitoring (for example, specialist visits, 
blood tests) which were estimated from GDG expert opinion and also the monthly 
costs of relapse to heavy drinking. However, within both sensitivity analyses, the 
ICERs for acamprosate and naltrexone were still well below the current NICE cost-
effectiveness threshold.  
7.11.5 Conclusions 
The economic analysis undertaken for this guideline showed that both acamprosate 
and naltrexone may be potentially cost-effective pharmacological interventions for 
the prevention of relapse among people in recovery from alcohol dependence. The 
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probability of either drug being the most cost-effective option at the NICE cost-
effectiveness threshold of £20,000 was 52% and 44% respectively. However, further 
research is necessary to establish whether these pharmacological interventions are 
clinically and cost-effective in the longer term, in terms of preventing future alcohol-
related diseases. Further clinical data, preferably based on appropriately controlled 
trials, is also needed to establish the clinical efficacy of disulfiram for relapse 
prevention. 
7.12 CHILDREN AND YOUNG PEOPLE 
7.12.1 Clinical review protocol  
A systematic search of the literature was conducted to evaluate pharmacological 
interventions for relapse prevention for children and young people. See Section 7.2 
for the aim of the review and the clinical questions. The clinical review protocol for 
this section can be found in Section 7.3.  
 
7.12.2 Studies considered  
Unlike the adult literature, the GDG were able to identify only three small pilot 
RCTs in this area for children and young people (Niederhofer & Staffen, 2003a; 
Niederhofer et al., 2003b; Niederhofer & Staffen, 2003c). Due to the limited number 
of studies and the heterogeneous nature of the outcomes, a narrative synthesis of the 
available literature was conducted by the review team in order to assess the efficacy 
of pharmacological interventions for children and young people.  
7.12.3 Evidence summary 
Niederhofer and Staffen (2003a) conducted a double blind placebo controlled study 
with 26 participants with a DSM–IV diagnosis of chronic or episode alcohol 
dependence. Participants ranged in age from 16 to 19 years. The participants were 
randomly allocated to treatment with acamprosate (1332 mg daily) or placebo for 90 
days. Participants were assessed at start of treatment, and at 30 and 90 days. Results 
revealed that the acamprosate group had a significantly higher proportions of days 
abstinent throughout the 90 days of treatment (p<0.001), as well as a higher duration 
of mean cumulative abstinence (p<0.01). There were no significant differences 
between the two groups with regards to side effects, and diarrhoea was the only 
reported side effect.  
 
Niederhofer and colleagues (2003b) assessed naltrexone compared with a placebo in 
a double blind placebo controlled study, with 30 participants ranging in age from 15 
to 19 years with a DSM–IV diagnosis of chronic or episodic alcohol dependence. All 
participants received 50 mg of naltrexone daily and were assessed at the start of 
treatment and at 30 and 90 days. At the 90 day assessment point, sixty of ninety 
participants completed treatment. Participants remained abstinent longer than those 
in the placebo group during 90 days of treatment (p<0.01) and had a longer duration 
of mean cumulative abstinence (69.8 days) than the placebo arm (22.8 days) (p<0.01). 
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It must be noted that it is not clear from the paper how many participants were 
randomised to each group; therefore the findings should be interpreted with caution. 
 
Lastly, Niederhofer and Staffen (2003c) compared disulfiram and placebo in a 
double blind placebo controlled trial with 26 adolescents (age range: 16 to 19 years) 
with DSM–IV chronic or episodic alcohol dependence. Participants received 200 mg 
of disulfiram daily and were assessed at the start of treatment, 30 and 90 days. 
Twenty-six of the 49 participants recruited completed the 90 days of double-blind 
treatment. Results indicated that on day 90 of treatment, 2 of the placebo treated 
patients compared with 7 disulfiram treated patients had been continuously 
abstinent (p=0.0063). Additionally, the duration of mean cumulative abstinence was 
significantly higher in the disulfiram group (68.5 days) than in the placebo group 
(29.7 days) (p=0.012).  
 
7.12.4 Clinical evidence summary 
Taken together, there is little evidence based on the results of three small RCTs to 
assess the efficacy of pharmacological interventions in young people and 
adolescents. The three small pilot studies do, however, provide some preliminary 
data indicating positive responses in young people and adolescents for 
pharmacological interventions when compared with placebo. Due to the poor 
methodological quality of these studies however, results should be interpreted with 
very considerable caution. As a result, recommendations for young people and 
adolescents have to rely on extrapolations from the data set for adults. 
7.13 ASSESSMENT, MONITORING AND SIDE EFFECT 
PROFILE 
All patients for whom medication is being considered require medical review and 
assessment of their general fitness and their renal and liver function. Medication 
should be used as an adjunct to psychosocial treatment, so their engagement in 
psychosocial treatment should also be monitored. For a full description of the side-
effects, contraindications and cautions, or interactions with other medications, 
prescribers must refer to the SPC or BNF.  
Acamprosate 
Acamprosate is a well tolerated medication with minimal side effects, 
contraindications or cautions associated with its use. The most common side effect is 
diarrhoea with abdominal pain, nausea, vomiting and pruritus also described. Its 
contraindications include pregnancy and breast feeding, renal insufficiency (serum 
creatinine >120 micromol/L) and severe hepatic failure (Childs- Pugh Classification 
C). There appear to be no drug interactions of clinical significance with alcohol.  
Naltrexone 
Naltrexone is also generally a well-tolerated medication with most trials reporting 
side effects similar to those reported with placebo or other drugs such as disulfiram 
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or acamprosate. The most common side effects reported for naltrexone included 
nausea, headache, abdominal pain, reduced appetite and tiredness. However in 
some of these studies, 100 mg per day rather than 50 mg per day was used. Nausea 
has been reported more commonly at the start, particularly in female, lighter 
drinkers which can be minimised by starting at 25 mg per day.  
 
Since it is an opiate antagonist naltrexone cannot be used in those patients using 
opioid agonist drugs for analgesia. In addition, if analgesia is required in an 
emergency, non-opioid medication will be required since naltrexone blockade will 
last for 48 to 72 hours after taking the last tablet. It is therefore helpful that patients 
carry a card stating that they are taking naltrexone in case of such an emergency. If 
future analgesia is likely, for example in planned surgery, naltrexone is also 
therefore not ideal.  
 
Hepatotoxicity was reported in association with use of naltrexone to treat obesity 
when high doses (>300 per day) were used. Reviews of available data suggest and 
current US guidelines recommend that hepatic toxicity is very unlikely to occur with 
doses of at 50 mg per day and that continued alcohol use is more likely than 
naltrexone to cause liver damage (FDA ‗black box‘, accessed May 2010). 
Nevertheless, naltrexone should not be used in those with acute liver failure and 
caution is suggested when serum aminotransferases are four to five times above 
normal (Anton et al., 2006; Kleber, 1985). Nevertheless, naltrexone has been used in 
patients with chronic hepatitis B and/or hepatitis C and no significant difference in 
LFT results with naltrexone at the recommended doses has been reported (Lozano 
Polo et al., 1997)  
 
There is no consistent advice or evidence about monitoring of liver function tests for 
adverse effects on hepatic function. It is therefore important that the patient 
understands about the risk of hepatotoxicity and to stop taking naltrexone and 
promptly seek medical attention if they have any concerns about side effects or start 
to feel unwell. Deterioration in LFTs or signs of liver failure have not been widely 
reported and increases generally normalise on stopping naltrexone. Before ascribing 
any increases to naltrexone, review other possible contributors such as other 
medications – prescribed, over-the-counter, complementary treatments, resumption 
of drinking. 
Disulfiram 
Given the potential seriousness of the disulfiram – alcohol interaction in addition to 
the potential adverse effects of disulfiram alone, prescribing needs due care and 
consideration. Patients must be warned about and have capacity to understand the 
disulfiram-alcohol reaction and be made aware of the presence of alcohol in 
foodstuffs, perfumes, aerosols etc. In addition, they should not have consumed 
alcohol for at least 24 hours before staring disulfiram and should also be warned that 
a reaction with alcohol may be experienced for up to 7 days after their last tablet. The 
alcohol challenge test is no longer recommended (SPC; BNF). Fatal disulfiram-
alcohol reactions have occurred with high doses of the drug (>1 g per day) and were 
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associated with cardiovascular complications such as hypotension or QTc on the 
ECG (Chick 1999; Kristenson, 1995). With the lower doses now prescribed more 
severe reactions after consuming alcohol are less likely to be seen (Malcolm et al., 
2008). Indeed, a survey of patients taking disulfiram found that for some an 
interaction only occurred when taking 800 to 1500 mg per day (Brewer, 1984).  
 
The SPC or BNF lists several significant medical and psychiatric contraindications to 
its use, including cardiovascular problems, severe personality disorder, suicidal risk 
or psychosis, pregnancy, breast-feeding. Caution is also advised in the presence of 
renal failure, hepatic or respiratory disease, diabetes mellitus and epilepsy. 
Nevertheless, against this background there is some evidence of its prescribing in a 
broad range of conditions including possible contraindications such as those with 
psychotic disorders or cocaine dependence or on methadone with no reports of 
significant adverse effects (Petrakis et al., 2005; Petrakis et al., 2000; Pani et al., 2010).  
 
Concerning the side effects of disulfiram alone, there are many fewer trials 
compared with acamprosate or naltrexone and some are older hence descriptions 
may be less comprehensive. Where reported, side effects and adverse events or 
reactions experienced include drowsiness, fatigue, abdominal pain, nausea, 
diarrhoea. Psychiatric problems were reported in some studies such as dysphoria or 
psychosis but the incidence was low. In newer trials comparing disulfiram with 
acamprosate or naltrexone, the reporting of side effects or adverse events is not 
dramatically different between the active drugs or placebo. Neuropathy has been 
reported by some but not all studies with onset commonly described over months to 
a year, though within days has been described (see Chick, 1999). From the Danish 
database, the estimate of rate of neuropathy was 1 in 15 000 patient years (Poulsen et 
al., 1992) though De Sousa and colleagues (2005) reported that 3 of the 50 (6%) 
patients taking disulfiram in their trial dropped out due to neuropathy.  
 
Use of disulfiram may be associated with the development of an acute hepatitis, 
which can be fatal. The nature and exact incidence or prevalence of hepatotoxicity is 
unclear however it appears rare, for example, 30 reports of hepatitis in previous 40 
years (Chick, 1999), 11 fatal liver reactions in 22 years (1968 to 1991). Based on 
estimates of number of patients taking disulfiram, the estimated the risk of dying 
from hepatotoxicity caused by disulfiram as 1:30,000 patients per year. However, 
some patients received disulfiram for nickel sensitivity who are reportedly at greater 
risk of hepatitis than those receiving disulfiram for alcoholism. Hepatotoxicity at 250 
mg per day after 13 days has been described though a review found disulfiram-
related hepatitis starting 16 to 120 days later though in one case, jaundice appeared 
within 5 days after taking 1.5 to 2 g per day (that is, up to 10 times above 
recommended dose) (Chick, 1999). Given the seriousness of hepatitis, a role for 
monitoring of liver function has been suggested but there is limited evidence to 
inform guidance. It is therefore important that the patient understands about the risk 
of hepatotoxicity and to stop taking disulfiram and promptly seek medical attention 
if they have any concerns about side effects or start to feel unwell. 
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Psychiatric complications such as psychosis or confusional states are potentially 
serious side-effects or adverse events and are more likely at higher doses (>500 mg 
per day; Chick, 1999). The Danish and WHO databases report respectively 4% and 
13% of all adverse effects of disulfiram were psychiatric (Poulsen et al., 1992). One 
clinical trial reported over 1 year in over 600 people reported no difference in 
psychiatric complications between those treated with disulfiram 250 mg per day, or 
disulfiram 1 mg per day or placebo with the incidence in disulfiram groups at 2.4% 
(Branchey et al., 1987). Nevertheless, in recent trials disulfiram has been used in 
patients with a variety of psychiatric comorbidities including depression, psychosis 
or schizophrenia without apparent psychiatric adverse events (see Chick, 1999; 
Petrakis et al., 2005; 2006). The rate and quality of adverse events with cocaine and 
disulfiram are similar to those seen with studies of alcohol dependence (Pettinati, 
2005; Carroll et al., 1998). Disulfiram has been also been used in patients maintained 
on methadone without reported serious adverse reactions (Ling, 1983) 
 
The reader is directed to two comprehensive reviews regarding the safety of 
disulfiram by Chick, (1999) and Malcolm and colleagues (2008). 
7.14 REVIEW OF OTHER PHARMACOLOGICAL 
INTERVENTIONS NOT LICENSED IN THE UK FOR 
RELAPSE PREVENTION 
7.14.1 Aim of review 
The aim of this review was to assess the effectiveness of pharmacological 
interventions not licensed in the UK for the treatment of alcohol misuse. The GDG 
advised the review team that a large range of pharmacological interventions have 
been evaluated, often in single trials, with heterogeneous outcomes. Therefore, a 
narrative synthesis of RCTs was conducted, with no attempt to use meta-analysis. 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this section of the guideline can be found in Appendix 16e.  
7.14.2 Studies considered 
A total of nine trials met inclusion criteria for this section of the guideline. There 
were two trials of extended release injectable naltrexone, two trials of nalmefene, 
three trials of SSRIs, one current trial of baclofen which has indicated preliminary 
findings, and six trials of anti-convulsants (two of topiramate, three of gabapentin 
and one of pregabalin). 
7.14.3 Extended release injectable naltrexone  
In addition to oral naltrexone, an injectable formulation is available which has 
therefore an extended half-life and can overcome poor compliance.  
 
In the US, naltrexone is also available in a once monthly extended release injectable 
formulation (380 mg) and has been used by some in the UK. Two RCTs have been 
published regarding its efficacy and safety. Kranzler and colleagues (2004) studied a 
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depot formulation in patients who were still drinking but wanted to stop and 
showed no efficacy on the primary outcome of reduced heavy drinking days. A 
longer time to first drink and a higher rate of abstinence were reported. The second 
study compared the 380 mg injectable formulation with one containing 190 mg over 
6 months in still drinking alcoholics, and found reduced heavy drinking was seen in 
all groups but greatest in higher dose of naltrexone (Garbutt et al., 2005). In addition, 
greater efficacy was seen in men and in those that had been sober for a week before 
their injection. A post-hoc analysis revealed that naltrexone reduced alcohol 
consumption during holiday periods in the US, generally a time of great risk of 
relapse (Lapham et al., 2009). 
 
 Side effects or adverse effects of the extended injectable formulation are reported as 
similar to oral naltrexone and include abdominal pain, nausea, anorexia, dizziness 
although hepatic safety profile appears similar to placebo (Lucey et al., 2008). 
However, a greater number of injection site reactions with naltrexone have been 
reported which may need medical attention and be due to poor injection technique 
(Garbutt et al., 2009). 
7.14.4 Nalmefene 
Like naltrexone, nalmefene is an opioid antagonist but with some kappa partial 
agonist activity or inverse agonist activity. It was initially proposed as a treatment 
for alcohol dependence since it has a longer half-life and was thought to have less 
risk of hepatotoxicity then naltrexone. The first RCT in alcohol dependence reported 
significantly fewer relapses with nalmefene (20 mg or 80 mg per day; Mason et al., 
1999). However, a second multisite RCT comparing 5 mg per day, 20 mg per day 
with 40 mg per day and placebo reported no efficacy for nalmefene (Anton et al., 
2004).  
7.14.5 SSRIs 
The efficacy of SSRIs in treating alcohol misuse without comorbid depression has 
been studied in three RCTs. They reported that SSRIs may have limited efficacy but 
importantly may also reduce the impact of psychosocial treatments in improving 
alcohol misuse in early-onset alcohol dependence. Kranzler and colleagues (1996) 
reported worse drinking outcomes in early-onset or type B alcoholics on fluoxetine 
compared with placebo. Pettianti and colleagues (2000) found that sertraline had no 
effect in type B alcoholics, whilst improving outcomes in type A. Chick and 
colleagues (2000) reported that type II alcoholics, as defined by Cloninger‘s TPQ, had 
worse outcomes compared with those on placebo and type I alcoholics. Therefore, 
these three studies suggest that in the absence of a depressive disorder, SSRIs may 
weaken improvements in alcohol misuse.  
 
One RCT has investigated whether combining naltrexone with sertraline is effective 
in improving drinking behaviour in native and non-native Alaskan Americans by 
randomising patients to daily naltrexone (50 mg), sertraline (100 mg), naltrexone 
plus sertraline, or placebo (O‘Malley et al., 2002). Naltrexone significantly improved 
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abstinence rates rather than reducing the risk of heavy drinking whilst sertraline had 
no further benefit. 
 
Overall given the difficulties in making a diagnosis of depression in such a 
population, and the limited efficacy shown when comorbid depression is present, an 
SSRI may not be the most appropriate first line antidepressant to use in alcohol 
misuse.  
7.14.6 Baclofen 
Baclofen, a GABA-B agonist increases abstinence rates in patients with alcohol-
related cirrhosis compared with placebo (Addolorato et al., 2008; 30 mg per day; 12 
weeks). It was well tolerated with little contribution to dropouts due to side effects; 
there were no adverse events reported. We are aware of a large RCT conducted in 
the US whose results are yet to be formally published but some of the data has been 
reported and suggest no efficacy for baclofen (Leggio et al., 2010). Key differences 
between the studies which are likely to increase likelihood of efficacy are: goal of 
abstinence, alcohol dependence requiring medically assisted withdrawal, higher 
anxiety levels.  
7.14.7 Anticonvulsants 
Topiramate, an anticonvulsant with a rich pharmacology including increasing 
GABA and reducing glutamatergic activity, has been shown to reduce heavy 
drinking to promote abstinence (Johnson et al., 2003; 2007). Unlike other trials of 
medication, the medication was started whilst the patients were still drinking but 
who were aiming for abstinence. Baltieri and colleagues (2008) reported that patients 
receiving topiramate (up to 300 mg per day) showed significantly better drinking 
outcomes early in the 12 week trial but not at 12 weeks compared with placebo. In 
addition, there were no significant differences in drinking outcomes between 
topiramate and naltrexone (50 mg per day), though there were trends suggesting 
topiramate was the more effective. An issue for topiramate has been its side-effect 
profile such as paresthesia (up to 50%), dizziness, taste perversion, anorexia leading 
to weight loss, and difficulty with memory or concentration. In the largest multisite 
trial (Johnson et al., 2007), 67 of 183 did not complete the study, of 34 had a limited 
adverse event (almost 20%). The dose is 25 mg increasing to 300 mg per day. Side 
effects are more pronounced and likely at higher doses and with more rapid 
titration.  
Gabapentin and pregabalin 
There is interest in both gabapentin and pregabalin for treating alcohol dependence 
since they have anticonvulsant and anxiolytic properties. They bind to calcium 
channels and reduce calcium currents resulting in reduced activity. In relapse 
prevention, gabapentin has been shown to increase time to heavy drinking and 
reduce alcohol craving (Brower et al., 2008; Furieri &Nakamura-Palacios, 2007; 
Mason et al., 2009). A small open study showed people who misused alcohol given 
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pregabalin remained abstinent longer than those given naltrexone (Martinotti et al., 
2008).  
7.14.8 Clinical summary 
A number of pharmacological interventions not licensed for use in the treatment of 
moderate and severe alcohol dependence were also considered in the review. The 
evidence indicates that SSRIs do not improve drinking behaviour in non-depressed 
alcoholics and may worsen drinking related outcome as well as reduce the efficacy 
of psychosocial interventions. The initial evidence for the efficacy of injectable 
naltrexone is encouraging, particularly in those that may not be as compliant with 
oral naltrexone. However, at the current time there is not enough evidence to 
support its routine use. The evidence for Nalmefene is limited and inconclusive, 
with only two RCTs with contradictory reported efficacy. There is limited evidence 
of the efficacy of Baclofen as a pharmacological intervention for alcohol dependence. 
There is limited and contradictory evidence for the efficacy of anti-convulsants in the 
treatment of alcohol dependence. Gabapentin and pregabalin were found to have 
some efficacy for reducing drinking. However, for topiramate the evidence was 
limited and this beneficial effect was not always found after 12 weeks of treatment. 
Furthermore, the side effects caused by the use of topiramate mean that when it is 
used the individual most be closely monitored and other pharmacological 
interventions need to be considered. Overall, there is evidence from a number of 
trials that some of these pharmacological interventions can reduce drinking and 
craving and may reduce associated problems with anxiety and insomnia. However, 
the evidence is limited and there are trials currently underway which will inform 
their potential role as an adjunct to psychosocial approaches. 
7.15 FROM EVIDENCE TO RECOMMENDATIONS 
The GDG reviewed the evidence for the clinical effectiveness and cost effectiveness 
of naltrexone and acamprosate for relapse prevention in individuals with alcohol 
dependence. A review was also carried out on the clinical effectiveness of disulfiram 
for relapse prevention in individuals with alcohol dependence, however as the 
evidence was much weaker and the potential for harm was greater, the GDG did not 
consider disulfiram as a suitable first-line pharmacological treatment for relapse 
prevention in individuals with alcohol dependence. Therefore, disulfiram was not 
considered in the guideline economic analysis. 
 
The clinical evidence for acamprosate suggested that individuals were likely to 
benefit from an increased chance of remaining completely abstinent from alcohol 
within the treatment and follow-up periods. The amount of baseline drinking did 
not seem to have an impact on the effectiveness of acamprosate in preventing a lapse 
to drinking, but the studies included for the review on acamprosate was limited to 
studies where the participants were classed as at least moderately dependent. There 
was little evidence reviewed to show the effectiveness of acamprosate on harmful or 
mildly dependent drinkers. The studies reviewed mainly included a psychological 
treatment in addition to acamprosate. From the clinical evidence, the GDG decided 
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to recommend acamprosate for relapse prevention in moderately to severely 
dependent drinkers combined with a psychological intervention as indicated in the 
license agreement. 
 
The review of naltrexone for relapse prevention suggested a reduced likelihood of 
relapsing to heavy drinking in participants randomised to naltrexone instead of 
placebo. Further analysis also found that individuals drinking more at baseline were 
more likely to benefit from naltrexone in preventing relapse than individuals 
drinking lower baseline levels. The main evidence for naltrexone effectiveness was 
in reducing rates of relapse and reducing the amount of alcohol consumed, but the 
evidence for an effect on abstinence was more limited. The studies reviewed almost 
always included a psychological treatment in addition to naltrexone.  
 
For both acamprosate and naltrexone the GDG took the view that the psychological 
intervention provide in combination with either of the drugs should be one of those 
identified as effective in Chapter 6 (that is, BCT, CBT, BT or SNBT) as this was likely 
to bring the most benefit.  
 
There was limited evidence comparing acamprosate with naltrexone for relapse 
prevention, and there was little evidence to suggest a benefit of one drug over the 
other. In studies comparing acamprosate plus naltrexone compared with 
acamprosate alone, naltrexone alone or placebo, there were no significant differences 
in outcomes in favour of the combination. 
 
The network meta-analysis that was undertaken to inform the guideline economic 
analysis demonstrated that acamprosate had a lower probability of relapse over 12 
months follow-up, compared with naltrexone, when used as an adjunct to 
psychological therapy. (Note the use of combined acamprosate and naltraxone was 
not included in the economic model due to uncertainty about the data, including 
concerns about the safety of the combined option.) The guideline economic analysis 
also demonstrated that acamprosate had the highest probability of being the most 
cost-effective adjunctive pharmacological treatment for relapse prevention (52% at a 
willingness-to-pay threshold of £20,000 per QALY). However, the network meta-
analysis and economic analysis considered only relapse prevention as an outcome 
and not the greater impact of naltrexone on the severity of drinking. Because of this 
limitation of the analysis the GDG did not feel that acamprosate should be the drug 
of choice for the treatment of alcohol related problems.  
 
From the clinical and cost-effectiveness evidence, the GDG decided to recommend 
naltrexone for relapse prevention in moderately to severely dependent drinkers and 
as with acamprosate in combination with a psychological intervention. 
 
The clinical evidence for disulfiram in relapse prevention was weaker than for 
acamprosate and naltrexone, with the trials versus other active interventions being 
open label. The double blind evidence for disulfiram versus placebo, suggested little 
benefit for disulfiram in maintaining abstinence or reducing drinking, however 
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open-label studies showed a large effect in favour of disulfiram on these outcomes 
when comparing disulfiram to other pharmacological agents. 
 
Due to the weaker available evidence for disulfiram for relapse prevention and 
higher potential risks requiring monitoring, the GDG decided to recommend 
disulfiram as a second-line treatment option for moderate to severe alcohol 
dependence for patients who are not suitable for acamprosate or naltrexone or have 
specified a preference for disulfiram and who aim to abstain from alcohol. GDG 
consensus was that having the patient witnessed taking their disulfiram by a family 
member or carer would improve adherence to treatment. 
 
There is limited and inconclusive evidence for the use of SSRIs, injectable naltrexone, 
nalmefene, baclofen, and anti-convulsants in the treatment of moderate to severe 
alcohol dependence. In addition to the lack of evidence, some of these non-licensed 
drugs also have side-effect profiles which are detrimental to effectiveness of 
treatment. For example, topiramate (an anti-convulsant) has a number of adverse 
side effects and when used, requires careful titration and monitoring. For others, 
there is evidence of potential harm due to their abuse liability (for example, GHB) 
and hence these interventions should not be used in the treatment of alcohol 
dependence. Although there is some evidence of efficacy for nalmefene, baclofen 
and some anti-convulsants, the evidence does not indicate any clear advantage of 
these interventions over other pharmacological interventions licensed for use in the 
treatment of alcohol dependence. Therefore, in the absence of a clear advantage over 
safer medications, the GDG decided that these pharmacological interventions should 
not be used in routine clinical practice. 
 
In the absence of any significant high quality evidence on pharmacological 
interventions with children and young people as well as older people the GDG 
decided to extrapolate from on the adult evidence base.  
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7.15.1 Recommendations  
Interventions for moderate and severe alcohol dependence  after successful 
withdrawal 
7.15.1.1 After a successful withdrawal for people with moderate and severe alcohol 
dependence, consider offering acamprosate or oral naltrexone42 in 
combination with an individual psychological intervention (cognitive 
behavioural therapies, behavioural therapies or social network and 
environment-based therapies) focused specifically on alcohol misuse (see 
6.23.1.15–6.23.1.18). [KPI]  
 
7.15.1.2 After a successful withdrawal for people with moderate and severe alcohol 
dependence, consider offering acamprosate or oral naltrexone42 in 
combination with behavioural couples therapy to service users who have a 
regular partner and whose partner is willing to participate in treatment (see 
6.23.1.18).  
 
7.15.1.3 After a successful withdrawal for people with moderate and severe alcohol 
dependence, consider offering disulfiram43 in combination with a 
psychological intervention to service users who: 
 have a goal of abstinence but for whom acamprosate and oral 
naltrexone are not suitable, or  
 prefer disulfiram and understand the relative risks of taking the drug 
(see 7.15.1.18). 
 
Drugs not to be routinely used for the treatment of alcohol misuse  
7.15.1.4 Do not use antidepressants (including selective serotonin reuptake inhibitors 
[SSRIs]) routinely for the treatment of alcohol misuse alone. 
 
7.15.1.5 Do not use gammahydroxybutyrate (GHB) for the treatment of alcohol 
misuse. 
 
7.15.1.6 Benzodiazepines should only be used for managing alcohol withdrawal and 
not as ongoing treatment for alcohol dependence. 
 
                                                 
42 At the time of publication (February 2011), oral naltrexone did not have UK marketing 
authorisation for this indication. Informed consent should be obtained and documented. 
43 All prescribers should consult the SPC for a full description of the contraindications and the special 
considerations of the use of disulfiram. 
FINAL DRAFT 
 433 
 
Assisted withdrawal in children and young people  
7.15.1.7 Offer inpatient care to children and young people aged 10-17 years who 
need assisted withdrawal.  
 
7.15.1.8 Base assisted withdrawal for children and young people aged 10–17 years 
on the recommendations for adults (see 5.31.1.17–5.31.1.18)  and in NICE 
clinical guideline 100. Consult the SPC and adjust drug regimens to take 
account of age, height and body mass, and stage of development of the child 
or young person44. 
Delivering pharmacological interventions 
7.15.1.9 Before starting treatment with acamprosate, oral naltrexone45 or disulfiram, 
conduct a comprehensive medical assessment (baseline urea and electrolytes 
and liver function tests including gamma glutamyl transferase [GGT]). In 
particular, consider any contraindications or cautions (see the SPC), and 
discuss these with the service user. 
 
7.15.1.10 After a careful review of the risks and benefits, specialists may 
consider offering acamprosate46 or oral naltrexone47 in combination with 
cognitive behavioural therapy to young people aged 16 and 17 years who 
have not engaged with or benefited from a multicomponent treatment 
programme. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
44 If a drug does not have UK marketing authorisation for use in children and young people under 18, 
informed consent should be obtained and documented. 
45 At the time of publication (February 2011), oral naltrexone did not have UK marketing 
authorisation for this indication. Informed consent should be obtained and documented. 
46 At the time of publication (February 2011), acamprosate did not have UK marketing authorisation 
for this indication or for use in children and young people under 18. Informed consent should be 
obtained and documented. 
47 At the time of publication (February 2011), oral naltrexone did not have UK marketing 
authorisation for this indication or for use in children and young people under 18. Informed consent 
should be obtained and documented. 
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Acamprosate 
7.15.1.11 If using acamprosate, start treatment as soon as possible after assisted 
withdrawal. Usually prescribe at a dose of 1998 mg (666 mg three times a 
day) unless the service user weighs less than 60 kg, and then a maximum of 
1.332 mg should be prescribed per day. Acamprosate should: 
  usually be prescribed for up to 6 months, or longer for those benefiting 
from the drug who want to continue with it48 
 be stopped if drinking persists 4–6 weeks after starting the drug. 
7.15.1.12 Service users taking acamprosate should stay under supervision, at 
least monthly, for 6 months, and at reduced but regular intervals if the drug 
is continued after 6 months. Do not use blood tests routinely, but consider 
them to monitor for recovery of liver function and as a motivational aid for 
service users to show improvement. 
 
Naltrexone 
7.15.1.13 If using oral naltrexone49, start treatment after assisted withdrawal. 
Start prescribing at a dose of 25 mg per day and aim for a maintenance dose 
of 50 mg per day. Draw the service user‘s attention to the information card 
that is issued with oral naltrexone about its impact on opioid-based 
analgesics. Oral naltrexone should:  
 usually be prescribed for up to 6 months, or longer for those benefiting 
from the drug who want to continue with it 
 be stopped if drinking persists 4–6 weeks after starting the drug. 
7.15.1.14 Service users taking oral naltrexone22 should stay under supervision, at 
least monthly, for 6 months, and at reduced but regular intervals if the drug 
is continued after 6 months. Do not use blood tests routinely, but consider 
them for older people, for people with obesity, for monitoring recovery of 
liver function and as a motivational aid for service users to show 
improvement. If the service user feels unwell advise them to stop the oral 
naltrexone immediately. 
 
 
 
 
                                                 
48 At the time of publication (February 2011), acamprosate did not have UK marketing authorisation 
for use longer than 12 months. Informed consent should be obtained and documented. 
49 At the time of publication (February 2011), oral naltrexone did not have UK marketing 
authorisation for this indication. Informed consent should be obtained and documented. 
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Disulfiram 
7.15.1.15 If using disulfiram, start treatment at least 24 hours after the last 
alcoholic drink consumed. Usually prescribe at a dose of 200 mg per day. 
For service users who continue to drink, if a dose of 200 mg (taken regularly 
for at least 1 week) does not cause a sufficiently unpleasant reaction to deter 
drinking, consider increasing the dose in consultation with the service user. 
7.15.1.16 Before starting treatment with disulfiram, test liver function, urea and 
electrolytes to assess for liver or renal impairment. Check the SPC for 
warnings and contraindications in pregnancy and in the following 
conditions: a history of severe mental illness, stroke, heart disease or 
hypertension. 
7.15.1.17 Make sure that service users taking disulfiram: 
 stay under supervision, at least every 2 weeks for the first 2 months, 
then monthly for the following 4 months  
 if possible, have a family member or carer, who is properly informed 
about the use of disulfiram, oversee the administration of the drug 
 
 are medically monitored at least every 6 months after the initial 6 
months of treatment and monitoring. 
7.15.1.18 Warn service users taking disulfiram, and their families and carers, 
about: 
 the interaction between disulfiram and alcohol (which may also be 
found in food, perfume, aerosol sprays and so on), the symptoms of 
which may include flushing, nausea, palpitations and, more seriously, 
arrhythmias, hypotension and collapse 
 
 the rapid and unpredictable onset of the rare complication of 
hepatotoxicity; advise service users that if they feel unwell or develop a 
fever or jaundice that they should stop taking disulfiram and seek 
urgent medical attention. 
7.16 PHARMACOTHERAPY FOR LESS SEVERELY 
DEPENDENT AND NON-DEPENDENT DRINKERS 
7.16.1 Clinical review protocol  
A review of pharmacological interventions for individuals who are less severely 
dependent or non-dependent was conducted. Due to limited literature in this patient 
population, a meta-analysis of RCTs could not be conducted. Therefore, a narrative 
synthesis of the available evidence as well as GDG expert opinion is presented. 
Information about the databases searched and the inclusion/ exclusion criteria used 
for this section of the guideline can be found in Appendix 16e. See Table 106 for the 
clinical review protocol followed for this review.  
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Table 106: Clinical review protocol for less severely dependent or non-
dependent populations 
Electronic databases MEDLINE, EMBASE, CINAHL, PsycINFO, Cochrane Library  
Date searched Database inception to March 2010 
Study design RCTs 
Patient population At least 80% of the sample meet the criteria for alcohol mild 
dependence (50 to 70 drinks per week) or harmful alcohol use 
(30 to 50 drinks per week) 
Excluded populations Those drinking >70 drinks per week (moderate and severe 
dependence); hazardous drinkers  
Pregnant women 
Interventions Any pharmacological intervention  
Comparator  Any other intervention 
Critical outcomes Discontinuing treatment for any reason 
Discontinuing treatment due to adverse events 
Lapsing (returning to a drinking state) 
Relapsing (returning to a heavy drinking state) 
PDA 
Cumulative abstinence duration 
DDD 
Total drinks consumed during treatment period 
Total days of heavy drinking during treatment 
Time to first drink 
Time to heavy drinking day 
  
7.16.2 Evidence summary  
In general, psychosocial approaches should be offered to all individuals who are 
problematic drinkers. For those for whom that has not worked or who are mildly 
dependent, medication may be considered. However the only medication that has 
been studied in this population is naltrexone since its underlying neurobiology is to 
reduce the positive reinforcement or pleasure associated with drinking. Whilst the 
majority of the trials included in our meta-analyses were abstinent prior to starting 
naltrexone, when taken to reduce drinking, patients are still drinking with the aim 
that naltrexone will reduce consumption.  
 
Heinälä and colleagues (2001) investigated whether naltrexone (50 mg) started 
without assisted withdrawal in treatment seeking drinking alcoholics. They showed 
that in combination with coping skills but not supportive therapy, naltrexone 
reduced risk of relapse to heavy drinking but did not improve abstinence or time to 
first drink. In this study, abstinence was not emphasised as part of coping skills, but 
was in supportive therapy.  
 
In less severely dependent and non-dependent drinkers, naltrexone (50 mg per day) 
has been shown to reduce the likelihood of any drinking (Kranzler et al., 2003). 
Interestingly, if they were taking medication (naltrexone or placebo) in a targeted 
manner that is, when anticipating a high risk situation, greater reductions in heavy 
drinking days were seen compared with taking medication daily. A follow-up trial 
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confirmed ‗targeted‘ naltrexone reduced drinks per day, but only in men (Kranzler et 
al., 2009). Notably both trials excluded people who had an unsuccessful attempt to 
reduce their drinking.  
 
Leeman and colleagues (2008) reported in pilot open study in heavy drinking young 
adults (18 to 25 yrs old) that targeted naltrexone (25 mg in some) as an adjunct to 
counselling was well tolerated and reduced drinking suggesting that this might be a 
way forward to improve outcomes from counselling along.  
 
Karhuvaara and colleagues (2007) reported that in heavy drinkers having a problem 
controlling their drinking (some may have been dependent) that nalmefene (20 mg 
per day) similarly reduced the number of heavy drinking days.  
7.16.3 Clinical Summary 
The evidence is limited to support the use of medication (specifically naltrexone) to 
reduce drinking in non-dependent or mild dependence and does not demonstrate 
equivalence with psychological interventions for this group.  
7.16.4 From evidence to recommendations 
The GDG considered that given the limited evidence to support the use of 
naltrexone in reduce drinking in non-dependent or mild dependence that it should 
only be used where psychological interventions alone have been effective. It should 
be prescribed in conjunction with a psychological intervention.  
7.17 COMORBIDITIES  
7.17.1 Introduction  
Individuals presenting for treatment with alcohol misuse may also present with 
features of other psychiatric disorders, most commonly anxiety or depression. For 
many, these symptoms will be closely linked with their alcohol misuse and lessen 
when drinking is reduced or stopped. For this reason, it is important to target their 
alcohol misuse rather than just starting treatment for a comorbid psychiatric 
disorder. Such comorbidity is associated with a poorer prognosis (Verheul et al., 
1998; Bradizza et al., 2006; Mason & Lehert, 2010), to increased rates of relapse 
(Driessen et al., 2001), poorer medication compliance, lower treatment attendance 
rates and higher rates of self-harm and suicidal behaviours (Martinez-Raga et al., 
2000). 
 
There are a variety of treatment approaches for someone with comorbid alcohol 
dependence and psychiatric disorder but they all emphasise integrated treatment for 
both disorders. However, this is not always easy to achieve with thresholds for 
referral to ‗addiction services‘ and ‗psychiatric services‘ differing and lack of 
dedicated dual disorder service. In addition, addiction services vary in their 
psychiatric expertise. Provision varies considerably across the UK despite initiatives 
FINAL DRAFT 
 438 
 
(Mental Health Policy-DH, 2002). The NICE guideline on psychosis with substance 
misuse will cover psychosis and substance misuse.  
Psychological treatment approaches aimed at addressing Axis 1 and Axis 2 disorders 
have been increasingly developed but in many cases alcohol dependence remains a 
diagnosis of exclusion even though in many cases the comorbid psychopathology 
has preceded the diagnosis of alcohol dependence. On the basis of this, one might 
question whether or not relapse rates could be influenced were treatment for co 
morbid disorders provided at the same time as those provided for alcohol 
dependence. 
7.17.2 Clinical review protocol 
The review of pharmacological interventions where there is significant comorbidity 
is considered in this section. A systematic search and GDG knowledge was used to 
identify RCTs or meta-analyses of medication in non-psychotic psychiatric disorders. 
We did not undertake further synthesis of the data since, apart from in depression, 
the number, nature and quality of the studies did not permit this. Two meta-analyses 
of treating comorbidity of alcohol dependence and depression were drawn on. The 
expertise of the GDG was used to focus on key trials of relevance to current practice 
in the UK. Information about the databases searched and the inclusion/ exclusion 
criteria used for this section of the guideline can be found in Appendix 16e. A 
summary of the available evidence is described below.  
 
Table 107: Clinical review protocol for pharmacological interventions in 
the present of comorbidities  
Electronic databases MEDLINE, EMBASE, CINAHL, PsycINFO, Cochrane Library  
Date searched Database inception to March 2010 
Study design RCTs 
Patient population At least 80% of the sample meet the criteria for alcohol 
dependence or harmful alcohol use (clinical diagnosis or 
drinking >30 drinks per week); diagnosed comorbidities 
Excluded populations Hazardous drinkers and those drinking <30 drinks per week 
Pregnant women 
Interventions Any pharmacological intervention (excluding acamprosate, 
naltrexone and disulfiram)  
Comparator  Any other intervention 
Critical Outcomes Discontinuing treatment for any reason 
Discontinuing treatment due to adverse events 
Lapsing (returning to a drinking state) 
Relapsing (returning to a heavy drinking state) 
% days abstinent 
Cumulative abstinence duration 
Drinks per drinking day 
Total drinks consumed during treatment period 
Total days of heavy drinking during treatment 
Time to first drink 
Time to heavy drinking day 
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7.17.3 Alcohol misuse comorbid with a psychiatric disorder 
This section considers two approaches for using pharmacotherapy and psychological 
interventions. First, its use for treating the alcohol misuse in the context of a non-
psychotic psychiatric disorder and second for treating the comorbid psychiatric 
disorder.  
Pharmacological interventions 
There are limited studies of disulfiram, acamprosate or naltrexone in people with a 
psychiatric disorder and alcohol dependence. The largest randomised controlled 
study assessed the efficacy and safety of disulfiram and naltrexone in 254 people 
who misused alcohol with an Axis I psychiatric disorder (Petrakis et al., 2005). It was 
a heterogenous group with some individuals having more than one diagnosis. 
Individuals were randomised to naltrexone (50 mg per day) or placebo (double-
blind) but openly randomised to disulfiram (250 mg per day) or nothing resulting in 
4 groups: naltrexone alone, placebo alone, naltrexone+disulfiram, placebo 
+disulfiram. There was no overall advantage of one medication over the other, no 
advantage of the combination of both medications over placebo. However, the 
abstinence rate at 77% is very high.  
 
A series of secondary analyses were then conducted to compare patients with and 
without particular axis 1 disorders within the group. In those with PTSD (37%) 
compared with those without (63%), either naltrexone or disulfiram alone or 
together improved alcohol outcomes (Petrakis et al., 2006). PTSD symptoms also 
improved with those in disulfiram showing the greatest improvement. Those with 
PTSD were more likely to report GI, emotional or neurological side-effects. By 
comparison, the presence or absence of current depression did not influence 
outcomes (Petrakis et al., 2007).  
 
In depressed alcoholics, Pettinati and colleagues (2010) reported that the 
combination of sertraline and naltrexone resulted in better abstinence rates than with 
use of either medication alone or placebo (23.8%; c2=12.9, df=1, p=0.001). Notably 
there was no difference between the groups in improvements in depressive 
symptoms, though reported a trend favouring the combination (83% versus 58%; c2= 
6.1, df=1, p=0.014).  
Psychological interventions 
Standard CBT was applied in four of the trials to treat alcohol dependence in 
addition to anxiety symptoms, panic disorder, insomnia and bipolar disorder. 
Cognitive Behaviour Therapy failed to demonstrate any significant improvement in 
relapse rates or percentage days abstinence with regard to alcohol use but did 
provide evidence of significant reduction in anxiety and avoidance symptoms 
(Schadé et al., 2005), improved sleep (Currie et al., 2004), improved mood, medication 
compliance and attendance rates (Schmitz et al., 2002). One trial failed to provide any 
evidence that CBT reduced either anxiety symptoms or percentage days abstinent 
when compared with treatment as usual (Bowen et al., 2000) although this was 
FINAL DRAFT 
 440 
 
attributed, in part, to systemic resistance to introducing CBT into the setting and the 
subsequent poor planning associated with providing the intervention. 
 
Integrated CBT, offered in two trials, also appeared to demonstrate limited 
effectiveness when applied to a population diagnosed with alcohol dependence and 
major depressive disorder when compared with Twelve Step Facilitation. One study 
(Glasner-Edwards et al., 2007) failed to demonstrate any improvement in mood or 
percent days abstinent amongst participants receiving ICBT compared with those 
receiving Twelve Step Facilitation. 
 
A psychodynamic approach using Dynamic Deconstructive Therapy (Gregory et al., 
2008) was applied in one of the trials to treat alcohol dependence or abuse with BPD. 
In this trial, DDP was compared with treatment as usual and results demonstrated a 
statistically significant improvement over time on each of the measures including 
parasuicide behaviours, a reduction in alcohol and drug use and fewer admissions to 
hospital. Integrated Group Therapy (Weiss et al., 2007) was applied in one trial 
where it was compared with Group Drug Counselling. Analysis indicated that 
participants undertaking the Integrated Group Therapy revealed significantly fewer 
days of substance use during treatment and at follow-up with decreased alcohol use 
accounting for most of the differences between the groups. 
7.17.4 Treatment of the comorbid psychiatric disorder 
This section focuses on the pharmacological and combined pharmacological and 
psychological interventions treatment of comorbid disorders. The issue of 
psychological interventions alone for harmful or dependent alcohol misuse has been 
considered in Chapter 6.  
Depression  
Several studies and trials have been performed to assess the efficacy of 
antidepressants in comorbid alcohol and depression, issues concerning methodology 
such as small numbers, unclear diagnoses, short treatment times, limit interpretation 
and translation to routine clinical practice. Two meta-analyses were undertaken of 
antidepressants in comorbid depression, one with substance misuse which included 
eight studies with alcohol dependence (Nunes & Levin, 2004) and a second that 
looked at the same studies in addition to one by another group and also examined 
SSRIs and ‗other‘ antidepressants separately (Torrens et al., 2005).  
 
In their review, Nunes and Levin (2004) included trials where patients met standard 
diagnostic criteria for current alcohol or other drug use and a current unipolar 
depressive disorder. The principal measure of effect size was the standardised 
difference between means on the Hamilton Depression Scale (HDS). Their meta-
analysis reported that antidepressant medication exerts a modest (SMD 0.38 (95% CI, 
0.18 to 0.58) beneficial effect in reducing HDS score for patients with combined 
depressive- and substance-use disorders. Those with lower placebo response rates 
had larger effect sizes. In such studies, the depression was diagnosed after at least a 
week of abstinence. On the other hand, where studies included people whose 
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depression was transient and/or directly related to their substance misuse, the 
placebo rate was high. This supports the widely held clinical practice of waiting to 
start an antidepressant once an individual is abstinent, but suggests that a week 
rather than 2 to 3 weeks may be acceptable. In addition psychosocial interventions 
also contributed to reduced effect sizes which may have acted via improving mood 
directly or through reducing substance misuse. The overall effect size for 
improvements in substance misuse were small (0.25 [95% CI, 0.08 to 0.42]) with 
improvements observed in studies where the effect size in improving depression 
was >0.5. Although it was noted that abstinence was rarely sustained. They 
concluded that an antidepressant ‗is not a stand-alone treatment, and concurrent 
therapy directly targeting the addiction is also indicated‘. 
 
Torrens and colleagues (2005) included studies of alcohol dependence and 
depression where explicit diagnostic criteria and methods for assessing the presence 
of comorbid depression (major depression or dysthymia) were used. This meta-
analysis also failed to find an overall effect of antidepressants on depressive 
symptoms. However there was a significant effect pooling the three studies using 
‗other antidepressants‘ (imipramine, desipramine, nefazodone; OR= 4.15 [95% CI, 
1.35 to 12.75]), whereas no significant effect was seen for SSRIs (OR= 1.85 [95% CI, 
0.73 to 4.68]). However the meta-analysis revealed no significant effect on reduction 
in alcohol consumption. Torrens also note that cocaine misuse in addition to 
comorbid alcohol and depression, can result in greater levels of depression and 
poorer prognosis as reported in Cornelius and colleagues (1998). 
 
Therefore, these two meta-analyses are in broad agreement that antidepressants do 
not reduce alcohol misuse. Whilst antidepressant effect is modest at best, waiting 
even for a week of abstinence to establish the diagnosis improves outcomes for 
depression. This is likely due to any transient depression due directly to their alcohol 
misuse or withdrawal period improving.  
 
Nevertheless if an antidepressant is indicated, in view of several trials showing no or 
limited efficacy with SSRIs as opposed to more positive results with mixed 
noradrenergic-serotonergic antidepressants, choosing ones with similar 
pharmacology is worth considering. Such antidepressants include tricyclics but these 
may not be appropriate due to the risk of cardiotoxicity with alcohol, particularly in 
overdose. Newer mixed noradrenergic-serotonergic antidepressant drugs include 
mirtazapine. Unfortunately, there are only two preliminary studies investigating 
mirtazapine in comorbid alcoholism and depression. An open label naturalistic 
study showed that mirtazapine (dose ranged on average from 17 mg per day to 23 
mg per day) was associated with improved mood and craving for alcohol (Yoon et 
al., 2006). A randomised double-blind trial comparing mirtazapine (average dose 45 
mg per day) with amitriptyline (average dose 125 mg per day) found that both drugs 
improved mood and alcohol craving with no difference between them (Altintoprak 
et al., 2008).  
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Anxiety 
Despite how commonly alcoholism and anxiety are linked, few studies have 
investigated how to manage this challenging comorbidity. A comprehensive 
assessment is required to define how alcohol and anxiety are related. An assisted 
withdrawal is often required and a longer ‗tail‘ of a benzodiazepine may be given to 
manage their anxiety initially. It is reported that anxiety may take up to 6 –8 weeks 
to reduce after stopping drinking. Benzodiazepines are also indicated for treating 
anxiety but due to concerns about vulnerability to dependence (see section 7.17.5), 
their use needs careful consideration.  
 
A series of studies from the same group have shown that an SSRI, paroxetine, is safe 
and well tolerated in people with alcohol misuse or dependence who may be still 
drinking and that it can significantly reduce social phobia compared with placebo 
(Randall et al., 2001; Book et al., 2008; Thomas & McCambridge, 2008). However, 
improvements in alcohol outcomes were either not reported or were no different to 
those in the placebo group and nonsignificant during the study. For instance, 
Thomas and McCambridge (2008) found that although paroxetine successfully 
treated comorbid social anxiety, their drinking overall did not improve though their 
drinking to cope with anxiety reduced. This emphasises that improving a comorbid 
disorder does not necessarily lead to improved drinking and as with for depression, 
alcohol focussed treatment must be delivered.  
 
In another study, Randall and colleagues (2001) investigated how simultaneous CBT 
treatment of alcohol misuse and social anxiety disorder compared with CBT 
treatment of alcoholism alone. Although drinking outcomes improved in both 
groups, those who received simultaneous treatment showed less improvement. 
Notably, social anxiety showed equal improvement in both groups. Similarly, an 
RCT in abstinent alcohol dependent individuals with either social phobia or 
agoraphobia who received either intensive relapse prevention for alcoholism with or 
without a CBT anxiety programme plus an SSRI (fluvoxamine) was available if 
wanted resulted in reduced anxiety symptoms but no impact on alcohol outcomes 
(Schadé et al., 2005).  
 
A meta-analysis of five studies of buspirone in alcoholism and anxiety concluded 
that anxiety improved with buspirone, but not alcohol consumption (Malec et al., 
2007).  
 
Benzodiazepines are used in the treatment of anxiety, however their use in people 
with alcohol problems is generally regarded as inappropriate. Clearly any such 
prescribing should be done with due consideration and monitoring however their 
use may be the best option if their anxiety improves without adverse consequences 
on their drinking. Mueller and colleagues (2005) monitored the clinical course of 
patients in their anxiety research programme over 12 years and reported that there 
little misuse of benzodiazepines in those who have coexisting anxiety disorders and 
alcohol use disorders.  
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Post-traumatic stress disorder 
PTSD is a commonly associated with alcohol misuse (see NICE, 2005). Longitudinal 
studies have shown that PTSD often predates alcohol misuse. Treatment for their 
PTSD can improve their substance misuse but once dependent, this will need to be 
treated before the patient can benefit from trauma-focused psychological treatments. 
 
In a placebo-controlled trial of sertraline treatment of PTSD in individuals with 
comorbid alcohol dependence, sertraline improved symptoms of PTSD but 
decreased alcohol use in only a small subset of the study population (Brady et al., 
2002). A more recent, placebo-controlled trial compared sertraline with placebo in 
the treatment of PTSD with co-occurring alcohol dependence (Brady et al., 2005). 
Both groups demonstrated a significant decrease in alcohol use. Cluster analysis 
revealed that sertraline was better in those less severely dependent with early onset 
PTSD whilst those more severely dependent with later onset PTSD improved more 
with placebo. Closer examination of this trial revealed that alcohol consumption 
tended to start improving before or together with improvements in PTSD symptoms 
(Back et al., 2006). They concluded that PTSD symptoms could have a strong impact 
on alcohol consumption and that PTSD treatment may be important to optimize 
outcomes for those comorbid for PTSD and alcohol dependence. 
ADHD 
The prevalence of alcohol misuse is higher in adults with ADHD than general 
population (Upadhyaya, 2007). Some features of ADHD are similar to those seen in 
fetal alcohol syndrome or spectrum disorders (FASD) and a comprehensive history 
should be taken to establish whether FASD is implicated. There are treatment and 
prognostic implications because those with FASD may respond differently to 
psychostimulants (O‘Malley & Nanson, 2002).  
 
Whilst psychostimulants are the first line treatment for ADHD, their use in people 
with comorbid substance misuse is complex and either medication must be 
adequately supervised or an alternative found (see the NICE guideline on ADHD).  
 
A 3-month double-blind placebo controlled RCT in adults with ADHD and alcohol 
use disorders reported improved ADHD symptoms from atomoxetine compared 
with placebo (Wilens et al., 2008). However there were inconsistent effects on alcohol 
with reduced cumulative number of heavy drinking days but not increased time to 
relapse of heavy drinking.  
7.17.5 Comorbid alcohol and drug misuse  
This section covers pharmacotherapy of comorbidities where it either plays a 
significant role in management e.g, opioid dependence, or where pharmacotherapy 
has not been shown to be generally efficacious e.g, cocaine. It does not cover 
comorbidity with drugs of misuse where psychosocial approaches are preferable and 
pharmacotherapy does not play a significant role, for example, cannabis, ecstasy, 
ketamine.  
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Comorbid opioid and alcohol dependence 
Alcohol dependence is a common comorbidity in opioid dependence. People with 
both alcohol and opioid dependence are at particularly high risk of drug related 
death due to the combined sedative effects of alcohol and opioids in overdose. Staff 
managing people who are opioid dependent should therefore routinely identify 
alcohol dependence in people presenting for treatment of primary opioid 
dependence, and either treat the alcohol dependence or refer to appropriate 
specialist alcohol services. 
 
The reader is referred to the NICE guideline (2008a; 2008b) and Orange Guideline 
(DH, 2009) for guidance about managing opiate dependence and alcohol misuse. 
Optimisation of their substitute pharmacotherapy is important though it does not 
seem to influence drinking whether this is with buprenorphine or methadone. 
However, it is recommended that drug misusers who are also misusing alcohol 
should be offered standard alcohol treatments such as assisted withdrawal and 
alcohol-focused psychosocial therapies as appropriate. 
 
Concerning pharmacotherapy for relapse prevention, naltrexone is not an option 
unless the individual is also abstinent from opioids. There is a small study of 
disulfiram in methadone maintained opioid addicts with problem drinking (Ling et 
al., 1983). No benefit of disulfiram was shown but also no adverse events were 
reported.  
 
There are no published studies of acamprosate in opioid dependent populations. 
Given its good tolerability and safety, there is no reason why acamprosate cannot be 
used to support abstinence from alcohol after the appropriate medical assessment. 
 
The paucity of trials investigating pharmacotherapeutic options to reduce alcohol 
misuse in opioid dependence is notable.  
Comorbid cocaine and alcohol misuse 
If cocaine is taken with alcohol, cocaethylene is produced which has a longer half-life 
than cocaine leading to enhanced effects. For instance, taken together cocaine and 
alcohol can result in greater euphoria and increased heart rate compared with either 
drug alone (McCance-Katz et al., 1993; 1995; Pennings et al., 2002).  
 
The reader is directed to NICE guidance regarding psychosocial management of 
cocaine (NICE, 2007a) since there is limited evidence for efficacy of a broad range of 
pharmacotherapeutic approaches for cocaine misuse alone. There have been several 
trials of naltrexone and disulfiram in comorbid alcohol and cocaine misuse but none 
with acamprosate.  
 
Naltrexone does not appear to significantly improve outcomes when added to 
psychosocial approaches for cocaine or alcohol in comorbid dependence (Schmitz et 
al., 2004 & 2009; Pettinati et al., 2008a). A series of studies have reported that 
disulfiram in comorbid cocaine and alcohol dependence results in better retention in 
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treatment and longer abstinence from cocaine or alcohol (Carroll et al., 1998; 2000). 
Although the initial rationale was that by reducing alcohol consumption, cocaine use 
would also reduce, effects on cocaine now appear somewhat independent of changes 
in alcohol consumption (Carroll et al., 2004).  
Comorbid nicotine and alcohol dependence  
It is fair to say that conventional wisdom has been to ‗give up one vice at a time‘. The 
idea of stopping smoking and drinking alcohol concurrently has often not been 
encouraged. In addition, it is our clinical impression that most patients do not want 
to consider quitting smoking until they have achieved some sobriety. However, it is 
likely that since the smoking bans came into place and support to stop smoking has 
become more available, more alcoholics will be interested in stopping smoking.  
 
Those who have achieved long-term abstinence from alcohol, have similar quit rates 
to non-alcoholics (Hughes & Kalman, 2006; Kalman et al., 2010). However, the length 
of abstinence does influence outcome with quitting smoking less likely in those in 
the early months of sobriety. Two randomised trials comparing concurrent with 
sequential treatment for alcohol and nicotine have been conducted. Joseph and 
colleagues (2004) compared giving smoking cessation treatment concurrently with 
an intensive programme for alcohol versus delaying the smoking cessation 
programme for 6 months. Whilst there was no difference in smoking cessation 
(~16%) between the groups, those who received the delayed intervention had higher 
rates of alcohol abstinence. However, there were no group differences in time to first 
relapse or number of days drinking in previous 6 months. Kalman and colleagues 
(2001) showed higher (19% versus 8%), but non-significant, smoking quit rates in 
alcoholics receiving concurrent smoking cessation interventions compared with 
those who received this intervention at 6 weeks. Regarding drinking outcomes, those 
who had the later smoking cessation intervention had greater relapse rates.  
 
A meta-analysis of RCTs of smoking cessation intervention for people in treatment 
for or recovery from an addiction, 5 of which were primarily alcohol, concluded that 
there was no detrimental effect on substance use outcomes from combined treatment 
(Prochaska et al., 2004). Indeed smoking cessation interventions during substance 
misuse treatment seemed to improve rather than compromise long-term sobriety. 
Regarding smoking cessation, short-term abstinence looked promising but this was 
not sustained in the longer-term.  
 
Therefore evidence does not strongly support a particular approach or time for 
quitting smoking, but it is very important that it is considered as part of their care 
plan. Some suggest whilst it is difficult to know conclusively that concurrent 
treatment should be avoided, this is a possibility and therefore only offered if the 
patient requests it (Kodl et al., 2006). Others cite that there is a wealth of evidence to 
suggest that treatment for smoking does not interfere with recovery in substance 
misuse (Fiore et al., 2008).  
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Concerning pharmacotherapeutic strategies, (Kalman et al., 2010) reviewed all 
studies which include those both in alcohol abstinence and when still drinking. They 
suggest that more intensive treatment is needed because standard (weekly 
counselling plus 21-mg patch for 8 to 12 weeks) treatment does not produce good 
results in drinking or recently sober alcoholics. In the absence of trials, standard 
protocols can be followed however a comprehensive medical assessment of any 
individual is needed given contraindications/cautions for some pharmacotherapy 
that might be relevant in alcoholism eg bupropion – history of seizures, varenicline – 
close monitoring in those with psychiatric disorders (see BNF, SPC). 
 
A full assessment of smoking and their attitudes to changing their smoking 
behaviour and cessation should be explored at initiation and throughout treatment. 
For management of smoking cessation, please refer to the relevant NICE guidance 
about services, pharmacotherapeutic and behavioural/psychological approaches.  
7.17.6 Clinical evidence summary  
Whilst comorbidity with a psychiatric disorder or another substance is common, 
there were few studies investigating pharmacological treatments. Some studies were 
older and therefore diagnostic criteria differed from those undertaken more recently; 
a proportion were of poor quality with small numbers.  
 
In the RCTs that included patients with alcohol dependence and a variety of 
psychiatric disorders, no benefit of medication (naltrexone, disulfiram or 
combination) on improving alcohol consumption was found. However, the abstinent 
rate was much higher than would normally be seen in routine clinical practice. 
Secondary analyses reported no advantage of medication in improving alcohol 
consumption when comparing those currently depressed versus non-depressed but 
did show a beneficial effect in those with PTSD compared with those without. This 
emphasises the importance of treatment targeted at their alcohol misuse is key rather 
than hoping an antidepressant will improve their drinking by improving mood. 
Whilst there were no adverse effects on their psychiatric disorder, no significant 
benefits were apparent either. A more recent trial in comorbid alcohol dependence 
and depression found that naltrexone but not sertraline improved alcohol outcomes 
with mood similarly improving in all groups. There are no studies of acamprosate in 
comorbidity however it could be considered given its good safety profile. There is 
little consistent evidence for the use of psychological interventions for the treatment 
of alcohol dependence in people with comorbid psychiatric disorders. Where 
evidence of benefit from some psychological interventions was identified it was 
often from mixed drug and alcohol populations from small single studies and was 
not judged sufficient evidence on which to base a recommendation.  
 
The two meta-analyses of treatment of comorbid depression broadly came to the 
same conclusion that antidepressants had a modest to no effect on improving 
depressive symptoms in those who are not at least a week sober. The effect of the 
antidepressant on alcohol use was also of limited benefit and where there was some, 
abstinence was not sustained. In those with severe depression, antidepressants may 
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improve mood, but alcohol-focussed treatment is still required. There is little 
evidence to suggest which antidepressant is best, although one meta-analysis 
suggested that SSRI were less effective than those with a mixed serotonergic-
noradrenergic pharmacology. However some of these medications also carry 
adverse safety profiles with alcohol and there is insufficient evidence about the 
newer antidepressants. In the few studies in those with an anxiety disorder, whilst 
antidepressant medication may improve anxiety symptoms this was not associated 
with a beneficial effect on alcohol consumption. The evidence for those with either 
comorbid depression or anxiety suggests that focusing on managing their alcohol 
misuse at the start is key since whilst medication may help their anxiety or 
depression, improvements in their alcohol misuse will not necessarily follow.  
  
There were only a few studies about the role of pharmacotherapy in those with 
alcohol and illicit drug misuse. Treatment of their illicit drug misuse must be 
optimised using psychosocial and/or pharmacological approaches as appropriate 
whilst monitoring the effect this has on their alcohol consumption to ensure alcohol 
does not substitute for reducing illicit drug misuse. Their alcohol misuse must also 
be specifically addressed. Many individuals with alcohol misuse smoke heavily and 
should be offered support to stop. There is limited evidence to suggest whether 
alcohol and nicotine should be given up simultaneously or sequentially therefore 
patient preference should guide the decision. 
 
7.17.7 Evidence to Recommendations 
The GDG noted that symptoms of anxiety and depression are common in people 
with harmful alcohol use or alcohol dependence. However, for many people the 
symptoms remit once abstinence or a significant reduction in alcohol consumption 
has been achieved. In addition, treatment for comorbid disorders (depression and 
anxiety) whilst people are consuming significant levels of alcohol does not appear to 
be effective. However, a number of patients have comorbid disorders which do not 
remit when alcohol consumption is reduced. The GDG therefore recommend that 
the first step in treating some presenting with alcohol misuse and comorbid 
depression/anxiety is to first treat the alcohol problem. Given the presence a 
comorbid disorder following a reduction in alcohol consumption is associated with a 
poorer long-term prognosis, 3 to 4 weeks after abstinence is achieved an assessment 
of the presence and need for treatment for any comorbid depression or anxiety 
should be considered. Some people with depressive disorders will require 
immediate treatment for example those at significant risk of suicide, and the 
recommendations below should not on any way stand in way of immediate 
treatment being provided in such a situation. In reviewing evidence for comorbid 
disorders the GDG did not find any treatment strategies or adjustments that should 
be made because of the comorbid problem and in view of this decided to refer to the 
relevant NICE guidelines (see NICE guideline on common mental health problems; 
NICE, 2011b). Given high prevalence of smoking in people with alcohol related 
problems the GDG thought it was important to emphasise need for effective 
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treatment in this population. For people with comorbid drug and alcohol misuse and 
psychotic disorders see NICE guideline on (NICE, 2011a) 
 
7.17.8 Recommendations  
7.17.8.1 For people who misuse alcohol and have comorbid depression or anxiety 
disorders, treat the alcohol misuse first as this may lead to significant 
improvement in the depression and anxiety. If depression or anxiety 
continues after 3 to 4 weeks of abstinence from alcohol, assess the depression 
or anxiety and consider referral and treatment in line with the relevant NICE 
guideline for the particular disorder50. [KPI] 
7.17.8.2  Refer people who misuse alcohol and have a significant comorbid mental 
health disorder, and those assessed to be at high risk of suicide, to a 
psychiatrist to make sure that effective assessment, treatment and risk-
management plans are in place.  
7.17.8.3 For the treatment of comorbid mental health disorders refer to the relevant 
NICE guideline for the particular disorder, and:  
 or alcohol misuse comorbid with opioid misuse actively treat both 
conditions; take into account the increased risk of mortality with taking 
alcohol and opioids together51  
 for alcohol misuse comorbid with stimulant, cannabis52 or 
benzodiazepine misuse actively treat both conditions. 
  
Service users who have been dependent on alcohol will need to be 
abstinent, or have very significantly reduced their drinking, to benefit 
from psychological interventions for comorbid mental health disorders. 
                                                 
50 See ‗Depression: the treatment and management of depression in adults‘, NICE clinical guideline 90 
(2009), available from www.nice.org.uk/guidance/CG90 and ‗Generalised anxiety disorder and panic 
disorder (with or without agoraphobia)  in adults: management in primary, secondary and 
community care‘, NICE clinical guideline 113 (2011), available from 
www.nice.org.uk/guidance/CG113  
51 See ‗Drug misuse: opioid detoxification‘, NICE clinical guideline 52 (2007), available from 
www.nice.org.uk/guidance/CG52 and ‗Drug misuse: psychosocial interventions‘, NICE clinical 
guideline 51 (2007), available from www.nice.org.uk/guidance/CG51 
52 See ‗Drug misuse: psychosocial interventions‘. NICE clinical guideline 51 (2007), available from: 
www.nice.org.uk/guidance/CG51 
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7.17.8.4 For comorbid alcohol and nicotine dependence, encourage service users to 
stop smoking and refer to ‗Brief interventions and referral for smoking 
cessation in primary care and other settings‘ (NICE public health guidance 
1). 
7.17.9 Research recommendation 
7.17.9.1 For people who are dependent on alcohol, which medication is most likely 
to improve concordance and thereby promote abstinence and prevent 
relapse?  
This question should be answered by: a) an initial development phase in which a 
series of qualitative and quantitative reasons for non-compliance/discontinuing 
drugs used in the treatment of alcohol are explored; b) a series of pilot trials of novel 
interventions developed to address the problems identified in (a) undertaken to 
support the design of a series of definitive trials; c) a (series of) definitive trial(s) of 
the interventions that were successfully piloted in (b) using a randomised controlled 
design that reports short-term (for example, 3 months) and longer-term (for 
example, 18 months) outcomes. The outcomes chosen should reflect both observer 
and service user-rated assessments of improvement and the acceptability of the 
intervention. Each individual study needs to be large enough to determine the 
presence or absence of clinically important effects, and mediators and moderators of 
response should be investigated. 
Why this is important 
Rates of attrition in trials of drugs to promote abstinence and prevent relapse in 
alcohol dependence are high (often over 65%), yet despite this the interventions are 
still clinically and cost effective. Retaining more service users in treatment could 
further significantly improve outcomes for people who misuse alcohol and ensure 
increased effectiveness in the use of health service resources. The outcome of these 
studies may also help improve clinical confidence in the use of effective medications 
(such as acamprosate and naltrexone), which despite their cost effectiveness are 
currently offered to only a minority of service users who are eligible in the UK 
healthcare system. Overall, the results of these studies will have important 
implications for the provision of pharmacological treatment for alcohol misuse in the 
NHS. 
7.18 WERNICKE-KORSAKOFF SYNDROME 
7.18.1 Aim of review 
The following section draws on the review of Wernicke-Korsakoff syndrome (WKS) 
and is developed as part of the NICE (2010b) guideline on the management of 
alcohol-related physical complications including the management of acute 
withdrawal. The GDG failed to identify any evidence for specific interventions in 
WKS beyond prevention strategies using thiamine which are covered in the other 
guideline (NICE, 2010b). The GDG therefore adopted a consensus based approach to 
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the review of the literature, synthesizing previously published narrative reviews to 
assist in development of the recommendations for this guideline.  
7.18.2 Narrative summary 
Wernicke's encephalopathy (WE) is traditionally thought of as a disorder of acute 
onset characterised by nystagmus, abducent and conjugate gaze palsies, ataxia of 
gait, and a global confusional state, occurring together or in various combinations 
(Victor et al., 1989). Wernicke first described the disorder in 1881 and the symptoms 
he recorded included disturbances of eye movement, ataxia of gait, polyneuropathy, 
and mental changes including apathy, decreased attention span and disorientation 
in time and space. Work by Alexander (1939) and then Jolliffe (1941) established that 
a deficiency in thiamine (vitamin B1) was central to causation and potential 
treatment of the disorder (Lishman, 1998). Korsakoff gave the first comprehensive 
account of the amnestic syndrome now known as Korsakoff psychosis (KP) in 1887 
which includes features such as delirium, but is characterised by recent memory loss 
with confabulation but with relative preservation of other intellectual functions. 
More recent work has highlighted a retrograde memory impairment with a 
‗temporal gradient‘, such that earlier memories are recalled better than more recent 
ones (Kopelman et al., 2009). The two disorders were brought together by Victor and 
colleagues in 1971 (Victor et al., 1971) and Wernicke-Korsakoff syndrome (WKS) is 
now considered to be a unitary disorder comprising acute WE which proceeds in a 
proportion of cases to KP. A major complicating factor is that the pathology of WE 
may not be associated with the classical clinical triad (see above) in up to 90% of 
patients (Harper et al., 1986). Therefore, it has been suggested that a presumptive 
diagnosis of WE should be made for any patient with a history of alcohol 
dependence who may be at risk. This includes anyone showing evidence of 
ophthalmoplegia, ataxia, acute confusion, memory disturbance, unexplained 
hypotension, hypothermia, coma, or unconsciousness (Cook, 2000).  
 
Untreated, WE leads to death in up to 20% of cases (Harper, 1979, Harper et al., 
1986), or KP in up to 85% of the survivors. A quarter of the latter group may then 
require long-term institutionalization (Victor et al., 1989). Furthermore, the incidence 
of KP has been reported to be rising in some parts of the UK (Ramayya & Jauhar, 
1997). For the reasons mentioned above it is probable that WE is under-diagnosed 
and inadequately treated in hospital, let alone in the community (Thomson & 
Marshall, 2006). We therefore do not know how often patients with alcohol 
dependence in the community unnecessarily suffer brain damage.  
 
Cognitive impairment is common in people with chronic alcohol use disorders, with 
between 50% and 80% experiencing mild to severe cognitive deficits (Bates et al., 
2002). The clinical and neuropsychological features of alcohol-related brain damage 
(ARBD) are well described, and the deficits appear to centre on visuospatial 
coordination, memory, abstract thinking and learning new information, with general 
knowledge, over-rehearsed information and verbal skills largely spared (Lishman, 
1998). Attempts have been made to describe the unique features of ‗alcoholic 
dementia‘ (Oslin & Cary, 2003), but there is a lack of evidence linking any specific 
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neuropathology with heavy alcohol intake (Joyce, 1994). A range of potential factors 
have been implicated in the causation of ARBD, including direct alcohol 
neurotoxicity, thiamine deficiency, traumatic brain injury, familial alcoholism, 
childhood psychopathology, age and education (Bates et al., 2002). Studies in people 
with features suggestive of WE have shown that their memory and general 
intellectual function are roughly equivalent (Bowden, 1990). Therefore, the effects of 
thiamine deficiency on cognition are more widespread than amnesia, with effects on 
visuospatial and abstracting functions being indicated (Jacobson et al., 1990).  
 
The mechanism by which chronic heavy alcohol consumption causes thiamine 
deficiency is by increasing metabolic demand, decreasing dietary intake and 
reducing hepatic storage capacity due to liver damage (Cook et al., 1998, Thomson et 
al., 1987). Brain cells require three thiamine-dependent enzymes to metabolise 
glucose (transketolase, pyruvate dehydrogenase complex, and α-ketoglutarate 
dehydrogenase) (Butterworth, 1989), and a deficiency of thiamine reduces the 
activity of these enzymes leading to brain cell death and reduced cognitive function 
(Butterworth, 1989). Cognitive impairment due to subclinical WKS in alcohol 
dependence may therefore be responsive to thiamine therapy. Abstinence can also 
improve cognition and therefore it remains the mainstay of any effective prevention 
programme. This is important as apart from thiamine there are no established 
pharmacotherapeutic strategies to specifically prevent impairment of or improve 
cognition once a deficit has been established.  
 
For those with established WKS appropriate rehabilitation, usually in supported 
accommodation for those with moderate and severe impairment is the correct 
approach as there is some evidence to suggest that people with WKS are capable of 
new learning, particularly if they live in a calm and well-structured environment 
and if new information is cued (Kopelman et al., 2009). There have been a few case 
reports of using medications to treat dementia in WKS with mixed results (Luykx et 
al., 2008; Cochrane et al., 2005). In an open study, the noradrenergic antidepressant, 
reboxetine did appear to improve cognitive performance in those who had WKS for 
less than a year (Reuster et al., 2003). Fluvoxamine has been shown to improve 
memory consolidation and/or retrieval in patients with WKS (Martin et al., 1995b). 
 
The NICE (2010b) guideline on the management of alcohol-related physical 
complications made recommendations about patients who did not have clinical 
features of WE, but were at high risk of developing it. They identified a high risk 
group who may be characterised by the following features:  
 alcohol-related liver disease  
 medically-assisted withdrawal from alcohol (planned or unplanned) 
 acute alcohol withdrawal 
 malnourishment or risk of malnourishment; this may include; 
o o weight loss in past year 
o o reduced BMI 
o o loss of appetite 
o o nausea and vomiting  
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o o a general impression of malnourishment  
 homelessness 
  hospitalised for acute illness 
 hospitalised for comorbidity or another alcohol issue.  
 
From the perspective of acute inpatient care, the Royal College of Psychiatrists‘ 
guideline also recommended the use of intramuscular thiamine because the group 
had concerns about the absorption of oral thiamine in a group undergoing assisted 
withdrawal. There is also a problem of lack of compliance with oral preparations in 
patients drinking heavily in the community, and so some authors advocate a choice 
between intravenous and intramuscular thiamine therapy (Thomson & Marshall, 
2006). Intramuscular Pabrinex has a lower incidence of anaphylactic reactions than 
the intravenous preparation at 1 per 5 million pairs of Pabrinex ampoules, which is 
far lower than many frequently used drugs that carry no special warning in the BNF 
(Thomson & Cook, 1997; Thomson & Marshall, 2006).  
 
Relatively little is also known about the outcomes of treatment of alcoholic Korsakoff 
syndrome. The large case study by Victor and colleagues (1971) reported that 25% 
recovered, 50% showed improvement over time and 25% remained largely 
unchanged. Other authors also believe that some improvement does occur in 
approximately 75% of patients over a number of years is they remain abstinent from 
alcohol (Kopelman et al., 2009). There is little evidence from research studies to 
design and inform effective rehabilitation specifically in WKS (Smith & Hillman, 
1999) although strategies developed in cognitive rehabilitation for a range of 
cognitive impairments may be of value (Cicerone et al., 2005). 
 
7.18.3 Evidence into recommendations 
The GDG accepted the evidence that thiamine as a key preventative role in WKS and 
adapted the recommendations developed by the Royal College of Psychiatrists 
group and developed the recommendation to take account of thiamine‘s use in a 
community based populations. The principle that due to the high risk of long term 
brain injury and the potentially serious consequences of WE, a high index of 
suspicion for WE be adopted and thiamine prescribed accordingly. A number of at 
risk groups are specified in the recommendation. The GDG also considered the care 
of people with established WKs and subsequent cognitive impairment. The limited 
data available suggested that continued abstinence from alcohol and a supportive 
and structured environment may have some beneficial effects for people with WKS 
and given the high morbidity and mortality in this group the GDG thought that that 
supported residential placement or for the those with mild impairment and 24 hour 
care for those with severe impairments should be made available.  
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7.18.4 Recommendations  
7.18.4.1 Follow the recommendations in NICE clinical guideline 100 on thiamine for 
people at high risk of developing, or with suspected, Wernicke‘s 
encephalopathy. In addition, offer parenteral thiamine followed by oral 
thiamine to prevent Wernicke-Korsakoff syndrome in people who are 
entering planned assisted alcohol withdrawal in specialist inpatient alcohol 
services or prison settings and who are malnourished or at risk of 
malnourishment (for example, people who are homeless) or have 
decompensated liver disease. 
7.18.4.2 For people with Wernicke-Korsakoff syndrome, offer long-term placement 
in: 
 supported independent living for those with mild cognitive 
impairment 
 supported 24-hour care for those with moderate or severe cognitive 
impairment. 
In both settings the environment should be adapted for people with cognitive 
impairment and support should be provided to help service users maintain 
abstinence from alcohol. 
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APPENDIX 1: SCOPE FOR THE DEVELOPMENT OF THE 
CLINICAL GUIDELINE 
1 Guideline title 
Alcohol dependence and harmful use: diagnosis, assessment and management of 
harmful drinking and alcohol dependence 
1.1 Short title 
Alcohol dependence and harmful alcohol use 
 
2 Background 
a) The National Institute for Health and Clinical Excellence (‗NICE‘ or ‗the 
Institute‘) has commissioned the National Collaborating Centre for Mental 
Health to develop a clinical guideline on alcohol dependence and harmful 
alcohol use for use in the NHS in England and Wales. This follows referral of the 
topic by the Department of Health. The guideline will provide recommendations 
for good practice that are based on the best available evidence of clinical and cost 
effectiveness. 
b) NICE clinical guidelines support the implementation of National Service 
Frameworks (NSFs) in those aspects of care where a Framework has been 
published. The statements in each NSF reflect the evidence that was used at the 
time the Framework was prepared. The clinical guidelines and technology 
appraisals published by NICE after an NSF has been issued have the effect of 
updating the Framework. 
c) NICE clinical guidelines support the role of healthcare professionals in 
providing care in partnership with patients, taking account of their individual 
needs and preferences, and ensuring that patients (and their carers and families, 
if appropriate) can make informed decisions about their care and treatment. 
3 Clinical need for the guideline  
a) There are two main sets of diagnostic criteria in current use, the International 
Classification of Mental and Behavioural Disorders 10th revision (ICD–10) and the 
Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM–IV). The 
ICD–10 definition of alcohol dependence (alcohol dependence syndrome) makes 
reference to a cluster of physiological, behavioural, and cognitive phenomena in 
which the use of alcohol takes a much higher priority than other behaviours. The 
DSM–IV defines a person with alcohol dependence as someone who continues 
the use of alcohol despite significant alcohol-related problems. In terms of 
harmful alcohol use, the ICD–10 defines 'harmful use‘ as a pattern of drinking 
that causes damage to physical and mental health. 
b) Psychiatric disorders and problems associated with alcohol dependence and 
harmful alcohol use include: depression, anxiety, personality disorders, post-
traumatic stress disorder, drug misuse, self-harm, suicide and brain damage. 
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Alcohol use disorders are also associated with a wide range of physical 
problems, including liver disease, various cancers, heart disease and stroke. 
c) The Alcohol Needs Assessment Research Project estimated that 38% of men and 
16% of women aged between 16 and 64 have an alcohol use disorder, and that 
6% of men and 2% of women have alcohol dependence. There is a lack of reliable 
UK data on prevalence rates of alcohol use disorders in children. 
4 The guideline 
a) The guideline development process is described in detail in two publications 
that are available from the NICE website (see ‗Further information‘). ‗The 
guideline development process: an overview for stakeholders, the public and the 
NHS‘ describes how organisations can become involved in the development of a 
guideline. ‗The guidelines manual‘ provides advice on the technical aspects of 
guideline development. 
d) This scope defines what this guideline will (and will not) examine, and what the 
guideline developers will consider. The scope is based on a referral from the 
Department of Health. 
e) The areas that will be addressed by the guideline are described in the following 
sections. 
4.1 Population  
4.1.1 Groups that will be covered 
a) Young people (10 years and older) and adults with a diagnosis of alcohol 
dependence or harmful alcohol use.  
4.1.2 Groups that will not be covered 
a) Children younger than 10 years. 
 
b) Pregnant women.  
4.2 Healthcare setting 
a) Care provided by primary, community and secondary healthcare and social care 
professionals who have direct contact with, and make decisions concerning, the 
care of young people and adults with alcohol dependence or harmful alcohol 
use. This will include: 
 care in general practice 
 community- and residential-based care, including inpatient treatment 
and rehabilitation 
 the primary/secondary care interface 
 transition through the range of healthcare services from childhood to 
older adulthood  
 the criminal justice system, including prison healthcare. 
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b) This is a guideline for alcohol services funded by or provided for the NHS. It will 
make recommendations for services provided within the NHS, social services, 
the independent sector and non-statutory services.  
4.3 Clinical management 
4.3.1 Areas that will be covered by the guideline 
b) Definitions of alcohol dependence and harmful alcohol use according to the 
main diagnostic classification systems (ICD–10 and DSM–IV).  
c) Early identification of alcohol dependence or harmful alcohol use in people in at-
risk populations, in particular treatment-seeking populations, and identification 
of factors that should lead to investigation into the possibility of alcohol 
dependence or harmful alcohol use (please refer also to the prevention and 
clinical management guidance currently under development, see section 5). 
d) Identifying people with alcohol dependence and harmful alcohol use in clinical 
practice, including the sensitivity and specificity of different methods, and 
thresholds. 
e) Assessment, including identification and management of risk, and assessment of 
severity of alcohol-related problems, dependence and alcohol withdrawal. 
f) Development of appropriate care pathways that support the integration of other 
NICE guidance on the management, treatment and aftercare of alcohol misuse. 
g) The range of care routinely available in the NHS. 
h) Pharmacological interventions, for example, initiation and duration of treatment, 
management of side effects and discontinuation. Specific pharmacological 
treatments considered will include: 
 opioid antagonists (naltrexone and nalmefene) 
 acamprosate 
 disulfiram 
 topiramate 
 baclofen 
 chlordiazepoxide 
 serotogenic agents (selective serotonin reuptake inhibitors and 
serotonin-3 receptor antagonist, ondansetron). 
i) Note that guideline recommendations will normally fall within licensed 
indications; exceptionally, and only if clearly supported by evidence, use outside 
a licensed indication may be recommended. The guideline will assume that 
prescribers will use a drug's summary of product characteristics to inform their 
decisions for individual patients. 
j) Common psychological and psychosocial interventions currently provided, for 
example, 12-step programmes, cognitive behavioural therapy, motivational 
enhancement therapy, relapse prevention, contingency management and 
community reinforcement approach. 
k) Low intensity psychological interventions, for example, referral to Alcoholics 
Anonymous and guided self-help. 
FINAL DRAFT 
 459 
 
l) Combined pharmacological and psychological/psychosocial treatments. 
m) Management of alcohol withdrawal in community and residential settings. 
n) Management of common mental health problems and drug misuse in the context 
of alcohol dependence, if this differs from their management alone.  
o) Prevention and management of neuropsychiatric complications of alcohol 
dependence or harmful alcohol use including: 
 alcohol related brain damage 
 Wernicke–Korsakoff syndrome. 
p) Sensitivity to different beliefs and attitudes of people of different genders, races 
and cultures, and issues of social exclusion. 
q) The role of family and carers in the treatment and support of people with alcohol 
dependence and harmful alcohol use (with consideration of choice, consent and 
help), and support that may be needed by family and carers (such as conjoint 
marital therapy and family therapy). 
r) The Guideline Development Group will consider making recommendations on 
complementary interventions or approaches to care relevant to alcohol 
dependence and harmful alcohol use. 
s) The Guideline Development Group will take reasonable steps to identify 
ineffective interventions and approaches to care. If robust and credible 
recommendations for re-positioning the intervention for optimal use, or 
changing the approach to care to make more efficient use of resources, can be 
made, they will be clearly stated. If the resources released are substantial, 
consideration will be given to listing such recommendations in the ‗Key 
priorities for implementation‘ section of the guideline. 
4.3.2 Areas that will not be covered by the guideline 
a) Treatments not normally made available by the NHS. 
b) The separate management of comorbid conditions. 
c) The management of acute alcohol withdrawal in the emergency department and 
general medical and surgical settings. This will be covered in 'Alcohol-use 
disorders in adults and young people: clinical management' (publication 
expected May 2010).  
d) The prevention and management of Wernicke's encephalopathy. This will be 
covered in 'Alcohol-use disorders in adults and young people: clinical 
management' (publication expected May 2010). 
4.4 Status 
4.4.1 Scope 
 This is the final scope.  
4.4.2 Guideline 
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 The development of the guideline recommendations will begin in 
March 2009. 
 
5 Further information 
 The guideline development process is described in:  
 ‗The guideline development process: an overview for stakeholders, the 
public and the NHS‘  
 ‗The guidelines manual‘.  
 These are available from the NICE website 
(www.nice.org.uk/guidelinesmanual). Information on the progress of 
the guideline will also be available from the website. 
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APPENDIX 2: DECLARATIONS OF INTERESTS BY GUIDELINE 
DEVELOPMENT GROUP MEMBERS 
With a range of practical experience relevant to alcohol dependence in the GDG, 
members were appointed because of their understanding and expertise in healthcare 
for people with alcohol dependence and support for their families and carers, 
including: scientific issues; health research; the delivery and receipt of healthcare, 
along with the work of the healthcare industry; and the role of professional 
organisations and organisations for people with alcohol dependence and their 
families and carers. 
 
To minimise and manage any potential conflicts of interest, and to avoid any public 
concern that commercial or other financial interests have affected the work of the 
GDG and influenced guidance, members of the GDG must declare as a matter of 
public record any interests held by themselves or their families which fall under 
specified categories (see below). These categories include any relationships they 
have with the healthcare industries, professional organisations and organisations for 
people with alcohol dependence and their families and carers. 
 
Individuals invited to join the GDG were asked to declare their interests before being 
appointed. To allow the management of any potential conflicts of interest that might 
arise during the development of the guideline, GDG members were also asked to 
declare their interests at each GDG meeting throughout the guideline development 
process. The interests of all the members of the GDG are listed below, including 
interests declared prior to appointment and during the guideline development 
process. 
 
Categories of interest 
 Paid employment 
 Personal pecuniary interest: financial payments or other benefits from either the 
manufacturer or the owner of the product or service under consideration in this 
guideline, or the industry or sector from which the product or service comes. This 
includes holding a directorship, or other paid position; carrying out consultancy 
or fee paid work; having shareholdings or other beneficial interests; receiving 
expenses and hospitality over and above what would be reasonably expected to 
attend meetings and conferences. 
 Personal family interest: financial payments or other benefits from the 
healthcare industry that were received by a member of your family.  
 Non-personal pecuniary interest: financial payments or other benefits received 
by the GDG member‘s organisation or department, but where the GDG member 
has not personally received payment, including fellowships and other support 
provided by the healthcare industry. This includes a grant or fellowship or other 
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payment to sponsor a post, or contribute to the running costs of the department; 
commissioning of research or other work; contracts with, or grants from, NICE. 
 
 Personal non-pecuniary interest: these include, but are not limited to, clear 
opinions or public statements you have made about alcohol dependence, holding 
office in a professional organisation or advocacy group with a direct interest in 
alcohol dependence, other reputational risks relevant to alcohol dependence. 
 
Declarations of interest 
Professor Colin Drummond - Chair, Guideline Development Group 
Employment Professor of Addiction Psychiatry and 
Honorary Consultant Addiction 
Psychiatrist, National Addiction Centre, 
Institute of Psychiatry, King's College 
London, and South London and Maudsley 
Foundation NHS Trust 
Personal pecuniary interest None 
Personal family interest None 
Non-personal pecuniary 
interest 
In receipt of research grants on alcohol 
research from the Medical Research 
Council, the European Commission, the 
Department of Health, the Home Office, the 
Scottish Government, and WHO (declared 
December 2008). 
 
A member of the WHO Expert Committee 
on Alcohol Problems and receive travel and 
subsistence while working for WHO 
(declared December 2008). 
 
I have received an educational grant from 
Alkermes Inc. (manufacturers of Vivitrol) to 
the value of £5,000 in 2008 which is held at 
the Institute of Psychiatry (declared 
December 2008). 
Personal non-pecuniary 
interest 
None 
Mr Adrian Brown 
Employment Alcohol Nurse Specialist, St Mary‘s 
Hospital, Imperial College 
Personal pecuniary interest Consultancy- attending focus groups of 
professionals and acting as ‗expert‘ on site 
at conference presentation. Archimedes 
Pharma- educational material for Wernicke-
Korsakoff and Pabrinex. Received £250 + 
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£550 and travel for two events (declared 
July 2009). 
Personal family interest None 
Non-personal pecuniary 
interest 
None 
Personal non-pecuniary 
interest 
None 
Professor Alex Copello 
Employment Professor of Addiction Research, University 
of Birmingham 
Personal pecuniary interest None 
Personal family interest None 
Non-personal pecuniary 
interest 
None 
Personal non-pecuniary 
interest 
None 
Dr Edward Day 
Employment Senior Lecturer and Consultant in 
Addiction Psychiatry, University of 
Birmingham 
Personal pecuniary interest None 
Personal family interest None 
Non-personal pecuniary 
interest 
None  
Personal non-pecuniary 
interest 
I am a principal investigator on two grants 
in the substance misuse field (ACTAS study 
and COMBAT studies). I have published 
papers on alcohol detoxification, 
management of Wernicke-Korsakoff 
syndrome and liver transplantation for 
alcoholic liver disease (declared March 
2009). 
Mr John Dervan 
Employment Lay member and retired Alcohol Treatment 
Agency CEO 
Personal pecuniary interest None  
Personal family interest None  
Non-personal pecuniary 
interest 
None  
Personal non-pecuniary 
interest 
Trustee, CASA Alcohol Services.  
(declared January 2009). 
Ms Jan Fry 
Employment Carer Representative and voluntary sector 
consultant 
Personal pecuniary interest None  
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Personal family interest None  
Non-personal pecuniary 
interest 
None  
Personal non-pecuniary 
interest 
None  
Mr Brendan Georgeson 
Employment Treatment Coordinator, Walsingham 
House, Bristol 
Personal pecuniary interest None 
Personal family interest None 
Non-personal pecuniary 
interest 
None  
Personal non-pecuniary 
interest 
Individual member of The Federation of 
Drug and Alcohol Professionals (declared 
January 2009). 
 
Member of the Society for the Study of 
Addiction (declared January 2009). 
 
Associate Member of the Institute of 
Healthcare Management (declared January 
2009). 
 
Trustee of Positive Images, a charity that 
uses film production to produce 
mentoring/training resources (declared 
April 2010). 
Dr Eilish Gilvarry 
Employment Consultant Psychiatrist (with specialist 
interest in adolescent addictions), and 
Assistant Medical Director, 
Northumberland, Tyne & Wear NHS 
Foundation Trust 
Personal pecuniary interest None 
Personal family interest None  
Non-personal pecuniary 
interest 
None  
Personal non-pecuniary 
interest 
None  
Ms Jayne Gosnall 
Employment Service User Representative and Treasurer 
of Salford Drug and Alcohol Forum 
Personal pecuniary interest None  
Personal family interest None  
Non-personal pecuniary 
interest 
None  
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Personal non-pecuniary 
interest 
 
None  
Dr Linda Harris 
Employment Clinical Director Wakefield Integrated 
Substance Misuse Service and Director of 
the RCGP Substance Misuse Unit 
Personal pecuniary interest None  
Personal family interest None  
Non-personal pecuniary 
interest 
In receipt of an educational grant from 
Schering Plough to support clinical 
leadership development support across the 
health and social care stakeholder groups 
working in the Wakefield Integrated 
Substance Misuse Service. This is being 
delivered in the full knowledge of the local 
PCT and is being conducted within ABPI 
guidance (declared January 2009). 
 
A grant has been deployed to fund an 
independent management consultancy firm 
called Healthskills Consulting Ltd, who 
have supported leadership development 
and O & D of the drug misuse treatment 
system. ABPI rules obeyed and PCT aware 
(declared March 2009). 
 
Over the years RCGP SMU has been in 
receipt of educational grants to support 
specials substance misuse workforce 
development and training standards 
(declared March 2009). 
Personal non-pecuniary 
interest 
None 
Dr John Lewis (Co-opted specialist paediatric adviser) 
Employment Consultant Community Paediatrician, Royal 
Cornwall Hospitals Trust 
Personal pecuniary interest None  
Personal family interest None  
Non-personal pecuniary 
interest 
None  
Personal non-pecuniary 
interest 
None  
Professor Anne Lingford-Hughes 
Employment Professor of Addiction Biology,  
Imperial College London and Central North 
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Janssen-Cilag; Paid speaker: educational 
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(declared January 2009). 
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Personal family interest None 
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alcohol detox (declared July 09).  
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Shortlisted for HTA grant for RCT of 
baclofen in alcohol dependence (declared 
January 2010). 
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September 2010). 
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APPENDIX 3: SPECIAL ADVISORS TO THE GUIDELINE 
DEVELOPMENT GROUP 
  
  
Dr John Lewis, Royal Cornwall Hospitals Trust  
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APPENDIX 4: ALCOHOL ASSESSMENT TOOLS 
The following assessment tools were referred to: 
 
 Alcohol Problems Questionnaire 
 
 Alcohol Use Disorders Identification Test (AUDIT) 
 
 Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-
Ar) 
 
 The Leeds Dependence Questionnaire 
 
 Severity of Alcohol Dependence Questionnaire (SADQ)
FINAL DRAFT 
 475 
 
ALCOHOL PROBLEMS QUESTIONNAIRE  
NAME:_______________________ DATE: ___________________________________  
We would like to find out if you have experienced any of the difficulties which other people with alcohol  
problems sometimes complain of.  
Below you will find a list of questions which we would like you to answer.  
 
Read each box carefully and answer either YES or NO by putting a TICK in the appropriate box (e.g. YES)  
            Yes         No 
IN THE LAST SIX MONTHS         Yes         No  
1. Have you tended to drink on your own more than you used to?…………………..  
2. Have you worried about meeting your friends again the day after a drinking 
session?…………………………………………………………………………………....  
3. Have you spent more time with drinking friends than other kinds of friends?……  
4. Have your friends criticised you for drinking too much? ……………………………  
5. Have you had any debts?………………………………………………………………  
6. Have you pawned any of your belongings to buy alcohol? ………………………..  
7. Do you find yourself making excuses about money?……………………………….  
8. Have you been caught out lying about money? …………………………………….  
9. Have you been in trouble with the police due to your drinking? …………………..  
10. Have you lost your driving licence for drinking and driving? ……………………..  
11. Have you been in prison? …………………………………………………………….  
12. Have you been physically sick after drinking? …………………………………..…  
13. Have you had diarrhoea after a drinking session? ………………………………...  
14. Have you had pains in your stomach after a drinking session? ………………..…  
15. Have you had pins and needles in your fingers or toes?………………………..…  
16. Have you had any accidents, needing hospital treatment after drinking? ……….  
17. Have you lost any weight? ……………………………………………………………  
18. Have you been neglecting yourself physically?…………………………………….  
19. Have you failed to wash for several days at a time?……………………………….  
20. Have you felt depressed for more than a week? …………………………………..  
21. Have you felt so depressed that you have felt like doing away with yourself? …  
22. Have you given up any hobbies you once enjoyed because of drinking? ………  
23. Do you find it hard to get the same enjoyment from your usual interests?………  
 
PLEASE MAKE SURE YOU HAVE ANSWERED ALL THE QUESTIONS WHICH APPLY 
TO YOU PLEASE TURN PAGE  
 
Copyright D.C. Drummond 1990  
 
 
FINAL DRAFT 
 476 
 
IF YOU ARE NOT MARRIED, MISS OUT QUESTIONS 24-32, GO TO QUESTION 33  
(These questions apply to you if you have lived with your spouse or partner during the last six months)  
IN THE LAST SIX MONTHS:  Yes         No 
 
24. Has your spouse complained of your drinking?………………………………....….  
25. Has your spouse tried to stop you from having a drink? …………………………..  
26. Has he/she refused to talk to you because you have been drinking? ……………  
27. Has he/she threatened to leave you because of your drinking?……….………….  
28. Has he/she had to put you to bed after you have been drinking?..……………….  
29. Have you shouted at him/her when you have been drinking?……………………..  
30. Have you injured him/her after you have been drinking? ………………………….  
31. Have you been legally separated from your spouse? ……………………….…….  
32. Has he/she refused to have sex with you because of drinking?…………………..  
 
 
IF YOU HAVE NO CHILDREN MISS OUT QUESTIONS 33-36, GO TO QUESTION 37.  
(These questions apply if you have lived with your children during the last six months)  
 
IN THE LAST SIX MONTHS:  Yes         No 
 
33. Have you children criticised your drinking? …………………………………………  
34. Have you had rows with your children about drinking?..…………………………..  
35. Do your children tend to avoid you when you have been drinking?……………...  
36. Have your children tried to stop you from having a drink? ………………………..  
 
 
IF YOU HAVE BEEN UNEMPLOYED FOR THE LAST SIX MONTHS, MISS OUT QUESTIONS 37-44  
 
IN THE LAST SIX MONTHS  Yes         No 
 
  
37. Have you found your work less interesting than you used to? ……………………  
38. Have you been unable to arrive on time for work due to your drinking?…………..  
39. Have you missed a whole day at work after a drinking session?…………………..  
40. Have you been less able to do your job because of your drinking?………………..  
41. Has anyone at work complained about you being late or absent?…………………  
42. Have you had any formal warnings from your employers?…………………………  
43. Have you been suspended or dismissed from work?……………………………….  
44. Have you had any accidents at work after drinking?………………………………..  
 
 
PLEASE MAKE SURE YOU HAVE ANSWERED ALL THE QUESTIONS WHICH APPLY TO YOU  
END OF QUESTIONNAIRE 
THANK YOU FOR YOUR HELP  
 
 
Copyright D.C. Drummond 1990  
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CASAA Research Division*  
AUDIT  
Please circle the answer that is correct for you.  
1. How often do you have a drink containing alcohol?  
NEVER 
MONTHLY OR 
LESS 
TWO TO FOUR 
TIMES A 
MONTH 
TWO TO THREE 
TIMES A WEEK 
FOUR OR 
MORE 
TIMES A 
WEEK 
NOTE:  For answering these questions, one “drink” is equal to 10 ounces of beer, or 
4 ounces of wine, or 1 ounce of liquor 
 
2. How many drinks containing alcohol do you have on a typical day when you are 
drinking?  
1 OR 2 2 OR 4 5 OR 6 7 TO 9 10 OR MORE 
3. How often do you have six or more drinks on one occasion?  
NEVER 
LESS THAN 
MONTHLY 
MONTHLY WEEKLY 
DAILY OR 
ALMOST 
DAILY 
 
4. How often during the last year have you found that you were not able to stop 
drinking once you had started?  
NEVER 
LESS THAN 
MONTHLY 
MONTHLY WEEKLY 
DAILY OR 
ALMOST 
DAILY 
5. How often during the last year have you failed to do what was normally expected 
from you because of drinking?  
NEVER 
LESS THAN 
MONTHLY 
MONTHLY WEEKLY 
DAILY OR 
ALMOST 
DAILY 
6. How often during the last year have you needed a first drink in the morning to get 
yourself going after a heavy drinking session?  
NEVER 
LESS THAN 
MONTHLY 
MONTHLY WEEKLY 
DAILY OR 
ALMOST 
DAILY 
7. How often during the last year have you had a feeling of guilt or remorse after 
drinking? 
NEVER 
LESS THAN 
MONTHLY 
MONTHLY WEEKLY 
DAILY OR 
ALMOST 
DAILY 
8. How often during the last year have you been unable to remember what happened 
the night before because you had been drinking? 
NEVER 
LESS THAN 
MONTHLY 
MONTHLY WEEKLY 
DAILY OR 
ALMOST 
DAILY 
 
FOR OFFICE USE ONLY  
______________Study  
________________ID  
________________Point  
________________Date  
________________Raid  
 
AUDOOO--  Revised 10/9/95 1 Page  
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9. Have you or someone else been injured as a result of your drinking? 
NEVER  
YES, BUT NOT 
IN THE LAST 
YEAR 
 
YES DURING 
THE LAST 
YEAR 
10. Has a relative or friend, or a doctor or other health worker been concerned about 
your drinking or suggested you cut down? 
NEVER  
YES, BUT NOT 
IN THE LAST 
YEAR 
 
YES DURING 
THE LAST 
YEAR 
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Scoring Rules for the AUDIT Screening Questionnaire  
 
Item 1  0 = Never  
1 = Monthly or less  
2 = Two to four times a month  
3 = Two to three times a week  
4 = Four or more times a week  
 
Item 2  0 = 1-2 drinks  
1 = 3-4 drinks 
2 = 5-6 drinks 
3 = two to three times a week 
4 = four or more times a week  
 
Item 3-8  0 = Never  
1 = Less than monthly  
2 = Monthly 
3 = Weekly  
4 = Daily or almost daily  
 
Item 9-10  0 = No  
1 = Yes, but not in the last year  
2 = Yes, during the last year  
 
Maximum possible score = 40  
 
A score of 8 or more indicates a strong likelihood of hazardous or 
harmful alcohol consumption, and warrants more careful 
assessment.  
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The Leeds Dependence Questionnaire  
 
On this page there are questions about the importance of alcohol and/or other drugs in 
your life 
Think about your drinking/other drug use in the last week and answer each question 
ticking the closest answer to how you see yourself.  
 
 
 
 
Never  Sometimes  Often  Nearly always  
1. Do you find yourself thinking about 
when you will next be able to have 
another drink or take more drugs?  
    
2. Is drinking or taking drugs more 
important than anything else you 
might do during the day?  
    
3. Do you feel that your need for drink 
or drugs is too strong to control?  
    
4. Do you plan your days around 
getting and taking drink or drugs?  
    
5. Do you drink or take drugs in a 
particular way in order to increase the 
effect it gives you?  
    
6. Do you take drink or other drugs 
morning, afternoon and evening?  
    
7. Do you feel you have to carry on 
drinking or taking drugs once you 
have started?  
    
8. Is getting the effect you want more 
important than the particular drink or 
drug you use?  
    
9. Do you want to take more drink or 
drugs when the effect starts to wear 
off?  
    
10. Do you find it difficult to cope with 
life without drink or drugs?  
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APPENDIX 5: STAKEHOLDERS AND EXPERTS WHO SUBMITTED 
COMMENTS IN RESPONSE TO THE CONSULTATION DRAFT OF 
THE GUIDELINE 
 
STAKEHOLDERS 
Alcohol Education and Research Council (AERC) Alcohol Academy, The 
Alcohol and Drug Service, The 
Alcohol Focus Scotland 
Association for Family Therapy and Systemic Practice (AFT) 
Association of Higher Education Programmes on Substance Misuse 
British Association for Counselling & Psychotherapy 
British Association for Psychopharmacology 
British Liver Trust 
Children‘s Society, The 
College of Mental Health Pharmacy 
Department for Education 
Department of Health 
Drinksense 
Kaleidoscope 
Lundbeck 
National Organisation for Fetal Alcohol Syndrome (NOFAS-UK) 
National Treatment Agency for Substance Misuse 
NHS Blackpool 
NHS County Durham and Darlington 
NHS Direct 
NHS Lothian 
National Institute for Health Research (NIHR) Evaluation, Trials and Studies 
Coordinating Centre – Health Technology Assessment 
Nottinghamshire Healthcare NHS Trust 
Public Health Wales NHS Trust 
Royal College of General Practitioners, Wales 
Royal College of Midwives 
Royal College of Nursing 
Royal College of Paediatrics and Child Health 
Royal College of Physicians & British Society for Gastroenterology 
Royal College of Psychiatrists 
Royal Pharmaceutical Society of Great Britain 
South Staffordshire & Shropshire NHS Foundation Trust 
Specialist Clinical Addiction Network (SCAN) 
St Mungo Housing Association Ltd 
Turning Point 
United Kingdom Clinical Pharmacy Association 
Young Women‘s Christian Association (YWCA) England & Wales 
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EXPERTS 
 
Dr Duncan Raistrick 
Professor Nick Heather 
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APPENDIX 6: RESEARCHERS CONTACTED TO REQUEST 
INFORMATION ABOUT STUDIES 
 
Dr Bert Aertgeerts 
Dr Lynn Alden 
Dr Gerard Connors 
Dr David Foy 
Dr Peter Friedmann 
Dr J. C. Garbutt 
Dr Ronan Hearne 
Dr Rachel Humeniuk 
Dr Hakan Kallmen 
Dr David Kavanagh 
Dr Mark Litt 
Professor Richard Longabaugh 
Professor Karl Mann 
Proffessor John Monterosso 
Dr Kathryn Rost 
Janice Vendetti (Project MATCH coordinating Centre) 
Dr Kim Walitzer 
Professor Paul Wallace 
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APPENDIX 7: CLINICAL QUESTIONS 
 
1. For people who misuse alcohol, what are their experiences of having 
problems with alcohol, of access to services and of treatment? 
 
2. For families and carers of people who misuse alcohol, what are their 
experiences of caring for people with an alcohol problem and what support is 
available for families and carers? 
 
3. In adults with alcohol misuse, what is the clinical efficacy, cost-effectiveness, 
and safety of, and patient satisfaction associated with different systems for the 
organisation of care? 
 
4. What are the most effective a) diagnostic and b) assessment tools for alcohol 
dependence and harmful alcohol use? 
 
5. What are the most effective ways of monitoring clinical progress in alcohol 
dependence and harmful alcohol use? 
 
6. To answer questions 4 and 5, what are the advantages, disadvantages, and 
clinical utility of: 
 The structure of the overall clinical assessment 
 Biological measures 
 Psychological/behavioural measures 
 Neuropsychiatric measures (including cognitive impairment) 
 Physical assessment? 
 
In adults in planned alcohol withdrawal, what is the clinical efficacy, cost 
effectiveness, safety of, and patient satisfaction associated with: 
 preparatory work before withdrawal 
 different drug regimens  
 the setting (that is, community, residential or inpatient)?  
 
In adults in planned alcohol withdrawal what factors influence the choice of setting 
in terms of clinical and cost effectiveness including: 
 severity of the alcohol disorder  
 physical comorbidities 
 psychological comorbidities 
 social factors 
 
7. In adults with harmful or dependent alcohol use what are the preferred 
structures for and components of community-based and residential specialist 
alcohol services to promote long-term clinical and cost-effective outcomes?  
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8. For people with alcohol dependence or harmful alcohol use is psychological 
treatment x when compared with y more clinically and cost-effective and does 
this depend on: 
 Presence of comorbidities 
 Subtypes (matching effects) 
 Therapist-related factors (quality, therapeutic alliance, competence, 
training, etc.) 
 
9. What are the most effective a) diagnostic and b) assessment tools for alcohol 
dependence and harmful alcohol use in children and young people (aged 10–
18 years)? 
 
10. What are the most effective ways of monitoring clinical progress in alcohol 
dependence and harmful alcohol use in children and young people (aged 10–
18 years)? 
 
11. For children and young people with alcohol dependence or harmful alcohol 
use is treatment x when compared with y more clinically and cost-effective and 
does this depend on the presence of comorbidities?  
 
12. For people with alcohol dependence or harmful alcohol, what 
pharmacological interventions are more clinically and cost-effective? In 
addition:  
(c) What are the impacts of severity and comorbities on outcomes? 
(d) When should pharmacological treatments be initiated and for what 
duration should they be prescribed? 
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APPENDIX 8: REVIEW PROTOCOLS 
 
Relevant questions 
8.1.1.1.1 EXAMPLE:2.1.1a For people with first-episode 
or early schizophrenia, what are the benefits 
and downsides of continuous antipsychotic 
drug53 treatment when compared with 
alternative management strategies at the 
initiation of treatment54? 
Sub-questions 2.1.3, 2.14a, 2.1.5a, 2.2.1, 2.2.5, 2.2.6, 2.2.7 
Chapter  
Sub-section  
Topic Group Pharmacology 
Sub-section lead  
Search strategy Databases: CINAHL, EMBASE, MEDLINE, PsycINFO, 
CENTRAL, CDSR, DARE 
Additional sources: Reference lists of included studies, 
systematic reviews published after 2002. 
Existing reviews  
 Updated  
 Not updated  
Search filters used SR and RCT (See Appendix 9) 
 
Question specific 
search filter 
N/A – generic searches conducted 
Amendments to 
filter/ search strategy 
None 
Eligibility criteria  
 Intervention Antipsychotic drugs licensed for use in the UK (BNF 
54): 
 
First-generation: 
 
 Benperidol 
 Chlorpromazine hydrochloride 
 Flupentixol 
 Fluphenazine hydrochloride 
 Haloperidol 
 Levomepromazine 
 Pericyazine 
 Perphenazine 
 Pimozide 
                                                 
53 The analysis will be conducted separately for each antipsychotic drug licensed for use in the UK. 
54 When administered within the recommended dose range (BNF 54). 
FINAL DRAFT 
 491 
 
 Prochlorperazine 
 Promazine hydrochloride 
 Sulpiride 
 Trifluoperazine 
 Zuclopenthixol acetate 
 Zuclopenthixol dihydrochloride 
 
Second-generation: 
 
  Amisulpride 
  Aripiprazole 
  Clozapine 
  Olanzapine 
  Quetiapine 
  Risperidone 
  Sertindole 
  Zotepine 
 
Antipsychotic depot injections: 
 
 Flupentixol decanoate 
 Fluphenazine decanoate 
 Haloperidol 
 Pipotiazine palmitate 
 Risperidone 
 Zuclopenthixol decanoate 
 Comparator Any relevant alternative management strategy 
 Population 
(including age, 
gender etc) 
Adults (18+) with first-episode or early schizophrenia 
 Outcomes 
 
(see Outcomes 
document for 
definitions) 
- Mortality (suicide & natural causes) 
- Global state (including relapse) 
- Service outcomes 
- Mental state 
- Psychosocial functioning 
- Behaviour 
- Engagement with services 
- Cognitive functioning 
- QoL 
- Satisfaction with treatment/ subjective well-being 
- Adherence to medication/ study protocol 
- Adverse events (including extrapyramidal side 
effects, weight gain, sedation/fatigue, sexual 
dysfunction, diabetes/disturbance of glucose 
homeostasis, increased prolactin, cardiotoxicity, 
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suicide, depression) 
 Study design RCT 
 Publication 
status 
[Published and unpublished (if criteria met)] 
 Year of study 2002–2007 
 
 Dosage [Enter relevant information] 
 
 Minimum 
sample size 
[Enter relevant information] 
 
 Study setting [Enter relevant information] 
 
Additional 
assessments 
An additional assessment will be undertaken to ensure 
that restriction to experimental study designs does not 
result in overlooking the effects of X that are difficult to 
quantify and have not been captured in these studies. 
 
Studies were categorised as short-term (<12 weeks), 
medium-term (12–51 weeks) and long-term (52 weeks 
or more). 
 
Sensitivity analyses: 
 
 Exclude studies without blinded/masked 
assessment  
 Exclude studies that didn‘t use ITT 
 Exclude studies that used LOCF 
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APPENDIX 9: SEARCH STRATEGIES FOR THE IDENTIFICATION 
OF CLINICAL STUDIES 
 
The search strategies should be referred to in conjunction with information set out in 
Section 3.2.9.  
 
For standard mainstream bibliographic databases (AMED, CINAHL, EMBASE, 
MEDLINE and PsycINFO) search terms on alcohol dependence and harmful alcohol 
use were combined with study design filters for systematic reviews, RCTs and 
qualitative research. For searches generated in databases with collections of study 
designs at their focus (DARE, CDSR, CENTRAL and HTA) search terms on alcohol 
dependence and harmful alcohol use were used without a filter. For focused 
searches, terms for case management and assertive community treatment (ACT) 
were combined with terms for alcohol dependence and harmful alcohol use, and 
filters for observational and quasi-experimental studies. The search strategies were 
initially developed for Medline before being translated for use in other 
databases/interfaces. 
 
A condensed version of the strategies constructed for use with the main databases 
searched follows:  
 
1. Guideline topic search strategy  
 
a. MEDLINE, EMBASE, PsycINFO – Ovid SP interface 
 
1.  exp alcohol abuse/ or (alcohol-related disorders or alcohol-induced disorders 
or  
 sobriety).sh.    
2.  (alcoholi$ or (alcohol$ and (abstinence or detoxification or intoxicat$ or  
rehabilit$ or withdraw$))).hw.     
3.  *abuse/ or *addiction/ or *drug abuse/ or *substance related disorders/   
4.  alcoholi$.ti,ab.   
5.  (drinker$1 or (drink$ adj2 use$1) or ((alcohol$ or drink$) adj5 (abstinen$ or 
abstain$ or abus$ or addict$ or attenuat$ or binge$ or crav$ or dependen$ or 
detox$ or disease$ or disorder$ or excessiv$ or harm$ or hazard$ or heavy or 
high risk or intoxicat$ or misus$ or overdos$ or (over adj dos$) or problem$ 
or rehab$ or reliance or reliant or relaps$ or withdraw$))).ti,ab.  
6. (control$ adj2 drink$).tw.     
7.  sobriet$.ti,ab,hw.     
8.  or/1-7 
 
* Search request #3 was used to search for evidence of systematic reviews only.  
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b. CINAHL – Ebsco interface 
 
S11  S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10  
S10  TI sobriet* or AB sobriet*  
S9  (TI control* N2 drink*) or (AB control* N2 drink*)  
S8  (TI drink* N5 abstinen* or AB drink* N5 abstinen* ) or (TI drink* N5  
abstain* or AB drink* N5 abstain* ) or (TI drink* N5 abus* or AB drink*  
N5 abus* ) or (TI drink* N5 addict* or AB drink* N5 addict* ) or (TI drink*  
N5 attenuat* or AB drink* N5 attenuat*) or (TI drink* N5 binge* or AB  
drink* N5 binge* ) or (TI drink* N5 crav* or AB drink* N5 crav* ) or (TI  
drink* N5 dependen* or AB drink* N5 dependen* ) or (TI drink* N5  
detox* or AB drink* N5 detox* ) or (TI drink* N5 disease* or AB drink* N5  
disease* ) or (TI drink* N5 disorder* or AB drink* N5 disorder* ) or (TI  
drink* N5 excessiv* or AB drink* N5 excessiv*) or (TI drink* N5 harm* or  
AB drink* N5 harm*) or (TI drink* N5 hazard* or AB drink* N5 hazard*)  
or (TI drink* N5 heavy or AB drink* N5 heavy) or (TI drink* N5 high risk  
or AB drink* N5 high risk) or (TI drink* N5 intoxicat* or AB drink* N5  
intoxicat*) or (TI drink* N5 misus* or AB drink* N5 misus*) or (TI drink*  
N5 overdos* or AB drink* N5 overdos*) or (TI drink* N5 over dos* or AB  
drink* N5 over dos*) or (TI drink* N5 problem* or AB drink* N5  
problem*) or (TI drink* N5 rehab* or AB drink* N5 rehab*)  or (TI drink*  
N5 reliance or AB drink* N5 reliance) or (TI drink* N5 reliant or AB drink*  
N5 reliant) or (TI drink* N5 relaps* or AB drink* N5 relaps*) or (TI drink*  
N5 withdraw* or AB drink* N5 withdraw*)  
S7  (TI alcohol* N5 abstinen* or AB alcohol* N5 abstinen*) or (TI alcohol* N5  
abstain* or AB alcohol* N5 abstain* ) or (TI alcohol* N5 abus* or AB  
alcohol* N5 abus* ) or (TI alcohol* N5 addict* or AB alcohol* N5 addict*)  
or (TI alcohol* N5 attenuat* or AB alcohol* N5 attenuat*) or (TI alcohol*  
N5 binge* or AB alcohol* N5 binge* ) or (TI alcohol* N5 crav* or AB  
alcohol* N5 crav*) or (TI alcohol* N5 dependen* or AB alcohol* N5  
dependen* ) or (TI alcohol* N5 detox* or AB alcohol* N5 detox* ) or (TI  
alcohol* N5 disease* or AB alcohol* N5 disease* ) or (TI alcohol* N5  
disorder* or AB alcohol* N5 disorder* ) or (TI alcohol* N5 excessiv* or AB  
alcohol* N5 excessiv*) or (TI alcohol* N5 harm* or AB alcohol* N5 harm* )  
or (TI alcohol* N5 hazard* or AB alcohol* N5 hazard*) or (TI alcohol* N5  
heavy or AB alcohol* N5 heavy) or (TI alcohol* N5 high risk or AB  
alcohol* N5 high risk) or (TI alcohol* N5 intoxicat* or AB alcohol* N5  
intoxicat*) or (TI alcohol* N5 misus* or AB alcohol* N5 misus*) or (TI  
alcohol* N5 overdos* or AB alcohol* N5 overdos*) or (TI alcohol* N5 over  
dos* or AB alcohol* N5 over dos*) or (TI alcohol* N5 problem* or AB  
alcohol* N5 problem*) or (TI alcohol* N5 rehab* or AB alcohol* N5 rehab*)  
or (TI alcohol* N5 reliance or AB alcohol* N5 reliance) or (TI alcohol* N5  
reliant or AB alcohol* N5 reliant) or (TI alcohol* N5 relaps* or AB alcohol*  
N5 relaps*) or (TI alcohol* N5 withdraw* or AB alcohol* N5 withdraw*)  
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S6  (TI drink* N2 use*) or (AB drink* N2 use* )  
S5  TI drinker* or AB drinker*  
S4  (MM "Substance Use Disorders") or (MM "Behavior, Addictive") or (MM  
"Substance Abuse")  
S3  MW alcoholi*  
S2  MW alcohol* and (abstinence or detoxification or intoxicat* or rehabilit* or  
withdraw*)  
S1  (MH "Alcohol Abuse") or (MH "Alcoholic Intoxication") or (MH  
"Alcoholism") or (MH "Alcohol-Related Disorders") or (MH "Alcohol  
Abuse Control (Saba CCC)") or (MH "Alcohol Abuse (Saba CCC)") 
 
* Search request #4 was used to search for evidence of systematic reviews only.  
 
 
c. Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of 
Effects, Cochrane Central Register of Controlled Trials – Wiley Interscience interface 
 
#1 MeSH descriptor Alcohol-Related Disorders, this term only 
#2 MeSH descriptor Alcohol-Induced Disorders, this term only 
#3 MeSH descriptor Alcoholic Intoxication, this term only 
#4 MeSH descriptor Alcoholism, this term only 
#5 (alcoholi*):ti or (alcoholi*):ab 
#6 (abstinence or detoxification or intoxicat* or rehabilit* or withdraw*):kw and  
(alcohol*):kw 
#7 MeSH descriptor Substance-Related Disorders, this term only 
#8 (drinker* or (drink* NEAR/2 use*) or ((alcohol* or drink*) NEAR/5 (abstinen*  
or abstain* or abus* or addict* or attenuat* or binge* or crav* or dependen* or  
detox* or disease* or disorder* or excessiv* or harm* or hazard* or heavy or 
high  
risk or intoxicat* or misus* or overdos* or over dose or over dosing or over 
doses  
or problem* or rehab* or reliance or reliant or relaps* or withdraw*))):ti or  
(drinker* or (drink* NEAR/2 use*) or ((alcohol* or drink*) NEAR/5 (abstinen*  
or abstain* or abus* or addict* or attenuat* or binge* or crav* or dependen* or  
detox* or disease* or disorder* or excessiv* or harm* or hazard* or heavy or 
high  
risk or intoxicat* or misus* or overdos* or over dose or over dosing or over 
doses  
or problem* or rehab* or reliance or reliant or relaps* or withdraw*))):ab 
#9 (control* NEAR/2 drink*):ti or (control* NEAR/2 drink*):ab 
#10 (sobriet*):ti or (sobriet*):ab 
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10) 
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2. Focused search strategies [generated post-consultation]  
Case management and assertive community treatment (ACT) 
 
a. MEDLINE, EMBASE, PsycINFO – Ovid SP interface 
 
1. (assertive community treatment or case management).sh. 
2. (act program$ or (assertive adj2 (communit$ or outreach$)) or ((case or care) 
adj3 management) or (care adj2 program$ adj2 approach$) or ((community or 
outreach) adj (program$ or support$ or therap$ or treat$)) or cpa or (madison 
adj4 model$) or pact or tcl or (training adj5 (community adj2 living))).tw. 
3. or/1-2 
 
b. CINAHL – Ebsco interface 
 
1. S1 or S2 
2. (mh "case management") or (mh "case managers") or (mh "case management 
(omaha)") or (mh "case management society of america") or (mh "american 
case management association")  
3. ―act program*‖ or (assertive n2 communit*) or (assertive n2 outreach*) or 
(care n3 management) or (care n2 program* n2 approach*) or (case n3 
management) or ―community program*‖ or ―community support*‖ or 
―community therap*‖ or ―community treat*‖ or cpa or (madison n4 model*) 
or ―outreach program*‖ or ―outreach support*‖ or ―outreach therap*‖ or 
―outreach treat*‖ or pact or tcl or (training n5 community n2 living)  
 
 
3. Systematic review search filter – this is an adaptation of a filter 
designed by the Health Information Research Unit of the McMaster 
University, Ontario. 
 
a. MEDLINE, EMBASE, PsycINFO – Ovid SP interface 
 
1 (literature review or systematic review$ or meta anal$).sh,id. or "review  
literature as topic"/ 
2 ((analy$ or evidence$ or methodol$ or quantativ$ or systematic$) adj5 
(overview$ or review$)).tw. or ((analy$ or  
assessment$ or evidence$ or methodol$ or quantativ$ or qualitativ$ or  
systematic$).ti. and review$.ti,pt.) or (systematic$ adj5 search$).ti,ab. 
3 ((electronic database$ or bibliographic database$ or computeri?ed  
database$ or online database$).tw,sh. or (bids or cochrane or embase or index  
medicus or isi citation or medline or psyclit or psychlit or scisearch or science 
citation  
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or (web adj2 science)).tw. or cochrane$.sh.) and (review$.ti,ab,sh,pt. or  
systematic$.ti,ab.) 
4 (metaanal$ or meta anal$ or metasynthes$ or meta synethes$).ti,ab. 
5 (research adj (review$ or integration)).ti,ab. 
6 reference list$.ab. 
7 bibliograph$.ab. 
8 published studies.ab. 
9 relevant journals.ab. 
10 selection criteria.ab. 
11 (data adj (extraction or synthesis)).ab. 
12 (handsearch$ or ((hand or manual) adj search$)).ti,ab. 
13 (mantel haenszel or peto or dersimonian or der simonian).ti,ab. 
14 (fixed effect$ or random effect$).ti,ab. 
15 meta$.pt. or (literature review or meta analysis or systematic review).md. 
16 ((pool$ or combined or combining) adj2 (data or trials or studies or  
results)).ti,ab. 
17 or/1-16 
 
b. CINAHL – Ebsco interface 
 
S32  S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13  
or S14 or S15 or S16 or S22 or S23 or S26 or S27 or S28 or S29 or S30 or S31  
S31  TI ( analy* N5 review* or evidence* N5 review* or methodol* N5 review* or  
quantativ* N5 review* or systematic* N5 review* ) or AB ( analy* N5 review* 
or assessment* N5 review* or evidence* N5 review* or methodol* N5 review*  
or qualitativ* N5 review* or quantativ* N5 review* or systematic* N5  
review* )  
S30  TI ( pool* N2 results or combined N2 results or combining N2 results ) or  
AB ( pool* N2 results or combined N2 results or combining N2 results )  
S29  TI ( pool* N2 studies or combined N2 studies or combining N2 studies ) or  
AB ( pool* N2 studies or combined N2 studies or combining N2 studies )  
S28  TI ( pool* N2 trials or combined N2 trials or combining N2 trials ) or AB (  
pool* N2 trials or combined N2 trials or combining N2 trials )  
S27  TI ( pool* N2 data or combined N2 data or combining N2 data ) or AB (  
pool* N2 data or combined N2 data or combining N2 data )  
S26  S24 and S25  
S25  TI review* or PT review*  
S24  TI analy* or assessment* or evidence* or methodol* or quantativ* or  
qualitativ* or systematic*  
S23  TI ―systematic* N5 search*‖ or AB ―systematic* N5 search*‖  
S22  (S17 or S18 or S19) and (S20 or S21)  
S21  TI systematic* or AB systematic*  
S20  TX review* or MW review* or PT review*   
S19  (MH "Cochrane Library")  
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S18  TI ( bids or cochrane or embase or ―index medicus‖ or ―isi citation‖ or 
medline or psyclit or psychlit or scisearch or ―science citation‖ or web N2 
science ) or AB ( bids  
or cochrane or ―index medicus‖ or ―isi citation‖ or psyclit or psychlit or  
scisearch or ―science citation‖ or web N2 science )  
S17  TI ( ―electronic database*‖ or ―bibliographic database*‖ or ―computeri?ed  
database*‖ or ―online database*‖ ) or AB ( ―electronic database*‖ or  
―bibliographic database*‖ or ―computeri?ed database*‖ or ―online  
database*‖ )  
S16  (MH "Literature Review")  
S15  PT systematic* or PT meta*  
S14  TI ( ―fixed effect*‖ or ―random effect*‖ ) or AB ( ―fixed effect*‖ or  
―random effect*‖ )  
S13  TI ( ―mantel haenszel‖ or peto or dersimonian or ―der simonian‖ ) or AB (  
―mantel haenszel‖ or peto or dersimonian or ―der simonian‖ )  
S12  TI ( handsearch* or "hand search*" or "manual search*" ) or AB (  
handsearch* or "hand search*" or "manual search*" )  
S11  AB "data extraction" or "data synthesis"  
S10  AB "selection criteria"  
S9  AB "relevant journals"  
S8  AB "published studies"  
S7  AB bibliograph*  
S6  AB "reference list*"  
S5  TI ( ―research review*‖ or ―research integration‖ ) or AB ( ―research  
review*‖ or ―research integration‖ )  
S4  TI ( metaanal* or ―meta anal*‖ or metasynthes* or ―meta synethes*‖ ) or  
AB ( metaanal* or ―meta anal*‖ or metasynthes* or ―meta synethes*‖ )  
S3  (MH "Meta Analysis")  
S2  (MH "Systematic Review")  
S1  (MH "Literature Searching+") 
 
 
4. Randomised controlled trial search filter  – this is an adaptation of a 
filter designed by the Health Information Research Unit of the McMaster 
University, Ontario. 
 
a. MEDLINE, EMBASE, PsycINFO – Ovid SP interface 
 
1 exp clinical trials/ or (crossover procedure or double blind procedure or  
placebo$ or randomization or random sample or single blind  
procedure).sh. 
2 exp clinical trial/ or cross-over studies/ or double-blind method/ or  
random allocation/ or randomized controlled trials as topic/ or single- 
blind method/ 
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3 exp clinical trials/ or (placebo or random sampling).sh,id. 
4 (clinical adj2 trial$).tw. 
5 (crossover or cross over).tw. 
6 (((single$ or doubl$ or trebl$ or tripl$) adj5 blind$) or mask$ or dummy or  
singleblind$ or doubleblind$ or trebleblind$ or tripleblind$).tw. 
7 (placebo$ or random$).mp. 
8 (clinical trial$ or controlled clinical trial$ or random$).pt. or treatment  
outcome$.md. 
9 animals/ not human$.mp. 
10 animal$/ not human$/ 
11 (animal not human).po. 
12 (or/1-8) not (or/9-11) 
 
b. CINAHL – Ebsco interface 
 
S11  S9 not S10  
S10  (MH "Animals") not (MH "Human")   
S9  S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8  
S8  (PT "Clinical Trial")  
S7  TI ( placebo* or random* ) or AB ( placebo* or random* )  
S6  TI ( single blind* or double blind* or treble blind* or mask* or dummy* or  
singleblind* or doubleblind* or trebleblind* or tripleblind* ) or AB ( single  
blind* or double blind* or treble blind* or mask* or dummy* or  
singleblind* or doubleblind* or trebleblind* or tripleblind* )  
S5  TI ( crossover or cross over ) or AB ( crossover or cross over )  
S4  TI clinical N2 trial* or AB clinical N2 trial*  
S3  (MH "Crossover Design") or (MH "Placebos") or (MH "Random  
Assignment") or (MH "Random Sample")  
S2  MW double blind* or single blind* or triple blind*  
S1  (MH "Clinical Trials+") 
 
5. Observational study filter – developed in-house.  
 
a. MEDLINE, EMBASE, PsycINFO – Ovid SP interface 
 
1. (case control study or case report  or case reports  or case study  or case 
control studies  or clinical study  or cohort analysis  or cohort studies  or 
correlational study  or cross sectional studies or cross sectional study  or 
epidemiologic studies  or family study or follow up or followup studies  or 
follow up studies or hospital based case control study or longitudinal studies 
or longitudinal study or observational study  or population based case control 
study or prospective studies or prospective study or retrospective studies or 
retrospective study).sh. 
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2. (((case or crosssectional or cross sectional or epidemiologic$ or observational) 
adj (study or studies)) or (case adj (control$ or report$)) or cohort$1 or cross 
sectional or followup$ or follow up$ or followed or longitudinal$ or 
prospective$ or retrospective$).tw. 
3. case reports.pt. 
4. or/1-3 
 
b. CINAHL – Ebsco interface 
 
S4 S1 or S2 or S3 
S3 pt case study  
S2 ((case or crosssectional or ―cross sectional‖ or epidemiologic* or 
observational) and (study or studies)) or ―case control*‖ or ―case report*‖ or 
cohort* or ―cross sectional‖ or followup* or ―follow up*‖ or followed or 
longitudinal* or prospective* or retrospective*(mh "case control studies+") or 
(mh "prospective studies+") or (mh "cross sectional  
studies") or (mh "case studies") or (mh "epidemiological research")  
S1  (mh "case control studies+") or (mh "prospective studies+") or (mh "cross 
sectional studies") or (mh "case studies") or (mh "epidemiological research")  
 
6. Quasi-experimental design filter – developed in-house.  
 
a. MEDLINE, EMBASE, PsycINFO – Ovid SP interface 
 
1. (nonequivalent control group or posttesting or pretesting or pretest posttest 
design or pretest posttest control group design or quasi experimental 
methods or quasi experimental study or time series or time series analysis).sh. 
2. (nonequivalent or non equivalent) adj3 control$) or posttest$ or post test$ or 
pre test$ or pretest$ or quasi experiment$ or quasiexperiment$ or timeseries 
or time series).tw. 
3. or/1-2 
 
b. CINAHL – Ebsco interface 
 
S3 S1 or S2 
S2 (mh "quasi experimental studies+") or (mh "pretest posttest design+")  
S1 (non equivalent n3 control*) or (nonequivalent n3 control*) or posttest* or 
―post test*‖ or ―pre test*‖ or pretest or ―quasi experiment*‖ or 
quasiexperiment* or timeseries or ―time series‖ 
 
Details of additional searches undertaken to support the development of this 
guideline are available on request.  
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Appendix 10: Clinical study data extraction form 
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APPENDIX 11: QUALITY CHECKLISTS FOR CLINICAL STUDIES 
AND REVIEWS 
The methodological quality of each study was evaluated using dimensions adapted 
from SIGN (SIGN, 2001). SIGN originally adapted its quality criteria from checklists 
developed in Australia (Liddel et al., 1996). Both groups reportedly undertook 
extensive development and validation procedures when creating their quality 
criteria. 
 
Quality Checklist for a Systematic Review or Meta-Analysis 
Study ID:  
Guideline topic: Key question no: 
Checklist completed by:  
SECTION 1: INTERNAL VALIDITY 
In a well-conducted systematic review: In this study this criterion is: 
(Circle one option for each question) 
1.1 The study addresses an 
appropriate and clearly 
focused question.  
 
Well covered  
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.2 A description of the 
methodology used is included. 
  
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.3 The literature search is 
sufficiently rigorous to identify 
all the relevant studies. 
 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.4 Study quality is assessed and 
taken into account. 
  
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.5 There are enough similarities 
between the studies selected to 
make combining them 
reasonable.  
 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
SECTION 2: OVERALL ASSESSMENT OF THE STUDY 
2.1 How well was the study done 
to minimise bias? Code ++, + or 
– 
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Notes on the use of the methodology checklist: systematic reviews and 
meta-analyses 
Section 1 identifies the study and asks a series of questions aimed at establishing the 
internal validity of the study under review — that is, making sure that it has been 
carried out carefully and that the outcomes are likely to be attributable to the 
intervention being investigated. Each question covers an aspect of methodology that 
research has shown makes a significant difference to the conclusions of a study.  
 
For each question in this section, one of the following should be used to indicate how 
well it has been addressed in the review: 
 well covered  
 adequately addressed  
 poorly addressed 
 not addressed (that is, not mentioned or indicates that this aspect of 
study design was ignored) 
 not reported (that is, mentioned but insufficient detail to allow 
assessment to be made) 
 not applicable. 
1.1 The study addresses an appropriate and clearly focused question  
Unless a clear and well-defined question is specified in the report of the review, it 
will be difficult to assess how well it has met its objectives or how relevant it is to the 
question to be answered on the basis of the conclusions. 
1.2 A description of the methodology used is included 
One of the key distinctions between a systematic review and a general review is the 
systematic methodology used. A systematic review should include a detailed 
description of the methods used to identify and evaluate individual studies. If this 
description is not present, it is not possible to make a thorough evaluation of the 
quality of the review, and it should be rejected as a source of level-1 evidence 
(though it may be useable as level-4 evidence, if no better evidence can be found). 
1.3 The literature search is sufficiently rigorous to identify all the  relevant 
studies 
A systematic review based on a limited literature search — for example, one limited 
to MEDLINE only — is likely to be heavily biased. A well-conducted review should 
as a minimum look at EMBASE and MEDLINE and, from the late 1990s onward, the 
Cochrane Library. Any indication that hand searching of key journals, or follow-up 
of reference lists of included studies, were carried out in addition to electronic 
database searches can normally be taken as evidence of a well-conducted review. 
1.4 Study quality is assessed and taken into account  
A well-conducted systematic review should have used clear criteria to assess 
whether individual studies had been well conducted before deciding whether to 
include or exclude them. If there is no indication of such an assessment, the review 
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should be rejected as a source of level-1 evidence. If details of the assessment are 
poor, or the methods are considered to be inadequate, the quality of the review 
should be downgraded. In either case, it may be worthwhile obtaining and 
evaluating the individual studies as part of the review being conducted for this 
guideline. 
1.5 There are enough similarities between the studies selected to make 
 combining them reasonable 
Studies covered by a systematic review should be selected using clear inclusion 
criteria (see question 1.4 above). These criteria should include, either implicitly or 
explicitly, the question of whether the selected studies can legitimately be compared. 
It should be clearly ascertained, for example, that the populations covered by the 
studies are comparable, that the methods used in the investigations are the same, 
that the outcome measures are comparable and the variability in effect sizes between 
studies is not greater than would be expected by chance alone. 
 
Section 2 relates to the overall assessment of the paper. It starts by rating the 
methodological quality of the study, based on the responses in Section 1 and using 
the following coding system:  
 
++ All or most of the criteria have been fulfilled.  
Where they have not been fulfilled, the conclusions of the study or review 
are thought very unlikely to alter. 
+ Some of the criteria have been fulfilled.  
Those criteria that have not been fulfilled or not adequately described are 
thought unlikely to alter the conclusions.  
– Few or no criteria fulfilled. 
The conclusions of the study are thought likely or very likely to alter.  
 
Quality checklist for an RCT 
Study ID:   
Guideline topic: Key question no: 
Checklist completed by:    
SECTION 1: INTERNAL VALIDITY  
In a well-conducted RCT study: In this study this criterion is: 
(Circle one option for each 
question) 
1.1  The study addresses an 
appropriate and clearly focused 
question. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.2  The assignment of subjects to 
treatment groups is randomised. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
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1.3  An adequate concealment method 
is used. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.4  Subjects and investigators are kept 
‗blind‘ about treatment allocation. 
 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.5  The treatment and control groups 
are similar at the start of the trial. 
 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.6  The only difference between 
groups is the treatment under 
investigation. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.7  All relevant outcomes are 
measured in a standard, valid and 
reliable way. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.8  What percentage of the 
individuals or clusters recruited 
into each treatment arm of the 
study dropped out before the 
study was completed? 
  
1.9  All the subjects are analysed in the 
groups to which they were 
randomly allocated (often referred 
to as intention-to-treat analysis).  
 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.10  Where the study is carried out at 
more than one site, results are 
comparable for all sites. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
SECTION 2: OVERALL ASSESSMENT OF THE STUDY  
2.1  How well was the study done to 
minimise bias? 
Code ++, + or –  
  
 
 
Notes on the use of the methodology checklist: RCTs  
 
Section 1 identifies the study and asks a series of questions aimed at establishing the 
internal validity of the study under review — that is, making sure that it has been 
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carried out carefully and that the outcomes are likely to be attributable to the 
intervention being investigated. Each question covers an aspect of methodology that 
research has shown makes a significant difference to the conclusions of a study.  
 
For each question in this section, one of the following should be used to indicate how 
well it has been addressed in the review: 
 
 well covered  
 adequately addressed  
 poorly addressed 
 not addressed (that is, not mentioned or indicates that this aspect of study 
design was ignored) 
 not reported (that is, mentioned but insufficient detail to allow assessment 
to be made) 
 not applicable. 
1.1 The study addresses an appropriate and clearly focused question 
Unless a clear and well-defined question is specified, it will be difficult to assess how 
well the study has met its objectives or how relevant it is to the question to be 
answered on the basis of its conclusions. 
1.2 The assignment of subjects to treatment groups is randomised 
Random allocation of patients to receive one or other of the treatments under 
investigation, or to receive either treatment or placebo, is fundamental to this type of 
study. If there is no indication of randomisation, the study should be rejected. If the 
description of randomisation is poor, or the process used is not truly random (for 
example, allocation by date or alternating between one group and another) or can 
otherwise be seen as flawed, the study should be given a lower quality rating. 
1.3 An adequate concealment method is used 
Research has shown that where allocation concealment is inadequate, investigators 
can overestimate the effect of interventions by up to 40%. Centralised allocation, 
computerised allocation systems or the use of coded identical containers would all 
be regarded as adequate methods of concealment and may be taken as indicators of 
a well-conducted study. If the method of concealment used is regarded as poor, or 
relatively easy to subvert, the study must be given a lower quality rating, and can be 
rejected if the concealment method is seen as inadequate. 
1.4 Subjects and investigators are kept ‘blind’ about treatment allocation 
Blinding can be carried out up to three levels. In single-blind studies, patients are 
unaware of which treatment they are receiving; in double-blind studies, the doctor 
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and the patient are unaware of which treatment the patient is receiving; in triple-
blind studies, patients, healthcare providers and those conducting the analysis are 
unaware of which patients receive which treatment. The higher the level of blinding, 
the lower the risk of bias in the study.  
1.5 The treatment and control groups are similar at the start of the trial 
Patients selected for inclusion in a trial should be as similar as possible, in order to 
eliminate any possible bias. The study should report any significant differences in 
the composition of the study groups in relation to gender mix, age, stage of disease 
(if appropriate), social background, ethnic origin or comorbid conditions. These 
factors may be covered by inclusion and exclusion criteria, rather than being 
reported directly. Failure to address this question, or the use of inappropriate 
groups, should lead to the study being downgraded. 
1.6 The only difference between groups is the treatment under 
 investigation 
If some patients receive additional treatment, even if of a minor nature or consisting 
of advice and counselling rather than a physical intervention, this treatment is a 
potential confounding factor that may invalidate the results. If groups are not treated 
equally, the study should be rejected unless no other evidence is available. If the 
study is used as evidence, it should be treated with caution and given a low quality 
rating. 
1.7 All relevant outcomes are measured in a standard, valid and reliable 
 way 
If some significant clinical outcomes have been ignored, or not adequately taken into 
account, the study should be downgraded. It should also be downgraded if the 
measures used are regarded as being doubtful in any way or applied inconsistently. 
1.8 What percentage of the individuals or clusters recruited into each treatment 
arm of the study dropped out before the study was  completed? 
The number of patients that drop out of a study should give concern if the number is 
very high. Conventionally, a 20% dropout rate is regarded as acceptable, but this 
may vary. Some regard should be paid to why patients drop out, as well as how 
many. It should be noted that the dropout rate may be expected to be higher in 
studies conducted over a long period of time. A higher dropout rate will normally 
lead to downgrading, rather than rejection, of a study. 
1.9 All the subjects are analysed in the groups to which they were randomly 
allocated (often referred to as intention-to-treat analysis) 
In practice, it is rarely the case that all patients allocated to the intervention group 
receive the intervention throughout the trial, or that all those in the comparison 
group do not. Patients may refuse treatment, or contraindications arise that lead 
them to be switched to the other group. If the comparability of groups through 
randomisation is to be maintained, however, patient outcomes must be analysed 
according to the group to which they were originally allocated, irrespective of the 
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treatment they actually received. (This is known as intention-to-treat analysis.) If it is 
clear that analysis is not on an intention-to-treat basis, the study may be rejected. If 
there is little other evidence available, the study may be included but should be 
evaluated as if it were a non-randomised cohort study. 
1.10 Where the study is carried out at more than one site, results are comparable 
for all sites 
In multi-site studies, confidence in the results should be increased if it can be shown 
that similar results have been obtained at the different participating centres. 
 
Section 2 relates to the overall assessment of the paper. It starts by rating the 
methodological quality of the study, based on the responses in Section 1 and using 
the following coding system: 
 
++ All or most of the criteria have been fulfilled.  
Where they have not been fulfilled, the conclusions of the study or review 
are thought very unlikely to alter. 
+ Some of the criteria have been fulfilled.  
Those criteria that have not been fulfilled or not adequately described are 
thought unlikely to alter the conclusions.  
– Few or no criteria fulfilled. 
The conclusions of the study are thought likely or very likely to alter.  
 
 
Quality checklist for a cohort study*  
Study ID: 
  
 Relevant questions: 
  
Guideline topic: 
 
Checklist completed by:  
 
SECTION 1: INTERNAL VALIDITY  
In a well conducted cohort study: In this study the criterion is: 
(Circle one option for each 
question) 
1.1  The study addresses an appropriate 
and clearly focused question. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
SELECTION OF SUBJECTS  
1.2 The two groups being studied are 
selected from source populations that 
are comparable in all respects other 
than the factor under investigation. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
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1.3 The study indicates how many of the 
people asked to take part did so, in 
each of the groups being studied. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.4 The likelihood that some eligible 
subjects might have the outcome at 
the time of enrolment is assessed and 
taken into account in the analysis. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.5 What percentage of individuals or 
clusters recruited into each arm of the 
study dropped out before the study 
was completed? 
 
  
1.6  Comparison is made between full 
participants and those lost to follow-
up, by exposure status. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
ASSESSMENT  
1.7  The outcomes are clearly defined. 
 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.8  The assessment of outcome is made 
blind to exposure status. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.9  Where blinding was not possible, 
there is some recognition that 
knowledge of exposure status could 
have influenced the assessment of 
outcome. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.1
0  
The measure of assessment of 
exposure is reliable. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.1
1  
Evidence from other sources is used 
to demonstrate that the method of 
outcome assessment is valid and 
reliable. 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
1.1
2  
Exposure level or prognostic factor is 
assessed more than once.  
 
Well covered      
Adequately 
addressed 
Poorly addressed  
Not addressed  
Not reported  
Not applicable 
CONFOUNDING  
1.1
3  
The main potential confounders are 
identified and taken into account in 
Well covered      
Adequately 
Not addressed  
Not reported  
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the design and analysis. addressed 
Poorly addressed  
Not applicable 
STATISTICAL ANALYSIS  
1.1
4  
Have confidence intervals been 
provided?  
 
  
SECTION 2: OVERALL ASSESSMENT OF THE STUDY  
2.1  How well was the study done to minimise 
the risk of bias or confounding, and to 
establish a causal relationship between 
exposure and effect? 
Code ++, + or –  
  
*A cohort study can be defined as a retrospective or prospective follow-up study. 
Groups of individuals are defined on the basis of the presence or absence of 
exposure to a suspected risk factor or intervention. This checklist is not appropriate 
for assessing uncontrolled studies (for example, a case series where there is no 
comparison [control] group of patients). 
Notes on the use of the methodology checklist: cohort studies  
The studies covered by this checklist are designed to answer questions of the type 
‗What are the effects of this exposure?‘ It relates to studies that compare a group of 
people with a particular exposure with another group who either have not had the 
exposure or have a different level of exposure. Cohort studies may be prospective 
(where the exposure is defined and subjects selected before outcomes occur) or 
retrospective (where exposure is assessed after the outcome is known, usually by the 
examination of medical records). Retrospective studies are generally regarded as a 
weaker design, and should not receive a 2++ rating. 
 
Section 1 identifies the study and asks a series of questions aimed at establishing the 
internal validity of the study under review —that is, making sure that it has been 
carried out carefully, and that the outcomes are likely to be attributable to the 
intervention being investigated. Each question covers an aspect of methodology that 
has been shown to make a significant difference to the conclusions of a study.  
Because of the potential complexity and subtleties of the design of this type of study, 
there are comparatively few criteria that automatically rule out use of a study as 
evidence. It is more a matter of increasing confidence in the likelihood of a causal 
relationship existing between exposure and outcome by identifying how many 
aspects of good study design are present and how well they have been tackled. A 
study that fails to address or report on more than one or two of the questions 
considered below should almost certainly be rejected. 
 
For each question in this section, one of the following should be used to indicate how 
well it has been addressed in the review: 
 well covered  
 adequately addressed  
 poorly addressed 
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 not addressed (that is, not mentioned or indicates that this aspect of 
study design was ignored) 
 not reported (that is, mentioned but insufficient detail to allow 
assessment to be made) 
 not applicable. 
1.1 The study addresses an appropriate and clearly focused question 
Unless a clear and well-defined question is specified, it will be difficult to assess how 
well the study has met its objectives or how relevant it is to the question to be 
answered on the basis of its conclusions. 
1.2 The two groups being studied are selected from source populations 
 that are comparable in all respects other than the factor under 
 investigation  
Study participants may be selected from the target population (all individuals to 
which the results of the study could be applied), the source population (a defined 
subset of the target population from which participants are selected) or from a pool 
of eligible subjects (a clearly defined and counted group selected from the source 
population). It is important that the two groups selected for comparison are as 
similar as possible in all characteristics except for their exposure status or the 
presence of specific prognostic factors or prognostic markers relevant to the study in 
question. If the study does not include clear definitions of the source populations 
and eligibility criteria for participants, it should be rejected. 
1.3 The study indicates how many of the people asked to take part did  so 
in each of the groups being studied  
This question relates to what is known as the participation rate, defined as the 
number of study participants divided by the number of eligible subjects. This should 
be calculated separately for each branch of the study. A large difference in 
participation rate between the two arms of the study indicates that a significant 
degree of selection bias may be present, and the study results should be treated with 
considerable caution. 
1.4 The likelihood that some eligible subjects might have the outcome at  the 
time of enrolment is assessed and taken into account in the  analysis  
If some of the eligible subjects, particularly those in the unexposed group, already 
have the outcome at the start of the trial, the final result will be biased. A well-
conducted study will attempt to estimate the likelihood of this occurring and take it 
into account in the analysis through the use of sensitivity studies or other methods. 
1.5 What percentage of individuals or clusters recruited into each arm of  the 
study dropped out before the study was completed? 
The number of patients that drop out of a study should give concern if the number is 
very high. Conventionally, a 20% dropout rate is regarded as acceptable, but in 
observational studies conducted over a lengthy period of time a higher dropout rate 
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is to be expected. A decision on whether to downgrade or reject a study because of a 
high dropout rate is a matter of judgement based on the reasons why people drop 
out and whether dropout rates are comparable in the exposed and unexposed 
groups. Reporting of efforts to follow up participants that drop out may be regarded 
as an indicator of a well-conducted study. 
1.6 Comparison is made between full participants and those lost to  follow-up 
by exposure status 
For valid study results, it is essential that the study participants are truly 
representative of the source population. It is always possible that participants who 
drop out of the study will differ in some significant way from those who remain part 
of the study throughout. A well-conducted study will attempt to identify any such 
differences between full and partial participants in both the exposed and unexposed 
groups. Any indication that differences exist should lead to the study results being 
treated with caution. 
1.7 The outcomes are clearly defined 
Once enrolled in the study, participants should be followed until specified end 
points or outcomes are reached. In a study of the effect of exercise on the death rates 
from heart disease in middle-aged men, for example, participants might be followed 
up until death, reaching a predefined age or until completion of the study. If 
outcomes and the criteria used for measuring them are not clearly defined, the study 
should be rejected. 
1.8 The assessment of outcome is made blind to exposure status 
If the assessor is blinded to which participants received the exposure, and which did 
not, the prospects of unbiased results are significantly increased. Studies in which 
this is done should be rated more highly than those where it is not done or not done 
adequately. 
1.9 Where blinding was not possible, there is some recognition that 
 knowledge of exposure status could have influenced the assessment  of 
outcome 
Blinding is not possible in many cohort studies. In order to assess the extent of any 
bias that may be present, it may be helpful to compare process measures used on the 
participant groups — for example, frequency of observations, who carried out the 
observations and the degree of detail and completeness of observations. If these 
process measures are comparable between the groups, the results may be regarded 
with more confidence. 
1.10 The measure of assessment of exposure is reliable  
A well-conducted study should indicate how the degree of exposure or presence of 
prognostic factors or markers was assessed. Whatever measures are used must be 
sufficient to establish clearly that participants have or have not received the 
exposure under investigation and the extent of such exposure, or that they do or do 
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not possess a particular prognostic marker or factor. Clearly described, reliable 
measures should increase the confidence in the quality of the study. 
1.11 Evidence from other sources is used to demonstrate that the method  of 
outcome assessment is valid and reliable 
The inclusion of evidence from other sources or previous studies that demonstrate 
the validity and reliability of the assessment methods used should further increase 
confidence in study quality. 
1.12 Exposure level or prognostic factor is assessed more than once 
Confidence in data quality should be increased if exposure level or the presence of 
prognostic factors is measured more than once. Independent assessment by more 
than one investigator is preferable. 
1.13 The main potential confounders are identified and taken into  account 
in the design and analysis 
Confounding is the distortion of a link between exposure and outcome by another 
factor that is associated with both exposure and outcome. The possible presence of 
confounding factors is one of the principal reasons why observational studies are not 
more highly rated as a source of evidence. The report of the study should indicate 
which potential confounders have been considered and how they have been 
assessed or allowed for in the analysis. Clinical judgement should be applied to 
consider whether all likely confounders have been considered. If the measures used 
to address confounding are considered inadequate, the study should be 
downgraded or rejected, depending on how serious the risk of confounding is 
considered to be. A study that does not address the possibility of confounding 
should be rejected. 
1.14 Have confidence intervals been provided? 
Confidence limits are the preferred method for indicating the precision of statistical 
results and can be used to differentiate between an inconclusive study and a study 
that shows no effect. Studies that report a single value with no assessment of 
precision should be treated with caution. 
 
Section 2 relates to the overall assessment of the paper. It starts by rating the 
methodological quality of the study, based on the responses in Section 1 and using 
the following coding system: 
 
++ All or most of the criteria have been fulfilled.  
Where they have not been fulfilled, the conclusions of the study or review 
are thought very unlikely to alter. 
+ Some of the criteria have been fulfilled.  
Those criteria that have not been fulfilled or not adequately described are 
thought unlikely to alter the conclusions.  
– Few or no criteria fulfilled. 
The conclusions of the study are thought likely or very likely to alter.  
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APPENDIX 12: SEARCH STRATEGIES FOR THE IDENTIFICATION 
OF HEALTH ECONOMICS EVIDENCE 
The search strategies should be referred to in conjunction with information set out in 
Section 3.2.16.  
 
For standard mainstream bibliographic databases (CINAHL, EMBASE, MEDLINE 
and PsycINFO) search terms on alcohol dependence and harmful alcohol use were 
combined with a search filter for health economic studies. For searches generated in 
topic-specific databases (HTA, NHS EED) search terms on alcohol dependence and 
harmful alcohol use were used without a filter. The search strategies were initially 
developed for Medline before being translated for use in other databases/interfaces. 
 
A condensed version of the strategies constructed for use with the main databases 
searched follows:  
 
1. Guideline topic search strategy  
 
a. MEDLINE, EMBASE, PsycINFO - Ovid SP interface 
 
1.  exp alcohol abuse/ or (alcohol-related disorders or alcohol-induced disorders 
or  
 sobriety).sh.    
2.  (alcoholi$ or (alcohol$ and (abstinence or detoxification or intoxicat$ or  
rehabilit$ or withdraw$))).hw.     
3.  alcoholi$.ti,ab.   
4.  (drinker$1 or (drink$ adj2 use$1) or ((alcohol$ or drink$) adj5 (abstinen$ or 
abstain$ or abus$ or addict$ or attenuat$ or binge$ or crav$ or dependen$ or 
detox$ or disease$ or disorder$ or excessiv$ or harm$ or hazard$ or heavy or 
high risk or intoxicat$ or misus$ or overdos$ or (over adj dos$) or problem$ 
or rehab$ or reliance or reliant or relaps$ or withdraw$))).ti,ab.  
5. (control$ adj2 drink$).tw.     
6.  sobriet$.ti,ab,hw.     
7.  or/1-6 
 
b. CINAHL - Ebsco interface 
 
S10  S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 
S9  TI sobriet* or AB sobriet*  
S8  (TI control* N2 drink*) or (AB control* N2 drink*)  
S7  (TI drink* N5 abstinen* or AB drink* N5 abstinen* ) or (TI drink* N5  
abstain* or AB drink* N5 abstain* ) or (TI drink* N5 abus* or AB drink*  
N5 abus* ) or (TI drink* N5 addict* or AB drink* N5 addict* ) or (TI drink*  
N5 attenuat* or AB drink* N5 attenuat*) or (TI drink* N5 binge* or AB  
drink* N5 binge* ) or (TI drink* N5 crav* or AB drink* N5 crav* ) or (TI  
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drink* N5 dependen* or AB drink* N5 dependen* ) or (TI drink* N5  
detox* or AB drink* N5 detox* ) or (TI drink* N5 disease* or AB drink* N5  
disease* ) or (TI drink* N5 disorder* or AB drink* N5 disorder* ) or (TI  
drink* N5 excessiv* or AB drink* N5 excessiv*) or (TI drink* N5 harm* or  
AB drink* N5 harm*) or (TI drink* N5 hazard* or AB drink* N5 hazard*)  
or (TI drink* N5 heavy or AB drink* N5 heavy) or (TI drink* N5 high risk  
or AB drink* N5 high risk) or (TI drink* N5 intoxicat* or AB drink* N5  
intoxicat*) or (TI drink* N5 misus* or AB drink* N5 misus*) or (TI drink*  
N5 overdos* or AB drink* N5 overdos*) or (TI drink* N5 over dos* or AB  
drink* N5 over dos*) or (TI drink* N5 problem* or AB drink* N5  
problem*) or (TI drink* N5 rehab* or AB drink* N5 rehab*)  or (TI drink*  
N5 reliance or AB drink* N5 reliance) or (TI drink* N5 reliant or AB drink*  
N5 reliant) or (TI drink* N5 relaps* or AB drink* N5 relaps*) or (TI drink*  
N5 withdraw* or AB drink* N5 withdraw*)  
S6  (TI alcohol* N5 abstinen* or AB alcohol* N5 abstinen*) or (TI alcohol* N5  
abstain* or AB alcohol* N5 abstain* ) or (TI alcohol* N5 abus* or AB  
alcohol* N5 abus* ) or (TI alcohol* N5 addict* or AB alcohol* N5 addict*)  
or (TI alcohol* N5 attenuat* or AB alcohol* N5 attenuat*) or (TI alcohol*  
N5 binge* or AB alcohol* N5 binge* ) or (TI alcohol* N5 crav* or AB  
alcohol* N5 crav*) or (TI alcohol* N5 dependen* or AB alcohol* N5  
dependen* ) or (TI alcohol* N5 detox* or AB alcohol* N5 detox* ) or (TI  
alcohol* N5 disease* or AB alcohol* N5 disease* ) or (TI alcohol* N5  
disorder* or AB alcohol* N5 disorder* ) or (TI alcohol* N5 excessiv* or AB  
alcohol* N5 excessiv*) or (TI alcohol* N5 harm* or AB alcohol* N5 harm* )  
or (TI alcohol* N5 hazard* or AB alcohol* N5 hazard*) or (TI alcohol* N5  
heavy or AB alcohol* N5 heavy) or (TI alcohol* N5 high risk or AB  
alcohol* N5 high risk) or (TI alcohol* N5 intoxicat* or AB alcohol* N5  
intoxicat*) or (TI alcohol* N5 misus* or AB alcohol* N5 misus*) or (TI  
alcohol* N5 overdos* or AB alcohol* N5 overdos*) or (TI alcohol* N5 over  
dos* or AB alcohol* N5 over dos*) or (TI alcohol* N5 problem* or AB  
alcohol* N5 problem*) or (TI alcohol* N5 rehab* or AB alcohol* N5 rehab*)  
or (TI alcohol* N5 reliance or AB alcohol* N5 reliance) or (TI alcohol* N5  
reliant or AB alcohol* N5 reliant) or (TI alcohol* N5 relaps* or AB alcohol*  
N5 relaps*) or (TI alcohol* N5 withdraw* or AB alcohol* N5 withdraw*)  
S5  (TI drink* N2 use*) or (AB drink* N2 use* )  
S4  TI drinker* or AB drinker*  
S3  MW alcoholi*  
S2  MW alcohol* and (abstinence or detoxification or intoxicat* or rehabilit* or  
withdraw*)  
S1  (MH "Alcohol Abuse") or (MH "Alcoholic Intoxication") or (MH  
"Alcoholism") or (MH "Alcohol-Related Disorders") or (MH "Alcohol  
Abuse Control (Saba CCC)") or (MH "Alcohol Abuse (Saba CCC)") 
 
c. Health Technology Assessment Database, NHS Economic Evaluation Database - 
Wiley Interscience interface 
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#1 MeSH descriptor Alcohol-Related Disorders, this term only 
#2 MeSH descriptor Alcohol-Induced Disorders, this term only 
#3 MeSH descriptor Alcoholic Intoxication, this term only 
#4 MeSH descriptor Alcoholism, this term only 
#5 (alcoholi*):ti or (alcoholi*):ab 
#6 (abstinence or detoxification or intoxicat* or rehabilit* or withdraw*):kw and  
(alcohol*):kw 
#7 MeSH descriptor Substance-Related Disorders, this term only 
#8 (drinker* or (drink* NEAR/2 use*) or ((alcohol* or drink*) NEAR/5 (abstinen*  
or abstain* or abus* or addict* or attenuat* or binge* or crav* or dependen* or  
detox* or disease* or disorder* or excessiv* or harm* or hazard* or heavy or 
high risk or intoxicat* or misus* or overdos* or over dose or over dosing or 
over doses  
or problem* or rehab* or reliance or reliant or relaps* or withdraw*))):ti or  
(drinker* or (drink* NEAR/2 use*) or ((alcohol* or drink*) NEAR/5 (abstinen*  
or abstain* or abus* or addict* or attenuat* or binge* or crav* or dependen* or  
detox* or disease* or disorder* or excessiv* or harm* or hazard* or heavy or 
high risk or intoxicat* or misus* or overdos* or over dose or over dosing or 
over doses  
or problem* or rehab* or reliance or reliant or relaps* or withdraw*))):ab 
#9 (control* NEAR/2 drink*):ti or (control* NEAR/2 drink*):ab 
#10 (sobriet*):ti or (sobriet*):ab 
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10) 
 
 
2 Health economics and quality-of-life search filter – this is an adaptation of a filter designed 
by the NHS Centre for Reviews and Dissemination at the University of York.  
 
a. MEDLINE, EMBASE, PsycINFO - Ovid SP interface 
 
1 (health care rationing or health priorities or medical savings accounts or  
resource allocation).sh,id. or "deductibles and coinsurance"/ 
2 (budget$ or cost$ or econom$ or expenditure$ or fee$1 or financ$ or health  
resource or money or pharmacoeconomic$ or socioeconomic).hw,id. 
3 (budget$ or cost$ or econom$ or expenditure$ or financ$ or fiscal or  
funding or pharmacoeconomic$ or socioeconomic$ or price or prices or  
pricing or (value adj3 money) or (burden adj3 (disease$ or illness$))).tw. 
4 exp "quality of life"/ or "value of life"/ or (quality adjusted life year$ or  
well being or wellbeing).sh,id. 
5 exp models, economic/ or (models, statistical or statistical model or  
(economics and models)).sh,id. 
6 health status indicators.sh,id. 
7 (daly or qol or hql or hqol or hrqol or hr ql or hrql or (quality adj2 life) or  
(adjusted adj2 life) or qaly$ or (health adj2 stat$) or well being or  
wellbeing or qald$ or qale$ or qtime$ or eq5d or eq 5d or qwb or ((quality  
FINAL DRAFT 
 517 
 
or value$) adj3 (life or survival or well$)) or hui$1 or (utilit$ adj1 (health  
or score$ or weigh$)) or (life adj2 year$) or health year equivalent$ or  
((disability or quality) adj adjusted) or utility value$ or (weight$ adj3  
preference$) or euroqol or euro qol or visual analog$ or standard gamble  
or time trade or qtwist or q twist or (valu$ adj2 quality)).tw. 
8 decision tree/ or decision trees/ 
9 (decision analy$ or monte carlo or markov or simulation model$ or rosser  
or disutili$ or willingness to pay or tto or hye or hyes or (resource adj  
(allocat$ or use$ or utilit$))).tw. 
10 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six  
or shortform thirtysix or shortform thirty six or short form thirtysix or  
short form thirty six).tw,tm,it. 
11 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six  
or short form six).tw,tm,it. 
12 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or  
shortform twelve or short form twelve).tw,tm,it. 
13 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or  
shortform sixteen or short form sixteen).tw,tm,it. 
14 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or  
shortform twenty or short form twenty).tw,tm,it. 
15 ec.fs. [ANDed with subject heading searches for the main population/topic] 
16 or/1-15 
17 animal$/ not human$.mp. 
18 animal$/ not human$/ 
19 (animal not human).po. 
20 16 not (or/17-19) 
 
b. CINAHL — Ebsco interface 
 
S19  S17 not S18  
S18  (MH "Animals") not (MH "Human")  
S17  S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13  
or S14 or S15 or S16  
S16  ti ( (sf20 or ―sf 20‖ or ―short form 20‖ or ―shortform 20‖ or ―sf twenty‖ or  
sftwenty or ―shortform twenty‖ or ―short form twenty‖) ) or ab ( (sf20 or  
―sf 20‖ or ―short form 20‖ or ―shortform 20‖ or ―sf twenty‖ or sftwenty or  
―shortform twenty‖ or ―short form twenty‖) )  
S15  ti ( (sf16 or ―sf 16‖ or ―short form 16‖ or ―shortform 16‖ or ―sf sixteen‖ or  
sfsixteen or ―shortform sixteen‖ or ―short form sixteen‖) ) or ab ( (sf16 or  
―sf 16‖ or ―short form 16‖ or ―shortform 16‖ or ―sf sixteen‖ or sfsixteen or  
―shortform sixteen‖ or ―short form sixteen‖) )  
S14  ti ( (sf12 or ―sf 12‖ or ―short form 12‖ or ―shortform 12‖ or ―sf twelve‖ or  
sftwelve or ―shortform twelve‖ or ―short form twelve‖) ) or ab ( (sf12 or  
―sf 12‖ or ―short form 12‖ or ―shortform 12‖ or ―sf twelve‖ or sftwelve or  
―shortform twelve‖ or ―short form twelve‖) )  
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S13  ti ( (sf6 or ―sf 6‖ or ―short form 6‖ or ―shortform 6‖ or ―sf six‖ or sfsix or  
―shortform six‖ or ―short form six‖) ) or ab ( (sf6 or ―sf 6‖ or ―short form  
6‖ or ―shortform 6‖ or ―sf six‖ or sfsix or ―shortform six‖ or ―short form  
six‖) )  
S12  ti ( (sf36 or ―sf 36‖ or ―short form 36‖ or ―shortform 36‖ or ―sf thirtysix‖ or  
―sf thirty six‖ or ―shortform thirtysix‖ or ―shortform thirty six ― or ―short  
form thirtysix‖ or ―short form thirty six‖) ) or ab ( (sf36 or ―sf 36‖ or ―short  
form 36‖ or ―shortform 36‖ or ―sf thirtysix‖ or ―sf thirty six‖ or ―shortform  
thirtysix‖ or ―shortform thirty six ― or ―short form thirtysix‖ or ―short  
form thirty six‖) )  
S11  ti ( (―decision analys*‖ or ―monte carlo‖ or markov or ―simulation  
model*‖ or rosser or disutili* or ―willingness to pay‖ or tto or hye or hyes  
or ―resource allocation‖ or ―resource use‖ or ―resource ulitit*‖ ) ) or ab (  
(―decision analys*‖ or ―monte carlo‖ or markov or ―simulation model*‖ or  
rosser or disutili* or ―willingness to pay‖ or tto or hye or hyes or  
―resource allocation‖ or ―resource use‖ or ―resource ulitit*‖) )  
S10  (mh "decision trees")  
S9  TI (daly or qol or hql or hqol or hrqol or ―hr ql‖ or hrql or qaly* or ―well  
being‖ or wellbeing or qald* or qale* or qtime* or eq5d or ―eq 5d‖ or qwb  
or hui or ―health year equivalent*‖ or ―utility value*‖ or euroqol or ―euro  
qol‖ or ―visual analog*‖ or ―standard gamble‖ or ―time trade‖ or qtwist or  
―q twist― or ―disability adjusted‖ or ―quality adjusted‖ ) or AB (daly or  
qol or hql or hqol or hrqol or ―hr ql‖ or hrql or qaly* or ―well being‖ or  
wellbeing or qald* or qale* or qtime* or eq5d or ―eq 5d‖ or qwb or hui or  
―health year equivalent*‖ or ―utility value*‖ or euroqol or ―euro qol‖ or  
―visual analog*‖ or ―standard gamble‖ or ―time trade‖ or qtwist or ―q  
twist― or ―disability adjusted‖ or ―quality adjusted‖ ) or (TI quality N2 life  
or AB quality N2 life) or (TI adjusted N2 life or AB adjusted N2 life) or (TI  
health N2 stat* or AB health N2 stat*) or (TI quality N3 life or AB quality  
N3 life) or (TI quality N3 survival or AB quality N3 survival) or (TI quality  
N3 well* or AB quality N3 well*) or (TI value N3 life or AB value N3 life)  
or (TI value N3 survival or AB value N3 survival) or (TI value N3 well* or  
AB value N3 well*) or (TI utilit* N1 health or AB utilit* N1 health) or (TI  
utilit* N1 score* or AB utilit* N1 score*) or (TI utilit* N1 weigh* or AB  
utilit* N1 weigh*) or (TI life N2 year* or AB life N2 year*) or (TI weight*  
N3 preference* or AB weight* N3 preference*) or (TI valu* N2 quality or  
AB valu* N2 quality) 
S8  (mh "health status indicators") or (MH "Models, Statistical")  
S7  (mh "psychological well-being") or (MH "Psychological Well-Being (Iowa  
NOC) (Non-Cinahl)") or (MH "Well-Being (Iowa NOC)")  
S6  (mh "quality of life+") or (MH "Economic Value of Life") or (MH "Quality- 
Adjusted Life Years")  
S5  TI ( budget* or cost* or econom* or expenditure* or financ* or fiscal or  
funding or pharmacoeconomic* or socioeconomic* or price or prices or  
pricing ) or AB ( budget* or cost* or econom* or expenditure* or financ* or  
fiscal or funding or pharmacoeconomic* or socioeconomic* or price or  
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prices or pricing ) or ( (TI value N3 money or AB value N3 money) or (TI  
burden N3 disease* or AB burden N3 disease*) or (TI burden N3 illness*  
or AB burden N3 illness*) )  
S4  mw (budget* or cost* or econom* or expenditure* or fee* or financ* or  
health resource or money or pharmacoeconomic* or socioeconomic)  
S3  (mh "economic value of life")  
S2  (mh "resource allocation") or (mh "health resource allocation")  
S1  (mh "medical savings accounts") 
 
 
Details of searches undertaken in EconLit are available on CD/on request.  
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APPENDIX 13: QUALITY CHECKLISTS FOR ECONOMIC STUDIES 
This checklist is designed to determine whether an economic evaluation provides 
evidence that is useful to inform the decision-making of the Guideline Development 
Group (GDG). It is not intended to judge the quality of the study per se or the 
quality of reporting. 
 
Study identification  
Including author, title, reference, year of publication  
Guideline topic:  Question no:  
Checklist completed by:  
Section 1: Applicability (relevance to specific guideline review 
question(s) and the NICE reference case). This checklist should 
be used first to filter out irrelevant studies.  
Yes/ Partly/ 
No/Unclear 
/NA  
Comments  
1.1  Is the study population appropriate for the guideline?    
1.2  Are the interventions appropriate for the guideline?    
1.3  Is the healthcare system in which the study was conducted 
sufficiently similar to the current UK NHS context?  
  
1.4  Are costs measured from the NHS and personal social 
services (PSS) perspective?  
  
1.5  Are all direct health effects on individuals included?    
1.6  
Are both costs and health effects discounted at an annual rate 
of 3.5%?  
  
1.7  Is the value of health effects expressed in terms of quality-
adjusted life years (QALYs)?  
  
1.8  Are changes in health-related quality of life (HRQoL) reported 
directly from patients and/or carers?  
  
1.9  Is the valuation of changes in HRQoL (utilities) obtained from a 
representative sample of the general public?  
  
1.10 Overall judgement: Directly applicable/Partially applicable/Not 
applicable 
There is no need to use section 2 of the checklist if the study is 
considered ‘not applicable’. 
  
Other comments:  
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Section 2: Study limitations (the level of methodological 
quality) This checklist should be used once it has been decided 
that the study is sufficiently applicable to the context of the 
clinical guideline.  
Yes/ Partly 
/No/ Unclear/ 
NA  
Comments 
2.1  Does the model structure adequately reflect the nature of the 
health condition under evaluation?  
  
2.2  Is the time horizon sufficiently long to reflect all important 
differences in costs and outcomes?  
  
2.3  Are all important and relevant health outcomes included?    
2.4  Are the estimates of baseline health outcomes from the best 
available source?  
  
2.5  Are the estimates of relative treatment effects from the best 
available source?  
  
2.6  Are all important and relevant costs included?    
2.7  Are the estimates of resource use from the best available 
source?  
  
2.8  Are the unit costs of resources from the best available 
source?  
  
2.9  Is an appropriate incremental analysis presented or can it be 
calculated from the data?  
  
2.10 Are all important parameters whose values are uncertain 
subjected to appropriate sensitivity analysis? 
  
2.11 Is there no potential conflict of interest?   
2.12 Overall assessment: Minor limitations/Potentially serious limitations/Very serious limitations 
Other comments:  
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Notes on use of Methodology checklist: economic evaluations 
For all questions: 
 
• answer ‗yes‘ if the study fully meets the criterion 
• answer ‗partly‘ if the study largely meets the criterion but differs in some 
important respect 
• answer ‗no‘ if the study deviates substantively from the criterion 
• answer ‗unclear‘ if the report provides insufficient information to judge whether 
the study complies with the criterion 
• answer ‗NA (not applicable)‘ if the criterion is not relevant in a particular instance. 
 
For ‗partly‘ or ‗no‘ responses, use the comments column to explain how the study 
deviates from the criterion. 
 
Section 1: applicability 
 
1.1 Is the study population appropriate for the guideline? 
The study population should be defined as precisely as possible and should be in 
line with that specified in the guideline scope and any related review protocols. This 
includes consideration of appropriate subgroups that require special attention. For 
many interventions, the capacity to benefit will differ for participants with differing 
characteristics. This should be explored separately for each relevant subgroup as 
part of the base-case analysis by the provision of estimates of clinical and cost 
effectiveness. The characteristics of participants in each subgroup should be clearly 
defined and, ideally, should be identified on the basis of an a priori expectation of 
differential clinical or cost effectiveness as a result of biologically plausible known 
mechanisms, social characteristics or other clearly justified factors. 
 
Answer ‗yes‘ if the study population is fully in line with that in the guideline 
question(s) and if the study differentiates appropriately between important 
subgroups. Answer ‗partly‘ if the study population is similar to that in the guideline 
question(s) but: (i) it differs in some important respects; or (ii) the study fails to 
differentiate between important subgroups. Answer ‗no‘ if the study population is 
substantively different from that in the guideline question(s). 
 
1.2 Are the interventions appropriate for the guideline? 
All relevant alternatives should be included, as specified in the guideline scope and 
any related review protocols. These should include routine and best practice in the 
NHS, existing NICE guidance and other feasible options. Answer ‗yes‘ if the analysis 
includes all options considered relevant for the guideline, even if it also includes 
other options that are not relevant. Answer ‗partly‘ if the analysis omits one or more 
relevant options but still contains comparisons likely to be useful for the guideline. 
Answer ‗no‘ if the analysis does not contain any relevant comparisons. 
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1.3 Is the healthcare system in which the study was conducted sufficiently similar to 
the current UK NHS context? 
This relates to the overall structure of the healthcare system within which the 
interventions were delivered. For example, an intervention might be delivered on an 
inpatient basis in one country whereas in the UK it would be provided in the 
community. This might significantly influence the use of healthcare resources and 
costs, thus limiting the applicability of the results to a UK setting. In addition, old 
UK studies may be severely limited in terms of their relevance to current NHS 
practice. 
 
Answer ‗yes‘ if the study was conducted within the UK and is sufficiently recent to 
reflect current NHS practice. For non-UK or older UK studies, answer ‗partly‘ if 
differences in the healthcare setting are unlikely to substantively change the cost-
effectiveness estimates. Answer ‗no‘ if the healthcare setting is so different that the 
results are unlikely to be applicable in the current NHS. 
 
1.4 Are costs measured from the NHS and personal social services (PSS) perspective? 
The decision-making perspective of an economic evaluation determines the range of 
costs that should be included in the analysis. NICE works in a specific context; in 
particular, it does not set the budget for the NHS. The objective of NICE is to offer 
guidance that represents an efficient use of available NHS and PSS resources. For 
these reasons, the perspective on costs used in the NICE reference case is that of the 
NHS and PSS. Productivity costs and costs borne by patients and carers that are not 
reimbursed by the NHS or PSS are not included in the reference case. The reference 
case also excludes costs to other government bodies, although these may sometimes 
be presented in additional analyses alongside the reference case. 
 
Answer ‗yes‘ if the study only includes costs for resource items that would be paid 
for by the NHS and PSS. Also answer ‗yes‘ if other costs have been included in the 
study, but the results are presented in such a way that the cost effectiveness can be 
calculated from an NHS and PSS perspective. Answer ‗partly‘ if the study has taken 
a wider perspective but the other non-NHS/PSS costs are small in relation to the 
total expected costs and are unlikely to change the cost-effectiveness results. Answer 
‗no‘ if non-NHS/PSS costs are significant and are likely to change the cost-
effectiveness results. Some interventions may have a substantial impact on non-
health outcomes or costs to other government bodies (for example, treatments to 
reduce illicit drug misuse may have the effect of reducing drug-related crime). In 
such situations, if the economic study includes non-health costs in such a way that 
they cannot be separated out from NHS/PSS costs, answer ‗no‘ but consider 
retaining the study for critical appraisal. If studies containing non-reference-case 
costs are retained, use the comments column to note why. 
 
1.5 Are all direct health effects on individuals included? 
In the NICE reference case, the perspective on outcomes should be all direct health 
effects, whether for patients or, when relevant, other people (principally carers). This 
is consistent with an objective of maximising health gain from available healthcare 
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resources. Some features of healthcare delivery that are often referred to as ‗process 
characteristics‘ may ultimately have health consequences; for example, the mode of 
treatment delivery may have health consequences through its impact on 
concordance with treatment. Any significant characteristics of healthcare 
technologies that have a value to people that is independent of any direct effect on 
health should be noted. These characteristics include the convenience with which 
healthcare is provided and the level of information available for patients. 
 
This question should be viewed in terms of what is excluded in relation to the NICE 
reference case; that is, non-health effects. 
 
Answer ‗yes‘ if the measure of health outcome used in the analysis excludes non-
health effects (or if such effects can be excluded from the results). Answer ‗partly‘ if 
the analysis includes some non-health effects but these are small and unlikely to 
change the cost-effectiveness results. Answer ‗no‘ if the analysis includes significant 
non-health effects that are likely to change the cost-effectiveness results. 
 
1.6 Are both costs and health effects discounted at an annual rate of 3.5%? 
The need to discount to a present value is widely accepted in economic evaluation, 
although the specific rate varies across jurisdictions and over time. NICE considers it 
appropriate to discount costs and health effects at the same rate. The annual rate of 
3.5%, based on the recommendations of the UK Treasury for the discounting of costs, 
applies to both costs and health effects. 
 
Answer ‗yes‘ if both costs and health effects (for example, quality-adjusted life years 
[QALYs]) are discounted at 3.5% per year. Answer ‗partly‘ if costs and effects are 
discounted at a rate similar to 3.5% (for example, costs and effects are both 
discounted at 3% per year). Answer ‗no‘ if costs and/or health effects are not 
discounted, or if they are discounted at a rate (or rates) different from 3.5% (for 
example, 5% for both costs and effects, or 6% for costs and 1.5% for effects). Note in 
the comments column what discount rates have been used. If all costs and health 
effects accrue within a short time (roughly a year), answer ‗NA‘. 
 
1.7 Is the value of health effects expressed in terms of quality adjusted life years 
(QALYs)? 
The QALY is a measure of a person‘s length of life weighted by a valuation of their 
health-related quality of life (HRQoL) over that period. 
 
Given its widespread use, the QALY is considered by NICE to be the most 
appropriate generic measure of health benefit that reflects both mortality and effects 
on HRQoL. It is recognised that alternative measures exist (such as the healthy-year 
equivalent), but few economic evaluations have used these methods and their 
strengths and weaknesses are not fully established. 
 
NICE‘s position is that an additional QALY should be given the same weight 
regardless of the other characteristics of the patients receiving the health benefit. 
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Answer ‗yes‘ if the effectiveness of the intervention is measured using QALYs; 
answer ‗no‘ if not. There may be circumstances when a QALY cannot be obtained or 
where the assumptions underlying QALYs are considered inappropriate. In such 
situations answer ‗no‘, but consider retaining the study for appraisal. Similarly, 
answer ‗no‘ but retain the study for appraisal if it does not include QALYs but it is 
still thought to be useful for GDG decision-making: for example, if the clinical 
evidence indicates that an intervention might be dominant, and estimates of the 
relative costs of the interventions from a costminimisation study are likely to be 
useful. When economic evaluations not using QALYs are retained for full critical 
appraisal, use the comments column to note why. 
 
1.8 Are changes in health-related quality of life (HRQoL) reported directly from 
patients and/or carers? 
In the NICE reference case, information on changes in HRQoL as a result of 
treatment should be reported directly by patients (and directly by carers when the 
impact of treatment on the carer‘s health is also important). When it is not possible to 
obtain information on changes in patients‘ HRQoL directly from them, data should 
be obtained from carers (not from healthcare professionals). 
 
For consistency, the EQ-5D is NICE‘s preferred measure of HRQoL in adults. 
However, when EQ-5D data are not available or are inappropriate for the condition 
or the effects of treatment, other multi-attribute utility questionnaires (for example, 
SF6D, QWB or HUI) or mapping methods from disease-specific questionnaires may 
be used to estimate QALYs. For studies not reporting QALYs, a variety of generic or 
disease-specific methods may be used to measure HRQoL. 
 
Answer ‗yes‘ if changes in patients‘ HRQoL are estimated by the patients 
themselves. Answer ‗partly‘ if estimates of patients‘ HRQoL are provided by carers. 
Answer ‗no‘ if estimates come from healthcare professionals or researchers. Note in 
the comments column how HRQoL was measured (EQ-5D, QWB, HUI and so on). 
Answer ‗NA‘ if the cost-effectiveness study does not include estimates of HRQoL 
(for example, studies reporting ‗cost per life year gained‘ or cost-minimisation 
studies). 
 
1.9 Is the valuation of changes in HRQoL (utilities) obtained from a representative 
sample of the general public? 
The NICE reference case specifies that the valuation of changes in HRQoL (utilities) 
reported by patients should be based on public preferences elicited using a choice-
based method (such as the time trade-off or standard gamble) in a representative 
sample of the UK population. 
 
Answer ‗yes‘ if HRQoL valuations were obtained using the EQ-5D UK tariff. Answer 
‗partly‘ if the valuation methods were comparable to those used for the EQ-5D. 
Answer ‗no‘ if other valuation methods were used. Answer ‗NA‘ if the study does 
not apply valuations to HRQoL (for studies not reporting QALYs). In the comments 
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column note the valuation method used (such as time trade-off or standard gamble) 
and the source of the preferences (such as patients or healthcare professionals). 
 
1.10 Overall judgement 
Classify the applicability of the economic evaluation to the clinical guideline, the 
current NHS situation and the context for NICE guidance as one of the following: 
 
• Directly applicable – the study meets all applicability criteria, or fails to meet one 
or more applicability criteria but this is unlikely to change the conclusions about cost 
effectiveness. 
• Partially applicable – the study fails to meet one or more applicability criteria, and 
this could change the conclusions about cost effectiveness. 
• Not applicable – the study fails to meet one or more applicability criteria, and this 
is likely to change the conclusions about cost effectiveness. Such studies would be 
excluded from further consideration and there is no need to continue with the rest of 
the checklist. 
 
Section 2: study limitations 
 
2.1 Does the model structure adequately reflect the nature of the health condition 
under evaluation? 
This relates to the choice of model and its structural elements (including cycle length 
in discrete time models, if appropriate). Model type and its structural aspects should 
be consistent with a coherent theory of the health condition under evaluation. The 
selection of treatment pathways, whether health states or branches in a decision tree, 
should be based on the underlying biological processes of the health issue under 
study and the potential impact (benefits and adverse consequences) of the 
intervention(s) of interest. 
 
Answer ‗yes‘ if the model design and assumptions appropriately reflect the health 
condition and intervention(s) of interest. Answer ‗partly‘ if there are aspects of the 
model design or assumptions that do not fully reflect the health condition or 
intervention(s) but that are unlikely to change the costeffectiveness results. Answer 
‗no‘ if the model omits some important aspect of the health condition or 
intervention(s) and this is likely to change the cost effectiveness results. Answer 
‗NA‘ for economic evaluations based on data from a clinical study which do not 
extrapolate treatment outcomes or costs beyond the study context or follow-up 
period. 
 
2.2 Is the time horizon sufficiently long to reflect all important differences in costs 
and outcomes? 
The time horizon is the period of analysis of the study: the length of follow-up for 
participants in a trial-based evaluation, or the period of time over which the costs 
and outcomes for a cohort are tracked in a modelling study. This time horizon 
should always be the same for costs and outcomes, and should be long enough to 
include all relevant costs and outcomes relating to the intervention. A time horizon 
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shorter than lifetime could be justified if there is no differential mortality effect 
between options, and the differences in costs and 
HRQoL relate to a relatively short period (for example, in the case of an acute 
infection). 
 
Answer ‗yes‘ if the time horizon is sufficient to include all relevant costs and 
outcomes. Answer ‗partly‘ if the time horizon may omit some relevant costs and 
outcomes but these are unlikely to change the cost-effectiveness results. Answer ‗no‘ 
if the time horizon omits important costs and outcomes and this is likely to change 
the cost-effectiveness results. 
 
2.3 Are all important and relevant health outcomes included? 
All relevant health outcomes should include direct health effects relating to harms 
from the intervention (adverse effects) as well as any potential benefits. 
 
Answer ‗yes‘ if the analysis includes all relevant and important harms and benefits. 
Answer ‗partly‘ if the analysis omits some harms or benefits but these would be 
unlikely to change the cost-effectiveness results. Answer ‗no‘ if the analysis omits 
important harms and/or benefits that would be likely to change the cost-
effectiveness results. 
 
2.4 Are the estimates of baseline health outcomes from the best available source? 
The estimate of the overall net treatment effect of an intervention is determined by 
the baseline risk of a particular condition or event and/or the relative effects of the 
intervention compared with the relevant comparator treatment. The overall net 
treatment effect may also be determined by other features of the people comprising 
the population of interest. 
 
The process of assembling evidence for economic evaluations should be systematic – 
evidence must be identified, quality assessed and, when appropriate, pooled, using 
explicit criteria and justifiable and reproducible methods. These principles apply to 
all categories of evidence that are used to estimate clinical and cost effectiveness, 
evidence for which will typically be drawn from a number of different sources. 
 
The sources and methods for eliciting baseline probabilities should be described 
clearly. These data can be based on ‗natural history‘ (patient outcomes in the absence 
of treatment or with routine care), sourced from cohort studies. Baseline 
probabilities may also be derived from the control arms of experimental studies. 
Sometimes it may be necessary to rely on expert opinion for particular parameters. 
 
Answer ‗yes‘ if the estimates of baseline health outcomes reflect the best available 
evidence as identified from a recent well-conducted systematic review of the 
literature. Answer ‗partly‘ if the estimates are not derived from a systematic review 
but are likely to reflect outcomes for the relevant group of patients in routine NHS 
practice (for example, if they are derived from a large UK-relevant cohort study). 
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Answer ‗no‘ if the estimates are unlikely to reflect outcomes for the relevant group in 
routine NHS practice. 
 
2.5 Are the estimates of relative treatment effects from the best available source? 
The objective of the analysis of clinical effectiveness is to produce an unbiased 
estimate of the mean clinical effectiveness of the interventions being compared. 
 
The NICE reference case indicates that evidence on outcomes should be obtained 
from a systematic review, defined as the systematic location, inclusion, appraisal and 
synthesis of evidence to obtain a reliable and valid overview of the data relating to a 
clearly formulated question. 
 
Synthesis of outcome data through meta-analysis is appropriate provided that there 
are sufficient relevant and valid data obtained using comparable measures of 
outcome. 
 
Head-to-head RCTs provide the most valid evidence of relative treatment effect. 
However, such evidence may not always be available. Therefore, data from non-
randomised studies may be required to supplement RCT data. Any potential bias 
arising from the design of the studies used in the assessment should be explored and 
documented. 
 
Data from head-to-head RCTs should be presented in the base-case analysis, if 
available. When head-to-head RCTs exist, evidence from indirect or mixed treatment 
comparison analyses may be presented if it is considered to add information that is 
not available from the head-to-head comparison. This indirect or mixed treatment 
comparison must be fully described and presented as additional to the base-case 
analysis. (A ‗mixed treatment comparison‘ estimates effect sizes using both head-to-
head and indirect comparisons.) 
 
If data from head-to-head RCTs are not available, indirect treatment comparison 
methods should be used. (An ‗indirect comparison‘ is a synthesis of data from a 
network of trials that compare the interventions of interest with other comparators.) 
 
When multiple interventions are being assessed that have not been compared within 
a single RCT, data from a series of pairwise head-to-head RCTs should be presented. 
Consideration should also be given to presenting a combined analysis using a mixed 
treatment comparison framework if it is considered to add information that is not 
available from the head-to-head comparison. 
 
Only indirect or mixed treatment comparison methods that preserve randomisation 
should be used. The principles of good practice for standard meta-analyses should 
also be followed in mixed and indirect treatment comparisons. 
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The methods and assumptions that are used to extrapolate short-term results to final 
outcomes should be clearly presented and there should be documentation of the 
reasoning underpinning the choice of survival function. 
 
Evidence for the evaluation of diagnostic technologies should normally incorporate 
evidence on diagnostic accuracy. It is also important to incorporate the predicted 
changes in health outcomes and costs resulting from treatment decisions based on 
the test result. The general principles guiding the assessment of the clinical and cost 
effectiveness of diagnostic interventions should be the same as for other 
technologies. However, particular consideration of the methods of analysis may be 
required, particularly in relation to evidence synthesis. Evidence for the effectiveness 
of diagnostic technologies should include the costs and outcomes for people whose 
test results lead to an incorrect diagnosis, as well as for those who are diagnosed 
correctly. 
 
As for other technologies, RCTs have the potential to capture the pathway of care 
involving diagnostic technologies, but their feasibility and availability may be 
limited. Other study designs should be assessed on the basis of their fitness for 
purpose, taking into consideration the aim of the study (for example, to evaluate 
outcomes, or to evaluate sensitivity and specificity) and the purpose of the 
diagnostic technology. 
 
Answer ‗yes‘ if the estimates of treatment effect appropriately reflect all relevant 
studies of the best available quality, as identified through a recent well-conducted 
systematic review of the literature. Answer ‗partly‘ if the estimates of treatment 
effect are not derived from a systematic review but are similar in magnitude to the 
best available estimates (for example, if the economic evaluation is based on a single 
large study with treatment effects similar to pooled estimates from all relevant 
studies). Answer ‗no‘ if the estimates of treatment effect are likely to differ 
substantively from the best available estimates. 
 
2.6 Are all important and relevant costs included? 
Costs related to the condition of interest and incurred in additional years of life 
gained as a result of treatment should be included in the base-case analysis. This 
should include the costs of handling non-adherence to treatment and treating side 
effects. Costs that are considered to be unrelated to the condition or intervention of 
interest should be excluded. If introduction of the intervention requires additional 
infrastructure to be put in place, consideration should be given to including such 
costs in the analysis. 
 
Answer ‗yes‘ if all important and relevant resource use and costs are included given 
the perspective and the research question under consideration. Answer ‗partly‘ if 
some relevant resource items are omitted but these are unlikely to affect the cost-
effectiveness results. Answer ‗no‘ if important resource items are omitted and these 
are likely to affect the cost-effectiveness results. 
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2.7 Are the estimates of resource use from the best available source? 
It is important to quantify the effect of the interventions on resource use in terms of 
physical units (for example, days in hospital or visits to a GP) and valuing those 
effects in monetary terms using appropriate prices and unit costs. Evidence on 
resource use should be identified systematically. When expert opinion is used as a 
source of information, any formal methods used to elicit these data should be clearly 
reported. 
 
Answer ‗yes‘ if the estimates of resource use appropriately reflect all relevant 
evidence sources of the best available quality, as identified through a recent well-
conducted systematic review of the literature. Answer ‗partly‘ if the estimates of 
resource use are not derived from a systematic review but are similar in magnitude 
to the best available estimates. Answer ‗no‘ if the estimates of resource use are likely 
to differ substantively from the best available estimates. 
 
2.8 Are the unit costs of resources from the best available source? 
Resources should be valued using the prices relevant to the NHS and PSS. Given the 
perspective of the NICE reference case, it is appropriate for the financial costs 
relevant to the NHS/PSS to be used as the basis of costing, although these may not 
always reflect the full social opportunity cost of a given resource. A first point of 
reference in identifying costs and prices should be any current official listing 
published by the Department of Health and/or the Welsh Assembly Government. 
 
When the acquisition price paid for a resource differs from the public list price (for 
example, pharmaceuticals and medical devices sold at reduced prices to NHS 
institutions), the public list price should be used in the base-case analysis. Sensitivity 
analysis should assess the implications of variations from this price. Analyses based 
on price reductions for the NHS will only be considered when the reduced prices are 
transparent and can be consistently available across the NHS, and if the period for 
which the specified price is available is guaranteed. 
 
National data based on healthcare resource groups (HRGs) such as the Payment by 
Results tariff can be used when they are appropriate and available. However, data 
based on HRGs may not be appropriate in all circumstances (for example, when the 
definition of the HRG is broad, or the mean cost probably does not reflect resource 
use in relation to the intervention(s) under consideration). In such cases, other 
sources of evidence, such as micro-costing studies, may be more appropriate. When 
cost data are taken from the literature, the methods used to identify the sources 
should be defined. When several alternative sources are available, a justification for 
the costs chosen should be provided and discrepancies between the sources 
explained. When appropriate, sensitivity analysis should have been undertaken to 
assess the implications for results of using alternative data sources. 
 
Answer ‗yes‘ if resources are valued using up-to-date prices relevant to the NHS and 
PSS. Answer ‗partly‘ if the valuations of some resource items differ from current 
NHS/PSS unit costs but this is unlikely to change the cost-effectiveness results. 
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Answer ‗no‘ if the valuations of some resource items differ substantively from 
current NHS/PSS unit costs and this is likely to change the cost-effectiveness results. 
 
2.9 Is an appropriate incremental analysis presented or can it be calculated from the 
data? 
An appropriate incremental analysis is one that compares the expected costs and 
health outcomes of one intervention with the expected costs and health outcomes of 
the next-best non-dominated alternative. 
 
Standard decision rules should be followed when combining costs and effects, and 
should reflect any situation where there is dominance or extended dominance. When 
there is a trade-off between costs and effects, the results should be presented as an 
incremental cost-effectiveness ratio (ICER): the ratio of the difference in mean costs 
to the difference in mean outcomes of a technology compared with the next best 
alternative. In addition to ICERs, expected net monetary or health benefits can be 
presented using values placed on a QALY gained of £20,000 and £30,000. 
 
For cost-consequence analyses, appropriate incremental analysis can only be done 
by selecting one of the consequences as the primary measure of effectiveness. 
 
Answer ‗yes‘ if appropriate incremental results are presented, or if data are 
presented that allow the reader to calculate the incremental results. Answer ‗no‘ if: 
(i) simple ratios of costs to effects are presented for each alternative compared with a 
standard intervention; or (ii) if options subject to simple or extended dominance are 
not excluded from the incremental analyses. 
 
2.10 Are all important parameters whose values are uncertain subjected to 
appropriate sensitivity analysis? 
There are a number of potential selection biases and uncertainties in any evaluation 
(trial- or model-based) and these should be identified and quantified where possible. 
There are three types of bias or uncertainty to consider: 
 
• Structural uncertainty – for example in relation to the categorisation of different 
states of health and the representation of different pathways of care. These structural 
assumptions should be clearly documented and the evidence and rationale to 
support them provided. The impact of structural uncertainty on estimates of cost 
effectiveness should be explored by separate analyses of a representative range of 
plausible scenarios. 
• Source of values to inform parameter estimates – the implications of different 
estimates of key parameters (such as estimates of relative effectiveness) must be 
reflected in sensitivity analyses (for example, through the inclusion of alternative 
scenarios). Inputs must be fully justified, and uncertainty explored by sensitivity 
analysis using alternative input values. 
• Parameter precision – uncertainty around the mean health and cost inputs in the 
model. Distributions should be assigned to characterise the uncertainty associated 
with the (precision of) mean parameter values. Probabilistic sensitivity analysis is 
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preferred, as this enables the uncertainty associated with parameters to be 
simultaneously reflected in the results of the model. In non-linear decision models – 
when there is not a straight-line relationship between inputs and outputs of a model 
(such as Markov models) – probabilistic methods provide the best estimates of mean 
costs and outcomes. Simple decision trees are usually linear. 
 
The mean value, distribution around the mean, and the source and rationale for the 
supporting evidence should be clearly described for each parameter included in the 
model. 
 
Evidence about the extent of correlation between individual parameters should be 
considered carefully and reflected in the probabilistic analysis. Assumptions made 
about the correlations should be clearly presented. 
 
Answer ‗yes‘ if an extensive sensitivity analysis was undertaken that explored all 
key uncertainties in the economic evaluation. Answer ‗partly‘ if the sensitivity 
analysis failed to explore some important uncertainties in the economic evaluation. 
Answer ‗no‘ if the sensitivity analysis was very limited and omitted consideration of 
a number of important uncertainties, or if the range of values or distributions around 
parameters considered in the sensitivity analysis were not reported. 
 
2.11 Is there no potential conflict of interest? 
The BMJ defines competing interests for its authors as follows: ―A competing 
interest exists when professional judgment concerning a primary interest (such as 
patients' welfare or the validity of research) may be influenced by a secondary 
interest (such as financial gain or personal rivalry). It may arise for the authors of a 
BMJ article when they have a financial interest that may influence, probably without 
their knowing, their interpretation of their results or those of others.‖Whenever a 
potential financial conflict of interest is possible, this should be declared. 
 
Answer ‗yes‘ if the authors declare that they have no financial conflicts of interest. 
Answer ‗no‘ if clear financial conflicts of interest are declared or apparent (for 
example, from the stated affiliation of the authors). Answer ‗unclear‘ if the article 
does not indicate whether or not there are financial conflicts of interest. 
 
2.12 Overall assessment 
The overall methodological study quality of the economic evaluation should be 
classified as one of the following: 
• Minor limitations – the study meets all quality criteria, or the study fails to meet 
one or more quality criteria but this is unlikely to change the conclusions about cost 
effectiveness. 
• Potentially serious limitations – the study fails to meet one or more quality 
criteria and this could change the conclusions about cost effectiveness. 
• Very serious limitations – the study fails to meet one or more quality criteria and 
this is highly likely to change the conclusions about cost effectiveness. Such studies 
should usually be excluded from further consideration. 
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APPENDIX 14: EXPERIENCE OF CARE: PERSONAL ACCOUNTS 
AND THEMATIC ANALYSIS 
Personal accounts from service users 
The writers of the personal accounts from people with alcohol problems were 
contacted through representatives on the GDG and through various agencies that 
had access to people with alcohol problems. The people who were approached to 
write the accounts were asked to consider a number of questions when composing 
their narratives. These included: 
 
 When did you first seek help for your alcohol problem and whom did you 
contact? (Please describe this first contact.)  
 What helped or did not help you gain access to services? Did a friend or 
family member help you gain access to these services?  
 Do you think that any life experiences led to the onset of the problem? If so, 
please describe if you feel able to do so. 
 In what ways has the alcohol problem affected your everyday life (such as 
education, employment and making relationships) and the lives of those 
close to you? 
 What possible treatments were discussed with you? 
 What treatment(s) did you receive? Please describe any drug treatment 
and/or psychological therapy. 
 Was the treatment(s) helpful? (Please describe what worked for you and 
what didn‘t work for you.) 
 How would you describe your relationship with your practitioner(s) (for 
example, your GP, alcohol service worker or other)  
 Did you use any other approaches to help your alcohol problem in addition 
to those provided by NHS services, for example private treatment? If so 
please describe what was helpful and not helpful. 
 Do you have any language support needs, including needing help with 
reading or speaking English? If so, did this have an impact on your 
understanding of the alcohol problem or on receiving treatment? 
 Did you attend a support group and was this helpful? Did family and 
friends close to you or people in your community help and support you? 
 How has the nature of the problem changed over time? 
 How do you feel now? 
 If your alcohol problem has improved, do you use any strategies to help 
you to stay well? If so, please describe these strategies. 
 
Each author signed a consent form allowing the account to be reproduced in this 
guideline. Three personal accounts from people with alcohol problems (one woman 
and two men) were received in total.  
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Personal account A  
It was in 2001: I was 48 years old and standing outside a shopping centre when a 
fellow alcoholic walked towards me. I said ‗hello‘ and he just stabbed me in the 
stomach. I was taken to hospital and treated as an inpatient for 10 days. In the 
morning I woke up with the DTs. A nurse came by and said I was suffering from 
shock and I answered that it was the DTs and that I was an alcoholic.  
 
I took my first drink in a pub at 14 years old; I then had a successful 25-year career 
with a brewery and was always a heavy drinker. The drinking became a serious 
problem when my career and marriage ended in 1993, by which time, in hindsight, I 
would say I was an alcoholic. 
 
In hospital doctors began to treat me for alcohol dependency, which consisted only 
of medication (daily doses of Librium), and on my release from hospital referred me 
to an alcohol treatment centre for assessment to decide which type/level of 
treatment I needed. It was the first time I had ever admitted that I had a problem, 
even to myself. 
 
When I was released from hospital I returned to my YMCA hostel and resumed 
where I left off—drinking cider 24/7 in my room, breaking the rules at the hostel. 
While in the streets with my ‗friends‘, I totally disregarded my referral to the 
treatment centre and went on my merry way towards oblivion. 
 
When I returned to the hostel the staff were constantly on my case to get help. I was 
searched on my way in and my room was searched on an ad hoc basis to ensure I 
wasn‘t drinking or taking drugs (a minor pastime I had developed) on the premises. 
I began to feel persecuted and quite bitter, and I showed my anger at my hostel key 
working sessions. However, when I was sober enough, which was very rare, I did 
admit to needing help. 
 
So in January 2002 I went to the alcohol treatment centre and was assessed. They 
informed me I would need medical detoxification and they would help to get a 
place; I was offered weekly key working sessions and advice in the meantime. 
 
I had to wait 10 months to get a detox placement at a psychiatric hospital. During 
that time I had to go to my weekly sessions, which I nearly gave up on quite a few 
times but the hostel staff kept on encouraging me to go, no matter how drunk I was, 
until I took up my placement. 
 
Detox was really hard for me despite the medication— I was disorientated, 
nauseous, shaking all the time, and I heard things almost constantly; I also couldn‘t 
hold a knife and fork so I could not eat hot food. On top of this, I had to attend two 
group sessions a day in the morning and evening, plus daily key working sessions, 
and have a daily injection of vitamin B plus my medication four times a day. 
However, after 2 weeks, even though I was still quite shaky, I was at last functioning 
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and through the group sessions I began to realise what I had been doing to my body 
and my mind. 
 
Towards the end of my time in the detox ward I contacted my keyworker at the 
YMCA hostel with a view to returning but after discussion we decided, as I was not 
in receipt of funding and had no care/social worker to help with any further support 
to recover, that I would attend an alcohol rehabilitation centre run by the YMCA for 
6 months. This enabled me to have continuous YMCA residency, which also meant I 
would be able to return to the hostel after the 6 months.  
 
The rehabilitation centre was really good for me; the staff were professional, tolerant 
and understanding. I learnt that my style of recovery there was eclectic and made up 
of the centre‘s own ideas plus bits of 12 step, CBT and holistic therapies plus 
transactional analysis. Group sessions took place daily in the morning followed by a 
staff and group lunch cooked by residents nominated for that day; cleaning and 
gardening were also chores for the residents so that we could learn our life skills 
again. We also went shopping so we could learn how to budget (that is, live within 
our means and not rely on shoplifting or some other kind of theft or fraud). The 
group sessions were varied, covering relapse prevention, life stories, self-esteem, 
self-confidence and triggers. Other topics, which were linked to recovery, were art 
therapy and open groups were we could talk about anything that affected us. I 
seemed to do OK and after 6 months I returned to the YMCA hostel a sober man for 
the first time in 15 years. 
 
I did not think I needed anymore support or treatment. I felt really fit both 
physically and mentally, and so resumed my previous friendships/relationships 
within the hostel feeling I was strong enough to stay clear of alcohol and drugs, but I 
was wrong. 
 
In hindsight I think I planned my relapse. I left the rehab centre on a Monday and 
took my first drink (a can of cider), 4 days later on the Friday with the other drinkers 
at a park bench thinking I could leave it at that, but by the end of the day I was 
totally drunk. I woke up next morning with a 3 litre bottle at the side of the bed and 
instinctively reached down for the first drink of the day, and, as soon as that was 
gone and feeling quite ill, I made my way to the off-licence and was back to square 
one. The relapse hit me very hard. All I could do was hide away from any family 
who would talk to me (only one son) and everyone who had supported my 
recovery. My denial was total and as I got worse so did the shoplifting and begging.  
 
It was whilst I was trying to outrun two security guards after stealing a three litre 
bottle of cider and a bottle of vodka that I had my first heart attack. I was taken to 
hospital and treated, but as soon as I was well enough the police arrested me for 
theft. Two days later I had a mild stroke and was strongly advised by my consultant 
to go back into recovery, but on my release I reasoned it hadn‘t worked the first time 
so why should it now? So I just traded on whatever sympathy I could get and just 
carried on as before. 
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A couple of months later I got into a drunken brawl followed by an altercation with 
the officers who were breaking it up and I suffered a more serious heart attack and 
again I ended up in hospital. But by now the doctors, police and the hostel were 
completely fed up with my antisocial behaviour as were the supermarkets, off-
licences and just about everyone else. On my recovery I was arrested and in court I 
was given an ultimatum—either take treatment willingly myself or go to prison, 
which I did not want. So I again entered treatment, which the police insisted on as 
they were adamant I would return to my old behaviour.  
 
My start in treatment was the same as the first time but much quicker—it began 
within 5 weeks at the alcohol treatment centre plus detox at the psychiatric hospital. 
This time I got funding for my rehabilitation which was at a different centre, but 
which offered a very similar style of treatment to where I was first treated. After 6 
months I was offered the chance to extend my recovery period by entering a third-
stage supported house, which was a semi-independent unit. I decided I needed this. 
 
I had another stroke whilst at the supported house. After 14 months as a resident, 
and with the help and support of the staff of the rehabilitation centre, I got my own 
flat and have remained alcohol and drug free for the last 6 years. My physical health 
is still giving my consultants cause for concern but I am recovering slowly and as 
soon as I am fit enough to undergo surgery I am hoping one day to be fit enough to 
return to the workplace. However, my years of abuse have cost me a high price in 
terms of my career, home, marriage, family (four children whom I didn‘t see for 10 
years) and my health.  
 
I have to say I could not have achieved any of this without all the support I have 
received from the YMCA (the hostel and rehabilitation centre), the hospitals, the 
alcohol treatment centre, the rehabilitation centre who ran the supported house 
where I was a resident and, begrudgingly, the police who were really very good 
about things considering my atrocious antisocial behaviour. 
 
I have worked hard to restore my relationships with my four children and two 
grandchildren, and have had considerable success. I had support throughout this 
process from my keyworker, to whom I will be forever grateful, and my ex-wife who 
I always thought, through my drunken years, hated my guts (she didn‘t – she just 
wanted me to get back to living again). 
 
Now I feel fairly good about myself and what I have achieved. But I don‘t feel pride 
in myself and I will never forgive myself for the man I became nor for the hurt I have 
caused the people I love and the things I have done. Also I am afraid to get too close 
to people or commit to any relationship because I feel I can never completely trust 
myself again. But, having said that and having explained the reasons to my current 
girlfriend, who is understanding of my fears, I am making positive headway in 
‗trusting me‘.  
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Personal account B  
I am 55 and I started drinking heavily 2 years ago. I had been drinking for a long 
time before that and was dependent on alcohol, but I thought I was in control. For a 
while I went to work and no one noticed there was a problem. Alcoholics always say 
they can handle it and that is also what I thought. But then it did start to affect my 
ability to do my job and one day I lost it and drove a car into the building where I 
worked. So I lost my job and my licence, and my stepmother had also recently died 
and so I started drinking heavily after this. I was always being picked up by the 
police and I also tried to commit suicide at this point in my life. 
 
When I was not drinking so much I tried to get help because my family wanted me 
to. I went to my GP first of all as he had always been helpful. He recommended I go 
to my local drug and alcohol service, and they sent me to a residential mental health 
hospital where I went on their detoxification programme on a voluntary basis. It was 
not a nice place at all, and the workers seemed far more concerned in getting people 
clean of heroin rather than helping people with alcohol problems. I was only there 
for 2 weeks and it did not help much. I went back to drinking when I got out. 
 
But over the next few years I had to go back to that ward twice for a week at a time 
because of my mental health problems (I had acute depression and had attempted 
suicide) and I also had another detoxification. I hated the attitude of the staff--I was 
supposed to have a meeting with the special care workers three times a week but it 
never happened. The groups were mostly made up of young people and they were 
drinkers and drug users together, so this did not work for me. The door was always 
locked and I felt I was a prisoner. The people I met all went back to booze. They 
wanted me to go to a rehabilitation place in the country, but I wouldn‘t go because it 
was for a year and it meant I would not see my family. 
 
When I was made to go to another hospital I saw a real difference in attitudes. The 
door was always open and one of the workers chatted to me for over an hour. I was 
only there for one night but if it had been longer I think it would have helped far 
more than the other hospital. They were there to help drinkers as much as drug 
users. 
 
My family was there for me when I was drinking. They told me early on that I had a 
drink problem but I always denied it. I was stealing from them and one weekend I 
even stole my son‘s whisky, which he was keeping for a special occasion. I denied it 
but then I realised what was happening to me and tried to get help. I live with my 
Mum in her house with my son and I have two brothers with families and a sister in 
Australia. They always tried to get me to get help. My Dad was there for me too. 
 
It was only earlier this year I realised I had a real problem and I needed help so I 
went back to hospital but I was barred because the last time I turned up and said I 
wanted help I was drunk. Their policy is that you can‘t turn up intoxicated.  
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I hit rock bottom when I was arrested for common assault in August 2009 and was 
sent to prison the next month. I went into detox on one of the wards. The staff were 
very good--they should swap jobs with staff in other services so other workers can 
see how it should be done when helping drinkers. I was always checked on, and I 
was able to talk to the officers and the therapists. I spent 2 weeks on this ward, and 2 
weeks on another ward. Someone from Adfam came and saw me and kept in touch 
after I left. It helped to have someone in touch with the family and me. She is non-
judgemental and says I can phone her when I need to talk.  
 
I had a 3-month sentence but I only did a month because of good behaviour. I had no 
idea I was going out. They woke me up at 6.30 and said ‗off you go‘ so I phoned my 
Mum. I was really shocked and at the beginning thought it was a joke. But going 
home clean made me and the family really happy. 
 
I started going to AA and liked it because it was for alcoholics who were more my 
age. But it was on Saturdays which made it difficult to attend so I have not been 
recently. 
 
I have cravings and triggers but I can control them. I think of something else and do 
something else like make myself a cup of tea. I still have good support from my GP 
who is a real family doctor and looks after my Mum. I really trust him. I am 
determined not to drink again. 
 
When I was a drinker I hated the way people treated me. They judge you without 
knowing you because of what you look like as a drinker. I think it is harder to get off 
drink than drugs. It can kill you getting off alcohol and people do not know this--
they think you can just stop. People seem to have more sympathy with drug addicts 
rather than alcoholics. People need to be educated about this, they just don‘t 
understand.  
 
I think services should get people who have managed to stop drinking to talk to 
others to help them. Experience is really important.  
 
Personal account C  
From a very early age my lifestyle was somewhat alcohol-orientated in as much as I 
started work at 16 in the shipping industry where alcohol was available on board 
ship at any time of day or night. We seemed to accept that this was part of our 
working life, although I never felt at that time as if I was dependent upon drinking 
alcohol. Outside of work my sporting interests also involved much alcohol. It is clear 
to me now that alcoholism is a progressive illness and it was later in life that my 
dependency was determined. 
  
My problem in the early stages did not seem to have affected my education or 
professional life. Indeed I went on to be very successful in my profession. However I 
realise that latterly I was a 'working alcoholic'. It was at this time and as I retired that 
FINAL DRAFT 
 539 
 
the lives of my wife and close family were badly affected. Although they initially 
supported me in seeking help I was not ready and really only paid 'lip service' to the 
help available just to please them. I really had no thought about how I was tearing 
the lives of my family apart. 
 
I denied any alcohol problem although I was told by my GP to stop drinking. 
However, my GP seemed to distance himself from the alcohol problem. In 
September 2001 I was diagnosed with severe depression and prescribed 
antidepressants. My GP also referred me to an antidepressant clinic, where I 
received individual counselling together with group therapy. I attended the clinic for 
a number of years—but I still drank. 
 
At one stage I tried private treatment which consisted of a one-to-one consultation 
and a prescription of naltrexone which I was to take when I felt the desire to drink or 
was subjected to an alcoholic environment. This was supposed to reduce my urge to 
drink at that time. However this did not help me at all although the clinic claims a 
huge success rate. 
 
In early 2005, even after attending the antidepressant clinics and seeking private 
treatment for heavy drinking, I was in a desperate state and contacted the Alcoholics 
Anonymous helpline. I attended AA meetings all that year. 
 
On one occasion, while very much under the influence of drink, I was taken by my 
wife and daughter to the GP‘s surgery and saw the practice nurse who immediately 
referred me to the local psychiatric hospital where I stayed for about a week for 
detoxification before being discharged. I then attended an alcohol/drug centre 
which led to an interview with a local alcohol and drug agency. The agency gave me 
one-to-one counselling before I was introduced to the 12 step programme, which had 
strict rules of no alcohol intake and attendance at at least three AA meetings per 
week. After 3 weeks into the course, I was banned from attending AA meetings 
because I was under the influence of drink. I was also suspended from the agency. 
 
I was nearly 70 years of age before I finally agreed to attend an interview at a 
rehabilitation centre. After then refusing to go to the first interview, with the 
encouragement of counsellors from the agency I entered a rehabilitation centre for 
primary rehabilitation. I was in primary rehabilitation for 6 weeks and completed 
steps one to five. I opted to continue into secondary rehabilitation for 12 weeks, 
completing steps six to twelve. I was given an intensive course of treatment 
consisting of one-to-one counselling and an in-depth understanding of the 12 step 
programme. 
  
The treatment at the centre, and afterwards supported by the agency and AA, was 
incredible. The 12 step programme with the agency did not work for me as it was 
only one day per week and I did not have any self-control over my drinking for the 
other 6 days, whereas the intensive course in rehab gave me the concentration of 
mind I needed away from outside influences. 
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I still attend AA meetings which are an essential part in keeping me in sobriety and 
are helpful not just for me but others in recovery. The fact that it is anonymous 
enables us to talk frankly and open without fear. My family, especially my wife who 
attends Al-Anon meetings, are very supportive. In the first 6 months of recovery I 
also attended aftercare sessions at the rehabilitation centre. Friends and community 
groups were also very supportive. Close friends and relations helped me 
considerably during the times when I was completely under the influence of alcohol, 
taking me to hospital, sitting and talking to me and generally supporting my wife 
and family. The community groups I belonged to supported me the best way they 
could and by not rejecting me. In recovery both friends and the community groups 
have supported me and welcomed me without reservation. Because of my heavy 
drinking I was not really aware of the support I received in those early days and it 
was some time before I really appreciated it. 
  
The nature of my problem has changed in as much as I am still an alcoholic but I do 
not drink. Life now is 'beyond my dreams' – there has been such an incredible 
change in my life and the lives of my family. However, I am still an alcoholic and 
live with the fear of going back to those dreadful days. I also live with guilt, anger 
and resentfulness of the things that have happened and for what I inflicted on others 
during my years of drinking. I have to learn to control these feelings. It all takes 
time, as does the trust I have to regain from all whom I hurt and cheated. When it 
does come, and it comes slowly, it is the greatest gift. I am lucky that after years of 
abusing my body physically and mentally, now at the age of nearly 75 I am fit and 
well. 
 
We all have our own ways of handling our lives in sobriety. However most of us 
acknowledge that talking to fellow alcoholics and close family is the best strategy for 
continuing in recovery. If we do not—and it does happen when we get into a 
'comfort zone'—then it shows in the way we conduct ourselves. Even now after 4 
years of sobriety I fail in this area, which causes problems with my close family, 
especially my wife. The one basic rule is not to take the first drink, day by day. 
 
Personal accounts from carers 
The methods used for obtaining the carers‘ accounts were the same as outlined 
above for service users but the questions included: 
 
 In what way do you care for someone with an alcohol problem?  
 How long have you been a carer of someone with an alcohol problem?  
 In what ways has being a carer affected your everyday life (such as schooling, 
employment and making relationships) and the lives of those close to you? 
 How involved are/were you in the treatment plans of the person with 
an alcohol problem?  
 Were you offered support by the person‘s practitioners (for example, 
their GP, alcohol service worker, or other)?  
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 How would you describe your relationship with the person‘s 
practitioner(s)?  
 Have you and your family been offered help or received 
assessment/treatment by a healthcare professional?  
 Did you attend a support group and was this helpful?  
 Did any people close to you help and support you in your role as a 
carer? 
Carer account A 
I remember very clearly the first time I felt I had become a carer of my youngest son, 
who was 16 at the time. It was around 9 p.m. one evening 13 years ago. This night 
would surely stay in my memory for ever. A young person who was completely out 
of control arrived home and brought mayhem to the family. He produced a large 
knife and I was standing at the other end of it in my kitchen not knowing what to do. 
Watching four policemen restrain my son and take him away shouting and 
screaming left us feeling numb with disbelief. This was the first time my son had got 
drunk and the 13 years since that first night have been a rollercoaster and have 
changed the lives of the whole family. It was when I seemed to begin to ‗care for‘ 
instead of ‗care about‘ my son. Over those years huge changes have taken place in 
my life and the lives of my husband and my older son. Many people in the local 
community have also been affected, and the devastation has been vast. I never saw 
myself as a carer, however my life took on a completely different meaning.  
 
Living with someone with an alcohol addiction does not stop life going on in other 
areas. During this time, my Dad had a heart attack and died in front of me. My Mum 
got sick and I was told she was going to die. I moved in with her for the last 5 weeks 
of her life to care for her while my husband tried to cope at home. Each morning I 
would hear stories from my husband involving the police, ambulance service and so 
on, and of the horror of the evening before. This is just one example of how life does 
not stop because you have someone misusing alcohol. It became a huge balancing 
act.  
 
My physical health suffered—I developed chronic fatigue syndrome and I went into 
a severe depression where I just felt I could not deal with life any longer. I remember 
clearly how close I came to taking my own life, but it really did seem to be the only 
way to escape the horrendous knock-on effect of watching my son getting sicker and 
sicker and slowly destroying his life. I had to give up work which led to financial 
implications and more stress for my husband. My relationship with my husband 
was affected hugely, and my relationship with my older son was also suffering. Any 
social life stopped when we became too afraid to leave the house, and holidays 
became non-existent. My whole day seemed to be geared towards trying to provide 
emotional and practical help to someone who just seemed to be going deeper and 
deeper into despair. I remember the evening we went out for 2 hours and came 
home to my son collapsed over the gas hob with two rings on and his arm inches 
away from the flame. Ten more minutes I am not sure we would have had a house to 
come home to or a son.  
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Over time we experienced violence towards ourselves, had many things smashed in 
the house, sat in police waiting rooms and court rooms, and found our son with both 
arms slashed by a razor. On one occasion we went from visiting our eldest son at 
university, to going straight to a young offenders institute to see our youngest son. 
Being completely naive about prison we felt humiliated and ashamed and tried to 
hold back the tears when our young lad appeared with a swollen face and black eye. 
I spent the 70-mile journey home sobbing my heart out.  
 
I sat by his bedside whilst he was on a drip after trying to take his own life for the 
second time; on the third occasion he insisted we did not call for help—we had to 
wait for him to be unconscious before doing so. Imagine how that felt when you 
knew it would be so easy to do nothing and hope that all the pain would stop, for 
him and for us. Only people who have been in this situation would know how we 
could even begin to think like this! It‘s so hard to believe it yourself, but the 
continuing despair and exhaustion just takes over.  
 
Try living with the fear – every time the phone would ring or the door would knock 
would it be the news we all dreaded? I remember once when he was missing for 3 
days, and I saw two police officers come up the drive. The difference this time was 
one of the officers was a police women and I thought, ‗this is it, they have sent a lady 
to give me the news‘. Imagine living with fear on that level every day and night! 
Also came embarrassment, shame, guilt, anxiety, anger, isolation, despair and 
feeling powerless. I had lost both my parents and had no time to grieve; I was trying 
to keep the family together, trying to cope with my son‘s needs and the drinking, 
trying to get someone to really listen, trying to find the energy to get out of bed 
because of my own illness and it felt overwhelming every day. 
 
Over the years my husband also suffered with depression and began to use alcohol 
to escape the problems. For 2 years I had to deal with both my son and husband, and 
eventually I had to leave my home, which did not feel secure, to stay with a friend. 
My marriage was in jeopardy after 31 years and my husband was on the edge of a 
complete breakdown. Thankfully, after I left, my husband decided to get help and 
stopped drinking. Four months later I returned back to my home. 
 
My eldest son also had to receive treatment for depression; his life was affected 
enormously in a whole variety of ways and it‘s taken time to even begin to rebuild 
any of the relationships. It felt impossible to give him time and support and it was 
difficult to enjoy the good things happening in his life. One of my happiest and yet 
saddest memories was his wedding, when I stood at the front of the church and gave 
a reading about love. The loss I felt that my youngest son was not present will 
always be there. Many social occasions were cancelled, destroyed, or not even 
thought about. There was a complete loss of normality. 
 
Was I a carer? My son‘s GP certainly did not see me as one—no information 
regarding any support services was ever given. Our relationship felt like a 
battleground. I had been taking my son to see different people since he has been 2 
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years old—if only someone had really listened to me regarding this. As a mother I 
had always known there was something not right and there were problems long 
before alcohol was introduced into my son‘s life. There were many times when my 
son was not drinking when a comprehensive assessment that considered his 
previous medical history could have taken place. It took from the first incident to 
last year to find a person who would listen. My son felt the same. Everyone kept 
blaming the drinking. In court my son said: ‗I have been seeing people all my life 
and people listen, but nobody has really heard what I am saying‘. 
 
Treatment for my son came first by a community programme, then residential 
treatment at the age of 19. As a Mum I never felt included in the process in any way 
and it would have been very valuable to have been given information and support in 
my own right even if my son had not wanted me to be involved with his treatment. 
Recovery needs to be for the whole family. Guidance around relapse would have 
been especially helpful. I felt elated when my son entered residential treatment for 
the first time, but then felt crushed when relapse came months later.  
  
After a period of 8 years waiting for the second attempt at residential treatment, I 
again felt crushed when half way through things collapsed. It goes against 
everything as a Mum to say ‗no‘ to requests from your son, especially for money for 
a place to stay and keep safe. Imagine how hard this is! Often it is the case that no 
advice is given to parents of children with alcohol problems, or the advice is 
conflicting and many are confused as to what they should be doing to support their 
child. We needed help for the whole family, not help to divide us. After 2 further 
years of chaos, I started to try again to find someone to listen. 
 
It was only because the mental health team would not listen to me that I requested a 
Carers Assessment. I felt my son was at real risk of harm to self and others and I felt 
it was the only way to get this fear put down in black and white, to have evidence 
that I had told someone. The ‗merry go round‘ of mental health services and alcohol 
services nearly tipped my own balance more than once. I had medical evidence that 
there were underlying problems long before the alcohol addiction took hold, and I 
felt this was essential for correct assessment. This was a complete failure in my eyes 
and later I was proved right. It did not help having a Carers Assessment worker who 
did not have any knowledge of addiction,  
 
The biggest help and support has been through attending 12 step meetings. I have 
attended Families Anonymous and also attended Al Anon. The meetings helped me 
focus on myself, and gave me a support network in my own right. I was not judged 
and felt completely understood. It was a personal development of my own, helping 
me to understand that there were no guarantees that my son would stop drinking, 
but that I needed to take care of myself. It also taught me how to look at my role in 
my son‘s addiction and to support him in a more valuable way. To even begin to 
stand back when my son could die was the hardest thing to do. These meetings were 
a 40-mile round trip each time, so there was a large chunk of time and quite a cost 
involved.  
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I have also attended two other support groups which were not 12 step. Both of these 
were of different value, but I sometimes find it difficult when groups get into talking 
about the problems too much and focus on the other person. I needed to learn new 
tools on how to cope with my situation. There were also many other things I needed 
to know, for example, how and where to go in an emergency, and finding out about 
these things was as hard for me as finding the correct services for my son. There was 
a lack of communication, a lack of information, battles around confidentiality, and a 
constant struggle. 
 
I have a couple of very close friends who supported me the best they could. That 
might mean when I was walking the streets in desperation and depressed myself 
that I could find my way to their house and there was always an open door. Alcohol 
addiction brought family rows and sometimes, after my Mum died, I just felt I 
needed somewhere to go even for a short while before returning to the chaos. The 
people closest to me (for example, my husband and my eldest son) were also 
affected and found it difficult to support me. This was a 24-hour situation and my 
husband had to continue to work to support the whole family and my eldest son 
needed to pursue his own life somehow. The main thing to do was try and support 
myself in my role as a carer by my own self-care. 
 
I have attended two residential family programmes which were also very useful; 
however, they had to be funded by us and were costly. I attended my first family 
programme when my son entered treatment for the first time several years ago. I 
wanted to learn how to deal with the situation in a better way, and during the 3 days 
of the course, I was able to look at my own feelings and confirm that getting help for 
myself was extremely important. It also helped me to look at ways of supporting and 
loving my son but not to support his drinking in any way. I attended the programme 
alone. My second 5-day residential course was 5 years ago. It helped me learn more 
about addiction, look at my own self-care and understand my behaviours around 
my son. It helped me gain the courage to do some of the things I needed to do but 
were extremely difficult. I also attended this alone, whilst my husband was at work 
and continuing to support the family. However, one person changing can start the 
process of change amongst others.  
 
Everything I have learnt and put into practice has helped me maintain my own 
emotional and physical health in a much more positive way today. It‘s taken a lot of 
work and courage. The biggest turning point for us all was the confirmation of 
underlying problems last year. My son can now understand his reasons for drinking 
when he does, which he has been trying to express for many years. Attitudes 
towards carers and family members need to change if people are to get well. You 
cannot have a relationship with the person‘s practitioner if that practitioner believes 
that only the person with the alcohol problem is involved. Our family spent years 
trying to get the right help for our son, which would have made such an enormous 
difference to not only his life but to all of our lives. There are no guarantees that he 
would still have not developed an addiction to alcohol; however, knowing that the 
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underlying problems were real would have helped us all see things in a different 
light. These years are lost.  
 
On New Year‘s Day this year we had our first family meal together for 10 years. 
Rebuilding relationships within the family is one of the main areas to restore. My 
son is doing well at the moment – he is working and gaining huge insight into 
himself. Unfortunately when there are changes in our son, things for us can change 
overnight, but we just have to deal with this as and when it comes. At present he is 
living with us, but only because of a relationship ending. At times it can still be very 
difficult, but clear boundaries help us all. 
 
Carer account B 
My partner had always been a heavy drinker and in his teens and twenties had used 
heroin. He came from a background of regular social drinking and his parents run a 
pub where he lived and served in the bar. This set a pattern of daytime and evening 
drinking every day. At weekends he would often drink a great deal and would be 
completely immobilised for at least a day with very bad hangovers and sickness. He 
was diagnosed with hepatitis C which had damaged/is damaging his liver and this 
was probably the cause of his extreme reaction to alcohol. 
 
Reacting to pleas from us, his family, he stopped drinking every evening in the local 
pub but we found out later that he was drinking after work and would also buy 
alcohol when he took the dog for a walk later in the evening. Over time, and 
coinciding with a change in family life with me taking up a high pressured and 
senior job and our children leaving home to go to university, he began to drink far 
more. His behaviour was dramatic and extremely upsetting as it was obvious that he 
was drinking to obliterate his misery and when he did drink like this he would 
become tearful and abusive dependent on his mood. He never drank at home but 
would go to parks or drink while walking around the area until he collapsed on 
benches or in the park and we had to go and find him. I made him go to the doctor 
who called out the local mental health team who put him on a high dosage of 
antidepressants, but things got worse not better and he then started to disappear 
overnight. As the GP said, the best thing he could do was to be arrested and dry out 
because he couldn‘t get help until he presented in a sober state. The police agreed 
but the nightmare of disappearances, us taking turns roaming the streets looking for 
him, trying to entice him home via phone calls, the muggings and beatings he got 
whilst collapsed on the streets, went on for years. He would go to AA to keep us 
quiet and also went to the GP every few weeks which, looking back, was the only 
indication that he wasn‘t trying to kill himself through drink. Friends tried to help 
and he was offered psychotherapist support by work but he would not go and he 
ignored friends. The only place he could go to whilst intoxicated was a drop-in 
centre which, for a while, successfully engaged him and allocated him a case worker. 
I tried to talk to the worker to find out how we could help or what was happening 
but because of stringent confidentiality issues I got no help or information at all. This 
did not happen when drugs came into the picture and I do feel that given my 
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partner‘s drunkenness, he did not understand or was given no guidance on how to 
opt out of the confidentiality issue.  
 
It was the downward spiral which completely takes over someone who is vulnerable 
and makes me wonder about the word ‗carer‘. You aren‘t caring for someone who is 
in this state except by trying to keep them from harm and trying to get them to eat 
and sleep. Well, you start like that but by the end you are so furious that even that 
gets withdrawn – a useless threat really as my partner did not care if he did not eat 
or if he smelt or slept in the park. The family kept ourselves to ourselves and it was 
dreadful to watch the effect it had on my younger child who was more vulnerable 
and a teenager at the time. The anger and anguish in the house was there all the time 
although we often tried to pretend we were a normal family watching EastEnders 
together. But all the time we would be watching and waiting for him to turn up so 
we could relax a bit. We even tried locking him in – all these desperate tactics made 
no difference. 
 
There was no one professionally who helped us in the first years and it was only 
when we found out by accident that my partner was back on heroin that any funded 
support for the family was offered. A local service for families of people with drug 
and alcohol problems helped us. We had a family meeting and were able to ring and 
talk to the key worker assigned to us. In meetings we wrote things down on flip 
charts and talked through lots of issues. This helped the children face up to their 
father and to write down their wishes for the future and their terms for us taking 
him back. But the support was not continued and we were led to believe that this 
was because he was being treated primarily as a drug user rather than as a 
dependent drinker and there was little funding for the latter. 
 
I think that for my partner drink was far more pernicious than drugs. It nearly 
destroyed our family because of the extreme moods, the anger it caused in all of us, 
the tears and the disappearances. On drugs he could lead a sort of normal life – so 
much so that we did not even know he was taking heroin for months. He finally 
stopped drinking when my children and I said we had to leave or to get help. We 
did not realise that he had just swapped his addiction.  
 
Families and friends find it far more difficult to deal with drink because it is so much 
part of our social makeup – and so available. It is impossible to stop someone 
drinking if they don‘t want to stop because they can get it at any time and it is 
relatively cheap. We tried a number of things but we had no support from 
professionals so we were sort of making it up as we went along. We made a lot of 
mistakes – like locking him in and attempting to forcibly remove cans and so on 
when he was on the streets – but we only found out why these were not useful 
tactics until later on. The web was informative but not personal and the family 
support group Al Anon was just not suitable for us, especially because the meetings 
were in the day time and I had a full-time job.  
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Eventually my partner reached rock bottom and was arrested for possession of Class 
A drugs. He was very drunk as well. From the moment of his arrest, all the help 
came pouring in – detox was arranged, community rehab set up, and a care manager 
appointed who worked with him on a care plan. We were also offered family 
therapy via these services. We did not take it up mainly because we felt we had gone 
through enough and we felt our coping skills and understanding of what to do next 
were stronger. We wanted him to go through rehab for himself. The 12-step therapy 
used by the rehab service helped him a lot and he started going to AA and NA 
several times a week. He has not had a drink – except for a few pretty dreadful slips 
– for nearly 3 years and has not used heroin. But when you are involved like this 
with a user, you are always on the lookout for slips or lapses. Ironically it would be 
better if such a lapse was drug related as I am still not at all sure where we would 
get the same support if he started drinking again. 
 
Being a ‗carer‘ of a dependent drinker is lonely, frustrating and terribly tragic—
tragic because the thing you learn is that you know if someone wants to drink and 
stay drunk, they can always find a way. Street culture becomes their family and the 
real family are left outside. 
 
Thematic analysis of people with parents who have alcohol problems  
Introduction 
A qualitative analysis was conducted using transcripts from people with parents 
who have alcohol problems, accessed from the NACOA website.  
Methods 
Using all the personal experiences available from NACOA submitted from 2004 
onwards, the review team analysed 46 48 accounts from people with parents who 
misuse alcohol, the large majority of whom were female. All accounts have been 
published on the website in their original form. The majority are written by people 
from the UK but there are also some from other countries, such as the US and 
Australia. Poems and letters were excluded from the analysis. Each transcript was 
read and re-read and sections of the text were collected under different headings 
using a qualitative software program (NVivo). Initially the text from the transcripts 
was divided into three broad headings that emerged from the data: impact of the 
parent‘s alcohol problems on the child‘s behaviour, thoughts and feelings; impact of 
the parent‘s alcohol problems on the child‘s psychological state/mental health; and 
support and services for the family and the child. Under these broad headings 
specific emergent themes identified separately by two researchers were extracted 
and regrouped under the subsections below. 
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Impact of parental alcohol problem on the child’s behaviour, thoughts and 
feelings 
Avoidance and concealing the truth  
In recounting the experiences, a common theme that emerged was fear, shame and 
embarrassment which led to avoidance, escapism and concealing the truth about 
their parent with the alcohol problem. These kinds of behaviours impinged on the 
child‘s ability to enjoy simple activities, such as have a friend over to the house:  
 
I became an expert at hiding my feelings. I was scared to get a girlfriend because I 
was worried that she might find out. I never invited friends round to stay. I’d do 
anything to avoid going home… I took a job after school that involved working 
until 10 p.m. and I thought that was great because I had a really good excuse not 
to be at home. [Participant 01] 
 
As children we never invited anyone home, the embarrassment would have been 
too much to bear. 
[Participant 18] 
 
I wouldn’t invite even my best friend round to my house, I couldn’t bear for 
anyone to see my father. I was worried they would talk about me, worried about 
what they would think of me. 
[Participant 24] 
 
I dreaded events where parents could attend. If my dad came, he'd be drunk, sing 
loudly and make a fool of himself. I didn't want him there, didn't want to be 
different to everyone else, what child does? 
[Participant 02] 
 
Some people even described trying to hide the problem from themselves in order to 
cope: 
 
I led a double life, hiding my feelings until I’d ‘forgotten’ I ever had any, saying I 
was ‘fine, thank you’ when I was falling apart and convincing myself that it 
‘wasn’t that bad’. 
[Participant 44] 
 
I realised that I had kept all my feelings bottled inside me for so many years. So 
hidden that even I hadn’t really noticed them. 
[Participant 48] 
 
Many also noted that they had no-one to talk to and very little support (see section 
0), and concealing the truth made this even more difficult for others, such as 
teachers/friends, to recognise that there was a problem:  
 
I couldn't talk about my dad's problem or my mum's illness to anyone, my school 
only found out she was ill 3 months before she died, when I ran out of a lesson in 
tears and had to explain to a teacher. 
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[Participant 38] 
 
On the surface we were all terribly polite and we never spoke about the insanity 
and fear that lurked beneath the surface of our daily rituals… we were the best-
mannered children in the world to strangers. 
[Participant 43] 
 
Others mentioned that when they tried to face the problem and discuss their worries 
directly with their parents, they were confronted with negative responses or abusive 
behaviour which prevented them from raising the issue again:  
 
I told her I was worried she was an alcoholic. She hit me hard across the head and 
shouted, you don’t know what that word means. It was the last time I tried to talk 
to her about her drinking until I was grown up and even then I daren’t do it in a 
direct and open way. 
[Participant 25] 
 
I was the first one to mention that she may have an alcohol problem, when I was 
15, following an argument between my parents… the encounter led to a period of 
ostracizement from the family home. 
[Participant 22] 
 
Relationships in childhood and later life 
A prominent theme was the development of personal relationships and friendships 
in childhood and in later life. Many of the accounts reported that it was a challenge 
to form or maintain relationships with others. This was frequently attributed to a 
lack of trust: 
 
I struggle to form relationships with people, it is ingrained into me that nobody 
can be trusted, and that all promises are false. When I do form relationships with 
people, I cling to them tightly because I am scared they will leave me and in the 
end frequently this obsession only serves to push them away. I find it difficult to 
talk to people, and open up. I think this is something I’ll never be able to do.  
[Participant 24] 
 
The effect of my childhood has caused me to not trust people (although I trust 2 
good friends now)…and to pursue unsuitable relationships with men (hardly 
surprising after all 4 of the men in my immediate family abused me). 
[Participant 25] 
 
Because of the struggle to form successful relationships, as well as the avoidance, 
many people described themselves as lonely and isolated: 
 
I became a very serious, lonely teenager who was not able to trust anyone. 
[Participant 29] 
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I feel negative about lots of things and have isolated myself from lots of people, 
know I should not be but it’s so hard just now. I feel so different to other people 
and compare myself to my work colleagues who had a normal upbringing. 
[Participant 26] 
 
 
If anyone saw her drunk I was so ashamed. As a teenager, that made me feel 
different and isolated. I was lonely. [Participant 25] 
 
As adults, a number of people described wanting to find partners who were 
different from their parents, primarily people who did not have an alcohol problem. 
However, some did also say that they were attracted to others with similar 
experiences:  
 
Having an alcoholic father made me determined never to get myself attached to a 
man with any kind of habit [Participant 38] 
 
I chose my husband and father of my two children very carefully…he drank very 
little and had no change in personality when he did and did not obsess about 
where the next drink was coming from [Participant 13] 
 
I'm in a good relationship, with another child of an alcoholic who shares a lot of 
the same understanding. [Participant 22] 
 
Triumph over adversity  
People described many situations in which negative experiences and beliefs from 
their childhood were turned around in order to change current emotions, thoughts 
and behaviours into positive ones. For example, taking on different parenting skills 
to those of their own parents in order to be better parents, or trying to make the best 
of a situation: 
 
I vowed, even as early as eight or nine, that I would never ever inflict this kind of 
torture – of being a child of an alcoholic parent – on a child myself 
[Participant 26] 
 
I had hoped that having a family of my own would help to fill the emptiness inside 
and provide some of the love, warmth and nurturing I had missed. In bringing 
them up we have completely turned my parent’s philosophy on its head 
 [Participant 43] 
 
I'd come to the conclusion that I was stronger than I thought I would ever be 
when faced with her eventual demise...I knew I had to find something positive to 
do with it; to have buried the experience along with her, would have been a crime.  
[Participant 14] 
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You know now that for every negative emotion there is an opposite positive...tears 
into laughter, fear into courage, co-dependency into mature friendship…shame 
into pride…lack of control into more control over your life, victim-hood into 
assertiveness  
[Participant 42] 
 
I learnt to channel my addictive tendencies into more positive things such as my 
great passion in life, surfing.  
[Participant 01] 
High levels of responsibility  
Another theme that emerged was that of increased responsibility. Some felt that they 
were forced to grow up quickly through practical and emotional burdens which are 
not usually considered the responsibility of a child:  
 
All my energy and time went into worrying about and saving my mother from 
her drunken dramas. It was extremely draining being the responsible one. I was 
not sleeping or eating properly, and constantly felt ill with headaches through 
stress.  
[Participant 10] 
 
I was forced into growing up too quickly and had to get on with things, doing my 
washing, making sure I had clean clothes for school or did my homework, getting 
myself a meal.  
[Participant 38] 
 
Without thinking about it I had denied huge parts of myself, learned to make 
myself invisible and to take care of myself. After all, nobody else was guaranteed 
to do it for me.  
[Participant 37] 
 
High levels of responsibility were commonly reported and often led to feelings of 
guilt and blame, as they felt that it was partly their fault that things had gone wrong 
and that in retrospect they could have done more to help their parent with the 
alcohol problem. Some even felt that the problem was actually theirs through over-
identification with their parent: 
 
I always blamed myself for all the hurt my mum caused me thinking everything 
was my fault  
[Participant 26] 
 
I felt immense guilt, perhaps if I’d been to see him more often this would not have 
happened. Maybe I could have prevented his drinking.  
[Participant 24] 
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It still feels like I'm 'carrying' her problem for her, because she never admitted she 
had one…I understood she had a problem; she didn't and so she thought it must 
be my problem.  
[Participant 22] 
 
I kind of treated her illness as my illness, as though we were both alcoholics and 
both had something to hide.  
[Participant 01] 
 
Other themes relating to impact on behaviour which were apparent but less 
prominent than those outlined above included: committing unlawful behaviours 
such as stealing; negative impacts on education and employment, such as failing 
exams or struggling to keep a job and experiencing a sense of relief at the death of 
the parent with the alcohol problem. Many also described suffering some form of 
abuse from family members or relations, which could have impacted on a variety of 
behavioural and cognitive outcomes.  
 
Impact on psychological state/mental health  
Fear, anxiety and worry  
A theme which repeatedly appeared was that of fear, and anxiety and worry. People 
described feeling scared about coming home from school, worrying about bad things 
that may happen to their parent and generally being on edge: 
 
Coming home from school was terrifying. I knew every floorboard that creaked, 
every door that squeaked and became expert at moving silently. I practised when 
he was out.  
[Participant 36] 
 
‘As a child I always knew something in my house was wrong. I had an anxious 
feeling most of the time and never really questioned it. I would lie awake worrying 
that we would get burgled and there was only me who could phone the police. My 
mind would go into overdrive with anxiety.  
[Participant 25] 
 
I do still worry about my mother, I do not think a part of me will ever rest about 
her drinking, until the day she dies.  
[Participant 10] 
 
Depression and feeling low 
Another theme that emerged was the experience of depression, unhappiness and 
despair, both during childhood and continuing into later adulthood. Some people 
even talked about suicidal feelings: 
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I was 16 when I realised that I couldn’t remember the last day that went by when 
I didn’t cry and feel utterly miserable and unhappy. I overdosed out of depression 
for something to change, for someone to notice, for someone to help me. 
[Participant 46] 
 
I suffered low self-esteem, a lack of sense of self, self harm, an eating disorder, 
attempted suicide, anxiety, and depression and welcomed an abusive lover into 
my life. 
[Participant 08] 
 
I am convinced that these experiences have played a major role in allowing my life 
to be subsumed on occasions by misery, fear and despair. 
[Participant 41] 
 
You have to work at being 'happy', and fight off continually, the bogey of 
depression. You are constantly saddened, and unable to ignore great grief and 
suffering of anyone in the world, and absorb everyone's trauma like a sponge. 
[Participant 35] 
 
I’m suffering severe depression now and frequently think about taking my own 
life, have had counselling; maybe not enough of it. 
[Participant 26] 
Anger  
Anger was another emotion which was frequently described in the experiences, 
although exact reasons underlying the anger were for the most part not described:  
 
Forgiveness was vital for me as I had years of fear and unresolved anger.  
[Participant 03] 
 
I got angry with the people that looked on the bright side, ‘always look on the 
bright side of life,’ Rubbish. ‘Things aren’t as bad as what they seem.’ Shut up. 
‘Things will get better, they always do.’ Anger. I was confused, I did want to get 
better, but I didn’t know how. 
[Participant 08] 
 
I have never ever forgiven myself for my behaviour towards her as a teenager. I’d 
slam doors, break things, scream, rant rave in frustration. 
[Participant 02] 
 
Own alcohol problems  
Another theme that emerged was the development of their own alcohol problems, 
both in adolescence and adulthood: 
 
Coming to terms with my mother’s alcoholism took me on a rather circuitous 
route involving my own deep struggles with the substance, over many years. It 
FINAL DRAFT 
 554 
 
was almost as if, despite vowing I would not end up like her, I had to experience it 
to understand it. 
[Participant 25] 
 
I was first drunk when I was 12 years old. I stayed drunk either in my head or 
physically, for the next 13 years it took away all the pain of being an object, OK it 
created so many other problems but killed the feelings when I was out my head. 
[Participant 40] 
 
Instead of breaking free from his restraints, I began drinking, just like he had! 
[Participant 43] 
 
They described how they accessed help for their own drinking problems and there 
were mixed views about whether talking to health professionals or attending self-
help groups made a difference, however the majority did report a positive outcome: 
 
I started to realise that my drinking was now problem drinking and sought help 
from a counsellor. After talking to the counsellor, who explained the progressive 
nature of alcoholism, that my drinking was alcoholic and that there was only one 
cure: i.e. total abstention, it all fell into place. 
[Participant 02] 
 
I sought treatment and found nightly doses of Amitriptyline to be helpful. I have 
also decided to take part in a course of psychotherapy. Though I look upon the 
drug as a temporary measure, I will not lose sight of the principle that whatever 
helps me to limit the impact of the most distressing and intrusive of my experience 
is a good thing. I have retained control in my purposeful dealings with medical 
and mental health professionals. 
[Participant 41] 
  
I was in AA, and although I needed them it took years to let anyone near me. 
When I get that old feeling I am still the same. I still feel that for an adult child 
AA is a hard place to be if they do not have some kind of support behind them. 
[Participant 40] 
 
My girlfriend knew that I was an alcoholic and she persuaded me to enter a 
treatment centre…I spent 12 weeks at the centre drying out and afterwards 
received lots of support by joining Alcoholics Anonymous, the self-help group for 
recovering alcoholics. I would never have stayed sober without them but it’s now 
been 10 years since I touched drink. 
[Participant 43] 
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Support and services for the family and children of parents who misuse 
alcohol 
Talking to somebody 
One of the most prominent themes that emerged when discussing help and support 
was the need to talk to somebody about what they were feeling and thinking. Many 
felt this was difficult to do, but once they did manage to talk to someone they felt 
relieved and found it helped to discuss their problems. A few people talked 
specifically about how having a supportive teacher to talk to was helpful: 
 
The worst part was feeling alone and that I could ask no one for help. I used to 
dream about talking to someone and the relief that would bring but felt disloyal 
for even having the thought…I wish I had felt that talking to someone was an 
option. It never even occurred to me. 
[Participant 25] 
 
There is support – and although the pain, guilt and shame does come back 
sometimes, facing it with honesty and knowing that you are not alone, gives you 
the freedom to move on and build a purposeful life with meaningful relationships 
that help you to grow. 
[Participant 44] 
 
I finally realised that I needed to tell someone outside of my family, so I spoke to a 
teacher which helped a lot. I wish I had done that earlier. I now realise how much 
easier it would have been if people had known. Looking back I can see that I needed 
help. My teacher suggested ways in which she could help, and it sounded great, 
although sadly it was too late. 
[Participant 01] 
 
Another apparent theme was how having a strong parent (who did not have a 
drinking problem) who tried to maintain some sort of stability at home was helpful: 
 
Despite all the problems alcohol caused, my Mother stood by us. She was torn 
apart but still put practical solutions in place. 
[Participant 36] 
 
My mother made enormous efforts to give us some normal family life but a lot of 
her attention was taken up with trying to keep my father calm and happy. 
[Participant 43] 
 
Talking to a professional and accessing treatment 
Some gained help from mental health professionals, and others tried to find out 
more information for themselves, for example from self-help books. Most found it 
helpful to talk to a professional and understand more about alcohol problems: 
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Just to hear about the disease in a non-judgmental way and to be heard can end 
years of isolation and be profoundly healing. She (doctor) was fantastic and told 
me that she had once watched a woman patient drink herself to death and had no 
intention of letting that happen again and referred me to the psychological 
services. That was the best thing that could have happened to me as I began to 
learn to cope without drinking and talk a bit about the shame that had kept me 
closed for so long. 
[Participant 25] 
 
I began to devour self-help books and trawl websites aimed at people like 
me…Initially just to experience the recognition was a relief. ‘Yes, exactly’ I’d say 
to myself. Then I began to ask ’why hasn’t anyone told me this before?’ 
[Participant 37] 
  
At college, my tutor organised counselling for me, I was really against the idea at 
first and went along determined not to take it seriously. But it really helped to 
have someone to talk to who wasn't involved in my life, who could see things from 
another perspective. 
[Participant 38] 
 
I have read all the self help books and I have to say if I hadn't read them to this day 
I don’t think I would have ever understood why I’m like I am. Sadly it took me 
nearly 20 years to realise the impact it had on me. I never realised until one day I 
sat in a counselling session. 
[Participant 33] 
 
However, the minority of people did mention negative experiences of accessing 
help: 
 
Three years previously I had gone to AA and found the experience profoundly 
disturbing. I thought of my mother over and over again, listening to very familiar 
stories and knew that I had to deal with my feelings about her as well and the two 
problems were inextricably connected. 
[Participant 25] 
 
Even in therapy, only the people who were there with me know what it’s really 
like – the pain, the terror, the blood, sweat and tears, the rage of helplessness and 
fear 
[Participant 46] 
 
Seeking help for the parent with an alcohol problem 
Another reoccurring theme which emerged was the children and other family 
members trying to access help on behalf of the parent with the alcohol problem. A 
few people described how the family were in a situation in which they felt they 
needed to get the parent sectioned in order to get help: 
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We were desperate at this stage and tried to convince the doctors to section her. 
This would have meant forcing her to have treatment in a mental health hospital. 
The doctor said he couldn’t and with that, I think her last chance went. 
[Participant 01] 
 
The only thing left we could do was to try and get him sectioned. The doctors 
agreed and were coming round the following day for him. 
[Participant 09] 
 
We had her sectioned with the thought that it would make her stop and realise 
what she was doing to her self and the people that cared about her. But she fell off 
the wagon again, I called an ambulance for my mum and they had a go at me for 
wasting their time, my mum could have died, what was I supposed to do?! 
[Participant 16] 
 
We tried getting social services involved as she was physically and emotionally 
neglecting us all. 
[Participant 23] 
 
In March of this year I fought for an appointment for my father at the local rehab 
clinic and took him myself. He was admitted and diagnosed with Wernicke’s 
Syndrome. 
[Participant 24] 
 
Others discussed trying to persuade their parent to access some form of help, but the 
majority reported an unsuccessful outcome: 
 
I have tried every trick in the book to get my dad to go and get help. But right 
now, it seems I am at a dead end 
[Participant 07] 
 
The subject of my mothers drinking is occasionally mentioned around my mother 
but her reply is she knows she needs help. She never seeks it. 
[Participant 18]  
Summary of thematic analysis 
There are some overarching themes experienced in childhood by people with 
parents who misuse alcohol. A dominant theme was that of avoidance and hiding 
the truth, which stemmed primarily from shame, fear and wanting a sense of 
normality. Concealing feelings and thoughts made approaching other people or 
services for support difficult, when most people just wanted to talk to somebody. 
This may have been exacerbated by feelings of anxiety and worry, in addition to a 
sense of guilt, self-blame and heightened responsibility towards the parent. When 
they did seek help on behalf of their parent, it seemed to occur in quite desperate 
circumstances, such as getting their parent sectioned. This suggests that children of 
parents who misuse alcohol do not, or cannot, access the services and support they 
need easily.  
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There were also overarching themes experienced in adulthood which seemed to 
originate from childhood experience. Many people struggled to form stable 
relationships which was often put down to lack of trust and self-isolation, which 
impacted on work, social life and the ability to maintain a successful relationship 
with a partner. Such problems could have originated from not being able to form 
‗normal‘ friendships in childhood. Depression, and to some extent anxiety, emerged 
as longstanding psychological problems attributed to various childhood experiences 
as well as personal traits such as low self-esteem. Development of own drinking 
problem was also a theme, in which alcohol was used to block out negative thoughts 
and experiences, or even used in an attempt to identify with the parent. There were 
also a range of common life choices which emerged, predominantly an impact on 
relationship choices and parenting skills. Some people also reported overcoming 
adversity by transferring the negative behaviours, thoughts and feelings into the 
positive ones.  
 
There are some limitations to the qualitative analysis for this guideline. As the 
review team relied only on transcripts submitted to NACOA, information on other 
issues that could be particularly pertinent for children with parents who misuse 
alcohol may not have been identified. Moreover, people who have visited the 
NACOA website to submit their accounts may over-represent a help-seeking 
population. Finally, while some accounts are based on experiences which occurred 
recently, others occurred a long time ago; therefore there may be differences in 
attitudes, information and services available. For these reasons this analysis was not 
included in Chapter 4. 
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APPENDIX 15: NETWORK META-ANALYSIS FOR THE 
ECONOMIC MODEL 
This section outline the network meta-analysis undertaken for the economic model 
assessing the cost effectiveness of pharmacological interventions for relapse 
prevention in people in recovery from alcohol dependence 
Clinical data considered in the network meta-analysis 
Clinical data for the network meta-analysis were derived from trials included in the 
guideline systematic literature review on pharmacological interventions for relapse 
prevention in people in recovery from alcohol dependence. This review included 33 
RCTs that reported relapse data for one or more of the interventions assessed in the 
economic analysis. The evidence network constructed based on the available data is 
shown in Figure 12. Inspection of the network and the available evidence indicated 
that 32 studies contributed to provision of direct or indirect evidence on the relative 
effect between the 3 interventions assessed in the economic model, and thus should 
be considered in network meta-analysis. The time horizon of these studies ranged 
from 3 to 12 months. Table 108 provides the relapse data included in the network 
meta-analysis the studies, as well as the time horizons of the studies considered. 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Evidence network for data on relapse to alcohol dependence. 
 
Table 108: Summary of the data reported in the RCTs included in the guideline 
systematic review on rates of relapse to alcohol dependence usedcin the network 
meta-analysis 
Study Timepoint  
(Months) 
Comparators Number of people 
relapsing (r) 
Number of people in 
each arm (n) 
1. Anton, 1999 3 1) Placebo 
2) Naltrexone 
38 
26 
63 
68 
2. Anton, 2005 3 1) Placebo 
2) Naltrexone 
47 
33 
80 
80 
3. Anton, 2006 12 1) Placebo 
2) Naltrexone 
3) Acamprosate 
126 
122 
117 
156 
155 
151 
4. Balldin, 2003 3 1) Placebo 
2) Naltrexone 
58 
53 
62 
56 
5. Besson, 1998 12 1) Placebo 47 55 
Placebo 
Acamprosate 
 
Naltrexone 
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3) Acamprosate 41 55 
6. Chick, 2000a 3 1) Placebo 
2) Naltrexone 
61 
64 
85 
90 
7. Chick, 2000b 6 1) Placebo 
3) Acamprosate 
242 
245 
292 
289 
8. Gastpar, 2002 3 1) Placebo 
2) Naltrexone 
36 
34 
87 
84 
9. Geerlings, 1997 6 1) Placebo 
3) Acamprosate 
116 
96 
134 
128 
10. Guardia, 2002 3 1) Placebo 
2) Naltrexone 
19 
8 
99 
93 
11. Heinala, 2001 3 1) Placebo 
2) Naltrexone 
54 
52 
58 
63 
12. Huang, 2005 3 1) Placebo 
2) Naltrexone 
4 
3 
20 
20 
13. Kiefer, 2003 6 1) Placebo 
2) Naltrexone 
3) Acamprosate 
32 
21 
22 
40 
40 
40 
14. Killeen, 2004 3 1) Placebo 
2) Naltrexone 
12 
21 
36 
51 
15. KRYSTAL2001 3 1) Placebo 
2) Naltrexone 
83 
143 
187 
378 
16. Latt, 2002 3 1) Placebo 
2) Naltrexone 
27 
19 
51 
56 
17. Lee, 2001 3 1) Placebo 
2) Naltrexone 
8 
8 
15 
24 
18. Monti, 2001 3 1) Placebo 
2) Naltrexone 
21 
18 
64 
64 
19. Morley, 2006 3 1) Placebo 
2) Naltrexone 
3) Acamprosate 
43 
39 
40 
61 
53 
55 
20. Morris, 2001 3 1) Placebo 
2) Naltrexone 
26 
19 
33 
38 
21. O‘Malley, 2008 3 1) Placebo 
2) Naltrexone 
28 
22 
34 
34 
22. Oslin, 1997 3 1) Placebo 
2) Naltrexone 
8 
3 
23 
21 
23. Oslin, 2008 6 1) Placebo 
2) Naltrexone 
76 
73 
120 
120 
24. Paille, 1995 12 1) Placebo 
3) Acamprosate 
144 
113 
177 
173 
25. Pelc, 1992 6 1) Placebo 
3) Acamprosate 
43 
35 
47 
55 
26. Pelc, 1997 3 1) Placebo 
3) Acamprosate 
46 
31 
62 
63 
27. Poldrugo, 1997 6 1) Placebo 
3) Acamprosate 
79 
58 
124 
122 
28. Sass, 1996 6 1) Placebo 
3) Acamprosate 
105 
73 
138 
137 
29. Tempesta, 2000 6 1) Placebo 
3) Acamprosate 
61 
49 
166 
164 
30. Volpicelli, 1992 3 1) Placebo 
2) Naltrexone 
19 
8 
35 
35 
31. Volpicelli, 1997 3 1) Placebo 
2) Naltrexone 
26 
17 
49 
48 
32. Whitworth, 1996 12 1) Placebo 
3) Acamprosate 
139 
129 
224 
224 
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Network meta-analysis – full random effects model 
A full random effects model (model 1) was constructed to estimate the relative effect 
between the k=3 interventions assessed, using data from the 32 RCTs summarised in 
Table 1. The data for each trial j comprised a binomial likelihood: 
 
rjk ~ Bin (pjk, njk) 
 
where pjk is the probability of relapse in trial j under treatment k, rjk is the number of 
people experiencing relapse in trial j under treatment k, and njk is the total number of 
people at risk of relapse in trial j under treatment k. 
 
The duration of the trials considered in the analysis varied from 3 to 12 months. The 
model assumed constant hazards exp(θjk) acting over a period Tj in months. Thus, 
the probability of relapse by the end of the period Tj for treatment k in trial j was: 
 
pjk(Tj) = 1 – exp (-exp(θjk) Tj) 
 
Treatment effects were modelled on the log-hazard rate scale and were assumed to 
be additive to the baseline treatment b in trial j: 
 
θjk = μjb    for k = b; 
θjk = μjb + δjkb   for k ≠ b 
 
where μjb is the log hazard of relapse for ‗baseline‘ treatment b in trial j and δjkb is the 
trial-specific log-hazard ratio of treatment k relative to treatment b. 
 
The full random effects model took into account the correlation structure induced by 
3 multi-arm trials included in the 32 RCTs; this type of model structure relies on the 
realisation of the bivariate normal distribution as a univariate marginal distribution 
and a univariate conditional distribution (Higgins & Whitehead, 1996): 
 
 
  
The trial-specific log-hazard ratios for every pair of interventions were assumed to 
come from a normal random effects distribution: 
 
δjkb ~ Normal (dkb, σ2) 
 
The mean of this distribution (dkb) is the true mean effect size between k and b and σ2 
is the variance of the normal distribution which was assumed to be common in all 
pairs of treatments. 
If  ~ N  
 
then  x₁  ~ N (μ₁ , σ²),  and ₁ ~ N (μ₂ +  ( ₁ - μ₁),  σ²) 
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Vague priors were assigned to trial baselines, mean treatment effects and common 
variance: 
 
μjb, dkb ~ Normal (0, 1002);  σ ~ Uniform (0,2) 
 
 
A separate random effects model (model 2) was constructed to estimate the baseline 
placebo effect, using relapse data from the 32 trials with a placebo arm included in 
the guideline systematic review. The placebo effect (φj) was again modelled on a log 
hazard scale and was assumed to come from a normal random effects distribution: 
 
φj ~ Normal (B, ω2) 
 
B ~ Normal (0, 1002); ω ~ Uniform (0,2) 
 
pj(Tj) = 1 – exp (-exp(φj) Tj) 
 
Subsequently, the absolute log hazard θjk of each drug k was estimated based on the 
treatment effect relative to placebo (estimated in model 1) added to a random value 
of the absolute log hazard of placebo (estimated in model 2). The output of the 
model that was used in the economic analysis was the probability of relapse for each 
intervention by the end of 12 months. 
 
Analysis was undertaken following Bayesian statistics principles and conducted 
using Markov chain Monte Carlo simulation techniques implemented in Winbugs 
1.4 (Lunn et al., 2000; Spiegelhalter et al., 2001). The first 60,000 iterations were 
discarded, and 300,000 further iterations were run; because of high autocorrelation 
observed in some model parameters, the model was thinned so that every 30th 
simulation was retained. Consequently, 10,000 posterior simulations were recorded. 
 
The goodness of fit of the model to the data was measured by calculating the 
residual deviance defined as the difference between the deviance for the fitted model 
and the deviance for the saturated model, where the deviance measures the fit of the 
model to the data points using the likelihood function. Under the null hypothesis 
that the model provides an adequate fit to the data, it is expected that residual 
deviance would have a mean equal to the number of unconstrained data points 
(Cooper et al., 2006). The residual deviance was calculated to be 44.86. This 
corresponds reasonably well with the number of unconstrained data points (67) of 
the model. 
The Winbugs code used to estimate the 12-month probability of relapse is 
provided in Table 109.  
 
 
Table 110 provides summary statistics of a number of model parameters, including 
the log hazard ratios of the two drugs versus placebo and the between-trials 
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variation. Results are reported as mean values with 95% credible intervals, which are 
analogous to CIs in frequentist statistics. 
Table 109: WinBUGs code used for network meta-anlysis to estimate 12-month 
probability of relapse 
 
model{ 
sw[1] <- 0 
for(i in 1:67){  
r[i] ~ dbin(p[i],n[i])                                                                   #binomial likelihood 
theta[i]<-mu[s[i]]+ delta[i]*(1-equals(t[i],b[i]))                      #baseline and treatment 
effects 
delta[i] ~ dnorm(md[i],taud[i])                                                #trial-specific log-hazard 
distributions 
taud[i] <- tau * (1 + equals(m[i],3) /3)                                     #precisions of log-
hazard distributions 
md[i] <- d[t[i]] - d[b[i]] + equals(m[i],3) * sw[i]                       #mean of random effect 
 
p[i] <- (1-exp(-lam[i]*w[i]/360))  # pr of event (w=days; 360 days = 12 mths) 
log(lam[i]) <- theta[i]                        # log rates for each arm                                                    
 
rhat[i] <- p[i] * n[i]                                                 #predicted events                                       
 
dev[i] <- -2 *r[i]*log(rhat[i]/r[i])                       #deviance residuals for data i   
} 
resdev <-sum(dev[])              #total deviance 
 
for (i in 2:67) { sw[i] <- (delta[i-1] - d[t[i-1]] + d[b[i-1]] ) /2} #adjustment for 3 arm 
trials 
 
#priors 
for(j in 1:32){ mu[j]~dnorm(0,.0001)}                              #vague priors for trial 
baselines 
tau <- 1/(sd*sd)                                #precision 
sd~dunif(0,2)                                                     #  vague prior for random effects 
standard deviation 
 
d[1]<-0 
for (k in 2:3){d[k] ~ dnorm(0,.0001)#vague priors for basic parameters 
log(hazr[k]) <-d[k] #hazard ratios 
 } 
 
#code for absolute effects on baseline (placebo, treatment 1) 
for (i in 1:33) { 
rb[i] ~ dbin(pb[i],nb[i]) #binomial likelihood 
pb[i] <- (1-exp(-lamb[i]*wb[i]/360))          # probability of event (w=days; 360 days 
= 12 mths) 
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log(lamb[i]) <- mub[sb[i]] # log rate 
} 
 
for (j in 1:33) {mub[j] ~ dnorm(mb,tab)}              # priors for outcome and trial-
specific events 
mb ~ dnorm(0,.001) 
tab <- 1/(sdb*sdb) 
sdb ~ dunif(0,2) 
 
#code for predicted effects at 360 days, on a probability scale. Baseline risks in 
mub[33] - new trial 
d.new[1] <-0 
for(k in 2:3) 
{d.new[k] ~ dnorm(d[k],tau)} 
for (k in 1:3) 
{theta360[k] <-mub[33] +d.new[k] 
log(lam360[k]) <-theta360[k] 
p360[k] <- (1-exp(-lam360[k])) 
} 
 
# prob that treatment k is best 
   for (k in 1:3)  { rk[k]  <- rank(d[],k) 
   best[k]  <- equals(rk[k],1)                          #Smallest is best (i.e. rank 1) 
   for (h in 1:3) { prob[h,k] <- equals(rk[k],h) }} 
} 
#initial values 1 
list( 
d=c(NA,0,0),sd=1,mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0, 
0,0),delta=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  
0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0, 0,0,0,0,0,  0,0,0,0,0, 0,0), sdb=1, 
mub=c(NA,0,0,0,0, 0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,    0,0,0,0,0,    0,0,0,0,0,   0,0,  NA), 
mb=1 
) 
 
#initial values 2 
list( 
d=c(NA,1,-1),sd=1.2,mu=c(0,0.5,0,2,0,0,  1,-1,-1,0,0,  -1,-1,-1,0,0,  1,1,1,0,-0.5,  
0,1,-1,0,1,  0.5,2,1,0.3, 0.2, 0.1),delta=c(0.5,0.5,0.6,0.4,0.3,  1,-1,-1,-1,-1,  0,1,0.3,0.2,0,  -
0.5,0,-1,-1,-1,  1,1,1,-1,0.1,  0.1,1,-1,-0.1,0,  0,1,1.5,0,-1,  -1,0,1,1,1,  1,-0.1,0.5,0,1,  
0,1,1,1,1,  -1,-1,-1,0,0, 1,1,1,0.5,0.5,  0,1,0,1,0, 0,1), sdb=0.7,mub=c(NA,0.5,0.7,-1,0.2,    
0.05,0.4,1,1,  1, -1,0.3,1,1,  0.2,0.3,0.4,-1,-1,  0.2,0.3,0.4,1.1,0.5,  -0.2,0,-1,0,-1,  0,0.4,-0.2, 
NA),mb=0.5 
) 
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Table 110: Summary statistics estimated from network meta-analysis 
 
Node Mean  SD MC 
error 
25% Median 75% Start  Sample 
p360[1] 0.8956 0.125 0.001383 0.5509 0.9433 1.0 60001 10000 
p360[2] 0.8253 0.1656 0.001840 0.4095 0.8741 0.9997 60001 10000 
p360[3] 0.8176 0.1691 0.001737 0.3894 0.8633 0.9996 60001 10000 
sd 0.2043 0.05914 0.00084 0.0984 0.2011 0.3293 60001 10000 
resdev 44.73 70.59 0.7011 -91.8 44.04 187.1 60001 10000 
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APPENDIX 16: INCLUDED/EXCLUDED STUDY TABLES 
 
The following appendices can be found on the CD accompanying this guideline. 
 
 16a- Experience of care study table 
 16b- Organisation of care study table 
 16c- Rehabilitation study table 
 16d- Psychological interventions study table 
 16e- Pharmacological interventions study table 
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APPENDIX 17: CLINICAL EVIDENCE FOREST PLOTS                              
 
The following appendices can be found on the CD accompanying this guideline. 
 
 17a: Organisation of care forest plots 
 17b: Rehabilitation forest plots 
 17c: Psychological interventions forest plots 
 17d: Pharmacological interventions forest plots 
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APPENDIX 18: GRADE EVIDENCE PROFILES 
 
The following appendices can be found on the CD accompanying this guideline. 
 
 18a: Organisation of care GRADE tables 
 18b: Rehabilitation GRADE tables 
 18c: Psychological interventions GRADE tables 
 18d: Pharmacological interventions GRADE tables 
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APPENDIX 19: EVIDENCE TABLES FOR ECONOMIC STUDIES 
 
This appendix can be found on the CD accompanying this guideline. 
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10 ABBREVIATIONS 
5HT 5-Hydroxytryptamine 
  
A&E Accident and Emergency 
AA Alcoholics Anonymous 
AAF Alcohol Attributable Fraction  
AAIS Adolescent Alcohol Involvement Scale 
ACE Addenbrooke‘s Cognitive Evaluation 
ACT assertive community treatment 
ADHD attention deficit hyperactivity disorder 
ADI Adolescent Drinking Index 
ADS Alcohol Dependence Scale 
AfC Agenda for Change 
AFSI alcohol-focused spousal involvement 
AGREE Appraisal of Guidelines for Research and Evaluation 
Instrument 
AHRQ Agency for Healthcare Research and Quality (United States) 
ALT alanine amino transferase 
AMED Allied and Complementary Medicine Database 
ANARP Alcohol Needs Assessment Research Project 
ANOVA analysis of variance 
APA American Psychiatric Association 
APQ Alcohol Problems Questionnaire 
AQ  Alcohol Questionnaire 
ASAM American Society of Addiction Medicine 
ASI Addiction Severity Index 
ASPD antisocial personality disorder 
AST aspartate amino transferase 
ATR Access to Recovery 
AUD alcohol-use disorder (can also mean Australian dollar) 
AUDIT Alcohol Use Disorders Identification Test 
AUDIT-C AUDIT Alcohol Consumption Questions 
AVI Swedish Alcohol Use Inventory 
AWS Alcohol Withdrawal Syndrome Scale 
  
BAC blood alcohol concentration 
BCT behavioural couples therapy 
BNF British National Formulary 
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BRT brief relationship therapy 
BSCT behavioural self-control training 
BSM(T) behavioural self-management (training) 
BST broad-spectrum treatment 
BT behavioural therapy 
  
Ca calcium 
CAD cumulative abstinence duration 
CAMHS child and adolescent mental health services 
CASI-A Comprehensive Addiction Severity Inventory for 
Adolescents 
CBI combined behavioural intervention 
CBMMT cognitive behavioural mood management training  
CBT cognitive behavioural therapy 
CCSE Cognitive Capacity Screening Examination 
CCM clinical case management 
CCoun1 couples counselling 
CDDR Customary Drinking and Drug Use Record 
CDP Comprehensive Drinker Profile 
CD-ROM compact disc – read-only memory 
CDSES Controlled Drinking Self-Efficacy Scale 
CDSR  Cochrane Database of Systematic Reviews 
CDU chemical dependency unit 
CE cue exposure 
CEAC cost-effectiveness acceptability curve 
CEAF cost-effectiveness acceptability frontier 
CENTRAL Cochrane Central Register of Controlled Trials 
CEO Chief Executive Officer 
CG control group 
CI confidence interval 
CIDI Composite  International Diagnostic Interview 
CINAHL Cumulative Index to Nursing and Allied Health Literature 
CISS Christo Inventory for Substance Misuse Services 
CIWA-AD Clinical Institute Withdrawal Assessment 
CIWA-Ar Clinical Institute Withdrawal Assessment Scale for Alcohol 
CLB Cognitive Laterality Battery 
CLDH Cognitive Lifetime Drinking History 
CM case management 
CMA Canadian Medical Association 
COMBINE combining medications and behavioural interventions 
CONT control 
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COPD chronic obstructive pulmonary disease 
CopSk coping skills  
COUNS counselling 
CPN community psychiatric nurse 
CRA community reinforcement approach 
CRD Centre for Reviews and Dissemination 
CRFT community reinforcement and family training 
CrI   
CS coping skills 
CSPRS Collaborative Study Psychotherapy Rating Scale 
CST communication skills training 
CSTF communication skills training with family therapy 
CT-8 conjoint therapy 
CTS Cognitive Therapy Scale 
CYT Cannabis Youth Trial 
  
DANOS Drug and Alcohol National Occupational Standards 
DARE  Cochrane Database of Abstracts of Reviews of Effects 
DCU drinker‘s check-up 
DDD drinks per drinking day 
DfES Department for Education and Skills 
DIS (C, –IV) Diagnostic Interview Schedule (for Children, fourth edition) 
DM deutschmark 
DPI Drinking Problems Index 
DRD2 dopamine receptor D2 
DrInC Drinker Inventory of Consequences 
DS directed social support 
DSM (-III, -IV, -R, -
V) 
Diagnostic and Statistical Manual of Mental Disorders of the 
American Psychiatric Association (3rd edition, 4th edition, 
Revised, 5th edition) 
DSML Drinking Self–Monitoring Log 
DSSI Delusions-Symptoms-States Inventory 
DTs delirium tremens 
DVLA Driver and Vehicle Licensing Agency 
  
ECE emotional cue exposure 
ECG electrocardiogram 
EconLIT economics literature search (the American Economic 
Association‘s electronic bibliography) 
EDNOS eating disorder not otherwise specified 
EDS Ethanol Dependence Syndrome scale 
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EED Economic Evaluation Database 
EMBASE Excerpta Medica Database 
EQ-5D European Quality of Life – 5 Dimensions 
  
FASD fetal alcohol syndrome or spectrum disorder 
FAST Fast Alcohol Screen Test 
FC full care 
FD fixed dosing 
FFT functional family therapy 
FRAMES feedback, responsibility, advice, menu, empathy, self-
efficacy 
FT full time 
  
GABA (-B) gamma-aminobutyric acid (type B) 
GAIN Global Appraisal of Individual Needs 
GBL gamma-butyrolactone 
GDG Guideline Development Group 
GGT gamma glutamyl transferase 
GHB gamma-hydroxybutyric acid 
GI gastrointestinal 
G-I-N Guidelines International Network 
GMI group motivational intervention 
GP general practitioner 
GRADE Grading of Recommendations: Assessment, Development 
and Evaluation 
GRP Guideline Review Panel 
GSC guided self change 
  
HCHS Hospital and Community Health Services 
HDS Hamilton Depression Scale 
HMIC Health Management Information Consortium 
HRQoL health-related quality of life 
HSD Honestly Significant Difference 
HTA Health Technology Assessment 
  
IATP individual assessment treatment program 
IBT individual-based treatment 
ICD–10 International Classification of Diseases,10th Revision 
ICER incremental cost effectiveness ratio 
ICP integrated care pathway 
ICQ Impaired Controlled Questionnaire  
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ICT interactional couples therapy 
ICP integrated care pathway 
IP  
ITT intention-to-treat 
IV intervariable 
  
KP Korsakoff psychosis  
  
LDH  Lifetime Drinking History 
LDQ Leeds Dependency Questionnaire 
LFT liver function test 
  
M/m mean 
MANOVA multivariate analysis of variance 
MAP Maudsley Addiction Profile 
(S)MAST (Short) Michigan Alcohol Screening Test 
MATCH Matching Alcoholism Treatments to Client Heterogeneity 
MD mean difference 
MDFT multi-dimensional family therapy  
MEDLINE Medical Literature Analysis and Retrieval System Online 
MET motivational enhancement therapy 
mGLuR metabotropic glutamate receptor 
M-H Mantel-Haenszel estimate 
MI motivational intervention 
MINDS  Minnesota Detoxification Scale 
MINI-CR Mini International Neuropsychiatric Interview – Clinician 
Rated 
MM medical management 
MM multi-modal treatment (in Appendix 16d) 
MMSE Mini-Mental Status Examination 
MoCAM Models of Care for Alcohol Misusers 
MOCE moderation-oriented cue exposure 
MSQ Motivational Structure Questionnaire 
MST multisystemic therapy 
MTC mixed treatment comparison 
  
NACOA National Association for Children of Alcoholics 
NATMS National Alcohol Treatment Monitoring System 
NCCMH National Collaborating Centre for Mental Health 
NDRL non-directive reflective listening 
NFC no further counselling after initial assessment  
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NHMRC National Health and Medical Research Council 
NHS National Health Service 
NIAAA National Institute on Alcohol Abuse and Alcoholism 
NICE National Institute for Clinical Excellence 
NIHR National Institute for Health Research 
NIMH National Institute of Mental Health 
NIS Neuropsychological Impairment Scale 
NLH National Library for Health 
NMB net monetary benefit 
NMDA N-methyl D-aspartate 
NNT number needed to treat 
NNTB number needed to treat for benefit 
NNTH number needed to treat for harm 
NS network support 
NSF National Service Framework 
NTA National Treatment Agency 
  
OB office-based 
OCD obsessive-compulsive disorder 
OLS ordinary least squares 
OR odds ratio 
OT occupational therapy 
  
PACT psychoeducational attention control treatment 
PAT Paddington Alcohol Test 
PCBT packaged CBT program 
PDA percent days abstinent 
PDHD  
PEI Personal Experience Inventory 
PI psychological intervention 
PICO Patient, Intervention, Comparison and Outcome 
PPA per-protocol analysis 
PRISM Psychiatric Research Interview for Substance and Mental 
Disorders 
PSBCT BCT and parental skills training 
PsycINFO  Psychological Information Database 
PSYDY psychodynamic therapy 
PSYEDU bibliotherapy/drinking guidelines 
PTSD post-traumatic stress disorder 
  
QALY quality-adjusted life year 
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q.d.s. quater die sumendus (four times a day) 
QF  Quantity–Frequency 
QTc corrected QT interval 
  
RAPI Rutgers Alcohol Problem Index 
RCGP Royal College of General Practitioners 
RCQ (-TV) Readiness to Change Questionnaire (– Treatment Version) 
RCT randomised controlled trial 
RESULT routine evaluation of the substance use ladder of treatments 
ROC receiver operating characteristic 
RP relapse prevention‘ 
RPME RP and MET 
RR risk ratio/relative risk 
RTCQ–TV Readiness to Change Questionnaire Treatment Version 
  
SADD Short Alcohol Dependence Data 
SADQ–C Severity of Alcohol Dependence Questionnaire – 
Community 
SASQ Single Alcohol Screening Question 
S-BCT standard behavioural couples therapy 
SBNT social behavioural network therapy 
SBSFT  
SC stepped care 
SCAN Specialist Clinical Addiction Network 
SCID SUDM  Structured Clinical Interview for the DSM – Substance Use 
Disorders Module 
SD standard deviation 
SG standard gamble 
SHM self-help manual 
SIGN Scottish Intercollegiate Guidelines Network 
SMART Self-Management and Recovery Training 
SMD standardised mean difference 
SNBT social network behavioural therapy 
SOCRATES Stages of Change Readiness and Treatment Eagerness Scale 
SPC Summary of Product Characteristics 
SSAGA Semi–Structured Assessment for the Genetics of Alcoholism 
SSRI selective serotonin reuptake inhibitor  
ST symptom-triggered 
SUDDS-IV Substance Use Disorders Diagnostic Schedule 
SWLSTG South West London and St George‘s 
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T-ASI Teen Addiction Severity Index 
TAU treatment as usual 
t.d.s. ter die sumendum (three times a day) 
TLFB  Timeline Followback 
TN true negative 
TOP Treatment Outcomes Profile 
TPQ Tridimensional Personality Questionnaire 
TRIP Turning Research Into Practice 
(I-, S-)TSF (dire, mot) (Intensive, Standard) Twelve-Step Facilitation (– directive 
approach and coping skills, – motivational approach and 
coping skills) 
TTO time trade-off 
  
U&E urea and electrolytes 
UK United Kingdom 
UKATT UK Alcohol Treatment Trial 
URICA University of Rhode Island Change Assessment 
US United States 
USD United States dollar 
  
VA Veterans Affairs 
VAS visual analogue scale 
VS volunteer support 
  
WAIS (-III, R) Wechsler Adult Intelligence Scale (– 3rd edition,– Revised) 
WE Wernicke's encephalopathy 
WHO World Health Organization 
WKS Wernicke-Korsakoff syndrome 
WMD weighted mean difference 
WTP willingness-to-pay 
 
 
